Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture

- Exelixis, Inc.

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority of U.S. provisional application 61/216,980, filed May 22, 2009, which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to the field of protein kinases and inhibitors thereof. In particular, the invention relates to inhibitors of mammalian target of rapamycin (mTOR) signaling pathways, and methods of their use and preparation.

2. Background of the Invention

Phosphatidylinositol 3-kinase (PI3Kα), a dual specificity protein kinase, is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. PTEN, a tumor suppressor which inhibits cell growth through multiple mechanisms, can dephosphorylate PIP3, the major product of PIK3CA. PIP3, in turn, is required for translocation of protein kinase B (AKT1, PKB) to the cell membrane, where it is phosphorylated and activated by upstream kinases. The effect of PTEN on cell death is mediated through the PIK3CA/AKT1 pathway.

PI3Kα has been implicated in the control of cytoskeletal reorganization, apoptosis, vesicular trafficking, proliferation and differentiation processes. Increased copy number and expression of PIK3CA is associated with a number of malignancies such as ovarian cancer (Campbell et al., Cancer Res 2004, 64, 7678-7681; Levine et al., Clin Cancer Res 2005, 11, 2875-2878; Wang et al., Hum Mutat 2005, 25, 322; Lee et al., Gynecol Oncol 2005, 97, 26-34), cervical cancer, breast cancer (Bachman, et al. Cancer Biol Ther 2004, 3, 772-775; Levine, et al., supra; Li et al., Breast Cancer Res Treat 2006, 96, 91-95; Saal et al., Cancer Res 2005, 65, 2554-2559; Samuels and Velculescu, Cell Cycle 2004, 3, 1221-1224), colorectal cancer (Samuels, et al. Science 2004, 304, 554; Velho et al. Eur J Cancer 2005, 41, 1649-1654), endometrial cancer (Oda et al. Cancer Res. 2005, 65, 10669-10673), gastric carcinomas (Byun et al., Int J Cancer 2003, 104, 318-327; Li et al., supra; Velho et al., supra; Lee et al., Oncogene 2005, 24, 1477-1480), hepatocellular carcinoma (Lee et al., id.), small and non-small cell lung cancer (Tang et al., Lung Cancer 2006, 51, 181-191; Massion et al., Am J Respir Crit. Care Med 2004, 170, 1088-1094), thyroid carcinoma (Wu et al., J Clin Endocrinol Metab 2005, 90, 4688-4693), acute myelogenous leukemia (AML) (Sujobert et al., Blood 1997, 106, 1063-1066), chronic myelogenous leukemia (CML) (Hickey and Cotter J Biol Chem 2006, 281, 2441-2450), and glioblastomas (Hartmann et al. Acta Neuropathol (Berl) 2005, 109, 639-642; Samuels et al., supra).

The mammalian target, mTOR is a protein kinase that integrates both extracellular and intracellular signals of cellular growth, proliferation, and survival. Extracellular mitogenic growth factor signaling from cell surface receptors and intracellular pathways that convey hypoxic stress, energy and nutrient status all converge at mTOR. mTOR exists in two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 is a key mediator of transcription and cell growth (via its substrates p70S6 kinase and 4E-BP1) and promotes cell survival via the serum and glucocorticoid-activated kinase SGK, whereas mTORC2 promotes activation of the pro-survival kinase AKT. Given its central role in cellular growth, proliferation and survival, it is perhaps not surprising that mTOR signaling is frequently dysregulated in cancer and other diseases (Bjornsti and Houghton Rev Cancer 2004, 4(5), 335-48; Houghton and Huang Microbiol Immunol 2004, 279, 339-59; Inoki, Corradetti et al. Nat Genet 2005, 37(1), 19-24).

mTOR is a member of the PIKK (PI3K-related Kinase) family of atypical kinases which includes ATM, ATR, and DNAPK, and its catalytic domain is homologous to that of PI3K. Dyregulation of PI3K signaling is a common function of tumor cells. In general, mTOR inhibition may be considered as a strategy in many of the tumor types in which PI3K signaling is implicated such as those discussed below.

Inhibitors of mTOR may be useful in treating a number of cancers, including the following: breast cancer (Nagata, Lan et al., Cancer Cell 2004, 6(2), 117-27; Pandolfi N Engl J Med 2004, 351(22), 2337-8; Nahta, Yu et al. Nat Clin Pract Oncol 2006, 3(5), 269-280); antle cell lymphoma (MCL) (Dal Col, Zancai et al. Blood 2008, 111(10), 5142-51); renal cell carcinoma (Thomas, Tran et al. Nat Med 2006, 12(1), 122-7; Atkins, Hidalgo et al. J Clin Oncol 2004, 22(5), 909-18; Motzer, Hudes et al. J Clin Oncol 2007, 25(25), 3958-64); acute myelogenous leukemia (AML) (Sujobert, Bardet et al. Blood 2005, 106(3), 1063-6; Billottet, Grandage et al. Oncogene 2006, 25(50), 6648-6659; Tamburini, Elie et al. Blood 2007, 110(3), 1025-8); chronic myelogenous leukemia (CML) (Skorski, Bellacosa et al. Embo J 1997, 16(20), 6151-61; Bai, Ouyang et al. Blood 2000, 96(13), 4319-27; Hickey and Cotter Biol Chem 2006, 281(5), 2441-50); diffuse large B cell lymphoma (DLBCL) (Uddin, Hussain et al. Blood 2006, 108(13), 4178-86); several subtypes of sarcoma (Hernando, Charytonowicz et al. Nat Med 2007, 13(6), 748-53; Wan and Helman Oncologist 2007, 12(8), 1007-18); rhabdomyosarcoma (Cao, Yu et al. Cancer Res 2008, 68(19), 8039-8048; Wan, Shen et al. Neoplasia 2006, 8(5), 394-401); ovarian cancer (Shayesteh, Lu et al. Nat Genet, 1999, 21(1), 99-102; (Lee, Choi et al. Gynecol Oncol 2005, 97(1) 26-34); endometrial tumors (Obata, Morland et al. Cancer Res 1998, 58(10), 2095-7; Lu, Wu et al. Clin Cancer Res 2008, 14(9), 2543-50); non small cell lung carcinoma (NSCLC) (Tang, He et al. Lung Cancer 2006, 51(2), 181-91; Marsit, Zheng et al. Hum Pathol 2005, 36(7), 768-76); small cell, squamous, large cell and adenocarcinoma (Massion, Taflan et al. Am J Respir Crit. Care Med 2004, 170(10), 1088-94); lung tumors in general (Kokubo, Gemma et al. Br J Cancer 2005, 92(9), 1711-9; Pao, Wang et al. Pub Library of Science Med 2005, 2(1), e17); colorectal tumors (Velho, Oliveira et al. Eur J Cancer 2005, 41(11), 1649-54; Foukas, Claret et al. Nature, 2006, 441(7091), 366-370), particularly those that display microsatellite instability (Goel, Arnold et al. Cancer Res 2004, 64(9), 3014-21; Nassif, Lobo et al. Oncogene 2004, 23(2), 617-28), KRAS-mutated colorectal tumors (Bos Cancer Res 1989. 49(17), 4682-9; Fearon Ann N Y Acad Sci 1995, 768, 101-10); gastric carcinomas (Byun, Cho et al. Int J Cancer 2003, 104(3), 318-27); hepatocellular tumors (Lee, Soung et al. Oncogene 2005, 24(8), 1477-80); liver tumors (Hu, Huang et al. Cancer 2003, 97(8), 1929-40; Wan, Jiang et al. Cancer Res Clin Oncol 2003, 129(2), 100-6); primary melanomas and associated increased tumor thickness (Guldberg, thor Straten et al. Cancer Res 1997, 57(17), 3660-3; Tsao, Zhang et al. Cancer Res 2000, 60(7), 1800-4; Whiteman, Zhou et al. Int J Cancer 2002, 99(1), 63-7; Goel, Lazar et al. J Invest Dermatol 126(1), 2006, 154-60); pancreatic tumors (Asano, Yao et al. Oncogene 2004, 23(53), 8571-80); prostate carcinoma (Cairns, Okami et al. Cancer Res 1997, 57(22), 4997-5000; Gray, Stewart et al. Br J Cancer 1998, 78(10), 1296-300; Wang, Parsons et al. Clin Cancer Res 1998, 4(3), 811-5; Whang, Wu et al. Proc Natl Acad Sci USA 1998, 95(9), 5246-50; Majumder and Sellers Oncogene 2005, 24(50) 7465-74; Wang, Garcia et al. Proc Natl Acad Sci USA 2006, 103(5), 1480-5; (Lu, Ren et al. Int J Oncol 2006, 28(1), 245-51; Mulholland, Dedhar et al. Oncogene 25(3), 2006, 329-37; Xin, Teitell et al. Proc Natl Acad Sci USA 12006, 03(20), 7789-94; Mikhailova, Wang et al. Adv Exp Med Biol 2008, 617, 397-405; Wang, Mikhailova et al. Oncogene 2008, 27(56), 7106-7117); thyroid carcinoma, particularly in the anaplastic subtype (Garcia-Rostan, Costa et al. Cancer Res 2005, 65(22), 10199-207); follicular thyroid carcinoma (Wu, Mambo et al. J Clin Endocrinol Metab 2005, 90(8), 4688-93); anaplastic large cell lymphoma (ALCL); hamaratomas, angiomyelolipomas, TSC-associated and sporadic lymphangioleiomyomatosis: Cowden's disease (multiple hamaratoma syndrome) (Bissler, McCormack et al. N Engl J Med 2008, 358(2), 140-151); sclerosing hemangioma (Randa M. S. Amin Pathology International 2008, 58(1), 38-44); Peutz-Jeghers syndrome (PJS); head and neck cancer (Gupta, McKenna et al. Clin Cancer Res 2002, 8(3), 885-892); neurofibromatosis (Ferner Eur J Hum Genet 2006, 15(2), 131-138; Sabatini Nat Rev Cancer 2006, 6(9), 729-734; Johannessen, Johnson et al. Current Biology 2008, 18(1), 56-62); macular degeneration; macular edema; myeloid leukemia; systemic lupus; and autoimmune lymphoproliferative syndrome (ALPS).

SUMMARY OF THE INVENTION

The following only summarizes certain aspects of the invention and is not intended to be limiting in nature. These aspects and other aspects and embodiments are described more fully below. All references cited in this specification are hereby incorporated by reference in their entirety. In the event of a discrepancy between the express disclosure of this specification and the references incorporated by reference, the express disclosure of this specification shall control.

We recognized the important role of PI3K and mTOR in biological processes and disease states and, therefore, realized that inhibitors of these protein kinases would be desirable. Accordingly, the invention provides compounds that inhibit, regulate, and/or modulate PI3K and/or mTOR and are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound, methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

A first aspect of the invention provides a Compound of Formula I:

  • or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof, where
  • R1 is phenyl optionally substituted with one, two, or three R6 groups; or
  • R1 is heteroaryl optionally substituted with one, two, or three R7;
  • R2 is heteroaryl substituted with R3, R3a, R3b, R3c, and R3d;
  • R3, R3a, R3b, R3c, and R3d are independently hydrogen, cyano, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, —SR12, —S(O)2R20, —C(O)OR4, halocarbonyl, —NR11R11a, —OR11a, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or alkyl substituted with one or two R16; or
  • two of R3, R3a, R3b, R3c, and R3d, when attached to the same carbon, form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl; and the other of R3, R3a, R3b, R3c, and R3d are independently hydrogen, cyano, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, —SR12, —S(O)2R20, —C(O)OR4, halocarbonyl, —NR11R11a, —OR11a, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or alkyl substituted with one or two R16;
  • R4 is alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, benzyl, or optionally substituted heterocycloalkylalkyl;
  • R5a and R5c are independently hydrogen or alkyl;
  • R5h is hydrogen or halo;
  • R5b is hydrogen, amino, or halo;
  • R5d, R5e, R5f, and R5g are hydrogen;
  • each R6, when R6 is present, is independently nitro; cyano; halo; alkyl; alkenyl; alkynyl; haloalkyl; —OR8a; —NR8R8a; —C(O)NR8R8a; —S(O)2R8; —NR8C(O)OR9; —NR8C(O)R9; —NR8S(O)2R8a; —NR8C(O)NR8aR9; carboxy, —C(O)OR9; halocarbonyl; alkylcarbonyl; alkyl substituted with one or two —C(O)NR8R8a; heteroaryl optionally substituted with 1, 2, or 3 R14; or optionally substituted heterocycloalkyl;
  • each R7, when R7 is present, is independently oxo; nitro; cyano; alkyl; alkenyl; alkynyl; halo; haloalkyl; hydroxyalkyl; alkoxyalkyl; —OR8a; —SR13; —S(O)R13; —S(O)2R13a; —NR8R8a; —C(O)NR8R8a; —NR8C(O)OR9; —NR8C(O)R9; —NR8S(O)2R8a; —NR8C(O)NR8aR9; —C(O)OR9; halocarbonyl; alkylcarbonyl; —S(O)2NR8R9; alkylsulfonylalkyl; alkyl substituted with one or two —NR8R8a; alkyl substituted with one or two —NR8C(O)R8a; alkyl substituted with one or two —NR8C(O)OR9; alkyl substituted with one or two —S(O)2R13a; optionally substituted cycloalkyl; optionally substituted cycloalkylalkyl; optionally substituted heterocycloalkyl; optionally substituted heterocycloalkylalkyl; optionally substituted phenyl; optionally substituted phenylalkyl; optionally substituted heteroaryl; or optionally substituted heteroarylalkyl;
  • each R8, R11, R15, R17, and R18 are independently hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, or haloalkyl;
  • each R8a, R11a, and R15a are independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, carboxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl;
  • R9 is hydrogen; alkyl; alkenyl; alkynyl; hydroxyalkyl; alkoxyalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; haloalkyl; hydroxyalkyl substituted with one, two, or three groups which are independently halo, amino, alkylamino, or dialkylamino; alkyl substituted with one or two aminocarbonyl; optionally substituted phenyl; optionally substituted phenylalkyl; optionally substituted cycloalkyl; optionally substituted cycloalkylalkyl; optionally substituted heteroaryl; optionally substituted heteroarylalkyl; optionally substituted heterocycloalkyl; or optionally substituted heterocycloalkylalkyl;
  • R12 is alkyl or optionally substituted phenylalkyl;
  • R13 is alkyl, hydroxyalkyl, or haloalkyl; and
  • R13a is hydroxy, alkyl, haloalkyl, hydroxyalkyl, or heterocycloalkyl optionally substituted with one or two groups which are independently halo, amino, alkylamino, dialkylamino, hydroxy, alkyl, or hydroxyalkyl;
  • each R14, when R14 is present, is independently amino, alkylamino, dialkylamino, acylamino, halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, or optionally substituted phenyl;
  • each R16 is independently —NR11R11a, —NR15S(O)R15a, —OC(O)R17, or —OR18; and
  • R20 is alkyl, haloalkyl, hydroxyalkyl, amino, alkylamino, dialkylamino, or heterocycloalkyl.

In a second aspect, the invention is directed to a pharmaceutical composition which comprises 1) a Compound of Formula I or a single stereoisomer or mixture of stereoisomers thereof, optionally as a pharmaceutically acceptable salt or solvate thereof and 2) a pharmaceutically acceptable carrier, excipient, or diluent.

In a third aspect of the invention is a method of inhibiting the in vivo activity of PI3K and/or mTOR, the method comprising administering to a patient an effective PI3K-inhibiting and/or mTOR-inhibiting amount of a Compound of Formula Ia Compound of Formula I or a single stereoisomer or mixture of stereoisomers thereof, optionally as a pharmaceutically acceptable salt or solvate thereof or pharmaceutical composition thereof.

In a fourth aspect, the Invention provides a method for treating a disease, disorder, or syndrome which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I or a single stereoisomer or mixture of stereoisomers thereof, optionally as a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a Compound of Formula I or a single stereoisomer or mixture of stereoisomers thereof, optionally as a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient, or diluent.

In a fifth aspect, the Invention provides a method for making a Compound of Formula I(a) which method comprises

(a) reacting the following, or a salt thereof:


where R1 is as defined in the Summary of the Invention for a Compound of Formula I; with an intermediate of Formula R2X where X is halo, and R2 is as defined in the Summary of the Invention for a Compound of Formula I to yield a Compound of the Invention of Formula I(a)


and optionally separating individual isomers; and optionally modifying any of the R1 and R2 groups; and optionally forming a pharmaceutically acceptable salt thereof; or

(b) reacting the following, or a salt thereof:


where R is halo or —B(OR′)2 (where both R′ are hydrogen or the two R′ together form a boronic ester), and R2 is as defined in the Summary of the Invention for a Compound of Formula I; with an intermediate of Formula R1Y where Y is halo when R is —B(OR′)2 and Y is —B(OR′)2 when R is halo, and R2 is as defined in the Summary of the Invention for a Compound of Formula Ito yield a Compound of the Invention of Formula I(a); and optionally separating individual isomers; and optionally modifying any of the R1 and R2 groups; and optionally forming a pharmaceutically acceptable salt, hydrate, solvate or combination thereof.

DETAILED DESCRIPTION OF THE INVENTION Abbreviations and Definitions

The following abbreviations and terms have the indicated meanings throughout:

Abbreviation Meaning br broad ° C. degrees Celsius d doublet dd doublet of doublet dt doublet of triplet DCM dichloromethane DIEA or DIPEA N,N-di-isopropyl-N-ethylamine DMA N,N-dimethylacetamide DME 1,2-dimethoxyethane DMF N,N-dimethylformamide DMSO dimethyl sulfoxide dppf 1,1′-bis(diphenylphosphano)ferrocene EI Electron Impact ionization g gram(s) GC/MS gas chromatography/mass spectrometry h or hr hour(s) HPLC high pressure liquid chromatography L liter(s) LC/MS liquid chromatography/mass spectrometry M molar or molarity m Multiplet MeOH methanol mg milligram(s) MHz megahertz (frequency) min minute(s) mL milliliter(s) μL microliter(s) μM micromolar μmol micromole(s) mM Millimolar mmol millimole(s) mol mole(s) MS mass spectral analysis N normal or normality nM nanomolar NMP N-methyl-2-pyrrolidone NMR nuclear magnetic resonance spectroscopy q Quartet rt Room temperature s Singlet t or tr Triplet THF tetrahydrofuran

The symbol “—” means a single bond, “═” means a double bond, “≡” means a triple bond, means a single or double bond. The symbol refers to a group on a double-bond as occupying either position on the terminus of a double bond to which the symbol is attached; that is, the geometry, E- or Z-, of the double bond is ambiguous. When a group is depicted removed from its parent Formula, the symbol will be used at the end of the bond which was theoretically cleaved in order to separate the group from its parent structural Formula.

When chemical structures are depicted or described, unless explicitly stated otherwise, all carbons are assumed to have hydrogen substitution to conform to a valence of four. For example, in the structure on the left-hand side of the schematic below there are nine hydrogens implied. The nine hydrogens are depicted in the right-hand structure. Sometimes a particular atom in a structure is described in textual Formula as having a hydrogen or hydrogens as substitution (expressly defined hydrogen), for example, —CH2CH2—. It is understood by one of ordinary skill in the art that the aforementioned descriptive techniques are common in the chemical arts to provide brevity and simplicity to description of otherwise complex structures.

If a group “R” is depicted as “floating” on a ring system, as for example in the Formula:


then, unless otherwise defined, a substituent “R” may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.

If a group “R” is depicted as floating on a fused ring system, as for example in the Formula e:


then, unless otherwise defined, a substituent “R” may reside on any atom of the fused ring system, assuming replacement of a depicted hydrogen (for example the —NH— in the Formula above), implied hydrogen (for example as in the Formula above, where the hydrogens are not shown but understood to be present), or expressly defined hydrogen (for example where in the Formula above, “Z” equals ═CH—) from one of the ring atoms, so long as a stable structure is formed. In the example depicted, the “R” group may reside on either the 5-membered or the 6-membered ring of the fused ring system.

When a group “R” is depicted as existing on a ring system containing saturated carbons, as for example in the Formula:


where, in this example, “y” can be more than one, assuming each replaces a currently depicted, implied, or expressly defined hydrogen on the ring; then, unless otherwise defined, where the resulting structure is stable, two “R′s” may reside on the same carbon. In another example, two R′s on the same carbon, including that carbon, may form a ring, thus creating a spirocyclic ring structure with the depicted ring as for example in the Formula:

“Acyl” means a —C(O)R radical where R is alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, or heterocycloalkylalkyl, as defined herein, e.g., acetyl, trifluoromethylcarbonyl, or 2-methoxyethylcarbonyl, and the like.

“Acylamino” means a —NRR′ radical where R is hydrogen, hydroxy, alkyl, or alkoxy and R′ is acyl, as defined herein.

“Acyloxy” means an —OR radical where R is acyl, as defined herein, e.g. cyanomethylcarbonyloxy, and the like.

“Administration” and variants thereof (e.g., “administering” a compound) in reference to a Compound of the invention means introducing the Compound or a prodrug of the Compound into the system of the animal in need of treatment. When a Compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., surgery, radiation, and chemotherapy, etc.), “administration” and its variants are each understood to include concurrent and sequential introduction of the Compound or prodrug thereof and other agents.

“Alkenyl” means a means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms which radical contains at least one double bond, e.g., ethenyl, propenyl, 1-but-3-enyl, and 1-pent-3-enyl, and the like.

“Alkoxy” means an —OR group where R is alkyl group as defined herein. Examples include methoxy, ethoxy, propoxy, isopropoxy, and the like.

“Alkoxyalkyl” means an alkyl group, as defined herein, substituted with at least one, specifically one, two, or three, alkoxy groups as defined herein. Representative examples include methoxymethyl and the like.

“Alkoxycarbonyl” means a —C(O)R group where R is alkoxy, as defined herein.

“Alkyl” means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), or pentyl (including all isomeric forms), and the like.

“Alkylamino” means an —NHR group where R is alkyl, as defined herein.

“Alkylaminoalkyl” means an alkyl group substituted with one or two alkylamino groups, as defined herein.

“Alkylaminoalkyloxy” means an —OR group where R is alkylaminoalkyl, as defined herein.

“Alkylcarbonyl” means a —C(O)R group where R is alkyl, as defined herein.

“Alkylsulfonyl” means an —S(O)2R group where R is alkyl, as defined herein.

“Alkylsulfonylalkyl” means an alkyl group, as defined herein, substituted with one or two —S(O)2R group where R is alkyl, as defined herein.

“Alkynyl” means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to 6 carbon atoms which radical contains at least one triple bond, e.g., ethynyl, propynyl, butynyl, pentyn-2-yl and the like.

“Amino” means —NH2.

“Aminoalkyl” means an alkyl group substituted with at least one, specifically one, two or three, amino groups.

“Aminoalkyloxy” means an —OR group where R is aminoalkyl, as defined herein.

“Aminocarbonyl” means a —C(O)NH2 group.

“Alkylaminocarbonyl” means a —C(O)NHR group where R is alkyl as defined herein.

“Aryl” means a monovalent six- to fourteen-membered, mono- or bi-carbocyclic ring, wherein the monocyclic ring is aromatic and at least one of the rings in the bicyclic ring is aromatic. Unless stated otherwise, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. Representative examples include phenyl, naphthyl, and indanyl, and the like.

“Arylalkyl” means an alkyl radical, as defined herein, substituted with one or two aryl groups, as defined herein, e.g., benzyl and phenethyl, and the like.

“Cyanoalkyl” means an alkyl group, as defined herein, substituted with one or two cyano groups.

“Cycloalkyl” means a monocyclic or fused bicyclic, saturated or partially unsaturated (but not aromatic), monovalent hydrocarbon radical of three to ten carbon ring atoms. Fused bicyclic hydrocarbon radical includes spiro and bridged ring systems. Unless stated otherwise, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. One or two ring carbon atoms may be replaced by a —C(O)—, —C(S)—, or —C(═NH)— group. More specifically, the term cycloalkyl includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl, or cyclohex-3-enyl, and the like.

“Cycloalkylalkyl” means an alkyl group substituted with at least one, specifically one or two, cycloalkyl group(s) as defined herein.

“Dialkylamino” means an —NRR′ radical where R and R′ are alkyl as defined herein, or an N-oxide derivative, or a protected derivative thereof, e.g., dimethylamino, diethylamino, N,N-methylpropylamino or N,N-methylethylamino, and the like.

“Dialkylaminoalkyl” means an alkyl group substituted with one or two dialkylamino groups, as defined herein.

“Dialkylaminoalkyloxy” means an —OR group where R is dialkylaminoalkyl, as defined herein. Representative examples include 2-(N,N-diethylamino)-ethyloxy, and the like.

“Dialkylaminocarbonyl” means a —C(O)NRR′ group where R and R′ are alkyl as defined herein.

“Fused ring system” means a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused ring systems share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. Fused ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused ring system. In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure. The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups.

“Halogen” or “halo” refers to fluorine, chlorine, bromine and iodine.

“Haloalkoxy” means an —OR′ group where R′ is haloalkyl as defined herein, e.g., trifluoromethoxy or 2,2,2-trifluoroethoxy, and the like.

“Haloalkyl” mean an alkyl group substituted with one or more halogens, specifically 1, 2, 3, 4, 5, or 6 halo atoms, e.g., trifluoromethyl, 2-chloroethyl, and 2,2-difluoroethyl, and the like.

“Halocarbonyl” means a —C(O)X group where X is halo.

“Heteroaryl” means a monocyclic or fused bicyclic or tricyclic monovalent radical of 5 to 14 ring atoms containing one or more, specifically one, two, three, or four ring heteroatoms where each heteroatom is independently —O—, —S(O)n— (n is 0, 1, or 2), —N═, —NH—, or N-oxide, with the remaining ring atoms being carbon, wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising the bicyclic radical is aromatic. One or two ring carbon atoms of any nonaromatic rings comprising a bicyclic radical may be replaced by a —C(O)—, —C(S)—, or —C(═NH)— group. Fused bicyclic radical includes bridged ring systems. Unless stated otherwise, the valency may be located on any atom of any ring of the heteroaryl group, valency rules permitting. When the point of valency is located on the nitrogen, Rx is absent. More specifically, the term heteroaryl includes, but is not limited to, 1,2,4-triazolyl, 1,3,5-triazolyl, phthalimidyl, pyridinyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, 2,3-dihydro-1H-indolyl (including, for example, 2,3-dihydro-1H-indol-2-yl or 2,3-dihydro-1H-indol-5-yl, and the like), isoindolyl, indolinyl, isoindolinyl, benzimidazolyl, benzodioxol-4-yl, benzofuranyl, cinnolinyl, indolizinyl, naphthyridin-3-yl, phthalazin-3-yl, phthalazin-4-yl, pteridinyl, purinyl, quinazolinyl, 5,6,7,8-tetrahydroquinazolinyl, quinoxalinyl, tetrazoyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isooxazolyl, oxadiazolyl, benzoxazolyl, quinolinyl, 5,6,7,8-tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl (including, for example, tetrahydroisoquinolin-4-yl or tetrahydroisoquinolin-6-yl, and the like), pyrrolo[3,2-c]pyridinyl (including, for example, pyrrolo[3,2-c]pyridin-2-yl or pyrrolo[3,2-c]pyridin-7-yl, and the like), benzopyranyl, 2,3-dihydrobenzofuranyl, benzo[d][1,3]dioxolyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, thiazolyl, isothiazolyl, thiadiazolyl, benzothiazolyl, benzothienyl, 6,7-dihydro-5H-cyclopenta[b]pyridinyl, 6,7-dihydro-5H-cyclopenta[c]pyridinyl, 6,7-dihydro-5H-cyclopenta[d]pyrimidinyl, 5,6,7,8-tetrahydro-5,8-ethanoquinazolin-4-yl, and 6,7,8,9-tetrahydropyrimido[4,5-b]indolizin-4-yl, and the N-oxide thereof and a protected derivative thereof.

“Heteroarylalkyl” means an alkyl group, as defined herein, substituted with at least one, specifically one or two heteroaryl group(s), as defined herein.

“Heterocycloalkyl” means a saturated or partially unsaturated (but not aromatic) monovalent monocyclic group of 3 to 8 ring atoms or a saturated or partially unsaturated (but not aromatic) monovalent fused or spirocyclic bicyclic group of 5 to 12 ring atoms in which one or more, specifically one, two, three, or four ring heteroatoms where each heteroatom is independently O, S(O)n (n is 0, 1, or 2), —NH—, or —N═, the remaining ring atoms being carbon. One or two ring carbon atoms may be replaced by a —C(O)—, —C(S)—, or —C(═NH)— group. Fused bicyclic radical includes bridged ring systems. Unless otherwise stated, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. When the point of valency is located on a nitrogen atom, Ry is absent. More specifically the term heterocycloalkyl includes, but is not limited to, azetidinyl, pyrrolidinyl, 2-oxopyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, piperidinyl, 4-piperidonyl, morpholinyl, piperazinyl, 2-oxopiperazinyl, tetrahydropyranyl, 2-oxopiperidinyl, thiomorpholinyl, thiamorpholinyl, perhydroazepinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, oxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolinyl, thiazolidinyl, quinuclidinyl, isothiazolidinyl, octahydrocyclopenta[c]pyrrolyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl, 2,6-diazaspiro[3.3]heptan-2-yl, tetrahydrofuryl, and tetrahydropyranyl, and the derivatives thereof and N-oxide or a protected derivative thereof.

“Heterocycloalkylalkyl” means an alkyl radical, as defined herein, substituted with one or two heterocycloalkyl groups, as defined herein, e.g., morpholinylmethyl, N-pyrrolidinylethyl, and 3-(N-azetidinyl)propyl, and the like.

“Hydroxyalkyl” means an alkyl group, as defined herein, substituted with at least one, particularly, 1, 2, 3, or 4, hydroxy groups.

“Phenylalkyl” means an alkyl group, as defined herein, substituted with one or two phenyl groups.

“Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that with respect to any molecule described as containing one or more optional substituents, only sterically practical and/or synthetically feasible compounds are meant to be included. “Optionally substituted” refers to all subsequent modifiers in a term, unless stated otherwise. A list of exemplary optional substitutions is presented below in the definition of “substituted.”

“Optionally substituted aryl” means an aryl group, as defined herein, optionally substituted with one, two, three, or four substituents where the substituents are independently acyl, acylamino, acyloxy, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkenyl, alkoxy, alkenyloxy, halo, hydroxy, alkoxycarbonyl, alkenyloxycarbonyl, amino, alkylamino, dialkylamino, nitro, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxy, cyano, alkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, or aminoalkoxy; or aryl is pentafluorophenyl. Within the optional substituents on “aryl”, the alkyl and alkenyl, either alone or as part of another group (including, for example, the alkyl in alkoxycarbonyl), are independently optionally substituted with one, two, three, four, or five halo (e.g. alkoxycarbonyl includes trifluoromethyloxycarbonyl).

“Optionally substituted arylalkyl” means an alkyl group, as defined herein, substituted with optionally substituted aryl, as defined herein.

“Optionally substituted cycloalkyl” means a cycloalkyl group, as defined herein, substituted with one, two, or three groups where the groups are independently acyl, acyloxy, acylamino, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkenyl, alkoxy, alkenyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, halo, hydroxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, nitro, alkoxyalkyloxy, aminoalkoxy, alkylaminoalkoxy, dialkylaminoalkoxy, carboxy, or cyano. Within the above optional substitutents on “cycloalkyl”, the alkyl and alkenyl, either alone or as part of another substituent on the cycloalkyl ring, are independently optionally substituted with one, two, three, four, or five halo, e.g. haloalkyl, haloalkoxy, haloalkenyloxy, or haloalkylsulfonyl.

“Optionally substituted cycloalkylalkyl” means an alkyl group substituted with at least one, specifically one or two, optionally substituted cycloalkyl groups, as defined herein.

“Optionally substituted heteroaryl” means a heteroaryl group optionally substituted with one, two, three, or four substituents where the substituents are independently acyl, acylamino, acyloxy, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkenyl, alkoxy, alkenyloxy, halo, hydroxy, alkoxycarbonyl, alkenyloxycarbonyl, amino, alkylamino, dialkylamino, nitro, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxy, cyano, alkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, aminoalkoxy, alkylaminoalkoxy, or dialkylaminoalkoxy. Within the optional substituents on “heteroaryl”, the alkyl and alkenyl, either alone or as part of another group (including, for example, the alkyl in alkoxycarbonyl), are independently optionally substituted with one, two, three, four, or five halo (e.g. alkoxycarbonyl includes trifluoromethyloxycarbonyl).

“Optionally substituted heteroarylalkyl” means an alkyl group, as defined herein, substituted with at least one, specifically one or two, optionally substituted heteroaryl group(s), as defined herein.

“Optionally substituted heterocycloalkyl” means a heterocycloalkyl group, as defined herein, optionally substituted with one, two, three, or four substituents where the substituents are independently acyl, acylamino, acyloxy, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkenyl, alkoxy, alkenyloxy, halo, hydroxy, alkoxycarbonyl, alkenyloxycarbonyl, amino, alkylamino, dialkylamino, nitro, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxy, cyano, alkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, aminoalkoxy, or phenylalkyl. Within the optional substituents on “heterocycloalkyl”, the alkyl and alkenyl, either alone or as part of another group (including, for example, the alkyl in alkoxycarbonyl), are independently optionally substituted with one, two, three, four, or five halo (e.g. alkoxycarbonyl includes trifluoromethyloxycarbonyl).

“Optionally substituted heterocycloalkylalkyl” means an alkyl group, as defined herein, substituted with at least one, specifically one or two, optionally substituted heterocycloalkyl group(s) as defined herein.

“Optionally substituted phenyl” means a phenyl group optionally substituted with one, two, or three substituents where the substituents are independently acyl, acylamino, acyloxy, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkenyl, alkoxy, alkenyloxy, halo, hydroxy, alkoxycarbonyl, alkenyloxycarbonyl, amino, alkylamino, dialkylamino, nitro, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxy, cyano, alkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, or aminoalkoxy. “Optionally substituted phenyl” in addition includes pentafluorophenyl. Within the optional substituents on “phenyl”, the alkyl and alkenyl, either alone or as part of another group (including, for example, the alkyl in alkoxycarbonyl), are independently optionally substituted with one, two, three, four, or five halo (e.g. alkoxycarbonyl includes trifluoromethyloxycarbonyl).

“Optionally substituted phenylalkyl” means an alkyl group, as defined herein, substituted with one or two optionally substituted phenyl groups, as defined herein.

“Oxo” means an oxygen which is attached via a double bond.

“Yield” for each of the reactions described herein is expressed as a percentage of the theoretical yield.

“Metabolite” refers to the break-down or end product of a Compound or its salt produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, “The Pharmacological Basis of Therapeutics” 8.sup.th Ed., Pergamon Press, Gilman et al. (eds), 1990 for a discussion of biotransformation). As used herein, the metabolite of a Compound of the invention or its salt may be the biologically active form of the Compound in the body. In one example, a prodrug may be used such that the biologically active form, a metabolite, is released in vivo. In another example, a biologically active metabolite is discovered serendipitously, that is, no prodrug design per se was undertaken. An assay for activity of a metabolite of a Compound of the present invention is known to one of skill in the art in light of the present disclosure.

“Patient” for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In a specific embodiment the patient is a mammal, and in a more specific embodiment the patient is human.

A “pharmaceutically acceptable salt” of a Compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference or S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977; 66:1-19 both of which are incorporated herein by reference.

Examples of pharmaceutically acceptable acid addition salts include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4′-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, p-toluenesulfonic acid, and salicylic acid and the like.

Examples of a pharmaceutically acceptable base addition salts include those formed when an acidic proton present in the parent Compound is replaced by a metal ion, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Specific salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tromethamine, N-methylglucamine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. “Platin(s),” and “platin-containing agent(s)” include, for example, cisplatin, carboplatin, and oxaliplatin.

“Prodrug” refers to compounds that are transformed (typically rapidly) in vivo to yield the parent Compound of the above Formula e, for example, by hydrolysis in blood. Common examples include, but are not limited to, ester and amide forms of a Compound having an active form bearing a carboxylic acid moiety. Examples of pharmaceutically acceptable esters of the compounds of this invention include, but are not limited to, alkyl esters (for example with between about one and about six carbons) the alkyl group is a straight or branched chain. Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to benzyl. Examples of pharmaceutically acceptable amides of the compounds of this invention include, but are not limited to, primary amides, and secondary and tertiary alkyl amides (for example with between about one and about six carbons). Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes.

“Therapeutically effective amount” is an amount of a Compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a Compound of the invention which constitutes a “therapeutically effective amount” will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their knowledge and to this disclosure.

“Preventing” or “prevention” of a disease, disorder, or syndrome includes inhibiting the disease from occurring in a human, i.e. causing the clinical symptoms of the disease, disorder, or syndrome not to develop in an animal that may be exposed to or predisposed to the disease, disorder, or syndrome but does not yet experience or display symptoms of the disease, disorder, or syndrome.

“Treating” or “treatment” of a disease, disorder, or syndrome, as used herein, includes (i) inhibiting the disease, disorder, or syndrome, i.e., arresting its development; and (ii) relieving the disease, disorder, or syndrome, i.e., causing regression of the disease, disorder, or syndrome. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art.

Embodiments of the Invention

The following paragraphs present a number of embodiments of compounds of the invention. In each instance the embodiment includes both the recited compounds, as well as a single stereoisomer or mixture of stereoisomers thereof, as well as a pharmaceutically acceptable salt thereof.

Embodiments (A1)

In one embodiment, the Compound of Formula I is that where R5a is hydrogen or alkyl and R5c, R5d, R5e, R5f, and R5g are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound of Formula I is that where R5a is alkyl and R5c, R5d, R5e, R5f, and R5g are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I.

Embodiments (A2)

In another embodiment, the Compound of Formula I is that where R5b is hydrogen, amino, or halo and R5a, R5c, R5d, R5e, R5f, R5g, and R5h are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound of Formula I is that where R5b is halo and R5a, R5c, R5d, R5e, R5f, R5g, and R5h are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound of Formula I is that where R5b is fluoro and R5a, R5c, R5d, R5e, R5f, R5g, and R5h are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound of Formula I is that where R5b is amino; R5a, R5c, R5d, R5e, R5f, R5g, and R5h are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I.

Embodiments (A3)

In another embodiment, the Compound of Formula I is that where R5c is hydrogen or alkyl and R5a, R5d, R5e, R5f, and R5g are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound of Formula I is that where R5c is alkyl and R5a, R5d, R5e, R5f, and R5g are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I.

Embodiments (A4)

In another embodiment, the Compound of Formula I is that where R5h is hydrogen or halo and R5a, R5c, R5d, R5e, R5f, R5g, and R5b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound of Formula I is that where R5h is halo and R5a, R5c, R5d, R5e, R5f, R5g, and R5b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound of Formula I is that where R5h is fluoro and R5a, R5c, R5d, R5e, R5f, R5g, and R5b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I.

Another embodiment of the Invention is directed to a Compound of Formula I(a)


where R1 and R2 are independently as defined in the Summary of the Invention for a Compound of Formula I.

Embodiment (1)

In another embodiment, the Compound of Formula I(a) is that where

  • R1 is phenyl optionally substituted with one, two, or three R6 groups; or
  • R1 is heteroaryl optionally substituted with one, two, or three R7;
  • R2 is heteroaryl substituted with R3, R3a, R3b, R3c, and R3d;
  • R3, R3a, R3b, R3c, and R3d are independently hydrogen; cyano; alkyl; alkenyl; halo; haloalkyl; hydroxyalkyl; alkoxyalkyl; cyanoalkyl; SR12; —S(O)2R20; carboxy; alkoxycarbonyl; halocarbonyl; —NR11R11a; —OR11a; phenyl optionally substituted with one or two groups which are independently alkyl or halo; phenylalkyl optionally substituted with one or two R19; cycloalkyl; cycloalkylalkyl; heterocycloalkyl optionally substituted with one or two groups which are independently alkyl, alkoxycarbonyl, or benzyloxycarbonyl; heterocycloalkylalkyl optionally substituted with one or two groups which are independently alkyl, alkoxycarbonyl, or benzyloxycarbonyl; heteroaryl; heteroarylalkyl; or alkyl substituted with one or two R16; or
  • two of R3, R3a, R3b, R3c, and R3d, when attached to the same carbon, form a cycloalkyl or a heterocycloalkyl; and the other of R3, R3a, R3b, R3c, and R3d are hydrogen;
  • each R6, when R6 is present, is independently nitro; cyano; halo; alkyl; halo; haloalkyl; —OR8a; —NR8R8a; —C(O)NR8R8a; —S(O)2R8; —NR8C(O)R9; —NR8S(O)2R8a; —NHC(O)NHR9; carboxy, —C(O)OR9; or heteroaryl optionally substituted with 1, 2, or 3 R14;
  • each R7, when R7 is present, is independently oxo; nitro; cyano; alkyl; alkenyl; halo; haloalkyl; hydroxyalkyl; alkoxyalkyl; —OR8a; —SR13; —S(O)R13; —S(O)2R13a; —NR8R8a; —C(O)NR8R8a; —NR8C(O)OR9; —NR8C(O)R9; —NR8S(O)2R8a; —NR8C(O)NR8aR9; —C(O)OR9; halocarbonyl; —S(O)2NR8R9; alkylsulfonylalkyl; alkyl substituted with one or two —NR8R8a; alkyl substituted with one or two —NR8C(O)R8a; alkyl substituted with one or two —NR8C(O)OR9; alkyl substituted with one or two —S(O)2R13a; cycloalkyl; cycloalkylalkyl; heterocycloalkyl optionally substituted with one or two groups which are independently alkyl or amino; phenyl; phenylalkyl; heterocycloalkylalkyl; heteroaryl; or heteroarylalkyl;
  • R8, R11, R15, R17, and R18 are independently hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, or haloalkyl;
  • R8a; R11a; and R15a are independently hydrogen; alkyl; alkenyl; alkynyl; haloalkyl; hydroxyalkyl; cyanoalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; alkoxyalkyl; carboxyalkyl; cycloalkyl; cycloalkylalkyl; heterocycloalkyl optionally substituted with one or two groups which are independently alkyl, alkoxycarbonyl, or benzyloxy; heterocycloalkylalkyl optionally substituted with one or two groups which are independently alkyl, alkoxycarbonyl, or benzyloxy; phenyl optionally substituted with one or two groups which are independently halo, alkyl, or alkoxy; phenylalkyl; heteroaryl; or heteroarylalkyl;
  • R9 is hydrogen; alkyl; alkenyl; alkynyl; hydroxyalkyl; alkoxyalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; haloalkyl; hydroxyalkyl substituted with one, two, or three groups which are independently halo, amino, alkylamino, or dialkylamino; alkyl substituted with one or two aminocarbonyl; phenyl; phenylalkyl; cycloalkyl; cycloalkylalkyl optionally substituted with one or two groups which are independently amino or alkyl; heterocycloalkyl optionally substituted with one or two groups which are independently alkyl, alkoxycarbonyl, or benzyloxy; or heterocycloalkylalkyl optionally substituted with one or two groups which are independently alkyl, alkoxycarbonyl, or benzyloxy;
  • R12 is alkyl or phenylalkyl;
  • R13 is alkyl, hydroxyalkyl, or haloalkyl; and
  • R13a is hydroxy, alkyl, haloalkyl, hydroxyalkyl, or heterocycloalkyl optionally substituted with one or two groups which are independently halo, amino, alkylamino, dialkylamino, hydroxy, alkyl, or hydroxyalkyl;
  • each R14, when R14 is present, is independently amino, alkylamino, dialkylamino, acylamino, halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, or phenyl;
  • each R16 is independently —NR11R11a, —NR15S(O)R15a, —OC(O)R17, or —OR18;
  • each R19 is independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; and
  • R20 is amino, alkylamino, dialkylamino, or heterocycloalkyl.

Embodiment (B)

In another embodiment, the Compound of Formula I(a) is that where R1 is heteroaryl optionally substituted with one, two, or three R7 groups; where each R7 independently of each other (when R7 is present) and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, pyrido[2,3-b]pyrazinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-c]pyridinyl, triazolo[1,5-a]pyridinyl, indolyl, 2,3-dihydrobenzofuranyl, benzo[b]thienyl, quinolinyl, benzimidazolyl, indazolyl, 1H-pyrrolo[2,3-b]pyridinyl, pyridinyl, pyrimidinyl, pyridazinyl, thienyl, thiazolyl, benzothiazolyl, imidazopyridinyl, pyrazolopyridinyl, pyrrolopyridinyl, or thiazolopyridinyl, where R1 is optionally substituted with one, two, or three R7; where each R7 independently of each other (when R7 is present) and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (H1)

In another embodiment, the Compound is according to Formula I(a) where R1 is a 9-membered heteroaryl optionally substituted with one, two, or three R7; where each R7 independently of each other (when R7 is present) and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is benzimidazolyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, 3H-imidazo[4,5-c]pyridinyl, indazolyl, 1H-pyrazolo[3,4-b]pyridinyl, indolyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, benzo[d]thiazolyl, thiazolo[4,5-b]pyridinyl, thiazolo[4,5-c]pyridinyl, thiazolo[5,4-c]pyridinyl, or thiazolo[5,4-b]pyridinyl, and R1 is optionally substituted with one, two, or three R7; where each R7 independently of each other (when R7 is present) and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B1)

In another embodiment, the Compound is according to Formula I(a) where R1 is 3H-imidazo[4,5-b]pyridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-c]pyridinyl, or 1H-imidazo[4,5-c]pyridinyl, where R1 is optionally substituted with one, two, or three R7 groups; where each R7 independently of each other (when R7 is present) and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 3H-imidazo[4,5-b]pyridin-5-yl, 1H-imidazo[4,5-b]pyridin-5-yl, 3H-imidazo[4,5-b]pyridin-6-yl, 1H-imidazo[4,5-b]pyridin-6-yl, 3H-imidazo[4,5-c]pyridin-6-yl, 1H-imidazo[4,5-c]pyridin-6-yl, 3H-imidazo[4,5-c]pyridin-5-yl, or 1H-imidazo[4,5-c]pyridin-5-yl, where R1 is optionally substituted with one, two, or three R7 groups; where each R7 independently of each other (when R7 is present) and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 3H-imidazo[4,5-b]pyridin-5-yl, 1H-imidazo[4,5-b]pyridin-5-yl, 3H-imidazo[4,5-b]pyridin-6-yl, 1H-imidazo[4,5-b]pyridin-6-yl, 3H-imidazo[4,5-c]pyridin-6-yl, 1H-imidazo[4,5-c]pyridin-6-yl, 3H-imidazo[4,5-c]pyridin-5-yl, or 1H-imidazo[4,5-c]pyridin-5-yl, where R1 is optionally substituted with one or two R7; each R7, when R7 is present, is independently halo, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl substituted with one or two —NR8R8a, alkyl substituted with one or two —NR8C(O)OR9, —NR8R8a, or —NR8C(O)OR9; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 3H-imidazo[4,5-b]pyridin-5-yl, 1H-imidazo[4,5-b]pyridin-5-yl, 3H-imidazo[4,5-b]pyridin-6-yl, 1H-imidazo[4,5-b]pyridin-6-yl, 3H-imidazo[4,5-c]pyridin-6-yl, 1H-imidazo[4,5-c]pyridin-6-yl, 3H-imidazo[4,5-c]pyridin-5-yl, or 1H-imidazo[4,5-c]pyridin-5-yl, where R1 is optionally substituted with one or two R7; each R7, when R7 is present, is independently halo, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl substituted with one or two —NR8R8a, alkyl substituted with one or two —NR8C(O)OR9, —NR8R8a, or —NR8C(O)OR9; R8 and R8a are independently hydrogen or alkyl; R9 is alkyl, benzyl, or haloalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B2)

In another embodiment, the Compound is according to Formula I(b1) or I(b2)


where R7, when R7 is present, is halo, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl substituted with one or two —NR8R8a, alkyl substituted with one or two —NR8C(O)OR9, —NR8R8a, or —NR8C(O)OR9; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(b1) or I(b2), where R7, when R7 is present, is alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkyl substituted with one or two —NR8C(O)OR9, —NR8R8a, or —NR8C(O)OR9; R8 is hydrogen or alkyl; R8a is hydrogen, alkyl, or haloalkyl; R9 is alkyl or benzyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(b1) or I(b2), where R7, when R7 is present, is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, monofluoromethyl, difluoromethyl, trifluoromethyl, 1-hydroxyethyl, 2-hydroxyethyl, amino, methylamino, ethylamino, methoxycarbonylamino, benzyloxycarbonylamino, aminomethyl, methylaminomethyl, or dimethylaminomethyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B3)

In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is benzo[d]thiazolyl, thiazolo[5,4-b]pyridinyl, thiazolo[5,4-c]pyridinyl, thiazolo[4,5-b]pyridinyl, or thiazolo[4,5-c]pyridinyl, where R1 is optionally substituted with one, two, or three R7 groups; where all other groups and each R7, when R7 is present, are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is benzo[d]thiazol-5-yl, benzo[d]thiazol-6-yl, thiazolo[5,4-b]pyridin-5-yl, thiazolo[5,4-b]pyridin-6-yl, thiazolo[5,4-c]pyridin-6-yl, thiazolo[4,5-b]pyridin-5-yl, thiazolo[4,5-b]pyridin-6-yl, or thiazolo[4,5-c]pyridin-6-yl, where R1 is optionally substituted with one, two, or three R7 groups; where all other groups and each R7, when R7 is present, are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is thiazolo[5,4-b]pyridin-6-yl or thiazolo[4,5-b]pyridin-6-yl optionally substituted with one R7 where R7 is alkyl, —NR8R8a, or —NR8C(O)OR9; and other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is thiazolo[5,4-b]pyridin-6-yl or thiazolo[4,5-b]pyridin-6-yl optionally substituted with one R7 where R7 is —NR8R8a; and other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is thiazolo[5,4-b]pyridin-6-yl or thiazolo[4,5-b]pyridin-6-yl optionally substituted with one R7 where R7 is alkyl, —NR8R8a, or —NR8C(O)OR9; each R8, R8a, and R9, independently of each other, are hydrogen or alkyl; and other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B4)

In another embodiment, the Compound is according to Formula I(c1) or I(c2)


where X1 is N or CH; R7 (when present), R2, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(c1) or I(c2) where X1 is N or CH; R7, when R7 is present, is alkyl, —NR8R8a, or —NR8C(O)R9; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(c1) or I(c2) where X1 is N or CH; R7, when R7 is present, is alkyl, —NR8R8a, or —NR8C(O)R9; each R8 and R8a are independently hydrogen or alkyl and R9 is alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is N or CH; R7, when R7 is present, is C1-3-alkyl, amino, or C1-3-alkylcarbonylamino; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(c1) or I(c2) where X1 is N or CH; R7, when R7 is present, is —NR8R8a where R8 and R8a are independently hydrogen or alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(c1) or I(c2) where X1 is N or CH; R7, when R7 is present, is —NR8R8a where R8 and R8a are independently hydrogen or C1-3-alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B4a)

In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is N; R7 (when present), R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c) where X1 is N; R7, when R7 is present, is alkyl, —NR8R8a, or —NR8C(O)R9; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is N; R7, when R7 is present, is alkyl, —NR8R8a, or —NR8C(O)R9; each R8 and R8a are independently hydrogen or alkyl and R9 is alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is N; R7, when R7 is present, is C1-3-alkyl, amino, or C1-3-alkylcarbonylamino; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is N; R7, when R7 is present, is —NR8R8a; each R8 and R8a are independently hydrogen or alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is N; R7, when R7 is present, is —NR8R8a; each R8 and R8a are independently hydrogen or C1-3-alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B4b)

In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is C; R7 (when present), R2, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is C; R7, when R7 is present, is alkyl, —NR8R8a, or —NR8C(O)R9; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is C; R7, when R7 is present, is alkyl, —NR8R8a, or —NR8C(O)R9; each R8 and R8a are independently hydrogen or alkyl and R9 is alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is C; R7, when R7 is present, is C1-3-alkyl, amino, or C1-3-alkylcarbonylamino; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is C; R7, when R7 is present, is —NR8R8a; each R8 and R8a are independently hydrogen or alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(c1) or I(c2) where X1 is C; R7, when R7 is present, is —NR8R8a; each R8 and R8a are independently hydrogen or C1-3-alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B5)

In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is benzimidazolyl optionally substituted with one, two, or three R7 groups; where all other groups and each R7 independently of each other (when R7 is present) are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is benzimidazolyl optionally substituted with one or two R7 groups; and all other groups and each R7 (when R7 is present) are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is benzimidazolyl optionally substituted with one R7; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B6)

In another embodiment, the Compound of Formula I is according to Formula I(d1) or I(d2)


where R7, when R7 is present, is alkyl, haloalkyl, alkoxyalkyl, —SR13, —NR8R8a, —NR8C(O)R9, —NR8C(O)OR9, —NR8C(O)NR8aR9, cycloalkyl, heterocycloalkyl, or heteroaryl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7, when R7 is present, is alkyl, alkoxyalkyl, —SR13, —NR8R8a, —NR8C(O)R9, —NR8C(O)OR9, cycloalkyl, heterocycloalkyl, or heteroaryl; R8 and R8a are independently hydrogen or alkyl; R9 is alkyl, alkoxyalkyl, or optionally substituted heterocycloalkylalkyl; R13 is alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7, when R7 is present, is alkyl, alkoxyalkyl, —SR13, —NR8R8a, —NR8C(O)R9, —NR8C(O)OR9, cycloalkyl, heterocycloalkyl, or heteroaryl; R8 and R8a are independently hydrogen or alkyl; R9 is alkyl; R13 is alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7, when R7 is present, is C1-3-alkyl, alkoxyalkyl, —SR13, —NR8R8a, —NR8C(O)R9, —NR8C(O)OR9, cycloalkyl, heterocycloalkyl, or heteroaryl; R8 and R8a are independently hydrogen or C1-3-alkyl; R9 is C1-3-alkyl; R13 is C1-3-alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7, when R7 is present, is methyl, ethyl, n-propyl, isopropyl, methoxymethyl, amino, methylamino, ethylamino, isopropylamino, dimethylamino, 3-piperidinylpropylcarbonylamino, methoxycarbonylamino, 2-(methoxy)-ethyloxycarbonylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, piperidinyl, or pyridinyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiment (B7)

In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is C1-3-alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is —NR8R8a; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is —NR8R8a; R8 and R8a are independently hydrogen or alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is —NR8R8a; R8 and R8a are independently hydrogen or C1-3-alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is —NR8C(O)OR9; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is —NR8C(O)OR9; R8 and R9 are independently hydrogen or alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is —NR8C(O)OR9; R8 and R9 are independently hydrogen or C1-3-alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is —SR13; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is haloalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is cycloalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(d1) or I(d2) where R7 is present and is cyclopropyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiment (B8)

In another embodiment, the Compound is according to Formula I(f)


where the R7 at the 2-position is —NR8R8a or —NR8C(O)OR9 and the other R7 is halo; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(f) where the R7 at the 2-position is —NR8R8a or —NR8C(O)OR9 and the other R7 is halo; R8, R8a, and R9 are independently hydrogen or alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(f) where the R7 at the 2-position is —NR8R8a or —NR8C(O)OR9 and the other R7 is halo; R8, R8a, and R9 are independently hydrogen or C1-3-alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(f) where the R7 at the 2-position is methoxycarbonylamino or amino and the other the R7 is fluoro; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiment (B9)

In another embodiment, the Compound is according to Formula I(a) where R1 is a 5-membered heteroaryl, where R1 is optionally substituted with one or two R7; each R7 (when present), and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B10)

In another embodiment, the Compound is according to Formula I(a) where R1 is thiazol-2-yl, thiazol-4-yl, or thiazol-5-yl, where R1 is optionally substituted with one or two R7; each R7 (when present), and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is thiazol-2-yl, thiazol-4-yl, or thiazol-5-yl, where R1 is optionally substituted with one R7; R7, all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B11)

In another embodiment, the Compound is according to Formula I(a) where R1 is thiazol-2-yl, thiazol-4-yl, or thiazol-5-yl, where R1 is optionally substituted with one or two R7; where each R7 (when present), where each R7 is independently alkyl, —NR8C(O)OR9, —C(O)NR8R8a, or —NR8R8a; each R8 and R8a are independently hydrogen or alkyl and R9 is alkyl (in another embodiment each alkyl in R8, R8a, and R9 are C1-3-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is thiazol-2-yl, thiazol-4-yl, or thiazol-5-yl, where R1 is optionally substituted with one or two R7; where each R7 (when present), where each R7 is independently alkyl, —NR8C(O)OR9, —C(O)NR8R8a, or —NR8R8a; each R8 and R8a are independently hydrogen or C1-3-alkyl and R9 is C1-3-alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is thiazol-2-yl, thiazol-4-yl, or thiazol-5-yl, where R1 is optionally substituted with one or two R7; each R7, when R7 is present, is independently methyl, or amino; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is thiazol-2-yl, thiazol-4-yl, or thiazol-5-yl, where R1 is substituted with two R7; where one R7, is alkyl and the other R7—NR8R8a; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B12)

In another embodiment, the Compound is according to Formula I(a) where R1 is thien-2-yl, thien-3-yl, thien-4-yl, or thien-5-yl, where R1 is optionally substituted with one or two R7 groups; where each R7 (when present), and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is thien-2-yl, thien-3-yl, thien-4-yl, or thien-5-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B13)

In another embodiment, the Compound is according to Formula I(a) where R1 is pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, or pyrazol-5-yl, where R1 is optionally substituted with one or two R7 groups; where each R7 (when present), and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, or pyrazol-5-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiment (B14)

In another embodiment, the Compound is according to Formula I(a) where R1 is a 6-membered heteroaryl, where R1 is optionally substituted with one or two R7 groups; where each R7 (when present), and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B15)

In another embodiment, the Compound is according to Formula I(a) where R1 is pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, where R1 is optionally substituted with one or two R7 groups; where each R7 (when present), and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, where R1 is optionally substituted with one R7 where R7 is —NR8R8a; R8 and R8a are independently hydrogen or alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, where R1 is optionally substituted with one R7 where R7 is —NR8R8a; R8 and R8a are independently hydrogen or C1-3-alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is R1 is 2-amino-pyrimidin-5-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B16)

In another embodiment, the Compound is according to Formula I(a) where R1 is pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridin-5-yl, or pyridin-6-yl, where R1 is optionally substituted with one or two R7 groups; where each R7 (when present), and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is pyridinyl where R1 is optionally substituted with one or two R7 where each R7 is independently halo, cyano, alkylsulfonylalkyl, —OR8a, —C(O)NR8R8a, S(O)2OH, —S(O)R13, —S(O)2R13a, —S(O)2NR8R9, —NR8R8a, —NR8C(O)OR9, —NR8C(O)R9, —NR8S(O)2R8a, or heterocycloalkyl optionally substituted with one amino; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B16a)

In another embodiment, the Compound is according to Formula I(a) where R1 is pyridinyl where R1 is optionally substituted with one or two R7 where each R7 is independently halo, cyano, alkylsulfonylalkyl, —OR8a, —C(O)NR8R8a, S(O)2OH, —S(O)R13, —S(O)2R13a, —S(O)2NR8R9, —NR8R8a, —NR8C(O)OR9, —NR8C(O)R9, —NR8S(O)2R8a, heterocycloalkyl optionally substituted with one amino; where

  • each R8 is independently hydrogen, haloalkyl, or alkyl;
  • each R8a is independently hydrogen, alkyl, benzyl, or phenyl which phenyl is optionally substituted with one or two groups which are independently halo or alkyl;
  • each R9 is independently hydrogen; alkyl; hydroxyalkyl; alkoxyalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; haloalkyl; hydroxyalkyl substituted with one, two, or three halo, heterocycloalkylalkyl optionally substituted with one alkyl; heterocycloalkyl optionally substituted with one alkyl; cycloalkylalkyl optionally substituted with one amino; cycloalkyl;
  • R13 is alkyl or hydroxyalkyl;
  • R13a is alkyl; hydroxyalkyl; heterocycloalkyl optionally substituted with one or two groups which are independently halo, amino, alkylamino, dialkylamino, hydroxy, alkyl, or hydroxyalkyl;
    and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B16b)

In another embodiment, the Compound of Formula I is according to Formula I(e)


where each R7 and R2 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(e) where each R7 is independently as defined in embodiment B16a and R2 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B16c)

In another embodiment, the Compound of Formula I is according to Formula I(e1)


where each R7 and R2 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(e) where each R7 is independently as defined in embodiment B16a and R2 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(e1) where the R7 in the 2-position is hydrogen, halo, cyano, alkoxy, alkyl, or —NR8R8a and the R7 in the 3-position is —NR8S(O)2R8a; and R2 and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(e1) where the R7 in the 2-position is hydroxy or —NR8R8a and the R7 in the 3-position is —S(O)R13, —S(O)2R13a, —S(O)2NR8R9; and R2 and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(e1) where the R7 in the 2-position is hydroxy or —NR8R8a and the R7 in the 3-position is —S(O)R13, —S(O)2R13a, —S(O)2NR8R9; R13 is hydroxyalkyl; R13a is alkyl or heterocycloalkyl optionally substituted with one group which is amino, alkyl, hydroxyalkyl, or hydroxy; each R8 and R8a are independently hydrogen or alkyl; R9 is hydrogen, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkyl substituted with one aminocarbonyl, or hydroxyalkyl which is substituted with one amino or 3 halo; and R2 and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B17)

In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is pyridazin-3-yl, pyridazin-4-yl, pyridazin-5-yl, or pyridazin-6-yl, where R1 is optionally substituted with one or two R7 groups; where each R7 (when present), and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is pyridazin-3-yl, pyridazin-4-yl, pyridazin-5-yl, or pyridazin-6-yl, where R1 is optionally substituted with one or two R7 groups where each R7 is independently —NR8R8a; R8 and R8a are independently hydrogen or alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 3-amino-pyridazin-6-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B18)

In another embodiment, the Compound is according to Formula I(a) where R1 is pyrazin-2-yl, pyrazin-3-yl, pyrazin-5-yl, or pyrazin-6-yl, where R1 is optionally substituted with one or two R7 groups; where each R7 (when present), and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is pyrazin-2-yl, pyrazin-3-yl, pyrazin-5-yl, or pyrazin-6-yl, where R1 is optionally substituted with one R7 where R7 is —NR8R8a; R8 and R8a are independently hydrogen or alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 5-amino-pyrazin-2-yl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B19)

In another embodiment, the Compound is according to Formula I(a) where R1 is 1H-pyrrolo[2,3-b]pyridinyl, optionally substituted with one or two R7 groups; where each R7, when R7 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 1H-pyrrolo[2,3-b]pyridin-5-yl, optionally substituted with one or two R7 groups; where each R7, when R7 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 1H-pyrrolo[2,3-b]pyridin-5-yl, optionally substituted with one R7; where the R7, when R7 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 1H-pyrrolo[2,3-b]pyridin-5-yl, optionally substituted with one R7; R7, when R7 is present, is methyl or ethyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B20)

In another embodiment, the Compound is according to Formula I(a) where R1 is indazolyl, optionally substituted with one or two R7 groups; where R7, when R7 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is indazol-5-yl or indazol-6-yl, where R1 is optionally substituted with one or two R7 groups; where R7, when R7 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is indazol-5-yl or indazol-6-yl, where R1 is optionally substituted with one R7; R7, when present, is alkyl or amino; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is indazol-5-yl, indazol-6-yl, or N-methyl-indazol-5-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiment (B21)

In another embodiment, the Compound is according to Formula I(a) where R1 is benzimidazolyl substituted with two R7 groups where each R7 is alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is benzimidazolyl substituted with two R7 groups where each R7 is C1-3-alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B22)

In another embodiment, the Compound is according to Formula I(a) where R1 is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinazolin-2-yl, quinazolin-3-yl, quinazolin-5-yl, quinazolin-6-yl, quinazolin-7-yl, or quinazolin-8-yl, where R1 is optionally substituted with one or two R7 groups; where each R7, when R7 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, quinazolin-2-yl, quinazolin-3-yl, quinazolin-5-yl, quinazolin-6-yl, quinazolin-7-yl, or quinazolin-8-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is quinolin-3-yl or quinazolin-6-yl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B24)

In another embodiment, the Compound is according to Formula I(a) where R1 is 2,3-dihydrobenzofuran-4-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, or 2,3-dihydrobenzofuran-7-yl, where R1 is optionally substituted with one or two R7 groups; where each R7, when R7 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 2,3-dihydrobenzofuran-4-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, or 2,3-dihydrobenzofuran-7-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is 2,3-dihydrobenzofuran-5-yl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B25)

In another embodiment, the Compound is according to Formula I(a) where R1 is indol-1-yl, indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, or indol-7-yl, where R1 is optionally substituted with one or two R7 groups; where each R7, when R7 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is indol-1-yl, indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, or indol-7-yl where R1 is optionally substituted with one R7 where R7 is alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is indol-5-yl optionally substituted with one R7 where R7 is alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B26)

In another embodiment, the Compound is according to Formula I(a) where R1 is [1,2,4]triazolo[1,5-a]pyridin-2-yl, [1,2,4]triazolo[1,5-a]pyridin-5-yl, [1,2,4]triazolo[1,5-a]pyridin-6-yl, [1,2,4]triazolo[1,5-a]pyridin-7-yl, or [1,2,4]triazolo[1,5-a]pyridin-8-yl, where R1 is optionally substituted with one or two R7 groups; where each R7, when R7 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is [1,2,4]triazolo[1,5-a]pyridin-2-yl, [1,2,4]triazolo[1,5-a]pyridin-5-yl, [1,2,4]triazolo[1,5-a]pyridin-6-yl, [1,2,4]triazolo[1,5-a]pyridin-7-yl, or [1,2,4]triazolo[1,5-a]pyridin-8-yl, where R1 is optionally substituted with one R7 where R7 is —NR8R8a; R8 and R8 are independently hydrogen or alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is [1,2,4]triazolo[1,5-a]pyridin-6-yl, or [1,2,4]triazolo[1,5-a]pyridin-7-yl, optionally substituted with one R7 where R7 is amino; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B27)

In another embodiment, the Compound is according to Formula I(g)


where Y is N or CH; and R2 and R7 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment the Compound of Formula I(g) is that where R7, when present, is —NR8R8a or —NR8C(O)R9; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment the Compound of Formula I(g) is that where R7, when present, is —NR8R8a or —NR8C(O)R9; R8 and R8a are independently hydrogen or alkyl; R9 is alkyl or haloalkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment the Compound of Formula I(g) is that where R7, when present, is —NR8R8a or —NR8C(O)R9; R8 and R8a are independently hydrogen or C1-3-alkyl; R9 is C1-3-alkyl or halo-C1-3-alkyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment the Compound of Formula I(g) is that where R7, when present, is amino or trifluoromethylcarbonylamino; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B28)

In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is pyrido[2,3-b]pyrazinyl optionally substituted with one or two R7 groups; where R7 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is unsubstituted pyrido[2,3-b]pyrazinyl where all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (B29)

In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl optionally substituted with one or two R7 groups; where R7 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is unsubstituted 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl where all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (C)

In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is phenyl optionally substituted with one, two, or three R6 groups; where each R6, when R6 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is phenyl optionally substituted with one or two R6 groups; where each R6, when R6 is present, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiments (C1)

In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is phenyl optionally substituted with one, two, or three R6 groups; where each R6 is independently nitro, halo, alkoxy, —OR8a, —S(O)2R8, —NR8R8a, —NR8S(O)2R8a, —NR8C(O)R9, —C(O)NR8R8a, —NR8C(O)NR8aR9, carboxy, alkoxycarbonyl, or heteroaryl optionally substituted with one or two R14; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound of Formula I is according to Formula I(a) where R1 is phenyl optionally substituted with one, two, or three R6 groups; where each R6 is independently —S(O)2R8, —C(O)NR8R8a or heteroaryl optionally substituted with one or two R14; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiment (C2)

In another embodiment, the Compound is according to Formula I(a) where R1 is phenyl optionally substituted with one, two, or three R6 groups; where each R6 is independently nitro, halo, alkoxy, —OR8a, —S(O)2R8, —NR8R8a, —NR8S(O)2R8a, —NR8C(O)R9, —C(O)NR8R8a, —NR8C(O)NR8aR9, carboxy, alkoxycarbonyl, or heteroaryl optionally substituted with one or two R14; each R8 is independently hydrogen or alkyl; each R8a is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; R9 is alkyl; R14, when present, is hydroxyalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1). In another embodiment, the Compound is according to Formula I(a) where R1 is phenyl optionally substituted with one, two, or three R6 groups; where each R6 is independently nitro, halo, alkoxy, —OR8a, —S(O)2R8, —NR8R8a, —NR8S(O)2R8a, —NR8C(O)R9, —C(O)NR8R8a, —NR8C(O)NR8aR9, carboxy, alkoxycarbonyl, or heteroaryl optionally substituted with one or two R14; each R8 is independently hydrogen or C1-3-alkyl; each R8a is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; R9 is C1-3-alkyl; R14, when present, is hydroxyalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

Embodiment (C3)

In another embodiment, the Compound is according to Formula I(a) where R1 is phenyl optionally substituted with one or two R6 groups where each R6 is independently nitro, chloro, methoxy, methylsulfonyl, amino, methylaminocarbonylamino, methylamino, carboxy, methylcarbonylamino, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, 2-monofluoroethylaminocarbonyl, 2,2-difluoroethylaminocarbonyl, 2,2,2-trifluoroethylaminocarbonyl, 1,1,1-trifluoroprop-2-ylaminocarbonyl, cyclopropylaminocarbonyl, pyrrolidinylaminocarbonyl, methoxycarbonyl, imidazolyl, imidazolyl substituted with hydroxymethyl, or pyrazolyl; and R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in any of Embodiments (A1), (A2), (A3), (A4), and (1).

In a Compound as described by any one of Formula I, I(a), I(b1), I(b2), I(c1), I(c2), I(d1), I(d2), I(e1), I(e2), I(f), and I(g), or by any of the above embodiments (1), (A1), (A2), (A3), (A4), (B), (H1), (H2), (B1), (B2), (B3), (B4), (B4a), (B4b), (B5), (B6), (B8), (B9), (B10), (B11), (B12), (B13), (B14), (B15), (B16), (B16a), (B16b), (B16c), (B17), (B18), (B19), (B20), (B21), (B22), (B23), (B24), (B25), (B26), (B27), (C), (C1), (C2), and (C3), R2 can be described according to any of the following embodiments.

Embodiments (D)

In another embodiment, R2 is a 6-membered heteroaryl substituted with R3, R3a, R3b, and R3c; R3, R3a, R3b, and R3c and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D1)

In another embodiment, R2 is pyrimidinyl substituted with R3, R3a, and R3b; where R3, R3a, R3b, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D2)

In another embodiment, R2 is according to Formula (a)


where R3, R3a, and R3b are independently hydrogen; alkyl; halo; hydroxyalkyl; cyanoalkyl; —NR11R11a; —S(O)2R20; optionally substituted cycloalkylalkyl; optionally substituted heterocycloalkyl; optionally substituted phenylalkyl; alkyl substituted with one or two R16; or —OR11a; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3, R3a, and R3b are independently hydrogen; alkyl; halo; hydroxyalkyl; cyanoalkyl; —NR11R11a; —S(O)2R20; cycloalkylalkyl; heterocycloalkyl optionally substituted with one or two alkyl; phenylalkyl optionally substituted with one or two R19; alkyl substituted with one or two R16; or —OR11a; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3, R3a, and R3b are independently hydrogen; alkyl; halo; hydroxyalkyl; cyanoalkyl; —NR11R11a; —S(O)2R20; cycloalkylalkyl; heterocycloalkyl optionally substituted with one or two alkyl; phenylalkyl optionally substituted with one or two R19; alkyl substituted with one or two R16; or —OR11a; each R19 is independently halo, alkyl, haloalkyl, alkoxy, amino, alkylamino, or dialkylamino; each R16 is independently —NR11R11a or —OC(O)R17; R17 is alkyl; each R11 is independently hydrogen, alkyl (in another embodiment each alkyl is C1-3-alkyl), or cycloalkyl; each R11a is independently hydrogen; alkyl (in another embodiment each alkyl is C1-3-alkyl); aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; phenyl; phenyl substituted with one alkoxy; phenylalkyl; heterocycloalkyl; heterocycloalkyl substituted with one or two alkyl; heterocycloalkylalkyl; heterocycloalkylalkyl substituted with one or two alkyl; R20 is amino, alkylamino, dialkylamino, or heterocycloalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3, R3a, and R3b are independently hydrogen; alkyl (in another embodiment alkyl is C1-3-alkyl); phenylalkyl optionally substituted with one or two groups which are independently halo, haloalkyl, alkoxy, amino, alkylamino, or dialkylamino; —NR11R11a; heterocycloalkyl; cycloalkylalkyl; alkyl substituted with one or two R16; or hydroxyalkyl; where each R11 is independently hydrogen or alkyl (in another embodiment each alkyl is C1-3-alkyl); each R11a is independently alkyl (in another embodiment each alkyl is C1-3-alkyl), phenyl optionally substituted with alkoxy, or is heterocycloalkyl optionally substituted with one or two alkyl; each R16 is independently amino, alkylamino, dialkylamino, or cyclopropylamino; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3)

In another embodiment, R2 is according to Formula (a) where R3 is hydrogen, halo, alkyl, cycloalkylalkyl, or phenylalkyl optionally substituted with one or two R19; R3a is hydrogen, alkyl, halo, optionally substituted heterocycloalkyl, or —NR11R11a; and R3b is hydrogen, alkyl, hydroxyalkyl, cyanoalkyl, or alkyl substituted with one or two R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3a)

In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two R19; R3a is alkyl; and R3b is hydrogen, alkyl, hydroxyalkyl, or alkyl substituted with one R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two R19; each R19 is independently halo, alkyl, haloalkyl, alkoxy, amino, alkylamino, or dialkylamino; R3a is alkyl (in another embodiment alkyl is C1-3-alkyl); and R3b is hydrogen, alkyl, hydroxyalkyl, or alkyl substituted with one R16; R16 is amino, alkylamino, dialkylamino, cyclopropylamino, or —OC(O)CH3; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3b)

In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two R19; R3a and R3b are alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two R19; each R19 are independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; R3a and R3b are alkyl (in another embodiment each alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two halo; R3a and R3b are alkyl (in another embodiment each alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two R19; each R19 are independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; R3a and R3b are methyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3c)

In another embodiment, R2 is according to Formula (a) where R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl); R3b is hydrogen, alkyl, or alkyl substituted with one R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 and R3a are alkyl (in another embodiment alkyl is C1-2-alkyl); R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3, R3a, and R3b are alkyl (in another embodiment each alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl); and R3b is alkyl substituted with one R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl); and R3b is alkyl substituted with one R16; R16 is amino, alkylamino, dialkylamino, or cycloalkylamino; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3d)

In another embodiment, R2 is according to Formula (a) where R3 is alkyl; R3a and R3b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is C1-2-alkyl; R3a and R3b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3e)

In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two R19; R3a is alkyl; and R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two R19; each R19 is independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; R3a is alkyl; and R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3f)

In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two R19; R3a is alkyl; and R3b is alkyl substituted with one R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is phenylalkyl optionally substituted with one or two R19; each R19 is independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; R3a is alkyl (in another embodiment alkyl is C1-2-alkyl); and R3b is alkyl substituted with one R16; R16 is amino, alkylamino, dialkylamino, or cycloalkylamino; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3g)

In another embodiment, R2 is according to Formula (a) where R3 is alkyl or phenylalkyl optionally substituted with one or two R19; R3a is alkyl; and R3b is hydrogen, alkyl, or alkyl substituted with R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is alkyl (in another embodiment alkyl is C1-2-alkyl) or phenylalkyl optionally substituted with one or two R19; R3a is alkyl (in another embodiment alkyl is C1-2-alkyl); and R3b is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), or alkyl substituted with R16; R16 is amino, alkylamino, dialkylamino, or cycloalkylamino; each R19 is independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3h)

In another embodiment, R2 is according to Formula (a) where R3 is optionally substituted phenyloxy; R3a is alkyl; and R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is phenyloxy optionally substituted with one or two groups which groups are independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; R3a is alkyl (in another embodiment alkyl is C1-2-alkyl); and R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is phenyloxy; R3a is alkyl (in another embodiment alkyl is C1-2-alkyl); and R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3i)

In another embodiment, R2 is according to Formula (a) where R3 is optionally substituted cycloalkylalkyl; R3a is alkyl; and R3b is hydrogen or alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is cycloalkylalkyl; R3a is alkyl (in another embodiment alkyl is C1-2-alkyl); and R3b is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3j)

In another embodiment, R2 is according to Formula (a) where R3 is alkyl; R3a is phenylalkyl optionally substituted with one or two R19; and R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is alkyl (in another embodiment alkyl is C1-2-alkyl); R3a is phenylalkyl optionally substituted with one or two R19; each R19 is independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; and R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is alkyl (in another embodiment alkyl is C1-2-alkyl); R3a is phenylalkyl; and R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D3k)

In another embodiment, R2 is according to Formula (a) where R3 is alkyl; R3a is —NR11R11a; and R3b is hydrogen or alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is alkyl (in another embodiment alkyl is C1-2-alkyl); R3a is —NR11R11a; R3b is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted phenyl, or optionally substituted phenylalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 is alkyl (in another embodiment alkyl is C1-2-alkyl); R3a is —NR11R11a; R3b is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, heterocycloalkyl, heterocycloalkylalkyl (optionally substituted with one or two alkyl), phenylalkyl, phenyl (optionally substituted with one or two groups which are independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D4)

In another embodiment, R2 is according to Formula (a) where R3a is alkyl (in another embodiment alkyl is C1-2-alkyl), or —NR11R11a; R3 and R3b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D4a)

In another embodiment, R2 is according to Formula (a) where R3a is alkyl (in another embodiment alkyl is C1-2-alkyl), and R3 and R3b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D4b)

In another embodiment, R2 is according to Formula (a) where R3a is —NR11R11a; R3 and R3b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3a is —NR11R11a; R3 and R3b are hydrogen; R11 is hydrogen or alkyl; R11a is optionally substituted phenyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3a is —NR11R11a; R3 and R3b are hydrogen; R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is phenyl optionally substituted with one or two groups which groups are independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D5)

In another embodiment, R2 is according to Formula (a) where R3 and R3a are hydrogen; R3b is —NR11R11a; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 and R3a are hydrogen; R3b is —NR11R11a; R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is optionally substituted phenyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 and R3a are hydrogen; R3b is —NR11R11a; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 and R3a are hydrogen; R3b is —NR11R11a; R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), or optionally substituted phenyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 and R3a are hydrogen; R3b is —NR11R11a; R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), or phenyl optionally substituted with one or two groups which groups are independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3 and R3a are hydrogen; R3b is —NR11R11a; R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), or phenyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D6)

In another embodiment, R2 is according to Formula (a) where R3 is hydrogen; R3a is alkyl (in another embodiment alkyl is C1-2-alkyl) or —NR11R11a; R3b is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D6a)

In another embodiment, R2 is according to Formula (a) where R3 is hydrogen; R3a is alkyl (in another embodiment alkyl is C1-2-alkyl); R3b is hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D6b)

In another embodiment, R2 is according to Formula (a) where R3a—NR11R11a; R3 and R3b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3a is —NR11R11a; R3 and R3b are hydrogen; R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), or optionally substituted phenyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3a is —NR11R11a; R3 and R3b are hydrogen; R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), or phenyl optionally substituted with one or two groups which groups are independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (a) where R3a is —NR11R11a; and R3 and R3b are hydrogen; R11 is hydrogen or alkyl (in another embodiment alkyl is C1-2-alkyl); R11a is hydrogen, alkyl (in another embodiment each alkyl is C1-2-alkyl), or phenyl optionally substituted with one alkoxy; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D6c)

In another embodiment, R2 is according to Formula (a) where R3, R3a, and R3b are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D6d)

In another embodiment, R2 is pyrimidin-2-yl, pyrimidin-4-yl, 5-(phenylmethyl)-6-methyl-pyrimidin-4-yl, 6-(phenylmethyl)-5-methyl-pyrimidin-4-yl, 5-(1-phenylethyl)-6-methyl-pyrimidin-4-yl, 2,6-dimethyl-5-(phenylmethyl)-pyrimidin-4-yl, 5-(phenylmethyl)-6-ethyl-pyrimidin-4-yl, 2-methyl-pyrimidin-4-yl, 5-methyl-pyrimidin-4-yl, 6-methyl-pyrimidin-4-yl, 5,6-dimethyl-pyrimidin-4-yl, 6-isopropyl-pyrimidin-4-yl, 5-methyl-6-ethyl-pyrimidin-4-yl, 5-isopropyl-6-methyl-pyrimidin-4-yl, 5-isoamyl-6-methyl-pyrimidin-4-yl, 5-ethyl-6-isopropyl-pyrimidin-4-yl, 5-methyl-6-isopropyl-pyrimidin-4-yl, 5-(phenylmethyl)-6-chloro-pyrimidin-4-yl, 5-(phenylmethyl)-pyrimidin-4-yl, 5-phenyloxy-6-methyl-pyrimidin-4-yl, 5-(cyclopropylmethyl)-6-methyl-pyrimidin-4-yl, 2-amino-pyrimidin-4-yl, 5-(2-chloro-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(3-chloro-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(4-chloro-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(2-fluoro-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(3-fluoro-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(4-fluoro-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(3,4-difluoro-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(3,5-difluoro-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(3-chloro-5-fluoro-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(1-(3-fluorophenyl)-ethyl)-6-methyl-pyrimidin-4-yl, 2,6-dimethyl-5-(4-fluoro-phenylmethyl)-pyrimidin-4-yl, 5-(2-methyl-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(3-methyl-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(4-methyl-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(4-chloro-3-(dimethylamino)-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(2-methoxy-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(3-methoxy-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(4-methoxy-phenylmethyl)-6-methyl-pyrimidin-4-yl, 2-(phenylamino)-pyrimidin-4-yl, 6-(phenylamino)-pyrimidin-4-yl, 6-(4-methoxy-phenylamino)-pyrimidin-4-yl, 5-methyl-6-(phenylamino)-pyrimidin-4-yl, 5-(2-trifluoromethyl-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(3-trifluoromethyl-phenylmethyl)-6-methyl-pyrimidin-4-yl, 5-(4-trifluoromethyl-phenylmethyl)-6-methyl-pyrimidin-4-yl, or 5-phenylmethyl-6-trifluoromethyl-pyrimidin-4-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D7)

In another embodiment, R2 is pyridinyl substituted with R3, R3a, R3b, and R3c; where R3, R3a, R3b, and R3c and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D7a)

In another embodiment, R2 is pyridinyl substituted with R3, R3a, R3b, and R3c where R3, R3a, R3b, and R3c are independently hydrogen, alkyl, or phenylalkyl optionally substituted with one or two R19; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is pyridinyl substituted with R3, R3a, R3b, and R3c; where R3, R3a, R3b, and R3c are independently hydrogen, alkyl, phenylalkyl, or phenylalkyl substituted with one or two halo; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D7b)

In another embodiment, R2 is pyridinyl substituted with R3, R3a, R3b, and R3c; where R3 is alkyl (in another embodiment alkyl is C1-2-alkyl); R3, R3a, R3b, and R3c are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D7c)

In another embodiment, R2 is pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-amino-pyridin-4-yl, 3-methyl-pyridin-2-yl, 2-methyl-3-(phenylmethyl)-pyridin-4-yl, 3-(2-fluoro-phenylmethyl)-2-methyl-pyridin-4-yl, 3-(3-fluoro-phenylmethyl)-2-methyl-pyridin-4-yl, or 3-(4-fluoro-phenylmethyl)-2-methyl-pyridin-4-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (D7d)

In another embodiment, R2 is according to Formula (b)


where R3, R3a, and R3b are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E)

In another embodiment, R2 is a 10-membered heteroaryl substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is a 10-membered heteroaryl and the 10-membered heteroaryl is quinazolin-2-yl, quinazolin-4-yl, quinazolin-5-yl, quinazolin-6-yl, quinazolin-7-yl, quinazolin-8-yl, pyrido[3,2-d]pyrimidin-4-yl, pyrido[4,3-d]pyrimidin-4-yl, pyrido[3,4-d]pyrimidin-4-yl, pyrido[2,3-d]pyrimidin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 5,6,7,8-tetrahydroquinazolin-4-yl, quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl, isoquinolin-8-yl, thieno[2,3-d]pyrimidin-4-yl, 7H-pyrrolo[2,3-d]pyrimidin-4-yl, 1H-pyrrolo[2,3-b]pyridin-4-yl, 1H-pyrrolo[3,2-c]pyridin-4-yl, thieno[2,3-b]pyridin-4-yl, thieno[3,2-c]pyridin-4-yl, 5,7-dihydrothieno[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[3,2-d]pyrimidin-4-yl, 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl, 6,7-dihydro-5H-pyrrolo[3,2-d]pyrimidin-4-yl, 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl, or 5,6-dihydroquinazolinyl where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E1)

In another embodiment, R2 is quinazolin-2-yl, quinazolin-4-yl, quinazolin-5-yl, quinazolin-6-yl, quinazolin-7-yl, or quinazolin-8-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E2)

In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d are independently hydrogen, halo, alkyl, haloalkyl, alkoxycarbonyl, optionally substituted phenyl, —S(O)2R20, —NR11R11a, or —OR11a; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E2a)

In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3c and R3d are hydrogen and R3, R3a, and R3b are independently cyano, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, alkoxyalkyl, —SR12; —S(O)2R20, —C(O)OR4, halocarbonyl, —NR11R11a, —OR11a, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or alkyl substituted with one or two R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3c and R3d are hydrogen and R3, R3a, and R3b are independently alkyl, halo, or —OR11a; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3c and R3d are hydrogen and R3, R3a, and R3b are independently alkyl, halo, or —OR11a; R11a is hydrogen, alkyl, or alkoxyalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E2b)

In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3b, R3c, and R3d are hydrogen, and R3 and R3a are independently cyano, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, alkoxyalkyl, —SR12, —S(O)2R20, —C(O)OR4, halocarbonyl, —NR11R11a, —OR11a, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or alkyl substituted with one or two R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3b, R3c, and R3d are hydrogen, and R3 and R3a are independently alkyl, halo, —S(O)2R20; —OR11a, or alkyl substituted with one R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3b, R3c, and R3d are hydrogen, and R3 and R3a are independently alkyl, halo, —S(O)2R20; — OR11a, or alkyl substituted with one R16; R11a is hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenyl, cycloalkylalkyl, phenylalkyl, or heteroaryl; R16 is amino, alkylamino, dialkylamino, or cycloalkylamino; R20 is alkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3b, R3c, and R3d are hydrogen, and R3 is —OR11a and R3a is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), or alkyl substituted with one R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3b, R3c, and R3d are hydrogen, and R3 is —OR11a and R3a is hydrogen, alkyl, or alkyl substituted with one R16; R11a is hydrogen or alkyl; R16 is amino, alkylamino, dialkylamino, or cycloalkylamino; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E2c)

In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen and R3 is cyano, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, alkoxyalkyl, —SR12, —S(O)2R20, —C(O)OR4, halocarbonyl, —NR11R11a, —OR11a, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or alkyl substituted with one or two R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen and R3 is alkyl, halo, haloalkyl, alkylsulfonyl, optionally substituted phenyl, carboxy, alkoxycarbonyl, —NR11R11a, alkyl substituted with one R16, or —OR11a; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen and R3 is alkyl, halo, haloalkyl, alkylsulfonyl, phenyl, carboxy, alkoxycarbonyl, —NR11R11a, alkyl substituted with one R16, or —OR11a; R11 is hydrogen or alkyl; R11a is hydrogen, alkyl, alkoxyalkyl, cyanoalkyl, or optionally substituted phenylalkyl; R16 is amino, alkylamino, dialkylamino, or cycloalkylamino; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen and R3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isoamyl, bromo, chloro, fluoro, iodo, trifluoromethyl, methylsulfonyl, phenyl, methoxycarbonyl, ethoxycarbonyl, amino, methylamino, ethylamino, n-propylamino, isopropylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, hydroxy, methoxy, ethyloxy, n-propoxy, isopropoxy, n-butyloxy, sec-butyloxy, isoamyloxy, 2-amino-ethyloxy, 2-(methylamino)-ethyloxy, 2-(dimethylamino)-ethyloxy, 3-amino-propyloxy, 3-(methylamino)-propyloxy, 3-(dimethylamino)-propyloxy, 2-methoxy-ethyloxy, cyanomethyloxy, and benzyloxy; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E2d)

In another embodiment, R2 is quinazolin-4-yl, pyrido[3,2-d]pyrimidin-4-yl, pyrido[4,3-d]pyrimidin-4-yl, pyrido[3,4-d]pyrimidin-4-yl, pyrido[2,3-d]pyrimidin-4-yl, 2-methyl-quinazolin-4-yl, 6-methyl-quinazolin-4-yl, 7-methyl-quinazolin-4-yl, 8-methyl-quinazolin-4-yl, 2-ethyl-quinazolin-4-yl, 2-phenyl-quinazolin-4-yl, 7-(quinolin-2-ylmethyloxy)-8-methoxy-quinazolin-4-yl, 7-(2-dimethylamino-ethyloxy)-8-methoxy-quinazolin-4-yl, 6-(3-dimethylamino-propyloxy)-8-methoxy-quinazolin-4-yl, 7-(cyclopropylmethyloxy)-8-methoxy-quinazolin-4-yl, 6-(cyanomethyloxy)-quinazolin-4-yl, 6-methoxy-quinazolin-4-yl, 7-methoxy-quinazolin-4-yl, 8-methoxy-quinazolin-4-yl, 6-ethoxy-quinazolin-4-yl, 6-(n-propoxy)-quinazolin-4-yl, 6,7-dimethoxy-quinazolin-4-yl, 7,8-dimethoxy-quinazolin-4-yl, 7-isoamyloxy-8-methoxy-quinazolin-4-yl, 5-bromo-quinazolin-4-yl, 6-bromo-quinazolin-4-yl, 7-bromo-quinazolin-4-yl, 8-bromo-quinazolin-4-yl, 5-chloro-quinazolin-4-yl, 6-chloro-quinazolin-4-yl, 7-chloro-quinazolin-4-yl, 8-chloro-quinazolin-4-yl, 5-fluoro-quinazolin-4-yl, 6-fluoro-quinazolin-4-yl, 7-fluoro-quinazolin-4-yl, 8-fluoro-quinazolin-4-yl, 5-iodo-quinazolin-4-yl, 6-iodo-quinazolin-4-yl, 7-iodo-quinazolin-4-yl, 8-iodo-quinazolin-4-yl, 6-bromo-7-chloro-quinazolin-4-yl, 6-iodo-7-chloro-quinazolin-4-yl, 6,8-dichloro-quinazolin-4-yl, 6,7-difluoro-quinazolin-4-yl, 6,8-dibromo-quinazolin-4-yl, 2-methyl-7-methoxy-quinazolin-4-yl, 2-ethyl-7-methoxy-quinazolin-4-yl, 2-methyl-6,7-dimethoxy-quinazolin-4-yl, 6-iodo-7-methoxy-quinazolin-4-yl, 6-chloro-7-methoxy-quinazolin-4-yl, 2-chloro-6-methoxy-quinazolin-4-yl, 6-bromo-7-methoxy-quinazolin-4-yl, 7-bromo-8-methoxy-quinazolin-4-yl, 7-bromo-6-methoxy-quinazolin-4-yl, 6-chloro-7,8-dimethoxy-quinazolin-4-yl, 6,7,8-trimethoxy-quinazolin-4-yl, 6-(2-methoxy-ethyloxy)-quinazolin-4-yl, 6-(benzyoxy)-quinazolin-4-yl, 6-hydroxy-quinazolin-4-yl, 7-(benzyoxy)-8-methoxy-quinazolin-4-yl, 7-hydroxy-8-methoxy-quinazolin-4-yl, 7-(benzyoxy)-6-methoxy-quinazolin-4-yl, 7-hydroxy-6-methoxy-quinazolin-4-yl, 6-iodo-8-methyl-quinazolin-4-yl, 6-methyl-8-bromo-quinazolin-4-yl, 2-ethoxycarbonyl-quinazolin-4-yl, 2-methylamino-quinazolin-4-yl, 2-ethylamino-quinazolin-4-yl, 2-(diethylamino)-quinazolin-4-yl, 2-(trifluoromethyl)-quinazolin-4-yl, 7-(trifluoromethyl)-quinazolin-4-yl, 8-(trifluoromethyl)-quinazolin-4-yl, 6-methylsulfonyl-quinazolin-4-yl, 7-methylsulfonyl-quinazolin-4-yl, quinazolin-4-yl, quinazolin-4-yl, or quinazolin-4-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E2e)

In another embodiment, R2 is pyrido[3,2-d]pyrimidin-4-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E3)

In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, or 6′,8′-dihydro-5′H-spiro[cyclopropane-1,7′-quinazoline]-4′-yl where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, or 6′,8′-dihydro-5′H-spiro[cyclopropane-1,7′-quinazoline]-4′-yl where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E3a)

In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, cyanoalkyl, —SR12, optionally substituted phenyl, —OR11a, alkyl substituted with one R16, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, or optionally substituted heteroaryl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, cyanoalkyl, —SR12, phenyl, —OR11a, alkyl substituted with one R16, heterocycloalkyl (optionally substituted with alkoxycarbonyl, phenylalkyloxycarbonyl, or alkyl), heterocycloalkylalkyl (optionally substituted with one or two halo), or heteroaryl; R12 is alkyl or phenylalkyl; R16 is NR11R11a, —NR15S(O)R15a, —OR18, or —OC(O)R17; R11 is hydrogen or alkyl; each R11a is independently hydrogen, alkyl, haloalkyl, alkoxyalkyl, carboxyalkyl, cycloalkyl, or cycloalkylalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E3b)

In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3a, R3b, R3c, and R3d are hydrogen, and R3 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3a, R3b, R3c, and R3d are hydrogen, and R3 is alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, optionally substituted phenyl, alkyl substituted with one R16, or —SR12; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3a, R3b, R3c, and R3d are hydrogen, and R3 is alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, phenyl, alkyl substituted with one R16, or —SR12; R12 is alkyl or optionally substituted phenylalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E3c)

In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3b, R3c, R3d are hydrogen, and R3 and R3a are independently alkyl, halo, optionally substituted phenyl, —SR12, or alkyl substituted with one R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3b, R3c, R3d are hydrogen, and R3 and R3a are independently alkyl, halo, phenyl, alkyl substituted with one R16, or —SR12; R12 is alkyl or phenyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3b, R3c, R3d are hydrogen, R3 is alkyl (in another embodiment alkyl is C1-2-alkyl), and R3a is alkyl (in another embodiment alkyl is C1-2-alkyl), halo, phenyl, alkyl substituted with one R16, —SR12; or R12 is alkyl or phenyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3b, R3c, R3d are hydrogen, R3 and R3a are alkyl, (in another embodiment each alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3b, R3c, R3d are hydrogen, R3 and R3a are halo; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3b, R3c, R3d are hydrogen, R3 is alkyl (in another embodiment alkyl is C1-2-alkyl), and R3a is hydrogen, alkyl, or alkyl substituted with R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E3d)

In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3c, R3d are hydrogen, and R3, R3a, and R3b are independently alkyl, alkenyl, halo, hydroxyalkyl, cyanoalkyl, alkyl substituted with R16, heterocycloalkyl, or heterocycloalkylalkyl (optionally substituted with one or two halo); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3c, R3d are hydrogen, and R3, R3a, and R3b are independently alkyl, alkenyl, halo, hydroxyalkyl, cyanoalkyl, alkyl substituted with R16, heterocycloalkyl, or heterocycloalkylalkyl (optionally substituted with one or two halo); R16 is NR11R11a where R11 is hydrogen or alkyl and R11a is alkyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or carboxyalkyl; or R16 is —NR15S(O)R15a where R15 and R15a are independently hydrogen or alkyl; or R16 is —OC(O)R17 where R17 is alkyl; R16 is —OR18 where R18 is alkyl or alkoxyalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E3e)

In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3c, R3d are hydrogen, and R3, R3a, and R3b are alkyl (in another embodiment each alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3c, R3d are hydrogen, R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl), and R3b is alkyl substituted with R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3c, R3d are hydrogen, R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl), and R3b is heterocycloalkylalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,6,7,8-tetrahydroquinazolin-4-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl, 5,6-dihydroquinazolin-4-yl, or 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3c, R3d are hydrogen, R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl), and R3b is heterocycloalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E3f)

In another embodiment, R2 is 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6,6-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6-methyl-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 2-(ethylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 2-(phenylmethylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 5-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 6-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl, 5,6,7,8-tetrahydroquinazolin-4-yl, 6-methyl-5,6,7,8-tetrahydroquinazolin-4-yl, 6-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl, 7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl, 7-methyl-7-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl, 6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl, or 7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E4)

In another embodiment, R2 is according to Formula (c)


where m is 0 or 1 and R3, R3a and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (c) where m is 0 or 1 and R3 and R3a, together with the carbon to which they are attached, form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (c) where m is 0 or 1 and R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (c) where m is 0 or 1 and R3 and R3a are halo; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E4a)

In another embodiment, R2 is according to formula (c), m is 1, R3 and R3a are as defined in any of the embodiments (E4d); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E4b)

In another embodiment, R2 is 6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl, 6,6-dichloro-5,6,7,8-tetrahydroquinazolin-4-yl, 6,6-difluoro-5,6,7,8-tetrahydroquinazolin-4-yl, 7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl, 7,7-dichloro-5,6,7,8-tetrahydroquinazolin-4-yl, 7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]-4′-yl, or 6′,8′-dihydro-5′H-spiro[cyclopropane-1,7′-quinazoline]-4′-yl, where R2 is substituted with R3b where R3b is hydrogen, alkyl, or haloalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E4d)

In another embodiment, R2 is according to Formula (d)


where m is 0 or 1; R3, R3a, R3b, and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (d) where m is 0 or 1; R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (d) where m is 0 or 1; R3 and R3a are halo; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (d) where m is 1; R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (d) where m is 1; R3 and R3a are halo; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (d) where m is 1; R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl); R3b is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, heterocycloalkyl (optionally substituted with alkoxycarbonyl, benzyloxycarbonyl, or alkyl), heterocycloalkylalkyl (optionally substituted with one or two halo), or alkyl substituted with one R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (d) where m is 1; R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl); R3b is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, heterocycloalkyl (optionally substituted with alkoxycarbonyl, benzyloxycarbonyl, or alkyl), heterocycloalkylalkyl (optionally substituted with one or two halo), or alkyl substituted with one R16; R16 is —NR11R11a, —NR15S(O)2R15a, —OC(O)R17, or —OR18; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (d) where m is 1; R3 and R3a are alkyl (in another embodiment each alkyl is C1-2-alkyl); R3b is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), cyanoalkyl, or alkyl substituted with one R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment, the Compound is according to Formula I(a), R2 is according to embodiments (E4d) and R1 is according to embodiments (Z)-(Z5).

Embodiments (E5a)

In another embodiment, R2 is according to Formula (e)


where R3, R3a, R3b, R3c, and R3d are positioned on any substitutable carbon of ring (e); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is according to Formula (e) where one of R3, R3a, R3b, R3c, and R3d is hydrogen, alkyl (in another embodiment each alkyl is C1-2-alkyl), or alkyl substituted with one R16 and the other of R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula or as defined in embodiment (1). In another embodiment, R2 is according to Formula (e) where one of R3, R3a, R3b, R3c, and R3d is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), or alkyl substituted with one R16 and the other of R3, R3a, R3b, R3c, and R3d are independently hydrogen or alkyl (in another embodiment each alkyl is C1-2-alkyl); and all other groups are as defined in the Summary of the Invention for a Compound of Formula or as defined in embodiment (1). In another embodiment, R2 is according to Formula (e) where one of R3, R3a, R3b, R3c, and R3d is hydrogen, alkyl (in another embodiment each alkyl is C1-2-alkyl), or alkyl substituted with one R16 and the other of R3, R3a, R3b, R3c, and R3d are alkyl, (in another embodiment each alkyl is C1-2-alkyl); and all other groups are as defined in the Summary of the Invention for a Compound of Formula or as defined in embodiment (1). In another embodiment, R2 is according to Formula (e) where one of R3, R3a, R3b, R3c, and R3d is hydrogen, alkyl (in another embodiment alkyl is C1-2-alkyl), or alkyl substituted with one R16, a second of R3, R3a, R3b, R3c, and R3d is hydrogen, and the other of R3, R3a, R3b, R3c, and R3d are alkyl (in another embodiment each alkyl is C1-2-alkyl); and all other groups are as defined in the Summary of the Invention for a Compound of Formula or as defined in embodiment (1).

In another embodiment, the Compound is according to Formula I(a), R2 is according to embodiments (E5a) and R1 is according to embodiments (Z)-(Z5).

Embodiments (E5b)

In another embodiment, R2 is according to Formula (f)


where R3b is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), cyanoalkyl, or alkyl substituted with one R16; and R3 is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), or alkenyl; and all other groups are as defined in the Summary of the Invention for a Compound of Formula or as defined in embodiment (1).

In another embodiment, the Compound is according to Formula I(a), R2 is according to embodiments (E5b) and R1 is according to embodiments (Z)-(Z5).

Embodiments (E5c)

In another embodiment, R2 is according to Formula (g)


where R3b is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), cyanoalkyl, or alkyl substituted with one R16; and R3 is alkyl (in another embodiment alkyl is C1-3-alkyl), hydroxyalkyl, alkoxyalkyl, or haloalkyl, and is located at the 6- or 7-position of the ring; and all other groups are as defined in the Summary of the Invention for a Compound of Formula or as defined in embodiment (1).

In another embodiment, the Compound is according to Formula I(a), R2 is according to embodiments (E5c) and R1 is according to embodiments (Z)-(Z5).

Embodiments (E5d)

In another embodiment, R2 is according to Formula (h)


where R3, R3a, R3b, and R3c and all other groups are as defined in the Summary of the Invention for a Compound of Formula or as defined in embodiment (1). In another embodiment, R2 is according to Formula (h) where R3b is hydrogen, alkyl, cyanoalkyl, or alkyl substituted with one R16; and all other groups are as defined in the Summary of the Invention for a Compound of Formula or as defined in embodiment (1). In another embodiment, R2 is according to Formula (h) where R3b is hydrogen, cyanoalkyl, alkyl (in another embodiment alkyl is C1-3-alkyl), or alkyl substituted with one R16; R3, R3a, and R3c are independently hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), alkenyl, halo, haloalkyl, hydroxyalkyl, —SR12, optionally substituted phenyl, —OR11a, alkyl substituted with one R16, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, or optionally substituted heteroaryl; and all other groups are as defined in the Summary of the Invention for a Compound of Formula or as defined in embodiment (1).

In another embodiment, the Compound is according to Formula I(a), R2 is according to embodiments (E5d) and R1 is according to embodiments (Z)-(Z5).

Embodiments (E6)

In another embodiment, R2 is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl, or isoquinolin-8-yl, where R2 is substituted with R3, R3a, R3b, and R3c; where R3, R3a, R3b, and R3c and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinolin-4-yl or isoquinolin-1-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E6a)

In another embodiment, R2 is quinolin-4-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl, or isoquinolin-8-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3b, R3c, and R3d are hydrogen; R3 and R3a are independently hydrogen, cyano, alkyl, halo, haloalkyl, —OR11a, phenyl, phenylalkyl optionally substituted with one or two R19, or alkyl substituted with one or two R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is quinolin-4-yl or isoquinolin-1-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3b, R3c, and R3d are hydrogen; R3 and R3a are independently R3 and R3a are independently hydrogen, cyano, alkyl (in another embodiment alkyl is C1-3-alkyl), halo, haloalkyl, —OR11a, phenyl, phenylalkyl optionally substituted with one or two R19, or alkyl substituted with one or two R16; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E6b)

In another embodiment, R2 is 6,7-dimethoxy-quinolin-4-yl, 7-cyano-quinolin-4-yl, 5-fluoro-quinolin-4-yl, 6-fluoro-quinolin-4-yl, 7-fluoro-quinolin-4-yl, 8-fluoro-quinolin-4-yl, 2-phenyl-quinolin-4-yl, 2-methyl-quinolin-4-yl, 2-methyl-7-methoxy-quinolin-4-yl, 2-trifluoromethyl-quinolin-4-yl, or isoquinolin-1-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E7)

In another embodiment, R2 is 5H-pyrrolo[3,2-d]pyrimidin-4-yl, thieno[2,3-d]pyrimidin-4-yl, 7H-pyrrolo[2,3-d]pyrimidin-4-yl, 1H-pyrrolo[2,3-b]pyridin-4-yl, 1H-pyrrolo[3,2-c]pyridin-4-yl, thieno[2,3-b]pyridin-4-yl, or thieno[3,2-c]pyridin-4-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is thieno[2,3-d]pyrimidin-4-yl or 7H-pyrrolo[2,3-d]pyrimidin-4-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is thieno[2,3-d]pyrimidin-4-yl or 7H-pyrrolo[2,3-d]pyrimidin-4-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen; R3 is hydrogen or alkyl (in another embodiment alkyl is C1-3-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is thieno[2,3-d]pyrimidin-4-yl, 5-methyl-thieno[2,3-d]pyrimidin-4-yl, or 7H-pyrrolo[2,3-d]pyrimidin-4-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E8)

In another embodiment, R2 is 5,7-dihydrothieno[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[3,2-d]pyrimidin-4-yl, 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl, 6,7-dihydro-5H-pyrrolo[3,2-d]pyrimidin-4-yl, or 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E8a)

In another embodiment, R2 is 5,7-dihydrothieno[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl, or 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E8b)

In another embodiment, R2 is 5,7-dihydrothieno[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl, or 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 5,7-dihydrothieno[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl, or 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen; R3 is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E8c)

In another embodiment, R2 is 5,7-dihydrothieno[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl, 7-ethyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl, 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl, 6-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl, 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl, 6-p-tolyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl, or 6-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E9)

In another embodiment, R2 is 7H-pyrrolo[2,3-d]pyrimidin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen; R3 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 7H-pyrrolo[2,3-d]pyrimidin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3, R3a, R3b, R3c, and R3d are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E10)

In another embodiment, R2 is 1H-pyrazolo[3,4-d]pyrimidin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen; R3 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 1H-pyrazolo[3,4-d]pyrimidin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3, R3a, R3b, R3c, and R3d are hydrogen; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (E11)

In another embodiment, R2 is 6,7,8,9-tetrahydropyrimido[4,5-b]indolizin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; where R3, R3a, R3b, R3c, and R3d and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 6,7,8,9-tetrahydropyrimido[4,5-b]indolizin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen; R3 is hydrogen or cyano; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, R2 is 6,7,8,9-tetrahydropyrimido[4,5-b]indolizin-4-yl or 10-cyano-6,7,8,9-tetrahydropyrimido[4,5-b]indolizin-4-yl; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment, the Compound is according to any of embodiments (B) and (H1) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (B) and (H1) and R2 is according to any one of embodiments (D2), (D3a)-(D3c), (D3g), (D3i), (E2), (E2b), (E3c), (E4a), (E4d), and (E5a)-(E5d).

In another embodiment, the Compound is according to any of embodiments (B1)-(B2) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (B1) and R2 is according to any one of embodiments (D2), (D3a)-(D3c), (D3g), (D3i), (E2), (E2b), (E3c), (E4a), (E4d), and (E5a)-(E5d).

In another embodiment, the Compound is according to any of embodiments (B3), (B4), (B4a), and (B4b) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (B4a) and R2 is according to any one of embodiments (D2), (D3a)-(D3c), (D3g), (D3i), (E2), (E2b), (E3c), (E4a), (E4d), and (E5a)-(E5d).

In another embodiment, the Compound is according to any of embodiments (B5), (B6), (B7), and (B8) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (B7) and R2 is according to any one of embodiments (D2), (D3a)-(D3c), (D3g), (D3i), (E2), (E2b), (E3c), (E4a), (E4d), and (E5a)-(E5d).

In another embodiment, the Compound is according to any of embodiments (B9)-(B13) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (B9)-(B13) and R2 is according to any one of embodiments (D2), (D3a)-(D3c), (D3g), (D3i), (E2), (E2b), (E3c), (E4a), (E4d), and (E5a)-(E5d).

In another embodiment, the Compound is according to any of embodiments (B16), (B16a)-(B16c), (B17), and (B18) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (B16a)-(B16c) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (B16a)-(B16c) and R2 is according to any one of embodiments (D2), (D3a)-(D3c), (D3g), (D3i), (E2), (E2b), (E3c), (E4a), (E4d), and (E5a)-(E5d).

In another embodiment, the Compound is according to any of embodiments (B19)-(B29) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (B19)-(B29) and R2 is according to any one of embodiments (D2), (D3a)-(D3c), (D3g), (D3i), (E2), (E2b), (E3c), (E4a), (E4d), and (E5a)-(E5d).

In another embodiment, the Compound is according to any of embodiments (C)-(C3) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (C2) and R2 is according to any one of embodiments (D)-(D2), (D3)-(D3k), (D4)-(D4b), (D5), (D6-D6d), (D7)-(D7d), (E)-(E2), (E2a)-(E2e), (E3)-(E3f), (E4)-(E4d), (E5a)-(E5d), (E6)-(E6b), (E7), (E8)-(E8c), and (E9)-(E11). In another embodiment, the Compound is according to any of embodiments (C2) and R2 is according to any one of embodiments (D2), (D3a)-(D3c), (D3g), (D3i), (E2), (E2b), (E3c), (E4a), (E4d), and (E5a)-(E5d).

Embodiments Z

In another embodiment, the Compound is that where R1 is benzimidazol-6-yl optionally substituted with one or two R7; and R7 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is benzimidazol-6-yl optionally substituted with one or two R7; each R7, when present, is alkyl, haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; and R8, R8a, and R9 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is benzimidazol-6-yl optionally substituted with one or two R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; R8 is hydrogen; R8a is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), or haloalkyl; R9 is hydrogen or alkyl (in another embodiment alkyl is C1-3-alkyl).

Embodiments Z1

In another embodiment, the Compound is that where R1 is thiazolo[5,4-b]pyridin-6-yl or thiazolo[4,5-b]pyridin-6-yl optionally substituted with one or two R7; and R7 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is thiazolo[5,4-b]pyridin-6-yl or thiazolo[4,5-b]pyridin-6-yl optionally substituted with one or two R7; each R7, when present, is independently alkyl, haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; and R8, R8a, and R9 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is thiazolo[5,4-b]pyridin-6-yl or thiazolo[4,5-b]pyridin-6-yl optionally substituted with one or two R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; R8 is hydrogen; R8a is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), or haloalkyl; R9 is hydrogen or alkyl (in another embodiment alkyl is C1-3-alkyl).

Embodiments Z2

In another embodiment, the Compound is that where R1 is 1H-imidazo[4,5-b]pyridin-5-yl, 1H-imidazo[4,5-b]pyridin-6-yl, 3H-imidazo[4,5-b]pyridin-5-yl, or 3H-imidazo[4,5-b]pyridin-6-yl where R1 is optionally substituted with R7; and R7 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is 1H-imidazo[4,5-b]pyridin-5-yl, 1H-imidazo[4,5-b]pyridin-6-yl, 3H-imidazo[4,5-b]pyridin-5-yl, or 3H-imidazo[4,5-b]pyridin-6-yl where R1 is optionally substituted with one or two R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; and R8, R8a, and R9 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is 1H-imidazo[4,5-b]pyridin-5-yl, 1H-imidazo[4,5-b]pyridin-6-yl, 3H-imidazo[4,5-b]pyridin-5-yl, or 3H-imidazo[4,5-b]pyridin-6-yl where R1 is optionally substituted with R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; R8 is hydrogen; R8a is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), or haloalkyl; R9 is hydrogen or alkyl (in another embodiment alkyl is C1-3-alkyl).

Embodiments Z3

In another embodiment, the Compound is that where R1 is 1H-imidazo[4,5-c]pyridin-6-yl or 3H-imidazo[4,5-c]pyridin-6-yl optionally substituted with one or two R7; and R7 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is 1H-imidazo[4,5-c]pyridin-6-yl or 3H-imidazo[4,5-c]pyridin-6-yl optionally substituted with one or two R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; and R8, R8a, and R9 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is 1H-imidazo[4,5-c]pyridin-6-yl or 3H-imidazo[4,5-c]pyridin-6-yl optionally substituted with one or two R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; R8 is hydrogen; R8a is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), or haloalkyl; R9 is hydrogen or alkyl (in another embodiment alkyl is C1-3-alkyl).

Embodiments Z4

In another embodiment, the Compound is that where R1 is benzo[d]thiazol-5-yl or benzo[d]thiazol-6-yl optionally substituted with one or two R7; and R7 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is benzo[d]thiazol-5-yl or benzo[d]thiazol-6-yl optionally substituted with one or two R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; and R8, R8a, and R9 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is benzo[d]thiazol-5-yl or benzo[d]thiazol-6-yl optionally substituted with one or two R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, —NR8R8a, —NR8C(O)OR9, or cycloalkyl; R8 is hydrogen; R8a is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), or haloalkyl; R9 is hydrogen or alkyl (in another embodiment alkyl is C1-3-alkyl).

Embodiments Z5

In another embodiment, the Compound is that where R1 is pyridin-3-yl optionally substituted with one or two R7; and R7 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is pyridin-3-yl optionally substituted with one or two R7; each R7, when present, is independently hydrogen, halo, cyano, hydroxy, alkoxy, alkyl, —NR8R8a, —NR8S(O)2R8a, —S(O)R13, —S(O)2R13a, or —S(O)2NR8R9; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is pyridin-3-yl optionally substituted with two R7; one R7 is hydrogen, halo, cyano, alkoxy, alkyl (in another embodiment alkyl is C1-3-alkyl), or —NR8R8a and the other R7 is —NR8S(O)2R8a; or one R7 is hydroxy or —NR8R8a and the other R7 is —S(O)R13, —S(O)2R13a, —S(O)2NR8R9; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R1 is pyridin-3-yl optionally substituted with two R7; one R7 is hydrogen, halo, cyano, alkoxy, alkyl (in another embodiment alkyl is C1-3-alkyl), or —NR8R8a and the other R7 is —NR8S(O)2R8a; or one R7 is hydroxy or —NR8R8a and the other R7 is —S(O)R13, —S(O)2R13a, —S(O)2NR8R9; R13 is hydroxyalkyl; R13a is alkyl or heterocycloalkyl optionally substituted with one group which is amino, alkyl, hydroxyalkyl, or hydroxy; each R8 and R8a are independently hydrogen or alkyl; R9 is hydrogen, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkyl substituted with one aminocarbonyl, or hydroxyalkyl which is substituted with one amino or 3 halo; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (X)

In another embodiment, the Compound is that where R6 is —S(O)2R8, —C(O)NR8R8a or heteroaryl optionally substituted with 1, 2, or 3 R14; and R8, R8a, and R14 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R6 is located in the para position of the phenyl ring to which it is attached; R6 is —C(O)NR8R8a or heteroaryl optionally substituted with 1, 2, or 3 R14; and R8, R8a, and R14 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R6 is located in the para position of the phenyl ring to which it is attached; R6 is —C(O)NR8R8a or heteroaryl optionally substituted with 1, 2, or 3 R14; R8 is hydrogen; R8a is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, or optionally substituted heterocycloalkyl; R14 is alkyl (in another embodiment alkyl is C1-3-alkyl) or alkoxycarbonyl. In another embodiment, the Compound is that where R6 is located in the para position of the phenyl ring to which it is attached; R6 is —C(O)NR8R8a, imidazolyl, or pyrazolyl where the imidazolyl and pyrazolyl are optionally substituted with 1, 2, or 3 R14; R8 is hydrogen; R8a is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, or optionally substituted pyrrolidinyl; R14 is alkyl (in another embodiment alkyl is C1-3-alkyl) or alkoxycarbonyl. In another embodiment, the Compound is that where R6 is located in the meta position of the phenyl ring to which it is attached; R6 is —S(O)2R8; and R8 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is that where R6 is located in the meta position of the phenyl ring to which it is attached; R6 is —S(O)2R8; R8 is alkyl.

Embodiments (J)

In another embodiment, the Compound is according to Formula I(h)


where R1, R3, R3a, and R3b are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound of Formula I(h) is that where R3, R3a, and R3b are as described in any of embodiments (D3a)-(D3c), (D3g), and (D3i); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (J), the Compound of Formula I(h) is that where R1 is according to any of embodiments (Z)-(Z5); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (K), the Compound of Formula I is according to Formula I(j)


where R3, R3a, R3b, and R6 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is of Formula I(j) where R3, R3a, and R3b are as defined in embodiments (E2b); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is of Formula I(j) where R3 is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), halo, —OR11a, or alkyl substituted with one R16; R3 is hydrogen; R3a is hydrogen or alkoxy; and R6 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (K), the Compound of Formula I(j) is that where R6 is according to embodiments (X); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (L), the Compound of Formula I is according to Formula I(k)


where R3, R3a, R3b, and R6 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound of Formula I(h) is that where R3, R3a, and R3b are as described in any of embodiments (D3a)-(D3c), (D3g), and (D3i); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (L), the Compound of Formula I(k) is that where R6 is according to embodiments (X); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (M), the Compound of Formula I is according to Formula I(m)


where R3, R3a, R3b, and R6 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is of Formula I(m) where R3 is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), or alkyl substituted with one R16, —OR11a; R3a is hydrogen or —OR11a; and R3b is hydrogen or alkyl; and R6 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is of Formula I(m) where R3, R3a, and R3b are as defined in embodiments (E6a); and R6 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (M), the Compound of Formula I(m) is that where R6 is according to embodiments (X); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (N), the Compound is of Formula I(n)


where R1 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1); and one of R3, R3a, and R3b and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment of embodiments (N), the Compound is of Formula I(n) where R3, R3a, R3b, and R1 are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is of Formula I(n) where R3, R3a, and R3b is as defined in embodiments (E2b); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is of Formula I(n) where R3 is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), halo, —OR11a, or alkyl substituted with one R16; R3 is hydrogen; R3a is hydrogen or alkoxy; and R1 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is of Formula I(n) where R1 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1); and two of R3, R3a, and R3b are hydrogen and the others are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is of Formula I(n) where R1 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1); and three of R3, R3a, and R3b are hydrogen and the others are independently as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (N), the Compound of Formula I(n) is that where R1 is according to any of embodiments (Z)-(Z5); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (P)

In another embodiment, the Compound is of Formula I(p)


where R1 is as defined in the Summary of the Invention for a Compound of Formula I; and one of R3, R3a, and R3b is hydrogen and the others are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is of Formula I(p) where R1 is as defined in the Summary of the Invention for a Compound of Formula I; and one of R3, R3a, and R3b are hydrogen and the others are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is of Formula I(p) where R1 is as defined in the Summary of the Invention for a Compound of Formula I; and two of R3, R3a, and R3b are hydrogen and the others are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is of Formula I(p) where R3 is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), or alkyl substituted with one R16, —OR11a; R3a is hydrogen or —OR11a; and R3b is hydrogen or alkyl; and R6 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound is of Formula I(p) where R3, R3a, and R3b are as defined in embodiments (E6a); and R6 is as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (P), the Compound of Formula I(p) is that where R1 is according to any of embodiments (Z)-(Z5); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments Q

In another embodiment, the Compound is of Formula I(q)


where R1 is as defined in the Summary of the Invention for a Compound of Formula I; and one of R3, R3a, and R3b is hydrogen and the others are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is of Formula I(q) where R1 is as defined in the Summary of the Invention for a Compound of Formula I; and two of R3, R3a, and R3b are hydrogen and the others are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is of Formula I(q) where R1 is as defined in the Summary of the Invention for a Compound of Formula I; and three of R3, R3a, and R3b are hydrogen and the others are independently as defined in the Summary of the Invention for a Compound of Formula I.

In another embodiment of embodiments (Q), the Compound of Formula I(q) is that where R1 is according to any of embodiments (Z)-(Z5); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiment (F)

In another embodiment, the Compound is of Formula I(r)


where R1, R3, R3a, and R3b are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound of Formula I(r) is where R3 and R3a are alkyl (in another embodiment alkyl is C1-3-alkyl) and R3b is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, or alkyl substituted with one R16; and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound of Formula I(r) is where R3 and R3a are halo and R3b is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, or alkyl substituted with one R16; and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1). In another embodiment, the Compound of Formula I(r) is where R3 and R3a together with the carbon to which they are attached form an optionally substituted cycloalkyl and R3b is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), haloalkyl, or alkyl substituted with one R16; and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

In another embodiment of embodiments (F), the Compound of Formula I(r) is that where R1 is according to any of embodiments (Z)-(Z5); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (S)

In another embodiment, the Compound is of Formula I(s)


where R3 is cyano, alkyl (in another embodiment alkyl is C1-3-alkyl), halo, haloalkyl, —SR12, alkylsulfonyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, carboxy, —C(O)OR4, —NR11R11a, or —OR11a; and R1, R3a, R3b, R4, R11, and R11a are independently as defined in the Summary of the Invention for a Compound of Formula I.

In another embodiment of embodiments (5), the Compound of Formula I(s) is that where R1 is according to any of embodiments (Z)-(Z5); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiments (T)

In another embodiment, the Compound is of Formula I(t)


where R1, R3, R3a, and R3b are independently as defined in the Summary of the Invention for a Compound of Formula I.

In another embodiment of embodiments (T), the Compound of Formula I(t) is that where R1 is according to any of embodiments (Z)-(Z5); and all other groups are as defined in the Summary of the Invention for a Compound of Formula I or as defined in embodiment (1).

Embodiment (U)

In another embodiment, the Compound is according to Formula I(a) where R1 is heteroaryl optionally substituted with one or two R7; each R7, when present, is independently halo, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, —NR8R8a, or —NR8C(O)OR9; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is according to Formula I(a) where R1 is heteroaryl optionally substituted with one or two R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), cycloalkyl, haloalkyl, —NR8R8a, or —NR8C(O)OR9; and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is according to Formula I(a) where R1 is heteroaryl optionally substituted with one or two R7; each R7, when present, is independently alkyl (in another embodiment alkyl is C1-3-alkyl), cycloalkyl, haloalkyl, —NR8R8a, or —NR8C(O)OR9; R8 is hydrogen; R8a is hydrogen, alkyl (in another embodiment alkyl is C1-3-alkyl), or haloalkyl; and R9 is hydrogen or alkyl (in another embodiment alkyl is C1-3-alkyl); and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I.

In another embodiment, the Compound is according to Formula I(a) where R2 is 5,6,7,8-tetrahydroquinolin-4-yl or 5,6,7,8-tetrahydroisoquinolin-1-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; and R1, R3, R3a, R3b, R3c, and R3d are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is according to Formula I(a) where R2 is 5,6,7,8-tetrahydroquinolin-4-yl or 5,6,7,8-tetrahydroisoquinolin-1-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3d is hydrogen; and R1, R3, R3a, R3b, and R3c are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is according to Formula I(a) where R2 is 5,6,7,8-tetrahydroquinolin-4-yl or 5,6,7,8-tetrahydroisoquinolin-1-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3b, R3c, and R3d are hydrogen; and R1, R3, and R3a are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is according to Formula I(a) where R2 is 5,6,7,8-tetrahydroquinolin-4-yl or 5,6,7,8-tetrahydroisoquinolin-1-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3a, R3b, R3c, and R3d are hydrogen; and R1, and R3 are independently as defined in the Summary of the Invention for a Compound of Formula I. In another embodiment, the Compound is according to Formula I(a) where R2 is 5,6,7,8-tetrahydroquinolin-4-yl or 5,6,7,8-tetrahydroisoquinolin-1-yl, where R2 is substituted with R3, R3a, R3b, R3c, and R3d; R3, R3a, R3b, R3c, and R3d are hydrogen; and R1 is as defined in the Summary of the Invention for a Compound of Formula I.

Another embodiment provides a pharmaceutical composition which comprises 1) a compound, as a single stereoisomer or mixture of stereoisomers thereof, according to any one of Formula I, (I(a), I(b1), I(b2), I(c1), I(c2), I(d1), I(d2), I(e), I(e1), I(f), I(g), I(h), I(j), I(k), I(m), I(n), I(p), I(q), I(r), I(s), and I(t) or according to any one of the above embodiments, optionally as a pharmaceutically acceptable salt thereof, and 2) a pharmaceutically acceptable carrier, excipient, and/or diluent thereof.

Another embodiment is a method of treating disease, disorder, or syndrome where the disease is associated with uncontrolled, abnormal, and/or unwanted cellular activities effected directly or indirectly by PI3K and/or mTOR which method comprises administering to a human in need thereof a therapeutically effective amount of a Compound of any of Formula I, (I(a), I(b1), I(b2), I(c1), I(c2), I(d1), I(d2), I(e), I(e1), I(f), I(g), I(h), I(j), I(k), I(m), I(n), I(p), I(q), I(r), I(s), and I(t), a Compound of any one of the above embodiments, or a Compound from Table 1, optionally as a pharmaceutically acceptable salt or pharmaceutical composition thereof. In another embodiment the disease is cancer. In another embodiment, the disease is cancer and the Compound is of Formula I(a) or a Compound from Table 1.

Embodiment (G)

Another embodiment is directed to a method of treating a disease, disorder, or syndrome which method comprises administering to a patient a therapeutically effective amount of a Compound of any of Formula I, (I(a), I(b1), I(b2), I(c1), I(c2), I(d1), I(d2), I(e), I(e1), I(f), I(g), I(h), I(j), I(k), I(m), I(n), I(p), I(q), I(r), I(s), and I(t), a Compound of any one of the above embodiments, or a Compound from Table 1, optionally as a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a Compound of Formula I, (I(a), I(b1), I(b2), I(c1), I(c2), I(d1), I(d2), I(e), I(e1), I(f), I(g), I(h), I(j), I(k), I(m), I(n), I(p), I(q), I(r), I(s), and I(t), a Compound of any one of the above embodiments, or a Compound from Table 1, and a pharmaceutically acceptable carrier, excipient, or diluent. In another embodiment the disease is cancer.

In another embodiment of any of the embodiments of Embodiment (G), the cancer is breast cancer, mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK-transformed anaplastic large cell lymphoma, diffuse large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervical cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, colon cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreatic cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangioma, glioblastoma, or head and neck cancer.

All Compounds in Table 1 were tested in the assays described in Biological Examples 1 and 3.

Embodiments (V)

In one embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 2.0 μM or less and is inactive for mTOR (when tested at a concentration of 3.0 μM or greater) or is selective for PI3K-alpha over mTOR by about 5-fold or greater, about 7-fold or greater, or about 10-fold or greater. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 1.0 μM or less and is inactive for mTOR (when tested at a concentration of 2.0 μM or greater) or is selective for PI3K-alpha over mTOR by about 5-fold or greater, about 7-fold or greater, or about 10-fold or greater. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.5 μM or less and is inactive for mTOR (when tested at a concentration of 2.0 μM or greater) or is selective for PI3K-alpha over mTOR by about 5-fold or greater, about 7-fold or greater, or about 10-fold or greater. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.3 μM or less and is inactive for mTOR (when tested at a concentration of 2.0 μM or greater) or is selective for PI3K-alpha over mTOR by about 5-fold or greater, about 7-fold or greater, or about 10-fold or greater. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.2 μM or less and is selective for PI3K-alpha over mTOR by about 5-fold or greater, about 7-fold or greater, or about 10-fold or greater. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.1 μM or less and is selective for PI3K-alpha over mTOR by about 5-fold or greater, about 7-fold or greater, or about 10-fold or greater. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.05 μM or less and is selective for PI3K-alpha over mTOR by about 5-fold or greater, about 7-fold or greater, or about 10-fold or greater. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.025 μM or less and is selective for PI3K-alpha over mTOR by about 5-fold or greater, about 7-fold or greater, or about 10-fold or greater. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.01 μM or less and is selective for PI3K-alpha over mTOR by about 5-fold or greater, about 7-fold or greater, or about 10-fold or greater.

Embodiments (W)

In one embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 2.0 μM or less and an mTOR-inhibitory activity of about 2.0 μM or less and the selectivity for one of the targets over the other does not exceed 3-fold. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 1.0 μM or less and an mTOR-inhibitory activity of about 1.0 μM or less and the selectivity for one of the targets over the other does not exceed 3-fold. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.5 μM or less and an mTOR-inhibitory activity of about 0.5 μM or less and the selectivity for one of the targets over the other does not exceed 3-fold. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.3 μM or less and an mTOR-inhibitory activity of about 0.3 μM or less and the selectivity for one of the targets over the other does not exceed 3-fold. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.15 μM or less and an mTOR-inhibitory activity of about 0.15 μM or less and the selectivity for one of the targets over the other does not exceed 2-fold. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.1 μM or less and an mTOR-inhibitory activity of about 0.1 μM or less. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.05 μM or less and an mTOR-inhibitory activity of about 0.05 μM or less. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.02 μM or less and an mTOR-inhibitory activity of about 0.02 μM or less. In another embodiment the Compound of the Invention has an PI3K-alpha-inhibitory activity of about 0.01 μM or less and an mTOR-inhibitory activity of about 0.01 μM or less.

In another embodiment, Compounds of the invention are also useful as inhibitors of PI3Kα and/or mTOR in vivo for studying the in vivo role of PI3Kα and/or mTOR in biological processes, including the diseases described herein. Accordingly, the invention also comprises a method of inhibiting PI3Kα and/or mTOR in vivo comprising administering a compound or composition of the invention to a mammal.

Representative Compounds

Representative compounds of Formula I are depicted below. The examples are merely illustrative and do not limit the scope of the invention in any way. Compounds of the invention are named according to systematic application of the nomenclature rules agreed upon by the International Union of Pure and Applied Chemistry (IUPAC), International Union of Biochemistry and Molecular Biology (IUBMB), and the Chemical Abstracts Service (CAS). Specifically, names in Table 1 were generated using ACD/Labs naming software 8.00 release, product version 8.08 or later.

Cmpd No. Structure Name 1 7-(2-methyl-1H-benzimidazol- 6-yl)-4-quinazolin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepine 2 7-(2-methyl-1H-benzimidazol- 6-yl)-4-pyrimidin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 3 4-(7-iodoquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 4 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(2-methylquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 5 ethyl 4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]quinazoline-2- carboxylate 6 N,N-diethyl-4-[7-(2-methyl- 1H-benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]quinazolin-2-amine 7 4-(2,6-diphenylpyrimidin-4- yl)-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 8 4-[6,7- bis(methyloxy)quinazolin-4- yl]-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydr-1,4-benzoxazepine 9 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 10 7-(2-methyl-1H-benzimidazol- 6-yl)-4-{6-(methyloxy)-7- [(phenylmethyl)oxy]quinazolin- 4-yl}-2,3,4,5-tetrahydro-1,4- benzoxazepine 11 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 12 4-(6-bromoquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 13 4-(6-chloroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 14 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(8-methylquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 15 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(6-methylquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 16 4-(6-iodoquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 17 4-(6-fluoroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 18 4-(7-fluoroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 19 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[8- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 20 4-(7-chloroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 21 4-(8-chloroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 22 4-(7-bromoquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 23 4-(6,7-difluoroquinazolin-4- yl)-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 24 4-(6-bromo-7- chloroquinazolin-4-yl)-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 25 4-(8-bromoquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 26 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(7-methylquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 27 4-(8-fluoroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 28 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[8- (trifluoromethyl)quinazolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine 29 4-(8-bromo-6- methylquinazolin-4-yl)-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 30 4-[7-bromo-8- (methyloxy)quinazolin-4-yl]- 7-(2-methyl-1H-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 31 4-[7-bromo-6- (methyloxy)quinazolin-4-yl]- 7-(2-methyl-1H-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 32 4-(6,8-dichloroquinazolin-4- yl)-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 33 4-[2-chloro-6- (methyloxy)quinazolin-4-yl]- 7-(2-methyl-1H-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 34 4-[7,8- bis(methyloxy)quinazolin-4- yl]-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 35 4-(7-chloro-6-iodoquinazolin- 4-yl)-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 36 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[7- (trifluoromethyl)quinazolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine 37 4-[6-iodo-7- (methyloxy)quinazolin-4-yl]- 7-(2-methyl-1H-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 38 4-[6-chloro-7- (methyloxy)quinazolin-4-yl]- 7-(2-methyl-1H-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 39 7-(2-methyl-1H-benzimidazol- 6-yl)-4-{8-(methyloxy)-7- [(phenylmethyl)oxy]quinazolin- 4-yl}-2,3,4,5-tetrahydro-1,4- benzoxazepine 40 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[7- (methylsulfonyl)quinazolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine 41 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[5-methyl-6- (phenylmethyl)pyrimidin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine 42 4-[6-chloro-7,8- bis(methyloxy)quinazolin-4- yl]-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 43 4-[6-bromo-7- (methyloxy)quinazlolin-4-yl]- 7-(2-methyl-1H-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 44 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(5-methylpyrimidin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 45 7-(2-methyl-1H-benzimidazol- 6-yl)-4-thieno[2,3- d]pyrimidin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 46 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 47 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(5-methylthieno[2,3- d]pyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 48 4-(5,6-dimethylpyrimidin-4- yl)-7-(2-methyl-1H- benimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 49 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[2-(methylthio)-6,7- dihydro-5H- cyclopenta[d]pyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 50 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6- (methylsulfonyl)quinazolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine 51 4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-6,7,8,9- tetrahydropyrimido[4,5- b]indolizine-10-carbonitrile 52 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(1H-pyrazolo[3,4- d]pyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 53 7-(2-methyl-1H-benzimidazol- 6-yl)-4-{2- [(phenylmethyl)thio]-6,7- dihydro-5H- cyclopenta[d]pyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepine 54 4-[2-(ethylthio)-6,7-dihydro- 5H-cyclopenta[d]pyrimidin-4- yl]-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 55 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6-methyl-5- (phenylmethyl)pyrimidin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine 56 4-(6-ethyl-5-methylpyrimidin- 4-yl)-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 57 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6,7,8- tris(methyloxy)quinazolin-4- tris(methyloxy)quinazolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine 58 4-(5,6-diethylpyrimidin-4-yl)- 7-(2-methyl-1H-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 59 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6-(1- methylethyl)pyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 60 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[7-(phenylmethyl)- 5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-4-yl]-2,3,4,5- tetrahydro-1,4-benzoxazepine 61 4-[5-ethyl-6-(1- methylethyl)pyrimidin-4-yl]- 7-(2-methyl-1H-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 62 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[5-methyl-6-(1- methylethyl)pyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 63 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(7-methyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 64 4-(5-ethyl-6-methylpyrimidin- 4-yl)-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 65 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 66 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6-methyl-5-(1- methylethyl)pyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 67 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6-methyl-5-(2- methylpropyl)pyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 68 4-(6-ethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 69 4-[5-(cyclopropylmethyl)-6- methylpyrimidin-4-yl]-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 70 4-[6-ethyl-5- (phenylmethyl)pyrimidin-4- yl]-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 71 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6-methyl-2- (methylthio)-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 72 4-{5-[(3- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 73 4-{5-[(3- chlorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 74 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6-methyl-5-(1- phenylethyl)pyrimidin-4-yl)]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 75 4-(5,7-dihydrothieno[3,4- d]pyrimidin-4-yl)-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 76 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(6-methyl-6,7-dihydro- 5H-cyclopenta[d]pyrimidin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 77 5-methyl-6-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepine- 4(5H)-yl]-N-phenylpyrimidin- 4-amine 78 7-(2-methyl-1H-benzimidazol- 6-yl)-4-{6-methyl-5-[(4- methylphenyl)methyl]pyrimidin- 4-yl}-2,3,4,5-tetrahydro-1,4- benzoxazepine 79 4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 80 4-{5-[(4- chlorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 81 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(6-methyl-5-{[3- (methyloxy)phenyl]methyl} pyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 82 7-(2-methyl-1H-benzimidazol- 6-yl)-4-{6-methyl-5-[(3- methylphenyl)methyl]pyrimidin- 4-yl}-2,3,4,5-tetrahydro-1,4- benzoxazepine 83 4-{5-[(3-chloro-5- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 84 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(6-methyl-5-{[2- (methyloxy)phenyl]methyl} pyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 85 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(2- methylpyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 86 7-(2-methyl-1H-benzimidazol- 6-yl)-4-{6-methyl-5-[(2- methylphenyl)methyl]pyrimidin- 4-yl}-2,3,4,5-tetrahydro-1,4- benzoxazepine 87 4-(6-cyclopropyl-6,7-dihydro- 5H-pyrrolo[3,4-d]pyrimidin-4- yl)-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 88 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6-(4-methylphenyl)- 6,7-dihydro-5H-pyrrolo[3,4- d]pyrimidin-4-yl]-2,3,4,5- tetrahydro-1,4-benzoxazepine 89 4-{5-[(3,4- difluorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 90 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(6-methyl-5-{[4- (trifluoromethyl)phenyl]methyl} pyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 91 4-(5-[(3,5- difluorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 92 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(6-methyl-5-{[3- (trifluoromethyl)phenyl]methyl} pyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 93 2-chloro-N,N-dimethyl-5-({4- methyl-6-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyrimidin-5- yl}methyl)aniline 94 4-{5-[1-(3- fluorophenyl)ethyl]-6- methylpyrimidin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 95 4-(7,7-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 96 4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyrimidin-2-amine 97 4-{5-[(4- fluorrophenyl)methyl]-2,6- dimethylpyrimidin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 98 7-(2-methyl-1H-benzimidazol- 6-yl)-4-quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 99 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[2- (trifluoromethyl)quinolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine 100 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(2-phenylquinolin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 101 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[2-methyl-3- (phenylmethyl)pyridin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 102 4-{3-[(4- fluorophenyl)methyl]-2- methylpyridin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 103 4-{3-[(3- fluorophenyl)methyl]-2- methylpyridin-4-yl}-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 104 7-(2-methyl-1H-benzimidazol- 6-yl)-4-pyridin-2-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 105 4-isoquinolin-1-yl-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 106 7-(2-methyl-1H-benzimidazol- 6-yl)-4-pyrimidin-2-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 107 methyl -6[(4-pyrimidin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-yl]carbamate 108 methyl {6-[4-(2- methylquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- benzimidazol-2-yl}carbamate 109 methyl [6-(4-quinazolin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-yl]carbamate 110 methyl {6-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- yl}carbamate 111 methyl (6-{4-[6,7- bis(methyloxy)quinazolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-yl)carbamate 112 methyl (6-{4-[6- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-yl)carbamate 113 methyl [6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-yl]carbamate 114 methyl [6-(4-quinolin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-yl]carbamate 115 methyl [1-methyl-5-(4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl)-1H-benzimidazol-2- yl]carbamate 116 1-methyl-5-(4-quinolin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-amine 117 methyl [1-methyl-6-(4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl)-1H-benzimidazol-2- yl]carbamate 118 2-(methyloxy)ethyl [6-(4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl)-1H-benzimidazol-2- yl]carbamate 119 methyl (6-{4-[6,7- bis(methyloxy)quinolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-yl)carbamate 120 4-piperidin-1-yl-N-[6-(4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl)-1H-benzimidazol-2- yl]butanamide 121 methyl [6-(4-isoquinolin-1-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-yl]carbamate 122 methyl {6-[4-(3- methylpyridin-2-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- yl}carbamate 123 7-(1H-benzimidazol-6-yl)-4- quinazolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 124 5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1,3- thiazol-2-amine 125 4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(2- methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzodiazepine 126 7-(1H-benzimidazol-6-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 127 7-(1-ethyl-1H-benzimidazol- 5-yl)-4-quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 128 7-(2-methyl-1,3-benzothiazol- 5-yl)-4-quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 129 7-(1,3-benzothiazol-5-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 130 7-(1-methyl-1H-benzimidazol- 5-yl)-4-quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzodiazepine 131 4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-[4- (1H-imidazol-2-yl)phenyl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 132 4-quinolin-4-yl-7-quinoxalin- 6-yl-2,3,4,5-tetrahydro-1,4- benzoxazepine 133 7-(1-methyl-1H-indol-5-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzodiazepine 134 N,N-dimethyl-3-(4-quinolin-4- yl-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)benzamide 135 7-(2,3-dihydro-1-benzofuran- 5-yl)-4-quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 136 7-(1H-indazol-6-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 137 7-(1H-pyrazol-4-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 138 7-(1H-indazol-5-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 139 7-(1-methyl-1H-indazol-5-yl)- 4-quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 140 5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 141 6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,2,4]triazolo[1,5- a]pyridin-2-amine 142 4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(1H- imidazo[4,5-b]pyridin-6-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 143 6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)quinazolin- 2-amine 144 6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)imidazo[1,2-a]pyrimidin-2- amine 145 6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)imidazo[1,2-a]pyridin-2- amine 146 7-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,2,4]triazolo[1,5- a]pyridin-2-amine 147 5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[4,5-b]pyridin- 2-amine 148 5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1,3- benzothiazol-2-amine 149 6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)pyridazin- 3-amine 150 4-{5-[(4- fluorrophenyl)methyl]-6- methylpyrimidin-4-yl}-7-(1,3- thiazol-5-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 151 5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)pyrazin-2- amine 152 4-(7,7-dimethyl-5,6,7,8- tetrahydroquinoazlin-4-yl)-7- (2-methyl-1,3-thiazol-5-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 153 5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)pyrimidin- 2-amine 154 5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-4-methyl- 1,3-thiazol-2-amine 155 6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-N- methylpyridine-3- carboxamide 156 5-[4-(7,7-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-4-methyl- 1,3-thiazol-2-amine 157 4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-6- (methyloxy)quinazolin-7-ol 158 4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]quinazolin-6-ol 159 4-[6-(ethyloxy)quinazolin-4- yl]-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 160 ({4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]quinazolin-6- yl}oxy)acetonitrile 161 N,N-dimethyl-3-({4-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]quinazolin-6- yl}oxy)propan-1-amine 162 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[6- (propyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 163 7-(2-methyl-1H-benzimidazol- 6-yl)-4-(6-{[2- (methyloxy)ethyl]oxy}quinazolin- 4-yl)-2,3,4,5-tetrahydro- 1,4-benzoxazepine 164 4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4-(5H)-yl]-8- (methyloxy)quinazolin-7-ol 165 N,N-dimethyl-2-({4-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-8- (methyloxy)quinazolin-7- yl}oxy)ethanamine 166 7-(2-methyl-1H-benzimidazol- 6-yl)-4-{8-(methyloxy)-7-[(2- methylpropyl)oxy]quinazolin- 4-yl}-2,3,4,5-tetrahydro-1,4- benzoxazepine 167 7-(2-methyl-1H-benzimidazol- 6-yl)-4-{8-(methyloxy)-7- [(quinolin-2- ylmethyl)oxy]quinazolin-4- yl}-2,3,4,5-tetrahydro-1,4- benzoxazepine 168 4-{7- [(cyclopropylmethyl)oxy]-8- (methyloxy)quinazolin-4-yl}- 7-(2-methyl-1H-benzimidazol- 6-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 169 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(5- methylpyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 170 4-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)benzamide 171 4-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-N- methylbenzamide 172 N-cyclopropyl-4-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)benzamide 173 4-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-N-[(3S)- pyrrolidin-3-yl]benzamide 174 N-(2,2-difluoroethyl)-4-(4-{5- [(4-fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)benzamide 175 methyl [6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- imidazo[4,5-b]pyridin-2- yl]carbamate 176 6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- imidazo[4,5-b]pyridin-2- amine 177 6-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 178 6-[4-(6-ethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 179 6-[4-(7-methyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 180 6-{4-[6,7- bis(methyloxy)quinazolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- amine 181 6-[4-(6-brromoquinazolin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 182 6-{4-[6- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- amine 183 6-[4-(6-iodoquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 184 6-{4-[7-bromo-6- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- amine 185 6-[4-(6-bromo-7- chloroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 186 6-[4-(6-chloroquinazolin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 187 6-[4-(6-fluoroquinazolin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 188 6-{4-[6,7- bis(methyloxy)quinolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- amine 189 6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-amine 190 6-(4-quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl)-1H-benzimidazol-2- amine 191 6-{4-[6,7- bis(methyloxy)quinolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 192 N-ethyl-6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-amine 193 N-(2-fluoroethyl)-5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-amine 194 5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-3H- imidazo[4,5-b]pyridin-2- amine 195 N,N-dimethyl-6-(4-quinolin-4- yl-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-amine 196 7-{2-[(methyloxy)methyl]- 1H-benzimidazol-6-yl}-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 197 7-(2-propyl-1H-benzimidazol- 6-yl)-4-quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 198 7-(2-cyclopentyl-1H- benzimidazol-6-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 199 7-(2-cyclopropyl-1H- benzimidazol-6-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 200 7-(2-cyclohexyl-1H- benzimidazol-6-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 201 7-(2-azetidin-3-yl-1H- benzimidazol-6-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1H-benzoxazepine 202 7-(2-piperidin-2-yl-1H- benzimidazol-6-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 203 7-[2-(1-methylethyl)-1H- benzimidazol-6-yl]-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 204 4-quinolin-4-yl-7-(3-thienyl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 205 7-quinolin-3-yl-4-quinolin-4- yl-2,3,4,5-tetrahydro-1,4- benzoxazepine 206 7-(1-benzothien-2-yl)-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 207 7-[2-(methylthio)-1H- benzimidazol-6-yl]-4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 208 N-ethyl-6-(4-quinolin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-amine 209 N-(1-methylethyl)-6-(4- quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl)-1H-benzimidazol-2- amine 210 methyl (6-{4-[6,7- bis(methyloxy)quinolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- yl)carbamate 211 4-(7-ethyl-5,6,7,8- tetrahydropyrido[3,4- d]pyrimidin-4-yl)-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 212 {5-[4-(4-pyrido[3,2- d]pyrimidin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl)phenyl]-1H-imidazol-2- yl}methanol 213 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- [4-(1H-imidazol-2-yl)phenyl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 214 7-(2,4-dimethyl-1H- benzimidazol-6-yl)-4- pyrido[3,2-d]pyrimidin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepine 215 6-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2- fluoroethyl)-1H-benzimidazol- 2-amine 216 6-(4-{5-[(4- fluorophenyl)merthyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- imidazo[4,5-c]pyridin-2-amine 217 6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 218 6-[4-(6-methylquinazolin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazpin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 219 7-(1H-benzimidazol-6-yl)-4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 220 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-ethyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 221 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (1H-imidazo[4,5-b]pyridin-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 222 7-(1-methyl-1H-pyrrolo[2,3- b[pyridin-5-yl)-4-quinolin-4- yl-2,3,4,5-tetrahydro-1,4- benzoxazepine 223 7-(1-ethyl-1H-pyrrolo[2,3- b]pyridin-5-yl)-4-quinolin-4- yl-2,3,4,5-tetrahydro-1,4- benzoxazepine 224 7-(2-cyclopropyl-3H- imidazo[4,5-b]pyridin-6-yl)-4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 225 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-propyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 226 5-(4-quinolin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl)pyridin-2-amine 227 6-(4-pyrido[3,2-d]pyrimidin- 4-yl-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- imidazo[4,5-b]pyridin-2- amine 228 N-ethyl-6-[4-(2- methylquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-amine 229 7-[2-(difluoromethyl)-3H- imidazo[4,5-b]pyridin-6-yl]-4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 230 N-ethyl-6-(4-pyrimidin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- imidazo[4,5-b]pyridin-2- amine 231 (2E)-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2- iminopyrimidin-1(2H)-ol 232 7-(1H-benzimidazol-6-yl)-4- (2-phenylquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 233 6-[4-(2-phenylquinazolin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- benzimidazol-2-amine 234 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 235 methyl {6-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- benzimidazol-2-yl}carbamate 236 6-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- benzimidazol-2-amine 237 N-ethyl-6-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 238 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- [2-(fluoromethyl)-3H- imidazo[4,5-b]pyridin-6-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 239 N-methyl-4-(4-quinolin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)benzamide 240 7-[4-(1H-benzimidazol-2- yl)phenyl]-4-[2-methyl-7- (methyloxy)quinoazlin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 241 4-(7-fluoroquinolin-4-yl)-7-(2- methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 242 4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]quinolin-7- carbonitrile 243 N-ethyl-4-(4-quinolin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)benzamide 244 N-propyl-4-(4-quinolin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)benzamide 245 4-(6-ethyl-5-methylpyrimidin- 4-yl)-7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 246 N-ethyl-6-[4-(2- methylquinolin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 247 N-ethyl-6-{4-[2-methyl-7- (methyloxy)quinolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 248 6-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl][1,3]thiazolo[5,4-b]pyridin- 2-amine 249 5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- indazol-3-amine 250 N-ethyl-6-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- imidazo[4,5-b]pyridin-2- amine 251 7-[4-(1H-imidazol-2- yl)phenyl]-4-(2- methylquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 252 1-{6-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3H- imidazo[4,5-b]pyridin-2- yl}ethanol 253 4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-N-phenylpyrimidin- 2-amine 254 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-ethyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 255 6-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-ethyl- 1H-benzimidazol-2-amine 256 7-[4-(1H-imidazol-2- yl)phenyl]-4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 257 4-(5,6-dimethylpyrimidin-4- yl)-7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 258 7-(2-methyl-1H-benzimidazol- 6-yl)-4-[2-methyl-7- (methyloxy)quinoazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 259 6-{4-[6,7- bis(methyloxy)quinazolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-N-ethyl- 1H-benzimidazol-2-amine 260 N-ethyl-6-[4-(2- ethylquinazolin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 261 6-{4-[6,7- bis(methyloxy)quinolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-N-ethyl- 1H-benzimidazol-2-amine 262 4-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyridin-2-amine 263 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (1H-pyrazolo[3,4-b]pyridin-5- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 264 6-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinbazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-ethyl- 1H-imidazo[4,5-b]pyridin-2- amine 265 7-[2-(difluoromethyl)-1H- benzimidazol-5-yl]-4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoazepine 266 5-[4-(2-methylquinazolin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 267 4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 7-(1H-pyrrolo[2,3-b]pyridin- 5-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 268 N-ethyl-6-[4-(7- fluoroquinolin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 269 4-{7-[2-(ethylamino)-1H- benzimidazol-6-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-N- methylquinazolin-2-amine 270 N-ethyl-4-{7-[2-(ethylamino)- 1H-benzimidazol-6-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}quinazolin-2-amine 271 N-ethyl-6-{4-[2-methyl-6,7- bis(methyloxy)quinazolin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 272 4-[6,7- bis(methyloxy)quinolin-4-yl]- 7-[4-(1H-imidazol-2- yl)phenyl]-2,3,4,5-tetrahydro- 1,4-benzoxazepine 273 5-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}pyridin-2- amine 274 7-(1H-indazol-5-yl)-4-[2- methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 275 N-ethyl-6-{4-[6- (phenylamino)pyrimidin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 276 N-ethyl-6-[4-(6-{[4- (methyloxy)phenyl]amino} pyrimidin-4-yl)-2,3,4,5- tetrahydro-1H-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 277 N-ethyl-6-(4-pyrimidin-4-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-amine 278 N-ethyl-6-{4-[6- (methyloxy)quinolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 279 N-ethyl-6-{4-[2-ethyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 280 7-(1H-benzimidazol-6-yl)-4- [2-methyl-7- (methyloxy)quinoazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 281 N-ethyl-6-[4-(7- fluoroquinazolin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 282 N-ethyl-6-[4-(8- fluoroquinolin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 283 N-ethyl-6-[4-(6- fluoroquinolin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 284 N-ethyl-6-[4-(6-{[3- (methyloxy)phenyl]amino} pyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 285 4-{7-[2-(ethylamino)-1H- benzimidazol-6-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-2- methylquinazolin-2-ol 286 5-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}pyrimidin- 2-amine 287 N-ethyl-6-{4-[5-methyl-6- (phenylamino)pyrimidin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 288 N-ethyl-6-{4-[7-(ethyloxy)-2- methylquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 289 6-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- amine 290 N-ethyl-6-[4-(2,6,6-trimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- amine 291 N-ethyl-6-{4-[7- (methyloxy)quinolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 292 5-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1,3- thiazol-2-amine 293 N-(5-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1,3- thiazol-2-yl)acetamide 294 7-(1,3-benzothiazol-6-yl)-4- [2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 295 N-ethyl-6-[4-(7-fluoro-2- methylquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- benzimidazol-2-amine 296 5-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1,3- dihydro-2H-benzimidazol-2- one 297 (1R)-1-(6-{4-[(7S)-7-ethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- yl)ethanamine 298 (1S)-1-(6-{4-[(7S)-7-ethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- yl)ethanamine 299 (2R)-3-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)-2-methylpropan- 1-ol 300 (2R)-N-({6,6-dimethyl-4-[7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)butan-2-amine 301 (2S)-3-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)-2-methylpropan- 1-ol 302 (2S)-3-[(2-amino-5-{4-[7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazolin-7-yl}pyridin-3- yl)sulfinyl]-2-methylpropan-1- ol 303 (2S)-3-[(2-amino-5-{4-[7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}pyridin-3- yl)sulfonyl]-2-methylpropan- 1-ol 304 (2S)-N-({6,6-dimethyl-4-[7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)butan-2-amine 305 (3R)-1-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)pyrrolidin-3-ol 306 (3S)-1-({2-[(3S)-3- aminopyrrolidin-1-yl]-5-[4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)pyrrolidin-3- amine 307 (3S)-1-({2-chloro-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)pyrrolidin-3- amine 308 {4-[7-(2- amino[1,3]thiazolo[5,4- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-2- yl}methanol 309 {4-[7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 7-yl}methanol 310 {5-[(4-fluorophenyl)methyl]- 4-methyl-6-[7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyrimidin-2- yl}methanol 311 {5-[4(fluorophenyl)methyl]- 4-methyl-6-[7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyrimidin-2- yl}methyl acetate 312 {6,6-dimethyl-4-[7-(2-methyl- 1H-imidazo[4,5-b]pyridin-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methanol 313 {6,6-dimethyl-4-[7-(2-methyl- 1H-imidazo[4,5-b]pyridin-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl acetate 314 1-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benbzoxazepin-7-yl]pyridin-3- yl}sulfonyl)-3- (hydroxymethyl)azetidin-3-ol 315 1-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)azetidin-3-ol 316 1-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl{sulfonyl)piperidin-3-ol 317 1-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)piperidin-4-ol 318 1-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl{sulfonyl)pyrrolidin-3-ol 319 1-(4-{7-[2-(difluoromethyl)- 1H-benzimidazol-5-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-2-yl)-N,N- dimethylmethanamine 320 1-(4[{7-[2-(difluoromethyl)- 1H-benzimidazol-5-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 2-yl)-N,N- dimethylmethanamine 321 1-(4[{7-[2-(fluoromethyl)-1H- benzimidazol-5-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-2-yl)-N,N- dimethylmethanamine 322 1-(4[{7-[2-(fluoromethyl)-1H- benzimidazol-5-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 2-yl)-N,N- dimethylmethanamine 323 1-(4-{7-[3,4- bis(methyloxy)phenyl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 2-yl)-N,N- dimethylmethanamine 324 1-(4-{7-[3-chloro-4- (methyloxy)phenyl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 2-yl)-N,N- dimethylmethanamine 325 1-(4[{7-[4-(1H-imidazol-2- yl)phenyl]-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl}-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-2-yl)- N,N-dimethylmethanamine 326 1-(4[{7-[4-chloro-3- (methyloxy)phenyl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 2-yl)-N,N- dimethylmethanamine 327 1-(6,6-dimethyl-4-{7-[3- (methyloxy)-4-{[2- (methyloxy)ethyl]oxy}phenyl]- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl}- 5,6,7,8-tetrahydroquinazolin- 2-yl)-N,N- dimethylmethanamine 328 1-(6,6-dimethyl-4-{7-[3- (methyloxy)phenyl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-5,6,7,8- tetrahydroquinazolin-2-yl)- N,N-dimethylmethanamine 329 1-(6,6-dimethyl-4-{7-[4- (methyloxy)phenyl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-5,6,7,8- tetrahydroquinazolin-2-yl)- N,N-dimethylmethanamine 330 1-(6,6-dimethyl-4-{7-[6- (methyloxy)pyridin-3-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-5,6,7,8- tetrahydroquinazolin-2-yl)- N,N-dimethylmethanamine 331 1-[4-{7-[2-(difluoromethyl)- 1H-ben zimidazol-5-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-6-methyl-5-(1- methylethyl)pyrimidin-2-yl]- N,N-dimethylmethanamine 332 1-[4-{7-[2-(fluoromethyl)-1H- benzimidazol-5-yl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-6-methyl-5-(1- methylethyl)pyrimidin-2-yl]- N,N-dimethylmethanamine 333 1-[4-{7-[3,4- bis(methyloxy)phenyl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-7- (methyloxy)quinazolin-2-yl]- N,N-dimethylmethanamine 334 1-{(7S)-7-ethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}-N,N- dimethylmethanamine 335 1-{4,5-dimethyl-6-[7-(2- methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)- yl]pyrimidin-2-yl}-N,N- dimethylmethanamine 336 1-{4-[7-(1,3-benzothiazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-2-yl}-N,N- dimethylmethanamine 337 1-{4-[7-(1,3-benzothiazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-2-yl}- N,N-dimethylmethanamine 338 1-{4-[7-(1,3-benzothiazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-6,6- dimethyl-7-(methyloxy)- 5,6,7,8-tetrahydroquinazolin- 2-yl}-N,N- dimethylmethanamine 339 1-{4-[7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-2-yl}- N,N-dimethylmethanamine 340 1-{4-[7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 7-yl}ethanol 341 1-{4-[7-(4-fluoro-2-methyl- 1H-benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 2-yl}-N,N- dimethylmethanamine 342 1-{4-[7-(6-fluoro-2-methyl- 1H-benzimidazol-5-yl)-2,3- dihydro-1,4- benzoxazepin- 4(5H)-yl]-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 2-yl}-N,N- dimethylmethanamine 343 1-{4-ethyl-5-methyl-6-[7-(2- methyl-1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]pyrimidin-2-yl}-N,N- dimethylmethanamine 344 1-{4-ethyl-5-methyl-6-[7-(2- methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoazepin-4(5H)- yl]pyrimnidin-2-yl}-N,N- dimethylmethanamine 345 1-{5-(cyclopropylmethyl)-4- methyl-6-[7-(2-methyl-1H- benzimidazo-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyrimidin-2-yl}- N,N-dimethylmethanamine 346 1-{5-(cyclopropylmethyl)-4- methyl-6-[7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]pyrimidin-2-yl}-N,N- dimethylmethanamine 347 1-{5-[(4- fluorophenyl)methyl]-4- methyl-6-[7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyrimidin-2-yl}- N,N-dimethylmethanamine 348 1-{5-[(4- fluorophenyl)methyl]-4- methyl-6-[7-(2-methyl-3H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]pyrimidin-2-yl}-N,N- dimethylmethanamine 349 1-{5-ethyl-4-methyl-6-[7-(2- methyl-1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]pyrimidin-2-yl}-N,N- dimethylmethanamine 350 1-{5-ethyl-4-methyl-6-[7-(2- methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)- yl]pyrimidin}-N,N- dimethylmethanamine 351 1-{6,6-dimethyl-4-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}-N,N- dimethylmethanamine 352 1-{6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methanamine 353 1-{6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}-N,N- dimethylmethanamine 354 1-{6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}-N-methylmethanamine 355 1-{6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]-7- (methyloxy)-5,6,7,8- tetrahydroquinazolin-2-yl}- N,N-dimethylmethanamine 356 1-{6,6-dimethyl-4-[7-(2- methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}-N,N- dimethylethanamine 357 1-{6-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2-yl}- N,N-dimethylmethanamine 358 1-{6-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2-yl}- N-methylmethanamine 359 1-{6-fluoro-4-[7-(2-methyl- 1H-imidazo[4,5-b]pyridin-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]quinazolin-2-yl}-N,N- dimethylmethanamine 360 1-cyclopropyl-N-({6,6- dimethyl-4-[7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)ethanamine 361 1-methyl-3-(4-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl}phenyl)urea 362 2-{6,6-dimethyl-4-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}propan-2-ol 363 2-amino-5-(4-{5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-N- methylpyridine-3-sulfonamide 364 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(1- methylethyl)pyridin-3- sulfonamide 365 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2,2,2- trifluoroethyl)pyridine-3- sulfonamide 366 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2- fluoroethyl)pyridine-3- sulfonamide 367 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2- hydroxy-1,1- dimethylethyl)pyridine-3- sulfonamide 368 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2- hydroxy-1- methylethyl)pyridine-3- sulfonamide 369 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2- hydroxy-2- methylpropyl)pyridine-3- sulfonamide 370 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2- hydroxyethyl)-N- methylpyridine-3-sulfonamide 371 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2- hydroxyethyl)pyridine-3- sulfonamide 372 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2- hydroxypropyl)pyridine-2- sulfonamide 373 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(3,3,3- trifluoro-2- hydroxypropyl)pyridine-3- sulfonamide 374 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(3- hydroxy-2,2- dimethylpropyl)pyridine-3- sulfonamide 375 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(3- hydroxypropyl)pyridine-3- sulfonamide 376 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N- (piperidin-2- ylmethyl)pyridine-3- sulfonamide 377 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N- (piperidin-3- ylmethyl)pyridine-3- sulfonamide 378 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N- (piperidin-4- ylmethyl)pyridine-3- sulfonamide 379 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N,N- dimethylpyridine-3- carboxamide 380 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N,N- dimethylpyridine-3- sulfonamide 381 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(1- methylpiperidin-4- yl)methyl]pyridine-3- sulfonamide 382 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydrquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(2R)- pyrrolidin-2- ylmethyl]pyridine-3- sulfonamide 383 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(2S)- pyrrolidin-2- ylmethyl]pyridine-3- sulfonamide 384 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N- [(3aR,5r,6aS)- octahydrocyclopenta[c]pyrrol- 5-ylmethyl]pyridine-3- sulfonamide 385 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(3R)-1- methylpyrrolidin-3- yl]pyridine-3-sulfonamide 386 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(3R)- piperidin-3-ylmethyl]pyridine- 3-sulfonamide 387 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(3R)- pyrrolidin-3-yl]pyridine-3- sulfonamide 388 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(3R)- pyrrolidin-3- ylmethyl]pyridine-3- sulfonamide 389 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(3S)- piperidin-3-ylmethyl]pyridine- 3-sulfonamide 390 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(3S)- pyrrolidin-2-yl]pyridine-3- sulfonamide 391 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[(3S)- pyrrolidin-3- ylmethyl]pyridine-3- sulfonamide 392 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-[2- (methyloxy)ethyl]pyridine-3- sulfonamide 393 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-{[(3S)- 1-methylpiperidin-3- yl]methyl}pyridine-3- sulfonamide 394 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-{[(3S)- 1-methylpyrrolidin-3- yl]methyl}pyridine-3- sulfonamide 395 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-ethyl- N-methylpyridine-3- sulfonamide 396 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N- ethylpyridine-3-sulfonamide 397 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N- methylpyridine-3-sulfonamide 398 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N- piperidin-4-yl]pyridine-3- sulfonamide 399 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 400 2-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydrquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonic acid 401 2-amino-5-[4-(6,6-dimethyl- 5,6-dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N- methylpyridine-3-sulfonamide 402 2-amino-N-(2,3- dihydroxypropyl)-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 403 2-amino-N-(2-amino-1,1- dimethylethyl)-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 405 2-amino-N-(2-amino-2- methylpropyl)-5-[4-(6,6,7- trimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 406 2-amino-N-(2-amino-2- methylpropyl)-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 407 2-amino-N-(2-amino-2- methylpropyl)-5-{4-[(7S)-7- ethyl-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 408 2-amino-N-(2-aminobutyl)-5- [4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 409 2-amino-N-(2-aminoethyl)-5- [4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 410 2-amino-N-(2-aminopropyl)- 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 411 2-amino-N-(3-amino-2,2- dimethylpropyl)-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazol-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 412 2-amino-N-(3-amino-2- hydroxypropyl)-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 413 2-amino-N-(3-amino-3- methylbutyl)-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 414 2-amino-N-(3-aminopropyl)- 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 415 2-amino-N-(azetidin-3- ylmethyl)-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydreo-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 416 2-amino-N-(trans-4- aminocyclohexyl)-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 417 2-amino-N,N-dimethyl-5-[4- (2,6,6-trimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 418 2-amino-N-[(1- aminocyclopropyl)methyl]-5- [4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 419 2-amino-N-[(1- methylpiperidin-4-yl)methyl]- 5-[4-(2,6,6-trimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 420 2-amino-N-[(1- methylpiperidin-4-yl)methyl]- 5-[4-(6,6,7-trimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoaxepin-7-yl]pyridine-3- sulfonamide 421 2-amino-N-[(3R)-1- methylpyrrolidin-3-yl]-5-[4- (2,6,6-trimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 422 2-amino-N-[(3R)-1- methylpyrrolidin-3-yl]-5-[4- (6,6,8-trimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 423 2-amino-N-[2- (dimethylamino)ethyl]-5-[4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 424 2-amino-N-{[(3S)-1- methylpyrrolidin-3- yl]methyl}-5-[4-(6,6,7- trimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 425 2-amino-N-8- azabicyclo[3.2.1]oct-3-yl-5- [4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 426 2-amino-N-azetidin-3-yl-5-[4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 427 2-amino-N-cyclobutyl-5-[4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-3- sulfonamide 428 2-chloro-5-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)benzamide 429 2-chloro-N-{2-chloro-5-[4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}-6- methylbenzenesulfonamide 430 3-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoazepin-7-yl]pyridin-3- yl}sulfonyl)propan-1-ol 431 3-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)propane-1,2-diol 432 3-(2,6-diazaspiro[3.3]hept-2- ylsulfonyl)-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 433 3-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)benzamide 434 3-(azetidin-1-ylsulfonyl)-5-[4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-2- amine 435 2-[(1R,4R)-2,5- diazabicyclo[2.2.1]hept-2- ylsulfonyl]-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 436 3-[(1S,4S)-2,5- diazabicyclo[2.2.1]hept-2- ylsulfonyl]-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 437 3-[(1S,4S)-2,5- diazabicyclo[2.2.1]hept-2- ylsulfonyl]-5-{4-[(7S)-7-ethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}pyridin-2- amine 438 3-[(3,3-difluoroazetidin-1- yl)sulfonyl]-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 439 3-[(3-amino-3-methylazetidin- 1-yl)sulfonyl]-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 440 3-[(3-amino-3- methylpyrrolidin-1- yl)sulfonyl]-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 441 3-[(3-amino-3- methylpyrrolidin-1- yl)sulfonyl]-5-{4-[(7S)-7- ethyl-2-methyl-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}pyridin-2- amine 442 3-[(3-amino-3- methylpyrrolidin-1- yl)sulfonyl]-5-{4-[(7S)-7- ethyl-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}pyridin-2- amine 443 3-[(3-aminoazetidin-1- yl)sulfonyl]-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 444 3-[(3-aminopiperidin-1- yl)sulfonyl]-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 445 3-[(3-aminopyrrolidin-1- yl)sulfonyl]-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 446 3-[(4-aminopiperidin-1- yl)sulfonyl]-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 447 3-{[(3R)-3-aminopyrrolidin-1- yl]sulfonyl}-5-[4-(6,6,7- trimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 448 3-{[(3R)-3-aminopyrrolidin-1- yl]sulfonyl}-5-[4-(6,6,8- trimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 449 3-{[(3R)-3-aminpyrrolidin-1- yl]sulfonyl}-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 450 3-{[(3R)-3-aminopyrrolidin-1- yl]sulfonyl}-5-[4-(6,6- dimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 451 3-{[(3R)-3-aminopyrrolidin-1- yl]sulfonyl}-5-{4-[(7S)-7- ethyl-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}pyridin-2- amine 452 3-{[(3S)-3-aminopyrrolidin-1- yl]sulfonyl}-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 453 3-{[(3S)-3-aminopyrrolidin-1- yl]sulfonyl}-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- ol 454 3-{[(3S)-3-aminopyrrolidin-1- yl]sulfonyl}-5-{4-[7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}pyridin-2- amine 455 3-{[3- (dimethylamino)azetidin-1- yl]sulfonyl}-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-2- amine 456 3-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}benzoic acid 457 3-amino-5-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridine-2- carboxamide 458 4-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfinyl)-2-methylbutan-2- ol 459 4-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)-2-methylbutan-2- ol 460 4-(2,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 461 4-(2-{[(3R)-3- fluoropyridin-1-yl]methyl}- 6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin 462 4-(2-{[(3R)-3- fluoropyridin-1-yl]methyl}- 6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 463 4-(2-{[(3S)-3- fluoropyrrolidin-1-yl]methyl}- 6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 464 4-(2-{[(3S)-3- fluoropyrrolidin-1-yl]methyl}- 6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 465 4-(2-ethenyl-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-7-(2-methyl-3H- imidazo[4,5-b]pyridin-6-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 466 4-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-N- methylbenzamide 468 4-(5-bromo-6- methylpyrimidin-4-yl)-7-(2- methyl-1H-imidazao[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 469 4-(5-ethyl-2,6- dimethylpyrimidin-4-yl)-7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 470 4-(5-ethyl-6-methylpyrimidin- 4-yl)-7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 471 4-(6,6-difluoro-5,6,7,8- tetrahydcroquinazolin-4-yl)-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 472 4-(6,6-dimethyl-2-pyridin-2- yl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-benzimidazol-6- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 473 4-(6,6-dimethyl-2-pyridin-2- yl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 474 4-(6,6-dimethyl-2-pyrrolidin- 2-yl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 475 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-3H-imidazo[4,5- c]pyridin-7-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 476 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- [5-(methyloxy)pyridin-3-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 477 4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- pyrido[2,3-b]pyrazin-7-yl- 2,3,4,5-tetrahydro-1,4- benzoxazepine 478 4-(6,6-dimethyl-5,6- dihydroquinazolin-4-yl)-7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 479 4-(6,6-dimethyl-5,6- dihydroquinazolin-4-yl)-7-[4- (1H-imidazo-2-yl)phenyl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 480 4-(6-azetidin-1-yl-5- methylpyrimidin-4-yl)-7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 481 4-(6-chloro-5- methylpyrimidin-4-yl)-7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 482 4-(6-ethyl-2-methyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 483 4-(6-ethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-imidaz[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 484 4-(7,7-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 485 4-(8,8-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 486 4-[(6S,7S)-6,7-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl]-7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 487 4-[(7S)-7-ethyl-2-methyl- 5,6,7,8-tetrahydroquinazolin- 4-yl]-7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 488 4-[(7S)-7-ethyl-5,6,7,8- tetrahydroquinazolin-4-yl]-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 489 4-[(8S)-8-ethenyl-6,7,8,9- tetrahydro-5H- cyclohept[d]pyrimidin-4-yl]- 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 490 4-[(8S)-3-ethyl-6,7,8,9- tetrahydro-5H- cyclohepta[d]pyrimidin-4-yl]- 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 491 4-[2,6-dimethyl-5-(1- methylethyl)pyrimidin-4-yl]- 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 492 4-[5-(cyclopropylmethyl)-2,6- dimethylpyrimidin-4-yl]-7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 493 4-[5-(cyclopropylmethyl)-6- methylpyrimidin-4-yl]-7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 494 4-[6,6-dimethyl-2-({[2- (methyloxy)ethyl]oxy}methyl)- 5,6,7,8-tetrahydroquinazolin- 4-yl]-7-(2-methyl-1H- benzimidazol-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 495 4-[6,6-dimethyl-2-({[2- (methyloxy)ethyl]oxy}methyl)- 5,6,7,8-tetrahydroquinazolin- 4-yl]-7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 496 4-[6,6-dimethyl-2-(1- pyrrolidin-1-ylethyl)-5,6,7,8- tetrahydroquinazolin-4-yl]-7- (2-methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 497 4-[6,6-dimethyl-2-(2- pyrrolidin-1-ylethyl)-5,6,7,8- tetrahydroquinazolin-4-yl]-7- (2-methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 498 4-[6,6-dimethyl-2-(morpholin- 4-ylmethyl)-5,6,7,8- tetrahydroquinazolin-4-yl]-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 499 4-[6,6-dimethyl-2-(piperidin- 1-ylmethyl)-5,6,7,8- tetrahydroquinazolin-4-yl]-7- (2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 500 4-[6,6-dimethyl-2-(pyrrolidin- 1-ylmethyl)-5,6,7,8- tetrahydroquinazolin-4-yl]-7- (2-methyl-1H-benzimidazol-5- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 501 4-[6,6-dimethyl-2-(pyrrolidin- 1-ylmethyl)-5,6,7,8- tetrahydroquinazolin-4-yl]-7- (2-methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 502 4′-[7-(2-methyl-3H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-7′,8′- dihydro-5′H- spiro[cyclopropane-1,6′- quinazoline] 503 4-{2-[(3,3-difluoropyrrolidin- 1-yl)methyl]-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl}-7-(2-methyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 504 4-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}aniline 505 4-{6,6-dimethyl-2-[(2R)- pyrrolidin-2-yl]-5,6,7,8- tetrahydroquinazolin-4-yl}-7- (2-methyl-1H-benzimidazol-5- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 506 4-{6,6-dimethyl-2-[(2R)- pyrrolidin-2-yl]-5,6,7,8- tetrahydroquinazolin-4-yl]-7- (2-methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 507 4-{6,6-dimethyl-2-[(2S)- pyrrolidin-2-yl]-5,6,7,8- tetrahydroquinazolin-4-yl}-7- (2-methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 508 4-{6,6-dimethyl-2- [(methyloxy)methyl]-5,6,7,8- tetrahydroquinazolin-4-yl}-7- (2-methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepine 509 5-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)pyridin-2- amine 510 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3- (ethylsulfonyl)pyridin-2- amine 511 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3- (hexahydropyrrolo[3,4- c]pyrrol-2(1H)- ylsulfonyl)pyridin-2-amine 512 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3- (methylsulfonyl)pyridin-2- amine 513 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3- (morpholin-4- ylsulfonyl)pyridin-2-amine 514 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3- (piperazin-1- ylsulfonyl)puridin-2-amine 515 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3- (pyrrolidin-1- ylsulfonyl)pyridin-2-amine 516 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3-[(4- methylpiperazin-1- yl)sulfonyl]pyridin-2-amine 517 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3- [(methylsulfonyl)methyl] pyridin-2-amine 518 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3- {[(1S,4S)-5-methyl-2,5- diazabicyclo[2.2.1]hept-2- yl]sulfonyl}pyridin-2-amine 519 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-3-{[3- (methylamino)azetidin-1- yl]sulfonyl}pyridin-2-amine 520 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N-(2- hydroxyethyl)-2- (methylamino)pyridine-3- sulfonamide 521 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-N,N- dimethylpyridine-3- sulfonamide 522 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- sulfonamide 523 5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyrimidin- 2-amine 524 5-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1,3- dihydro-2H-indol-2-one 525 5-methyl-N-(1-methylethyl)-6- [7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)- yl]pyrimidin-4-amine 526 6-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 527 6-(4-{2- [(dimethylamino)methyl]-7- (methyloxy)quinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 529 6-[7-(1H-benzimidazol-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-2,5- dimethyl-N-phenylpyrimidin- 4-amine 530 6-[7-(1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 2,5-dimethyl-N- phenyl]pyrimidin-4-amine 531 6-[7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5- methyl-N-(1-methylpiperidin- 4-yl)pyrimidin-4-amine 532 6-[7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5- methyl-N-(tetrahydro-2H- pyran-4-yl)pyrimidin-4-amine 533 6-[7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5- methyl-N-[(1-methylpiperidin- 4-yl)methyl]pyrimidin-4- amine 534 6-[7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5- methyl-N-[2-(1- methylpyrrolidin-2- yl)ethyl]pyrimidin-4-amine 535 6-[7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-N,5- dimethyl-N-[(1R)-1- phenylethyl]pyrimidin-4- amine 536 6-[7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-N,5- dimethyl-N-[(1S)-1- phenylethyl]pyrimidin-4- amine 537 6-{4-[(7S)-7-ethyl-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- amine 538 6-{4-[2,5-dimethyl-6- (phenylamino)pyrimidin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-N--ethyl- 1H-benzimidazol-2-amine 539 6-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 540 6-{4-[5-methyl-6- (phenylamino)pyrimidin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- amine 541 7-(1H-benzimidazol-6-yl)-4- pyrimidin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 542 7-(1H-imidazo[4,5-b]pyridin- 6-yl)-4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 543 7-(1H-imidazo[4,5-b]pyridin- 6-yl)-4-pyrimidin-4-yl-2,3,4,5- tetrahydro-1,4-benzoxazepine 544 7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)-4- (2,6,6-trimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 545 7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)-4- (6,6-dimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 546 7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)-4- [(7S)-7-methyl-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 547 7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)-4- [5-(cyclopropylmethyl)-2,6- dimethylpyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 548 7-(2-ethyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(2,6,6- trimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 550 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(2,6,6- trimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 551 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(5-methyl-6- morpholin-4-yl]pyrimidin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 552 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(6,6,7,8- tetramethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 553 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-6,6,7- trimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 554 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(6,6,8- trimethyl-5,6- dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 555 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(6-methyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 556 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(7-methyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 557 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(7-methyl- 7H-pyrrolo[2,3-d]pyrimidin-4- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 558 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-(7-methyl-7- phenyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 559 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-[(7R)-7- methyl-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 560 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-[(7S)-7- methyl-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 561 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-[2-methyl-5- (morpholin-4- ylsulfonyl)pyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 562 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-[5- (trifluoromethyl)-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 563 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-[5-methyl-6- (4-methylpiperazin-1- yl)pyrimidin-4-yl]-2,3,4,5- tetrahydro-1,4-benzoxazepine 564 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-[6-methyl-5- (1-methylethyl)pyrimidin-4- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine 565 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-[7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 566 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-[7- (trifluoromethyl)-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 567 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-{7- [(methyloxy)methyl]-5,6,7,8- tetrahydrquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepine 568 7-(2-methyl-1H-imidazo[4,5- b]pyridin-6-yl)-4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 569 7-(3,4-dihydro-2H-pyrido[2,3- b][1,4]oxazin-7-yl)-4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 570 7-[4-(1H-imidazol-4- yl)phenyl]-4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 571 7-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2H- pyrido[2,3-e][1,2,4]thiadiazin- 3(4H)-one 1,1-dioxide 572 7-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2H- pyrido[3,2-b][1,4]oxazin- 3(4H)-one 573 7-{6-chloro-5- [(difluoromethyl)oxy]pyridin- 3-yl}-4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepine 574 7-{6-chloro-5- [(methylsulfonyl)methyl] pyridin-3-yl}-4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 575 8-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)-8- azabicyclo[3.2.1]octan-3- amine 576 ethyl {6-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- yl}carbamate 577 methyl (6-{4-[(7S)-7-ethyl-2- methyl-5,6,7,8- tetrahydroquinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- yl)carbamate 578 methyl (6-{4-[(7S)-7-ethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- yl)carbamate 579 methyl [6-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- benzimidazol-2-yl]carbamate 580 methyl [6-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-1H- imidazo[4,5-b]pyridin-2- yl[carbamate 581 methyl {2-chloro-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}carbamate 582 methyl {6-[4-(6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 4-yl)-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- yl}carbamate 583 methyl {6-[4-(6,6-dimethyl- 5,6-dihydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- yl}carbamate 584 N-({5-[(4- fluorophenyl)methyl]-4- methyl-6-[7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyrimidin-2- yl}methyl)cyclopropanamine 585 N-({6,6-dimethyl-4-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-2- (methyloxy)ethanamine 586 N-({6,6-dimethyl-4-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-2- fluoroethanamine 587 N-({6,6-dimethyl-4-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)cyclobutanamine 588 N-({6,6-dimethyl-4-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2- yl}methyl)cyclopropanamine 589 N-({6,6-dimethyl-4-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)ethanamine 590 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-2- (methyloxy)ethanamine 591 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-2,2,2- trifluoroethanamine 592 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-2,2- difluoroethanamine 593 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-2- fluoroethanamine 594 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-2-methylpropan- 1-amine 595 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-2-methylpropan- 2-amine 596 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)alanine 597 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)cyclobutanamine 598 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2- yl}methyl)cyclopentanamine 599 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2- yl}methyl)cyclopropanamine 600 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)ethanamine 601 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2- yl)methyl)methanesulfonamide 602 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-N- ethylethanamine 603 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-N-ethylpropan- 2-amine 604 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-N- methylcyclopropanamaine 605 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-N- methylethanamine 606 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)-N- methylpropan-2-amine 607 N-({6,6-dimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}methyl)propan-2-amine 608 N-(2-chloro-5-{4-[7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}pyridin-3- yl)methanesulfonamide 609 N-(4-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl}phenyl)acetamide 610 N,5-dimethyl-6-[7-(2-methyl- 1H-imidazo[4,5-b]pyridin-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]pyrimidin-4-amine 611 N,N,2-trimethyl-4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)- yl]pyrimidine-5-sulfonamide 612 N,N-dimethyl-1-{4-[7-(2- methyl-1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5-(1- methylethyl)pyrimidin-2- yl}methanamine 613 N,N-dimethyl-1-{4-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]-7- (methyloxy)quinazolin-2- yl}methanamine 614 N,N-dimethyl-1-{4-methyl-5- (1-methylethyl)-6-[7-(2- methyl-3H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)- yl]pyrimidin-2- yl}methanamine 615 N,N-dimethyl-1-{4-methyl-6- [7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-5-(1- methylethyl)pyrimidin-2- yl}methanamine 616 N-[2-chloro-5-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)puyridin-3- yl]methanesulfonamide 617 N-[6-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-yl]acetamide 618 N-[6-(4-{2- [(dimethylamino)methyl]-7- (methyloxy)quinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-yl]acetamide 619 N-{2-(dimethylamino)-5-[4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}methanesulfonamide 620 N-{2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}methanesulfonamide 621 N-{2-chloro-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl[phenyl)methanesulfonamide 622 N-{2-chloro-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}acetamide 623 N-{2-chloro-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}methanesulfonamide 624 N-{2-chloro-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}-N- methylmethanesulfonamide 625 N-{2-cyano-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}methanesulfonamide 626 N-{5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2- (ethyloxy)pyridin-3- yl}methanesulfonamide 627 N-{5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2- (methylamino)pyridin-3- yl}methanesulfonamide 628 N-{5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2- (methyloxy)pyridin-3- yl}methanesulfonamide 629 N-{5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2- (phenylamino)pyridin-3- yl}methanesulfonamide 630 N-{5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2- [(phenylmethyl)amino]pyrimidin- 3-yl}methanesulfonamide 631 N-{5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2- [(phenylmethyl)oxy]pyridin-3- yl}methanesulfonamide 632 N-{5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2- fluoropyridin-3- yl}methanesulfonamide 633 N-{5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-2- methylpyridin-3- yl}methanesulfonamide 634 N-{5-[4-(6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}methanesulfonamide 635 N-{6-[7-(2-cyclopropyl-1H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5- methylpyrimidin-4-yl}-N,N′- dimethylethane-1,2-diamine 636 N~2~-({2-amino-5-[4-(6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]pyridin-3- yl}sulfonyl)glycinamide 637 N-ethyl-2,5-dimethyl-6-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)- yl]pyrimidin-4-amine 638 N-ethyl-3-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}benzamide 639 N-ethyl-5-methyl-6-[7-(2- methyl-1H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)- yl]pyrimidin-4-amine 640 N-ethyl-6-[4-(5-methyl-6-{[4- (methyloxy)phenyl]amino} pyrimidin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 641 N-ethyl-6-[4-(7-fluoro-2- methylquinazolin-4-yl)-2,3,4,5- tetrahydro-1,4-benzoxazepin- 7-yl]-1H-benzimidazol-2- amine 642 N-ethyl-6-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- amine 643 N-ethyl-6-{4-[6-(ethylamino)- 5-methylpyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- benzimidazol-2-amine 644 N-methyl-3-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}benzamide 645 phenylmethyl (2S)-2-{6,6- dimethyl-4-[7-(2-methyl-3H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}pyrrolidine-1-carboxylate 646 phenylmethyl [(1S)-1-(6-{4- [(7S)-7-ethyl-2-methyl- 5,6,7,8-tetrahydroquinazolin- 4-yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl}-1H- imidazo[4,5-b]pyridin-2- yl)ethyl]carbamate 647 phenylmethyl [(1S)-1-{6-[4- (6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl]-1H- imidazo[4,5-b]pyridin-2- yl}ethyl]carbamate 648 1-(6,6-dimethyl-4-{7-[4- (methyloxy)-3-{[2- (methyloxy)ethyl]oxy}phenyl]- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl}- 5,6,7,8-tetrahydroquinazolin- 2-yl)-N,N- dimethylmethanamine 649 1-{4-[7-{3- [(difluoromethyl)oxy]-4- (methyloxy)phenyl}-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-6,6-dimethyl- 5,6,7,8-tetrahydroquinazolin- 2-yl}-N,N- dimethylmethanamine 650 1-[5-(4-{2- [(dimethylamino)methyl]-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-2- (methyloxy)phenyl]ethanone 651 4-[7-(1H-benzimidazol-5-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-2-amine 652 1-(6,6-dimethyl-4-{7-[4- (methyloxy)-3- (methylsulfonyl)phenyl]-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl}-5,6,7,8- tetrahydroquinazolin-2-yl)- N,N-dimethylmethanamine 653 N,N-dimethyl-1-{4-methyl-6- [7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-5-propylpyrimidin- 2-yl}methanamine 654 N,N-dimethyl-1-{4-methyl-6- [7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-5-prop-2-en-1- ylpyrimidin-2- yl}methanamine 655 N,N-dimethyl-1-{4-methyl-6- [7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-5-(2- methylpropyl)pyrimidin-2- yl}methanamine 656 N-[5-(4-{2- [(dimethylamino)methyl]-6- methyl-5-(1- methylethyl)pyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7-yl)-2- (methyloxy)phenyl]methane- sulfonamide 657 6-(4-{2- [(dimethylamino)methyl]-6- methyl-5-propylpyrimidin-4- yl}-2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 658 1-{4-[7-(1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-7- (methyloxy)quinazolin-2-yl}- N,N-dimethylmethanamine 659 N,N-dimethyl-1-{4-[7-(2- methyl-1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzxazepin-4(5H)-yl]-7- (methyloxy)quinazolin-2- yl}methanamine 660 5-[(4-fluorophenyl)methyl]-4- methyl-6-[7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyrimidin-2-amine 661 6-{4-[2-methyl-7- (methyloxy)quinazolin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl}[1,3]thiazolo[5,4-b]pyridin- 2-amine 662 6-(4-{2- [(dimethylamino)methyl]-5- ethyl-6-methylpyrimidin-4- yl}-2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 663 6-(4-{5-(cyclopropylmethyl)- 2-[(dimethylamino)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 664 N,N-dimethyl-1-{4-methyl-6- [7-(2-methyl-1H- benzimidazol-6-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-5-[2- (methyloxy)ethyl]pyrimidin-2- yl}methanamine 665 6-(4-{2- [(dimethylamino)methyl]-6- methyl-5-(2- methylpropyl)pyrimidin-4- yl}-2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 666 1-{5-bromo-4-methyl-6-[7-(2- methyl-1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]pyrimidin-2-yl}-N,N- dimethylmethanamine 667 6-(4-{2- [(dimethylamino)methyl]-6- methyl-5-[2- (methyloxy)ethyl]pyrimidin-4- yl}-2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 668 1-{6,6-dimethyl-4-[7-(2- methyl-1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]- 5,6,7,8-tetrahydroquinazolin- 2-yl}ethanamine 669 6-[4-(2,6,6-trimethyl-5,6,7,8- tetrahydroquinazolin-4-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl][1,3]thiazolo[5,4-b]pyridin- 2-amine 670 6-(4-{2- [(dimethylamino)methyl]-6- methyl-5-prop-2-en-1- ylpyrimidin-4-yl}-2,3,4,5- tetrahyhdro-1,4-benzoxazepin- 7-yl)[1,3]thiazolo[5,4- b]pyridin-2-amine 671 6-(4-{2- [(dimethylamino)methyl]-5,6- dimethylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 672 1-{4,5-dimethyl-6-[7-(2- methyl-1H-benzimidazol-6- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]pyrimidin-2-yl}-N,N- dimethylmethanamine 673 6-(4-{5-bromo-2- [(dimethylamino)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 674 6-(4-{2- [(dimethylamino)methyl]-6- methyl-5-(1- methylethyl)pyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 675 7-(2-methyl-1H-benzimidazol- 5-yl)-4-[6-methyl-5-(1- methylethyl)pyridmin-4-yl]- ylmethyl)pyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepine 676 4-[2-(fluoromethyl)-6,6- dimethyl-5,6,7,8- tetrahydroquinazolin-4-yl]-7- (2-methyl-1H-benzimidazol-5- yl)-2,3,4,5-tetrahydro-1,4- benzoxazepine 677 1-{5-chloro-4-methyl-6-[7-(2- methyl-1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]pyrimidin-2-yl}-N,N- dimethylmethanamine 678 6-(4-{5-chloro-2- [(dimethylamino)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 679 2-fluoro-N-({4-methyl-6-[7- (2-methyl-1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5-(1- methylethyl)pyrimidin-2- yl}methyl)ethanamine 680 6-{4-[2-{[(2- fluoroethyl)amino]methyl}-6- methyl-5-(1- methylethyl)pyrimidin-4-yl]- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl}[1,3]thiazolo[5,4-b]pyridin- 2-amine 681 N,N-dimethyl-1-{4-methyl-6- [7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-5-phenylpyrimidin- 2-yl}methanamine 682 6-(4-{2- [(dimethylamino)methyl]-6- methyl-5-phenylpyrimidin-4- yl}-2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine 683 N′-{5-[(4- fluorophenyl)methyl]-4- methyl-6-[7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]pyrimidin-2-yl}- N,N-dimethylethane-1,2- diamine 684 {4-[7-(2- amino[1,3]thiazolo[5,4- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]- 6,6-dimethyl-5,6,7,8- tetrahydroquinazolin-2- yl}acetonitrile 685 N-ethyl-N-({4-methyl-6-[7-(2- methyl-1H-benzimidazol-5- yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-5-(1- methylethyl)pyrimidin-2- yl}methyl)ethanamine 686 {4-methyl-6-[7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-5-(1- methylethyl)pyrimidin-2- yl}methyl acetate 687 {4-methyl-6-[7-(2-methyl-1H- benzimidazol-5-yl)-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-5-(1- methylethyl)pyrimidin-2- yl}methanol 688 4-[7-(1H-benzimidazol-5-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-6- methylpyrimidin-2-amine 689 5-[(4-fluorophenyl)methyl]-4- [7-(3H-imidazo[4,5-b]pyridin- 6-yl)-2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-6- methylpyrimidin-2-amine 690 5-[(4-fluorophenyl)methyl]-4- methyl-6-[7-(2-methyl-3H- imidazo[4,5-b]pyridin-6-yl)- 2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]pyrimidin-2-amine 691 1-{4-[7-(3H-imidazo[4,5- b]pyridin-6-yl)-2,3-dihydro- 1,4-benzoxazepin-4(5H)-yl]-7- (methyloxy)quinazolin-2-yl}- N,N-dimethylmethanamine 692 6-(4-{2-amino-5-[(4- fluorophenyl)methyl]-6- methylpyrimidin-4-yl}- 2,3,4,5-tetrahydro-1,4- benzoxazepin-7- yl)[1,3]thiazolo[5,4-b]pyridin- 2-amine

Useful Intermediates: 4-[6,7-bis(methyloxy)quinolin-4-yl]-7-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepine; 4-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-2-nitroaniline; 4-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}benzene-1,2-diamine; N-[5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidine-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-yl]acetamide; 7-bromo-4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine; 4-[6,7-bis(methyloxy)quinazolin-4-yl]-7-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepine; 7-bromo-4-[6-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine.

General Administration

In one aspect, the invention provides pharmaceutical compositions comprising an inhibitor of PI3K and/or mTOR according to the invention and a pharmaceutically acceptable carrier, excipient, or diluent. In certain other specific embodiments, administration is by the oral route. Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, specifically in unit dosage forms suitable for simple administration of precise dosages.

The compositions will include a conventional pharmaceutical carrier or excipient and a Compound of the invention as the/an active agent, and, in addition, may include carriers and adjuvants, etc.

Adjuvants include preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.

The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

One specific route of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active Compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active Compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the like, to thereby form a solution or suspension.

Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of the present invention with for example suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.

Dosage forms for topical administration of a Compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

Compressed gases may be used to disperse a Compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.

Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. In one example, the composition will be between about 5% and about 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.

Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990). The composition to be administered will, in any event, contain a therapeutically effective amount of a Compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this invention.

The compounds of the invention, or their pharmaceutically acceptable salts or solvates, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific Compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy. The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the Compound being used. The determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art.

If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent(s) within its approved dosage range. Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.

General Synthesis

Compounds of this invention can be made by the synthetic procedures described below. The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis.), or Bachem (Torrance, Calif.), or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this invention can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure. The starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.

Unless specified to the contrary, the reactions described herein take place at atmospheric pressure and over a temperature range from about −78° C. to about 150° C., more specifically from about 0° C. to about 125° C. and more specifically at about room (or ambient) temperature, e.g., about 20° C. Unless otherwise stated (as in the case of an hydrogenation), all reactions are performed under an atmosphere of nitrogen.

Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups regenerate original functional groups by routine manipulation or in vivo. Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes.

The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms or quaternized nitrogen atoms in their structure. Compounds of the Invention may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention.

Some of the compounds of the invention contain an active ketone —C(O)CF3 and may exist in part or in whole as the —C(OH2)CF3 form. Regardless of whether the Compound is drawn as the —C(O)CF3 or —C(OH2)CF3 form, both are included within the scope of the Invention. Although an individual Compound may be drawn as the —C(O)CF3 form, one of ordinary skill in the art would understand that the Compound may exist in part or in whole as the —C(OH2)CF3 form and that the ratio of the two forms may vary depending on the Compound and the conditions in which it exists.

Some of the compounds of the invention may exist as tautomers. For example, where a ketone or aldehyde is present, the molecule may exist in the enol form; where an amide is present, the molecule may exist as the imidic acid; and where an enamine is present, the molecule may exist as an imine. All such tautomers are within the scope of the invention. Further, for example, in this application R1 can be 5-oxo-1H-1,2,4-triazol-3-yl, depicted structurally as


Both 5-oxo-1H-1,2,4-triazol-3-yl and the structure 100 include, and are equivalent to, 3-hydroxy-4H-1,2,4-triazol-5-yl and its structure


In another example, in this application R1 can be 2-imino-1(2H)-hydroxy-pyrimidin-5-yl, depicted structurally as


Both 2-imino-1(2H)-hydroxy-pyrimidin-5-yl and the structure 101 include, and are equivalent to, N-oxide of 2-amino-pyrimidin-5-yl and its structure 201:


Regardless of which structure or which terminology is used, each tautomer is included within the scope of the Invention.

The present invention also includes N-oxide derivatives and protected derivatives of compounds of the Invention. For example, when compounds of the Invention contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. When compounds of the Invention contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable “protecting group” or “protective group”. A comprehensive list of suitable protective groups can be found in T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. 1991, the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of the Invention can be prepared by methods well known in the art.

Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystallization.

In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

The chemistry for the preparation of the compounds of this invention is known to those skilled in the art. In fact, there may be more than one process to prepare the compounds of the invention. The following examples illustrate but do not limit the invention. All references cited herein are incorporated by reference in their entirety.

An intermediate of formula 4 where PG is a nitrogen-protecting group, R5a and R5c are independently hydrogen or alkyl, R5h is hydrogen or halo, R5b is hydrogen, amino, or halo, and R5d, R5e, R5f, and R5g are hydrogen can be prepared according to Scheme 1.

In particular, an intermediate of formula 4a can be prepared according to Scheme 1a.

An intermediate of Formula 1a is commercially available or can be prepared using methods known to one of ordinary skill in the art. In particular an intermediate of formula 1a where R5b is hydrogen and R5h is hydrogen, bromo, or chloro is commercially available. An intermediate of formula 1a where R5h is hydrogen and R5b is bromo, chloro, iodo, or fluoro is commercially available. An intermediate of formula 1a where R5h is fluoro and R5b is hydrogen can be prepared using procedures described in J. of Med. Chem., 2004, 47(12), 3163-3179. An intermediate of formula 1a where R5h is hydrogen and R5b is amino can be prepared from the corresponding, commercially-available nitro intermediate using procedures known to one of ordinary skill in the art.

An intermediate of formula 2a where R5a is hydrogen or methyl is commercially available. The intermediate of formula 1a is treated with an intermediate of formula 2a in the presence of a reducing agent such as sodium borohydride, in a solvent(s) such as tetrahydrofuran and/or methanol and allowed to react at a temperature of about 40° C. for approximately 4 hours. The solvent is then removed and the reaction is taken up in a solvent(s) such as ethyl acetate and/or saturated sodium bicarbonate. To this suspension a nitrogen-protecting group precursor, such as di-tert-butyl dicarbonate, is added and the mixture is allowed to stir at room temperature overnight to yield an intermediate of formula 3a where PG is a nitrogen-protecting group.

Intermediate 3a is then treated with a catalyst, such as triphenylphosphine, in the presence of a dehydrating agent such as diisopropyl azodicarboxylate, in a solvent such as DCM. The reaction is allowed to proceed at room temperature for approximately 12 hours and the resulting product is optionally purified by column chromatography to yield an intermediate of formula 4a. Alternatively, the intermediate of formula 4a can be prepared by treating the intermediate of formula 3a with Burgess' reagent.

An intermediate of formula 5 where each R is hydrogen or both R′s when taken together form a cyclic boronic ester, PG is a nitrogen-protecting group, R5a and R5c are independently hydrogen or alkyl, R5h is hydrogen or halo, R5b is hydrogen, amino, or halo, R5e, R5f, and R5g are hydrogen, and R1 is as defined in the Summary of the Invention for a Compound of Formula I can be prepared according to Scheme 2.


where the intermediate of formula 4 is prepared as described in Scheme 1.

In particular, an intermediate of formula 5a where R5a is hydrogen or alkyl, R5h is hydrogen or halo, R5b is hydrogen, amino, or halo, and R1 is as defined in the Summary of the Invention for a Compound of Formula I, can be prepared according to Scheme 2a.


The intermediate of formula 4a, prepared as described in Scheme 1a, is treated with a boronic acid of formula R1B(OH)2 or


which are commercially available or can be prepared using procedures known to one of ordinary skill in the art. The reaction is carried out in the presence of a catalyst such as Pd(dppf)2Cl2, a base such as potassium carbonate, and in a solvent such as DME at about 80° C. for about 2 hours. The product can then be purified by chromatography to yield an intermediate of formula 5a.

Alternatively, an intermediate of formula 5, as defined above, can be prepared as described in Scheme 4.

In particular, an intermediate of formula 5b where PG is a nitrogen-protecting group and R1 is as defined in the Summary of the Invention for a Compound of Formula I can be prepared according to Scheme 4a.


An intermediate of formula 13, where PG is a nitrogen-protecting group, is prepared as described in Scheme 1a. 13 is treated with triisopropylborate in a solvent such as THF at a temperature of about −60° C., followed by dropwise addition of a base such as n-butyllithium in tetrahydrofuran. The reaction was allowed to proceed for about 30 minutes, was treated with an acid such as hydrochloric acid, and allowed to warm to room temperature to yield an intermediate of formula 14a. Intermediate 14a is then treated with an intermediate of formula R1X (where X is a halide, and which is commercially available or can be prepared using procedures known to one of ordinary skill in the art), in the presence of a base such as potassium carbonate, in the presence of a catalyst such as tetrakis(triphenylphosphine)palladium(0), and in a solvent(s) such as 1,2-dimethoxyethane and/or water. The reaction is allowed to proceed under nitrogen and stirred at reflux for about 3 hours to yield an intermediate of formula 5b.

In particular, a Compound of the Invention where Y is ═CH— or ═N—, R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h are hydrogen; R1 is benzimidazol-6-yl substituted at the 2-position with one R7; R7 is alkyl; R2 and all other groups are independently as defined in the Summary of the Invention for a Compound of Formula I, can be prepared according to Scheme 6a.


The nitro of the intermediate of formula 17a, prepared as described above in Scheme 4, is reduced in the presence of H2 and palladium on carbon in a solvent(s) such as methanol and/or acetic acid to yield an intermediate of formula 18a. The intermediate of formula 18a is then treated with an intermediate of formula R7C(O)OH, in the presence of a coupling agent such as HATU, in the presence of a base such as DIEA, in a solvent(s) such as DMF and/or acetic acid. The product can be purified by column chromatography to yield a Compound of Formula I(x).

A Compound of the Invention of Formula I where R5a and R5c are independently hydrogen or alkyl, R5h is hydrogen or halo, R5b is hydrogen, amino, or halo, R5e, R5f, and R5g are hydrogen, and R1 and R2 are independently as defined in the Summary of the Invention for a Compound of Formula I can be prepared as described in Scheme 5,


where X is halo or hydroxy.

In particular, a Compound of Formula I(w) where R5a is hydrogen or alkyl, R5h is hydrogen or halo, R5b is hydrogen, amino, or halo, and R1 and R2 are independently as defined in the Summary of the Invention for a Compound of Formula I can be prepared as described in Scheme 5a.


The protecting group on the intermediate of formula 5a is removed. When the protecting group is Boc, it can be removed with HCl to yield an intermediate of formula 6a. The intermediate of formula R2X (where X is a leaving group such as halo) is commercially available or can be prepared using procedures described herein or procedures known to one of ordinary skill in the art. The intermediate of formula 6a is then treated with R2X, in the presence of a base such as Hünig's base or NMP, in a solvent such as DMF, at a temperature of about 50° C. The product can be purified by column chromatography to yield an intermediate of Formula I(w).

In particular, a Compound of Formula I(a) where R1 and R2 are independently as defined in the Summary of the Invention for a Compound of Formula I can be prepared according to Scheme 5b.


The protecting group on intermediate of formula 5b, prepared as described in Scheme 4a, is removed. When the protecting group is Boc, it can be removed with HCl to yield an intermediate of formula 6b. Intermediate 6b is then treated with an intermediate of formula R2X where X is a leaving group such as halo using standard alkylating conditions to yield a Compound of Formula I(a).

A Compound of Formula I(aa) where one of Y1 and Y2 is ═CH— and the other is ═N—, R1 is benzimidazol-6-yl substituted at the 2-position with one R7; R7 and R2 are independently as defined in the Summary of the Invention for a Compound of Formula I can be prepared according to Scheme 6a using conditions known to one of ordinary skill in the art.

An intermediate of formula 17 is prepared by 1) treating an intermediate of formula 14a, prepared as described in Scheme 4a, with an intermediate of formula


where X is halo using standard Suzuki coupling conditions; followed by 2) treating the with and intermediate of formula R2X using standard alkylating conditions. 17 is then hydrogenated in the presence of palladium on carbon in a solvent such as acetic acid to yield the intermediate of formula 18. 18 is then treated with an acid of formula R7C(O)OH to yield the Compound of Formula I(aa).

Alternatively, a Compound of Formula I(aa) can be prepared according to Scheme 6b.


The intermediate of formula 18 is treated with an intermediate of formula 23 in the presence of glacial acetic acid, optionally in the presence of triethyl orthoformate, and heated to yield an a Compound of Formula I(aa).

A Compound of Formula I(v) where R2 is as defined in the Summary of the Invention for a Compound of Formula I can be prepared according to Scheme 7a.


The Compound of Formula I(u) where R is alkyl, prepared using procedures according to Scheme 5b, is treated with a base such as LiOH, in a solvent(s) such as THF and/or water to yield the hydrolyzed Compound of Formula I(y).

A Compound of Formula I(z) where R2, R8, and R8a are independently as defined in the Summary of the Invention for a Compound of Formula I can be prepared according to Scheme 7b.


The Compound of Formula I(v1) where X is halo or hydroxy can be prepared according to Scheme 7a or prepared by making the acid chloride from a Compound of Formula I(v). The Compound of Formula I(v1) is then treated with an amine of formula NHR8R8a optionally in the presence of a base such as DIEA in a solvent such as THF to yield a Compound of Formula I(z).

A Compound of Formula I where R1, R2, R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h can be prepared according to the following scheme (where R is —B(OH)2 and Y is halo, or R is halo and Y is —B(OH)2) using Suzuki coupling procedures known to one of ordinary skill in the art.

In particular, a Compound of Formula I(a) where R1 and R2 are independently as defined in the Summary of the Invention for a Compound of Formula I can be prepared as described in Scheme 8a.


An intermediate of formula 19 (where each R is hydrogen or the two R's together form a boronic ester), which can be prepared by following step 1 of Scheme 4a and subsequent deprotection, is treated with an intermediate of formula R2X in a solvent such as dioxane/H2O and in the presence of a base such as DIPEA. The resulting mixture is heated to about 90° C. to yield an intermediate of formula 20. 20 is treated with an intermediate of formula R1X where X is halo and R1 is as defined in the Summary of the Invention for a Compound of Formula I in a solvent such as DMF/water, in the presence of a base such as DIEA, in the presence of a catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II). The reaction is heated to about 95° C. 20 is then optionally purified to yield a Compound of Formula I(a).

Alternatively, a Compound of Formula I(a) where R1 and R2 are independently as defined in the Summary of the Invention for a Compound of Formula I can be prepared as described in Scheme 8b.


An intermediate of formula 21 where Y is halo, which can be prepared by following Scheme 1a followed by deprotection, is treated with an intermediate of formula R2X where X is halo, a base such as DIEA in a solvent such as 1-butanol and heated to yield an intermediate of formula 22. 22 is then treated with an intermediate of formula R1B(OR)2 (where each R is hydrogen or the two R together form a boronic ester), in the presence of a base such as potassium carbonate and in the presence of a catalyst such as dichloro[1,1-bis(diphenylphosphino]ferrocenepalladium (II) dichloromethane adduct in a solvent such as dimethoxyethane/water. The reaction was heated and yielded a Compound of Formula I(a).

SYNTHETIC EXAMPLES Reagent Preparation 1

STEP 1: A solution of methyl 2-amino-5-bromo-4-methoxybenzoate (75 mg, 0.29 mmol) and ammonium formate (38 mg, 0.8 mmol) in formamide (1 mL) was heated at 165° C. for 18 h. The mixture was allowed to cool to room temperature then diluted with an excess of water. The solid formed was collected by filtration and washed with water then ethyl acetate and dried to give 6-bromo-7-methoxyquinazolin-4(3H)-one (53 mg, 72% yield) as a pale yellow solid. MS (EI) for C9H7BrN2O2: 255, 257 (MH+).

STEP 2: 6-bromo-7-methoxyquinazolin-4(3H)-one (53 mg, 0.21 mmol) was taken into thionyl chloride (1.5 mL) followed by addition of catalytic DMF. The mixture was heated to 80° C. for 2 h then concentrated. The residue was partitioned with ethyl acetate and saturated aqueous sodium bicarbonate. The organic phase was washed with brine then dried over anhydrous sodium sulfate, filtered and concentrated to give 6-bromo-4-chloro-7-methoxyquinazoline (36 mg, 62% yield) as a brown solid. MS (EI) for C9H6BrClN2O: 275 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagents were prepared.

4-chloro-7-(methylsulfonyl)quinazoline. Synthesized according to the method of reagent preparation 1 using 7-(methylsulfonyl)quinazolin-4(3H)-one in step 2. 1H NMR (400 MHz, d6-DMSO): 8.36 (d, 1H), 8.34 (s, 1H), 8.18 (d, 1H), 8.02 (dd, 1H), 3.36 (s, 3H).

4,7-dichloro-6-iodoquinazoline. Synthesized according to the method of reagent preparation 1 using methyl 2-amino-4-chloro-5-iodobenzoate in step 1. MS (EI) for C8H3Cl21N2: 325 (MH+).

4-chloro-6-iodo-8-methylquinazoline. Synthesized according to the method of reagent preparation 1 using 2-amino-5-iodo-3-methylbenzoic acid in step 1. MS (EI) for C9H6ClIN2: 305 (MH+).

4-chloro-6-(phenylmethoxy)-quinazoline. Prepared according to the method of reagent preparation 1 using 2-amino-5-benzyloxybenzoic acid methyl ester (J. Org. Chem. 2001, 66(8), 2784-2788) in step 1. MS (EI) for C15H11ClN2O: 271 (MH+).

4,6-dichloro-7-methoxy-quinazoline. Prepared according to the method of reagent preparation 1 using 5-chloro-4-methoxyanthranilic acid (US 80-126838) in step 1. MS (EI) for C9H6Cl2N2O: 271 (MH+).

4-chloro-7,8-dimethoxy-quinazoline. Prepared according to the method of reagent preparation 1 using 2-amino-3,4-dimethoxybenzoic acid methyl ester (U.S. Pat. No. 4,287,341) in step 1. MS (EI) for C10H9ClN2O2: 225 MH+).

7-(benzyloxy)-4-chloro-8-methoxyquinazoline. Prepared according to the method of reagent preparation 1 using 2-amino-3-methoxy-4-(phenylmethoxy)benzoic acid (J. Med. Chem. 1992, 35(14), 2703-10) in step 1. MS (EI) for C16H13ClN2O2: 301 MH+).

4,6-dichloro-7,8-dimethoxyquinazoline. Prepared according to the method of reagent preparation 1 using 2-amino-5-chloro-3,4-dimethoxybenzoic acid (U.S. Pat. No. 4,287,341) in step 1. MS (EI) for C10H8Cl2N2O2: 260 MH+).

6-bromo-4,7-dichloroquinazoline. Synthesized according to the method of reagent preparation 1 by using 2-amino-5-bromo-4-chlorobenzoic acid in step 1. MS (EI) for C8H3BrCl2N2: 277 (MH+).

4-chloro-6-iodo-7-methoxyquinazoline. Synthesized according to the method of reagent preparation 1 by N-iodosuccinimide iodination of methyl 2-amino-4-methoxybenzoate to give methyl 5-iodo-2-amino-4-methoxybenzoate then proceeding with step 1. 1H NMR (400 MHz, CDCl3): 8.97, (s, 1H), 8.75, 7.31 (s, 1H), 4.08 (s, 3H). GC-MS for C9H6ClIN2O: 319 (M+).

7-bromo-4-chloro-8-methoxyquinazoline and 7-bromo-4-chloro-6-methoxyquinazoline. Synthesized according to the method of reagent preparation 1 by nitration and hydrogenation of methyl 4-bromo-3-methoxybenzoate to give a separable mixture of methyl 4-bromo-3-methoxy-2-aminobenzoate and methyl 4-bromo-5-methoxy-2-aminobenzoate then proceeding with step 1 individually. 7-bromo-4-chloro-8-methoxyquinazoline: 1H NMR (400 MHz, CDCl3): 9.09, (s, 1H), 7.92 (d, 1H), 7.87 (d, 1H), 4.21 (s, 3H). GC-MS for C9H6BrClN2O: 272 (M+). 7-bromo-4-chloro-6-methoxyquinazoline: 1H NMR (400 MHz, CDCl3): 8.95, (s, 1H), 8.40 (d, 1H), 7.45 (d, 1H), 4.18 (s, 3H), GC-MS for C9H6BrClN2O: 272 (M+).

8-bromo-4-chloro-6-methyl-quinazoline. Synthesized according to the method of reagent preparation 1 using 2-amino-3-bromo-5-methylbenzoic acid in step 1. GC-MS (EI) for C9H6BrClN2: 257 (M+).

4-chloro-6-(methylsulfonyl)quinazoline. Synthesized according to the method of reagent preparation 1 using 6-(methylsulfonyl)quinazolin-4(3H)-one in step 2. 6-(methylsulfonyl)quinazolin-4(3H)-one was obtained by the one step oxidation of 6-(methylthio)quinazolin-4(3H)-one (J. Med. Chem. 1983, 26(3), 420-5). MS (EI) for C9H7ClN2O2: 242 (M+).

Reagent Preparation 2 4-chloro-5-methyl-6-(phenylmethyl)pyrimidine

Prepared from 4,6-dichloro-5-methylpyrimidine and benzyl zinc bromide (0.5 M solution in tetrahydrofuran) according to the procedure described in WO 2007/146824 as a colorless oil. 1H NMR (400 MHz, CDCl3): 8.78 (s, 1H), 7.33-7.18 (m, 5H), 4.19 (s, 2H), 2.36 (s, 3H); MS (EI) for C12H11ClN2: 219 (MH+).

Reagent Preparation 3 4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline

STEP 1: To a cooled (0° C.) solution of 4,4-dimethylcyclohexanone (21 g, 0.17 mol) and dimethyl carbonate (45 g, 0.50 mol) in THF (400 mL) was added NaH (60% wt/wt in mineral oil, 17 g, 0.43 mol) portionwise over 30 minutes. The resulting slurry was allowed to stir at ambient temperature for 30 minutes followed by two hours at reflux. The reaction mixture was cooled (0° C.) and MeOH (30 mL) was added dropwise over 20 minutes. The resulting slurry was partitioned between 10% aqueous citric acid and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo. Purification by vacuum distillation provided methyl 2-hydroxy-5,5-dimethylcyclohex-1-enecarboxylate (22.5 g, 75% yield). 1H NMR (400 MHz, CDCl3) δ 12.15 (s, 1H), 3.75 (s, 3H), 2.29 (t, 2H), 2.03 (s, 2H), 1.44 (t, 2H), 0.96 (s, 6H); MS (EI) for C10H16O3: 184 (M+).

STEP 2: A solution of methyl 2-hydroxy-5,5-dimethylcyclohex-1-enecarboxylate (10.0 g, 54 mmol) and ammonium acetate (10 g, 130 mmol) in ethanol (50 mL) was heated to reflux for 2 hours. The reaction was concentrated to one third original volume, and then diluted with ethyl acetate (100 mL). The organic solution was washed with water (100 mL) and brine (50 mL) and then dried over anhydrous sodium sulfate. After filtration and concentration, the residue was purified by silica gel column chromatography (ethyl acetate/hexanes, 1:8) to afford methyl 2-amino-5,5-dimethylcyclohex-1-enecarboxylate (7.42 g, 75% yield) as a yellow solid. MS (EI) for C10H17NO2: 184 (MH+).

STEP 3: 2-amino-5,5-dimethylcyclohex-1-enecarboxylate (7.42 g, 40 mmol) was dissolved in N,N-dimethylformamide dimethylacetal (50 mL) and heated to 110° C. for 18 hours. The resulting solution was cooled to room temperature and concentrated to provide methyl 2-((dimethylamino)methyleneamino)-5,5-dimethylcyclohex-1-enecarboxylate (9.5 g, 98% yield) as an oil. 1H NMR (400 MHz, CDCl3): 3.65 (s, 3H), 3.49 (s, 1H), 2.95 (s, 6H), 2.35 (m, 2H), 2.15 (br s, 2H), 1.41 (t, 2H), 0.95 (s, 6H); MS (EI) for C13H22N2O2: 239 (MH+).

STEP 4: A solution of methyl 2-((dimethylamino)methyleneamino)-5,5-dimethylcyclohex-1-enecarboxylate (9.5 g, 40 mol) in 7.0M ammonia in methanol (35 mL) was stirred at 25° C. for 90 minutes then concentrated to an oil. The residue was purified by silica gel column chromatography (ethyl acetate/hexanes, 1:8) to give 6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4(3H)-one (6.41 g, 90% yield) as a white solid. 1H NMR (400 MHz, d6-DMSO): 7.96 (s, 1H), 2.52 (t, 2H), 2.14 (s, 2H), 1.48 (t, 2H), 0.93 (s, 6H); MS (EI) for C10H14N2O: 179 (MH+).

STEP 5: To 6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4(3H)-one (6.41 g, 36 mmol) in chloroform (10 mL) added phosphorus oxychloride (10 mL) and refluxed for 2 hours. The mixture was concentrated to an oil, then diluted with ethyl acetate (80 mL) and washed with saturated sodium carbonate (50 mL) and brine (25 mL). The solution was dried over anhydrous sodium sulfate, filtered and concentrated, then the residue purified by silica gel column chromatography (ethyl acetate/hexanes, 1:8) to give 4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (5.3 g, 75% yield) as a yellow solid. 1H NMR (400 MHz, CDCl3): 8.72 (s, 1H), 2.52 (t, 2H), 2.14 (s, 2H), 1.48 (t 2H), 0.93 (s, 6H); MS (EI) for C10H13ClN2: 197 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 or 2 the following reagents were prepared. Alternative starting materials were available commercially unless otherwise indicated.

4-chloro-6-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine. Prepared according to the method of reagent preparation 3; using 4-methyl-2-oxo-cyclopentanecarboxylic acid methyl ester (J. Chem. Soc. Perkin Trans 1 1987, 7, 1485-8) in step 2. 1H NMR (400 MHz, CDCl3): 8.78 (s, 1H), 3.20 (m, 2H), 2.70 (m, 3H), 1.22 (d, 3H). GC/MS (EI) for C8H9ClN2: 168 (M+).

4-chloro-6-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine. Prepared according to the method of reagent preparation 3 using 1-cyclopropyl-4-oxo-3-piperidinecarboxylic acid methyl ester (Heterocycles, 1999, 50(2), 867-874) in step 2. 1H NMR (400 MHz, CDCl3): 8.78 (s, 1H), 3.79 (s, 2H), 2.98 (m, 4H), 1.88 (m, 1H), 0.60 (m, 2H), 0.54 (m, 2H). MS (EI) for C10H12ClN3: 210 (MH+).

4-chloro-6-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine. Prepared according to the method of reagent preparation 3 using 1-cyclopropyl-4-oxo-3-pyrrolidinecarboxylic acid methyl ester in step 2. MS (EI) for C9H10ClN3: 196 (MH+).

4-chloro-6-p-tolyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine. Prepared according to the method of reagent preparation 3 using 1-(4-methylphenyl)-4-oxo-3-pyrrolidinecarboxilic acid ethyl ester in step 2. 1H NMR (400 MHz, CDCl3): 8.92 (s, 1H), 7.14 (d, 2H), 6.62 (d, 2H), 4.70 (m, 4H), 2.30 (s, 3H). MS (EI) for C13H12ClN3: 246 (MH+).

4-chloro-7-methyl-7-phenyl-5,6,7,8-tetrahydroquinazoline. Prepared according to the method of reagent preparation 3 using 4-methyl-2-oxo-4-phenyl cyclohexanecarboxylic acid methyl ester (J. Org. Chem. 1991, 56(21), 6199-205) in step 1. MS (EI) for C15H15ClN2: 259 (MH+).

4-chloro-5-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine: Synthesized according to the method of reagent preparation 3 using ethyl 2-oxo-5-phenylcyclopentanecarboxylate in step 2. MS (EI) for C13H11ClN2: 231 (MH+).

4-chloro-7,7-dimethyl-5,6,7,8-tetrahydroquinazoline: Synthesized according to the method of reagent preparation 3 using ethyl 4,4-dimethyl-2-oxocyclohexanecarboxylate in step 2. 1H NMR (400 MHz, CDCl3): 8.91 (s, 1H), 2.90 (s, 2H), 2.88 (tr, 2H), 1.73 (tr, 2H), 1.07 (s, 6H); MS (EI) for C10H13ClN2: 197 (MH+).

4′-chloro-7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]. Prepared according to the method of reagent preparation 3 using spiro[2.5]octan-6-one in step 1. 1H NMR (400 MHz, CDCl3) δ 8.73 (s, 1H), 3.00 (t, 2H), 2.63 (s, 2H), 1.69 (t, 2H), 0.52 (s, 4H); MS (EI) for C10H11ClN2: 194 (M+).

4-chloro-6,6-difluoro-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using 4,4-difluorocyclohexanone in step 1. MS (EI) for C8H7ClF2N2: 204 (M+).

(R)-4-chloro-7-methyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using (R)-3-methylcyclohexanone in step 1. MS (EI) for C9H11ClN2: 182 (M+).

4-chloro-2,6-dimethyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using 4-methylcyclohexanone in step 1 and 1,1-dimethoxy-N,N-dimethylethanamine in step 3. MS (EI) for C10H13ClN2: 196 (M+).

4-chloro-6-ethyl-2-methyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using 4-ethylcyclohexanone in step 1 and 1,1-dimethoxy-N,N-dimethylethanamine in step 3. MS (EI) for C11H15ClN2: 210 (M+).

4-chloro-7-(trifluoromethyl)-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using methyl 2-hydroxy-4-(trifluormethyl)cyclohex-1-enecarboxylate in step 2. MS (EI) for C9H8ClF3N2: 236 (M+).

(trans)-4-chloro-6,7-dimethyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using (trans) 3,4-dimethylcyclohexanone in step 1. MS (EI) for C10H13ClN2: 196 (M+).

4-chloro-6-(trifluoromethyl)-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using 4-(trifluormethyl)cyclohexanone in step 1. MS (EI) for C9H8ClF3N2: 236 (M+).

(S)-4-chloro-7-methyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using (S)-3-methylcyclohexanone (US20060293364) in step 1. MS (EI) for C9H11ClN2: 182 (M+).

4-chloro-5-(trifluoromethyl)-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using methyl 2-hydroxy-6-(trifluormethyl)cyclohex-1-enecarboxylate in step 2. MS (EI) for C9H8ClF3N2: 236 (M+).

4-chloro-7-vinyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using 3-vinylcyclohexanone (J. Med. Chem. 1987, 30, 1177-1186) in step 1. MS (EI) for C10H11ClN2: 194 (M+).

4-chloro-8,8-dimethyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using 2,2-dimethylcyclohexanone in step 1. MS (EI) for C10H13ClN2: 196 (M+).

4-chloro-6,6,7-trimethyl-5,6-dihydroquinazoline. Synthesized according to the method of reagent preparation 3 using 3,4,4-trimethylcyclohex-2-enone (J. Am. Chem. Soc. 1994, 116, 2902-2913) in step 1. MS (EI) for C11H13ClN2: 208 (M+).

(S)-4-chloro-8-vinyl-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidine. Synthesized according to the method of reagent preparation 3 using (S)-3-vinylcycloheptanone (prepared using procedure for (S)-3-vinylcyclohexanone in Org. Lett. 2003, 5, 97-99, but starting with (Z)-cyclohept-2-enone) in step 1. MS (EI) for C11H13ClN2: 208 (M+).

4-chloro-6,6-dimethyl-5,6-dihydroquinazoline. Synthesized according to the method of reagent preparation 3 using 4,4-dimethylcyclohex-2-enone in step 1. MS (ES) for C10H11ClN2: 195 (MH+).

4-chloro-6,6,8-trimethyl-5,6-dihydroquinazoline. Synthesized according to the method of reagent preparation 3 using 2,4,4-trimethylcyclohex-2-enone in step 1. MS (EI) for C11H13ClN2: 209 (MH+).

4-chloro-6,6,7,8-tetramethyl-5,6-dihydroquinazoline. Synthesized according to the method of reagent preparation 3 using 2,3,4,4-tetramethylcyclohex-2-enone (J. Org. Chem. 1981, 46, 1515-1521) in step 1. MS (EI) for C12H15ClN2: 223 (MH+).

(S)-4-chloro-7-ethyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 3 using (S)-3-ethylcyclohexanone (Tetrahedron: Asymmetry, 1997, 8, 1253-1257) in step 1. MS (EI) for C10H13ClN2: 197 (MH+).

Reagent Preparation 4

Step 1: A solution of methyl 4-methyl-2-oxocyclopentanecarboxylate (0.42 g, 2.69 mmol), 2-methyl-2-thiopseudourea sulfate (1.10 g, 7.9 mmol) and potassium hydroxide (0.50 g, 8.9 mmol) in water (12 mL) was stirred at 25° C. for 30 minutes, and then heated to reflux for 4 hours. The reaction was cooled to 0° C. by adding ice and a precipitate was formed. The solid product was removed by filtration and the filter cake dried to give 6-methyl-2-(methylthio)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (0.19 g, 43% yield) as a white solid. 1H NMR (400 MHz, d6-DMSO): 2.87 (m, 2H), 2.53 (s, 3H), 2.37 (m, 2H), 2.28 (s, 3H), 1.49 (m, 1H), 1.02 (d, 3H).

Step 2: A solution of 6-methyl-2-(methylthio)-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one (0.19 g, 0.97 mmol) in phosphorous oxychloride (5.0 mL) was heated to 95° C. for 1 hour. After cooling the reaction was concentrated, and the residue dissolved in ethyl acetate (50 mL) and washed with cold water (25 mL), 0.1 M aqueous sodium hydroxide (25 mL) and brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was chromatographed on silica gel (diethyl ether/hexanes, 1:10) and the product containing fractions concentrated. The residue thus obtained was purified further by preparative reverse phase HPLC (0.1% aqueous ammonium acetate-acetonitrile to give 4-chloro-6-methyl-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (25 mg, 12% yield) as an oil. 1H NMR (400 MHz, d6-DMSO): 3.12 (m, 2H), 2.61 (m, 2H), 2.56 (s, 3H), 1.25 (m, 1H), 1.18 (d, 3H); MS (EI) for C9H11ClN2S: 215 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents the following reagents were prepared.

4-chloro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine. Synthesized according to the method of reagent preparation 4 by replacement of step 1 with 1,2,3,5,6,7-hexahydro-2-thioxo-4H-cyclopentapyrimidin-4-one S-alkylation with iodomethane and proceeding to step 2. 1H NMR (400 MHz, CDCl3): 3.00 (tr, 2H), 2.92 (tr, 2H), 2.56 (s, 3H), 2.14 (m, 2H).

2-(benzylthio)-4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine. Synthesized according to the method of reagent preparation 4 by replacement of step 1 with 1,2,3,5,6,7-hexahydro-2-thioxo-4H-cyclopentapyrimidin-4-one S-alkylation with benzyl bromide and proceeding to step 2. 1H NMR (400 MHz, CDCl3): 7.43 (d, 2H), 7.27 (tr, 2H), 7.22-7.18 (m, 1H), 4.38 (s, 2H), 2.95 (tr, 2H), 2.86 (tr, 2H), 2.08 (m, 2H).

4-chloro-2-(ethylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine. Synthesized according to the method of reagent preparation 4 by replacement of step 1 with 1,2,3,5,6,7-hexahydro-2-thioxo-4H-cyclopentapyrimidin-4-one S-alkylation with iodoethane and proceeding to step 2. 1H NMR (400 MHz, CDCl3): 3.08 (q, 2H), 2.93 (tr, 2H), 2.86 (tr, 2H), 2.08 (m, 2H), 1.32 (tr, 3H).

Reagent Preparation 5

STEP 1: A solution of ethyl 4-methyl-3-oxopentanoate (3.0 g, 19.0 mmol) and potassium carbonate (7.86 g, 56.9 mmol) in THF (40 mL) was stirred at room temperature for 3 h under N2 (g). The mixture was cooled to 0° C. and methyl iodide (3.23 g, 22.8 mmol) was added dropwise over 5 min. The reaction mixture was allowed to warm to room temperature and stirred for 16 h. Subsequent filtration and concentration provided ethyl 2,4-dimethyl-3-oxopentanoate (2.89 g, 89% yield) as a clear yellow oil that was used without further purification. MS (EI) for C9H16O3: 172 (MH+).

STEP 2: To anhydrous ethanol (110 mL) was added sodium metal (1.16 g, 50.4 mmol) and the mixture was stirred until dissolution was complete. To this solution was added thiourea (1.79 g, 23.5 mmol) and ethyl 2,4-dimethyl-3-oxopentanoate (2.89 g, 16.8 mmol). The reaction mixture was stirred at 85° C. for 20 h then cooled and concentrated. The residue was diluted with water, the pH adjusted to 4 with 1 N hydrochloric acid then extracted with ethyl acetate (3×80 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to provide 6-isopropyl-5-methyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (2.40 g, 78% yield) as a tan solid that was used without further purification. C8H12N2OS: 185 (MH+).

STEP 3: To a solution of 30% hydrogen peroxide (12 mL) and water (23 mL) was slowly added 6-isopropyl-5-methyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (1.0 g, 5.4 mmol). The reaction mixture was stirred at 70° C. for 3 h. After cooling to room temperature, saturated sodium carbonate was slowly added until the pH reached 10. To this mixture was slowly added a 1 M solution of sodium thiosulfate until residual peroxide was quenched, whereupon the aqueous solution was concentrated to dryness. The residue was suspended in chloroform (100 mL), filtered to remove inorganic salts and the filtrate concentrated to provide 6-isopropyl-5-methylpyrimidin-4-ol (0.25 g, 30% yield) as a white solid that was used without further purification. MS (EI) for C8H12N2O: 153 (MH+).

STEP 4: To 6-isopropyl-5-methylpyrimidin-4-ol (0.25 g, 1.6 mmol) was added neat phosphorous oxychloride (5 mL) and the mixture stirred at 70° C. for 3 h. After cooling to room temperature the solution was concentrated, diluted with water then neutralized by portionwise addition of saturated sodium carbonate solution. The aqueous mixture was extracted with ethyl acetate and the organic solution washed with brine then dried over anhydrous sodium sulfate. Filtration and concentration provided 4-chloro-6-isopropyl-5-methylpyrimidine (30 mg, 11% yield) as a brown oil that was used without further purification. MS (EI) for C8H11ClN2: 170 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagents were prepared.

4-chloro-5-(cyclopropylmethyl)-6-methylpyrimidine. Synthesized according to the method of reagent preparation 5 using methyl 3-oxobutanoate and (bromomethyl)cyclopropane in step 1. MS (EI) for C9H11ClN2: 182 (MH).

4-chloro-5-(4-chlorobenzyl)-6-methylpyrimidine. Synthesized according to the method of reagent preparation 5 using methyl 3-oxobutanoate and 1-(bromomethyl)-4-chlorobenzene in step 1. MS (EI) for C12H10Cl2N2: 254 (MH+).

4-chloro-5-(3,5-difluorobenzyl)-6-methylpyrimidine. Synthesized according to the method of reagent preparation 5 using methyl 3-oxobutanoate and 1-(bromomethyl)-3,5-difluorobenzene in step 1. MS (EI) for C12H9ClF2N2: 255 (MH+).

4-chloro-6-methyl-5-(3-(trifluoromethyl)benzyl)pyrimidine. Synthesized according to the method of reagent preparation 5 using methyl 3-oxobutanoate and 1-(chloromethyl)-3-(trifluoromethyl)benzene in step 1. MS (EI) for C13H10ClF3N2: 287 (MH+).

4-chloro-5-(1-(3-fluorophenyl)ethyl)-6-methylpyrimidine. Synthesized according to the method of reagent preparation 5 using methyl 3-oxobutanoate and 1-(3-fluorophenyl)ethyl methanesulfonate in step 1. MS (EI) for C13H12ClFN2: 251 (MH+).

4-chloro-5-(4-chloro-3-fluorobenzyl)-6-methylpyrimidine. Synthesized according to the method of reagent preparation 5 using methyl 3-oxobutanoate and 4-(bromomethyl)-1-chloro-2-fluorobenzene in step 1. MS (EI) for C12H9Cl2FN2: 272 (MH+).

4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidine. Synthesized according to the method of reagent preparation 5 using methyl 3-oxobutanoate and 1-(bromomethyl)-4-fluorobenzene in step 1. MS (EI) for C12H10ClFN2: 237 (MH+).

4-chloro-5-(2-fluorobenzyl)-6-methylpyrimidine. Prepared according to the method of reagent preparation 5 by using methyl 3-oxobutanoate and 1-(bromomethyl)-2-fluorobenzene in step 1. 1H NMR (400 MHz, CDCl3): 8.79 (1H), 7.28 to 7.12 (m, 1H), 7.14 to 6.97 (m, 2H), 6.82 (dd, 1H), 4.19 (s, 2H), 2.47 (s, 3H), GC-MS for C12H10ClFN2: 236 (M+).

4-chloro-5-ethyl-6-isopropylpyrimidine. Prepared according to reagent preparation 5 by using ethyl isobutyrylacetate and iodoethane in step 1. MS (EI) for C9H13ClN2: 184 (M+).

5-benzyl-4-chloro-6-methylpyrimidine. Prepared according to reagent preparation 5 by using ethyl 2-benzylacetoacetate in step 2. MS (EI) for C12H11ClN2: 219 (MH+).

4-chloro-6-ethyl-5-methyl-pyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxopentanoate in step 1. 1H NMR (400 MHz, CDCl3): 8.74 (s, 1H), 2.85 (q, 2H), 2.39 (s, 3H), 1.30 (t, 3H); MS (EI) for C7H9ClN2: 158 (MH+).

4-chloro-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 5 using ethyl 2-oxocyclohexanecarboxylate in step 2. 1H NMR (400 MHz, CDCl3): 8.7 (s, 1H), 2.90 (m, 2H), 2.78 (m, 2H), 1.88 (m, 4H). MS (EI) for C8H9ClN2: 169 (MH+).

4-chloro-5,6-diethyl-pyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxopentanoate and iodoethane in step 1.

4-chloro-6-methyl-5-(1-methylethyl)-pyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 2-iodopropane in step 1. 1H NMR (400 MHz, DMSO-d6): 8.70 (s, 1H), 3.49 (h, 1H), 2.60 (s, 3H), 1.34 (d, 6H); MS (EI) for C8H11ClN2: 171 (MH+).

4-chloro-5-isobutyl-6-methylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 1-iodo-2-methylpropane in step 1. MS (EI) for C9H13ClN2: 184 (M+).

5-benzyl-4-chloro-6-ethylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxopentanoate and benzyl bromide in step 1. 1H NMR (400 MHz, CDCl3): 8.83 (s, 1H), 7.27 (m, 3H), 7.08 (m, 2H), 4.22 (s, 2H), 2.79 (q, 2H), 1.20 (t, 3H); MS (EI) for C13H13ClN2: 234 (MH+).

4-chloro-5-(3-fluorobenzyl)-6-methylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 3-fluorobenzylbromide in step 1. MS (EI) for C12H10ClFN2: 237 (MH+).

4-chloro-5-(3-chlorobenzyl)-6-methylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 3-chlorobenzylbromide in step 1. MS (EI) for C12H10Cl2N2: 253 (MH+).

4-chloro-6-methyl-5-phenoxy-pyrimidine. Prepared according to reagent preparation 5 by using ethyl 3-oxo-2-phenoxybutanoate in step 2. MS (EI) for C11H9ClN2O: 221 (MH+).

4-chloro-6-methyl-5-(1-phenylethyl)pyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and (1-bromoethyl)benzene in step 1. MS (EI) for C13H13ClN2: 233 (MH+).

4-chloro-5-(2-chlorobenzyl)-6-methylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 2-chlorobenzyl bromide in step 1.

4-chloro-6-methyl-5-(4-methylbenzyl)pyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 4-methylbenzyl bromide in step 1. 1H NMR (400 MHz, CDCl3): 8.76 (s, 1H), 7.10 (d, 2H), 6.99 (d, 2H), 4.15 (s, 2H), 2.50 (s, 3H), 2.32 (s, 3H); MS (EI) for C13H13ClN2: 233 (MH+).

4-chloro-5-(4-methoxybenzyl)-6-methylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 4-methoxybenzyl bromide in step 1. 1H NMR (400 MHz, CDCl3): 8.76 (s, 1H), 7.02 (d, 2H), 6.83 (d, 2H), 4.13 (s, 2H), 3.78 (s, 3H), 2.51 (s, 3H); MS (EI) for C13H13ClN2O: 249 (MH+).

4-chloro-5-(3-methoxybenzyl)-6-methylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 3-methoxybenzyl bromide in step 1. 1H NMR (400 MHz, DMSO-d6): 8.81 (s, 1H), 7.22 (m, 1H), 6.81 (m, 1H), 6.70 (s, 1H), 6.63 (d, 1H), 4.17 (s, 2H), 3.71 (s, 3H), 2.47 (s, 3H); MS (EI) for C13H13ClN2O: 249 (MH+).

4-chloro-6-methyl-5-(3-methylbenzyl)pyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 3-methylbenzyl bromide in step 1. 1H NMR (400 MHz, CDCl3): 8.77 (s, 1H), 7.18 (m, 1H), 7.05 (d, 1H), 6.88 (m, 2H), 4.16 (s, 2H), 2.50 (s, 3H), 2.31 (s, 3H); MS (EI) for C13H13ClN2: 233 (MH+).

5-benzyl-4-chloropyrimidine. Prepared according to reagent preparation 5 by using ethyl 2-benzyl-3-hydroxyacrylate (J. Am. Chem. Soc. 1974, 96, 2121-2129) in step 2. MS (EI) for C11H93ClN2: 205 (MH+).

4-chloro-5-(3-chloro-5-fluorobenzyl)-6-methylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 3-chloro-5-fluorobenzyl bromide in step 1. MS (EI) for C12H9Cl2FN2: 271 (MH+).

4-chloro-5-(2-methoxybenzyl)-6-methylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 2-methoxylbenzyl bromide in step 1. 1H NMR (400 MHz, methanol-d4): 8.71 (s, 1H), 7.23 (m, 1H), 6.98 (d, 1H), 6.83 (m, 1H), 6.71 (d, 1H), 4.16 (s, 2H), 3.85 (s, 3H), 2.45 (s, 3H).

4-chloro-6-methyl-5-(2-methylbenzyl)pyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 2-methylbenzyl bromide in step 1. 1H NMR (400 MHz, methanol-d4): 8.77 (s, 1H), 7.23 (d, 1H), 7.12 (m, 1H), 7.03 (m, 1H), 6.45 (d, 1H), 4.16 (s, 2H), 2.43 (s, 3H), 2.42 (s, 3H).

4-chloro-5-(3,4-difluorobenzyl)-6-methylpyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 3,4-difluorobenzyl bromide in step 1. MS (EI) for C12H9ClF2N2: 255 (MH+).

4-chloro-6-methyl-5-(4-(trifluoromethyl)benzyl)pyrimidine. Prepared according to reagent preparation 5 by using methyl 3-oxobutanoate and 1-(chloromethyl)-4-(trifluoromethyl)-benzene in step 1. MS (EI) for C13H10ClF3N2: 287 (MH+).

5-benzyl-4-chloro-6-(trifluoromethyl)pyrimidine. Prepared according to reagent preparation 5 by using ethyl 4,4,4-trifluoroacetoacetate and benzyl bromide in step 1. MS (EI) for C12H8ClF3N2: 272 (M+).

4-chloro-6,6-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine. Synthesized according to the method of reagent preparation 5 using ethyl 4,4-dimethyl-2-oxo-cyclopentanecarboxylate in step 2. MS (EI) for C9H11ClN2: 183 (MH+).

Reagent Preparation 6 6-chloro-5-methyl-N-phenylpyrimidin-4-amine

STEP 1: To a mixture of 4,6-dichloro-5-methylpyrimidine (2.27 g, 13.9 mmol) and aniline (1.0 g, 10.7 mmol) in isopropanol (15 mL) was added concentrated aqueous hydrochloric acid (1.5 mL) and heated to reflux for 2.5 h. The mixture was then concentrated and the residue triturated with ethyl acetate:isopropanol 4:1. The solid was collected by filtration and washed with additional ethyl acetate:isopropanol 4:1 then dried to give 6-chloro-5-methyl-N-phenylpyrimidin-4-amine (2.0 g, 67% yield). 1H NMR (400 MHz, d6-DMSO): 8.85 (s, 1H), 8.26 (s, 1H), 7.60 (d, 2H), 7.35 (tr, 2H), 7.11 (tr, 1H), 2.31 (s, 3H). MS (EI) for C11H10ClN3: 220 (MH+).

Reagent Preparation 8

STEP 1: To a suspension of potassium tert-butoxide (10.6 g, 95.0 mmol) in tetrahydrofuran (100 mL) were added methyl acetoacetate (10.0 g, 86.0 mmol) and tert-butanol (0.83 mL, 8.6 mmol) at room temperature. The resulting solution was stirred for 1 h, and then 4-fluorobenzylbromide (11.2 mL, 90 mmol) was added. The reaction mixture was stirred at room temperature for 18 h, and then partitioned between water and ethyl acetate. The aqueous layer was extracted with ethyl acetate (3×), the combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Column chromatography of the residue on silica (5-20% ethyl acetate in hexanes) gave methyl 2-(4-fluorobenzyl)-3-oxobutanoate (14.5 g, 75% yield) as a colorless oil which was used in the next step without further purification.

STEP 2: To a suspension of acetamidine hydrochloride (0.54 g, 5.71 mmol) in methanol (8 mL) was added a 30% solution of sodium methoxide in methanol (1.1 mL, 5.7 mmol), and the resulting solution was stirred at room temperature for 45 min. Then, a solution of methyl 2-(4-fluorobenzyl)-3-oxobutanoate (0.80 g, 3.57 mmol) in methanol (3 mL) was added dropwise, and the resulting mixture was stirred at room temperature for 22 h. Water (100 mL) was added, and the mixture was extracted with chloroform (4×50 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated to provide 5-(4-fluorobenzyl)-2,6-dimethylpyrimidin-4-ol (0.74 g, 89% yield) as a colorless solid. 1H NMR (400 MHz, methanol-d4): 7.21 (m, 2H), 6.96 (m, 2H), 3.84 (s, 2H), 2.35 (s, 3H), 2.25 (s, 3H); MS (EI) for C13H13FN2O: 233 (MH+).

STEP 3: A solution of 5-(4-fluorobenzyl)-2,6-dimethylpyrimidin-4-ol (730 mg, 3.14 mmol) in phosphorus oxychloride (10 mL) was stirred at 60° C. for 90 min. The reaction mixture was concentrated and ethyl acetate (50 mL) was added to the residue. The organic solution was washed with saturated sodium bicarbonate (50 mL), water (50 mL), and brine (50 mL), dried over sodium sulfate, filtered and concentrated. Column chromatography of the residue on silica (5-40% ethyl acetate in hexanes) afforded 4-chloro-5-(4-fluorobenzyl)-2,6-dimethylpyrimidine (527 mg, 67% yield) as a colorless solid. 1H NMR (400 MHz, CDCl3): 7.21 (m, 2H), 6.98 (m, 2H), 4.12 (s, 2H), 2.67 (s, 3H), 2.45 (s, 3H); MS (EI) for C13H12ClFN2: 250 (M+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagents were prepared.

4-Chloro-7-methyl-5,6,7,8-tetrahydroquinazoline. Prepared according to the method of reagent preparation 8 by using ethyl 4-methyl-2-oxocyclohexanecarboxylate and formamidine formate in step 2. GC-MS for C9H11ClN2: 182 (M+).

4-Chloro-6-ethyl-5,6,7,8-tetrahydroquinazoline. Prepared according to the method of reagent preparation 8 by using methyl 5-ethyl-2-oxocyclohexanecarboxylate and formamidine formate in step 2. GC-MS for C10H13ClN2: 196 (M+).

4-Chloro-5-ethyl-2,6-dimethylpyrimidine. Synthesized according to the method of reagent preparation 8 by using ethyliodide in step 1. MS (EI) for C8H11ClN2: 171 (MH+).

4-Chloro-5-(cyclopropylmethyl)-2,6-dimethylpyrimidine. Synthesized according to the method of reagent preparation 8 by using cyclopropylmethylbromide in step 1. MS (EI) for C10H13ClN2: 197 (MH+).

4-Chloro-2,6,6-trimethyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 8 by using methyl 5,5-dimethyl-2-oxocyclohexanecarboxylate in step 2. MS (EI) for C11H15ClN2: 211 (MH+).

4-Chloro-6,6-dimethyl-2-(pyridin-2-yl)-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 8 by using 2-hydroxy-5,5-dimethylcyclohex-1-enecarboxylate and picolinimidamide hydrochloride in step 2. MS (ES) for C15H16ClN3: 274 (MH+).

2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)propan-2-ol. Synthesized according to the method of reagent preparation 8 using 2-hydroxy-5,5-dimethylcyclohex-1-enecarboxylate and 2-hydroxy-2-methylpropanimidamide hydrochloride in step 2. MS (ES) for C13H19ClN2: 255 (MH+).

4-chloro-2,6-dimethyl-5-(1-methylethyl)pyrimidine. Synthesized according to the method of reagent preparation 8 by using 2-iodopropane in step 1. MS (EI) for C9H13ClN2: 185 (MH+).

(7S)-4-chloro-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 8 by using methyl (4S)-4-ethyl-2-oxocyclohexanecarboxylate (reagent preparation 3) in step 2. MS (EI) for C11H15ClN2: 211 (MH+).

4-chloro-6,6-dimethyl-2-(2-pyrrolidin-1-ylethyl)-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 8 by using 1-pyrrolidinepropanimidamide in step 2. MS (EI) for C16H24ClN3: 294 (MH+).

Reagent Preparation 9

STEP 1: To a solution of phenylmethyl 2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (J. Bioorg. Med. Chem. 2007, 1106-1116) (2.4 g, 9.78 mmol) in THF (35 mL) was added dropwise a 1M solution of lithium bis(trimethylsilyl)amide in THF (11 mL) at −78° C. The solution was warmed up to 0° C., stirred at this temperature for 1 h, then cooled again to −78° C. 3-Fluorobenzaldehyde (1.3 mL, 12.7 mmol) was added in one portion. The reaction was stirred for 4 h while allowing it to slowly warm up to 0° C. Then, saturated ammonium chloride (20 mL) was added, and the layers were separated. The aqueous layer was extracted with ethyl acetate (2×20 mL) and the combined organic layers were washed with saturated sodium chloride (50 mL), dried over sodium sulfate, filtered and concentrated. Column chromatography on silica (gradient 20 to 100% ethyl acetate in hexanes) afforded phenylmethyl 3-[(3-fluorophenyl)(hydroxy)methyl]-2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (2.4 g, 66% yield) as mixture of diastereomers. MS (EI) for C21H20FNO4: 370.1 (MH+).

STEP 2: Mesyl chloride (0.31 mL, 3.97 mmol) was added in one portion to a solution of phenylmethyl 3-[(3-fluorophenyl)(hydroxy)methyl]-2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (0.73 g, 1.98 mmol) in anhydrous pyridine (5 mL) at 0° C. The reaction mixture was warmed up to room temperature and stirred for 1 h. Water (5 mL) and ethyl acetate (5 mL) were added, the layers were separated, and the aqueous layer was extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with saturated sodium chloride (15 mL) dried over sodium sulfate, filtered and concentrated to afford phenylmethyl 3-{(3-fluorophenyl)[methylsulfonyl)oxy]methyl}-2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate. MS (EI) for C22H22FNO6S: 448.1 (MH+).

STEP 3: Phenylmethyl 3-{(3-fluorophenyl)[methylsulfonyl)oxy]methyl}-2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate from step 2 was dissolved in THF (30 mL) and potassium tert-butoxide (1.11 g, 9.9 mmol) was added in one portion. After 15 min the reaction mixture was quenched with saturated ammonium chloride (20 mL). The layers were separated and the aqueous layer was extracted with 5:1 chloroform/isopropanol (3×20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated. Column chromatography in silica (10% methanol in dichloromethane) afforded 3-[(3-fluorophenyl)methyl)-2-methylpyridin-4(1H)-one (0.230 g, 53% for two steps) 1H NMR (400 MHz, CDCl3): 7.30 (d, 1H), 7.18-7.13 (m, 1H), 6.97 (d, 1H), 6.87-6.79 (m, 2H), 6.35 (d, 1H), 3.91 (s, 2H), 2.22 (s, 3H). MS (EI) for C13H12FNO: 218.1 (MH+).

STEP 4: A solution of 3-[(3-fluorophenyl)methyl)-2-methylpyridin-4(1H)-one (0.07 g, 0.32 mmol) in phosphorous oxychloride (3 mL) was heated to 55° C. for 16 h. Then the solution was cooled to room temperature and concentrated. The remaining residue was dissolved in ethyl acetate (10 mL), washed with 5% sodium bicarbonate (2×5 mL), and saturated sodium chloride (5 mL), dried over sodium sulfate, filtered and concentrated to afford 4-chloro-3-[(3-fluorophenyl)methyl]-2-methylpyridine. 1H NMR (400 MHz, CDCl3): 8.33 (d. 1H), 7.30-7.23 (m, 2H), 6.92-6.85 (m, 2H), 6.76 (d, 1H), 4.22 (s, 2H), 2.54 (s, 3H). MS (EI) for C13H11ClF: 236.0 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagents were prepared.

3-benzyl-4-chloro-2-methylpyridine. Synthesized according to the method of reagent preparation 9 using benzaldehyde in step 1. 1H NMR (400 MHz, CDCl3): 8.30 (d, 1H), 7.29-7.19 (m, 4H), 7.08 (d, 2H), 4.22 (s, 2H), 2.51 (s, 3H); MS (EI) for C13H12ClN: 218 (MH+).

4-chloro-3-(4-fluorobenzyl)-2-methylpyridine. Synthesized according to the method of reagent preparation 9 using 4-fluorobenzaldehyde in step 1. 1H NMR (400 MHz, CDCl3): 8.32 (d, 1H), 7.29 (d, 1H), 7.05-6.95 (m, 4H), 4.19 (s, 2H), 2.54 (s, 3H); MS (EI) for C13H11ClFN: 236 (MH+).

Reagent Preparation 10

STEP 1: To a solution of ethyl 3-bromobutanoate (6.0 mL, 42 mmol) in N,N-dimethylformamide (20 mL) at 0° C. was added piperidine (8.0 mL, 80 mmol) and the mixture was warmed to room temperature then stirred 16 h. The reaction mixture was diluted with ethyl acetate (200 mL) and washed with a solution of brine and 2.0M aqueous sodium hydroxide (4:1 v/v). The organic phase was then dried over anhydrous sodium sulfate, filtered and concentrated to give ethyl 4-piperidin-1-ylbutanoate (6.8 g, 81% yield) as brown oil. MS (EI) for C11H21NO2: 200 (MH+).

Step 2: To a solution of potassium hydroxide (11 g, 0.20 mol) in water (40 mL) was added a solution of ethyl 4-piperidin-1-ylbutanoate (6.8 g, 34 mmol) in ethanol (30 mL) and the mixture was stirred at 35° C. for 2 hours. The reaction was quenched by dropwise addition of 37% aqueous hydrochloric acid (15 mL) and the mixture was concentrated then dried under vacuum. The residue was suspended in chloroform (100 mL) followed by addition of catalytic N,N-dimethylformamide (0.2 mL) then dropwise addition of oxalyl chloride (15 mL, 170 mmol) and the mixture was stirred at 25° C. for 18 hours. The reaction mixture was concentrated to afford crude 4-piperidin-1-ylbutanoyl chloride hydrochloride. To a suspension of the 4-piperin-1-ylbutanoyl chloride hydrochloride (ca. 40 mmol) and 2-methyl-2-thiopseudourea sulfate (5.6 g, 20 mmol) in acetonitrile (100 mL) was added triethylamine (20 mL, 0.27 mol) in portions while cooling in an ice bath. The reaction was then allowed to warm to 25° C. over 1 h. The reaction mixture was filtered through Celite with an acetonitrile wash (100 mL). The filtrate was concentrated to afford methyl N,N′-bis-(4-piperidin-1-ylbutanoyl)imidothiocarbamate (10.6 g, 79% yield) as a brown oil that was used without further purification. MS (EI) for C20H36N4O2S: 397 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents bis-[2-(methoxy)ethoxy][(methylthio)methylidene]biscarbamate was prepared according to the method of reagent preparation 10 using 2-methoxyethyl chloroformate in step 2. MS (EI) for C10H18N2O6S: 295 (MH+).

Reagent Preparation 11

STEP 1: To a solution of 6-bromo-2-methyl-1H-imidazo[4,5-b]pyridine (3.40 g, 16.0 mmol) and diisopropylethylamine (6.5 mL, 65 mmol) in N,N-dimethylformamide (20 mL) cooled in an ice bath was added dropwise isobutyl chloroformate (2.51 mL, 19.2 mmol) and the mixture was warmed to room temperature. After 1 hour the reaction was diluted with ethyl acetate (80 mL) and washed with water (60 mL), 10% aqueous citric acid (40 mL) and brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to a slurry. The residue was triturated diethyl ether (100 mL) and the solid isolated by filtration to give isobutyl 6-bromo-2-methyl-1H-imidazo[4,5-b]pyridine-1-carboxylate (2.3 g, 46% yield). MS (EI) for C12H14BrN3O2: 313 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 isobutyl 2-(4-bromophenyl)-1H-imidazole-1-carboxylate was prepared according to the method of reagent preparation 11 using 2-(4-bromophenyl)-1H-imidazole and isobutyl chloroformate in step 1. MS (EI) for C14H15BrN2O2: 324 (MH+).

Isobutyl 6-bromo-1H-benzo[d]imidazole-1-carboxylate. Prepared according to the method of reagent preparation 11 using 5-bromo-1H-benzo[d]imidazole in step 1. MS (EI) for C12H13BrN2O2: 297/299 (MH+).

Reagent Preparation 12 5-Bromo-1-ethyl-1H-benzimidazole

5-bromo-1-ethyl-1H-benzimidazole was prepared in 3 steps from 1,4-dibromo-2-nitrobenzene according to the method described in (Bioorg. and Med. Chem. Lett. 2003, 13, 2485-2488). MS (EI) for C9H9BrN2: 226 (MH+).

Reagent Preparation 13 N-(5-bromothiazolo[5,4-b]pyridin-2-yl)benzamide

STEP 1: To a solution of ammonium thiocyanate (0.4 g, 5.0 mmol) in acetone (5 mL) was slowly added benzoyl chloride (0.6 mL, 5.0 mmol) and the suspension was heated to reflux for ten minutes. A solution of 6-bromo-2-chloro-3-pyridinamine (1.0 g, 4.8 mmol) in acetone (10 mL) was then added and the reaction mixture was refluxed for one hour. After cooling to room temperature the mixture was poured into water and partitioned with ethyl acetate (250 mL). The layers were separated and the aqueous layer was further extracted with ethyl acetate (2×, 100 mL). The combined organic layers were washed with brine (2×, 100 mL), dried over sodium sulfate, filtered and concentrated until a suspension formed. The white solid was collected by filtration to give N-(6-bromo-2-chloropyridin-3-ylcarbamothioyl)benzamide (1.6 g, 89%). 1H NMR (400 MHz, d6-DMSO): 12.62 (br s, 1H), 12.00 (br s, 1H), 8.37 (d, 1H), 8.00 (2d, 2H), 7.79 (d, 1H), 7.69 (t, 1H), 7.57 (t, 2H). MS (EI) for C13H9BrClN3OS: 370 (MH+).

STEP 2: A solution of N-(6-bromo-2-chloropyridin-3-ylcarbamothioyl)benzamide (1.5 g, 4.0 mmol) and sodium ethoxide (0.54 g, 8.0 mmol) in 1-methyl-2-pyrrolidinone (10 mL) was heated to 120° C. for 8 hours. After cooling the reaction mixture to room temperature the mixture was poured into water. The resulting solid was collected by filtration, then washed sequentially with water and diethyl ether. The filter cake was dried to give N-(5-bromothiazolo[5,4-b]pyridin-2-yl)benzamide (1.02 g, 76%). 1H NMR (400 MHz, d6-DMSO): 13.2 (br s, 1H), 8.16-8.10 (m, 3H), 7.72 (d, 1H), 7.70 (t, 1H), 7.59 (t, 2H). MS (EI) for C13H8BrN3OS: 336 (MH+).

Reagent Preparation 14

STEP 1: To a solution of 2-amino-5-bromopyridine (5.0 g, 29 mmol) in dioxane (60 mL) was added ethoxycarbonylisothiocyanate (3.4 mL, 29 mmol) in a dropwise manner and the mixture was allowed to stir for 18 h at room temperature. The mixture was then concentrated and the residue triturated with 10% ethyl acetate in hexanes. The solid was collected by filtration and dried to afford ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}carbamate (6.2 g, 69%) as a colorless solid. MS (EI) for C9H10BrN3O2S: 305 (MH+).

STEP 2: {[(5-Bromopyridin-2-yl)amino]carbonothioyl}carbamate was converted to 6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine according to methods in the literature, see 1) Monatshefte fuer Chemie, 1983, 114(6-7), 789-98 and 2) Synthesis, 2003, 11, 1649-1652. Thus, a mixture of hydroxylamine hydrochloride (375 mg, 5.4 mmol) and DIPEA (560 uL, 3.2 mmol) in 1:1 methanol:ethanol (8 mL) was stirred for 10 minutes at room temperature followed by addition of {[(5-bromopyridin-2-yl)amino]carbonothioyl}carbamate (500 mg, 1.62 mmol) and the resulting suspension was stirred for 2 h at room temperature then brought to 60° C. for an additional 2 h. The resulting solution was then cooled to room temperature and concentrated. The residue was then partitioned with ethyl acetate and saturated aqueous sodium bicarbonate. The organic solution was washed with brine, dried over anhydrous sodium sulfate then filtered and concentrated to give 6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine (340 mg, 98% yield) as a colorless crystalline solid. MS (EI) for C6H5BrN4: 214 (MH+).

STEP 3: A solution of 6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine (340 mg, 1.6 mmol), di-tert-butyl dicarbonate (370 mg, 1.6 mmol) and catalytic DMAP was stirred at 35° C. in THF (5 mL) for 18 h. An additional equivalent of di-tert-butyl dicarbonate was then added and stirring was continued for 48 h. The solution was then partitioned with ethyl acetate and water. The organic phase was washed with brine, dried over anhydrous sodium sulfate then filtered and concentrated. The residue was taken into dichloromethane and insoluble starting material was removed by filtration. The filtrate was concentrated and purified by silica gel chromatography to afford bis-(1,1-dimethylethyl)(6-bromo[1,2,4]triazolo[1,5-c]pyridine-2-yl)imidodicarbonate (284 mg, 43% yield) as an off white solid. 1H NMR (400 MHz, d6-DMSO): 9.45 (s, 1H), 7.91 (d, 1H), 7.86 (d, 1H), 1.41 (s, 18H).

Using analogous synthetic techniques and substituting with alternative starting reagents bis(1,1-dimethylethyl)(5-bromo-4-methyl-1,3-thiazol-2-yl)imidodicarbonate was prepared, according to the method of reagent preparation 14 using 5-bromo-4-methylthiazol-2-amine in step 3 and conducting the protection step at reflux temperature. 1H NMR (400 MHz, CDCl3): 2.30 (s, 3H), 1.53 (s, 18H).

Reagent Preparation 15 6-bromo-1-trityl-1H-imidazo[4,5-b]pyridine and 6-bromo-3-trityl-3H-imidazo[4,5-b]pyridine

STEP 1: A suspension of 2,3-diamino-5-bromopyridine (3.0 g, 16.00 mmol) in formic acid (30 mL) was heated to reflux for 3 hours. After cooling the reaction mixture to room temperature it was concentrated and the residue was taken into 50% ethyl acetate in toluene (100 mL) then concentrated and the process repeated once more to remove excess formic acid. The resulting solid was triturated with ethyl acetate and the solid residue collected by filtration to give 6-bromo-1H-imidazo[4,5-b]pyridine (3.7 g, 95%). GCMS (EI) for C6H4BrN3: 198 (M+).

STEP 2: To a solution of 6-bromo-1H-imidazo[4,5-b]pyridine (2.7 g, 11.0 mmol) in dimethylformamide (30 mL) at 0° C. was added 60% sodium hydride in mineral oil (0.53 g, 13.2 mmol) and the reaction mixture was stirred for 30 minutes, followed by the addition of a solution of triphenylmethyl chloride (3.2 g, 11.55 mmol) in dimethylformamide (5 mL). The reaction mixture was stirred at room temperature for 24 hours then quenched by the careful addition of water then partitioned with ethyl acetate (250 mL). The organic phase was washed with 10% aqueous citric acid (2×, 100 mL), brine (100 mL), saturated sodium bicarbonate (100 mL), brine (100 mL) then dried over anhydrous sodium sulfate, filtered and concentrated. Silica gel chromatography (hexane ethyl acetate 9:1 to 4:1) provided 6-bromo-3-trityl-3H-imidazo[4,5-b]pyridine (1.8 g, 37%). 1H NMR (400 MHz, CDCl3): 8.18 (d, 1H), 8.14 (d, 1H), 8.02 (s, 1H), 7.36-7.28 (m, 10H), 7.18-7.14 (m, 5H) and 6-bromo-1-trityl-1H-imidazo[4,5-b]pyridine (2.9 g, 60%) 1H NMR (400 MHz, CDCl3): 8.50 (d, 1H), 8.14 (s, 1H), 7.38-7.34 (m, 10H), 7.16-7.12 (m, 5H), 6.84 (d, 1H).

Reagent Preparation 16 N-(7-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)acetamide

STEP 1: To a solution of 7-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (prepared using the procedure in WO2006038116) (0.150 g, 0.704 mmol), diisopropylethylamine (0.363 g, 2.81 mmol), catalytic DMAP (0.09 g, 0.07 mmol) in anhydrous THF (4 mL) was added acetic anhydride (0.216 g, 2.11 mmol). The reaction mixture was stirred at 50° C. for 22 h under N2 (g). After cooling to room temperature the mixture was concentrated, diluted with ethyl acetate (50 mL), washed with saturated sodium bicarbonate (40 mL), brine (40 mL), and dried over anhydrous sodium sulfate. Filtration and concentration followed by column chromatography of the residue on silica (95:5 dichlormethane/methanol) afforded N-(7-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)acetamide (0.170 g, 95% yield) as a brown oil. MS (EI) for C8H7BrN4O: 256 (MH+).

Reagent Preparation 17 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine

Step 1: To a solution of methyl 5,5-dimethyl-2-oxocyclohexanecarboxylate (6.0 g, 33 mmol) and 2-chloroacetimidamide hydrochloride (4.6 g, 36 mmol) in methanol (30 mL) was added sodium methoxide (4.4 M in MeOH, 9.0 mL, 40 mmol). The reaction mixture was stirred at ambient temperature for three hours and then concentrated. The resulting residue was partitioned between ethyl acetate and aqueous sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated. Purification by silica gel chromatography provided 2-(chloromethyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-ol (4.2 g, 57% yield) as a white solid. MS (ES) for C11H15ClN2O: 227 (MH+).

Step 2: To a solution of 2-(chloromethyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-ol (2.5 g, 11 mmol) in THF (10 mL) was added dimethyl amine (2M in THF, 16.5 mL, 33 mmol). The reaction mixture was heated (60° C.) for two hours and then partitioned between ethyl acetate and sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to provide 2-((dimethylamino)methyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-ol, which was used in step 3 without further purification. MS (ES) for C13H21N3O: 236 (MH+).

Step 3: To a solution of the final residue from step 2 in CHCl3 (10 mL) was added POCl3 (10 mL). The reaction mixture was heated (90° C.) for two hours and concentrated. This residue was partitioned between dichloromethane and aqueous sodium bicarbonate and the resulting organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by silica gel chromatography (5-10% concentrated aqueous ammonia in methanol) in chloroform provided 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (1.3 g, 48% yield). 1H NMR (400 MHz, CD3OD) δ 4.52 (s, 2H), 3.02 (s, 6H), 2.98 (t, 2H), 2.61 (s, 2H), 1.71 (t, 2H), 1.06 (s, 6H); MS (ES) for C13H20ClN3: 254 (MH+)

Using analogous synthetic techniques and substituting with alternative starting reagents the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

(S)-4-chloro-2-((3-fluoropyrrolidin-1-yl)methyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 17 using (S)-3-fluoropyrrolidine in step 2. MS (ES) for C15H21ClFN3: 298 (MH+).

(R)-4-chloro-2-((3-fluoropyrrolidin-1-yl)methyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 17 using (R)-3-fluoropyrrolidine in step 2. MS (ES) for C15H21ClFN3: 298 (MH+).

4-chloro-2-((3,3-difluoropyrrolidin-1-yl)methyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 17 using 3,3-difluoropyrrolidine in step 2. MS (ES) for C15H20ClF2N3: 316 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-methylethanamine. Synthesized according to the method of reagent preparation 17 using N-methylethanamine in step 2. MS (ES) for C14H22ClN3: 268 (MH+).

4-chloro-6,6-dimethyl-2-(piperidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 17 using piperidine in step 2. MS (ES) for C16H24ClN3: 294 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-methylpropan-2-amine. Synthesized according to the method of reagent preparation 17 using N-methylpropan-2-amine in step 2. MS (ES) for C15H24ClN3: 282 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-methylcyclopropanamine. Synthesized according to the method of reagent preparation 17 using N-methylcyclopropanamine in step 2. MS (ES) for C15H22ClN3: 280 (MH+).

Benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(isopropyl)carbamate. Synthesized according to the method of reagent preparation 17 using propane-2-amine in step 2 followed by Cbz protection. MS (ES) for C22H28ClN3O2: 402 (MH+).

4-chloro-6,6-dimethyl-2-(pyrrolidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 17 using pyrrolidine in step 2. MS (ES) for C15H22ClN3: 280 (MH+).

(S)-1-(4-chloro-7-ethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Synthesized according to the method of reagent preparation 17 using (S)-methyl 4-ethyl-2-hydroxycyclohex-1-enecarboxylate in step 1. MS (ES) for C13H20ClN3: 254 (MH+).

{4-chloro-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-2-yl}methyl acetate. Synthesized according to the method of reagent preparation 17 using 2-(chloromethyl)-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-ol and sodium acetate in acetic acid in step 2. MS (ES) for C15H14ClFN2O2: 309 (MH+).

4-chloro-2-(methoxymethyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 17 using sodium methoxide in step 2. MS (ES) for C12H17ClN2O: 241 (MH+).

Benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(ethyl)-carbamate. Prepared according to the method of reagent preparation 17 by using ethylamine in step 2 followed by Cbz protection. MS (EI) for C21H26ClN3O2: 388 (MH+).

Benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(2-fluoroethyl)carbamate. Prepared according to the method of reagent preparation 17 by using fluoroethylamine in step 2 followed by Cbz protection. MS (EI) for C21H25ClFN3O2: 406 (MH+).

N-[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl]cyclopropanamine. Prepared according to the method of reagent preparation 17 by using cyclopropylamine in step 2. MS (EI) for C14H20ClN3: 266 (MH+).

Benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(cyclobutyl)-carbamate. Prepared according to the method of reagent preparation 17 by using cyclobutylamine in step 2 followed by Cbz protection. MS (EI) for C23H28ClN3O2: 414 (MH+).

1-(4-Chloro-5-(cyclopropylmethyl)-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of reagent preparation 17 by using methyl 2-(cyclopropylmethyl)-3-oxobutanoate (reagent preparation 8) in step 1. MS (EI) for C12H18ClN3: 240 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-ethylethanamine. Prepared according to the method of reagent preparation 17 by using diethylamine in step 2. MS (EI) for C15H24ClN3: 282 (MH+).

4-((4-Chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)morpholine. Prepared according to the method of reagent preparation 17 by using morpholine in step 2. MS (EI) for C15H22ClN3O: 296 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-ethylpropan-2-amine. Prepared according to the method of reagent preparation 17 by using ethylisopropylamine in step 2. MS (EI) for C16H26ClN3: 296 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-2-methylpropan-2-amine. Prepared according to the method of reagent preparation 17 by using tert-butylamine in step 2. MS (EI) for C15H24ClN3: 282 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-2-methylpropan-1-amine. Prepared according to the method of reagent preparation 17 by using iso-butylamine in step 2. MS (EI) for C15H24ClN3: 282 (MH+).

Benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(2,2-difluoroethyl)carbamate. Prepared according to the method of reagent preparation 17 by using 2,2-difluoroethylamine in step 2 followed by Cbz protection. MS (EI) for C21H24ClF2N3O2: 424 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-2,2,2-trifluoroethanamine. Prepared according to the method of reagent preparation 17 by using 2,2,2-trifluoroethylamine in step 2. MS (EI) for C13H17ClF3N3: 308 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-1-cyclopropylethanamine. Prepared according to the method of reagent preparation 17 by using 1-cyclopropylethanamine in step 2. MS (EI) for C16H24ClN3: 294 (MH+).

(4-Chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl acetate. Prepared according to the method of reagent preparation 17 by using potassium acetate in step 2. MS (EI) for C13H17ClN2O2: 269 (MH+).

Benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(cyclopentyl)carbamate. Prepared according to the method of reagent preparation 17 by using cyclopentylamine in step 2 followed by Cbz protection. MS (EI) for C24H30ClN3O2: 428 (MH+).

Ethyl 2-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methylamino)propanoate. Prepared according to the method of reagent preparation 17 by using alanine ethyl ester in step 2. MS (EI) for C16H24ClN3O2: 326 (MH+).

1-(4-Chloro-5,6-dimethylpyrimidin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of reagent preparation 17 by using methyl 2-methyl-3-oxobutanoate in step 1 in step 2. MS (EI) for C9H14ClN3: 200 (MH+).

1-(4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine. Synthesized according to the method of reagent preparation 17 using methyl 2-(4-fluorobenzyl)-3-oxobutanoate in step 1. 1H NMR (400 MHz, CDCl3): 7.08-7.05 (m, 2H), 7.00-6.96 (m, 2H), 4.14 (s, 2H), 3.68 (s, 2H), 2.51 (s, 3H), 2.38 (s, 6H).

1-(4-chloro-5-isopropyl-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine. Synthesized according to the method of reagent preparation 17 using methyl 2-acetyl-3-methylbutanoate in step 1. MS (EI) for C11H18N3C1: 228, 230 (MH+, Cl isotope pattern).

(S)-benzyl sec-butyl((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)carbamate Synthesized according to the method of reagent preparation 17 using (5)-butan-2-amine in step 2 followed Cbz-protection prior to step 3. MS (ES) for C23H30ClN3O2: 416 (MH+).

(R)-benzyl sec-butyl((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)carbamate Synthesized according to the method of reagent preparation 17 using (R)-butan-2-amine in step 2 followed Cbz-protection prior to step 3. MS (ES) for C23H30ClN3O2: 416 (MH+).

1-(4-chloro-6-ethyl-5-methylpyrimidin-2-yl)-N,N-dimethylmethanamine Synthesized according to the method of reagent preparation 17 using methyl 2-methyl-3-oxopentanoate in step 1. MS (ES) for C10H16ClN3: 214 (MH+).

1-(4-chloro-5-isopropylpyrimidin-2-yl)-N,N-dimethylmethanamine Synthesized according to the method of reagent preparation 17 using methyl 2-methyl-3-oxopentanoate (Elaridi et al. Tetrahedron: Asymmetry 2005, 16(7), 1309-1319) in step 1.

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-methyl-2-nitrobenzenesulfonamide Synthesized according to the method of reagent preparation 17 using methylamine in step 2 followed by protection as the 2-nitrobenzenesulfonamide prior to step 3. 1H NMR (400 MHz, CDCl3) δ 8.18-8.13 (m, 1H), 7.71-7.62 (m, 2H), 7.61-7.57 (m, 1H), 4.69 (s, 2H), 3.08 (d, 3H), 2.73 (t, 2H), 2.47 (s, 2H), 1.60 (t, 2H), 1.01 (s, 6H); MS (ES) for C18H21ClN4O4S: 425 (MH+).

N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)methanesulfonamide Synthesized according to the method of reagent preparation 17 using ammonia in step 2 followed by mesylation prior to step 3. 1H NMR (400 MHz, CDCl3) δ 4.49 (d, 2H), 3.01 (s, 3H), 2.90 (t, 2H), 2.54 (s, 2H), 1.67 (t, 2H), 1.05 (s, 6H); MS (ES) for C12H18ClN3O2S: 304 (MH+).

1-(4-chloro-5-ethyl-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine. Synthesized according to the method of reagent preparation 17 using ethyl 2-ethyl-3-oxobutanoate in step 1. 1H NMR (400 MHz, CDCl3) δ 3.64 (s, 2H), 2.78 (q, 2H), 2.58 (s, 3H), 2.36 (s, 6H), 1.19 (t, 3H); MS (ES) for C10H16ClN3: 214 (MH+).

4-chloro-6,6-dimethyl-2-({[2-(methyloxy)ethyl]oxy}methyl)-5,6,7,8-tetrahydroquinazoline. Synthesized according to the method of reagent preparation 17 using sodium hydride and 2-methoxyethanol in N,N-dimethylformamide) in step 2. MS (ES) for C14H21ClN2O2: 285 (MH+).

N-[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl]-2-(methyloxy)ethanamine. Synthesized according to the method of reagent preparation 17 using 2-methoxyethanamine in step 2. MS (ES) for C14H22ClN3O: 284 (MH+).

N-((4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidin-2-yl)methyl)cyclopropanamine. Prepared according to the method of reagent preparation 17 by using methyl 2-(4-fluorobenzyl)-3-oxobutanoate in step 1 and cyclopropylamine in step 2. MS (EI) for C16H17ClFN3: 306 (MH+).

1-(4-chloro-7-methoxy-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of reagent preparation 17 using methyl 5,5-dimethyl-2-oxocyclohex-3-enecarboxylate (Can. J. Chem., 1981, 59, 601-608) in step 1. MS (ES) for C14H22ClN3O: 284 (MH+).

Reagent Preparation 18 Phenylmethyl(2R)-2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate

STEP 1: To sodium methoxide (30 wt % in methanol, 8 mg, 0.05 mmol) was added a solution of (R)-benzyl 2-cyanopyrrolidine-1-carboxylate (189 mg, 0.82 mmol) in methanol (1 mL) at room temperature and the reaction mixture was stirred for one hour. Ammonium chloride (44 mg, 0.82 mmol) was introduced and the stirring was continued for an additional two hours, followed by the addition of methyl 5,5-dimethyl-2-oxocyclohexanecarboxylate (100 mg, 0.54 mmol) and sodium methoxide (30 wt % in methanol, 293 mg, 1.63 mmol). The stirring was continued for two more hours. The reaction mixture was quenched with water (10 mL), neutralized with 1 N hydrochloric acid and extracted with ethyl acetate (3×10 mL). The combined extract was washed with water (20 mL) and brine, dried over sodium sulfate, filtered, concentrated and purified by gradient flash chromatography (25% to 95% ethyl acetate in hexane) to give phenylmethyl(2R)-2-(4-hydroxy-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate (186 mg, 90%). MS (EI) for C22H27N3O3: 381 (MH+).

STEP 2: A mixture phenylmethyl(2R)-2-(4-hydroxy-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate (150 mg, 0.39 mmol) and phosphorous oxychloride (1 mL) in chloroform (3 mL) was stirred at 80° C. for one hour. After cooling to room temperature the reaction mixture was concentrated and the residue was partitioned between saturated sodium bicarbonate (20 mL) and ethyl acetate (20 mL). The mixture was stirred for 15 minutes and pH was maintained above 7 by the addition of solid sodium bicarbonate. The organic layer was separated and washed with water (10 mL) and brine, dried over sodium sulfate, filtered and concentrated to give phenylmethyl(2R)-2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate (117 mg, 74%). MS (EI) for C22H26ClN3O2: 400 (MH+).

Using analogous synthetic techniques and substituting with alternative starting materials in step 1 the following reagents of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

Phenylmethyl(2S)-2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate. Prepared according to the method of reagent preparation 18 by using (S)-benzyl 2-cyanopyrrolidine-1-carboxylate in step 1 (118 mg, 75%). MS (EI) for C22H26ClN3O2: 400 (MH+).

Phenylmethyl 2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate. Prepared according to the method of reagent preparation 18 by using (R,S)-benzyl 2-cyanopyrrolidine-1-carboxylate in step 1 (118 mg, 75%). MS (EI) for C22H26ClN3O2: 400 (MH+).

Reagent Preparation 19 Phenylmethyl{[6-bromo-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl}methylcarbamate

STEP 1: To a mixture of 2-[(benzyloxycarbonyl)(methyl)amino]acetic acid (0.42 g, 1.88 mmol), O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.75 g, 1.97 mmol) in N,N-dimethylformamide (3.0 mL), N,N-diisopropylethylamine (0.72 mL, 4.12 mmol) was added and the reaction mixture was stirred for 30 minutes at room temperature, followed by the addition of 5-bromo-2,3-diaminopyridine (0.35 g, 1.86 mmol), then stirred for 16 hours. It was diluted with ethyl acetate (50 mL), washed with aqueous lithium chloride (2×20 mL) and brine, dried over sodium sulfate, filtered and concentrated. Gradient flash chromatography (35% to 85% ethyl acetate in hexane) provided phenylmethyl{2-[(2-amino-5-bromopyridin-3-yl)amino]-2-oxoethyl}methylcarbamate (0.70 g, 96%). MS (EI) for C16H17BrN4O3: 394 (MH+).

STEP 2: A solution of phenylmethyl{2-[(2-amino-5-bromopyridin-3-yl)amino]-2-oxoethyl}methylcarbamate (0.30 g, 0.76 mmol) in acetic acid (7.5 mL) was heated in a microwave apparatus (250 W) for 30 min. at 120° C. After cooling it to room temperature the reaction mixture was concentrated and the pH was adjusted to 8 by the addition of saturated aqueous sodium bicarbonate. The precipitating solid was collected by filtration, washed with water and dried in vacuo to give phenylmethyl[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)methyl]methylcarbamate (0.22 g, 76%). MS (EI) for C16H15BrN4O2: 376 (MH+).

STEP 3: To a solution of phenylmethyl[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)methyl]methylcarbamate (0.22 g, 0.59 mmol) in N,N-dimethylformamide (3.0 mL) was added 60% sodium hydride in mineral oil (56 mg, 1.48 mmol) and the reaction mixture was stirred for 30 minutes at room temperature, followed by the addition of 2-(trimethylsilyl)ethoxymethyl chloride (0.11 mL, 0.62 mmol). The reaction mixture was stirred at room temperature for 16 hours then it was quenched by the careful addition of saturated aqueous ammonium chloride and partitioned with ethyl acetate (20 mL) and water (20 mL). The organic layer was separated and washed with 10% aqueous citric acid (2×20 mL) and brine (20 mL), dried over sodium sulfate, filtered and concentrated. Gradient flash chromatography (15% to 35% ethyl acetate in hexane) gave phenylmethyl{[6-bromo-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl}methylcarbamate (0.28 g, 93%). MS (EI) for C22H29BrN4O3Si: 506 (MH+).

Using analogous synthetic techniques and substituting with alternative starting materials and reagents in step 1 or step 2 and step 3 the following reagents of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

Phenylmethyl{(1R)-1-[6-bromo-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl]ethyl}({[2-(trimethylsilyl)ethyl]oxy}methyl)carbamate. Synthesized according to the method of reagent preparation 19 by using 5-bromo-2,3-diaminopyridine and N-(benzyloxycarbonyl)-D-alanine in step 1 and 2-(trimethylsilyl)ethoxymethyl chloride in step 3. MS (EI) for C28H43BrN34O4Si2: 636 (MH+).

Phenylmethyl{(1S)-1-[6-bromo-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl]ethyl}({[2-(trimethylsilyl)ethyl]oxy}methyl)carbamate. Synthesized according to the method of reagent preparation 19 by using 5-bromo-2,3-diaminopyridine and N-(benzyloxycarbonyl)-L-alanine in step 1 and 2-(trimethylsilyl)ethoxymethyl chloride in step 3. MS (EI) for C28H43BrN34O4Si2: 636 (MH+).

7-Bromo-2-methyl-3-({[2-(methyloxy)ethyl]oxy}methyl)-3H-imidazo[4,5-c]pyridine and 7-bromo-2-methyl-1-({[2-(methyloxy)ethyl]oxy}methyl)-1H-imidazo[4,5-c]pyridine. Synthesized according to the method of reagent preparation 19 by using 5-bromopyridine-3,4-diamine and triethyl orthoacetate in step 2 and methoxyethoxymethyl chloride in step 3. 1H NMR (400 MHz, CDCl3): 8.83 (s, 2H), 8.44 (s, 2H), 5.88 (s, 2H), 5.66 (s, 2H), 3.36 (s, 3H), 3.37 (s, 3H), 2.98 (s, 4H), 2.91 (s, 4H), 2.73 (s, 3H), 2.75 (s, 3H); MS (EI) for C11H14BrN3O2: 301 (MH+).

1-(6-Bromo-3H-imidazo[4,5-b]pyridin-2-yl)ethanol. Synthesized according to the method of reagent preparation 19 by using D,L-lactic acid in step 1. MS (EI) for C8H8BrN3O: 241 (MH−).

Tert-butyl 6-bromo-2-(difluoromethyl)-1H-benzo[d]imidazole-1-carboxylate. Synthesized according to the method of reagent preparation 19 using 4-bromobenzene-1,2-diamine and difluoroacetic acid in step 1 and BOC protection with di-tert-butyl dicarbonate in step 3. MS (EI) for 6-bromo-2-(difluoromethyl)-1H-benzo[d]imidazole (step 2) C8H5BrF2N2: 247, 249 (MH+, Br isotope pattern).

1,1-Dimethylethyl 6-bromo-2,4-dimethyl-1H-benzimidazole-1-carboxylate. Synthesized according to the method of reagent preparation 19 using 5-bromo-3-methylbenzene-1,2-diamine and acetylation using acetyl chloride in tetrahydrofuran in step 1 the BOC protection with di-tert-butyl dicarbonate in step 3. MS (EI) for C14H17BrN2O2: 267, 269 (M-Boc, Br isotope pattern).

1,1-Dimethylethyl 5-bromo-6-fluoro-2-methyl-1H-benzimidazole-1-carboxylate. Synthesized according to the method of reagent preparation 19 using 4-bromo-5-fluorobenzene-1,2-diamine and triethyl orthoacetate in step 2 and BOC protection with di-tert-butyl dicarbonate in step 3. MS (EI) for C13H14BrFN2O2: 271, 273 (M-Boc, Br isotope pattern).

2-Methylpropyl 5-bromo-4-fluoro-2-methyl-1H-benzimidazole-1-carboxylate. Synthesized according to the method of reagent preparation 19 using 5 4-bromo-3-fluorobenzene-1,2-diamine and acetylation with acetic anhydride in tetrahydrofurane in step 1 then treatment with isobutyl chloroformate in step 3. MS (EI) for C13H14BrN2O2: 328, 330 (MH+, Br isotope pattern).

6-Bromo-2-ethyl-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridine. Synthesized according to the method of reagent preparation 19 by using 5-bromo-2,3-diaminopyridine and trimethyl orthopropionate in step 2 and 2-(trimethylsilyl)ethoxymethyl chloride in step 3. MS (EI) for C14H22BrN3OSi: 357 (MH+).

2-Methylpropyl 6-bromo-2-cyclopropyl-3H-imidazo[4,5-b]pyridine-3-carboxylate. Synthesized according to the method of reagent preparation 19 by using 5-bromo-2,3-diaminopyridine and acylation with cyclopropylcarbonyl chloride in step 1 and treatment with isobutyl chloroformate in step 3. MS (EI) for C14H16BrN3O2: 339 (MH+).

2-Methylpropyl 5-bromo-2-(fluoromethyl)-1H-benzimidazole-1-carboxylate. Synthesized according to the method of reagent preparation 19 using 4-bromobenzene-1,2-diamine and fluoroacetic acid in step 1 then treatment with isobutyl chloroformate in step 3. MS (EI) for C13H14BrFN2O2: 330 (MH+).

Reagent Preparation 20

STEP 1: To a solution of 4-methoxyanthranilic acid (5.0 g, 30.0 mmol) in a mixture of 10% methanol in tetrahydrofuran (100 mL) was added dropwise (trimethylsilyl)diazomethane (2.0 M solution in diethyl ether, 18.0 mL, 36.0 mmol) at 0° C. The reaction mixture was stirred for 16 hours at room temperature then quenched by the addition of glacial acetic acid (0.1 mL). The reaction mixture was concentrated and the residue was partitioned between saturated sodium bicarbonate (50 mL) and ethyl acetate (250 mL). The organic layer was separated and washed with water (50 mL), saturated sodium bicarbonate (50 mL) and brine (50 mL), dried over sodium sulfate, filtered and concentrated to give methyl 2-amino-4-methoxybenzoate as an oil (5.4 g, quantitative). MS (EI) for C9H11NO3: 182 (MH+).

STEP 2: To a mixture of methyl 2-amino-4-methoxybenzoate (5.4 g, 30.0 mmol) and chloroacetonitrile (2.8 mL, 45.0 mmol) was added anhydrous hydrogen chloride (4M solution in 1,4-dioxane, 20.0 mL, 80 mmol) and the reaction mixture was stirred at 50° C. for 30 minutes. After cooling it to room temperature the resulting slurry was diluted with diethyl ether (100 mL) and the stirring was continued for an additional 30 minutes. The off-white precipitate was collected by filtration, washed with diethyl ether and dried in vacuo to provide 2-(chloromethyl)-7-(methyloxy)quinazolin-4-ol hydrochloride (7.5 g, 96%). MS (EI) for C10H9ClN2O2: 225 (MH+).

STEP 3: To a solution of dimethylamine (2M solution in tetrahydrofuran, 40.0 mL, 80.0 mmol) was added 2-(chloromethyl)-7-(methyloxy)quinazolin-4-ol hydrochloride (7.5 g, 29 mmol) and the reaction mixture was stirred for 90 minutes at 50° C. After cooling it to room temperature the reaction mixture was concentrated and the residue was partitioned between water (100 mL) and ethyl acetate (250 mL). The organic layer was separated and washed with water (100 mL), saturated sodium bicarbonate (100 mL) and brine (100 mL), dried over sodium sulfate, filtered and concentrated to give 2-[(dimethylamino)methyl]-7-(methyloxy)quinazolin-4-ol (6.6 g, 97%). MS (EI) for C12H15N3O2: 234 (MH+).

STEP 4: A solution of 2-[(dimethylamino)methyl]-7-(methyloxy)quinazolin-4-ol (6.6 g, 28.0 mmol) in a mixture of chloroform (15.0 mL) and phosphorous oxychloride (15.0 mL) was heated to reflux for 90 minutes. After cooling it to room temperature the reaction mixture was concentrated and the residue was partitioned between saturated sodium bicarbonate (100 mL) and ethyl acetate (400 mL) and the mixture was stirred for 30 minutes. The organic layer was separated and washed with saturated sodium bicarbonate (2×100 mL) and brine (200 mL), dried over sodium sulfate, filtered and concentrated. Purification by silica gel column chromatography using 15% methanol containing 0.5% triethylamine in ethyl acetate provided 1-[4-chloro-7-(methyloxy)quinazolin-2-yl]-N,N-dimethylmethanamine (7.0 g, quantitative). MS (EI) for C12H14ClN3O: 252 (MH+).

Using analogous synthetic techniques and substituting with alternative starting materials in step 2 the following reagents of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

1-(4-chloro-6-fluoroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of reagent preparation 20 by using methyl 2-amino-5-fluorobenzoate in step 2. MS (EI) for C11H11ClFN3: 240 (MH+).

Reagent Preparation 21 5-Bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine

STEP 1: To a mixture of 5-bromo-1H-pyrrolo[2,3-b]pyridine (207 mg, 1.05 mmol), sodium hydride (29 mg, 1.21 mmol) in tetrahydrofuran (5 mL) was added iodomethane (164 mg, 1.15 mol) then stirred for 2 h at room temperature. The reaction mixture was carefully quenched with water then extracted with ethyl acetate (3×). The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography to give 5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine. MS (EI) for C8H7BrN2: 209, 211 (MH+, Br pattern).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagent was prepared. 5-bromo-1-ethyl-1H-pyrrolo[2,3-b]pyridine. Synthesized according to the method of reagent preparation 21 using iodoethane. MS (EI) for C9H9BrN2: 223, 225 (MH+, Br pattern).

Reagent Preparation 22 (4-(4-Bromophenyl)-1H-imidazol-2-yl)methanol

STEP 1: To a solution of ethyl thiooxamate (10.0 g, 75 mmol) in dichloromethane (400 mL) was slowly added trimethyloxonium tetrafluoroborate (13.1 g, 89 mmol) at 0° C. After 10 min the ice bath was removed, and the reaction mixture was stirred overnight. The solvent was removed to afford ethyl 2-imino-2-(methylthio)acetate (12.0 g, 66.6%) as tetrafluoroborate salt which was used without further purification.

STEP 2: A mixture of 2-amino-4-bromoacetophenone hydrochloride (4.0 g, 16.0 mmol), sodium acetate (6.1 g, 90.0 mmol), acetic acid (4.6 mL, 80.0 mmol) and ethyl 2-imino-2-(methylthio)acetate (7.7 g, 32.0 mmol) in dioxane (40 mL) was stirred at 95° C. overnight. The reaction mixture was carefully neutralized with saturated NaHCO3 solution and extracted with ethyl acetate. The organic solution was dried over sodium sulfate and concentrated. Purification by silica gel column chromatography (ethyl acetate:hexanes 1:1) afforded ethyl 4-(4-bromophenyl)-1H-imidazole-2-carboxylate (3.53 g, 75.0%). MS (EI) for C12H11BrN2O2: 296 (MH+).

STEP 3: To a solution of ethyl 4-(4-bromophenyl)-1H-imidazole-2-carboxylate (1.30 g, 4.40 mmol) in THF (30 mL) was slowly added Red-Al (65 wt % in toluene, 2.0 mL, 6.16 mmol) at −25° C. The reaction mixture was stirred for 4 h at the same temperature then slowly warmed to 0° C. over 1 h and quenched with 20% sodium tartrate solution (30 mL). The reaction was extracted with ethyl acetate (70 mL) and the organic layer was left for 3 h at room temperature. A solid separated and was collected by filtration, washed with ethyl acetate and dried to afford (4-(4-bromophenyl)-1H-imidazol-2-yl)methanol (778 mg, 71.0%). MS (EI) for C10H9BrN2O: 254.1 (MH+).

Reagent Preparation 23

Step 1: To a slurry of 2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ylboronic acid hydrochloride salt (5.7 g, 25 mmol) (example 8, step 1) and 4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) (3.0 g, 15 mmol) in dioxane (75 mL) and H2O (75 mL) was added DIPEA (17 mL, 100 mmol) and the resulting mixture was heated (90° C.). After 72 hours the solution was concentrated and partitioned between 2M aqueous sodium hydroxide and ethyl ether. The aqueous layer was neutralized and extracted with chloroform. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. Trituration with ethyl ether provided [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (4.2 g, 80% yield) as a white solid. 1H NMR (400 MHz, d6-DMSO) δ 8.68 (s, 1H), 7.77 (s, 1H), 7.64 (dd, 1H), 6.86 (dd, 1H), 5.04 (s, 2H), 4.46 (m, 2H), 4.18 (m, 2H), 2.80 (t, 2H), 2.52 (s, 2H), 1.58 (t, 2H), 0.86 (s, 6H); MS (ES) for C19H24BN3O3: 354 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

[4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid. Synthesized according to the method of reagent preparation 23 using 4-chloro-6,6,7-trimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 1. 1H NMR (400 MHz, d6-DMSO) δ 8.34 (s, 1H), 7.94 (s, 2H), 7.66 (s, 1H), 7.62 (dd, 1H), 6.90 (d, 1H), 6.12 (s, 1H), 4.59 (s, 2H), 4.33 (m, 2H), 3.83 (m, 2H), 2.65 (s, 2H), 1.89 (s, 3H), 0.94 (s, 6H); MS (ES) for C20H24BN3O3: 366 (MH+).

[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid. Synthesized according to the method of reagent preparation 23 using 4-chloro-6,6-dimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 1. 1H NMR (400 MHz, d6-DMSO) δ 8.39 (s, 1H), 7.93 (s, 2H), 7.68 (s, 1H), 7.62 (dd, 1H), 6.89 (d, 1H), 6.29 (d, 1H), 6.23 (d, 1H), 4.61 (s, 2H), 4.32 (m, 2H), 3.84 (m, 2H), 2.69 (s, 2H), 0.97 (s, 6H); MS (ES) for C19H22BN3O3: 352 (MH+).

{4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid. Synthesized according to the method of reagent preparation 23 using 4-chloro-7-methoxyquinazoline (reagent preparation 1) in step 1. MS (ES) for C18H18BN3O4: 352 (MH+).

[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid. Synthesized according to the method of reagent preparation 23 using 4-chloro-2,6,6-trimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 8) in step 1. MS (EI) for C20H26BN3O3: 368 (MH+).

{4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid. Synthesized according to the method of reagent preparation 23 using (S)-4-chloro-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 8) in step 1. MS (ES) for C20H26BN3O3: 368 (MH+).

{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid. Synthesized according to the method of reagent preparation 23 using (S)-4-chloro-7-ethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 1. 1H NMR (400 MHz, d6-DMSO) δ 8.33 (d, 1H), 7.96 (s, 2H), 7.68 (d, 1H), 7.61 (dd, 1H), 6.89 (d, 1H), 4.69 (d, 1H), 4.59 (d, 1H), 4.37 (dt, 1H), 4.25 (dt, 1H), 3.84 (t, 2H), 2.84 (dd, 1H), 2.75 (m, 1H), 2.46 (m, 1H), 2.26 (dd, 1H), 1.89 (m, 1H), 1.70 (m, 1H), 1.37 (m, 2H), 1.10 (m, 1H), 0.95 (t, 3H); MS (ES) for C19H24BN3O3: 354 (MH+).

[4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid. Synthesized according to the method of reagent preparation 23 using 4-chloro-6,6,8-trimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 1. 1H NMR (400 MHz, d6-DMSO) δ 8.45 (s, 1H), 7.94 (s, 2H), 7.67 (d, 1H), 7.62 (dd, 1H), 6.90 (d, 1H), 5.99 (d, 1H), 4.59 (s, 2H), 4.32 (m, 2H), 3.83 (m, 2H), 2.66 (d, 2H), 1.97 (s, 3H), 0.93 (s, 6H); MS (ES) for C20H24BN3O3: 366 (MH+).

(4-{2-[(dimethylamino)methyl]-7-methoxy-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid. Synthesized according to the method of reagent preparation 23 using 1-(4-chloro-7-methoxy-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 1. MS (ES) for C23H33BN4O4: 441 (MH+).

(4-{2-[(dimethylamino)methyl]-7-methoxyquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid. Synthesized according to the method of reagent preparation 23 using 1-(4-chloro-7-methoxyquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 20) in step 1. MS (ES) for C21H25BN4O4: 409 (MH+).

Reagent Preparation 24

N-(5-bromo-2-chloropyridin-3-yl)methanesulfonamide

STEP 1: A solution of 5-bromo-2-chloropyridin-3-amine (1.0 g, 4.8 mmol) and diisopropylethylamine (1.85 mL, 10.6 mmol) in dichloromethane (25 mL) was cooled to 0° C., and then methanesulfonyl chloride (750 uL, 9.6 mmol) was added slowly. The reaction mixture was stirred at 0° C. for 15 min and was then warmed to rt. After stirring for 2 h, water was added, and then the biphasic mixture was partitioned. The organic phase was dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was then dissolved in dioxane (10 mL) and water (10 mL). Potassium carbonate (2.76 g, 20 mmol) was added, and the reaction mixture was stirred for 15 h at rt. Water was then added to the mixture which was subsequently acidified with aqueous citric acid (10%). The aqueous mixture was extracted twice with ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (gradient, 100% hexanes to 50% hexanes:50% ethyl acetate) to provide N-(5-bromo-2-chloropyridin-3-yl)methanesulfonamide (520 mg, 1.82 mmol, 38% yield) as a light pink solid. 1H NMR (400 MHz, CDCl3) δ 8.27 (d, 1H), 8.14 (d, 1H), 6.83 (br s, 1H), 3.11 (s, 3H); MS (EI) for C6H6BrClN2O2S: 285, 287, 289 (Br+Cl isotopes, MH+).

Reagent Preparation 25

STEP 1: To a solution of (R)-pyrrolidin-3-ol (32 mg, 0.37 mmol) and potassium carbonate (102 mg, 0.74 mmol) in dioxane (2 mL) and water (400 uL) was added 2-amino-5-bromopyridine-3-sulfonyl chloride (100 mg, 0.37 mmol, prepared according to the methods in WO2008144463). The reaction mixture was stirred for 2 h at rt. Saturated sodium bicarbonate was then added, and the aqueous solution was extracted twice with ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated in vacuo to provide (R)-1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ol (87.3 mg, 0.27 mmol, 73% yield) as a white solid. 1H NMR (400 MHz, DMSO-D6-d6) δ 8.31 (d, 1H), 7.92 (d, 1H), 6.85 (br s, 2H), 5.02 (br s, 1H), 4.23 (dt, 1H), 3.38-3.25 (m, 3H), 3.14-3.06 (m, 1H), 1.92-1.81 (m, 1H), 1.77-1.67 (m, 1H); MS (EI) for C9H12BrN3O3S: 322, 324 (Br isotopes, MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagents were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

2-amino-5-bromo-N-(2-methoxyethyl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 2-methoxyethanamine in step 1.

2-amino-5-bromo-N-(2,2,2-trifluoroethyl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 2,2,2-trifluoroethanamine in step 1.

2-amino-5-bromo-N-(2-hydroxyethyl)-N-methylpyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 2-(methylamino)ethanol in step 1.

2-amino-5-bromo-N-(2-hydroxypropyl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 1-aminopropan-2-ol in step 1. MS (EI) for C8H12BrN3O3S: 310, 312 (Br isotopes, MH+).

2-amino-N-(azetidin-3-yl)-5-bromopyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using tert-butyl 3-aminoazetidine-1-carboxylate in step 1.

2-amino-5-bromo-N-(2,3-dihydroxypropyl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 3-aminopropane-1,2-diol in step 1. MS (EI) for C8H12BrN3O4S: 326, 328 (Br isotopes, MH+).

1-(2-amino-5-bromopyridin-3-ylsulfonyl)piperidin-3-ol. Prepared according to the methods described in reagent preparation 25 using piperidin-3-ol in step 1. MS (EI) for C10H14BrN3O3S: 336, 338 (Br isotopes, MH+).

2-amino-N-(3-amino-2,2-dimethylpropyl)-5-bromopyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 2,2-dimethylpropane-1,3-diamine in step 1. MS (EI) for C10H17BrN4O2S: 337, 339 (Br isotopes, MH+).

2-amino-5-bromo-N-(3-hydroxy-2,2-dimethylpropyl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 3-amino-2,2-dimethylpropan-1-ol in step 1. MS (EI) for C10H16BrN3O3S: 338, 340 (Br isotopes, MH+).

2-amino-5-bromo-N-(1-hydroxy-2-methylpropan-2-yl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 2-amino-2-methylpropan-1-ol in step 1. MS (EI) for C9H14BrN3O3S: 324, 326 (Br isotopes, MH+).

tert-butyl 4-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate. Prepared according to the methods described in reagent preparation 25 using tert-butyl 4-(aminomethyl)piperidine-1-carboxylate in step 1. MS (EI) for C16H25BrN4O4S: 393, 395 (Br isotopes, MH+-t-butyl).

2-amino-5-bromo-N-((1-methylpiperidin-4-yl)methyl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using (1-methylpiperidin-4-yl)methanamine in step 1. MS (EI) for C12H19BrN4O2S: 363, 365 (Br isotopes, MH+).

tert-butyl 1-((2-amino-5-bromopyridine-3-sulfonamido)methyl)cyclopropylcarbamate. Prepared according to the methods described in reagent preparation 25 using tert-butyl 1-(aminomethyl)cyclopropylcarbamate in step 1. MS (EI) for C14H21BrN4O4S: 365, 367 (Br isotopes, MH+-t-butyl).

tert-butyl trans-4-(2-amino-5-bromopyridine-3-sulfonamido)cyclohexylcarbamate. Prepared according to the methods described in reagent preparation 25 using tert-butyl trans-4-aminocyclohexylcarbamate in step 1.

benzyl 1-(2-amino-5-bromopyridine-3-sulfonamido)propan-2-ylcarbamate. Prepared according to the methods described in reagent preparation 25 using benzyl 1-aminopropan-2-ylcarbamate in step 1.

2-amino-5-bromo-N-ethylpyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using ethylamine in step 1. 1H NMR (400 MHz, CDCl3) δ 8.28 (d, 1H), 8.07 (d, 1H), 5.63 (br s, 2H), 4.61 (t, 1H), 3.06-2.97 (m, 2H), 1.14 (t, 3H); MS (EI) for C7H10BrN3O2S: 280, 282 (Br isotopes, MH+).

2-amino-5-bromo-N-isopropylpyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using isopropylamine in step 1. 1H NMR (400 MHz, CDCl3) δ 8.28 (d, 1H), 8.09 (d, 1H), 5.59 (br s, 2H), 4.52 (d, 1H), 3.50-3.39 (m, 1H), 1.11 (d, 6H); MS (EI) for C8H12BrN3O2S: 294, 296 (Br isotopes, MH+).

2-amino-5-bromo-N-(2-(dimethylamino)ethyl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using N,N-dimethylethane-1,2-diamine in step 1. 1H NMR (400 MHz, CDCl3) δ 8.27 (d, 1H), 8.08 (d, 1H), 5.66 (br s, 2H), 2.99-2.93 (m, 2H), 2.36-2.30 (m, 2H), 2.12 (s, 6H); MS (EI) for C9H15BrN4O2S: 323, 325 (Br isotopes, MH+).

2-amino-5-bromo-N-(2-hydroxyethyl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 2-aminoethanol in step 1. 1H NMR (400 MHz, CDCl3) δ 8.29 (d, 1H), 8.08 (d, 1H), 5.65 (br s, 3H), 5.23 (br s, 1H), 3.76-3.67 (m, 3H), 3.16-3.07 (m, 3H); MS (EI) for C7H10BrN3O5S: 296, 298 (Br isotopes, MH+).

1-(2-amino-5-bromopyridin-3-ylsulfonyl)-3-(hydroxymethyl)azetidin-3-ol. Prepared according to the methods described in reagent preparation 25 using 3-(hydroxymethyl)azetidin-3-ol (prepared according to procedures described in WO2007044515) in step 1. 1H NMR (400 MHz, CD3OD) δ 8.28 (d, 1H), 8.00 (d, 1H), 3.90-3.84 (m, 2H), 3.70-3.64 (m, 2H), 3.32-3.29 (m, 2H); MS (EI) for C9H12BrN3O4S: 338, 340 (Br isotopes, MH+).

2-(2-amino-5-bromopyridine-3-sulfonamido)acetamide. Prepared according to the methods described in reagent preparation 25 using 2-aminoacetamide hydrochloride in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.26 (d, 1H), 8.18 (br s, 1H), 7.90 (d, 1H), 7.34 (br s, 1H), 7.12 (br s, 1H), 6.84 (br s, 2H), 3.45 (s, 2H); MS (EI) for C7H9BrN4O3S: 309, 311 (Br isotopes, MH+).

tert-butyl 3-(2-amino-5-bromopyridine-3-sulfonamido)-2-hydroxypropylcarbamate. Prepared according to the methods described in reagent preparation 25 using tert-butyl 3-amino-2-hydroxypropylcarbamate in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.26 (d, 1H), 7.88 (d, 1H), 6.82 (br s, 2H), 6.74 (t, 1H), 5.02 (d, 1H), 3.50-3.42 (m, 1H), 2.88 (t, 2H), 2.82 (dd, 1H), 2.57 (dd, 1H), 1.37 (s, 9H); MS (EI) for C13H21BrN4O5S: 369, 371 (Br isotopes, MH+-t-Bu).

5-bromo-3-(3-(dimethylamino)azetidin-1-ylsulfonyl)pyridin-2-amine. Prepared according to the methods described in reagent preparation 25 using N,N-dimethylazetidin-3-amine hydrochloride in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (d, 1H), 7.92 (d, 1H), 6.90 (br s, 2H), 3.88-3.76 (m, 2H), 3.63-3.54 (m, 2H), 3.07-2.97 (m, 1H), 1.96 (s, 6H); MS (EI) for C10H15BrN4O2S: 335, 337 (Br isotopes, MH+).

5-bromo-N-(2-hydroxyethyl)-2-(methylamino)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 5-bromo-2-(methylamino)pyridine-3-sulfonyl chloride (prepared from 5-bromo-N-methylpyridin-2-amine using analogous conditions to those described in WO2008144463) and 2-aminoethanol in step 1.

1H NMR (400 MHz, CDCl3) δ 8.28 (d, 1H), 8.00 (d, 1H), 7.10-7.03 (m, 1H), 6.48-6.39 (m, 1H), 3.93 (t, 1H), 3.60 (q, 2H), 3.04-2.96 (m, 5H); MS (EI) for C8H12BrN3O3S: 310, 312 (Br isotopes, MH+).

N-(1-(2-amino-5-bromopyridin-3-ylsulfonyl)azetidin-3-yl)-N-methyl-2-nitrobenzenesulfonamide. Prepared according to the methods described in reagent preparation 25 using N-(azetidin-3-yl)-N-methyl-2-nitrobenzenesulfonamide in step 1. 1H NMR (400 MHz, CDCl3) δ 8.32 (d, 1H), 8.06-8.03 (m, 1H), 8.00 (d, 1H), 7.77-7.72 (m, 2H), 7.70-7.65 (m, 1H), 5.78 (br s, 2H), 4.90-4.80 (m, 1H), 4.19-4.08 (m, 2H), 4.01 (dd, 2H), 2.91 (s, 3H); MS (EI) for C15H16BrN5O6S: 506, 508 (Br isotopes, MH+).

tert-butyl 4-(2-amino-5-bromopyridin-3-ylsulfonyl)piperazine-1-carboxylate. Prepared according to the methods described in reagent preparation 25 using tert-butyl piperazine-1-carboxylate in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.34 (d, 1H), 7.86 (d, 1H), 6.90 (br s, 2H), 3.40-3.35 (m, 4H), 3.09-3.02 (m, 4H), 1.37 (s, 9H); MS (EI) for C14H21BrN4O4S: 367, 365 (Br isotopes, MH+-t-Bu).

3-(3-amino-3-methylazetidin-1-ylsulfonyl)-5-bromopyridin-2-amine. Prepared according to the methods described in reagent preparation 25 using 3-methylazetidin-3-amine hydrochloride (prepared by procedures described in WO2007007057 followed by benzylidene deprotection) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (d, 1H), 7.88 (d, 1H), 6.86 (br s, 2H), 3.58-3.47 (m, 4H), 2.06 (br s, 2H), 1.22 (s, 3H); MS (EI) for C9H13BrN4O2S: 321, 323 (Br isotopes, MH+).

tert-butyl 2-(2-amino-5-bromopyridine-3-sulfonamido)-2-methylpropylcarbamate. Prepared according to the methods described in reagent preparation 25 using tert-butyl 2-amino-2-methylpropylcarbamate in step 1. 1H NMR (400 MHz, CDCl3) δ 8.26 (d, 1H), 8.08 (d, 1H), 5.89 (br s, 1H), 5.60 (br s, 2H), 5.04 (t, 1H), 3.12 (d, 2H), 1.46 (s, 9H), 1.19 (s, 6H); MS (EI) for C14H23BrN4O4S: 367, 369 (Br isotopes, MH+-t-Bu).

tert-butyl 5-((2-amino-5-bromopyridine-3-sulfonamido)methyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate. Prepared according to the methods described in reagent preparation 25 using tert-butyl 5-(aminomethyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (prepared from substrates described in WO2004006846) in step 1. 1H NMR (400 MHz, CDCl3) δ 8.28 (d, 1H), 8.06 (d, 1H), 5.65 (br s, 2H), 5.03 (t, 1H), 3.41 (br s, 2H), 3.17 (br s, 2H), 2.93 (t, 2H), 2.63-2.54 (m, 2H), 2.14-1.98 (m, 3H), 1.46 (s, 9H), 1.09-0.98 (m, 2H); MS (EI) for C18H27BrN4O4S: 419, 421 (Br isotopes, MH+-t-Bu).

tert-butyl 1-(2-amino-5-bromopyridine-3-sulfonamido)butan-2-ylcarbamate. Prepared according to the methods described in reagent preparation 25 using tert-butyl 1-aminobutan-2-ylcarbamate in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.28 (d, 1H), 7.89 (d, 1H), 6.78 (br s, 2H), 6.57 (d, 1H), 3.33-3.26 (m, 1H), 2.77-2.65 (m, 2H), 1.53-1.39 (m, 1H), 1.37 (s, 9H), 1.28-1.15 (m, 1H), 0.76 (t, 3H); MS (EI) for C14H23BrN4O4S: 367, 369 (Br isotopes, MH+-t-Bu).

tert-butyl 4-(2-amino-5-bromopyridine-3-sulfonamido)-2-methylbutan-2-ylcarbamate. Prepared according to the methods described in reagent preparation 25 using tert-butyl 4-amino-2-methylbutan-2-ylcarbamate in step 1. 1H NMR (400 MHz, CDCl3) δ 8.27 (d, 1H), 8.06 (d, 1H), 5.64 (br s, 2H), 5.07 (br s, 1H), 4.41 (br s, 1H), 2.98 (q, 2H), 1.93-1.85 (m, 2H), 1.41 (s, 9H), 1.22 (s, 6H); MS (EI) for C15H25BrN4O4S: 381, 383 (Br isotopes, MH+-t-Bu).

2-amino-N-(2-amino-2-methylpropyl)-5-bromopyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 2-methylpropane-1,2-diamine in step 1. 1H NMR (400 MHz, CDCl3) δ 8.27 (d, 1H), 8.07 (d, 1H), 5.69 (br s, 2H), 2.73 (s, 2H), 1.12 (s, 6H); MS (EI) for C9H15BrN4O2S: 323, 325 (Br isotopes, MH+).

tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)azetidin-3-ylcarbamate. Prepared according to the methods described in reagent preparation 25 using tert-butyl azetidin-3-ylcarbamate in step 1. 1H NMR (400 MHz, CDCl3) δ 8.31 (d, 1H), 8.00 (d, 1H), 5.76 (br s, 2H), 4.80 (br s, 1H), 4.50-4.36 (m, 1H), 4.11 (t, 2H), 3.75 (t, 2H), 1.42 (s, 9H); MS (EI) for C13H19BrN4O4S: 407, 409 (Br isotopes, MH+).

tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)piperidin-4-ylcarbamate sulfonamide. Prepared according to the methods described in reagent preparation 25 using tert-butyl piperidin-4-ylcarbamate in step 1.

2-amino-5-bromo-N-(2-hydroxy-2-methylpropyl)pyridine-3-sulfonamide. Prepared according to the methods described in reagent preparation 25 using 1-amino-2-methylpropan-2-ol in step 1.

2-Amino-5-bromo-N,N-dimethylpyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using dimethylamine in step 1. MS (EI) for C7H10BrN3O2S: 280 (MH+).

5-Bromo-3-(morpholinosulfonyl)pyridin-2-amine. Prepared according to the method of reagent preparation 25 by using morpholine in step 1. MS (EI) for C9H12BrN3O3S: 322 (MH+).

5-Bromo-3-(4-methylpiperazin-1-ylsulfonyl)pyridin-2-amine. Prepared according to the method of reagent preparation 25 by using N-methylpiperazine in step 1. MS (EI) for C10H15BrN4O2S: 335 (MH+).

3-(Azetidin-1-ylsulfonyl)-5-bromopyridin-2-amine. Prepared according to the method of reagent preparation 25 by using N-methylpiperazine in step 1. MS (EI) for C8H10BrN3O2S: 292 (MH+).

2-Amino-5-bromo-N-methylpyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using methylamine in step 1. MS (EI) for C6H8BrN3O2S: 266 (MH+).

1-(2-Amino-5-bromopyridin-3-ylsulfonyl)azetidin-3-ol. Prepared according to the method of reagent preparation 25 by using azetidinol in step 1. MS (EI) for C8H10BrN3O3S: 308 (MH+).

5-Bromo-3-(pyrrolidin-1-ylsulfonyl)pyridin-2-amine. Prepared according to the method of reagent preparation 25 by using pyrrolidine in step 1. MS (EI) for C9H12BrN3O2S: 306 (MH+).

1-(2-Amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ol. Prepared according to the method of reagent preparation 25 by using 3-pyrrolidinol in step 1. MS (EI) for C9H12BrN3O3S: 322 (MH+).

2-Amino-5-bromo-N-cyclobutylpyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using cyclobutylamine in step 1. MS (EI) for C9H12BrN3O2S: 306 (MH+).

2-Amino-5-bromopyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using ammoniumhydroxide in step 1. MS (EI) for C5H6BrN3O2S: 252 (MH+).

2-Amino-5-bromo-N-ethyl-N-methylpyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using N-methylethylamine in step 1. MS (EI) for C8H12BrN3O2S: 294 (MH+).

5-Bromo-3-(3,3-difluoroazetidin-1-ylsulfonyl)pyridin-2-amine. Prepared according to the method of reagent preparation 25 by using 3,3-difluoroazetidine in step 1. MS (EI) for C8H8BrF2N3O2S: 328 (MH+).

2-Amino-5-bromo-N-(1-hydroxypropan-2-yl)pyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using 2-aminopropan-1-ol in step 1. MS (EI) for C8H12BrN3O3S: 310 (MH+).

2-Amino-5-bromo-N-(2-fluoroethyl)pyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using 2-fluoroethylamine in step 1. MS (EI) for C7H9BrFN3O2S: 298 (MH+).

tert-Butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate. Prepared according to the method of reagent preparation 25 by using tert-butyl pyrrolidin-3-ylcarbamate in step 1. MS (EI) for C14H21BrN4O4S: 365 (MH+-tBu).

1-(2-Amino-5-bromopyridin-3-ylsulfonyl)piperidin-4-ol. Prepared according to the method of reagent preparation 25 by using 4-hydroxypiperidine in step 1. MS (EI) for C10H14BrN3O3S: 336 (MH+)

tert-Butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)piperidin-3-ylcarbamate. Prepared according to the method of reagent preparation 25 by using tert-butyl piperidin-3-ylcarbamate in step 1. MS (EI) for C15H23BrN4O4S: 379 (MH+-tBu).

tert-Butyl 2-(2-amino-5-bromopyridine-3-sulfonamido)ethylcarbamate. Prepared according to the method of reagent preparation 25 by using tert-butyl 2-aminoethylcarbamate in step 1. MS (EI) for C12H19BrN4O4S: 339 (MH+-tBu).

2-Amino-5-bromo-N-(3-hydroxypropyl)pyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using 3-hydroxypropylamine in step 1. MS (EI) for C8H12BrN3O3S: 310 (MH+).

tert-Butyl 3-(2-amino-5-bromopyridine-3-sulfonamido)propylcarbamate. Prepared according to the method of reagent preparation 25 by using tert-butyl 2-aminopropylcarbamate in step 1. MS (EI) for C13H21BrN4O4S: 353 (MH+-tBu).

2-Amino-5-bromo-N-(3,3,3-trifluoro-2-hydroxypropyl)pyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using 3-amino-1,1,1-trifluoropropan-2-ol in step 1. MS (EI) for C8H9BrF3N3O3S: 364 (MH+).

tert-Butyl 5-(2-amino-5-bromopyridin-3-ylsulfonyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate. Prepared according to the method of reagent preparation 25 by using tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate in step 1. MS (EI) for C16H23BrN4O4S: 391 (MH+-tBu)

tert-Butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)-3-methylpyrrolidin-3-ylcarbamate. Prepared according to the method of reagent preparation 25 by using tert-butyl 3-methylpyrrolidin-3-ylcarbamate in step 1. MS (EI) for C15H23BrN4O4S: 379 (MH+-tBu).

(1S,4S)-tert-Butyl 5-(2-amino-5-bromopyridin-3-ylsulfonyl)-2,5-diazabicyclo[2.2.1]-heptane-2-carboxylate. Prepared according to the method of reagent preparation 25 by using (1S,4S)-tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate in step 1. MS (EI) for C15H21BrN4O4S: 377 (MH+-tBu).

(R)-tert-Butyl 2-((2-amino-5-bromopyridine-3-sulfonamido)methyl)pyrrolidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using (R)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate in step 1. MS (EI) for C15H23BrN4O4S: 335 (MH+-Boc).

(S)-tert-Butyl 2-((2-amino-5-bromopyridine-3-sulfonamido)methyl)pyrrolidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using (S)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate in step 1. MS (EI) for C15H23BrN4O4S: 335 (MH+-Boc).

(1R,4R)-tert-Butyl 5-(2-amino-5-bromopyridin-3-ylsulfonyl)-2,5-diazabicyclo[2.2.1]-heptane-2-carboxylate. Prepared according to the method of reagent preparation 25 by using (1R,4R)-tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate in step 1. MS (EI) for C15H21BrN4O4S: 377 (MH+-Boc).

tert-Butyl 4-(2-amino-5-bromopyridine-3-sulfonamido)piperidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using tert-butyl 4-aminopiperidine-1-carboxylate in step 1. MS (EI) for C15H23BrN4O4S: 379 (MH+-Boc).

5-Bromo-3-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)pyridin-2-amine. Prepared according to the method of reagent preparation 25 by using (1S,45)-2-methyl-2,5-diazabicyclo[2.2.1]heptane in step 1. MS (EI) for C11H15BrN4O2S: 347 (MH+).

(S)-tert-Butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate. Prepared according to the method of reagent preparation 25 by using (S)-tert-butyl pyrrolidin-3-ylcarbamate in step 1. MS (EI) for C14H21BrN4O4S: 421 (MH+).

(R)-tert-Butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate. Prepared according to the method of reagent preparation 25 by using (R)-tert-butyl pyrrolidin-3-ylcarbamate in step 1. MS (EI) for C14H21BrN4O4S: 421 (MH+).

tert-Butyl 8-(2-amino-5-bromopyridin-3-ylsulfonyl)-8-azabicyclo[3.2.1]octan-3-ylcarbamate. Prepared according to the method of reagent preparation 25 by using tert-butyl 8-azabicyclo[3.2.1]octan-3-ylcarbamate (WO 2009055077) in step 1. MS (EI) for C17H25BrN4O4S: 461 (MH+).

2,2,2-Trichloroethyl 3-(2-amino-5-bromopyridine-3-sulfonamido)-8-azabicyclo[3.2.1]octane-8-carboxylate. Prepared according to the method of reagent preparation 25 by using 2,2,2-trichloroethyl 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (WO 2009055077) in step 1. MS (EI) for C15H18BrCl3N4O4S: 535 (MH+).

(R)-tert-Butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)pyrrolidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using (S)-tert-butyl 3-(aminomethyl)pyrrolidine-1-carboxylate in step 1. MS (EI) for C15H23BrN4O4S: 435 (MH+).

(S)-tert-Butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)pyrrolidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using (R)-tert-butyl 3-(aminomethyl)pyrrolidine-1-carboxylate in step 1. MS (EI) for C15H23BrN4O4S: 435 (MH+).

(R)-tert-Butyl 3-(2-amino-5-bromopyridine-3-sulfonamido)pyrrolidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using (R)-tert-butyl 3-aminopyrrolidine-1-carboxylate in step 1. MS (EI) for C14H21BrN4O4S: 421 (MH+).

(S)-tert-Butyl 3-(2-amino-5-bromopyridine-3-sulfonamido)pyrrolidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using (S)-tert-butyl 3-aminopyrrolidine-1-carboxylate in step 1. MS (EI) for C14H21BrN4O4S: 421 (MH+).

tert-Butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using tert-butyl 3-(aminomethyl)piperidine-1-carboxylate in step 1. MS (EI) for C16H25BrN4O4S: 449 (MH+).

tert-Butyl 2-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using tert-butyl 2-(aminomethyl)piperidine-1-carboxylate in step 1. MS (EI) for C16H25BrN4O4S: 449 (MH+).

(R)-tert-Butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using (S)-tert-butyl 3-(aminomethyl)piperidine-1-carboxylate in step 1. MS (EI) for C16H25BrN4O4S: 449 (MH+).

(S)-tert-Butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate. Prepared according to the method of reagent preparation 25 by using (R)-tert-butyl 3-(aminomethyl)piperidine-1-carboxylate in step 1. MS (EI) for C16H25BrN4O4S: 449 (MH+).

(S)-2-amino-5-bromo-N-((1-methylpiperidin-3-yl)methyl)pyridine-3-sulfonamide. Prepared according to the method of reagent preparation 25 by using (R)-(1-methylpiperidin-3-yl)methanamine in step 1. MS (EI) for C12H19BrN4O2S: 363 (MH+).

2-amino-5-bromo-N-[(3R)-1-methylpyrrolidin-3-yl]pyridine-3-sulfonamide. Synthesized according to the method of reagent preparation 25 by using (R)-1-methylpyrrolidin-3-amine hydrochloride (synthesized according to the method of Journal of Medicinal Chemistry (2002), 45(3), 721-739) in step 1. MS (EI) for C10H15BrN4O2S: 334, 336 (MH+, Br isotope pattern).

2-amino-5-bromo-N-{[(3S)-1-methylpyrrolidin-3-yl]methyl}pyridine-3-sulfonamide. Synthesized according to the method of reagent preparation 25 by using (R)-(1-methylpyrrolidin-3-yl)methanamine hydrobromide (synthesized according to the methods of WO 2006028904 for the synthesis of benzyl[[(R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]methyl]carbamate, WO 2006002047 for the synthesis of (S)-benzyl pyrrolidin-3-ylmethylcarbamate and Journal of Medicinal Chemistry (2002), 45(3), 721-739 for the synthesis of (R)-benzyl (1-methylpyrrolidin-3-yl)methylcarbamate, using (R)-3-(aminomethyl)-1-(tert-butyloxycarbonyl)pyrrolidine as starting material) in step 1. MS (EI) for C11H17BrN4O2S: 348, 350 (MH+, Br isotope pattern).

tert-Butyl 6-(2-amino-5-bromopyridin-3-ylsulfonyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate. Prepared according to the method of reagent preparation 25 by using tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate in step 1. MS (EI) for C15H21BrN4O4S: 377 (MH+-tBu).

(S)-tert-Butyl 1-(5-bromo-2-chloropyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate. Prepared according to the methods described in reagent preparation 25 using 5-bromo-2-chloropyridine-3-sulfonyl chloride and (S)-tert-butyl pyrrolidin-3-ylcarbamate in step 1. 1H NMR (400 MHz, CDCl3) δ 8.61 (d, 1H), 8.52 (d, 1H), 4.67 (s, 1H), 4.25 (s, 1H), 3.57 (m, 4H), 3.34 (m, 1H), 2.22 (m, 1H), 1.92 (m, 1H), 1.45 (s, 9H); MS (ES) for C14H19BrClN3O4S: 440, 442 (Br isotopes, MH+).

tert-Butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)azetidine-1-carboxylate. Prepared according to the methods described in reagent preparation 25 using tert-butyl 3-(aminomethyl)azetidine-1-carboxylate in step 1. MS (ES) for C14H21BrN4O4S: 421, 423 (Br isotopes, MH+).

Reagent Preparation 26 N-(5-bromo-2-methylpyridin-3-yl)methanesulfonamide

STEP 1: A solution of 5-bromo-2-methylpyridin-3-amine (187 mg, 1.0 mmol) and diisopropylethylamine (523 uL, 3.0 mmol) in dichloromethane (5 mL) was cooled to 0° C., and then methanesulfonyl chloride (155 uL, 2.0 mmol) was added slowly. The reaction mixture was stirred at 0° C. for 8 min and was then warmed to rt. After stirring for 1 h, the volatile materials were removed in vacuo. The residue was then dissolved in methanol (2.5 mL) and aqueous sodium hydroxide (2 M, 1.5 mL, 3 mmol) was added. The reaction mixture was stirred for 1 h 40 min at rt. Water was then added to the mixture which was subsequently extracted twice with dichloromethane. The combined organic extracts were extracted with aqueous citric acid (10%). The organic phase was discarded, and the aqueous phase was basified to pH ˜7.5 with aqueous sodium hydroxide (1 M). The aqueous mixture was extracted three times with dichloromethane. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (50% hexanes:50% ethyl acetate) to provide N-(5-bromo-2-methylpyridin-3-yl)methanesulfonamide (111 mg, 0.42 mmol, 42% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.58 (s, 1H), 8.44 (d, 1H), 7.87 (d, 1H), 3.10 (s, 3H), 2.47 (s, 3H); MS (EI) for C7H9BrN2O2S: 265, 267 (Br isotopes, MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagents were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

N-(5-Bromo-2-chlorophenyl)methanesulfonamide. Prepared according to the methods described in reagent preparation 26 using 5-bromo-2-chloroaniline in step 1. 1H NMR (400 MHz, CDCl3) δ 7.83 (d, 1H), 7.32-7.23 (m, 2H), 6.80 (br s, 1H), 3.06 (s, 3H); MS (EI) for C7H7BrClNO2S: 282, 284, 286 (Br+Cl isotopes, MH+).

N-(5-Bromo-2-methoxypyridin-3-yl)methanesulfonamide. Prepared according to the methods described in reagent preparation 26 using 5-bromo-2-methoxypyridin-3-amine in step 1. 1H NMR (400 MHz, CDCl3) δ 7.97 (d, 1H), 7.90 (d, 1H), 6.73 (br s, 1H), 4.00 (s, 3H), 3.05 (s, 3H); MS (EI) for C7H9BrN2O3S: 281, 283 (Br isotopes, MH+).

N-(5-Bromo-2-cyanopyridin-3-yl)methanesulfonamide. Prepared according to the methods described in reagent preparation 26 using 3-amino-5-bromopicolinonitrile in step 1. 1H NMR (400 MHz, CDCl3) δ 8.55 (d, 1H), 8.29 (d, 1H), 7.00 (br s, 1H), 3.21 (s, 3H); MS (EI) for C7H6BrN3O2S: 276, 278 (Br isotopes, MH+).

N-(5-Bromopyridin-3-yl)methanesulfonamide. Prepared according to the methods described in reagent preparation 26 using 5-bromopyridin-3-amine in step 1. MS (EI) for C6H7BrN2O2S: 251, 253 (Br isotopes, MH+).

N-(5-Bromo-2-chloropyridin-3-yl)-2-chloro-6-methylbenzenesulfonamide. Prepared according to the methods described in reagent preparation 26 using 5-bromo-2-chloropyridin-3-amine and 2-chloro-6-methylbenzene-1-sulfonyl chloride in step 1. MS (EI) for C12H9BrCl2N2O2S: 393, 395, 397 (Br+Cl isotopes, MH+).

N-(5-Bromo-2-fluoropyridin-3-yl)methanesulfonamide. Prepared according to the methods described in reagent preparation 26 using 5-bromo-2-fluoropyridin-3-amine in step 1. MS (EI) for C6H6BrFN2O2S: 269, 271 (Br isotopes, MH+).

N-(5-Bromo-2-chloropyridin-3-yl)acetamide. Prepared according to the methods described in reagent preparation 26 using 5-bromo-2-chloropyridin-3-amine and acetyl chloride in step 1.

Methyl 5-bromo-2-chloropyridin-3-ylcarbamate. Prepared according to the methods described in reagent preparation 26 using 5-bromo-2-chloropyridin-3-amine and methyl chloroformate in step 1.

Reagent Preparation 27 5-bromo-2-chloro-3-(methylsulfonylmethyl)pyridine

STEP 1: A mixture of 5-bromo-2-chloro-3-(chloromethyl)pyridine (124 mg, 0.52 mmol) and sodium methanesulfinate (52 mg, 0.52 mmol) in dioxane (1.4 mL) and water (1.4 mL) was heated to 110° C. in a microwave reactor for 15 min. After cooling to rt, water was added to the reaction mixture which was subsequently extracted twice with ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated in vacuo to provide 5-bromo-2-chloro-3-(methylsulfonylmethyl)pyridine (140 mg, 0.49 mmol, 94% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 8.63 (d, 1H), 8.21 (d, 1H), 4.70 (s, 2H), 3.10 (s, 3H); MS (EI) for C7H7BrClNO2S: 284, 286, 288 (Br+Cl isotopes, MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagent was prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

5-Bromo-3-(methylsulfonylmethyl)pyridin-2-amine. Prepared according to the methods described in reagent preparation 27 using 5-bromo-3-(bromomethyl)pyridin-2-amine hydrochloride in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.03 (d, 1H), 7.59 (d, 1H), 6.35 (br s, 2H), 4.44 (s, 2H), 2.95 (s, 3H); MS (EI) for C7H9BrN2O2S: 265, 267 (Br isotopes, MH+).

Reagent Preparation 28 N-(5-bromo-2-chloropyridin-3-yl)-N-methylmethanesulfonamide

STEP 1: A solution of N-(5-bromo-2-chloropyridin-3-yl)methanesulfonamide (96 mg, 0.34 mmol, reagent preparation 24) in DMF (1 mL) was treated with potassium carbonate (93 mg, 0.68 mmol) and iodomethane (33 uL, 0.51 mmol) at rt for 18 h. Water was then added, and the resulting aqueous mixture was extracted twice with ethyl acetate. The combined organic extracts were washed with aqueous lithium chloride (10%) followed by water, dried over magnesium sulfate, filtered, and concentrated in vacuo to provide N-(5-bromo-2-chloropyridin-3-yl)-N-methylmethanesulfonamide (91.2 mg, 0.304 mmol, 90% yield) as a light yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.46 (d, 1H), 8.00 (d, 1H), 3.32 (s, 3H), 3.07 (s, 3H); MS (EI) for C7H8BrClN2O2S: 299, 301, 303 (Br+Cl isotopes, MH+).

Reagent Preparation 29 5-bromo-2-chloro-3-(difluoromethoxy)pyridine

To a solution of 5-bromo-2-chloropyridin-3-ol (150 mg, 0.72 mmol) in DMF (5 mL) was added potassium carbonate (298 mg, 2.2 mmol). The mixture was heated to 70° C. and bromodifluoromethane was bubbled through for 3 min. After cooling to rt, water was added, and the resulting aqueous mixture was extracted twice with ethyl acetate. The organic extracts were washed with aqueous lithium chloride (10%) followed by water, dried over magnesium sulfate, filtered, and concentrated in vacuo to provide 5-bromo-2-chloro-3-(difluoromethoxy)pyridine (159 mg, 0.61 mmol, 85% yield) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 8.36 (d, 1H), 7.76 (d, 1H), 6.61 (t, 1H); MS (EI) for C6H3BrClF2NO: 258 (M+).

Reagent Preparation 30 N-(5-bromo-2-ethoxypyridin-3-yl)methanesulfonamide

STEP 1: A solution of 5-bromo-2-chloro-3-nitropyridine (100 mg, 0.42 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (315 uL, 2.11 mmol) in ethanol (1 mL) was heated to 50° C. for 50 min and then cooled to rt. Water was added and the resulting aqueous mixture was extracted twice with ethyl acetate. The combined organic extracts were washed with 1 N HCl, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (gradient, 100% hexanes to 90% hexanes:10% ethyl acetate) to provide 5-bromo-2-ethoxy-3-nitropyridine (52.2 mg, 0.211 mmol, 50% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.42 (d, 1H), 8.36 (d, 1H), 4.55 (q, 2H), 1.45 (t, 3H); MS (EI) for C7H7BrN2O3: 246, 248 (M).

STEP 2: To a solution of 5-bromo-2-ethoxy-3-nitropyridine (75.2 mg, 0.304 mmol) in ethyl acetate (3 mL) was added tin(II) chloride (289 mg, 1.52 mmol), and the mixture was heated to reflux for 2 h. After cooling to rt, 50% aqueous sodium hydroxide was added dropwise until a sticky brown solid completely formed. Sodium sulfate was then added, and the mixture was stirred for several minutes. The solids were then removed by filtration. The filtrate was dried over sodium sulfate, filtered, and concentrated in vacuo to provide 5-bromo-2-ethoxypyridin-3-amine (53 mg, 0.25 mmol, 80% yield) as a dark blue film. 1H NMR (400 MHz, CDCl3) δ 7.56 (d, 1H), 6.97 (d, 1H), 4.37 (q, 2H), 3.85 (br s, 2H), 1.40 (dd, 3H); MS (EI) for C7H9BrN2O: 217, 219 (Br isotopes, MH+).

STEP 3: A solution of 5-bromo-2-ethoxypyridin-3-amine (53 mg, 0.25 mmol) and diisopropylethylamine (96 uL, 0.55 mmol) in dichloromethane (1 mL) was cooled to 0° C. and methanesulfonyl chloride (39 uL, 0.5 mmol) was added. The mixture was allowed to warm to rt over 15 h, and then water was added. The resulting mixture was extracted with dichloromethane. The organic extract was dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was dissolved in methanol (500 uL) and dioxane (500 uL), and then sodium hydroxide (2 M, 190 uL, 0.38 mmol) was added. The mixture was heated to 60° C. and 3 drops of aqueous sodium hydroxide (50%) were added. After stirring a further 30 min, the mixture was cooled to rt. Dilution with water was followed by acidification with aqueous citric acid (10%) and then two extractions with ethyl acetate. The combined organic extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (gradient 100% hexanes to 70% hexanes:30% ethyl acetate) to provide N-(5-bromo-2-ethoxypyridin-3-yl)methanesulfonamide (32.1 mg, 0.11 mmol, 43% yield) as a colorless film. 1H NMR (400 MHz, CDCl3) δ 7.95 (d, 1H), 7.89 (d, 1H), 6.75 (br s, 1H), 4.42 (q, 2H), 3.05 (s, 3H), 1.41 (t, 3H); MS (EI) for C8H11BrN2O3S: 295, 297 (Br isotopes, MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagent was prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

N-(2-(Benzyloxy)-5-bromopyridin-3-yl)methanesulfonamide. Prepared according to the methods described in reagent preparation 30 using benzyl alcohol in step 1. 1H NMR (400 MHz, CDCl3) δ 8.00 (d, 1H), 7.91 (d, 1H), 7.44-7.34 (m, 5H), 6.71 (br s, 1H), 5.40 (s, 2H), 2.99 (s, 3H); MS (EI) for C13H13BrN2O3S: 357, 359 (Br isotopes, MH+).

Reagent Preparation 31 N-(2-amino-5-bromopyridin-3-yl)methanesulfonamide

STEP 1: To a solution of 5-bromo-3-nitropyridin-2-amine (218 mg, 1 mmol) in THF (5 mL) was added DMAP (183 mg, 1.5 mmol) and di-tert-butyl dicarbonate (655 mg, 3 mmol). After stirring 40 min at rt, the volatile materials were removed in vacuo, and the resulting residue was purified by flash chromatography (gradient, 100% hexanes to 70% hexanes:30% ethyl acetate). The isolated material indicated the addition of two Boc groups by 1H NMR. This material was dissolved in ethyl acetate (8 mL) and was treated with excess N,N-dimethylethylenediamine. After stirring for 17 h at rt, the reaction mixture was diluted with ethyl acetate. The resulting solution was washed with aqueous citric acid (10%) followed by water, dried over magnesium sulfate, filtered, and concentrated in vacuo to provide tert-butyl 5-bromo-3-nitropyridin-2-ylcarbamate (270 mg, 0.85 mmol, 85% yield) as an orange solid. 1H NMR (400 MHz, CDCl3) δ 9.48 (br s, 1H), 8.74 (d, 1H), 8.63 (d, 1H), 1.56 (s, 9H); MS (EI) for C10H12BrN3O4: 316, 318 (Br isotopes, M−H).

STEP 2: Iron powder (293 mg, 5.2 mmol) was added to a solution of tert-butyl 5-bromo-3-nitropyridin-2-ylcarbamate (167 mg, 0.52 mmol) in acetic acid (2.5 mL). The mixture was stirred at 60° C. for 1 h 20 min before cooling to rt. The mixture was then diluted with ethyl acetate, and solids were removed by filtration through celite. The filtrate was washed with water followed by saturated aqueous sodium bicarbonate. The organic phase was dried over magnesium sulfate, filtered, and concentrated in vacuo to provide tert-butyl 3-amino-5-bromopyridin-2-ylcarbamate (96.3 mg, 0.33 mmol, 64% yield) as a gray solid. 1H NMR (400 MHz, CDCl3) δ 7.83 (d, 1H), 7.20 (d, 1H), 6.95 (br s, 1H), 4.42 (br s, 2H), 1.51 (s, 9H); MS (EI) for C10H14BrN3O2: 232, 234 (Br isotopes, MH+-t-butyl).

STEP 3: A solution of tert-butyl 3-amino-5-bromopyridin-2-ylcarbamate (96.3 mg, 0.33 mmol) and diisopropylethylamine (128 uL, 074 mmol) in dichloromethane (2 mL) was cooled to 0° C., and to it was added methanesulfonyl chloride (52 uL, 0.67 mmol). The mixture was allowed to warm to rt over 2 h. The mixture was then diluted with dichloromethane and was then washed with aqueous citric acid (10%) followed by water. The organic phase was then dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (gradient, 100% hexanes to 70% hexanes:30% ethyl acetate) to provide tert-butyl 5-bromo-3-(N-(methylsulfonyl)methylsulfonamido)pyridin-2-ylcarbamate (77 mg, 0.17 mmol, 52% yield) as a colorless film. 1H NMR (400 MHz, CDCl3) δ 8.64 (d, 1H), 7.79 (d, 1H), 7.10 (s, 1H), 3.44 (s, 6H), 1.52 (s, 9H); MS (EI) for C12H18BrN3O6S2: 388, 390 (Br isotopes, MH+-t-butyl).

STEP 4: A solution of tert-butyl 5-bromo-3-(N-(methylsulfonyl)methylsulfonamido)pyridin-2-ylcarbamate (68 mg, 0.15 mmol) and N,N-dimethylethylenediamine (169 uL, 1.5 mmol) in dioxane (1 mL) was stirred at rt for 70 min. After diluting with ethyl acetate, the mixture was washed with aqueous citric acid (10%) followed by water. The organic phase was then dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was then diluted with dichloromethane which was then washed with 1 N HCl. After partitioning, the organic phase was dried over magnesium sulfate, filtered, and concentrated in vacuo to provide tert-butyl 5-bromo-3-(methylsulfonamido)pyridin-2-ylcarbamate (57 mg, 0.15 mmol, quantitative yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.24 (d, 1H), 8.07 (d, 1H), 2.98 (s, 3H), 1.54 (s, 9H); MS (EI) for C10H16BrN3O4S: 310, 312 (Br isotopes, MH+-t-butyl).

STEP 5: A solution of tert-butyl 5-bromo-3-(methylsulfonamido)pyridin-2-ylcarbamate (57 mg, 0.15 mmol) in methanol (1 mL) and HCl (4 M in dioxane, 375 uL, 1.5 mmol) was heated to 60° C. for 90 min. The volatile materials were then removed in vacuo to provide N-(2-amino-5-bromopyridin-3-yl)methanesulfonamide as its hydrochloride salt in quantitative yield. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (br s, 1H), 7.95 (d, 1H), 7.54 (d, 1H), 6.42 (br s, 1H), 3.02 (s, 3H); MS (EI) for C6H8BrN3O2S: 266, 268 (Br isotopes, MH+).

Reagent Preparation 32 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine

To a solution of 5-bromo-1H-pyrazolo[3,4-b]pyridine (1.4 g, 7.2 mmol) and dihydropyran (3.3 mL, 36.0 mmol) in tetrahydrofuran (20 mL) was added (±)-camphorsulfonic acid (250 mg) and the reaction mixture was stirred at 65° C. for 16 hours. After cooling to room temperature it was diluted with ethyl acetate (250 mL), washed with saturated aqueous sodium bicarbonate (2×100 mL) and brine (100 mL), dried over sodium sulfate, filtered and concentrated. Gradient column chromatography (10% to 30% ethyl acetate in hexane) provided 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine (1.8 g, 90%). MS (EI) for C11H12BrN3O: 283 (MH+).

Reagent Preparation 33 2-Amino-5-bromo-N,N-dimethylnicotinamide

To a suspension of 2-amino-5-bromonicotinic acid (0.35 g, 1.61 mmol) in tetrahydrofuran (5 mL) was added dimethylamine (0.8 mL of a 2M solution in tetrahydrofuran, 1.60 mmol), diethylphosphoryl cyanide (0.29 g, 1.77 mmol), and triethylamine (0.34 g, 3.38 mmol) at 0° C. The mixture was stirred at 0° C. for 30 min and then at room temperature for 4 h. Concentration and purification by column chromatography on silica (5-10% methanol in dichloromethane) gave the title Compound as a white solid. MS (EI) for C8H10BrN3O: 244 (MH+).

Reagent Preparation 34 5-Bromo-3-(ethylsulfonyl)pyridin-2-amine

STEP 1: 2-Amino-5-bromopyridine-3-sulfonyl chloride (94 mg, 0.35 mmol) was taken into THF (2 mL) followed by addition of anhydrous hydrazine (40 uL, 1.4 mmol) and the mixture was stirred for 10 minutes at room temperature. The mixture was concentrated and dried to give 2-amino-5-bromopyridine-3-sulfonohydrazide as a white solid, which was then taken into ethanol (2 mL) followed by addition of sodium acetate (320 mg, 3.9 mmol) and ethyl iodide (140 uL, 1.75 mmol). The mixture was refluxed for 12 h then cooled to room temperature and concentrated. The residue was partitioned with ethyl acetate and water and the organic phase washed with brine then dried over sodium sulfate, filtered and concentrated to give 5-bromo-3-(ethylsulfonyl)pyridin-2-amine (67 mg, 72%) as a yellow oil. MS (EI) for C7H9N2SO2Br: 265, 267 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagents were prepared.

5-Bromo-3-(methylsulfonyl)pyridin-2-amine. Synthesized according to the method of reagent preparation 34 using iodomethane. GCMS (EI) for C6H7N2SO2Br: 250, 252 (M+).

3-(2-amino-5-bromopyridin-3-ylsulfonyl)propane-1,2-diol. Synthesized according to the method of reagent preparation 34 using 3-bromopropane-1,2-diol followed by silica gel chromatography using ethyl ether then ethyl acetate as eluent. MS (EI) for C7H9N2SO2Br: 311, 313 (MH+).

3-(2-amino-5-bromopyridin-3-ylsulfonyl)propan-1-ol. Synthesized according to the method of reagent preparation 34 using 3-bromopropan-1-ol followed by silica gel chromatography using ethyl ether as eluent. MS (EI) for C7H9N2SO2Br: 295, 297 (MH+).

(S)-3-(2-amino-5-bromopyridin-3-ylsulfonyl)-2-methylpropan-1-ol. Synthesized according to the method of reagent preparation 34 using (S)-3-bromo-2-methylpropan-1-ol followed by silica gel chromatography using 4:1 ethyl ether:hexanes as eluent. MS (EI) for C7H9N2SO2Br: 309, 311 (MH+).

(R)-3-(2-amino-5-bromopyridin-3-ylsulfonyl)-2-methylpropan-1-ol. Synthesized according to the method of reagent preparation 34 using (R)-3-bromo-2-methylpropan-1-ol followed by silica gel chromatography using 4:1 ethyl ether:hexanes as eluent. MS (EI) for C7H9N2SO2Br: 309, 311 (MH+).

Reagent Preparation 35 6-bromo-2-methyl-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazo[4,5-b]pyridine

To a solution of 6-bromo-2-methyl-1H-imidazo[4,5-b]pyridine (3.0 g, 14.1 mmol) in a mixture of N,N-dimethylformamide and tetrahydrofuran (30 mL, 2:1) at 0° C. was added 60% sodium hydride in mineral oil (0.68 g, 17.0 mmol) and the reaction mixture was stirred for 30 minutes, followed by the addition of 2-(trimethylsilyl)ethoxymethyl chloride (2.7 mL, 14.9 mmol). The reaction mixture was stirred for 16 hours at room temperature then it was quenched by the careful addition of water and diluted with ethyl acetate (250 mL), washed with brine (3×150 mL), dried over sodium sulfate, filtered and concentrated. Gradient column chromatography (10% to 30% ethyl acetate in hexane) provided 6-bromo-2-methyl-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazo[4,5-b]pyridine (4.4 g, 92%). 1H NMR (400 MHz, CDCl3): 8.41 (s, 1H), 8.12 (s, 1H), 5.67 (s, 2H), 3.62 (m, 2H), 2.76 (s, 3H), 0.96 (m, 2H), 0.00 (s, 9H). MS (EI) for C13H20BrN3OSi: 342, 344 (MH+, Br iotope pattern).

Reagent Preparation 36 6-bromo-N-ethyl-3-(methoxymethyl)-3H-imidazo[4,5-b]pyridin-2-amine and 6-bromo-N-ethyl-N,3-bis(methoxymethyl)-3H-imidazo[4,5-b]pyridin-2-amine

Step 1: To a cooled (0° C.) solution of 5-bromopyridine-2,3-diamine (5.0 g, 27 mmol) in NMP (20 mL) was added isothiocyanatoethane (2.3 mL, 26 mmol). The resulting solution was heated (65° C.) for four hours and then cooled to ambient temperature before 1,3-diisopropylcarbodiimide (4.2 mL, 27 mmol) was added. The reaction mixture was stirred for 18 hours, diluted with water and the resulting suspension was collected by filtration. Trituration with ethyl acetate provided 6-bromo-N-ethyl-3H-imidazo[4,5-b]pyridin-2-amine (4.8 g, 75% yield) as a brown solid. 1H NMR (400 MHz, d6-DMSO) δ 11.41 (bs, 1H), 7.91 (s, 1H), 7.53 (s, 1H), 7.17 (s, 1H), 3.33 (q, 2H), 1.17 (t, 3H); MS (ES) for C8H9BrN4: 241 (MH+).

Step 2: To a cooled (0° C.) solution of 6-bromo-N-ethyl-3H-imidazo[4,5-b]pyridin-2-amine (0.36 g, 1.5 mmol) in DMF was added NaH (60% dispersion in mineral oil, 0.060 g, 1.5 mmol) portionwise over 15 minutes. The reaction mixture was stirred for 15 minutes and then chloro(methoxy)methane (0.12 mL, 1.5 mmol) was added dropwise over 15 minutes. The resulting slurry was allowed to warm to ambient temperature and was stirred for two hours and was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by silica gel chromatography provided both 6-bromo-N-ethyl-N,3-bis(methoxymethyl)-3H-imidazo[4,5-b]pyridin-2-amine (0.091 g, 18%) and 6-bromo-N-ethyl-3-(methoxymethyl)-3H-imidazo[4,5-b]pyridin-2-amine (0.15 g, 35% yield). Bisprotected product: MS (ES) for C12H17BrN4O2: 329 (MH+). Monoprotected product: 1H NMR (400 MHz, CDCl3) δ 8.03 (d, 1H), 7.73 (d, 1H), 5.42 (s, 2H), 4.98 (s, 1H), 3.59 (q, 2H), 3.36 (s, 3H), 1.34 (t, 3H); MS (ES) for C10H13BrN4O: 285 (MH+).

Reagent Preparation 37 7-Bromo-2H-pyrido[2,3-e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxide

STEP 1: 2-Amino-5-bromopyridine-3-sulfonyl chloride (reagent preparation 25) (95.5 mg, 0.35 mmol) was treated with 0.5M ammonia in dioxane solution (7 mL) and the mixture was stirred for 1 h at room temperature. Concentrated aqueous ammonia (2 mL) was then added to the mixture then stirred an additional 12 h. The mixture was then concentrated and the residue suspended in water (5 mL). The solid was collected by filtration and dried to give 2-amino-5-bromopyridine-3-sulfonamide (55.7 mg, 89%).

STEP 2: 2-Amino-5-bromopyridine-3-sulfonamide as obtained above (0.22 mmol) was taken into THF (2 mL) followed by addition of diisopropylethylamine (115 uL, 0.66 mmol). Phosgene (20 W % in toluene, 120 uL, 0.22 mmol) was added carefully and the mixture was allowed to stir for 1 h at room temperature. The mixture was partitioned with ethyl acetate and 0.5M aqueous hydrochloric acid. The organic phase was then extracted once with saturated aqueous sodium bicarbonate. The organic layer was discarded and the aqueous phase carefully acidified to pH 1-2 with concentrated aqueous hydrochloric acid. The aqueous mixture was then extracted once with ethyl acetate, dried over sodium sulfate, filtered and concentrated to give 7-bromo-2H-pyrido[2,3-e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxide (17.3 mg, 28%) as a solid. MS (EI) for C6H4N3O3SBr: 277, 279 (M−).

Reagent Preparation 38 2-amino-5-bromopyridine-3-sulfonic acid

STEP 1: 2-Amino-5-bromopyridine-3-sulfonyl chloride (100 mg, 0.37 mmol) was taken into 1:1 aqueous dioxane (3 mL) and the mixture was basified to pH 14 by drop wise addition of 50% aqueous sodium hydroxide solution. The mixture was warmed to 75° C. for 0.5 h then cooled to room temperature and concentrated. The residue was taken into water (2 mL) and carefully acidified to pH 1-2 by concentrated aqueous hydrochloric acid addition and cooled to 0° C. After 1 h at 0° C. the crystalline solid obtained was collected by filtration and dried to give 2-amino-5-bromopyridine-3-sulfonic acid as a solid. 1H NMR (DMSO-d6): 8.24 (d, 1H), 8.06 (d, 1H). MS (EI) for C5H5N2SO3Br: 253, 255 (MH+, Br pattern).

Reagent Preparation 39 N-(5-bromo-2-(dimethylamino)pyridin-3-yl)methanesulfonamide

STEP 1: 5-Bromo-2-chloro-3-nitropyridine (J. Heterocyclic Chem. 2003, 40, 261) (128 mg, 0.54 mmol) was taken into THF (0.25 mL) followed by addition of 40 W % aqueous dimethylamine (0.25 mL) and the resulting solution was stirred for 1 h at room temperature. The mixture was then partitioned with ethyl ether and 1 M aqueous hydrochloric acid. The organic solution was then washed with additional 1 M aqueous hydrochloric acid (3×) then dried over magnesium sulfate, filtered and concentrated to give 5-bromo-N,N-dimethyl-3-nitropyridin-2-amine. MS (EI) for C7H8N3O2Br: 246, 248 (MH+, Br pattern).

STEP 2: 5-Bromo-N,N-dimethyl-3-nitropyridin-2-amine as obtained in step 1 (0.54 mmol) was taken into ethyl acetate (10 mL) followed by addition of tin (II) chloride (522 mg, 2.8 mmol) and the mixture was heated to reflux for 15 minutes then cooled to room temperature. 50 W % aqueous sodium hydroxide was added drop wise to the mixture until a precipitate formed then solid sodium sulfate was added. The mixture was filtered and the filter cake washed with ethyl acetate. The organic filtrate was concentrated to give 5-bromo-N2,N2-dimethylpyridine-2,3-diamine (53 mg, 45%) was an amorphous residue. MS (EI) for C7H10N3Br: 216, 218 (MH+, Br pattern).

STEP 3: 5-Bromo-N2,N2-dimethylpyridine-2,3-diamine (53 mg, 0.25 mmol) was taken into THF (2 mL) followed by addition of diisopropylethylamine (213 uL, 1.25 mmol) and methanesulfonyl chloride (95 ul, 1.25 mmol). The mixture was allowed to stir for 48 h at room temperature then partitioned with ethyl acetate and water. The organic phase was washed with brine then dried over sodium sulfate, filtered and concentrated. The residue was taken into methanol (3 mL) followed by addition of potassium hydroxide (108 mg, 10 eq) in a minimum of water. The mixture was stirred for 15 minutes at room temperature then partitioned with ethyl acetate and 10% aqueous citric acid. The organic solution was dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography to give N-(5-bromo-2-(dimethylamino)pyridin-3-yl)methanesulfonamide (27.9 mg, 39%). MS (EI) for C8H12N3SO2Br: 294, 296 (MH+, Br pattern).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagents were prepared.

N-(2-(Benzylamino)-5-bromopyridin-3-yl)methanesulfonamide. Synthesized according to the method of reagent preparation 39 using benzylamine in step 1. MS (EI) for C13H14N3SO2Br: 356, 358 (MH+, Br pattern).

N-(5-Bromo-2-(phenylamino)pyridin-3-yl)methanesulfonamide. Synthesized according to the method of reagent preparation 39 using neat aniline at 75° C. in step 1. MS (EI) for C12H12N3SO2Br: 342, 344 (MH+, Br pattern).

N-(5-Bromo-2-(methylamino)pyridin-3-yl)methanesulfonamide. Synthesized according to the method of reagent preparation 39 using methylamine in step 1. MS (EI) for C7H10N3SO2Br: 280, 282 (MH+, Br pattern).

Reagent Preparation 40 1,1-dimethylethyl {(3S)-1-[(5-bromo-2-hydroxypyridin-3-yl)sulfonyl]pyrrolidin-3-yl}carbamate and 1,1-dimethylethyl[(3S)-1-({5-bromo-2-[(3S)-3-({[(1,1-dimethylethyl)oxy]carbonyl}amino)pyrrolidin-1-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-yl]carbamate

STEP 1: To a solution of 3-amino-5-bromo-2-chloropyridine (0.23 g, 1.1 mmol) in acetonitrile (3.0 mL) at −15° C. was added a solution of sodium nitrite (0.091 g, 1.3 mmol) in water (1.20 mL), followed by the addition of concentrate hydrochloric acid (1.8 mL, 21.3 mmol) and the reaction mixture was stirred for 5 minutes. A 30 wt % solution of sulfur dioxide in acetic acid 3.0 mL, 1.3 mmol) was prepared and introduced into the reaction mixture, followed by the addition of a solution of copper(II) chloride 0.091 g, 0.68 mmol) in water (1.2 mL). The stirring was continued for an additional 3 hours at −5° C. The pH of the mixture was adjusted to 8 by the addition of a solution of potassium hydrogenphosphate and 2M aqueous sodium hydroxide and partitioned with ethyl acetate (50 mL). The organic layer was separated and washed with water (10 mL) and brine (10 mL), dried over sodium sulfate, filtered and concentrated to give 5-bromo-2-chloropyridine-3-sulfonyl chloride (0.20 g, 63%).

STEP 2: A mixture of 5-bromo-2-chloropyridine-3-sulfonyl chloride (0.19 g, 0.65 mmol), (3S)-(−)-3-(tert-butoxycarbonylamino)pyrrolidine (0.18 g, 0.98 mmol) and N,N-diisopropylethylamine (0.34 mL, 1.95 mmol) in dichloromethane (1.5 mL) was stirred for 16 hours at room temperature. The reaction mixture was partitioned between dichloromethane (50 mL) and brine (10 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The resulting crude product was dissolved in a mixture of 1,4-dioxane (1.5 mL) and 2M aqueous sodium hydroxide (1.5 mL) and stirred at 100° C. for 2 hours. After cooling to room temperature the reaction mixture was concentrated and the residue was partitioned between brine (20 mL) and ethyl acetate (50 mL). The organic layer was separated and washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. Gradient flash chromatography (25% to 50% ethyl acetate in hexane) followed by 10% methanol in dichloromethane provided 1,1-dimethylethyl[(3S)-1-({5-bromo-2-[(3S)-3-({[(1,1-dimethylethyl)oxy]carbonyl}amino)pyrrolidin-1-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-yl]carbamate (80 mg, 21%), MS (EI) for C23H36BrN5O6S: 591 (MH+); and 1,1-dimethylethyl{(3S)-1-[(5-bromo-2-hydroxypyridin-3-yl)sulfonyl]pyrrolidin-3-yl}carbamate (35 mg, 13%); MS (EI) for C14H20BrN3O5S: 423 (MH+).

Reagent Preparation 41 4-[(2-amino-5-bromopyridin-3-yl)sulfonyl]-2-methylbutan-2-ol and 4-[(2-amino-5-bromopyridin-3-yl)sulfinyl]-2-methylbutan-2-ol

STEP 1: To a solution of 2-amino-5-bromopyridine-3-sulfonyl chloride (reagent preparation 25, step 1) (0.40 g, (1.47 mmol) in a mixture of 1,4-dioxane (8.0 mL) and water (1.0 mL) was added triphenylphosphine (1.64 g, 6.25 mmol) and the reaction mixture was stirred for 50 minutes at room temperature. Potassium carbonate (0.35 g, 2.50 mmol) was introduced, followed by 4-bromo-2-methyl-2-butanol (Tetrahedron Letters 2000, 41(38), 7337-7340) (0.31 g, 1.86 mmol) and the reaction mixture was stirred at 80° C. for 16 hours. After cooling to room temperature the reaction mixture was concentrated and the residue was partitioned between brine (50 mL) and ethyl acetate (100 mL). The organic layer was separated and washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. Gradient flash chromatography (25% to 50% ethyl acetate in hexane) provided 4-[(2-amino-5-bromopyridin-3-yl)thio]-2-methylbutan-2-ol (0.18 g, 42%); MS (EI) for C10H15BrN2OS: 292 (MH+).

STEP 2A: To a solution of 4-[(2-amino-5-bromopyridin-3-yl)thio]-2-methylbutan-2-ol (90 mg, 0.31 mmol) in a mixture of methanol (750 μL), acetone (750 μL) and water (450 μL) was added potassium peroxymonosulfate (285 mg, 0.46 mmol) and the reaction mixture was stirred for 15 minutes at room temperature. The reaction mixture was partitioned between water (20 mL) and ethyl acetate (50 mL). The organic layer was separated and washed with water (20 mL) and brine (20 mL), dried over sodium sulfate, filtered and concentrated. Purification by flash chromatography (35% to 80% ethyl acetate in hexane) gave 4-[(2-amino-5-bromopyridin-3-yl)sulfonyl]-2-methylbutan-2-ol (48 mg, 48%); MS (EI) for C10H15BrN2O3S: 323 (MH+).

STEP 2B: To a solution of 4-[(2-amino-5-bromopyridin-3-yl)thio]-2-methylbutan-2-ol (83 mg, 0.28 mmol) in a mixture of methanol (750 μL), acetone (750 μL) and water (450 μL) was added potassium peroxymonosulfate (131 mg, 0.21 mmol) and the reaction mixture was stirred for 90 minutes at 0° C. The reaction mixture was partitioned between water (20 mL) and ethyl acetate (50 mL). The organic layer was separated and washed with water (20 mL) and brine (20 mL), dried over sodium sulfate, filtered and concentrated. Purification by flash chromatography (35% to 80% ethyl acetate in hexane) gave 4-[(2-amino-5-bromopyridin-3-yl)sulfinyl]-2-methylbutan-2-ol (52 mg, 60%); MS (EI) for C10H15BrN2O2S: 308 (MH+).

Using analogous synthetic techniques and substituting with alternative starting materials in step 1 the following reagents of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

(2S)-3-[(2-amino-5-bromopyridin-3-yl)sulfonyl]-2-methylpropan-1-ol. Prepared according to the method of reagent preparation 41 by using (S)-(+)-3-bromo-2-methyl-1-propanol in step 1. MS (EI) for C9H13BrN2O3S: 310 (MH+).

(2S)-3-[(2-amino-5-bromopyridin-3-yl)sulfinyl]-2-methylpropan-1-ol. Prepared according to the method of reagent preparation 41 by using (S)-(+)-3-bromo-2-methyl-1-propanol in step 1. MS (EI) for C9H13BrN2O2S: 294 (MH+).

Reagent Preparation 42 (4-chloro-5,6,7,8-tetrahydroquinazolin-7-yl)methanol

Ozone was bubbled through a cooled (−78° C.) solution of 4-chloro-7-vinyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3, 0.35 g, 1.8 mmol) in methanol (5 mL) and dichloromethane (30 mL) until a blue color persisted. The solution was then sparged with N2 for 10 minutes and sodium borohydride (0.14 g, 3.6 mmol) was added portionwise. After 30 minutes the reaction mixture was partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and then concentrated in vacuo to provide (4-chloro-5,6,7,8-tetrahydroquinazolin-7-yl)methanol (0.32 g, 90% yield) as a waxy solid. MS (ES) for C9H11ClN2O: 199 (MH+).

Reagent Example 43 1-(4-chloro-5,6,7,8-tetrahydroquinazolin-7-yl)ethanol

Step 1: Ozone was bubbled through a cooled (−78° C.) solution of 4-chloro-7-vinyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3, 0.38 g, 2.0 mmol) in dichloromethane (45 mL) until a blue color persisted. The solution was then sparged with N2 for 10 minutes and triphenylphosphine (0.52 g, 2.0 mmol) was added portionwise. After one hour, the reaction mixture was partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and then concentrated in vacuo. Purification by silica gel chromatography provided 4-chloro-5,6,7,8-tetrahydroquinazoline-7-carbaldehyde (0.33 g, 85% yield) as a viscous oil. MS (ES) for C9H9ClN2O: 197 (MH+).

Step 2: To a cooled (0° C.) solution of 4-chloro-5,6,7,8-tetrahydroquinazoline-7-carbaldehyde (0.10 g, 0.51 mmol) in THF (5 mL) was added a solution of MeMgBr (3.0 M in ethyl ether, 0.40 mL, 1.2 mmol). The resulting mixture was stirred at ambient temperature for 30 minutes and then partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by silica gel chromatography provided 1-(4-chloro-5,6,7,8-tetrahydroquinazolin-7-yl)ethanol (0.09 g, 83% yield) as a waxy solid. MS (ES) for C10H13ClN2O: 213 (MH+).

Reagent Example 44 4-chloro-7-(methoxymethyl)-5,6,7,8-tetrahydroquinazoline

To a slurry of (4-chloro-5,6,7,8-tetrahydroquinazolin-7-yl)methanol (reagent preparation 42, 0.80 g, 0.40 mmol), potassium carbonate (0.11 g, 0.81 mmol) and THF (15 mL) was added iodomethane (0.09 mL, 0.60 mmol). The reaction mixture was stirred for 18 hours and then partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by silica gel chromatography provided 4-chloro-7-(methoxymethyl)-5,6,7,8-tetrahydroquinazoline (0.03 g, 35% yield) as a waxy solid. MS (ES) for C10H13ClN2O: 213 (MH+).

Reagent Preparation 45 2-(azidomethyl)-4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline

STEP 1: To a solution of 2-(chloromethyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4(3H)-one (150 mg, 0.66 mmol, reagent preparation 17) in DMF (3 mL) was added sodium azide (215 mg, 3.3 mmol). The resulting mixture was stirred at rt for 35 min. Water was added and the resulting mixture was extracted twice with ethyl acetate. The combined organic extracts were washed with aqueous lithium chloride (10%), dried over magnesium sulfate, filtered, and concentrated in vacuo to provide 2-(azidomethyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4(3H)-one (151 mg, 0.65 mmol, 98% yield) as a waxy yellow solid. 1H NMR (400 MHz, CDCl3) δ 11.70 (br s, 1H), 4.41 (s, 2H), 2.66 (t, 2H), 2.33 (s, 2H), 1.58 (t, 3H), 1.00 (s, 6H); MS (EI) for C11H15N5O: 234 (MH+).

STEP 2: A solution of 2-(azidomethyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4(3H)-one (151 mg, 0.65 mmol) in chloroform (1.2 mL) was treated with phosphorus oxychloride (600 uL) at 60° C. for 1 h 20 min. After cooling to rt, the volatile materials were removed in vacuo, and the resulting residue was dissolved in ethyl acetate. The organic solution was washed with saturated aqueous sodium bicarbonate, and the aqueous phase was back extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated in vacuo to provide 2-(azidomethyl)-4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (136 mg, 0.54 mmol, 83% yield) as an orange oil. 1H NMR (400 MHz, CDCl3) δ 4.47 (s, 2H), 2.94 (t, 2H), 2.55 (s, 2H), 1.68 (t, 2H), 1.05 (s, 6H); MS (EI) for C11H14ClN5: 252 (MH+).

Reagent Preparation 46 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylethanamine

STEP 1: To a solution of dimethylamine (2M solution in tetrahydrofuran, 4.0 mL, 8.0 mmol) was added 2-(1-chloroethyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-ol (synthesized according to the method of reagent preparation 18 using 2-chloropropionitrile in step 1) (50 mg, 0.21 mmol) and the reaction mixture was stirred in a sealed tube for 16 hours at 80° C. After cooling to room temperature the reaction mixture was concentrated and the residue was partitioned between brine (50 mL) and ethyl acetate (50 mL). The organic layer was separated and washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated to give 2-[1-(dimethylamino)ethyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-ol (50 mg, 96%). MS (EI) for C14H23N3O: 250 (MH+).

STEP 2: A solution of 2-[1-(dimethylamino)ethyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-ol (50 mg, 0.20 mmol) in a mixture of chloroform (1.5 mL) and phosphorous oxychloride (0.5 mL) was heated to reflux for 90 minutes. After cooling to room temperature the reaction mixture was concentrated and the residue was partitioned between saturated aqueous sodium bicarbonate (20 mL) and ethyl acetate (20 mL). The mixture was stirred for 15 minutes and pH was maintained above 7 by the addition of solid sodium bicarbonate. The organic layer was separated and washed with water (10 mL) and brine, dried over sodium sulfate, filtered and concentrated to give 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylethanamine (46 mg, 85%). MS (EI) for C14H22ClN3: 268 (MH+).

Using analogous synthetic techniques and substituting with alternative starting materials in step 1 the following reagent was prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

4-chloro-6,6-dimethyl-2-(1-pyrrolidin-1-ylethyl)-5,6,7,8-tetrahydroquinazoline. Prepared according to the method of reagent preparation 46 by using pyrrolidine in step 1. MS (EI) for C16H24ClN3: 294 (MH+).

Reagent Preparation 47 methyl 6-bromo-1H-imidazo[4,5-c]pyridin-2-ylcarbamate

A solution of 2-bromo-5-nitropyridin-4-amine (1.5 g, 6.9 mmol) in acetic acid (20 mL) was added in portions into a 75° C. suspension of iron powder (1.5 g, 27 mmol) in acetic acid (20 mL). The reaction mixture was stirred at 75° C. for 2 h, cooled to room temperature, and filtered through celite. To the filtrate was added 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (1.4 g, 6.9 mmol), and the mixture was stirred at 65° C. for 60 h. The reaction mixture was cooled to room temperature and concentrated. The solid residue was triturated with dichloromethane and dried to give the title Compound (1.8 g, quantitative yield) as an orange solid. MS (EI) for C8H7BrN4O2: 271/273 (MH+).

Reagent Preparation 48 tert-butyl 3-(bis(tert-butoxycarbonyl)amino)-5-bromo-1H-indazole-1-carboxylate

To a cooled (0° C.) solution of 5-bromo-1H-indazol-3-amine (0.30 g, 1.4 mmol), DIPEA (2.5 mL, 14 mmol) and di-tert-butyl dicarbonate (1.5 g, 7.0 mmol) in THF (15 mL) was added DMAP (0.09 g, 0.70 mmol). The reaction mixture was then stirred at ambient temperature for three hours. The resulting solution was diluted with ethyl acetate (75 mL) and washed with saturated aqueous ammonium chloride (2×50 mL). The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by silica gel chromatography provided tert-butyl 3-(bis(tert-butoxycarbonyl)amino)-5-bromo-1H-indazole-1-carboxylate (0.44 g, 61%) as a waxy solid. 1H NMR (400 MHz, CDCl3) δ 8.04 (t, 1H), 7.68 (dd, 1H), 7.66-7.58 (m, 1H), 1.53 (s, 18H), 1.43 (s, 9H); MS (EI) for C22H30BrN3O6: 512 (MH+).

Reagent Preparation 49 6-chloro-N-phenylpyrimidine-4-amine

STEP 1: 6-Chloropyrimidin-4-ol (500 mg, 3.85 mmol), aniline (420 μL, 4.62 mmol) and N,N-diisopropylethylamine (1 mL) in diethylene glycol dimethyl ether (5 mL) was heated to 120° C. and stirred for 8 h. The mixture was cooled to room temperature then diluted with actone:diethyl ether solution (1:1, 15 ml) to give a precipitate. The solid collected by filtration and washed with acetone then dried to afford 6-(phenylamino)pyrimidin-4-ol (255 mg, 35.5%). MS (EI) for C10H9N3O: 188.2 (MH+).

STEP 2: 6-(Phenylamino)pyrimidin-4-ol (253 mg, 1.35 mmol) was dissolved in neat phosphorous oxychloride (5 mL) and stirred for 3 h at 95° C. then cooled to room temperature and concentrated. The residue was poured into an ice water slurry and extracted with dichloromethane. The extract was washed saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and the solvent evaporated to afford 6-chloro-N-phenylpyrimidine-4-amine (220 mg) which was used without further purification.

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following reagents were prepared.

6-Chloro-N-(4-methoxyphenyl)pyrimidin-4-amine. Synthesized according to the method of reagent preparation 49 using 4-methoxyaniline in step 1.

6-Chloro-N-(3-methoxyphenyl)pyrimidin-4-amine. Synthesized according to the method of reagent preparation 49 using 3-methoxyaniline in step 1.

6-Chloro-N-(4-methoxyphenyl)-5-methylpyrimidin-4-amine. Synthesized according to the method of reagent preparation 49 using 6-chloro-5-methylpyrimidin-4-ol and 4-methoxyaniline in step 1.

6-Chloro-5-methyl-N-phenylpyrimidin-4-amine. Synthesized according to the method of reagent preparation 49 using 6-chloro-5-methylpyrimidin-4-ol and aniline in step 1.

Reagent Preparation 50 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-methyl-1H-indazole

STEP 1: A suspension of 5-bromo-1H-indazole (200 mg, 1.02 mmol), cesium carbonate (661 mg, 2.00 mmol), and iodomethane (156 mg, 1.10 mmol) in dimethylformamide (3 mL) was stirred at room temperature for 15 h. The mixture was partitioned between 5% lithium chloride and ethyl acetate, the aqueous layer was extracted with ethyl acetate (2×), the combined organic extracts were washed with 1 N sodium hydroxide, and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography on silica (hexanes/ethyl acetate 4:1) gave 5-bromo-1-methyl-1H-indazole (150 mg, 70% yield) as an orange solid. MS (EI) for C8H7BrN2: 212 (MH+).

STEP 2: A suspension of 5-bromo-1-methyl-1H-indazole (150 mg, 0.71 mmol), bis(pinacolato)diboron (200 mg, 0.78 mmol), potassium acetate (206 mg, 2.10 mmol), and dichloro[1,1-bis(diphenylphosphino]ferrocenepalladium (II) dichloromethane adduct (36 mg, 0.04 mmol) in dimethyl sulfoxide (4 mL) was degassed with nitrogen, and then stirred at 80° C. for 18 h. The reaction mixture was cooled to room temperature and partitioned between water and ethyl acetate. The mixture was filtered through celite and then the layers were separated. The aqueous layer was extracted with ethyl acetate (2×), the combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography on silica (hexanes/ethyl acetate 7:3) provided 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-methyl-1H-indazole (158 mg, 86% yield) as a yellow oil. MS (EI) for C14H19BN2O2: 259 (MH+).

Reagent Preparation 51 1,1-dimethylethyl 7-bromo-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

STEP 1: Commercially-available 5-bromo-2-hydroxybenzaldehyde (4.0 g, 10 mmol) and 2-aminoethanol were combined in THF/MeOH (100 mL, 10:1) and sodium borohydride (0.76 g, 2.0 mmol) was added with stirring. The resulting reaction mixture was stirred at 40° C. for 4 h, concentrated on a rotary evaporator then diluted with EtOAc (50 mL) and saturated NaHCO3 (30 mL). To this suspension was added di-tert-butyl dicarbonate (2.83 g, 13 mmol). The mixture was stirred at rt overnight. The organic layer was washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated on a rotary evaporator. Hexane was subsequently added to the crude reaction product which resulted in the formation of a white solid. This slurry was filtered to obtain tert-butyl-5-bromo-2-hydroxybenzyl(2-hydroxyethyl)carbamate (6.8 g, 98%) as a white solid. MS (EI) for C14H20BrNO4, found 346 (MH+).

STEP 2: tent-Butyl-5-bromo-2-hydroxybenzyl(2-hydroxyethyl)carbamate (3.46 g, 10 mmol) and triphenylphosphine (3.96 g, 15 mmol) were combined in DCM (100 mL) and diisopropyl azodicarboxylate (3.03 g, 15 mmol) was added. The resulting reaction mixture was stirred at rt for 12 h. The reaction mixture was washed with water, dried, filtered, and concentrated on a rotary evaporator. The resulting crude product was purified via silica gel chromatography eluting with 8:2 hexane/ethyl acetate to give the desired product (1.74 g, 53%) as a white solid. MS (EI) for C14H18BrNO3, found 328 (MH+).

Example 1 4-{3-[(3-fluorophenyl)methyl]-2-methylpyridin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine

STEP 1: To 5-bromo-2-methylbenzimidazole (38 g, 180 mmol) in THF (400 mL) was added di-tert-butyl dicarbonate (39 g, 189 mmol). The reaction mixture was stirred at room temperature for 24 h and then concentrated. Ethyl acetate (400 mL) was added to the residue, and the solution was washed with 10% aqueous citric acid (2×100 mL), water (100 mL), and brine (100 mL), dried over sodium sulfate, and concentrated. Column chromatography on silica (gradient 20-30% ethyl acetate in hexane) provided 1,1-dimethylethyl 6-bromo-2-methyl-1H-benzimidazole-1-carboxylate (27 g, 48% yield) as a beige solid. MS (EI) for C13H15BrN2O2: 312 (MH+).

STEP 2: A solution of 1,1-dimethylethyl 7-bromo-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (30.0 g, 91.4 mmol) and triisopropyl borate (22.4 g, 119 mmol) in THF (300 mL) was cooled to −78° C., and a 2.5 M solution of n-butyllithium in hexanes (47.6 mL, 119 mmol) was added dropwise over 40 min at this temperature. The reaction mixture was stirred at −78° C. for an additional 30 min, then quenched by dropwise addition of 2 N hydrochloric acid (80 ml), and allowed to warm up to room temperature. Ethyl acetate (100 mL) and water (100 mL) were added, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (100 mL). The combined organic layers were washed with water, dried over sodium sulfate, and concentrated. Hexane (200 mL) was added to the residue and the mixture was stirred overnight. The precipitate was filtered, washed several times with hexane, and dried to give (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (23.4 g, 87%) as a colorless solid. MS (EI) for C14H20BNO5: 294 (MH+).

STEP 3: A suspension of 1,1-dimethylethyl 6-bromo-2-methyl-1H-benzimidazole-1-carboxylate (11.3 g, 36 mmol), (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (11.7 g, 40 mmol), dichloro[1,1-bis(diphenyl-phosphino]ferrocenepalladium (II) dichloromethane adduct (3.0 g, 10 mol %) in dioxane (115 mL) and water (28.5 mL) was degassed with nitrogen, and then diisopropylethylamine (18.6 g, 144 mmol) was added. The reaction mixture was stirred at 90° C. for 220 min, cooled to room temperature, and concentrated. Column chromatography on silica of the residue (gradient 25-30% ethyl acetate in hexane) afforded 1,1-dimethylethyl 7-(1-{[(1,1-dimethylethyl)oxy]carbonyl}-2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (13.2 g, 76% yield) as an amorphous solid. MS (EI) for C27H33N3O5: 480 (MH+).

STEP 4: A solution of 1,1-dimethylethyl 7-(1-{[(1,1-dimethylethyl)oxy]carbonyl}-2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (13.1 g, 27 mmol) in a mixture of methanol (20 mL) and 4 N hydrogen chloride in dioxane (30 mL) was refluxed for 15 min. After cooling to room temperature ethyl ether (100 mL) was added, and the reaction mixture was concentrated. Another portion of ethyl ether (100 mL) was added, the precipitate was filtered off, washed several times with ethyl ether, and dried to give 7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine dihydrochloride (8.9 g, 93% yield) as a light beige solid. 1HNMR (400 MHz, CD3OD): 7.93 (s, 1H), 7.86-7.67 (m, 4H), 7.28 (s, 1H), 4.54 (s, 2H), 4.33-4.23 (m, 2H), 3.65-3.54 (m, 2H), 2.91 (s, 3H); MS (EI) for C17H17N3O: 280 (MH+).

STEP 5: A mixture of 4-chloro-3-[(3-fluorophenyl)methyl]-2-methylpyridine (42 mg, 0.178 mmol) synthesized according to reagent preparation 9,7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine hydrochloride (94 mg, 0.267 mmol), and n-tributylamine (0.3 mL, 1.2 mmol) in a minimal amount of n-butanol to form a solution, was stirred in a sealed tube at 180° C. for 6 d. The reaction mixture was then cooled to ambient temperature and diluted with water (5 mL) and the aqueous layer was extracted with ethyl acetate (3×7 mL). The combined organic layers were dried over sodium sulfate, and concentrated. The residue was taken up in methanol and purified by preparative reverse phase HPLC to afford 4-{3-[(3-fluorophenyl)methyl]-2-methylpyridin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (20 mg, 23% yield). 1H NMR (400 MHz, CD3OD): 8.22 (d, 1H), 7.50-7.47 (m, 3H), 7.22-7.15 (m, 3H), 7.02 (d, 1H), 6.94-6.89 (m, 1H), 6.83 (d, 1H), 6.77-6.75 (m, 4H), 4.27 (s, 2H), 4.25-4.22 (m, 2H), 4.18 (s, 2H), 3.60-3.57 (m, 2H), 2.59 (s, 3H), 2.29 (s, 3H). MS (EI) for C30H27FN4O: 479.2 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 5 the following compounds of the invention were prepared. Protecting group introduction and removal steps were conducted as required according to literature techniques appropriate for a given protecting group (see for example: Greene and Wuts, Protective Groups in Organic Synthetic, Wiley-Interscience). Alternative starting materials were obtained commercially unless otherwise indicated.

7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared as the dihydrochloride salt according to the method of example 1 using 4-chloroquinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 8.82 (s, 1H), 8.28 (d, 1H), 8.06-7.70 (m, 7H), 7.61 (dd, 1H), 7.02 (d, 1H), 5.46 (s, 2H), 4.66-4.61 (m, 2H), 4.56-4.49 (m, 2H), 2.81 (s, 3H); MS (EI) for C25H21N5O: 408 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared according to the method of example 1 using 4-chloropyrimidine in step 5. 1H NMR (400 MHz, d6-DMSO): 12.25 (d, 1H), 8.49 (s, 1H), 8.17 (dd, 1H), 7.85 (br s, 1H), 7.74 (s, 1H), 7.58-7.35 (m, 3H), 7.08-7.00 (m, 2H), 4.87 (br s, 2H), 4.15 (br s, 4H), 3.34 (s, 3H); MS (EI) for C21H19N5O: 358 (MH+).

4-(7-iodoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared according to the method of example 1 using 4-chloro-7-iodoquinazoline in step 5. 1H NMR (400 MHz, CDCl3): 8.67 (s, 1H), 8.31 (s, 1H), 7.71-7.65 (m, 3H), 7.62 (d, 1H), 7.53-7.49 (m, 2H), 7.44 (dd, 1H), 7.13 (d, 1H), 4.95 (s, 2H), 4.47-4.42 (m, 2H), 4.26-4.21 (m, 2H), 2.68 (s, 3H); MS (EI) for C25H20IN5O: 534 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared according to the method of example 1 using 4-chloro-2-methylquinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 12.26 (br s, 1H), 8.02 (d, 1H), 7.78-7.38 (m, 7H), 7.02 (d, 1H), 5.05 (br s, 2H), 4.44 (m, 2H), 4.20 (m, 2H), 3.34 (s, 3H), 2.48 (s, 3H); MS (EI) for C26H23N5O: 422 (MH+).

ethyl 4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazoline-2-carboxylate: Prepared as the dihydrochloride salt according to the method of example 1 using ethyl-4-chloro-2-quinazoline carboxylate in step 5. 1H NMR (400 MHz, d6-DMSO): 8.24 (d, 1H), 8.04-7.94 (m, 3H), 7.89-7.81 (m, 3H), 7.74-7.68 (m, 1H), 7.60 (dd, 1H), 7.04 (d, 1H), 5.30 (s, 2H), 4.58-4.51 (m, 2H), 4.49-4.42 (m, 2H), 4.26 (q, 2H), 2.84 (s, 3H), 1.11 (t, 3H); MS (EI) for C28H25N5O3: 480 (MH+).

N,N-diethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-2-amine: Prepared as the dihydrochloride salt according to the method of example 1 by sequential use of 2,4-dichloroquinazoline and N,N-diethylamine in step 5. 1H NMR (400 MHz, d6-DMSO): 12.1 (br s, 1H), 8.11 (br d, 1H), 8.07 (d, 1H), 7.92 (s, 1H), 7.87-7.82 (m, 3H), 7.79 (td, 1H), 7.59 (dd, 1H), 7.43 (br t, 1H), 6.99 (d, 1H), 5.30 (s, 2H), 4.64-4.58 (m, 2H), 4.45 (br s, 2H), 3.58 (br s, 4H), 2.83 (s, 3H), 1.34-0.68 (m, 6H); MS (EI) for C29H30N6O: 479.2 (MH+).

4-(2,6-diphenylpyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared as the dihydrochloride salt according to the method of example 1 using 4-chloro-2,6-diphenylpyrimidine in step 5. 1H NMR (400 MHz, d6-DMSO): 8.62-8.37 (m, 2H), 8.29-8.22 (m, 2.5H), 8.11-8.00 (m, 0.5H), 7.96 (d, 1H), 7.89-7.66 (m, 2H), 7.61-7.49 (m, 7.5H), 7.42-7.32 (m, 0.5H), 7.10 (d, 1H), 5.27-5.05 (m, 2H), 4.49 (br s, 1H), 4.29 (br s, 3H), 2.83 (s, 3H); MS (EI) for C33H27N5O: 510.3 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared as the dihydrochloride salt according to the method of example 1 using 4-chloroquinoline in step 5. 1H NMR (400 MHz, d6-DMSO): 8.57 (d, 1H), 8.32 (d, 1H), 8.10-7.96 (m, 4H), 7.89-7.84 (m, 2H), 7.72-7.64 (m, 2H), 7.03 (d, 1H), 6.98 (d, 1H), 5.32 (s, 2H), 4.65-4.62 (m, 2H), 4.43-4.39 (m, 2H), 2.84 (s, 3H); MS (EI) for C26H22N4O: 407 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[2-(trifluoromethyl)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared according to the method of example 1 using 4-chloro-2-(trifluoromethyl)quinoline in step 5. 1H NMR (400 MHz, d6-DMSO): 12.30 (br s, 1H), 8.05-8.15 (m, 2H), 7.75-7.85 (m, 2H), 7.40-7.66 (m, 5H), 7.28 (s, 1H), 7.05-7.10 (d, 1H), 4.85 (s, 2H), 4.40-4.45 (m, 2H), 3.98-4.05 (m, 2H), 3.36 (s, 3H). MS (EI) for C27H21F3N4O: 475 (M+H), 473 (M−H).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(2-phenylquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared according to the method of example 1 using 4-chloro-2-phenylquinoline in step 5. 1H NMR (400 MHz, d6-DMSO): 12.35-12.21 (m, 1H), 8.17-8.10 (m, 2H), 8.07-7.98 (m, 2H), 7.92-7.65 (m, 3H), 7.62-7.41 (m, 8H), 7.07 (d, 1H), 4.80 (s, 2H), 4.40-4.33 (m, 2H), 4.05-3.95 (m, 2H), 2.52 (s, 3H). MS (EI) for C32H26N4O: 483 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-pyridin-2-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared according to the methods of example 1 using 2-chloropyridine in step 5. 1H NMR (400 MHz, CD3OD): 8.04-8.08 (m, 1H), 7.67 (d, 1H), 7.54-7.38 (m, 4H), 7.01 (d, 1H), 6.89 (d, 1H), 6.57-6.53 (m, 1H), 4.81 (s, 2H), 4.14 (s, 4H), 2.58 (s, 3H); MS (EI) for C22H20N4O: 357 (MH+).

4-isoquinolin-1-yl-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared according to the method of example 1 using 1-chloroisoquinoline in step 5. 1H NMR (400 MHz, CD3OD): 8.15 (d, 1H), 8.03 (d, 1H), 7.84 (d, 1H), 7.71 (d, 1H), 7.69 (td, 1H), 7.61-7.49 (m, 5H), 7.35 (d, 1H), 7.15 (d, 1H), 4.63 (s, 2H), 4.43-4.40 (m, 2H), 3.92-3.88 (m, 2H), 2.66 (s, 3H); MS (EI) for C26H22N4O: 407 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-pyrimidin-2-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine: Prepared according to the method of example 1 using 2-chloropyrimidine in step 5. 1H NMR (400 MHz, CD3OD): 8.22 (d, 2H), 7.56-7.53 (m, 2H), 7.42 (d, 1H), 7.32 (dt, 2H), 6.93 (d, 1H), 6.46 (t, 1H), 4.86 (s, 2H), 4.18-4.14 (m, 2H), 4.06-4.02 (m, 2H), 2.49 (s, 3H); MS (EI) for C21H19N5O: 358 (MH+).

4-[7,8-bis(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-7,8-dimethoxy-quinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, d6-DMSO): 8.45 (d, 1H), 7.80 (d, 1H), 7.68 (m, 1H), 7.53 (m, 2H), 7.41 (d, 1H) 7.37 (d, 1H), 7.02 (d, 1H), 5.08 (s, 2H), 4.48 (br s, 3H), 4.20 (br s, 2H), 3.93 (s, 3H), 3.86 (s, 3H), 1.78 (s, 3H); MS (EI) for C27H25N5O3: 468 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 7-(benzyloxy)-4-chloro-8-methoxyquinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, d6-DMSO): 8.47 (s, 1H), 7.75 (d, 1H), 7.65 (m, 2H), 7.53 (m, 4H), 7.40 (m, 4H), 7.33 (m, 1H), 7.02 (d, 2H), 5.36 (s, 2H), 5.36 (br s, 2H), 5.08 (s, 2H), 4.48 (br s, 2H), 4.18 (br s, 2H), 3.91 (s, 3H); MS (EI) for C33H29N5O3: 544 (MH+).

4-[6-chloro-7,8-bis(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4,6-dichloro-7,8-dimethoxyquinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, d6-DMSO): 8.55 (s, 1H), 7.83 (s, 1H), 7.74 (d, 1H), 7.53 (dd, 2H), 7.46 (m, 1), 7.04 (d, 1H), 5.02 (s, 2H), 4.48 (br s, 3H), 4.14 (br s, 2H), 4.06 (s, 3H), 4.00 (s, 3H); MS (EI) for C27H24ClN5O3: 502 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6,7,8-tris(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-6,7,8-trimethoxyquinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 8.68 (s, 1H), 7.93 (m, 2H), 7.83 (q, 2H), 7.63 (d, 1H), 7.26 (m, 1), 7.04 (d, 1H), 5.42 (s, 2H), 4.66 (br s, 3H) 4.40 (br s, 2H), 3.96 (s, 6H), 2.82 (s, 3H), 2.51 (s, 3H); MS (EI) for C28H27N5O4: 498 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-6-methyl-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (reagent preparation 4) in step 5. 1H NMR (400 MHz, d6-DMSO): 7.93 (br s, 2H), 7.84 (d, 1H), 7.73 (m, 2H), 7.57 (dd, 1) 7.06 (d, 1H), 5.01 (s, 2H), 4.30 (br s, 2H) 4.16 (br s, 2H), 3.21 (dd, 1H), 2.81 (s, 3H), 2.71 (dd, 1H), 2.64 (dd, 1H), 2.35 (dd, 1H); MS (EI) for C26H27N5OS: 458 (MH+).

4-(5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-5,7-dihydrothieno[3,4-d]pyrimidine in step 5. 1H NMR (400 MHz, d6-DMSO): 8.42 (s, 1H), 7.93 (s, 1H), 7.84 (d, 1H), 7.78 (m, 2H), 7.58 (d, 1H), 7.08 (d, 1H), 5.03 (s, 2H), 4.42 (s, 2H) 4.37 (br s, 2H), 4.18 (br s, 2H), 4.07 (s, 2H), 2.80 (s, 3H); MS (EI) for C23H21N5OS: 416 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-6-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (reagent preparation 3) in step 5. 1H NMR (400 MHz, d6-DMSO): 8.10 (s, 1H), 7.89 (s, 1H), 7.80 (d, 1H), 7.73 (m, 2H), 7.56 (dd, 1H), 7.07 (d, 1H), 5.12 (m, 2H), 4.37 (br s, 2H) 4.26 (br s, 2H), 3.32 (dd, 1H), 3.01 (q, 1H), 2.80 (m, 1H), 2.75 (s, 3H), 1.07 (d, 3H); MS (EI) for C25H25N5O: 412 (MH+).

4-(6-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-6-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine (reagent preparation 3) in step 5. 1H NMR (400 MHz, d6-DMSO): 8.63 (s, 1H), 7.81 (s, 1H), 7.78 (d, 1H), 7.62 (m, 2H), 7.47 (d, 1H), 7.12 (d, 1H), 5.00 (br s, 2H), 4.90 (s, 2H), 4.51 (s, 2H), 4.33 (br s, 2H), 4.22 (br s, 2H), 3.42 (m, 1H), 2.87 (s, 3H), 0.83 (m, 4H); MS (EI) for C26H26N6O: 439 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(4-methylphenyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-6-p-tolyl-6,7-dihydro-5H-pyrrolo[3,4-c]pyrimidine (reagent preparation 3) in step 5. 1H NMR (400 MHz, d6-DMSO): 8.47 (m, 2H), 7.89 (d, 2H), 7.77 (m, 3H), 7.67 (d, 1H), 7.59 (d, 1H), 7.44 (d, 1H), 7.07 (d, 1H), 5.54 (s, 2H), 4.61 (m, 4H), 7.87 (s, 3H), 2.38 (m, 4H); MS (EI) for C30H28N6O: 489 (MH+).

4-[2-chloro-6-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 2,4-dichloro-6-methoxyquinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 7.97 (s, 1H), 7.93 (d, 1H), 7.86 (d, 1H), 7.83 (dd, 1H), 7.68 (d, 1H), 7.63 (dd, 1H), 7.48 (dd, 1H), 7.20 (d, 1H), 7.09 (d, 1H), 5.14 (s, 2H), 4.53 (m, 2H), 4.22 (m, 1H), 3.60 (s, 3H), 2.82 (s, 3H). MS (EI) for C26H22ClN5O2: 472 (MH+).

4-[6-chloro-7-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4,6-dichloro-7-methoxy-quinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, d6-DMSO): 8.74 (s, 1H), 8.20 (s, 1H), 8.02 (s, 1H), 7.92 (d, 1H), 7.86 (s, 2H), 7.64 (dd, 1H), 7.38 (s, 1H), 7.06 (d, 1H), 5.34 (s, 2H), 4.62 (m, 2H), 4.38 (m, 2H), 4.06 (s, 3H), 2.81 (s, 3H). MS (EI) for C26H22ClN5O2: 472 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-thieno[2,3-c]pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chlorothieno[2,3-d]pyrimidine in step 5. 1H NMR (400 MHz, d6-DMSO): 8.38 (s, 1H), 7.78 (d, 1H), 7.72 (d, 1H), 7.66 (d, 1H), 7.62 (br s, 1H), 7.51 (br s, 0.5H), 7.49 (br s, 0.5H), 7.46 (dd, 1H), 7.36 (dd, 1H), 6.99 (d, 1H), 5.24 (s, 2H), 4.42 (m, 2H), 4.32 (m, 2H), 2.50 (s, 3H). MS (EI) for C23H20N5OS: 414 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-5,6,7,8-tetrahydroquinazoline (reagent preparation 5) in step 5. 1H NMR (400 MHz, d6-DMSO): 8.68 (s, 1H), 7.95 (d, 1H), 7.86 (s, 0.5H), 7.83 (s, 0.5H), 7.80-7.76 (m, 2H), 7.59 (dd, 1H), 7.05 (d, 1H), 5.12 (s, 2H), 4.48 (m, 2H), 4.21 (m, 2H), 2.82 (s, 3H), 2.76 (m, 2H), 1.78 (m, 2H), 1.62 (m, 2H). MS (EI) for C25H25N5O: 412 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(5-methylthieno[2,3-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-5-methylthieno[2,3-d]pyrimidine in step 5. 1H NMR (400 MHz, d6-DMSO): 8.38 (s, 1H), 7.94 (d, 1H), 7.84 (d, 0.5H), 7.82 (d, 0.5H), 7.79 (d, 0.5H), 7.77 (d, 0.5H), 7.73 (d, 1H), 7.57 (dd, 1H), 7.41 (d, 1H), 7.15 (d, 1H), 4.88 (s, 2H), 4.31 (m, 2H), 3.96 (m, 2H), 2.81 (s, 3H), 2.55 (d, 3H). MS (EI) for C24H21N5OS: 428 (MH+).

4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile. Synthesized according to the method of example 1 using 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile in step 5. 1H NMR (400 MHz, d6-DMSO): 8.44 (s, 1H), 7.66 (d, 1H), 7.62 (m, 1H), 7.51 (dd, 1H), 7.46 (m, 1H), 7.36 (dd, 1H), 7.05 (d, 1H), 4.40 (s, 2H), 4.37 (m, 2H), 4.31 (m, 2H), 3.84 (m, 2H), 3.14 (m, 2H), 2.50 (s, 3H). MS (EI) for C28H25N7O: 476 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-1H-pyrazolo[3,4-d]pyrimidine in step 5. 1H NMR (400 MHz, d6-DMSO): 8.30 (br s, 1H), 7.92 (s, 1H), 7.85 (d, 1H), 7.76 (dd, 1H), 7.56 (dd, 1H), 7.06 (d, 1H), 5.31 (s, 2H), 4.42 (br s, 4H), 2.80 (s, 3H). MS (EI) for C22H19N7O: 398 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[7-(phenylmethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 7-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine in step 5. 1H NMR (400 MHz, d6-DMSO): 12.38 (br s, 1H), 8.53 (s, 1H), 7.96 (d, 1H), 7.86 (d, 0.5H), 7.84 (d, 0.5H), 7.81 (s, 1H), 7.78 (s, 0.5H), 77.75-7.70 (m, 2.5H), 7.58 (dd, 1H), 7.48 (m, 3H), 7.06 (d, 1H), 5.00 (d, 2H), 4.54 (br s, 2H), 4.44 (br s, 2H), 4.10 (m, 2H), 3.58 (m, 2H), 3.18 (m, 2H), 2.86 (m, 2H), 2.80 (s, 3H). MS (EI) for C31H30N6O: 503 (MH+).

4-(7-fluoroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-7-fluoroquinazoline in step 5. 1H NMR (400 MHz, methanol-d4): 8.51 (s, 1H), 8.18 (dd, 1H), 7.68 (m, 1H), 7.63 (m, 1H), 7.54 (d, 1H), 7.51 (m, 1H), 7.46 (m, 1H), 7.41 (dd, 1H), 7.33 (m, 1H), 7.05 (d, 1H), 5.13 (s, 2H), 4.49 (m, 2H), 4.30 (m, 2H), 2.59 (s, 3H), 1.97 (s, 3H); MS (EI) for C25H20FN5O: 426 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[8-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-8-methoxyquinazoline in step 5. 1H NMR (400 MHz, methanol-d4): 8.53 (s, 1H), 7.67 (m, 1H), 7.63 (m, 1H), 7.59 (m, 1H), 7.54 (d, 1H), 7.51 (m, 1H), 7.45 (m, 2H), 7.29 (d, 1H), 7.06 (d, 1H), 5.08 (s, 2H), 4.47 (m, 2H), 4.26 (m, 2H), 4.00 (s, 3H), 2.59 (s, 3H), 1.97 (s, 3H); MS (EI) for C26H23N5O2: 438 (MH+).

4-(7-chloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4,7-dichloro-quinazoline in step 5. 1H NMR (400 MHz, methanol-d4): 8.51 (s, 1H), 8.09 (d, 1H), 7.76 (m, 1H), 7.69 (m, 1H), 7.63 (m, 1H), 7.56-7.44 (m, 4H), 7.05 (d, 1H), 5.13 (s, 2H), 4.49 (m, 2H), 4.30 (m, 2H), 2.59 (s, 3H); MS (EI) for C25H20ClN5O: 442 (MH+).

4-(8-chloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4,8-dichloro-quinazoline in step 5. 1H NMR (400 MHz, methanol-d4): 8.58 (s, 1H), 8.04 (m, 1H), 7.93 (m, 1H), 7.68 (m, 1H), 7.62 (d, 1H), 7.54 (d, 1H), 7.52 (dd, 1H), 7.46 (m, 2H), 7.06 (d, 1H), 5.11 (s, 2H), 4.49 (m, 2H), 4.30 (m, 2H), 2.59 (s, 3H); MS (EI) for C25H20ClN5O: 442 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[5-methyl-6-(phenylmethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as trifluoroacetate salt according to the method of example 1 by using 4-chloro-5-methyl-6-(phenylmethyl)-pyrimidine (synthesized according to reagent preparation 2) in step 5. 1H NMR (400 MHz, methanol-d4): 8.52 (s, 1H), 7.87 (s, 1H), 7.78 (s, 2H), 7.66 (m, 1H), 7.54 (dd, 1H), 7.33-7.16 (m, 5H), 7.06 (d, 1H), 5.12 (s, 2H), 4.46 (m, 2H), 4.24 (m, 2H), 4.19 (s, 2H), 2.87 (s, 3H), 2.33 (s, 3H); MS (EI) for C29H27N5O: 462 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-isopropyl-pyrimidine in step 5. 1H NMR (400 MHz, methanol-d4): 8.38 (s, 1H), 7.73 (d, 1H), 7.66 (m, 1H), 7.52 (d, 1H), 7.45 (m, 2H), 7.05 (d, 1H), 6.76 (s, 1H), 4.23 (br. s, 2H), 4.16 (m, 2H), 2.81 (h, 1H), 1.97 (s, 3H), 1.22 (d, 6H); MS (EI) for C24H25N5O: 400 (MH+).

4-[5-ethyl-6-(1-methylethyl)pyrimidin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-ethyl-6-isopropylpyrimidine (synthesized according to reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.44 (s, 1H), 7.64 (s, 1H), 7.55-7.40 (m, 4H), 7.05 (d, 1H), 4.62 (s, 2H), 4.34 (m, 2H), 3.86 (m, 2H), 2.75 (q, 2H), 2.58 (s, 3H), 1.23 (m, 9H); MS (EI) for C26H29N5O: 428 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-methyl-5-[(4-methylphenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-methyl-5-(4-methylbenzyl)pyrimidine (synthesized according to reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.46 (s, 1H), 7.50 (m, 2H), 7.41 (dd, 1H), 7.19 (dd, 1H), 7.03 (d, 2H), 6.98 (d, 1H), 6.93 (d, 2H), 6.64 (m, 1H), 4.50 (s, 2H), 4.29 (m, 2H), 3.95 (s, 2H), 3.89 (m, 2H), 2.60 (s, 3H), 2.24 (s, 3H), 2.21 (s, 3H); MS (EI) for C30H29N5O: 476 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-5-{[4-(trifluoromethyl)phenyl]-methyl}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-methyl-5-(4-(trifluoromethyl)benzyl)pyrimidine (synthesized according to reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.49 (s, 1H), 7.49 (m, 4H), 7.43 (dd, 1H), 7.23 (d, 2H), 7.16 (dd, 1H), 7.00 (d, 1H), 6.68 (m, 1H), 4.51 (s, 2H), 4.31 (m, 2H), 4.08 (s, 2H), 3.88 (m, 2H), 2.60 (s, 3H), 2.20 (s, 3H); MS (EI) for C30H26F3N5O: 530 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (reagent preparation 4) in step 5. 1H NMR (400 MHz, d6-DMSO): 7.64 (m, 2H), 7.51 (d, 1H), 7.46 (dd, 1H), 7.37 (dd, 1H), 7.01 (d, 1H), 4.94 (s, 2H), 4.24 (m, 2H), 4.20 (m, 2H), 3.00 (t, 2H), 2.64 (t, 2H), 2.42 (s, 3H), 1.92 (s and m, 5H). MS (EI) for C25H25N5OS: 444 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-{2-[(phenylmethyl)thio]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 2-(benzylthio)-4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine (reagent preparation 4) in step 5. 1H NMR (400 MHz, d6-DMSO): 7.84 (s, 1H), 7.69 (m, 3H), 7.53 (dd, 1H), 7.18 (m, 5H), 7.06 (d, 1H), 5.00 (s, 2H), 4.31 (s and m, 4H), 4.12 (m, 2H), 3.06 (t, 2H), 2.82 (s, 3H), 2.69 (t, 2H), 1.96 (m, 2H). MS (EI) for C31H29N5OS: 520 (MH+).

4-[2-(ethylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-2-(ethylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (reagent preparation 4) in step 5. 1H NMR (400 MHz, d6-DMSO): 7.93 (d, 1H), 7.85 (d, 1H), 7.77 (dd, 1H), 7.72 (d, 1H), 7.56 (dd, 1H), 7.07 (d, 1H), 5.00 (s, 2H), 4.36 (m, 2H), 4.16 (m, 2H), 3.04 (m, 4H), 2.80 (s, 3H), 2.70 (t, 2H), 1.95 (m, 2H), 1.16 (t, 3H). MS (EI) for C26H27N5OS: 458 (MH+).

4-(7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 1 using 4-chloro-7,7-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 5. 1H NMR (400 MHz, d3-MeOH): 8.32 (s, 1H), 7.61 (d, 1H), 7.51 (s, 1H), 7.49 (d, 1H), 7.45 (dd, 1H), 7.39 (dd, 1H), 7.03 (d, 1H), 4.82 (s, 2H), 4.34 (t, 2H), 4.02 (t, 2H), 2.78 (t, 2H), 2.57 (s, 3H), 2.52 (s, 2H), 1.56 (t, 2H), 1.06 (s, 6H). MS (EI) for C27H29N5O: 440 (MH+).

4-[6-bromo-7-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 6-bromo-4-chloro-7-methoxyquinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, DMSO-d6): 8.54 (s, 1H), 8.21 (s, 1H), 7.77 (m, 2H), 7.53 (m, 3H), 7.32 (s, 1H), 7.05 (d, 1H), 5.04 (s, 2H), 4.50 (m, 2H), 4.14 (m, 2H), 4.00 (s, 3H); MS (EI) for C26H22BrN5O2: 516 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(5-methylpyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as trifluoroacetate salt according to the method of example 1 by using 4-chloro-5-methylpyrimidine in step 5. 1H NMR (400 MHz, DMSO-d6): 8.78 (br. s, 1H), 8.28 (br. s, 1H), 7.96 (s, 1H), 7.85 (d, 1H), 7.78 (m 2H), 7.60 (m, 1H), 7.07 (d, 1H), 5.17 (s, 2H), 4.47 (m, 2H), 4.28 (m, 2H), 2.82 (s, 3H), 2.41 (s, 3H); MS (EI) for C22H21N5O: 372 (MH+).

4-(5,6-dimethylpyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5,6-dimethylpyrimidine in step 5. 1H NMR (400 MHz, DMSO-d6): 12.00 (br. s, 1H), 8.35 (s, 1H), 7.65 (m, 1H), 7.61 (m, 1H), 7.50 (m, 2H), 7.38 (dd, 1H), 7.03 (d, 1H), 4.62 (s, 2H), 4.32 (m, 2H), 3.81 (m, 2H), 2.33 (s, 3H), 2.20 (s, 3H), 1.91 (s, 3H); MS (EI) for C23H23N5O: 386 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-5-(phenylmethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 5-benzyl-4-chloro-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, DMSO-d6): 12.26 (br. s, 1H), 8.51 (s, 1H), 7.50 (br. s, 2H), 7.46 (dd, 1H), 7.36-7.24 (m, 3H), 7.18 (d, 1H), 7.11 (d, 2H), 7.00 (d, 1H), 6.81 (s, 1H), 4.47 (s, 2H), 4.27 (m, 2H), 4.03 (s, 2H), 3.79 (m, 2H), 2.17 (s, 3H), 1.91 (s, 3H); MS (EI) for C29H27N5O: 462 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-5-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-methyl-5-(1-methylethyl)-pyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, DMSO-d6): 8.43 (s, 1H), 7.63 (s, 1H), 7.52 (m, 3H), 7.37 (dd, 1H), 7.06 (d, 1H), 4.42 (s, 2H), 4.30 (m, 2H), 3.68 (m, 2H), 3.31 (h, 1H), 1.89 (s, 3H), 1.33 (d, 6H); MS (EI) for C25H27N5O: 414 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-5-(2-methylpropyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-isobutyl-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, DMSO-d6): 12.30 (br. s, 1H), 8.37 (s, 1H), 7.62 (m, 2H), 7.49 (m, 2H), 7.37 (d, 1H), 7.01 (d, 1H), 4.59 (s, 2H), 4.33 (m, 2H), 3.75 (m, 2H), 2.61 (d, 2H), 2.37 (s, 3H), 1.68 (m, 1H), 0.53 (d, 6H); MS (EI) for C26H29N5O: 428 (MH+).

4-{5-[(3-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-(3-fluorobenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, DMSO-d6): 12.35 (br. s, 1H), 8.51 (s, 1H), 7.49 (m, 3H), 7.35 (m, 1H), 7.19 (d, 1H), 7.10 (m, 1H), 7.00 (d, 1H), 6.92 (m, 3H), 4.49 (s, 2H), 4.27 (m, 2H), 4.05 (s, 2H), 3.78 (m, 2H), 2.52 (s, 3H), 2.17 (s, 3H); MS (EI) for C29H26FN5O: 480 (MH+).

4-{5-[(3-chlorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-(3-chlorobenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, DMSO-d6): 12.31 (br. s, 1H), 8.51 (s, 1H), 7.50 (m, 2H), 7.47 (dd, 1H), 7.33 (m, 2H), 7.19 (dd, 1H), 7.14 (s, 1H), 7.04 (m, 1H), 7.00 (d, 1H), 6.95 (d, 1H), 4.51 (s, 2H), 4.28 (m, 2H), 4.05 (s, 2H), 3.78 (m, 2H), 2.52 (s, 3H), 2.17 (s, 3H); MS (EI) for C29H26ClN5O: 496 (MH+)

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-5-(1-phenylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-methyl-5-(1-phenylethyl)pyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, DMSO-d6): 8.60 (s, 1H), 7.76 (d, 1H), 7.72 (s, 1H), 7.54 (dd, 1H), 7.49 (d, 1H), 7.34-7.18 (m, 5H), 7.06 (d, 1H), 7.01 (s, 1H), 4.61-4.44 (m, 3H), 4.37 (m, 1H), 4.28 (m, 1H), 3.87 (m, 1H), 3.77 (m, 1H), 2.77 (s, 3H), 2.11 (s, 3H), 1.66 (d, 3H); MS (EI) for C30H29N5O: 476 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-5-{[3-(methyloxy)phenyl]methyl}-pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-(3-methoxybenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, DMSO-d6): 12.27 (br. s, 1H), 8.50 (s, 1H), 7.47 (m, 3H), 7.26 (m, 1H), 7.16 (d, 1H), 7.00 (d, 1H), 6.85 (m, 2H), 6.65 (m, 2H), 4.50 (s, 2H), 4.28 (m, 2H), 3.99 (s, 2H), 3.79 (m, 2H), 3.55 (s, 3H), 2.51 (s, 3H), 2.17 (s, 3H); MS (EI) for C30H29N5O2: 492 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-methyl-5-[(3-methylphenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-methyl-5-(3-methylbenzyl)pyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, DMSO-d6): 12.21 (d, 1H), 8.48 (s, 1H), 7.50 (m, 1H), 7.43 (dd, 1H), 7.38 (d, 1H), 7.21 (m, 1H), 7.13 (m, 1H), 7.04 (m, 1H), 6.98 (dd, 1H), 6.89 (m, 2H), 6.72 (dd, 1H), 4.45 (s, 2H), 4.26 (m, 2H), 3.93 (m, 2H), 3.77 (m, 2H), 2.49 (s, 3H), 2.14 (s, 3H), 2.04 (d, 3H); MS (EI) for C30H29N5O: 476 (MH+).

4-{5-[(3-chloro-5-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-(3-chloro-5-fluorobenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.49 (s, 1H), 7.52 (m, 2H), 7.44 (dd, 1H), 7.27 (d, 1H), 7.06 (m, 1H), 7.00 (d, 1H), 6.88 (m, 2H), 6.76 (d, 1H), 4.54 (s, 2H), 4.30 (m, 2H), 4.04 (s, 2H), 3.88 (m, 2H), 2.59 (s, 3H), 2.22 (s, 3H); MS (EI) for C29H25ClFN5O: 514 (MH+).

4-{5-[(3,4-difluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-(3,4-difluorobenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, DMSO-d6): 12.22 (br. s, 1H), 8.50 (s, 1H), 7.62-7.43 (m, 3H), 7.32 (m, 1H), 7.18 (m, 1H), 7.14 (m, 1H), 6.99 (m, 2H), 6.88 (m, 1H), 4.50 (s, 2H), 4.27 (m, 2H), 4.01 (s, 2H), 3.76 (m, 2H), 2.51 (s, 3H), 2.17 (s, 3H); MS (EI) for C29H25F2N5O: 498 (MH+).

4-{5-[(4-fluorophenyl)methyl]-2,6-dimethylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-(4-fluorobenzyl)-2,6-dimethylpyrimidine (reagent preparation 8) in step 5. 1H NMR (400 MHz, DMSO-d6): 12.25 (br. s, 1H), 7.61-7.43 (m, 3H), 7.18 (dd, 2H), 7.11 (d, 1H), 7.00 (d, 1H), 6.94 (d, 1H), 4.44 (s, 2H), 4.21 (m, 2H), 3.97 (s, 2H), 3.75 (m, 2H), 2.51 (s, 3H), 2.41 (s, 3H), 2.11 (s, 3H); MS (EI) for C30H28FN5O: 494 (MH+).

4-(7-chloro-6-iodoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4,7-dichloro-6-iodoquinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, DMSO-d6): 12.26 (br. s, 1H), 8.59 (s, 1H), 8.49 (s, 1H), 7.99 (s, 1H), 7.77 (m, 2H), 7.58-7.47 (m, 3H), 7.04 (d, 1H), 5.08 (s, 2H), 4.52 (m, 2H), 4.16 (m, 2H); MS (EI) for C25H19Cl1N5O: 568 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[7-(methylsulfonyl)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-7-(methylsulfonyl)quinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, methanol-d4): 8.62 (s, 1H), 8.31 (m, 2H), 7.94 (dd, 1H), 7.68 (s, 1H), 7.65 (d, 1H), 7.55 (d, 1H), 7.51 (dd, 1H), 7.46 (dd, 1H), 7.04 (d, 1H), 5.19 (s, 2H), 4.51 (m, 2H), 4.35 (m, 2H), 3.21 (s, 3H), 2.59 (s, 3H); MS (EI) for C26H23N5O3S: 486 (MH+).

4-(6-ethyl-5-methylpyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-ethyl-5-methyl-pyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.36 (s, 1H), 7.63 (s, 1H), 7.52 (m, 2H), 7.46 (dd, 1H), 7.42 (dd, 1H), 7.04 (d, 1H), 4.68 (s, 2H), 4.33 (m, 2H), 3.92 (m, 2H), 2.73 (q, 2H), 2.58 (s, 3H), 2.30 (s, 3H), 1.22 (t, 3H); MS (EI) for C24H25N5O: 400 (MH+).

4-(5,6-diethylpyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5,6-diethyl-pyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.39 (s, 1H), 7.66 (s, 1H), 7.54 (m, 2H), 7.46 (m, 2H), 7.04 (d, 1H), 4.70 (s, 2H), 4.35 (m, 2H), 3.92 (m, 2H), 2.77 (m, 4H), 2.60 (s, 3H), 1.24 (t, 3H), 1.20 (t, 3H); MS (EI) for C25H28N5O: 414 (MH+).

4-[6-ethyl-5-(phenylmethyl)pyrimidin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 5-benzyl-4-chloro-6-ethylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.52 (s, 1H), 7.50 (d, 1H), 7.466 (s, 1H), 7.42 (dd, 1H), 7.24 (m, 4H), 7.08 (m, 2H), 6.99 (d, 1H), 6.70 (d, 1H), 4.50 (s, 2H), 4.28 (m, 2H), 4.04 (s, 2H), 3.89 (m, 2H), 2.61 (s, 3H), 2.51 (q, 2H), 1.10 (t, 3H); MS (EI) for C30H30N5O: 476 (MH+).

5-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-N-phenylpyrimidin-4-amine. Prepared as acetate salt according to the method of example 1 by using 6-chloro-5-methyl-N-phenylpyrimidin-4-amine (reagent preparation 6) in step 5. 1H NMR (400 MHz, methanol-d4): 8.07 (s, 1H), 7.64 (s, 1H), 7.53-7.38 (m, 6H), 7.27 (m, 2H), 7.07 (d, 1H), 7.03 (m, 1H), 4.57 (s, 2H), 4.32 (m, 2H), 3.82 (m, 2H), 2.58 (s, 3H), 2.19 (s, 3H), 1.97 (s, 3H); MS (EI) for C28H26N6O: 463 (MH+).

4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-amine. Prepared as acetate salt according to the method of example 1 by using 2-amino-4-chloropyrimidine in step 5. 1H NMR (400 MHz, methanol-d4): 7.72-7.65 (m, 3H), 7.52 (d, 1H), 7.46 (m, 2H), 7.06 (d, 1H), 6.35 (d, 1H), 4.17 (m, 4H), 2.58 (s, 3H), 1.94 (s, 3H); MS (EI) for C21H20N6O: 373 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-5-{[2-(methyloxy)phenyl]methyl}-pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-(2-methoxybenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.48 (s, 1H), 7.52 (d, 1H), 7.43 (dd, 1H), 7.39 (s, 1H), 7.31 (m, 1H), 7.20 (dd, 1H), 6.98 (d, 2H), 6.95 (m, 1H), 6.86 (d, 1H), 6.60 (d, 1H), 6.50 (d, 1H), 4.42 (s, 2H), 4.29 (m, 2H), 3.90 (m, 2H), 3.77 (s, 2H), 3.22 (s, 3H), 2.61 (s, 3H), 2.15 (s, 3H); MS (EI) for C30H29N5O2: 492 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-methyl-5-[(2-methylphenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-methyl-5-(2-methylbenzyl)pyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.50 (s, 1H), 7.51 (d, 1H), 7.45 (dd, 1H), 7.38 (s, 1H), 7.18 (m, 3H), 7.00 (d, 1H), 6.90 (d, 1H), 6.77 (d, 1H), 6.27 (d, 1H), 4.41 (s, 2H), 4.35 (m, 2H), 3.90 (m, 2H), 3.70 (s, 2H), 3.62 (s, 3H), 2.16 (s, 3H), 1.78 (s, 3H); MS (EI) for C30H29N5O: 476 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[2-methyl-3-(phenylmethyl)pyridin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as acetate salt according to the method of example 1 by using 3-benzyl-4-chloro-2-methylpyridine (reagent preparation 9) in step 5. 1H NMR (400 MHz, methanol-d4): 8.20 (d, 1H), 7.49 (d, 1H), 7.44 (m, 2H), 7.20 (m, 4H), 7.15 (d, 1H), 7.02 (m, 3H), 6.66 (d, 1H), 4.30 (s, 2H), 4.25 (m, 2H), 4.16 (s, 2H), 3.62 (m, 2H), 2.60 (s, 3H), 2.29 (s, 3H), 1.96 (s, 3H); MS (EI) for C30H28N4O: 461 (MH+).

4-{3-[(4-fluorophenyl)methyl]-2-methylpyridin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-3-(4-fluorobenzyl)-2-methylpyridine (reagent preparation 9) in step 5. 1H NMR (400 MHz, methanol-d4): 8.21 (d, 1H), 7.50 (m, 2H), 7.44 (dd, 1H), 7.17 (dd, 1H), 7.13 (d, 1H), 7.03 (d, 1H), 6.99 (m, 2H), 6.88 (m, 2H), 6.68 (s, 1H), 4.22 (m, 4H), 4.13 (s, 2H), 3.56 (m, 2H), 2.60 (s, 3H), 2.28 (s, 3H); MS (EI) for C30H27FN4O: 479 (MH+).

4-[6,7-bis(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6,7-dimethoxyquinazoline in step 5. 1H NMR (400 MHz, Methanol-D4): 8.50 (1H), 7.74 (br, 1H), 7.70 (br, 1H), 7.62 to 7.53 (m, 3H), 7.17 (s, 1H), 7.14 (s, 1H), 7.09 (d, 1H), 5.14 (s, 2H), 4.60 (m, 2H), 4.27 (m, 2H), 3.96 (s, 3H), 3.54 (s, 3H), 2.66 (s, 3H), MS (EI) for C27H25N5O3: 468 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-7-methoxyquinazoline in step 5. 1H NMR (400 MHz, DMSO-D6): 8.48, (s, 1H), 7.99 (d, 1H), 7.71 to 7.67 (m, 2H), 7.62 to 7.50 (m, 2H), 7.45 (d, 1H), 7.18 (d, 1H), 7.13 (dd, 1H), 7.03 (d, 1H), 5.10 (s, 2H), 4.49 (m, 2H), 4.20 (m, 2H), 3.91 (s, 3H), 2.54 (s, 3H), MS (EI) for C26H23N5O2: 438 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 7-(benzyloxy)-4-chloroquinazoline in step 5. 1H NMR (400 MHz, Methanol-D4): 8.43, (s, 1H), 7.99 (d, 2H), 7.54 to 7.49 (m, 2H), 7.45 to 7.41 (m, 3H), 7.38 to 7.29 (m, 3H), 7.18 (d, 1H), 7.08 (dd, 2H), 5.20 (s, 2H), 4.97 (s, 2H), 4.52 (m, 2H), 4.10 (m, 2H), 3.56 (s, 3H), 2.59 (s, 3H), MS (EI) for C33H29N5O3: 544 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-methoxyquinazoline in step 5. 1H NMR (400 MHz, Methanol-D4): 8.47, (s, 1H), 7.70 (d, 1H), 7.65 (dd, 2H), 7.54 to 749 (m, 2H), 7.44 (dd, 1H), 7.40 (dd, 1H), 7.15 (d, 1H), 7.07 (d, 1H), 5.00 (s, 2H), 4.52 (m, 2H), 4.19 (m, 2H), 3.49 (s, 3H), 2.60 (s, 3H), MS (EI) for C26H23N5O2: 438 (MH+).

4-(6-bromoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 6-bromo-4-chloroquinazoline in step 5. 1H NMR (400 MHz, DMSO-D6): 8.61, (s, 1H), 8.17 (d, 1H), 7.95 (dd, 1H), 7.77 to 7.73 (m, 3H), 7.44 (dd, 2H), 7.49 (br, 1H), 7.04 (d, 1H), 5.06 (s, 2H), 4.52 (m, 2H), 4.16 (m, 2H), 2.51 (s, 3H), MS (EI) for C25H20BrN5O: 486 (MH+).

4-(6-chloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4,6-dichloroquinazoline in step 5. 1H NMR (400 MHz, DMSO-D6): 8.59, (s, 1H), 8.04 (d, 1H), 7.87 to 7.81 (m, 4H), 7.77 (d, 1H), 7.55 (dd, 1H), 7.47 (br, 1H), 7.04 (d, 1H), 5.08 (s, 2H), 4.52 (m, 2H), 4.18 (m, 2H), 2.51 (s, 3H), MS (EI) for C25H23N5O2: 441 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(8-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-8-methylquinazoline in step 5. 1H NMR (400 MHz, Methanol-D4): 8.56, (s, 1H), 7.90 (d, 1H), 7.65 (dd, 2H), 7.57 to 7.37 (m, 6H), 7.05 (d, 1H), 5.04 (s, 2H), 4.45 (m, 2H), 4.24 (m, 2H), 2.63 (s, 3H), 2.58 (s, 3H), MS (EI) for C26H23N5O: 422 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-methylquinazoline in step 5. 1H NMR (400 MHz, Methanol-D4): 8.45, (s, 1H), 7.85 (br, 1H), 7.72 to 7.64 (m, 2H), 7.56 to 7.47 (m, 4H), 7.07 (d, 1H), 5.05 (s, 2H), 4.50 (m, 2H), 4.23 (m, 2H), 2.59 (s, 3H), 2.38 (s, 3H), MS (EI) for C26H23N5O: 422 (MH+).

4-(6-iodoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-iodoquinazoline in step 5. 1H NMR (400 MHz, DMSO-D6): 8.61, (s, 1H), 8.33 (d, 1H), 8.08 (d, 1H), 7.83 to 7.74 (m, 2H), 7.59 to 7.47 (m, 4H), 7.05 (d, 1H), 5.05 (s, 2H), 4.51 (m, 2H), 4.15 (m, 2H), 2.53 (s, 3H), MS (EI) for C25H20IN5O: 534 (MH+).

4-(6-fluoroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-fluoroquinazoline in step 5. 1H NMR (400 MHz, DMSO-D6): 8.56, (s, 1H), 7.88 (dd, 1H), 7.80 to 7.70 (m, 4H), 7.58 to 7.42 (m, 2H), 7.47 (dd, 1H), 7.05 (d, 1H), 5.10 (s, 2H), 4.53 (m, 2H), 4.20 (m, 2H), 2.54 (s, 3H), MS (EI) for C25H20FN5O: 426 (MH+).

4-(6,7-difluoroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6,7-difluoroquinazoline in step 5. 1H NMR (400 MHz, DMSO-D6): 8.56, (s, 1H), 8.01 (dd, 1H), 7.87 to 7.70 (m, 3H), 7.55 to 7.51 (m, 2H), 7.45 (d, 1H), 7.02 (d, 1H), 5.11 (s, 2H), 4.53 (m, 2H), 4.20 (m, 2H), 2.53 (s, 3H), MS (EI) for C25H19F2N5: 444 (MH+).

4-(6-bromo-7-chloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 6-bromo-4,7-dichloroquinazoline in step 5. 1H NMR (400 MHz, DMSO-D6): 8.60, (s, 1H), 8.33 (s, 1H), 8.06 (s, 1H), 7.79 (br, 2H), 7.59 to 7.50 (m, 2H), 7.00 (d, 1H), 5.10 (s, 2H), 4.529 (m, 2H), 4.18 (m, 2H), 2.53 (s, 3H), MS (EI) for C25H19BrClN5O: 522 (MH+).

4-[7-bromo-8-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 7-bromo-4-chloro-8-methoxyquinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, DMSO-D6): 8.56, (s, 1H), 7.72 to 7.63 (m, 3H), 7.54 to 7.45 (m, 2H), 7.41 (dd, 1H), 7.00 (d, 1H), 5.11 (s, 2H), 4.49 (m, 2H), 4.21 (m, 2H), 4.02 (s, 3H), 2.51 (s, 3H), MS (EI) for C26H22BrN5O2: 516 (MH+).

4-[7-bromo-6-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by 7-bromo-4-chloro-6-methoxyquinazoline in step 5. 1H NMR (400 MHz, DMSO-D6): 8.52, (s, 1H), 8.09 (s, 1H), 7.83 (br, 1H), 7.55 (dd, 2H), 7.40 (d, 1H), 7.18 (s, 1H), 7.05 (d, 1H), 5.08 (s, 2H), 4.55 (m, 2H), 4.13 (m, 2H), 3.60 (s, 3H), 2.51 (s, 3H), MS (EI) for C26H22BrN5O2: 516 (MH+).

4-[6-iodo-7-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-iodo-7-methoxyquinazoline in step 5. 1H NMR (400 MHz, DMSO-D6): 8.53, (s, 1H), 8.40 (s, 1H), 7.78 (br, 1H), 7.73 (br, 1H), 7.54 (dd, 1H), 7.51 (s, 1H) 7.21 (s, 1H), 7.05 (d, 1H), 5.02 (s, 2H), 4.50 (m, 2H), 4.13 (m, 2H), 3.97 (s, 3H), 2.51 (s, 3H), MS (EI) for C26H22IN5O2: 564 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-7-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 8) in step 5. 1H NMR (400 MHz, DMSO-D6): 8.34 (s, 1H), 7.65 to 7.59 (m, 2H), 7.51 to 7.46 (m, 2H), 7.36 (dd, 1H), 7.02 (d, 1H), 4.70 (dd, 2H), 4.39 (m, 1H), 4.24 (m, 1H), 3.94 to 3.82 (m, 2H), 2.94 to 2.80 (m, 2H), 2.57 to 2.46 (m, 1H), 2.51 (s, 3H), 2.26 (dd, 1H), 1.92 (m, 1H), 1.82 (dd, 1H), 1.15 (m, 1H), 1.04 (d, 3H), MS (EI) for C26H27N5O2: 426 (MH+).

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 5. 1H NMR (400 MHz, Methano-D4): 8.35 (s, 1H), 7.65 (br, 1H), 7.54 to 7.42 (m, 4H), 7.03 (d, 1H), 4.70 (dd, 2H), 4.35 (m, 2H), 3.95 (m, 2H), 2.78 (t, 2H), 2.58 (s, 3H), 2.50 (s, 2H), 1.68 (t, 2H), 0.90 (s, 6H), MS (EI) for C27H29N5O: 440 (MH+).

4-(6-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-ethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 8) in step 5. 1H NMR (400 MHz, Methanol-D4): 8.33 (s, 1H), 7.65 (br, 1H), 7.51 (dd, 2H), 7.45 to 7.39 (m, 2H), 7.03 (d, 1H), 4.69 (dd, 2H), 4.45 (m, 1H), 4.24 (m, 1H), 4.07 (m, 1H), 3.83 (m, 1H), 2.85 (dd, 1H), 2.72 (m, 1H), 2.58 (s, 3H), 2.54 (br, 1H), 2.40 (m, 1H), 1.93 (m, 1H), 1.49 to 1.26 (m, 3H), 0.75 (t, 3H), MS (EI) for C27H29NO: 440 (MH+).

4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.47 (s, 1H), 7.54-7.50 (m, 2H), 7.43 (d, 1H), 7.24 (d, 1H), 7.11-7.05 (m, 2H), 7.02-6.92 (m, 3H), 6.76 (s, 1H), 4.53 (s, 2H), 4.30 (t, 2H), 4.01 (s, 2H), 3.90 (t, 2H), 2.60 (s, 3H), 2.22 (s, 3H); MS (EI) for C29H26FN5O: 480 (MH+).

4-(7-bromoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 7-bromo-4-chloroquinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 12.26 (br s, 1H), 8.52 (s, 1H), 8.02-7.96 (m, 2H), 7.71-7.61 (m, 3H), 7.54-7.48 (m, 2H), 7.41 (d, 1H), 6.99 (d, 1H), 4.49 (t, 2H), 4.22 (t, 2H), 2.51 (s, 3H); MS (EI) for C25H20BrN5O: 487 (MH+).

4-(8-bromoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the acetate salt according to the method of example 1 by using 8-bromo-4-chloroquinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 12.26 (br s, 1H), 8.61 (s, 1H), 8.18 (d, 2H), 8.06 (d, 1H), 7.71-7.66 (m, 2H), 7.52 (d, 2H), 7.45-7.39 (m, 2H), 7.01 (d, 1H), 5.13 (s, 2H), 4.49 (t, 2H), 4.23 (t, 2H), 2.51 (s, 3H); MS (EI) for C25H20BrN5O: 487 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(7-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the acetate salt according to the method of example 1 by using 4-chloro-7-methylquinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 12.26 (br s, 1H), 8.50 (s, 1H), 7.95 (d, 1H), 7.67 (s, 2H), 7.58 (s, 1H), 7.54-7.49 (m, 2H), 7.40 (d, 1H), 7.33 (d, 1H), 7.01 (d, 1H), 5.09 (s, 2H), 4.49 (t, 2H), 4.19 (t, 2H), 2.51 (s, 3H), 2.48 (s, 3H); MS (EI) for C26H23N5O: 422 (MH+).

4-(8-fluoroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-8-fluoroquinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 8.60 (s, 1H), 7.98 (s, 1H), 7.93 (d, 1H), 7.89-7.81 (m, 3H), 7.74 (t, 1H), 7.61 (d, 1H), 7.54 (m, 1H), 7.05 (d, 1H), 5.23 (s, 2H), 4.56 (t, 2H), 4.31 (t, 2H), 2.82 (s, 3H); MS (EI) for C25H20FN5O: 426 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[8-(trifluoromethyl)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-8-(trifluoromethyl)quinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 8.61 (s, 1H), 8.33 (d, 1H), 8.21 (d, 1H), 7.80-7.74 (m, 2H), 7.67-7.54 (m, 2H), 7.22 (s, 1H), 7.10 (s, 1H), 7.03-6.96 (m, 1H), 5.18 (s, 2H), 4.52 (t, 2H), 4.27 (t, 2H), 2.63 (s, 3H); MS (EI) for C26H20F3N5O: 476 (MH+).

4-(6,8-dichloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4,6,8-trichloroquinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 8.64 (s, 1H), 8.19 (s, 1H), 8.00 (s, 1H), 7.80-7.76 (m, 2H), 7.59-7.43 (m, 3H), 7.04 (d, 1H), 5.09 (s, 2H), 4.55 (t, 2H), 4.20 (t, 2H), 2.50 (s, 3H); MS (EI) for C25H19Cl2N5O: 477 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[7-(trifluoromethyl)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-7-(trifluoromethyl)quinazoline in step 5. 1H NMR (400 MHz, d6-DMSO): 12.00 (br. s, 1H), 8.62 (s, 1H), 8.29 (d, 1H), 8.11 (s, 1H), 7.88 (s, 1H), 7.82-7.71 (m, 3H), 7.67 (d, 1H), 7.57 (d, 1H), 7.03 (d, 1H), 5.21 (s, 2H), 4.53 (t, 2H), 4.29 (t, 2H), 2.70 (s, 3H); MS (EI) for C26H20F3N5O: 476 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(methylsulfonyl)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the acetate salt according to the method of example 1 by using 4-chloro-6-(methylsulfonyl)quinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, methanol-d4): 8.68 (d, 1H), 8.63 (s, 1H), 8.24 (d, 1H), 7.95 (d, 1H), 7.77 (s, 1H), 7.72 (s, 1H), 7.54-7.51 (m, 3H), 7.05 (d, 1H), 5.20 (s, 2H), 4.53 (t, 2H), 4.37 (t, 2H), 3.06 (s, 3H), 2.59 (s, 3H); MS (EI) for C26H23N5O3S: 486 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[5-methyl-6-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6-isopropyl-5-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.31 (s, 1H), 7.54 (s, 1H), 7.44-7.40 (m, 2H), 7.39-7.31 (m, 2H), 6.95 (d, 1H), 4.55 (s, 2H), 4.24 (t, 2H), 3.80 (t, 2H), 3.21 (m, 1H), 2.49 (s, 3H), 2.20 (s, 3H), 1.12 (d, 6H); MS (EI) for C25H27N5O: 414 (MH+).

4-(5-ethyl-6-methylpyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 1 by using 4-chloro-5-ethyl-6-methylpyrimidine in step 5. 1H NMR (400 MHz, methanol-d4): 8.50 (s, 1H), 7.90 (s, 1H), 7.83-7.77 (m, 2H), 7.72 (s, 1H), 7.55 (d, 1H), 7.05 (d, 1H), 5.17 (s, 2H), 4.50 (t, 2H), 4.26 (t, 2H), 2.88 (s, 3H), 2.80 (q, 2H), 2.53 (s, 3H), 1.23 (t, 3H); MS (EI) for C24H25N5O: 400 (MH+).

4-[5-(cyclopropylmethyl)-6-methylpyrimidin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as described in example 1 using 4-chloro-5-(cyclopropylmethyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.36 (s, 1H), 7.64 (s, 1H), 7.57-7.41 (m, 4H), 7.04 (d, 1H), 4.65 (s, 2H), 4.35 (t, 1H), 3.89 (t, 2H), 2.71 (d, 2H), 2.58 (s, 3H), 2.49 (s, 3H), 0.86 (m, 1H), 0.36 (m, 2H), 0.04 (m, 2H); MS (EI) for C26H27N5O: 426 (MH+).

4-{5-[(4-chlorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 using 4-chloro-5-(4-chlorobenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.47 (s, 1H), 7.55-7.51 (m, 2H), 7.43 (d, 1H), 7.21-7.17 (m, 3H), 7.06-6.98 (m, 3H), 6.71 (s, 1H), 4.51 (s, 1H), 4.31 (t, 2H), 3.99 (s, 2H), 3.88 (t, 2H), 2.60 (s, 3H), 2.21 (s, 3H); MS (EI) for C29H26ClN5O: 497 (MH+).

4-{5-[(3,5-difluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 using 4-chloro-5-(3,5-difluorobenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.49 (s, 1H), 7.52-7.49 (m, 2H), 7.45 (d, 1H), 7.28 (d, 1H), 7.00 (d, 1H), 6.90 (s, 1H), 6.83 (t, 1H), 6.68 (d, 2H), 4.55 (s, 2H), 4.30 (t, 2H), 4.07 (s, 2H), 3.89 (t, 2H); MS (EI) for C29H25F2N5O: 498 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-5-{[3-(trifluoromethyl)phenyl]methyl}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 using 4-chloro-6-methyl-5-(3-(trifluoromethyl)benzyl)pyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.49 (s, 1H), 7.55-7.48 (m, 3H), 7.45-7.37 (m, 2H), 7.35 (s, 1H), 7.30 (d, 1H), 7.24 (d, 1H), 7.00 (d, 1H), 6.88 (s, 1H), 4.57 (s, 2H), 4.28 (t, 2H), 4.15 (s, 2H), 3.88 (t, 2H), 2.60 (s, 3H), 2.21 (s, 3H); MS (EI) for C30H26F3N5O: 530 (MH+).

2-chloro-N,N-dimethyl-5-({4-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-5-yl}methyl)aniline. Prepared as the trifluoroacetate salt according to the method of example 1 using 4-chloro-5-(4-chloro-3-fluorobenzyl)-6-methylpyrimidine (reagent preparation 5) in step 5, subsequent side reaction displacement of the 3 fluoro by dimethyl amine yielded the title compound. 1H NMR (400 MHz, methanol-d4): 8.64 (s, 1H), 7.80-7.77 (m, 2H), 7.67 (d, 1H), 7.53 (d, 1H), 7.29 (d, 1H), 7.16 (s, 1H), 7.05 (d, 1H), 6.91 (s, 1H), 6.73 (d, 1H), 5.03 (s, 2H), 4.39 (t, 2H), 4.18 (t, 2H), 4.05 (s, 2H), 2.88 (s, 3H), 2.63 (s, 6H), 2.32 (s, 3H); MS (EI) for C31H31ClN6O: 540 (MH+).

4-{5-[1-(3-fluorophenyl)ethyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the acetate salt according to the method of example 1 using 4-chloro-5-(1-(3-fluorophenyl)ethyl)-6-methylpyrimidine (reagent preparation 5) in step 5. 1H NMR (400 MHz, methanol-d4): 8.51 (s, 1H), 7.50-7.43 (m, 3H), 7.32-7.25 (m, 1H), 7.17 (d, 1H), 7.05-6.95 (m, 4H), 6.83 (s, 1H), 4.60 (q, 1H), 4.43-4.35 (m, 2H), 4.26-4.19 (m, 1H), 3.99-3.91 (m, 1H), 3.82-3.74 (m, 1H), 2.60 (s, 3H), 2.14 (s, 3H), 1.63 (d, 3H); MS (EI) for C30H28FN5O: 494 (MH+).

4-(8-bromo-6-methylquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 8-bromo-4-chloro-6-methylquinazoline (reagent preparation 1) in step 5. 1H NMR (400 MHz, d6-DMSO): 12.25 (br. s, 1H), 8.59 (s, 1H), 8.05 (s, 1H), 7.80-7.76 (m, 2H), 7.65 (s, 1H), 7.55 (d, 1H), 7.47-7.41 (m, 2H), 7.03 (d, 1H), 5.07 (s, 2H), 4.51 (t, 2H), 4.17 (t, 2H), 2.50 (s, 3H), 2.35 (s, 3H); MS (EI) for C26H22BrN5O: 501 (MH+).

1-{4-ethyl-5-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine. Prepared according to the method of example 1 by using 1-(4-chloro-6-ethyl-5-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 5. 1H NMR (400 MHz, DMSO-d6) δ 7.74-7.30 (m, 5H), 7.00 (d, 1H), 4.60 (s, 2H), 4.32-4.25 (m, 2H), 3.84-3.76 (m, 2H), 3.37 (s, 2H), 2.64 (q, 2H), 2.49 (s, 3H), 2.20 (s, 3H), 2.14 (s, 6H), 1.15 (t, 3H); MS (EI) for C27H32N6O: 457 (MH+).

N,N-dimethyl-1-{4-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(1-methylethyl)pyrimidin-2-yl}methanamine. Prepared according to the method of example 1 by using 1-(4-chloro-5-isopropylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 5. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, 1H), 7.63 (s, 1H), 7.57 (d, 1H), 7.51 (d, 1H), 7.46 (dd, 1H), 7.37 (dd, 1H), 7.00 (d, 1H), 4.63 (s, 2H), 4.35-4.29 (m, 2H), 3.86-3.80 (m, 2H), 3.38 (s, 2H), 3.16-3.05 (m, 2H), 2.50 (s, 3H), 2.11 (s, 6H), 1.88 (s, 3H), 1.25 (d, 6H); MS (EI) for C27H32N6O: 457 (MH+).

1-{5-ethyl-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine. Prepared as an acetate salt by the method of example 1 using 1-(4-chloro-5-ethyl-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 5. 1H NMR (400 MHz, DMSO-d6) δ 7.69 (br s, 1H), 7.60 (d, 1H), 7.53 (br s, 1H), 7.46 (dd, 1H), 7.40-7.34 (m, 1H), 7.00 (d, 1H), 4.61 (s, 2H), 4.34-4.28 (m, 2H), 3.83-3.76 (m, 2H), 3.42-3.38 (m, 2H), 2.62 (q, 2H), 2.50 (s, 3H), 2.36 (s, 3H), 2.12 (s, 6H), 1.89 (s, 3H), 1.16 (t, 3H); MS (EI) for C27H32N6O: 457 (MH+).

4-[6,6-dimethyl-2-({[2-(methyloxy)ethyl]oxy}methyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6,6-dimethyl-2-({[2-(methyloxy)ethyl]oxy}methyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 5. 1H NMR (400 MHz, d6-DMSO): 7.64 (d, 2H), 7.47 (dd, 2H), 7.38 (dd, 1H), 7.01 (d, 1H), 4.63 (s, 2H), 4.29 (m, 2H), 3.86 (m, 2H), 3.56 (m, 2H), 3.38 (m, 2H), 3.32 (brs, 2H), 3.17 (s, 3H), 2.70 (m, 2H), 2.49 (s, 3H), 2.47 (s, 2H) 1.60 (m, 2H), 0.87 (s, 6H); MS (EI) for C31H37N5O3: 528 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-(methyloxy)ethanamine. Prepared according to the method of example 1 by using N-[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl]-2-(methyloxy)ethanamine (reagent preparation 17) in step 5. 1H NMR (400 MHz, d6-DMSO): 9.50 (brs, 1H), 7.98 (s, 2H), 7.82 (s, 2H), 7.61 (dd, 1H), 7.05 (d, 1H), 5.08 (brs, 1H), 4.49 (s, 2H), 4.28 (s, 2H), 4.12 (s, 2H), 3.56 (s, 1H), 3.20 (s, 3H), 3.12 (m, 2H), 2.86 (s, 3H), 2.78 (m, 2H), 2.54 (s, 2H), 2.51 (s, 3H), 1.60 (m, 2H), 0.87 (s, 6H); MS (EI) for C31H38N6O2: 527 (MH+).

4-[6,6-dimethyl-2-(pyrrolidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using 4-chloro-6,6-dimethyl-2-(pyrrolidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 5. 1H NMR (400 MHz, Methanol-d4): 7.70 (br, 1H), 7.63 (br, 1H), 7.56 to 7.44 (m, 3H), 7.02 (d, 1H), 4.83 (s, 2H), 4.39 (m, 2H), 4.18 (s, 2H), 4.01 (m, 2H), 3.17 (m, 4H), 2.88 (t, 2H), 2.59 (s, 3H), 2.51 (s, 2H), 1.88 (m, 4H), 1.69 (t, 2H), 0.92 (s, 6H); MS (EI) for C32H38N6O: 523 (MH+).

4-{6,6-dimethyl-2-[(2R)-pyrrolidin-2-yl]-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-1H-benzimidazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 1 by using phenylmethyl(2R)-2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate (reagent preparation 18) in step 5 followed by Cbz group deprotection. 1H NMR (400 MHz, Methanol-d4): 7.70 (s, 1H), 7.63 (s, 1H), 7.54 (d, 1H), 7.47 (m, 2H), 7.00 (d, 1H), 4.84 (s, 2H), 4.46 (m, 1H), 4.37 (m, 2H), 4.01 (m, 2H), 3.13 (m, 2H), 2.80 (t, 2H), 2.59 (s, 3H), 2.52 (dd, 2H), 2.32 (m, 1H), 1.94 (m, 1H), 1.85 (m, 1H), 1.76 (m, 1H), 1.70 (t, 2H), 0.93 (d, 6H); MS (EI) for C31H36N6O: 509 (MH+).

{5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}methyl acetate. Prepared according to the method of example 1 by using {4-chloro-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-2-yl}methyl acetate (reagent preparation 17) in step 5. 1H NMR (400 MHz, Methanol-d4): 7.57 (s, 1H), 7.50 (s, 1H), 7.43 (d, 1H), 7.25 (d, 1H), 7.09 (m, 2H), 7.03 to 6.93 (m, 3H), 6.83 (d, 1H), 5.07 (s (2H), 4.54 (s, 2H), 4.25 (m, 2H), 4.01 (s, 2H), 3.87 (m, 2H), 2.62 (s, 3H), 2.22 (s, 3H), 2.10 (s, 3H); MS (EI) for C32H30FN5O3: 552 (MH+).

{5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}methanol. Prepared according to the method of example 1 by using {4-chloro-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-2-yl}methyl acetate (reagent preparation 17) in step 5, followed by acetate hydrolysis using standard techniques. 1H NMR (400 MHz, Methanol-d4): 7.57 to 7.53 (m, 2H), 7.41 (d, 1H), 7.27 (d, 1H), 7.09 (m, 2H), 7.03 to 6.94 (m, 3H), 6.89 (d, 1H), 4.57 (s (2H), 4.55 (s, 2H), 4.26 (m, 2H), 4.00 (s, 2H), 3.91 (m, 2H), 2.59 (s, 3H), 2.21 (s, 3H); MS (EI) for C30H28FN5O2: 510 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-fluoroethanamine. Prepared as diacetate salt according to the method of example 1 by using phenylmethyl[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl](2-fluoroethyl)carbamate (reagent preparation 17) in step 5 followed by Cbz deprotection. 1H NMR (400 MHz, methanol-d4): 7.66 (d, 1H), 7.59 (d, 1H), 7.52 (d, 1H), 7.46 (m, 2H), 7.02 (d, 1H), 4.78 (s, 2H), 4.44 (m, 2H), 4.35 (m, 2H), 4.01 (m, 2H), 3.86 (s, 2H), 2.93 (m, 2H), 2.79 (m, 2H), 2.58 (s, 3H), 2.52 (s, 2H), 1.95 (s, 6H), 1.68 (m, 2H), 0.92 (s, 6H); MS (EI) for C30H35FN6O: 515 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclopropanamine. Prepared as acetate salt according to the method of example 1 by using N-[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl]cyclopropanamine (reagent preparation 17) in step 5. 1H NMR (400 MHz, methanol-d4): 7.68 (d, 1H), 7.64 (d, 1H), 7.52 (d, 1H), 7.47 (m, 2H), 7.00 (d, 1H), 4.81 (s, 2H), 4.33 (m, 2H), 4.02 (m, 2H), 3.83 (s, 2H), 2.78 (m, 2H), 2.58 (s, 3H), 2.52 (s, 2H), 2.17 (m, 1H), 1.95 (s, 3H), 1.67 (m, 2H), 0.93 (s, 6H), 0.33 (m, 4H); MS (EI) for C31H36N6O: 509 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)ethanamine. Prepared as acetate salt according to the method of example 1 by using benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(ethyl)carbamate (reagent preparation 17) in step 5 followed by Cbz deprotection. 1H NMR (400 MHz, methanol-d4): 7.66 (s, 1H), 7.60 (d, 1H), 7.53-7.43 (m, 3H), 7.03 (d, 1H), 4.81 (s, 2H), 4.36 (m, 2H), 4.02 (m, 2H), 3.98 (s, 2H), 2.88 (q, 2H), 2.80 (t, 2H), 2.58 (s, 3H), 2.52 (s, 2H), 1.90 (s, 3H), 1.69 (t, 2H), 1.10 (t, 3H), 0.92 (s, 6H); MS (EI) for C30H36N6O: 497 (MH+).

1-{5-(cyclopropylmethyl)-4-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine. Prepared as dihydrochloride salt according to the method of example 1 by using 1-(4-chloro-5-(cyclopropylmethyl)-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 5. 1H NMR (400 MHz, methanol-d4): 8.00 (s, 1H), 7.88 (m, 2H), 7.81 (d, 1H), 7.60 (dd, 1H), 7.08 (d, 1H), 5.20 (s, 2H), 4.58 (m, 2H), 4.54 (s, 2H), 4.24 (m, 2H), 2.92 (s, 6H), 2.81 (s, 3H), 2.74 (d, 2H), 2.59 (s, 3H), 0.86 (m, 1H), 0.44 (m, 2H), 0.02 (m, 2H); MS (EI) for C20H34N6O: 483 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclobutanamine. Prepared as acetate salt according to the method of example 1 by using benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(cyclobutyl)carbamate (reagent preparation 17) in step 5 followed by Cbz deprotection. 1H NMR (400 MHz, methanol-d4): 7.67 (s, 1H), 7.62 (s, 1H), 7.54-7.44 (m, 3H), 7.03 (d, 1H), 4.81 (s, 2H), 4.35 (m, 2H), 4.03 (m, 2H), 3.83 (s, 2H), 3.50 (m, 1H), 2.79 (t, 2H), 2.58 (s, 3H), 2.52 (s, 2H), 2.04 (m, 2H), 1.92 (s, 3H), 1.83 (m, 2H), 1.66 (m, 2H), 0.93 (s, 6H); MS (EI) for C32H38N6O: 523 (MH+).

4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-N-phenylpyrimidin-2-amine. Prepared by the method of example 1 using 2-anilino-4-chloropyrimidine in step 5. 1H NMR (400 MHz, DMSO-d6) δ 12.03 (br s, 1H), 9.01 (s, 1H), 7.98 (d, 1H), 7.50 (m, 9H), 7.01 (d, 1H), 6.89 (t, 1H), 4.87 (br s, 2H), 4.24 (s, 4H), 2.48 (s, 3H); MS (EI) for C27H24N6O: 449.1 (MH+).

1-{6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine. The trihydrochloride salt was prepared as in example 1 using 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 5. 1H NMR (400 MHz, CD3OD) δ 8.03 (s, 1H), 7.97 (s, 1H), 7.91 (dd, 1H), 7.81 (d, 1H), 7.62 (dd, 1H), 7.07 (d, 1H), 5.32 (s, 2H), 4.62-4.55 (m, 4H), 4.39-4.31 (m, 2H), 2.88 (s, 6H), 2.97-2.80 (m, 2H), 2.62 (s, 2H), 1.71 (t, 2H), 0.92 (s, 6H); MS (ES) for C30H36N6O: 497.2 (MH+).

4-(2-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The trihydrochloride salt was prepared as in example 1 using (S)-4-chloro-2-((3-fluoropyrrolidin-1-yl)methyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent example 17) in step 5. 1H NMR (400 MHz, CD3OD) δ 7.99 (s, 1H), 7.92-7.86 (m, 1H), 7.84 (bs, 1H), 7.79 (d, 1H), 7.61 (dd, 1H), 7.09 (d, 1H), 5.41-5.20 (m, 1H), 5.19-5.02 (m, 2H), 4.64-4.55 (m, 2H), 4.55-4.48 (m, 2H), 4.24-4.13 (m, 2H), 3.88-3.50 (m, 4H), 2.88 (s, 3H), 2.90-2.79 (m, 2H), 2.64-2.51 (m, 2H), 2.25 (s, 2H), 1.70 (t, 2H), 0.91 (d, 6H); MS (ES) for C32H37FN6O: 541.4 (MH+).

4-(2-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The trihydrochloride salt was prepared as in example 1 using (R)-4-chloro-2-((3-fluoropyrrolidin-1-yl)methyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 5. 1H NMR (400 MHz, CD3OD) δ 7.95 (s, 1H), 7.89-7.84 (m, 1H), 7.80 (s, 1H), 7.78 (s, 1H), 7.59 (dd, 1H), 7.09 (d, 1H), 5.44-5.23 (m, 1H), 5.00 (s, 2H), 4.52 (s, 2H), 4.50-4.45 (m, 2H), 4.16-4.07 (m, 2H), 3.59 (s, 4H), 2.88 (s, 3H), 2.91-2.78 (m, 2H), 2.55 (s, 2H), 2.36-2.19 (m, 2H), 1.70 (t, 2H), 0.90 (d, 6H); MS (ES) for C32H37FN6O: 541.4 (MH+).

4-(6,6-dimethyl-2-pyridin-2-yl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The trihydrochloride salt was prepared as in example 1 using 4-chloro-6,6-dimethyl-2-(pyridin-2-yl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 5. 1H NMR (400 MHz, d6-DMSO) δ 8.80 (d, 1H), 8.48 (d, 1H), 8.10 (s, 1H), 8.01 (d, 1H), 7.98 (s, 1H), 7.85 (d, 1H), 7.79 (d, 1H), 7.69 (t, 1H), 7.57 (d, 1H), 6.99 (d, 1H), 5.26 (s, 2H), 4.55 (bs, 2H), 4.30 (bs, 2H), 2.94 (t, 2H), 2.85 (s, 3H), 2.64 (s, 2H), 1.62 (t, 2H), 0.92 (s, 6H); MS (ES) for C32H32N6O: 517.3 (MH+).

2-{6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}propan-2-ol. The dihydrochloride salt was prepared as in example 1 using 2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)propan-2-ol (reagent preparation 17) in step 5. 1H NMR (400 MHz, CD3OD) δ 7.88 (s, 1H), 7.78 (s, 2H), 7.74 (d, 1H), 7.53 (dd, 1H), 7.01 (d, 1H), 5.16 (s, 2H), 4.54-4.46 (m, 2H), 4.31-4.24 (m, 2H), 2.89 (t, 2H), 2.85 (s, 3H), 2.61 (s, 2H), 1.70 (t, 2H), 1.39 (d, 6H), 0.96 (s, 6H); MS (ES) for C30H35N5O2: 498.2 (MH+).

N,N-dimethyl-1-{4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(1-methylethyl)pyrimidin-2-yl}methanamine. Synthesized according to the method of example 1 using 1-(4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 5. 1H NMR (400 MHZ, CDCl3): 9.84 (br, 1H), 7.69 (br, 1H), 7.41 (dd, 2H), 7.23 (br, 1H), 7.03-6.97 (m, 3H), 6.92-6.88 (m, 2H), 6.69 (br, 1H), 4.35 (s, 2H), 4.21 (tr, 2H), 3.91 (s, 2H), 3.83 (tr, 2H), 3.60 (s, 2H), 2.67 (s, 3H), 2.39 (s, 6H), 2.23 (s, 3H). MS (EI) for C32H33N6OF: 537 (MH+).

N,N-dimethyl-1-{4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(1-methylethyl)pyrimidin-2-yl}methanamine. Synthesized according to the method of example 1 using 1-(4-chloro-5-isopropyl-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 5. 1H NMR (400 MHZ, DMSO-d6): 10.85 (br, 1H), 8.02 (s, 1H), 7.99 (s, 1H), 7.83 (m, 2H), 7.55 (d, 1H), 6.98 (d, 1H), 5.04 (br s, 2H), 4.47 (br s, 2H), 4.43 (s, 2H), 3.95 (br s, 2H), 3.14 (m, 1H), 2.81 (s, 3H), 2.67 (s, 6H), 2.56 (s, 3H), 1.32 (d, 6H). MS (EI) for C28H34N6O: 471 (MH+).

N-({5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}methyl)cyclopropanamine. Prepared as acetate salt according to the method of example 1 by using N-((4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidin-2-yl)methyl)cyclopropanamine (reagent preparation 17) in step 5 1H NMR (400 MHz, methanol-d4): 7.59 (s, 1H), 7.53 (d, 1H), 7.44 (dd, 1H), 7.34 (d, 1H), 7.10 (m, 3H), 6.99 (m, 3H), 4.67 (s, 2H), 4.25 (m, 2H), 4.05 (s, 2H), 3.90 (m, 2H), 3.85 (s, 2H), 2.66 (s, 3H), 2.22 (s, 3H), 2.17 (m, 1H), 1.94 (s, 3H), 0.37 (m, 2H), 0.32 (m, 2H); MS (EI) for C33H33FN6O: 549 (MH+).

4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyridin-2-amine. Prepared according to the method of example 1 using 4-chloro-2-nitropyridine in step 5 followed by nitro group reduction using palladium on carbon hydrogenation in methanol at 35 psi. 1H NMR (400 MHz, CD3OD) δ 7.76-7.62 (m, 2H), 7.60-7.37 (m, 4H), 7.07 (d, 1H), 6.57 (dd, 1H), 6.06 (d, 1H), 4.82 (s, 2H), 4.29-4.18 (m, 2H), 4.06-3.97 (m, 2H), 2.59 (s, 3H).

Example 2 Methyl (6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-yl)carbamate

STEP 1: 1,1-dimethylethyl 7-bromo-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (10 g, 30.5 mmol) was taken into hot ethanol (10 mL) followed by addition of 4 M hydrogen chloride in dioxane solution (2.1 eq, 16 mL) and the resulting solution was allowed to slowly cool to ambient temperature over one hour. An excess of ethyl ether was then added and the resulting slurry was filtered. The filter cake was washed with ethyl ether and dried to give 7-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepine hydrochloride (7.9 g, 98% yield) as a colorless crystalline solid. MS (EI) for C9H10NOBr: 229 (MH+).

STEP 2: A mixture of 7-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepine hydrochloride (300 mg, 1.13 mmol), 4-chloro-6,7-dimethoxyquinoline (253 mg, 1.13 mmol), and potassium carbonate (470 mg, 3.40 mmol) in N-methylpyrrolidine (2 mL) was stirred at 160° C. for 17 h. Ethyl acetate (75 mL) was added and the mixture was washed with water (3×25 mL) and brine (25 mL), dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5) afforded 4-[6,7-bis(methyloxy)quinolin-4-yl]-7-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepine (80 mg). MS (EI) for C20H19BrN2O3: 416 (MH+).

STEP 3: A mixture 4-[6,7-bis(methyloxy)quinolin-4-yl]-7-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepine (78 mg, 0.19 mmol), 4-amino-3-nitrophenylboronic acid pinacol ester (59 mg, 0.23 mmol), potassium carbonate (105 mg, 0.76 mmol), and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (20 mg, 0.02 mmol) in dimethoxyethane (3 mL) was stirred at 80° C. for 3 h. Ethyl acetate (50 mL) was added and the mixture was washed with water (20 mL), and brine (20 mL), dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5) gave 4-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-2-nitroaniline (56 mg, 63% yield). MS (EI) for C26H24N4O5: 473 (MH+).

STEP 4: A solution of 4-{-4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-2-nitroaniline (56 mg, 0.12 mmol) in methanol (20 mL) was hydrogenated at 30 psi over 10% Pd—C (25 mg) for 4 h. The catalyst was filtered off, and the filtrate was concentrated to give 4-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}benzene-1,2-diamine (40 mg, 77% yield) as a brown oil. MS (EI) for C26H26N4O3: 443 (MH STEP 5: To a solution of 4-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}benzene-1,2-diamine (40 mg, 0.09 mmol) in acetic acid (2 mL) was added 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (19 mg, 0.09 mmol) and the reaction mixture was stirred at 80° C. for 30 min. After cooling to room temperature the mixture was concentrated, and purified by preparative reverse phase HPLC to provide methyl (6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-yl)carbamate (17 mg, 25% yield) as a brown solid. 1H NMR (400 MHz, CD3OD): 8.30 (d, 1H), 7.78 (m, 2H), 7.68 (m, 2H), 7.60 (m, 1H), 7.27 (d, 2H), 7.11 (d, 1H), 7.04 (d, 1H), 5.17 (s, 2H), 4.64 (m, 2H), 4.25 (m, 2H), 4.01 (s, 3H), 3.96 (s 3H), 3.63 (s, 3H); MS (EI) for C29H27N5O5: 526 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in steps 2, 3 or 5 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

Methyl[6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. Synthesized according to the method of example 2 using 4-chloroquinoline in step 2. 1H NMR (400 MHz, d6-DMSO): 8.72 (d, 1H), 8.03 (d, 1H), 7.96 (d, 1H), 7.69 (m, 3H), 7.53 (m, 2H), 7.46 (d, 1H), 7.39 (d, 1H), 7.11 (d, 1H) 7.02 (d, 1H) 4.63 (s, 2H), 4.38 (br s, 2H), 3.81 (br s, 2H), 3.77 (s, 3H); MS (EI) for C27H23N5O3: 466 (MH+).

Methyl [1-methyl-5-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. Synthesized according to the method of example 2 using 4-chloroquinoline in step 2 and 4-methylamino-3-nitrophenylboronic acid pinacol ester (Bioorg. Med. Chem. Lett. 2007, 17(19), 5406-5409) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.62 (d, 1H), 8.01 (d, 1H), 7.94 (d, 1H), 7.70 (m, 3H), 7.64 (m, 2H), 7.51 (m, 4H), 7.13 (d, 1H) 7.01 (d, 1H) 4.64 (s, 2H), 4.39 (br s, 2H), 3.82 (br s, 2H), 3.64 (s, 3H), 3.54 (s, 3H); MS (EI) for C28H25N5O3: 480 (MH+).

1-Methyl-5-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine. Synthesized according to the method of example 2 using 4-chloroquinoline in step 2 and 4-methylamino-3-nitrophenylboronic acid pinacol ester (Bioorg. Med. Chem. Lett. 2007, 17(19), 5406-5409) in step 3. Material obtained as a co-product in the formation of methyl [1-methyl-5-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. 1H NMR (400 MHz, d6-DMSO): 8.62 (d, 1H), 8.04 (d, 1H), 7.96 (d, 1H), 7.68 (m, 2H), 7.52 (m, 2H), 7.42 (s, 1H), 7.13 (dt, 2H) 7.08 (d, 1H), 7.04 (d, 1H), 6.48 (br s, 2H), 4.68 (s, 2H), 4.38 (br s, 2H), 3.81 (br s, 2H), 3.52 (s, 3H); MS (EI) for C26H23N5O: 422 (MH+).

Methyl [1-methyl-6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. Synthesized according to the method of example 2 using 4-chloroquinoline in step 2 and 4-nitro-3-methylaminophenylboronic acid pinacol ester (Bioorg. Med. Chem. Lett. 2007, 17(19), 5406-5409) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.63 (d, 1H), 8.02 (d, 1H), 7.94 (d, 1H), 7.71 (m, 2H), 7.62 (s, 1H), 7.50 (m, 4H), 7.13 (d, 1H) 7.03 (d, 1H) 4.64 (s, 2H), 4.40 (br s, 2H), 3.81 (br s, 2H), 3.63 (s, 3H), 3.55 (s, 3H); MS (EI) for C28H25N5O3: 480 (MH+).

2-(Methyloxy)ethyl [6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. Synthesized according to the method of example 2 using 4-chloroquinoline in step 2 and 1,3-bis-[2-(methoxy)-ethoxycarbonyl]-2-methyl-2-thiopseudourea (reagent preparation 10) in step 5. 1H NMR (400 MHz, d6-DMSO): 8.62 (d, 1H), 8.03 (d, 1H), 7.94 (d, 1H), 7.71 (m, 3H), 7.53 (m, 2H), 7.47 (d, 1H), 7.38 (m, 1H), 7.11 (d, 1H) 7.01 (d, 1H) 4.64 (s, 2H), 4.31 (br s, 2H), 3.83 (br s, 2H), 3.61 (m, 2H), 3.34 (br s, 2H), 3.30 (s, 3H); MS (EI) for C29H27N5O4: 510 (MH+).

4-Piperidin-1-yl-N-[6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]butanamide. Synthesized according to the method of example 2 using 4-chloroquinoline in step 2 and 1,3-bis-[3-(piperidin-1-yl)propylcarbonyl]-2-methyl-2-thiopseudourea (reagent preparation 10) in step 5. 1H NMR (400 MHz, d6-DMSO): 9.22 (br s, 1H), 8.67 (d, 1H), 8.33 (d, 1H), 7.95 (m, 3H), 7.78 (s, 1H), 7.73 (t, 1H), 7.57 (m, 3H), 6.98 (d, 2H), 5.31 (s, 2H), 4.61 (br s, 2H), 4.41 (br s, 2H), 3.43 (d, 2H), 3.11 (m, 2H), 2.91 (m, 2H), 2.59 (m, 2H), 2.02 (m, 2H), 1.81 (m, 2H); MS (EI) for C34H36N6O2: 561 (MH+).

Methyl [6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. Synthesized according to the method of example 2 using 4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidine in step 2. 1H NMR (400 MHz, DMSO-D6): 11.70 (bs, 1H), 8.50 (s, 1H), 7.49 (s, 1H), 7.38-7.46 (m, 2H), 7.09-7.16 (m, 5H), 6.99 (d, 1H), 6.88 (s, 1H), 4.48 (s, 2H), 4.23-4.30 (m, 2H), 4.00 (s, 2H), 3.74-3.81 (m, 5H), 2.16 (s; 3H); MS (EI) for C30H27FN6O3: 539 (MH+).

Methyl [6-(4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. Prepared according to the method of example 2 by using 4-chloropyrimidine in step 2. 1H NMR (400 MHz, DMSO-d6): 8.49 (s, 1H), 8.17 (d, 1H), 7.80 (s, 1H), 7.60 (s, 1H), 7.44 (m, 2H), 7.34 (m, 1H), 7.03 (m, 2H), 4.87 (s, 2H), 4.15 (s, 4H), 3.76 (s, 3H); MS (EI) for C22H20N6O3: 417 (MH+).

Methyl {6-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-yl}carbamate. Prepared according to the method of example 2 by using 4-chloropyrrolo[2,3-d]pyrimidine in step 2. 1H NMR (400 MHz, DMSO-d6): 12.25 (br. s, 1H), 8.30 (s, 1H), 7.78 (d, 1H), 7.67 (s, 1H), 7.57 (d, 1H), 7.47 (m, 2H), 7.35 (m, 1H), 7.04 (d, 1H), 6.92 (s, 1H), 5.25 (s, 2H), 4.39 (m, 4H), 3.84 (s, 3H); MS (EI) for C24H21N7O3: 456 (MH+).

Methyl {6-[4-(3-methylpyridin-2-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-yl}carbamate. Prepared according to the method of example 2 by using 2-chloro-3-methylpyridine in step 2. 1H NMR (400 MHz, DMSO-d6): 11.69 (br. s, 1H), 8.07 (m, 1H), 7.59 (d, 1H), 7.54 (d, 1H), 7.51 (d, 1H), 7.44 (m, 2H), 7.32 (dd, 1H), 7.06 (d, 1H), 6.89 (m, 1H), 4.42 (s, 2H), 4.28 (m, 2H), 3.76 (s, 3H), 3.65 (m, 2H), 2.30 (s, 3H); MS (EI) for C24H23N5O3: 430 (MH+).

Methyl {6-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-yl}carbamate. Prepared according to the method of example 2 by using 4-chloro-2-methylquinazoline in step 2. 1H NMR (400 MHz, DMSO-d6): 7.99 (d, 1H), 7.74 (m, 1H), 7.68 (d, 1H), 7.61 (m, 2H), 7.44 (m, 3H), 7.34 (d, 1H), 7.00 (d, 1H), 5.01 (s, 2H), 4.42 (m, 2H), 4.17 (m, 2H), 3.74 (s, 3H), 2.45 (s, 3H); MS (EI) for C27H24N6O3: 481 (MH+).

Methyl [6-(4-quinazolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. Prepared as trifluoroacetate salt according to the method of example 2 by using 4-chloroquinazoline in step 2. 1H NMR (400 MHz, DMSO-d6): 8.84 (s, 1H), 8.31 (s, 1H), 7.83 (d, 1H), 7.78-7.69 (m, 3H), 7.56-7.46 (m, 3H), 7.01 (d, 1H), 5.45 (s, 2H), 4.63 (m, 2H), 4.54 (m, 2H), 3.81 (s, 3H); MS (EI) for C26H22N6O3: 4678 (MH+).

Methyl [6-(4-isoquinolin-1-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. Prepared as trifluoroacetate salt according to the method of example 2 by using 1-chloroisoquinoline in step 2. 1H NMR (400 MHz, methanol-d4): 8.26 (d, 1H), 8.04 (d, 1H), 7.96 (m, 1H), 7.83 (m, 2H), 7.68 (m, 5H), 7.56 (d, 1H), 7.21 (d, 1H), 5.14 (s, 2H), 4.67 (m, 2H), 4.14 (m, 2H), 3.96 (s, 3H); MS (EI) for C27H23N5O3: 466 (MH+).

Methyl (6-{4-[6,7-bis(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-yl)carbamate. Prepared according to the method of example 2 by using 4-chloro-6,7-dimethoxyquinazoline in step 2. 1H NMR (400 DMSO-D6): 8.49 (1H), 7.73 (br, 1H), 7.62 (br, 1H), 7.49 (dd, 1H), 7.44 (d, 1H), 7.35 (dd, 1H), 7.20 (s, 1H), 7.09 (d, 2H), 5.02 (s, 2H), 4.53 (m, 2H), 4.06 (m, 2H), 3.90 (s, 3H), 3.75 (s, 3H), 3.54 (s, 3H), MS (EI) for C28H26N6O5: 527 (MH+).

Methyl (6-{4-[6-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-yl)carbamate. Prepared according to the method of example 2 by using 4-chloro-6-methoxyquinazoline in step 2. 1H NMR (400 DMSO-D6): 8.53 (1H), 7.75 (d, 2H), 7.62 (br, 1H), 7.52 to 7.42 (m, 3H), 7.35 (dd, 1H), 7.17 (s, 1H), 7.05 (d, 1H), 5.04 (s, 2H), 4.53 (m, 2H), 4.11 (m, 2H), 3.78 (s, 3H), 3.58 (s, 3H), MS (EI) for C27H24N6O4: 497 (MH+).

Example 3 5-(4-{5-[(4-Fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-amine

STEP 1: A mixture of N-(5-bromo-1,3-thiazol-2-yl)acetamide (1.00 g, 4.5 mmol), (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (example 1, step 2) (1.59 g, 5.4 mmol), potassium carbonate (2.50 g, 18 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.33 g, 0.45 mmol), 1,4-dioxane (20 mL), and water (2 mL) was degassed with nitrogen for 2 min, and then stirred at 95° C. for 16 h. The reaction mixture was cooled, diluted with ethyl acetate (100 mL), and filtered through celite. The filtrate was washed with brine (2×30 mL), dried over sodium sulfate, and concentrated. Column chromatography on silica (gradient 20-85% ethyl acetate in hexane) gave 1,1-dimethylethyl 7-[2-(acetylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.99 g, 56% yield). MS (EI) for C19H23N3O4: 390 (MH+).

STEP 2: A solution of 1,1-dimethylethyl 7-[2-(acetylamino)-1,3-thiazole-5-yl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (300 mg, 0.77 mmol) in a mixture of methanol (2 mL) and 4 N hydrogen chloride in dioxane (2 mL) was refluxed for 1 min. After cooling to room temperature the reaction mixture was concentrated, and azeotroped with methanol (3×) to give N-[5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-yl]acetamide hydrochloride (221 mg, 88% yield) as a colorless solid. MS (EI) for C14H15N3O2S: 290 (MH+).

STEP 3: A mixture of N-[5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-yl]acetamide hydrochloride (220 mg, 0.68 mmol), 4-chloro-5-[(4-fluorophenyl)methyl]-6-methylpyrimidine (reagent preparation 5) (152 mg, 0.64 mmol) and diisopropylethylamine (500 mg, 3.87 mmol) in N-methylpyrrolidine (4 mL) was heated in a microwave reactor at 120° C. for 3 h. The reaction mixture was concentrated, diluted with water (10 mL), the precipitate was filtered off, washed with water (2×5 mL) and methanol (5 mL), and dried to provide N-[5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidine-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-yl]acetamide (147 mg, 47% yield) as a off-white solid. MS (EI) C26H24FN5O2S: 490 (MH+).

STEP 4: A solution of N-[5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidine-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-yl]acetamide (75 mg, 0.15 mmol) in 6 N hydrochloric acid (4 mL) was stirred at 95° C. for 15 h. After cooling to room temperature the mixture was neutralized with 50% aqueous sodium hydroxide, concentrated to dryness, and the solid residue extracted with ethanol (3×10 mL). Evaporation of the solvent and purification of the residue by preparative HPLC afforded 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-amine (43 mg, 62% yield) as a colorless solid. 1H NMR (400 MHz, CD3OD): 8.46 (s, 1H), 7.21 (m, 1H), 7.11 (m, 4H), 6.98 (s, 1H), 6.90 (d, 1H), 6.61 (m, 1H), 4.46 (s, 2H), 4.26 (ms, 2H), 3.97 (s, 2H), 3.87 (m, 2H), 2.21 (s, 3H); MS (EI) C24H22FN5OS: 448 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in steps 1 or 3 and conducting protecting group removal step 4 as required according to literature techniques appropriate for a given protecting group (see for example: Greene and Wuts, Protective Groups in Organic Synthetic, Wiley-Interscience) the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

4-{5-[(4-Fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 3 using isobutyl 6-bromo-2-methyl-3H-imidazo[4,5-b]pyridine-3-carboxylate (reagent preparation 11) in step 1. 1H NMR (400 MHz, CDCl3): 8.62 (s, 1H), 7.42 (d, 2H), 7.11 (d, 1H), 7.03 (m, 2H), 6.95 (t, 2H), 6.79 (s, 1H), 4.47 (s, 2H), 4.26 (br s, 2H), 3.97 (s, 2H), 3.88 (br s, 2H), 2.77 (s, 3H), 2.27 (s, 3H); MS (EI) for C28H25FN6O: 481 (MH+).

7-(1H-Benzimidazol-6-yl)-4-quinazolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 3 by using 6-bromo-1H-benzo[d]imidazole in step 1 and 4-chloroquinazoline in step 3. 1H NMR (400 MHz, methanol-d4): 8.53 (s, 1H), 8.21 (s, 1H), 8.12 (d, 1H), 7.80 (m, 3H), 7.68 (d, 1H), 7.63 (m, 1H), 7.53 (m, 3H), 7.07 (d, 1H), 5.13 (s, 2H), 4.49 (m, 2H), 4.30 (m, 2H), 1.96 (s, 3H); MS (EI) for C24H19N5O: 394 (MH+).

4-{5-[(4-Fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-[4-(1H-imidazol-2-yl)phenyl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 3 by using isobutyl 2-(4-bromophenyl)-1H-imidazole-1-carboxylate in step 1 and 4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidine (reagent preparation 5) in step 3. 1H NMR (400 DMSO-D6): 8.51 (1H), 8.01 (d, 2H), 7.54 (d, 3H), 7.20 (br 1H), 7.12 (d, 5H), 7.02 (d, 1H), 6.91 (br, 1H), 4.49 (s, 2H), 4.29 (m, 2H), 3.97 (s, 2H), 3.78 (s, 2H), 2.16 (s, 3H), MS (EI) for C30H26N5FO: 492 (MH+).

7-(1-Ethyl-1H-benzimidazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 3 by using 5-bromo-1-ethyl-1H-benzimidazole (reagent preparation 12) in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, d6-DMSO): 8.57 (d, 1H), 8.31 (d, 1H), 8.07-7.91 (m, 6H), 7.82 (s, 1H), 7.72-7.62 (m, 2H), 7.03-6.98 (m, 2H), 5.31 (s, 2H), 4.63 (t, 1H), 4.47-4.38 (m, 4H), 1.51 (t, 3H); MS (EI) for C27H24N4O: 421 (MH+).

7-(2-Methyl-1,3-benzothiazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 3 by using 5-bromo-2-methylbenzothiazole in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, d6-DMSO): 8.57 (d, 1H), 8.33 (d, 1H), 8.27 (s, 1H), 8.14 (d, 1H), 8.06 (s, 1H), 8.01-7.92 (m, 2H), 7.77 (d, 1H), 7.71-7.65 (m, 2H), 7.03-6.98 (m, 2H), 5.31 (s, 2H), 4.62 (t, 2H), 4.42 (t, 2H), 2.84 (s, 3H); MS (EI) for C26H21N3OS: 424 (MH+).

7-(1,3-Benzothiazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 3 by using 5-bromobenzothiazole in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, d6-DMSO): 9.47 (s, 1H), 8.57 (d, 1H), 8.46 (s, 1H), 8.33 (d, 1H), 8.29 (d, 1H), 8.11 (s, 1H), 8.01-7.92 (m, 2H), 7.88 (d, 1H), 7.73-7.66 (m, 2H), 7.03-6.99 (m, 2H), 5.31 (s, 2H), 4.63 (t, 2H), 4.42 (t, 2H); MS (EI) for C25H19N3OS: 410 (MH+).

7-(1-Methyl-1H-benzimidazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the acetate salt according to the method of example 3 by using 5-bromo-1-methylbenzimidazole in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, d6-DMSO): 8.61 (d, 1H), 8.23 (s, 1H), 8.09 (d, 1H), 7.97-7.93 (m, 2H), 7.81 (s, 1H), 7.75 (t, 1H), 7.68-7.59 (m, 3H), 7.56-7.50 (m, 1H), 7.07 (d, 1H), 7.02 (d, 1H), 4.81 (s, 2H), 4.43 (t, 2H), 3.95 (t, 2H), 3.88 (s, 3H); MS (EI) for C26H22N4O: 407 (MH+).

7-(1H-Benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 3 by using 5-bromobenzimidazole in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, d6-DMSO): 9.02 (br. s, 1H), 8.57 (d, 1H), 8.33 (d, 1H), 8.03-7.92 (m, 4H), 7.87-7.76 (m, 2H), 7.71-7.61 (m, 2H), 7.04-6.97 (m, 2H), 5.31 (s, 2H), 4.63 (t, 2H), 4.41 (t, 2H); MS (EI) for C25H20N4O: 393 (MH+).

4-Quinolin-4-yl-7-(3-thienyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 3 by using thiophen-3-ylboronic acid in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, d6-DMSO): 8.56 (d, 1H), 8.32 (d, 1H), 8.01-7.91 (m, 3H), 7.85 (s, 1H), 7.71-7.65 (m, 2H), 7.63-7.58 (m, 2H), 6.97-6.91 (m, 2H), 5.25 (s, 2H), 4.60 (t, 2H), 4.40 (t, 2H); MS (EI) for C22H18N2OS: 359 (MH+).

7-Quinolin-3-yl-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 3 by using quinolin-3-ylboronic acid in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, d6-DMSO): 9.39 (s, 1H), 8.77 (s, 1H), 8.56 (d, 1H), 8.34 (d, 1H), 8.21 (s, 1H), 8.11 (d, 2H), 8.02-7.94 (m, 2H), 7.85-7.80 (m, 2H), 7.74-7.68 (m, 2H), 7.09 (d, 1H), 7.02 (d, 1H), 5.34 (s, 2H), 4.67 (t, 2H), 4.44 (t, 2H); MS (EI) for C27H21N3O: 404 (MH+).

7-(1-Benzothien-2-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 3 by using benzothiophen-2-ylboronic acid in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, d6-DMSO): 8.58 (d, 1H), 8.31 (d, 1H), 8.06 (s, 1H), 8.01-7.92 (m, 3H), 7.88-7.84 (m, 2H), 7.72-7.65 (m, 2H), 7.44-7.34 (m, 2H), 7.00 (d, 1H), 6.96 (d, 1H), 5.29 (s, 2H), 4.63 (t, 2H), 4.39 (t, 2H); MS (EI) for C26H20N2OS: 409 (MH+).

N-[2-chloro-5-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridin-3-yl]methanesulfonamide. Prepared according to the method of example 3 by using N-(5-bromo-2-chloropyridin-3-yl)methanesulfonamide (reagent preparation 24) in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6) δ 8.12 (s, 1H), 7.88 (d, 1H), 7.64 (d, 1H), 7.45 (dd, 1H), 7.03 (d, 1H), 4.70 (s, 2H), 4.37-4.30 (m, 2H), 3.93-3.86 (m, 2H), 3.69 (s, 2H), 2.89 (s, 3H), 2.70 (t, 2H), 2.43 (s, 2H), 2.37 (s, 6H), 1.59 (t, 2H), 0.91-0.82 (m, 6H); MS (EI) for C28H35ClN6O3S: 571, 573 (Cl isotopes, MH+).

7-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 3 using 5-bromo-1-methyl-1H-indole (reagent preparation 21) in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, DMSO-d6): 8.62 (d, 1H), 8.58 (d, 1H), 8.23 (d, 1H), 8.01 (d, 1H), 7.94 (d, 1H), 7.74 (d, 1H), 7.68 (t, 1H), 7.62 (dd, 1H), 7.58 (dd, 1H), 7.53 (t, 1H), 7.12 (d, 1H), 7.03 (d, 1H), 6.52 (d, 1H), 4.66 (s, 2H), 4.38 (m, 2H), 3.85 (s, 3H), 3.82 (m, 2H); MS (EI) for C26H22N4O2: 407.1 (MH+).

7-(1-ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 3 using 5-bromo-1-ethyl-1H-indole (reagent preparation 21) in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, DMSO-d6): 8.62 (d, 1H), 8.57 (d, 1H), 8.22 (d, 1H), 8.01 (d, 1H), 7.94 (d, 1H), 7.74 (d, 1H), 7.69 (t, 1H), 7.64 (dd, 1H), 7.61 (dd, 1H), 7.50 (t, 1H), 7.12 (d, 1H), 7.03 (d, 1H), 6.52 (d, 1H), 4.66 (s, 2H), 4.42 (m, 2H), 4.31 (qr. 2H), 3.85 (s, 3H), 3.82 (m, 2H), 1.39 (t, 3H); MS (EI) for C27H24N4O2: 421.2 (MH+).

5-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridin-2-amine. Synthesized according to the method of example 3 using 5-bromopyridin-2-amine in step 1 and 4-chloroquinoline in step 3. 1H NMR (400 MHz, DMSO-d6): 8.61 (d, 1H), 8.24 (d, 1H), 7.99 (d, 1H), 7.93 (d, 1H), 7.71-7.69 (m, 2H), 7.59 (m, 1H), 7.50 (m, 1H), 7.44 (dd, 1H), 7.04 (d, 1H), 7.00 (dd, 1H), 6.52 (d, 1H), 6.04 (s, 2H), 4.61 (s, 2H), 4.34 (m, 2H), 3.80 (m, 2H), 1.88 (s, 3H, AcOH); MS (EI) for C23H20N4O2: 369.13 (MH+).

4-[6,7-bis(methyloxy)quinolin-4-yl]-7-[4-(1H-imidazol-2-yl)phenyl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 3 using 2-(4-bromophenyl)-1H-imidazole in step 1 and 4-chloro-6,7-dimethoxyquinoline in step 3. 1H NMR (400 MHz, DMSO-d6): 8.47 (d, 1H), 8.01 (d, 2H), 7.87 (d, 1H), 7.77 (d, 2H), 7.65 (dd, 1H), 7.31 (s, 1H), 7.16 (bs, 2H), 7.12 (d, 1H), 7.10 (s, 1H), 6.94 (d, 1H), 4.65 (s, 2H), 4.44 (m, 2H), 3.89 (s, 3H), 3.77 (m, 2H), 3.54 (s, 3H); MS (EI) for C29H26N4O3: 478.9 (MH+).

7-[4-(1H-imidazol-2-yl)phenyl]-4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 3 using 2-(4-bromophenyl)-1H-imidazole in step 1 and 4-chloro-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 12.5 (s, 1H), 8.02 (d, 2H), 7.99 (d, 1H), 7.78-7.74 (m, 4H), 7.70 (m, 1H), 7.59 (m, 1H), 7.43 (m, 1H), 7.26 (bs, 1H), 7.03 (d, 2H), 5.06 (s, 2H), 4.74 (s, 2H), 4.19 (s, 2H), 2.46 (s, 3H); MS (EI) for C27H23N5O: 434.0 (MH+).

5-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Synthesized according to the method of example 3 using 5-bromo-2-aminopyridine in step 1 and 4-chloro-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 8.21 (m, 1H), 7.97 (dd, 1H), 7.75 (m, 1H), 7.69 (m, 1H), 7.66 (m, 1H), 7.57 (m, 1H), 7.40 (m, 2H), 6.97 (d, 1H), 6.52 (d, 1H), 6.03 (s, 2H), 5.00 (s, 2H), 4.42 (s, 2H), 4.17 (s, 2H), 2.46 (s, 3H); MS (EI) for C23H21N5O: 384.2 (MH+).

4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-7-(1H-pyrrolo[2,3-b]pyridin-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 3 using 5-bromo-1H-pyrrolo[2,3-b]pyridine in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 11.7 (s, 1H), 8.49 (s, 1H), 8.16 (s, 1H), 7.90 (d, 1H), 7.71 (s, 1H), 7.53 (m, 2H), 7.11 (s, 1H), 7.03 (d, 2H), 6.50 (m, 1H), 5.02 (s, 2H), 4.44 (s, 2H), 4.15 (d, 2H), 3.87 (s, 3H), 2.43 (s, 3H); MS (EI) for C26H23N5O2: 438.2 (MH+).

(5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine. Synthesized according to the method of example 3 using 5-bromo-2-aminopyridine in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 11.9 (s, 1H, AcOH), 8.21 (d, 1H), 7.87 (d, 1H), 7.67 (dd, 1H), 7.55 (m, 1H), 7.38 (dd, 1H), 7.10 (d, 1H), 7.02 (dd, 1H), 6.96 (d, 1H), 6.52 (d, 1H), 6.03 (s, 2H), 4.96 (s, 2H), 4.38 (m, 2H), 4.13 (m, 2H), 3.87 (s, 3H), 2.42 (s, 3H), 1.90 (s, 3H, AcOH); MS (EI) for C24H23N5O2: 413.9 (MH+).

7-(1H-indazol-5-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 3 using 5-bromo-1H-pyrazolo[3,4-b]pyridine in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 13.1 (s, 1H), 11.9 (s, 1H, AcOH), 8.12 (s, 1H), 7.99 (m, 1H), 7.92 (d, 1H), 7.69 (m, 1H), 7.64 (m, 2H), 7.53 (d, 1H), 7.10 (d, 1H), 7.05 (dd, 1H), 7.02 (dd, 1H), 5.04 (s, 2H), 4.45 (m, 2H), 4.17 (bs, 2H), 3.88 (s, 3H), 2.43 (s, 3H), 1.90 (s, 3H, AcOH); MS (EI) for C26H23N5O2: 437.9 (MH+).

5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyrimidin-2-amine. Synthesized according to the method of example 3 using 5-bromo-2-aminopyrimidine in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 8.55 (s, 2H), 7.86 (d, 1H), 7.62 (d, 1H), 7.45 (dd, 2H), 7.10 (d, 1H), 7.03 (dd, 1H), 6.99 (d, 1H), 6.75 (s, 2H), 4.97 (s, 2H), 4.42 (bs, 2H), 4.12 (bs, 2H), 3.87 (s, 3H), 2.42 (s, 3H); MS (EI) for C23H22N6O2: 415.0 (MH+).

5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1,3-thiazol-2-amine. Synthesized according to the method of example 3 using 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 7.86 (d, 1H), 7.39 (d, 1H), 7.30 (s, 1H), 7.26 (dd, 1H), 7.10 (m, 3H), 7.01 (dd, 1H), 6.90 (d, 1H), 4.90 (s, 2H), 4.36 (m, 2H), 4.12 (m, 2H), 3.87 (s, 3H), 2.42 (s, 3H); MS (EI) for C22H21N5O2S: 419.9 (MH+).

N-(5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1,3-thiazol-2-yl)acetamide. Synthesized according to the method of example 3 using 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 7.86 (d, 1H), 7.78 (s, 1H), 7.63 (d, 1H), 7.46 (dd, 1H), 7.10 (d, 1H), 6.98 (dd, 1H), 6.57 (d, 1H), 4.96 (s, 2H), 4.41 (m, 2H), 4.14 (m, 2H), 3.87 (s, 3H), 2.41 (s, 3H), 2.16 (s, 3H); MS (EI) for C24H23N5O3S: 462.1 (MH+).

7-(1,3-benzothiazol-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 3 using 6-bromobenzo[d]thiazole in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 9.40 (s, 1H), 8.46 (d, 1H), 8.16 (dd, 1H), 7.88 (d, 1H), 7.80 (dd, 1H), 7.78 (d, 1H), 7.61 (dd, 1H), 7.10 (d, 1H), 7.05 (m, 2H), 5.03 (s, 2H), 4.47 (m, 2H), 4.15 (m, 2H), 3.87 (s, 3H), 2.42 (s, 3H), 1.90 (s, 3H, AcOH); MS (EI) for C26H22N4O2S: 455.1 (MH+).

5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1,3-dihydro-2H-benzimidazol-2-one. Synthesized according to the method of example 3 using 5-bromo-1H-benzo[d]imidazol-2(3H)-one in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 10.7 (d, 2H), 7.90 (d, 1H), 7.58 (s, 1H), 7.24 (d, 1H), 7.14 (d, 1H), 7.04 (d, 2H), 7.01 (m, 3H), 4.98 (s, 2H), 4.42 (s, 2H), 4.14 (s, 2H), 2.43 (s, 3H); MS (EI) for C26H23N5O3: 453.9 (MH+).

5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1,3-dihydro-2H-indol-2-one. Synthesized according to the method of example 3 using 5-bromoindolin-2-one in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6): 10.4 (s, 1H), 7.87 (d, 1H), 7.58 (s, 1H), 7.48 (s, 1H), 7.43 (t, 2H), 7.10 (s, 1H), 6.99 (dd, 1H), 6.97 (d, 1H), 6.89 (d, 1H), 4.98 (s, 2H), 4.42 (s, 2H), 4.13 (s, 2H), 3.89 (s, 3H), 3.53 (s, 2H), 2.42 (s, 2H); MS (EI) for C27H24N4O3: 452.9 (MH+).

N-[6-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide. Prepared according to the method of example 3 by using N-(6-bromo[1,3]thiazolo[5,4-b]pyridin-2-yl)acetamide (Journal of Heterocyclic Chemistry (200), 40(2), 621-628) in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. MS (EI) for C30H35N7O2S 558 (MH+).

6-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine. Prepared according to the method of example 3 by using N-(6-bromo[1,3]thiazolo[5,4-b]pyridin-2-yl)acetamide (Journal of Heterocyclic Chemistry (200), 40(2), 621-628) in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.40 (d, 1H), 7.90 (s, 2H), 7.84 (d, 1H), 7.74 (d, 1H), 7.54 (dd, 1H), 7.01 (d, 1H), 4.67 (s, 2H), 4.32 (s, 2H), 3.89 (s, 2H), 3.43 (s, 2H), 2.68 (m, 2H), 2.46 (m, 2H), 2.20 (s, 6H), 1.60 (m, 2H), 0.84 (s, 6H); MS (EI) for C28H33N7OS: 516 (MH+).

1-(4-{7-[2-(fluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of example 3 by using 1,1-dimethylethyl 5-bromo-2-(fluoromethyl)-1H-benzimidazole-1-carboxylate (reagent preparation 19) in step 1, and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, Methanol-D4): 7.79 (br, 1H), 7.67 to 7.60 (m, 2H), 7.56 (d, 1H), 7.50 (d, 1H), 7.04 (d, 1H), 5.62 (d, 2H), 4.79 (s, 2H), 4.37 (m, 2H), 4.01 (m, 2H), 3.91 (s, 2H), 2.79 (t, 2H), 2.59 (s, 6H), 2.52 (s, 2H), 1.70 (t, 2H), 0.92 (s, 6H); MS (EI) for C30H35FN6O: 515 (MH+).

1-(4-{7-[2-(fluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of example 3 by using 1,1-dimethylethyl 5-bromo-2-(fluoromethyl)-1H-benzimidazole-1-carboxylate (reagent preparation 19) in step 1, and 1-{4-chloro-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-2-yl}-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, Methanol-D4): 7.66 (br, 2H), 7.46 (d, 1H), 7.38 (d, 1H), 7.09 (m, 2H), 7.01 to 6.93 (m, 4H), 5.63 (d, 2H), 4.77 (s, 2H), 4.36 (m, 2H), 4.02 (m, 2H), 3.91 (br, 4H), 2.59 (s, 2H), 2.26 (s, 3H); MS (EI) for C32H32FN6O: 555 (MH+).

1-[4-{7-[2-(fluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6-methyl-5-(1-methylethyl)pyrimidin-2-yl]-N,N-dimethylmethanamine. Prepared according to the method of example 3 using 1,1-dimethylethyl 5-bromo-2-(fluoromethyl)-1H-benzimidazole-1-carboxylate (reagent preparation 19) in step 1, and 1-[4-chloro-6-methyl-5-(1-methylethyl)pyrimidin-2-yl]-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, Methanol-D4): 7.78 (br, 1H), 7.65 (br, 1H), 7.58 to 7.50 (m, 3H), 7.04 (d, 1H), 5.62 (d, 2H), 4.62 (s, 2H), 4.37 (m, 2H), 3.86 (m, 2H), 3.37 (m, 1H), 2.56 (s, 3H), 2.54 (s, 3H), 1.41 (d, 6H); MS (EI) for C28H33FN6O: 489 (MH+).

1-{4-[7-(4-fluoro-2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine. Prepared according to the method of example 3 by using 1,1-dimethylethyl 5-bromo-4-fluoro-2-methyl-1H-benzimidazole-1-carboxylate (reagent preparation 19) in step 1, and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, Methanol-D4): 7.49 (br, 1H), 7.59 (d, 1H), 7.36 (d, 1H), 7.28 (d, 1H), 7.01 (d, 1H), 4.75 (s, 2H), 4.36 (m, 2H), 4.00 (m, 2H), 3.80 (s, 2H), 2.79 (t, 2H), 2.56 (s, 3H), 2.49 (br, 6H), 1.65 (t, 2H), 0.91 (s, 6H); MS (EI) for C30H35FN6O: 515 (MH+).

4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-7-[4-(1H-imidazol-2-yl)phenyl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 3 by using isobutyl 2-(4-bromophenyl)-1H-imidazole-1-carboxylate (reagent preparation 11) in step 1 and 4-chloro-6,6-dimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, methanol-d4): 8.38 (s, 1H), 7.92 (m, 2H), 7.70 (m, 2H), 7.59 (m, 1H), 7.53 (m, 1H), 7.15 (brs, 2H), 7.07 (d, 1H), 6.33 (d, 1H), 6.26 (d, 1H), 4.71 (s, 2H), 4.36 (m, 2H), 3.97 (m, 2H), 2.78 (s, 2H), 1.01 (s, 6H); MS (EI) for C28H27N5O: 450 (MH+).

1-(4-{7-[4-(1H-imidazol-2-yl)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared as dihydrochloride salt according to the method of example 3 by using isobutyl 2-(4-bromophenyl)-1H-imidazole-1-carboxylate (reagent preparation 11) in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4): 8.00 (m, 4H), 7.85 (s, 1H), 7.68 (s, 2H), 7.64 (dd, 1H), 7.09 (d, 1H), 5.04 (s, 2H), 4.52 (m, 2H), 4.42 (s, 2H), 4.18 (m, 2H), 2.93 (s, 6H), 2.85 (t, 2H), 2.55 (s, 2H), 1.70 (t, 2H), 0.89 (s, 6H); MS (EI) for C31H36N6O: 509 (MH+).

7-[4-(1H-imidazol-2-yl)phenyl]-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 3 by using 2-(4-bromophenyl)-1H-imidazole in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6); δ 11.99 (s, 1H), 8.10-7.94 (m, 3H), 7.86-7.75 (m, 3H), 7.65-7.57 (m, 3H), 7.27 (s, 1H), 7.15-7.09 (m, 2H), 7.06-6.99 (d, 1H), 5.15 (s, 2H), 4.55-4.47 (m, 2H), 4.30-4.22 (m, 2H), 3.90 (3H), 2.46 (s, 3H); MS (EI) for C28H25N5O2: 464 (MH+).

7-[4-(1H-imidazol-4-yl)phenyl]-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 3 by using 4-(4-bromophenyl)-1H-imidazole in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6); δ 12.2 (s, 1H), 7.93-7.84 (m, 3H), 7.78-7.61 (m, 5H), 7.57-7.50 (m, 1H), 7.11 (d, 1H), 7.05-7.00 (m, 2H), 5.01 (s, 2H), 4.48-4.40 (m, 2H), 4.18-4.11 (m, 2H), 3.88 (s, 3H), 2.43 (s, 3H); MS (EI) for C28H25N5O2: 464 (MH+).

7-[4-(1H-benzimidazol-2-yl)phenyl]-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 3 by using 2-(4-bromophenyl)-1H-benzo[d]imidazole in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6); δ 8.36-7.85 (m, 7H), 7.73-7.59 (m, 3H), 7.33-7.20 (m, 3H), 7.15-7.11 (m, 1H), 7.07-6.99 (m, 1H), 5.39 (s, 2H), 4.69-4.58 (m, 2H), 4.53-4.40 (m, 2H), 3.95 (s, 3H), 2.54 (s, 3H); MS (EI) for C32H27N5O2: 514 (MH+).

4-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}aniline. Prepared according to the method of example 3 by using 4-bromoaniline in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6); δ 7.89 (d, 1H), 7.51-7.47 (m, 1H), 7.37-7.28 (m, 3H), 7.11-7.08 (m, 1H), 7.04-6.99 (m, 1H), 6.96-6.92 (m, 1H), 6.65-6.60 (m, 2H), 5.19 (s, 2H), 4.95 (s, 2H), 4.41-4.35 (m, 2H), 4.15-4.09 (m, 2H), 3.88 (s, 3H), 2.43 (s, 3H); MS (EI) for C25H24N4O2: 413 (MH+).

{5-[4-(4-pyrido[3,2-d]pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)phenyl]-1H-imidazol-2-yl}methanol. Prepared according to the method of example 3 by using (4-(4-bromophenyl)-1H-imidazol-2-yl)methanol (reagent preparation 22) in step 1 and 4-chloropyrido[3,2-d]pyrimidine in step 3. 1H NMR (400 MHz, DMSO-d6) δ 12.03 (br s, 1H), 9.01 (d, 1H), 8.57 (s, 1H), 8.50 (d, 1H), 7.80 (m, 8H), 7.02 (d, 1H), 5.50 (br s, 1H), 5.20 (s, 2H), 4.52 (s, 4H), 4.34 (s, 2H); MS (EI) for C26H22N6O2: 451.1 (MH+)

7-(2,4-dimethyl-1H-benzimidazol-6-yl)-4-pyrido[3,2-d]pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 3 by using tert-butyl 6-bromo-2,4-dimethyl-1H-benzo[d]imidazole-1-carboxylate (reagent preparation 19) in step 1 and 4-chloropyrido[3,2-d]pyrimidine in step 3. 1H NMR (400 MHz, DMSO-d6) δ 12.03 (br s, 1H), 9.01 (d, 1H), 8.57 (s, 1H), 8.50 (d, 1H), 7.70 (s, 1H), 7.50 (m, 3H), 7.25 (s, 1H), 6.98 (d, 1H), 5.20 (s, 2H), 4.51 (s, 2H), 4.25 (s, 2H), 3.31 (s, 3H), 2.51 (s, 3H); MS (EI) for C25H22N6O: 423.1 (MH+).

1-(4-{7-[3,4-bis(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of example 3 by using 4-bromo-1,2-dimethoxybenzene in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6): 7.62 (d, 1H), 7.47-7.42 (m, 1H), 7.19-7.13 (m, 2H), 7.04-6.96 (m, 2H), 4.61 (s, 2H), 4.28 (t, 2H), 3.87-3.81 (m, 5H), 3.78 (s, 3H), 3.37 (s, 2H), 2.69 (t, 2H), 2.45 (s, 2H), 2.15 (s, 6H), 1.59 (t, 2H), 0.86 (s, 6H); MS (EI) for C30H38N4O3: 503 (MH+).

1-(6,6-dimethyl-4-{7-[6-(methyloxy)pyridin-3-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of example 3 by using 5-bromo-2-methoxypyridine in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6): 8.45 (d, 1H), 8.00-7.95 (m, 1H), 7.65 (d, 1H), 7.46 (m, 1H), 7.00 (d, 1H), 6.91 (d, 1H), 4.62 (s, 2H), 4.30 (m, 2H), 3.91-3.83 (m, 5H), 3.36 (m, 2H), 2.69 (t, 2H), 2.43 (s, 2H), 2.13 (s, 6H), 1.59 (t, 2H), 0.85 (s, 6H); MS (EI) for C28H35N5O2: 474 (MH+).

1-(6,6-dimethyl-4-{7-[3-(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of example 3 by using 1-bromo-3-methoxybenzene in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6): 7.66 (d, 1H), 7.50-7.45 (m, 1H), 7.36 (t, 1H), 7.22-7.18 (m, 1H), 7.15 (m, 1H), 7.00 (d, 1H), 6.93-6.88 (m, 1H), 4.62 (s, 2H), 4.29 (t, 2H), 3.85 (t, 2H), 3.81 (s, 3H), 2.68 (t, 2H), 2.44 (s, 2H), 2.12 (s, 6H), 1.59 (t, 2H), 0.85 (s, 6H); MS (EI) for C29H36N4O2: 473 (MH+).

1-[4-{7-[3,4-bis(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-7-(methyloxy)quinazolin-2-yl]-N,N-dimethylmethanamine. Prepared according to the method of example 3 using 4-bromo-1,2-dimethoxybenzene in step 1 and 1-(4-chloro-7-methoxyquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6): 7.95 (d, 1H), 7.64 (d, 1H), 7.47-7.43 (m, 1H), 7.20-7.14 (m, 3H), 7.09-7.01 (m, 2H), 6.95 (d, 1H), 5.04 (s, 2H), 4.44 (m, 2H), 4.19 (m, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.79 (s, 3H), 3.48 (s, 2H), 2.17 (s, 6H); MS (EI) for C29H32N4O4: 501 (MH+).

1-{4-[7-(1,3-benzothiazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-2-yl}-N,N-dimethylmethanamine. Synthesized according to the method of example 3 using 5-bromobenzo[d]thiazole in step 1. 1H NMR (400 MHz, d6-DMSO): 9.47 (s, 1H), 8.25 (d, 1H), 8.23 (d, 1H), 7.64 (m, 2H), 7.14 (d, 4H), 7.10 (m, 1H), 7.03 (d, 1H), 4.64 (s, 2H), 4.38-4.34 (m, 4H), 4.01 (s, 2H), 3.87 (m, 2H); MS (EI) for C31H30FN5OS: 540 (MH+).

1-{4-[7-(1,3-benzothiazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine. Synthesized according to the method of example 3 using 5-bromobenzo[d]thiazole in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO): 9.44 (s, 1H), 8.37 (d, 1H), 8.25 (d, 1H), 7.86 (d, 1H), 7.80 (dd, 1H), 7.64 (dd, 1H), 7.05 (d, 1H), 4.81 (s, 2H), 4.42 (m, 2H), 4.31 (s, 2H), 3.97 (br t, 2H), 2.80 (s, 6H), 2.75 (t, 2H), 1.62 (t, 2H), 0.86 (s, 6H); MS (EI) for C29H33N5OS: 500 (MH+).

1-{4-[7-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine. Synthesized according to the method of example 3 using 5-bromo-6-fluoro-2-methyl-1H-benzo[d]imidazole (reagent preparation 19) in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO) δ 7.88-7.78 (m, 2H), 7.69 (s, 1H), 7.42 (d, 1H), 7.06 (d, 1H), 4.90 (s, 2H), 4.48-4.39 (m, 2H), 4.33 (s, 2H), 4.06-3.99 (m, 2H), 2.80 (s, 3H), 2.79 (s, 6H), 2.75 (t, 2H), 2.48 (s, 2H), 1.59 (t, 2H), 0.85 (s, 6H); MS (EI) for C30H35FN6O: 515 (MH+).

1-(4-{7-[2-(difluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine. Synthesized according to the method of example 3 using tert-butyl 6-bromo-2-(difluoromethyl)-1H-benzo[d]imidazole-1-carboxylate (reagent preparation 19) in step 1 and 1-(4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHZ, CDCl3): 7.50-7.26 (br, 2H), 7.33 (dd, 1H), 7.25 (dd, 1H), 6.99 (d, 1H), 6.95 (tr, CHF2, 1H), 6.92-6.81 (m, 5H), 6.54 (br s, 1H), 4.10 (br s, 4H), 3.81 (s, 2H), 3.70 (s, 2H), 3.61 (tr, 2H), 2.47 (s, 6H), 2.17 (s, 3H). MS (EI) for C32H31N6OF3: 573 (MH+).

1-[4-{7-[2-(difluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6-methyl-5-(1-methylethyl)pyrimidin-2-yl]-N,N-dimethylmethanamine. Synthesized according to the method of example 3 using tert-butyl 6-bromo-2-(difluoromethyl)-1H-benzo[d]imidazole-1-carboxylate (reagent preparation 19) in step 1 and 1-(4-chloro-5-isopropyl-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHZ, CDCl3): 7.50-7.26 (br, 2H), 7.38-7.32 (br m, 2H), 7.15 (br, 1H), 7.03 (d, 1H), 6.94 (tr, CHF2, 1H), 4.13 (br s, 2H), 3.66 (s, 2H), 3.43 (br, 2H), 3.24 (m, 1H), 2.50 (s, 6H), 2.47 (s, 3H), 1.21 (d, 6H). MS (EI) for C28H32N6OF2: 507 (MH+).

1-(4-{7-[2-(difluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Synthesized according to the method of example 3 using tert-butyl 6-bromo-2-(difluoromethyl)-1H-benzo[d]imidazole-1-carboxylate (reagent preparation 19) in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHZ, CDCl3): 7.50-7.26 (br, 2H), 7.36 (br d, 1H), 7.31 (br dd, 1H), 7.20 (br, 1H), 7.02 (d, 1H), 6.97 (tr, CHF2, 1H), 4.16 (tr, 2H), 4.07 (br, 2H), 3.65 (s, 2H), 3.60 (br s, 2H), 2.73 (tr, 2H), 2.47 (s, 6H), 2.22 (br s, 2H), 1.50 (tr, 2H), 0.86 (s, 6H). MS (EI) for C30H34N6OF2: 533 (MH+).

1-(6,6-dimethyl-4-{7-[3-(methyloxy)-4-{[2-(methyloxy)ethyl]oxy}phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of example 3 by using 4-bromo-2-methoxy-1-(2-methoxyethoxy)benzene in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, (DMSO-d6): 7.62 (d, 1H), 7.47-7.43 (m, 1H), 7.18 (d, 1H), 7.15-7.11 (m, 1H), 7.04-6.95 (m, 2H), 4.60 (s, 2H), 4.28 (m, 2H), 4.10 (m, 2H), 3.87-3.82 (m, 5H), 3.67 (m, 2H), 3.36 (m, 2H), 3.32 (s, 3H), 2.69 (t, 2H), 2.45 (s, 2H), 2.14 (s, 6H), 1.59 (t, 2H), 0.86 (s, 6H); MS (EI) for C32H42N4O4: 547 (MH+).

1-(6,6-dimethyl-4-{7-[4-(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of example 3 by using 1-bromo-4-methoxybenzene in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, (DMSO-d6): 7.61-7.54 (m, 3H), 7.43-7.38 (m, 1H), 7.04-6.95 (m, 3H), 4.60 (s, 2H), 4.27 (m, 2H), 3.85 (m, 2H), 3.79 (s, 3H), 3.36 (m, 2H), 2.68 (t, 2H), 2.44 (s, 2H), 2.13 (s, 6H), 1.59 (t, 2H), 0.85 (s, 6H); MS (EI) for C29H36N4O2: 473 (MH+).

1-(4-{7-[3-chloro-4-(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of example 3 by using 4-bromo-2-chloro-1-methoxybenzene in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, (DMSO-d6): 7.70 (d, 1H), 7.65 (d, 1H), 7.62-7.57 (m, 1H), 7.48-7.43 (m, 1H), 7.22 (d, 1H), 6.98 (d, 1H), 4.60 (s, 2H), 4.28 (m, 2H), 3.89 (s, 3H), 3.85 (m, 2H), 3.36 (m, 2H), 2.69 (t, 2H), 2.44 (s, 2H), 2.13 (s, 6H), 1.59 (t, 2H), 0.86 (s, 6H); MS (EI) for C29H35ClN4O2: 507 (MH+).

Example 4 4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-propyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine

STEP 1: A mixture of 2-amino-5-bromo-3-nitropyridine (0.31 g, 1.4 mmol [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (0.50 g, 1.4 mmol), [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (103 mg, 0.1 mmol), diisopropylethylamine (0.94 g, 7.1 mmol), 1,4-dioxane (20 mL), and water (2 mL) was stirred at 90° C. for 4 hours. The reaction mixture was cooled, diluted with ethyl acetate (100 mL) then filtered through celite. The filtrate was washed with 50 mL portion each of 5% aqueous citric acid, water, then brine solution, dried over sodium sulfate, filtered and concentrated to give a brown solid residue. It was washed with 35% ethyl acetate-hexane to give 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-nitropyridin-2-amine (0.63 g, 97% yield). MS (EI) for C24H26N6O3: 447 (MH+).

STEP 2: A mixture of 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-nitropyridin-2-amine (0.63 g, 1.4 mmol), 10% palladium on charcoal (0.50 g) in 30 mL of methanol was shaken in a Parr hydrogenation at 38 psi for 18 hours. The reaction mixture was filtered through a pad of celite and concentrated to give to give 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine (0.58 g, 99% yield). MS (EI) for C24H28N6O: 417 (MH+).

STEP 3: To a solution of 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine (32 mg, 0.077 mmol) and triethylamine (11 uL, 0.077 mmol) in tetrahydrofuran (1 mL) was add butyryl chloride (7.0 uL, 0.077 mmol), and the resulting mixture was stirred at room temperature for one hour. The reaction mixture was concentrated to give N-{2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}butanamide crude product (50 mg). MS (EI) for C28H34N6O2: 487 (MH+).

STEP 4: N-{2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}butanamide (50 mg) was dissolved in acetic acid (0.2 mL) and heated in a microwave oven at 150 watts, 120° C. for 30 minutes. The reaction mixture was concentrated, dissolved in methanol (2 mL) and purified by preparative reverse phase HPLC (0.1% aqueous ammonium acetate-acetonitrile) to give 4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-propyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (12 mg, 32% yield), 1H NMR (400 MHz, Methanol-d4): 8.51 (br, 1H), 8.37 (s, 1H), 8.06 (s, 1H), 7.61 (s, 1H), 7.51 (d, 1H), 7.10 (d, 1H), 4.74 (s, 2H), 4.36 (m, 2H), 3.96 (m, 2H), 2.94 (t, 2H), 2.77 (t, 2H), 2.48 (s, 2H), 1.89 (m, 2H), 1.66 (t, 2H), 1.01 (t, 3H), 0.81 (s, 6H); MS (EI) for C28H32N6O: 469 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in steps 3 or step 4 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-ethyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 4 by omitting step 3, and using trimethyl orthopropionate and 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine in step 4. 1H NMR (400 MHz, Methanol-d4): 8.77 (br, 1H), 8.34 (s, 1H), 8.06 (s, 1H), 7.59 (s, 1H), 7.50 (d, 1H), 7.09 (d, 1H), 4.74 (s, 2H), 4.38 (m, 2H), 3.94 (m, 2H), 2.97 (q, 2H), 2.77 (t, 2H), 2.47 (s, 2H), 1.67 (t, 2H), 1.26 (t, 3H), 0.90 (s, 6H); MS (EI) for C27H30N6O: 455 (MH+).

7-(2-cyclopropyl-3H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 4 by using cyclopropylcarbonyl chloride in step 3. 1H NMR (400 MHz, Methanol-d4): 8.41 (br, 1H), 8.25 (s, 1H), 7.88 (s, 1H), 7.47 (s, 1H), 7.41 (d, 1H), 7.01 (d, 1H), 4.64 (s, 2H), 4.27 (m, 2H), 3.86 (m, 2H), 2.70 (t, 2H), 2.39 (s, 2H), 2.08 (m, 1H), 1.56 (t, 2H), 1.11 (m, 4H), 0.79 (s, 6H); MS (EI) for C28H30N6O: 467 (MH+).

7-[2-(difluoromethyl)-3H-imidazo[4,5-b]pyridin-6-yl]-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 4 by omitting step 3, and using difluoroacetic acid and 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine in step 4. 1H NMR (400 MHz, Methanol-d4): 8.70 (br, 1H), 8.34 (s, 1H), 8.23 (s, 1H), 7.64 (s, 1H), 7.55 (d, 1H), 7.12 (d, 1H), 7.05 (t, 1H), 4.63 (s, 2H), 4.37 (m, 2H), 3.95 (m, 2H), 2.79 (t, 2H), 2.49 (s, 2H), 1.66 (t, 2H), 0.88 (s, 6H); MS (EI) for C26H26F2N6O: 477 (MH+).

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-[2-(fluoromethyl)-3H-imidazo[4,5-b]pyridin-6-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine hydrochloride. Prepared according to the method of example 4 by omitting step 3, and using fluoroacetic acid and 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine in step 4. 1H NMR (400 MHz, Methanol-44): 8.66 (br, 1H), 8.52 (s, 1H), 8.21 (s, 1H), 7.74 (s, 1H), 7.56 (d, 1H), 7.09 (d, 1H), 5.69 (d, 1H), 5.13 (s, 2H), 4.47 (m, 2H), 4.32 (m, 2H), 2.84 (t, 2H), 2.61 (s, 2H), 1.69 (t, 2H), 0.94 (s, 6H); MS (EI) for C26H27FN6O: 459 (MH+).

7-[2-(difluoromethyl)-1H-benzimidazol-5-yl]-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 4 by omitting step 3, and using difluoroacetic acid and 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine in step 4. 1H NMR (400 MHz, DMSO-d6): 8.38 (s, 1H), 7.83 (br, 1H), 7.74 to 7.67 (m, 2H), 7.61 (d, 1H), 7.54 (d, 1H), 7.31 (t, 1H), 7.05 (d, 1H), 4.64 (s, 2H), 4.33 (m, 2H), 3.80 (m, 2H), 2.70 (t, 2H), 2.47 (s, 2H), 1.60 (t, 2H), 0.83 (s, 6H); MS (EI) for C27H27F2N5O: 476 (MH+).

Example 5 4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine

STEP 1: A solution of 6-bromo-2-methyl-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazo[4,5-b]pyridine (reagent preparation 35) (0.43 g, 1.30 mmol), [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) (0.45 g, 1.30 mmol) and N,N-diisopropylethylamine (1.10 mL, 6.50 mmol) in N,N-dimethylformamide (4 mL), and water (1 mL) was degassed by bubbling nitrogen gas for five minutes followed by the addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (52 mg, 0.065 mmol), then stirred at 95° C. for 16 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (100 mL), and filtered through a pad of Celite. The filtrate was washed with 1M aqueous lithium chloride (50 mL) and brine, dried over sodium sulfate, filtered and concentrated. Column chromatography on silica (gradient 1-2% 7N ammonia in methanol in chloroform) gave 4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-[2-methyl-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazo[4,5-b]pyridin-6-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine (0.54 g, 73% yield). MS (EI) for C32H42N6O2Si: 571 (MH+).

STEP 2: A solution of 4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-[2-methyl-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazo[4,5-b]pyridin-6-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine (0.54 g, 0.95 mmol) in a mixture of methanol (30 mL) and concentrated hydrochloric acid (1 mL) was stirred at reflux for 16 hours. On cooling to room temperature the solution was concentrated and the pH was adjusted to ˜9 by the addition of 50% aqueous sodium hydroxide and diluted with ethyl acetate (100 mL). The organic layer was washed with 2M aqueous sodium hydroxide (20 mL) and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The precipitating white solid was collected by filtration and washed with hexane to provide 4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (0.28 g, 67%). 1H NMR (400 MHz, d6-DMSO): 8.53 (d, 1H), 8.38 (s, 1H), 8.03 (d, 1H), 7.70 (d, 1H), 7.54 (dd, 1H), 7.05 (d, 1H), 4.63 (s, 2H), 4.33 (m, 2H), 3.85 (m, 2H), 2.72 (m, 2H), 2.58 (s, 3H), 2.47 (s, 2H), 1.60 (m, 2H), 0.86 (s, 6H); MS (EI) for C26H28N6O: 441 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in steps 1 and conducting protecting group removal in step 2 as required according to literature techniques appropriate for a given protecting group (see for example: Greene and Wuts, Protective Groups in Organic Synthetic, Wiley-Interscience) the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl][1,3]thiazolo[5,4-b]pyridin-2-amine. Prepared according to the method of example 5 by using N-(6-bromo[1,3]thiazolo[5,4-b]pyridin-2-yl)acetamide (Journal of Heterocyclic Chemistry (2003), 40, 261-268) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.38 (m, 2H), 7.88 (brs, 2H), 7.83 (d, 1H), 7.72 (d, 1H), 7.76 (dd, 1H), 7.05 (d, 1H), 4.63 (s, 2H), 4.33 (m, 2H), 3.83 (m, 2H), 2.72 (m, 2H), 2.46 (s, 2H), 1.61 (m, 2H), 0.83 (s, 6H); MS (EI) for C25H26N6OS: 459 (MH+).

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(1H-pyrazolo[3,4-b]pyridin-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 5 by using 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine (reagent preparation 32) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO): 13.71 (s, 1H), 8.82 (d, 1H), 8.43 (d, 1H), 8.38 (s, 1H), 8.18 (d, 1H), 7.74 (d, 1H), 7.58 (dd, 1H), 7.07 (d, 1H), 4.66 (s, 2H), 4.34 (m, 2H), 3.85 (m, 2H), 2.71 (m, 2H), 2.45 (s, 2H), 1.59 (m, 2H), 0.84 (s, 6H); MS (EI) for C25H26N6O: 427 (MH+).

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 5 by using 6-bromo-1-(triphenylmethyl)-1H-imidazo[4,5-b]pyridine (reagent preparation 15) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.64 (s, 1H), 8.48 (s, 1H), 8.39 (s, 1H), 8.22 (brs, 1H), 7.75 (d, 1H), 7.58 (dd, 1H), 7.06 (d, 1H), 4.67 (s, 2H), 4.35 (m, 2H), 3.85 (m, 2H), 2.72 (m, 2H), 2.46 (s, 2H), 1.61 (m, 2H), 0.85 (s, 6H); MS (EI) for C25H26N6O: 427 (MH+).

3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared according to the method of example 5 by using [4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) and 1,1-dimethylethyl {(3R)-1-[(2-amino-5-bromopyridin-3-yl)sulfonyl]pyrrolidin-3-yl}carbamate (reagent preparation 25) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.57 (d, 1H), 8.41 (s, 1H), 8.02 (d, 1H), 7.58 (d, 1H), 7.47 (dd, 1H), 7.02 (d, 1H), 6.75 (brs, 2H), 6.26 (dd, 2H), 4.63 (s, 2H), 4.33 (m, 2H), 3.84 (m, 2H), 3.37 (m, 2H), 3.27 (m, 2H), 2.89 (m, 1H), 2.71 (s, 2H), 1.86 (m, 3H), 1.53 (m, 1H), 0.95 (s, 6H); MS (EI) for C28H33N7O3S: 548 (MH+).

3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine. Prepared according to the method of example 5 by using {4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) and 1,1-dimethylethyl {(3R)-1-[(2-amino-5-bromopyridin-3-yl)sulfonyl]pyrrolidin-3-yl}carbamate (reagent preparation 25) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.53 (d, 1H), 8.33 (s, 1H), 7.99 (d, 1H), 7.57 (d, 1H), 7.44 (dd, 1H), 7.01 (d, 1H), 6.75 (brs, 2H), 4.70 (dd, 2H), 4.36 (m, 1H), 4.24 (m, 1H), 3.86 (m, 2H), 3.36 (m, 2H), 3.26 (m, 2H), 2.87, 2.83 (m, dd, 3H), 2.27 (dd, 1H), 1.89 (m, 3H), 1.68 (m, 1H), 1.52 (m, 1H), 1.37 (m, 2H), 1.11 (m, 1H), 0.94 (t, 3H); MS (EI) for C28H35N7O3S: 550 (MH+).

2-amino-N-(2-amino-2-methylpropyl)-5-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridine-3-sulfonamide. Prepared according to the method of example 5 by using {4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) and 2-amino-N-(2-amino-2-methylpropyl)-5-bromopyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.48 (d, 1H), 8.33 (s, 1H), 8.01 (d, 1H), 7.54 (d, 1H), 7.42 (dd, 1H), 7.01 (d, 1H), 7.72 (brs, 2H), 4.69 (dd, 2H), 4.37 (m, 1H), 4.23 (m, 1H), 3.85 (m, 2H), 2.93 (m, 2H), 2.60 (s, 2H), 2.27 (dd, 1H), 1.87 (m, 1H), 1.70 (m, 1H), 1.35 (m, 2H), 1.10 (m, 1H), 0.93 (t, 3H), 0.92 (s, 6H); MS (EI) for C28H37N7O3S: 552 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as hydrochloride, according to the method of example 5 by using {4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) and 6-bromo-2-methyl-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazo[4,5-b]pyridine (reagent preparation 35) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.84 (d, 1H), 8.78 (s, 1H), 8.39 (d, 1H), 8.24 (brd, 1H), 7.95 (d, 1H), 7.68 (dd, 1H), 7.35 (d, 1H), 7.31 (s, 1H), 7.04 (d, 1H), 5.46 (s, 2H), 4.68 (m, 2H), 4.50 (m, 2H), 3.96 (s, 3H), 2.78 (s, 3H); MS (EI) for C25H22N6O2: 439 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[2-(methyloxy)ethyl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(2-methoxyethyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, 1H), 8.37 (s, 1H), 8.06 (d, 1H), 7.96 (br s, 1H), 7.59 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.69 (br s, 2H), 4.62 (s, 2H), 4.35-4.28 (m, 2H), 3.86-3.80 (m, 2H), 3.29 (t, 2H), 3.15 (s, 3H), 2.94 (t, 2H), 2.71 (t, 2H), 2.44 (s, 2H), 1.60 (t, 2H), 0.84 (s, 6H); MS (EI) for C27H34N6O4S: 539 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2,2,2-trifluoroethyl)pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(2,2,2-trifluoroethyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.43 (d, 1H), 8.36 (s, 1H), 8.04 (d, 1H), 7.56 (s, 1H), 7.46-7.39 (m, 2H), 7.02 (d, 1H), 6.56 (br s, 2H), 5.16-5.07 (m, 2H), 4.62 (s, 2H), 4.35-4.26 (m, 2H), 3.86-3.80 (m, 2H), 2.71 (t, 2H), 2.45 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C26H29F3N6O3S: 563 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxyethyl)-N-methylpyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(2-hydroxyethyl)-N-methylpyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.54 (d, 1H), 8.37 (s, 1H), 8.00 (d, 1H), 7.60 (d, 1H), 7.47 (dd, 1H), 7.02 (d, 1H), 6.79 (br s, 2H), 4.87 (t, 1H), 4.62 (s, 2H), 4.35-4.28 (m, 2H), 3.89-3.77 (m, 2H), 3.54 (q, 2H), 3.19 (t, 2H), 2.79 (s, 3H), 2.71 (s, 2H), 2.45 (s, 2H), 1.61 (d, 2H), 0.85 (s, 6H); MS (EI) for C27H34N6O4S: 539 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxypropyl)pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(2-hydroxypropyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.05 (d, 1H), 7.58 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.71 (br s, 2H), 4.62 (s, 2H), 4.35-4.27 (m, 2H), 3.87-3.80 (m, 2H), 3.63-3.55 (m, 1H), 2.75-2.64 (m, 4H), 2.44 (s, 2H), 1.60 (t, 2H), 0.98 (d, 3H), 0.84 (d, 6H); MS (EI) for C27H34N6O4S: 539 (MH+).

2-amino-N-azetidin-3-yl-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared as a diacetate salt according to the method of example 5 by using tert-butyl 3-(2-amino-5-bromopyridine-3-sulfonamido)azetidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, 1H), 8.37 (s, 1H), 8.03 (d, 1H), 7.59 (d, 1H), 7.45 (dd, 1H), 7.03 (d, 1H), 6.70 (br s, 2H), 4.62 (s, 2H), 4.35-4.27 (m, 2H), 4.00-3.90 (m, 1H), 3.86-3.79 (m, 2H), 3.25 (d, 4H), 2.71 (t, 2H), 2.44 (s, 2H), 1.88 (s, 6H), 1.60 (t, 2H), 0.84 (s, 6H); MS (EI) for C27H33N7O3S: 536 (MH+).

2-amino-N-(2,3-dihydroxypropyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(2,3-dihydroxypropyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.05 (d, 1H), 7.58 (d, 1H), 7.44 (dd, 1H), 7.02 (d, 1H), 6.72 (br s, 2H), 4.85 (br s, 1H), 4.66-4.51 (m, 3H), 4.36-4.26 (m, 2H), 3.87-3.78 (m, 2H), 3.50-3.43 (m, 1H), 3.29-3.19 (m, 2H), 2.90 (dd, 1H), 2.71 (t, 2H), 2.62 (dd, 1H), 2.44 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C27H34N6O5S: 555 (MH+).

1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)piperidin-3-ol. Prepared according to the method of example 5 by using 1-(2-amino-5-bromopyridin-3-ylsulfonyl)piperidin-3-ol (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.56 (d, 1H), 8.37 (s, 1H), 7.94 (d, 1H), 7.59 (d, 1H), 7.47 (dd, 1H), 7.03 (d, 1H), 6.78 (br s, 2H), 5.00 (d, 1H), 4.62 (s, 2H), 4.36-4.27 (m, 2H), 3.88-3.78 (m, 2H), 3.60-3.43 (m, 2H), 3.42-3.29 (m, 1H), 2.71 (t, 2H), 2.60 (t, 1H), 2.47-2.42 (m, 3H), 1.79-1.67 (m, 2H), 1.60 (t, 2H), 1.50-1.36 (m, 1H), 1.26-1.12 (m, 1H), 0.84 (s, 6H); MS (EI) for C29H36N6O4S: 565 (MH+).

2-amino-N-(3-amino-2,2-dimethylpropyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared as an acetate salt according to the method of example 5 by using 2-amino-N-(3-amino-2,2-dimethylpropyl)-5-bromopyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.05 (d, 1H), 7.58 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.71 (br s, 2H), 4.62 (s, 2H), 4.35-4.26 (m, 2H), 3.87-3.78 (m, 2H), 2.71 (t, 2H), 2.58 (s, 2H), 2.44 (s, 2H), 2.34 (s, 2H), 1.88 (s, 3H), 1.59 (t, 2H), 0.84 (s, 6H), 0.75 (s, 6H); MS (EI) for C29H39N7O3S: 566 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(3-hydroxy-2,2-dimethylpropyl)pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(3-hydroxy-2,2-dimethylpropyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.04 (d, 1H), 7.62-7.55 (m, 2H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.72 (br s, 2H), 4.62 (s, 2H), 4.50 (t, 1H), 4.34-4.28 (m, 2H), 3.86-3.79 (m, 2H), 3.08 (d, 2H), 2.71 (t, 2H), 2.58 (d, 2H), 2.44 (s, 2H), 1.60 (t, 2H), 0.84 (s, 6H), 0.75 (s, 6H); MS (EI) for C29H38N6O4S: 567 (MH+).

N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide. Prepared according to the method of example 5 by using N-(5-bromopyridin-3-yl)methanesulfonamide (reagent preparation 26) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 10.11 (s, 1H), 8.61 (d, 1H), 8.42-8.33 (m, 2H), 7.79 (t, 1H), 7.67 (d, 1H), 7.51 (dd, 1H), 7.08 (d, 1H), 4.67 (s, 2H), 4.39-4.32 (m, 2H), 3.88-3.81 (m, 2H), 3.11 (s, 3H), 2.71 (t, 2H), 2.43 (s, 2H), 1.59 (t, 2H), 0.84 (s, 6H); MS (EI) for C25H29N5O3S: 480 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxy-1,1-dimethylethyl)pyridine-3-sulfonamide. Prepared as an acetate salt according to the method of example 5 by using 2-amino-5-bromo-N-(1-hydroxy-2-methylpropan-2-yl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.48 (d, 1H), 8.37 (s, 1H), 8.09 (d, 1H), 7.56 (d, 1H), 7.43 (dd, 1H), 7.02 (d, 1H), 6.69 (br s, 2H), 4.61 (s, 2H), 4.35-4.28 (m, 2H), 3.88-3.79 (m, 2H), 3.21 (s, 2H), 2.71 (t, 2H), 2.44 (s, 2H), 1.82 (s, 3H), 1.60 (t, 2H), 1.03 (s, 6H), 0.84 (s, 6H); MS (EI) for C28H36N6O4S: 553 (MH+).

2-chloro-N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}-6-methylbenzenesulfonamide. Prepared according to the method of example 5 by using N-(5-bromo-2-chloropyridin-3-yl)-2-chloro-6-methylbenzenesulfonamide (reagent preparation 26) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.48 (br s, 1H), 8.39 (s, 1H), 7.94 (d, 1H), 7.62 (d, 1H), 7.51-7.41 (m, 3H), 7.34 (dd, 1H), 7.06 (d, 1H), 4.68 (s, 2H), 4.41-4.34 (m, 2H), 3.90-3.83 (m, 2H), 2.71 (t, 2H), 2.52 (s, 3H), 2.40 (s, 2H), 1.59 (t, 2H), 0.82 (s, 6H); MS (EI) for C31H31Cl2N5O3S: 624, 626 (Cl isotopes, MH+).

N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-fluoropyridin-3-yl}methanesulfonamide. Prepared according to the method of example 5 by using N-(5-bromo-2-fluoropyridin-3-yl)methanesulfonamide (reagent preparation 26) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.27 (s, 1H), 8.07 (d, 1H), 7.68 (s, 1H), 7.53 (d, 1H), 7.08 (d, 1H), 4.67 (s, 2H), 4.40-4.32 (m, 2H), 3.89-3.82 (m, 2H), 3.15 (s, 3H), 2.71 (t, 2H), 2.43 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C25H28FN5O3S: 498 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(piperidin-4-ylmethyl)pyridine-3-sulfonamide. Prepared as an acetate salt according to the method of example 5 by using tert-butyl 4-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, 1H), 8.37 (s, 1H), 8.05 (d, 1H), 7.59 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.68 (br s, 2H), 4.62 (s, 2H), 4.35-4.28 (m, 2H), 3.87-3.79 (m, 2H), 2.97-2.87 (m, 2H), 2.71 (t, 2H), 2.63 (d, 2H), 2.39 (dd, 4H), 1.84 (s, 3H), 1.64-1.51 (m, 4H), 1.51-1.35 (m, 1H), 1.04-0.90 (m, 2H), 0.84 (s, 6H); MS (EI) for C30H39N7O3S: 578 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(1-methylpiperidin-4-yl)methyl]pyridine-3-sulfonamide. Prepared as a diacetate salt according to the method of example 5 by using 2-amino-5-bromo-N-((1-methylpiperidin-4-yl)methyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, 1H), 8.37 (s, 1H), 8.04 (d, 1H), 7.58 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.67 (br s, 2H), 4.62 (s, 2H), 4.36-4.28 (m, 2H), 3.87-3.79 (m, 2H), 2.76-2.60 (m, 6H), 2.44 (s, 2H), 2.08 (s, 3H), 1.89 (s, 6H), 1.75-1.66 (m, 2H), 1.63-1.52 (m, 4H), 1.32-1.20 (m, 1H), 1.10-0.95 (m, 2H), 0.84 (s, 6H); MS (EI) for C31H41N7O3S: 592 (MH+).

2-amino-N-[(1-aminocyclopropyl)methyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared as a diacetate salt according to the method of example 5 by using tert-butyl 1-((2-amino-5-bromopyridine-3-sulfonamido)methyl)cyclopropylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.05 (d, 1H), 7.58 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.70 (br s, 2H), 4.62 (s, 2H), 4.34-4.27 (m, 2H), 3.86-3.79 (m, 2H), 2.77 (s, 2H), 2.70 (t, 2H), 2.44 (s, 2H), 1.89 (s, 6H), 1.59 (t, 2H), 0.84 (s, 6H), 0.32 (d, 1H); MS (EI) for C28H35N7O3S: 550 (MH+).

2-amino-N-(trans-4-aminocyclohexyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using tert-butyl trans-4-(2-amino-5-bromopyridine-3-sulfonamido)cyclohexylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, 1H), 8.37 (s, 1H), 8.07 (d, 1H), 7.59 (d, 1H), 7.46 (dd, 1H), 7.03 (d, 1H), 6.66 (br s, 2H), 4.62 (s, 2H), 4.35-4.28 (m, 2H), 3.87-3.80 (m, 2H), 2.89-2.78 (m, 1H), 2.71 (t, 2H), 2.44 (s, 2H), 2.42-2.36 (m, 1H), 1.68-1.55 (m, 6H), 1.27-1.07 (m, 2H), 0.98-0.81 (m, 8H); MS (EI) for C30H39N7O3S: 578 (MH+).

2-amino-N-[(1-methylpiperidin-4-yl)methyl]-5-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared as a diacetate salt according to the method of example 5 by using [4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) and 2-amino-5-bromo-N-((1-methylpiperidin-4-yl)methyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, 1H), 8.05 (d, 1H), 7.60 (d, 1H), 7.45 (dd, 1H), 7.03 (d, 1H), 6.67 (br s, 2H), 4.57 (s, 2H), 4.30-4.24 (m, 2H), 3.86-3.79 (m, 2H), 2.70-2.61 (m, 6H), 2.40 (s, 2H), 2.33 (s, 3H), 2.08 (s, 3H), 1.87 (s, 6H), 1.69 (t, 2H), 1.62-1.50 (m, 4H), 1.32-1.19 (m, 1H), 1.08-0.95 (m, 2H), 0.84 (s, 6H); MS (EI) for C32H43N7O3S: 606 (MH+).

2-amino-N-[(1-methylpiperidin-4-yl)methyl]-5-[4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using [4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) and 2-amino-5-bromo-N-((1-methylpiperidin-4-yl)methyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.03 (d, 1H), 7.84 (t, 1H), 7.55 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.67 (br s, 2H), 6.13 (d, 1H), 4.62 (s, 2H), 4.37-4.29 (m, 2H), 3.88-3.78 (m, 2H), 2.72-2.60 (m, 6H), 2.07 (s, 3H), 1.88 (s, 3H), 1.74-1.62 (m, 2H), 1.61-1.50 (m, 2H), 1.34-1.16 (m, 1H), 1.09-0.95 (m, 2H), 0.91 (s, 6H); MS (EI) for C32H41N7O3S: 604 (MH+).

2-amino-N-(2-aminopropyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using benzyl 1-(2-amino-5-bromopyridine-3-sulfonamido)propan-2-ylcarbamate (reagent preparation 25) in step 1 followed by Cbz deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.49 (d, 1H), 8.37 (s, 1H), 8.04 (d, 1H), 7.58 (s, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.69 (br s, 2H), 4.62 (s, 2H), 4.35-4.27 (m, 2H), 3.87-3.79 (m, 2H), 3.01 (t, 2H), 2.71 (s, 2H), 2.60 (t, 1H), 2.45 (s, 2H), 1.78-1.70 (m, 3H), 1.60 (s, 2H), 0.85 (s, 6H); MS (EI) for C27H35N7O3S: 538 (MH+).

N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}acetamide. Prepared according to the method of example 5 by using N-(5-bromo-2-chloropyridin-3-yl)acetamide (reagent preparation 26) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H), 8.68 (s, 1H), 8.52 (d, 1H), 8.43 (d, 1H), 7.77 (d, 1H), 7.57 (dd, 1H), 7.04 (d, 1H), 5.08 (s, 2H), 4.54-4.45 (m, 2H), 4.23-4.13 (m, 2H), 2.77 (t, 2H), 2.54 (s, 2H), 2.17 (d, 3H), 1.58 (t, 2H), 0.86 (s, 6H); MS (EI) for C26H28ClN5O2: 478 (MH+).

methyl {2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}carbamate. Prepared according to the method of example 5 by using methyl 5-bromo-2-chloropyridin-3-ylcarbamate (reagent preparation 26) in step 1. 1H NMR (400 MHz, CD3OD) δ 8.56 (d, 1H), 8.36-8.31 (m, 2H), 7.60 (d, 1H), 7.51 (dd, 1H), 7.09 (d, 1H), 4.73 (s, 2H), 4.40-4.32 (m, 2H), 4.00-3.92 (m, 2H), 3.82 (s, 3H), 2.80 (t, 2H), 2.48 (s, 2H), 1.69 (t, 2H), 0.90 (s, 6H); MS (EI) for C26H28ClN5O3: 494 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-ethylpyridine-3-sulfonamide. Prepared by the method of example 5 using 2-amino-5-bromo-N-ethylpyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.04 (d, 1H), 7.79 (br s, 1H), 7.61-7.48 (m, 2H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.67 (br s, 2H), 4.62 (s, 2H), 4.36-4.27 (m, 2H), 3.88-3.77 (m, 2H), 2.80 (q, 2H), 2.70 (t, 2H), 2.44 (s, 2H), 1.60 (t, 2H), 0.97 (t, 3H), 0.84 (s, 6H); MS (EI) for C26H32N6O3S: 509 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(1-methylethyl)pyridine-3-sulfonamide. Prepared by the method of example 5 using 2-amino-5-bromo-N-isopropylpyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.49-8.43 (m, 1H), 8.37 (s, 1H), 8.05 (d, 1H), 7.76 (br s, 1H), 7.57 (d, 1H), 7.44 (dd, 1H), 7.02 (d, 1H), 6.66 (br s, 2H), 4.61 (s, 2H), 4.35-4.27 (m, 2H), 3.86-3.79 (m, 2H), 3.24-3.13 (m, 1H), 2.69 (t, 2H), 2.44 (s, 2H), 1.59 (t, 2H), 0.96 (d, 6H), 0.84 (s, 6H); MS (EI) for C27H34N6O3S: 523 (MH+).

2-amino-N-[2-(dimethylamino)ethyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared by the method of example 5 using 2-amino-5-bromo-N-(2-(dimethylamino)ethyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.42 (d, 1H), 8.36 (s, 1H), 8.02 (d, 1H), 7.72 (br s, 1H), 7.56 (d, 1H), 7.42 (dd, 1H), 7.01 (d, 1H), 6.69 (br s, 2H), 4.61 (s, 2H), 4.34-4.27 (m, 2H), 3.87-3.79 (m, 2H), 2.80 (t, 2H), 2.71 (t, 2H), 2.44 (s, 2H), 2.20 (t, 2H), 2.03 (s, 6H), 1.59 (t, 2H), 0.84 (s, 6H); MS (EI) for C28H37N7O3S: 552 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxyethyl)pyridine-3-sulfonamide. Prepared by the method of example 5 using 2-amino-5-bromo-N-(2-hydroxyethyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.48 (d, 1H), 8.37 (s, 1H), 8.04 (d, 1H), 7.87 (br s, 1H), 7.58 (d, 1H), 7.44 (dd, 1H), 7.02 (d, 1H), 6.69 (br s, 2H), 4.70 (br s, 1H), 4.62 (s, 2H), 4.36-4.27 (m, 2H), 3.87-3.80 (m, 2H), 3.36 (t, 2H), 2.80 (t, 2H), 2.71 (t, 2H), 2.44 (s, 2H), 1.60 (t, 2H), 0.84 (s, 6H); MS (EI) for C26H32N6O4S: 525 (MH+).

1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-3-(hydroxymethyl)azetidin-3-ol. Prepared by the method of example 5 using 1-(2-amino-5-bromopyridin-3-ylsulfonyl)-3-(hydroxymethyl)azetidin-3-ol (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (d, 1H), 8.37 (s, 1H), 7.99 (d, 1H), 7.61 (d, 1H), 7.50 (dd, 1H), 7.03 (d, 1H), 6.79 (br s, 2H), 5.74 (br s, 1H), 4.94 (br s, 1H), 4.62 (s, 2H), 4.35-4.27 (m, 2H), 3.88-3.73 (m, 4H), 3.54 (d, 2H), 3.32 (s, 2H), 2.71 (t, 2H), 2.46 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C28H34N6O5S: 567 (MH+).

N2-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)glycinamide. Prepared by the method of example 5 using 2-(2-amino-5-bromopyridine-3-sulfonamido)acetamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.08 (br s, 1H), 8.05 (d, 1H), 7.58 (d, 1H), 7.45 (dd, 1H), 7.31 (br s, 1H), 7.12 (br s, 1H), 7.02 (d, 1H), 6.75 (br s, 2H), 4.62 (s, 2H), 4.35-4.27 (m, 2H), 3.88-3.79 (m, 2H), 3.43 (s, 2H), 2.71 (t, 2H), 2.45 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C26H31N7O4S: 538 (MH+).

(3R)-1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-ol. Prepared by the method of example 5 using (R)-1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ol (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.54 (d, 1H), 8.37 (s, 1H), 8.00 (d, 1H), 7.59 (d, 1H), 7.47 (dd, 1H), 7.02 (d, 1H), 6.76 (s, 2H), 5.03 (d, 1H), 4.62 (s, 2H), 4.35-4.28 (m, 2H), 4.27-4.20 (m, 1H), 3.86-3.80 (m, 2H), 3.45-3.27 (m, 4H (buried)), 3.16-3.10 (m, 1H), 2.71 (t, 2H), 2.45 (s, 2H), 1.93-1.81 (m, 1H), 1.73 (s, 1H), 1.60 (t, 2H), 0.85 (s, 6H), 0.85 (s, 6H); MS (EI) for C28H34N6O4S: 551 (MH+).

(3R)-1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-ol. Prepared by the method of example 5 using tert-butyl 3-(2-amino-5-bromopyridine-3-sulfonamido)-2-hydroxypropylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.05 (d, 1H), 7.58 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.71 (br s, 2H), 4.62 (s, 2H), 4.35-4.26 (m, 2H), 3.87-3.77 (m, 2H), 3.43-3.23 (m, 2H (buried)), 2.82 (dd, 1H), 2.75-2.61 (m, 3H), 2.47-2.37 (m, 3H), 1.60 (t, 2H), 0.84 (s, 6H); MS (EI) for C27H35N7O4S: 554 (MH+).

3-{[3-(dimethylamino)azetidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared by the method of example 5 using 5-bromo-3-(3-(dimethylamino)azetidin-1-ylsulfonyl)pyridin-2-amine (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.62 (d, 1H), 8.37 (s, 1H), 8.00 (d, 1H), 7.63 (d, 1H), 7.50 (dd, 1H), 7.03 (d, 1H), 6.82 (br s, 2H), 4.62 (s, 2H), 4.36-4.29 (m, 2H), 3.87-3.78 (m, 4H), 3.63-3.56 (m, 2H), 3.02 (p, 1H), 2.71 (t, 2H), 2.45 (s, 2H), 1.94 (s, 6H), 1.59 (t, 2H), 0.84 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxyethyl)-2-(methylamino)pyridine-3-sulfonamide. Prepared by the method of example 5 using 5-bromo-N-(2-hydroxyethyl)-2-(methylamino)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.60 (d, 1H), 8.37 (s, 1H), 8.06 (d, 1H), 7.85 (t, 1H), 7.58 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.57 (q, 1H), 4.76 (t, 1H), 4.62 (s, 2H), 4.35-4.28 (m, 2H), 3.87-3.80 (m, 2H), 3.37 (q, 2H), 2.97 (d, 3H), 2.81 (q, 2H), 2.71 (t, 2H), 2.44 (s, 2H), 1.60 (t, 2H), 0.84 (s, 6H); MS (EI) for C27H34N6O4S: 539 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-{[3-(methylamino)azetidin-1-yl]sulfonyl}pyridin-2-amine. Prepared by the method of example 5 using N-(1-(2-amino-5-bromopyridin-3-ylsulfonyl)azetidin-3-yl)-N-methyl-2-nitrobenzenesulfonamide (reagent preparation 25) in step 1 followed by 2-benzenesulfonyl-group deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (d, 1H), 8.37 (s, 1H), 7.98 (d, 1H), 7.62 (d, 1H), 7.49 (dd, 1H), 7.03 (d, 1H), 6.79 (br s, 2H), 4.62 (s, 2H), 4.35-4.29 (m, 2H), 3.90-3.80 (m, 4H), 3.54-3.45 (m, 2H), 3.43-3.35 (m, 1H), 2.71 (t, 2H), 2.45 (s, 2H), 2.07 (s, 3H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C28H35N7O3S: 550 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(piperazin-1-ylsulfonyl)pyridin-2-amine. Prepared by the method of example 5 using tert-butyl 4-(2-amino-5-bromopyridin-3-ylsulfonyl)piperazine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.57 (d, 1H), 8.37 (s, 1H), 7.92 (d, 1H), 7.60 (d, 1H), 7.47 (dd, 1H), 7.03 (d, 1H), 6.80 (br s, 2H), 4.62 (s, 2H), 4.36-4.29 (m, 2H), 3.87-3.78 (m, 2H), 2.99-2.90 (m, 4H), 2.75-2.65 (m, 6H), 2.44 (s, 2H), 1.59 (t, 2H), 0.84 (s, 6H); MS (EI) for MS (EI) for C28H35N7O3S: 550 (MH+).

N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]phenyl}methanesulfonamide. Prepared by the method of example 5 using N-(5-bromo-2-chlorophenyl)methanesulfonamide (reagent preparation 26) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 9.58 (s, 1H), 8.35 (s, 1H), 7.68-7.57 (m, 3H), 7.56-7.45 (m, 2H), 7.05 (d, 1H), 4.65 (s, 2H), 4.37-4.29 (m, 2H), 3.88-3.80 (m, 2H), 3.07 (s, 3H), 2.70 (t, 2H), 2.43 (s, 2H), 1.59 (t, 2H), 0.84 (s, 6H); MS (EI) for C26H29ClN4O3S: 513 (MH+).

3-[(3-amino-3-methylazetidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared by the method of example 5 using 3-(3-amino-3-methylazetidin-1-ylsulfonyl)-5-bromopyridin-2-amine (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (d, 1H), 8.37 (s, 1H), 7.98 (d, 1H), 7.61 (d, 1H), 7.49 (dd, 1H), 7.03 (d, 1H), 6.78 (br s, 2H), 4.62 (s, 2H), 4.36-4.28 (m, 2H), 3.87-3.79 (m, 2H), 3.60-3.48 (m, 4H), 2.71 (t, 2H), 2.45 (s, 2H), 2.02 (s, 2H), 1.60 (t, 2H), 1.19 (s, 3H), 0.85 (s, 6H); MS (EI) for MS (EI) for C28H35N7O3S: 550 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-[(methylsulfonyl)methyl]pyridin-2-amine. Prepared by the method of example 5 using 5-bromo-3-(methylsulfonylmethyl)pyridin-2-amine (reagent preparation 27) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.28 (d, 1H), 7.73 (d, 1H), 7.53 (d, 1H), 7.37 (dd, 1H), 7.01 (d, 1H), 6.22 (s, 2H), 4.60 (s, 2H), 4.47 (s, 2H), 4.34-4.25 (m, 2H), 3.87-3.80 (m, 2H), 2.95 (s, 3H), 2.71 (t, 2H), 2.45 (s, 2H), 1.60 (t, 2H), 0.86 (s, 6H); MS (EI) for C26H31N5O3S: 494 (MH+).

7-{6-chloro-5-[(methylsulfonyl)methyl]pyridin-3-yl}-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared by the method of example 5 using 5-bromo-2-chloro-3-(methylsulfonylmethyl)pyridine (reagent preparation 27) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.74 (d, 1H), 8.36 (s, 1H), 8.23 (d, 1H), 7.73 (d, 1H), 7.57 (dd, 1H), 7.10 (d, 1H), 4.72 (s, 2H), 4.68 (s, 2H), 4.40-4.33 (m, 2H), 3.88-3.81 (m, 2H), 3.11 (s, 3H), 2.71 (t, 2H), 2.42 (s, 2H), 1.59 (t, 2H), 0.84 (s, 6H); MS (EI) for C26H29ClN4O3S: 513 (MH+).

2-amino-N-(2-amino-1,1-dimethylethyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared as an acetate salt by the method of example 5 using tert-butyl 2-(2-amino-5-bromopyridine-3-sulfonamido)-2-methylpropylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.49 (d, 1H), 8.37 (s, 1H), 8.08 (d, 1H), 7.56 (d, 1H), 7.44 (dd, 1H), 7.02 (d, 1H), 6.68 (br s, 2H), 4.61 (s, 2H), 4.35-4.27 (m, 2H), 3.87-3.79 (m, 2H), 2.71 (t, 2H), 2.44 (s, 2H), 2.42 (s, 2H), 1.89 (s, 4H), 1.60 (t, 2H), 1.02 (s, 6H), 0.84 (s, 6H); MS (EI) for C28H37N7O3S: 552 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]pyridine-3-sulfonamide. Prepared by the method of example 5 using tert-butyl 5-((2-amino-5-bromopyridine-3-sulfonamido)methyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, 1H), 8.37 (s, 1H), 8.03 (d, 1H), 7.77 (br s, 1H), 7.58 (d, 1H), 7.44 (dd, 1H), 7.02 (d, 1H), 6.68 (br s, 2H), 4.62 (s, 2H), 4.36-4.26 (m, 2H), 3.88-3.77 (m, 2H), 2.79-2.63 (m, 3H), 2.54-2.34 (m, 9H), 1.95-1.82 (m, 3H), 1.82-1.70 (m, 1H), 1.59 (t, 2H), 0.82 (s, 6H), 0.80-0.67 (m, 2H); MS (EI) for C32H41N7O3S: 604 (MH+).

2-amino-N-(2-aminobutyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared by the method of example 5 using tert-butyl 1-(2-amino-5-bromopyridine-3-sulfonamido)butan-2-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.04 (d, 1H), 7.58 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.70 (br s, 2H), 4.62 (s, 2H), 4.35-4.27 (m, 2H), 3.86-3.79 (m, 2H), 2.75-2.65 (m, 4H), 2.62-2.54 (m, 1H), 2.48-2.41 (m, 3H), 1.64-1.55 (m, 4H), 1.39-1.25 (m, 1H), 1.16-1.03 (m, 1H), 0.84 (s, 6H), 0.76 (t, 3H); MS (EI) for MS (EI) for C28H37N7O3S: 552 (MH+).

N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-methylpyridin-3-yl}methanesulfonamide. Prepared by the method of example 5 using N-(5-bromo-2-methylpyridin-3-yl)methanesulfonamide (reagent preparation 26) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.59 (d, 1H), 8.36 (s, 1H), 7.82 (d, 1H), 7.66 (d, 1H), 7.52 (dd, 1H), 7.07 (d, 1H), 4.65 (s, 2H), 4.39-4.29 (m, 2H), 3.90-3.79 (m, 2H), 3.07 (s, 3H), 2.71 (t, 2H), 2.53 (s, 3H), 2.44 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C26H31N5O3S: 494 (MH+).

2-amino-N-(3-amino-3-methylbutyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared by the method of example 5 using tert-butyl 4-(2-amino-5-bromopyridine-3-sulfonamido)-2-methylbutan-2-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, 1H), 8.37 (s, 1H), 8.04 (d, 1H), 7.58 (d, 1H), 7.44 (dd, 1H), 7.02 (d, 1H), 6.66 (br s, 2H), 4.62 (s, 2H), 4.36-4.27 (m, 2H), 3.87-3.79 (m, 2H), 2.89-2.80 (m, 2H), 2.71 (t, 2H), 2.45 (s, 2H), 1.59 (t, 2H), 1.43-1.34 (m, 2H), 0.90 (s, 6H), 0.84 (s, 6H); MS (EI) for C29H39N7O3S: 566 (MH+).

N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}-N-methylmethanesulfonamide. Prepared by the method of example 5 using N-(5-bromo-2-chloropyridin-3-yl)-N-methylmethanesulfonamide (reagent preparation 28) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.34 (s, 1H), 8.28 (s, 1H), 7.79 (s, 1H), 7.64 (d, 1H), 7.05 (d, 1H), 4.65 (s, 2H), 4.40-4.24 (m, 2H), 3.87-3.76 (m, 2H), 3.23 (s, 3H), 3.21 (s, 3H), 2.75-2.61 (m, 2H), 2.41 (s, 2H), 1.64-1.48 (m, 2H), 0.81 (s, 6H); MS (EI) for C26H30ClN5O3S: 528 (MH+).

7-{6-chloro-5-[(difluoromethyl)oxy]pyridin-3-yl}-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared by the method of example 5 using 5-bromo-2-chloro-3-(difluoromethoxy)pyridine (reagent preparation 29) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.64 (d, 1H), 8.36 (s, 1H), 8.08 (d, 1H), 7.81 (d, 1H), 7.66 (dd, 1H), 7.47 (t, 1H), 7.09 (d, 1H), 4.67 (s, 2H), 4.40-4.33 (m, 2H), 3.88-3.80 (m, 2H), 2.71 (t, 2H), 2.42 (s, 2H), 1.59 (t, 2H), 0.83 (s, 6H); MS (EI) for C25H25F2ClN4O2: 487 (MH+).

N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-(methyloxy)pyridin-3-yl}methanesulfonamide. Prepared by the method of example 5 using N-(5-bromo-2-methoxypyridin-3-yl)methanesulfonamide (reagent preparation 26) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.36 (s, 1H), 8.27 (d, 1H), 7.83 (d, 1H), 7.59 (d, 1H), 7.46 (dd, 1H), 7.04 (d, 1H), 4.64 (s, 2H), 4.36-4.28 (m, 2H), 3.95 (s, 3H), 3.88-3.79 (m, 2H), 3.07 (s, 3H), 2.71 (t, 2H), 2.44 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C26H31N5O4S: 510 (MH+).

N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-(ethyloxy)pyridin-3-yl}methanesulfonamide. Prepared by the method of example 5 using N-(5-bromo-2-ethoxypyridin-3-yl)methanesulfonamide (reagent preparation 30) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 9.27 (br s, 1H), 8.36 (s, 1H), 8.24 (d, 1H), 7.81 (d, 1H), 7.59 (d, 1H), 7.45 (dd, 1H), 7.04 (d, 1H), 4.63 (s, 2H), 4.40 (q, 2H), 4.36-4.29 (m, 2H), 3.88-3.80 (m, 2H), 3.06 (s, 3H), 2.71 (t, 2H), 2.44 (s, 2H), 1.60 (t, 2H), 1.37 (t, 3H), 0.85 (s, 6H); MS (EI) for C27H33N5O4S: 524 (MH+).

3-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2-carboxamide. Prepared by the method of example 5 using 3-amino-5-bromopicolinonitrile in step 1. The nitrile substituent hydrolyzes to the carboxamide under the aqueous reaction conditions for the coupling. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.06 (d, 1H), 7.93 (d, 1H), 7.65 (d, 1H), 7.48 (dd, 1H), 7.37-7.31 (m, 2H), 7.06 (d, 1H), 6.90 (br s, 2H), 4.66 (s, 2H), 4.38-4.32 (m, 2H), 3.87-3.81 (m, 2H), 2.71 (t, 2H), 2.41 (s, 2H), 1.59 (t, 2H), 0.83 (s, 6H); MS (EI) for C25H28N6O2: 445 (MH+).

N-{2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide. Prepared as an acetate salt by the method of example 5 using N-(2-amino-5-bromopyridin-3-yl)methanesulfonamide (reagent preparation 31) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.13 (d, 1H), 7.60 (d, 1H), 7.51 (d, 1H), 7.37 (dd, 1H), 7.00 (d, 1H), 6.07 (br s, 2H), 4.60 (s, 2H), 4.32-4.26 (m, 2H), 3.87-3.79 (m, 2H), 2.97 (s, 3H), 2.71 (t, 2H), 2.45 (s, 2H), 1.91 (s, 3H), 1.60 (t, 2H), 0.86 (s, 6H); MS (EI) for C25H30N6O3S: 495 (MH+).

N-{2-cyano-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide. Prepared as an acetate salt by the method of example 5 using N-(5-bromo-2-cyanopyridin-3-yl)methanesulfonamide (reagent preparation 26) in step 1. This coupling was completed using water free conditions to prevent nitrile hydrolysis. 1H NMR (400 MHz, DMSO-d6) δ 8.68 (br s, 1H), 8.37 (s, 1H), 8.03 (s, 1H), 7.77 (s, 1H), 7.61 (d, 1H), 7.09 (d, 1H), 4.71 (s, 2H), 4.42-4.35 (m, 2H), 3.91-3.83 (m, 2H), 3.09 (br s, 3H), 2.71 (t, 2H), 2.42 (s, 2H), 1.91 (s, 1H), 1.59 (t, 2H), 0.82 (d, 6H); MS (EI) for C26H28N6O3S: 505 (MH+).

N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-[(phenylmethyl)oxy]pyridin-3-yl}methanesulfonamide. Prepared by the method of example 5 using N-(2-(benzyloxy)-5-bromopyridin-3-yl)methanesulfonamide (reagent preparation 30) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 9.41 (br s, 1H), 8.36 (s, 1H), 8.27 (d, 1H), 7.85 (d, 1H), 7.60 (d, 1H), 7.57-7.52 (m, 2H), 7.47 (dd, 1H), 7.43-7.36 (m, 2H), 7.36-7.30 (m, 1H), 7.04 (d, 1H), 5.45 (s, 2H), 4.64 (s, 2H), 4.35-4.29 (m, 2H), 3.88-3.80 (m, 2H), 3.01 (s, 3H), 2.71 (t, 2H), 2.44 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C32H35N5O4S: 586 (MH+).

2-amino-N-(2-amino-2-methylpropyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared by the method of example 5 using 2-amino-N-(2-amino-2-methylpropyl)-5-bromopyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.45 (br s, 1H), 8.37 (s, 1H), 8.02 (d, 1H), 7.57 (s, 1H), 7.43 (dd, 1H), 7.02 (d, 1H), 6.71 (br s, 2H), 4.62 (s, 2H), 4.35-4.28 (m, 2H), 3.86-3.80 (m, 2H), 2.71 (t, 2H), 2.54 (s, 2H), 2.44 (s, 2H), 1.59 (t, 2H), 0.92 (s, 6H), 0.84 (s, 6H); MS (EI) for C28H37N7O3S: 552 (MH+).

3-[(3-aminoazetidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared by the method of example 5 using tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)azetidin-3-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (d, 1H), 8.37 (s, 1H), 7.98 (d, 1H), 7.61 (d, 1H), 7.49 (dd, 1H), 7.03 (d, 1H), 6.77 (br s, 2H), 4.62 (s, 2H), 4.36-4.29 (m, 2H), 3.91-3.80 (m, 4H), 3.57 (p, 1H), 3.39 (t, 2H), 2.71 (t, 2H), 2.45 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C27H33N7O3S: 536 (MH+).

N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide. Prepared by the method of example 5 using N-(5-bromo-2-chloropyridin-3-yl)methanesulfonamide (reagent preparation 24) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 9.86 (br s, 1H), 8.56 (d, 1H), 8.36 (s, 1H), 8.04 (d, 1H), 7.72 (d, 1H), 7.57 (dd, 1H), 7.08 (d, 1H), 4.67 (s, 2H), 4.39-4.32 (m, 2H), 3.89-3.81 (m, 2H), 3.16 (s, 3H), 2.71 (t, 2H), 2.43 (s, 2H), 1.59 (t, 2H), 0.84 (s, 6H); MS (EI) for C25H28ClN5O3S: 514 (MH+).

1-{6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3H-imidazo[4,5-b]pyridin-2-yl}ethanol. Prepared according to the method of example 5 by using 1-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)ethanol (reagent preparation 19) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.56 (br, 1H), 8.34 (s, 1H), 8.11 (br, 1H), 7.61 (s, 1H), 7.54 (d, 1H), 7.10 (d, 1H), 5.11 (m, 1H), 4.73 (s, 2H), 4.37 (m, 2H), 3.95 (m, 2H), 2.79 (t, 2H), 2.48 (s, 2H), 1.68 (t, 2H), 1.64 (d, 3H), 0.88 (s, 6H); MS (EI) for C27H30N6O2: 471 (MH+).

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-[5-(methyloxy)pyridin-3-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 5 by using 3-bromo-5-methoxypyridine and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, DMSO-d6): 8.49 (s, 1H), 8.40 (s, 1H), 8.26 (s, 1H), 7.75 (s, 1H), 7.59 (m, 2H), 7.07 (d, 1H), 4.65 (s, 2H), 4.35 (m, 2H), 3.90 (s, 3H), 3.84 (m, 2H), 2.67 (t, 2H), 2.44 (s, 2H), 1.57 (t, 2H), 0.82 (s, 6H); MS (EI) for C25H28N4O2: 417 (MH+).

7-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one. Prepared according to the method of example 5 by using 7-bromo-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, DMSO-d6): 8.38 (s, 1H), 8.21 (s, 1H), 7.70 (s, 1H), 7.62 (s, 1H), 7.53 (d, 1H), 7.07 (d, 1H), 4.68 (s, 2H), 4.62 (s, 2H), 4.33 (m, 2H), 3.82 (m, 2H), 2.71 (t, 2H), 2.45 (s, 2H), 1.56 (t, 2H), 0.84 (s, 6H); MS (EI) for C26H27N5O3: 458 (MH+).

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-pyrido[2,3-b]pyrazin-7-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 5 by using 7-bromopyrido[2,3-b]pyrazine and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, DMSO-d6): 9.56 (s, 1H), 9.13 (s, 1H), 9.10 (s, 1H), 8.78 (s, 1H), 8.39 (s, 1H), 8.05 (s, 1H), 7.88 (d, 1H), 7.14 (d, 1H), 4.71 (s, 2H), 4.41 (m, 2H), 3.85 (m, 2H), 2.71 (t, 2H), 2.49 (s, 2H), 1.62 (t, 2H), 0.84 (s, 6H); MS (EI) for C26H26N6O: 439 (MH+).

1-{6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}-N-methylmethanamine. Prepared according to the method of example 5 by using phenylmethyl{[6-bromo-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl}methylcarbamate (reagent preparation 19) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.62 (br, 1H), 8.35 (s, 1H), 8.10 (s, 1H), 7.62 (br, 1H), 7.53 (d, 1H), 7.09 (d, 1H), 4.74 (s, 2H), 4.38 (m, 2H), 4.22 (s, 2H), 3.97 (m, 2H), 2.77 (t, 2H), 2.59 (s, 3H), 2.48 (s, 2H), 1.68 (t, 2H), 0.88 (s, 6H); MS (EI) for C27H31N7O: 470 (MH+).

1-{6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}-N,N-dimethylmethanamine. Prepared according to the method of example 5 by using phenylmethyl({6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl}methyl)methylcarbamate in step 2. 1H NMR (400 MHz, Methanol-d4): 8.58 (s, 1H), 8.34 (s, 1H), 8.11 (s, 1H), 7.62 (br, 1H), 7.52 (d, 1H), 7.10 (d, 1H), 4.74 (s, 2H), 4.35 (m, 2H), 3.96 (m, 2H), 3.81 (s, 2H), 2.77 (t, 2H), 2.48 (s, 2H), 2.39 (s, 6H), 1.77 (t, 2H), 0.90 (s, 6H); MS (EI) for C28H33N7O: 484 (MH+).

Phenylmethyl[(1S)-1-(6-{4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)ethyl]carbamate. Prepared according to the method of example 5 by using phenylmethyl{(1S)-1-[6-bromo-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl]ethyl}({[2-(trimethylsilyl)ethyl]oxy}methyl)carbamate (reagent preparation 19) and {4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.54 (br, 1H), 8.05 (br, 1H), 7.61 (s, 1H), 7.48 (d, 1H), 7.41 to 7.29 (m, 5H), 7.09 (d, 1H), 4.77 (d, 2H), 4.61 (d, 2H), 4.43 (m, 1H), 4.20 (m, 1H), 4.04 (m, 1H), 3.95 (m, 1H), 3.88 (s, 3H), 3.29 (m, 1H), 2.87 (m, 1H), 2.78 (m, 1H), 2.60 (m, 1H), 2.35 (s, 3H), 2.29 (m, 1H), 1.96 (m, 1H), 1.69 (m, 1H), 1.63 (d, 3H), 1.41 (m, 2H), 1.16 (m, 1H), 0.99 (t, 3H); MS (EI) for C36H39N7O3: 618 (MH+).

Phenylmethyl[(1S)-1-{6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}ethyl]carbamate. Prepared according to the method of example 5 by using phenylmethyl{(1S)-1-[6-bromo-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl]ethyl}({[2-(trimethylsilyl)ethyl]oxy}methyl)carbamate (reagent preparation 19) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.56 (br, 1H), 8.36 (br, 1H), 8.09 (br, 1H), 7.60 (s, 1H), 7.51 (d, 1H), 7.42 to 7.25 (m, 5H), 7.10 (d, 1H), 5.17 to 5.03 (dd, 2H), 4.73 (s, 2H), 4.61 (m, 1H), 4.37 (m, 1H), 3.95 (m, 1H), 2.79 (t, 2H), 2.48 (s, 2H), 1.72 to 1.56 (m, 5H), 0.90 (s, 6H); MS (EI) for C35H37N7O3: 604 (MH+).

(1S)-1-(6-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)ethanamine. Prepared according to the method of example 5 by using phenylmethyl{(1S)-1-[6-bromo-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl]ethyl}({[2-(trimethylsilyl)ethyl]oxy}methyl)carbamate (reagent preparation 19) and {4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.56 (s, 1H), 8.31 (s, 1H), 8.15 (s, 1H), 7.59 (s, 1H), 7.50 (d, 1H), 7.07 (d, 1H), 4.80 (m, 2H), 4.60 (q, 1H), 4.44 (m, 1H), 4.26 (m, 1H), 4.07 to 3.91 (m, 2H), 2.96 to 2.81 (m, 2H), 2.60 (m, 1H), 2.33 (m, 1H), 1.98 (m, 1H), 1.73 (m, 1H), 1.68 (d, 3H), 1.41 (m, 2H), 1.16 (m, 1H), 0.99 (t, 3H); MS (EI) for C27H31N7O: 470 (MH+).

(1R)-1-(6-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)ethanamine. Prepared according to the method of example 5 by using phenylmethyl{(1R)-1-[6-bromo-3-({[2-(trimethylsilyl)ethyl]oxy}methyl)-3H-imidazo[4,5-b]pyridin-2-yl]ethyl}({[2-(trimethylsilyl)ethyl]oxy}methyl)carbamate (reagent preparation 19) and {-4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.59 (s, 1H), 8.31 (s, 1H), 8.12 (s, 1H), 7.61 (s, 1H), 7.50 (d, 1H), 7.09 (d, 1H), 4.80 (m, 2H), 4.53 (m, 1H), 4.43 (m, 1H), 4.27 (m, 1H), 4.06 to 3.93 (m, 2H), 2.96 to 2.78 (m, 2H), 2.62 (m, 1H), 2.32 (m, 1H), 1.95 (m, 1H), 1.75 (m, 1H), 1.67 (d, 3H), 1.41 (m, 2H), 1.16 (m, 1H), 0.99 (t, 3H); MS (EI) for C27H31N7O: 470 (MH+).

3-[(3-amino-3-methylpyrrolidin-1-yl)sulfonyl]-5-{4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine. Prepared according to the method of example 5 by using 1,1-dimethylethyl {1-[(2-amino-5-bromopyridin-3-yl)sulfonyl]-3-methylpyrrolidin-3-yl}carbamate (reagent preparation 25) and {4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.37 (s, 1H), 7.97 (s, 1H), 7.41 (s, 1H), 7.29 (d, 1H), 6.94 (d, 1H), 4.64 (m, 2H), 4.27 (m, 1H), 4.05 (m, 1H), 3.94 (m, 2H), 3.47 (m, 1H), 3.31 (m, 1H), 3.12 (m, 2H), 2.81 to 2.66 (m, 2H), 2.49 (m, 1H), 2.28 (s, 3H), 2.21 (m, 1H), 1.90 (m, 1H), 1.84 (m, 2H), 1.62 (m, 1H), 1.36 (m, 2H), 1.14 (s, 3H), 1.09 (m, 1H), 0.99 (t, 3H); MS (EI) for C30H39N7O3S: 578 (MH+).

3-{[(3S)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-ol. Prepared according to the method of example 5 by using 1,1-dimethylethyl {(3S)-1-[(5-bromo-2-hydroxypyridin-3-yl)sulfonyl]pyrrolidin-3-yl}carbamate (reagent preparation 40) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.53 (d, 2H), 8.00 (s, 1H), 7.57 (s, 1H), 7.41 (d, 1H), 7.03 (d, 1H), 5.12 (s, 2H), 4.45 (m, 1H), 4.29 (m, 1H), 3.93 (m, 1H), 3.72 to 3.55 (m, 6H), 2.85 (t, 2H), 2.56 (s, 2H), 2.35 (m, 1H), 2.06 (m, 1H), 1.69 (t, 2H), 0.93 (s, 6H); MS (EI) for C28H34N6O4S: 551 (MH+).

(3S)-1-({2-[(3S)-3-aminopyrrolidin-1-yl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-amine. Prepared according to the method of example 5 by using 1,1-dimethylethyl[(3S)-1-({5-bromo-2-[(3S)-3-({[(1,1-dimethylethyl)oxy]carbonyl}amino)pyrrolidin-1-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-yl]carbamate (reagent preparation 40) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.56 (s, 1H), 8.55 (s, 1H), 8.53 (s, 1H), 7.74 (s, 1H), 7.52 (d, 1H), 7.01 (d, 1H), 5.12 (s, 2H), 4.47 (m, 2H), 4.32 (m, 3H), 4.22 (m, 1H), 4.05 (m, 2H), 3.85 (m, 1H), 3.74 to 3.56 (m, 5H), 2.85 (t, 2H), 2.59 (s, 2H), 2.35 (m, 2H), 2.22 (m, 2H), 1.70 (t, 2H), 0.93 (s, 6H); MS (EI) for C32H42N8O3S: 619 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3R)-1-methylpyrrolidin-3-yl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-[(3R)-1-methylpyrrolidin-3-yl]pyridine-3-sulfonamide (reagent preparation 25) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.45 (s, 1H), 8.34 (s, 1H), 8.17 (s, 1H), 7.50 (s, 1H), 7.42 (d, 1H), 7.04 (d, 1H), 4.71 (s, 2H), 4.33 (m, 2H), 3.96 (m, 2H), 3.84 (m, 1H), 2.94 (m, 1H), 2.83 to 2.69 (m, 4H), 2.61 (m, 1H), 2.47 (s, 2H), 2.45 (s, 3H), 1.74 to 1.65 (m, 3H), 0.91 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-{[(3S)-1-methylpyrrolidin-3-yl]methyl}pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-{[(3S)-1-methylpyrrolidin-3-yl]methyl}pyridine-3-sulfonamide (reagent preparation 25) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.44 (br, 1H), 8.34 (s, 1H), 8.17 (s, 1H), 7.50 (s, 1H), 7.40 (d, 1H), 7.05 (d, 1H), 4.70 (s, 2H), 4.31 (m, 2H), 3.97 (m, 2H), 3.16 (m, 1H), 3.04 (t, 2H), 2.94 (d, 2H), 2.67 (t, 2H), 2.67 (s, 3H), 2.47 (s, 2H), 2.52 (m, 1H), 2.10 (m, 1H), 1.90 (m, 1H), 1.65 (m, 3H), 0.92 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

2-amino-N-{[(3S)-1-methylpyrrolidin-3-yl]methyl}-5-[4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared according to the method of 5 by using 2-amino-5-bromo-N-{[(3S)-1-methylpyrrolidin-3-yl]methyl}pyridine-3-sulfonamide (reagent preparation 25) and [4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.35 (s, 1H), 8.25 (s, 1H), 8.07 (s, 1H), 7.37 (s, 1H), 7.32 (d, 1H), 6.97 (d, 1H), 6.07 (s, 1H), 4.58 (s, 2H), 4.23 (m, 2H), 3.84 (m, 2H), 2.86 to 2.78 (m, 3H), 2.72 (m, 2H), 2.63 (s, 2H), 2.46 (m, 1H), 2.40 (s, 3H), 2.34 (m, 1H), 1.93 (m, 1H), 1.83 (s, 3H), 1.46 (m, 1H), 0.99 (s, 6H); MS (EI) for C31H39N7O3S: 590 (MH+).

4-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-2-methylbutan-2-ol. Prepared according to the method of example 5 by using 4-[(2-amino-5-bromopyridin-3-yl)sulfonyl]-2-methylbutan-2-ol (reagent preparation 41) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.52 (s, 1H), 8.35 (s, 1H), 8.14 (s, 1H), 7.50 (s, 1H), 7.43 (d, 1H), 7.06 (d, 1H), 4.70 (s, 2H), 4.30 (m, 2H), 3.95 (m, 2H), 3.35 (m, 2H), 2.79 (t, 2H), 2.48 (s, 2H), 1.82 (m, 2H), 1.68 (t, 2H), 1.15 (s, 6H), 0.90 (s, 6H); MS (EI) for C29H37N5O4S: 552 (MH+).

4-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfinyl)-2-methylbutan-2-ol. Prepared according to the method of example 5 by using 4-[(2-amino-5-bromopyridin-3-yl)sulfinyl]-2-methylbutan-2-ol (reagent preparation 41) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.40 (s, 1H), 8.34 (s, 1H), 8.03 (s, 1H), 7.51 (s, 1H), 7.42 (d, 1H), 7.05 (d, 1H), 4.68 (s, 2H), 4.33 (m, 2H), 3.94 (m, 2H), 3.20 (m, 2H), 2.79 (t, 2H), 2.47 (s, 2H), 1.80 (m, 2H), 1.67 (t, 2H), 1.21 (s, 6H), 0.88 (s, 6H); MS (EI) for C29H37N5O3S: 536 (MH+).

N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-[(phenylmethyl)amino]pyridin-3-yl}methanesulfonamide. Prepared according to the method of example 5 by using N-{5-bromo-2-[(phenylmethyl)amino]pyridin-3-yl}methanesulfonamide (reagent preparation 39) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-D4): 8.26 (s, 1H), 8.06 (s, 1H), 7.64 (s, 1H), 7.37 to 7.08 (m, 7H), 6.94 (d, 1H), 4.59 (s, 2H), 4.57 (s, 2H), 4.20 (m, 2H), 3.85 (m, 2H), 2.91 (s, 3H), 2.67 (t, 2H), 2.36 (s, 1.59 (t, 2H), 1.21 (s, 6H), 0.82 (s, 6H); MS (EI) for C32H36N6O3S: 585 (MH+).

N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-(methylamino)pyridin-3-yl}methanesulfonamide. Prepared according to the method of example 5 by using N-[5-bromo-2-(methylamino)pyridin-3-yl]methanesulfonamide (reagent preparation 39) and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.35 (s, 1H), 8.13 (s, 1H), 7.71 (s, 1H), 7.44 (s, 1H), 7.39 (d, 1H), 7.03 (d, 1H), 4.68 (s, 2H), 4.32 (m, 2H), 3.94 (m, 2H), 3.00 (s, 3H), 2.98 (s, 3H), 2.79 (t, 2H), 2.46 (s, 2H), 1.67 (t, 2H), 0.90 (s, 6H); MS (EI) for C26H32N6O3S: 509 (MH+).

(2S)-3-[(2-amino-5-{4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-3-yl)sulfinyl]-2-methylpropan-1-ol. Prepared according to the method of example 5 by using (2S)-3-[(2-amino-5-bromopyridin-3-yl)sulfinyl]-2-methylpropan-1-ol (reagent preparation 41) and {4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.42 (s, 1H), 8.36 (br, 1H), 8.02 (br, 1H), 7.93 (d, 1H), 7.52 (br, 1H), 7.40 (d, 1H), 7.08 (m, 2H), 7.01 (d, 1H), 5.03 (s, 2H), 4.43 (m, 2H), 4.22 (m, 2H), 3.90 (s, 3H), 3.64 (dd, 0.5H), 3.57 to 3.46 (m, 1.5H), 3.40 (dd, 0.5H), 3.14 (dd, 0.5H), 3.01 (dd, 0.5H), 2.82 (dd, 0.5H), 2.15 (m, 1H), 1.12 (dd, 3H); MS (EI) for C27H29N5O4S: 520 (MH+).

(2S)-3-[(2-amino-5-{4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-3-yl)sulfonyl]-2-methylpropan-1-ol. Prepared according to the method of example 5 by using (2S)-3-[(2-amino-5-bromopyridin-3-yl)sulfonyl]-2-methylpropan-1-ol (reagent preparation 41) and {4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, Methanol-d4): 8.42 (s, 1H), 8.34 (br, 1H), 8.07 (br, 1H), 7.89 (d, 1H), 7.44 (s, 1H), 7.35 (d, 1H), 7.08 (m, 2H), 6.94 (d, 1H), 4.96 (s, 2H), 4.34 (m, 2H), 4.14 (m, 2H), 3.84 (s, 3H), 3.41 (m, 2H), 3.31 (dd, 1H), 2.98 (dd, 1H), 2.12 (m, 1H), 0.99 (d, 3H); MS (EI) for C27H20N5O5S: 536 (MH+).

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-[4-(1H-imidazol-2-yl)phenyl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 5 by using 2-methylpropyl 2-(4-bromophenyl)-1H-imidazole-1-carboxylate (reagent preparation 11) in step 1 followed by isobutylcarbamate deprotection. 1H NMR (400 MHz, DMSO-d6): 12.54 (s, 1H), 8.38 (s, 1H), 8.00 (d, 2H), 7.74 (d, 2H), 7.72 (m, 1H), 7.57 (m, 1H), 7.27 (m, 1H), 7.04 (m, 2H), 4.65 (s, 2H), 4.34 (m, 2H), 3.84 (m, 2H), 2.71 (t, 2H), 2.47 (s, 2H), 1.61 (t, 2H), 0.85 (s, 6H); MS (EI) for C28H20N5O: 452 (MH+).

N-ethyl-6-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine. Prepared according to the method of example 5 by using 6-bromo-N-ethyl-1-[(methyloxy)methyl]-1H-imidazo[4,5-b]pyridin-2-amine (reagent preparation 36) and [4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1 followed by MOM deprotection. 1H NMR (400 MHz, methanol-d4): 8.15 (d, 1H), 7.64 (d, 1H), 7.55 (d, 1H), 7.43 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.31 (m, 2H), 3.99 (m, 2H), 3.46 (q, 2H), 2.75 (t, 2H), 2.47 (s, 2H), 2.41 (s, 3H), 1.66 (t, 2H), 1.30 (t, 3H), 0.91 (s, 6H); MS (EI) for C27H30N6O: 455 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as acetate salt according to the method of example 5 by using 6-bromo-2-methyl-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazo[4,5-b]pyridine (reagent preparation 35) and [4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1 followed by SEM deprotection. 1H NMR (400 MHz, methanol-d4): 8.52 (d, 1H), 8.05 (d, 1H), 7.63 (d, 1H), 7.50 (dd, 1H), 7.09 (d, 1H), 4.73 (s, 2H), 4.33 (m, 2H), 4.00 (m, 2H), 2.75 (t, 2H), 2.64 (s, 3H), 2.47 (s, 2H), 2.41 (s, 3H), 1.96 (s, 3H), 1.66 (t, 2H), 0.91 (s, 6H); MS (EI) for C27H30N6O: 455 (MH+).

7-(1H-benzimidazol-6-yl)-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 5 by using isobutyl 6-bromo-1H-benzo[d]imidazole-1-carboxylate (reagent preparation 11) in step 1. 1H NMR (400 MHz, methanol-d4): 8.34 (s, 1H), 8.18 (s, 1H), 7.78 (s, 1H), 7.64 (d, 1H), 7.56-7.46 (m, 3H), 7.04 (d, 1H), 4.67 (s, 2H), 4.33 (m, 2H), 3.94 (m, 2H), 2.78 (t, 2H), 2.48 (s, 2H), 1.66 (t, 2H), 0.89 (s, 6H); MS (EI) for C26H27N5O: 426 (MH+).

3-{[(3S)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as acetate salt according to the method of example 5 by using (S)-tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.48 (d, 1H), 8.33 (s, 1H), 8.10 (d, 1H), 7.48 (d, 1H), 7.41 (dd, 1H), 7.05 (d, 1H), 4.70 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.73 (m, 1H), 3.55 (m, 2H), 3.35 (m, 1H), 2.79 (t, 2H), 2.49 (s, 2H), 2.25 (m, 1H), 1.93 (s, 3H), 1.88 (m, 2H), 1.69 (t, 2H), 0.91 (s, 6H); MS (EI) for C28H35N7O3S: 550 (MH+).

3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as acetate salt according to the method of example 5 by using (R)-tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.48 (d, 1H), 8.33 (s, 1H), 8.10 (d, 1H), 7.48 (d, 1H), 7.41 (dd, 1H), 7.05 (d, 1H), 4.70 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.66 (m, 1H), 3.55 (m, 2H), 3.35 (m, 1H), 2.79 (t, 2H), 2.49 (s, 2H), 2.25 (m, 1H), 1.93 (s, 3H), 1.88 (m, 2H), 1.69 (t, 2H), 0.91 (s, 6H); MS (EI) for C28H35N7O3S: 550 (MH+).

8-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine. Prepared according to the method of example 5 by using tert-butyl 8-(2-amino-5-bromopyridin-3-ylsulfonyl)-8-azabicyclo[3.2.1]octan-3-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. MS (EI) for C31H39N7O3S: 590 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3R)-pyrrolidin-3-ylmethyl]pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using (R)-tert-butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)pyrrolidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.45 (d, 1H), 8.33 (s, 1H), 8.16 (d, 1H), 7.50 (d, 1H), 7.41 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.15 (m, 1H), 2.98-2.89 (m, 3H), 2.79 (t, 2H), 2.48 (s, 2H), 2.09 (m, 1H), 1.90 (s, 3H), 1.69 (t, 2H), 0.92 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

2-amino-N-8-azabicyclo[3.2.1]oct-3-yl-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using 2,2,2-trichloroethyl 3-(2-amino-5-bromopyridine-3-sulfonamido)-8-azabicyclo[3.2.1]octane-8-carboxylate (reagent preparation 25) in step 1 followed by Troc deprotection. 1H NMR (400 MHz, methanol-d4): 8.53 (s, 1H), 8.49 (d, 1H), 8.45 (s, 1H), 7.67 (d, 1H), 7.48 (dd, 1H), 7.06 (d, 1H), 5.15 (s, 2H), 4.47 (m, 2H), 4.31 (m, 2H), 4.01 (m, 2H), 3.44 (m, 1H), 2.86 (t, 2H), 2.60 (s, 2H), 2.46 (m, 2H), 2.26-2.08 (m, 6H), 1.71 (t, 2H), 0.96 (s, 6H); MS (EI) for C31H39N7O3S: 590 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3S)-pyrrolidin-3-ylmethyl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using (S)-tert-butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)pyrrolidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.45 (d, 1H), 8.33 (s, 1H), 8.16 (d, 1H), 7.49 (d, 1H), 7.41 (dd, 1H), 7.05 (d, 1H), 4.71 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.26-3.06 (m, 3H), 2.94 (d, 2H), 2.85 (m, 1H), 2.80 (t, 2H), 2.48 (s, 2H), 2.43 (m, 1H), 2.04 (m, 1H), 1.69 (t, 2H), 1.62 (m, 1H), 0.92 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3R)-pyrrolidin-3-yl]pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using (R)-tert-butyl 3-(2-amino-5-bromopyridine-3-sulfonamido)pyrrolidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.48 (d, 1H), 8.33 (s, 1H), 8.18 (d, 1H), 7.50 (d, 1H), 7.41 (dd, 1H), 7.05 (d, 1H), 4.70 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.90 (m, 1H), 3.20 (m, 3H), 2.80 (t, 2H), 2.49 (s, 2H), 2.11 (m, 1H), 1.92 (s, 3H), 1.88 (m, 2H), 1.68 (t, 2H), 0.91 (s, 6H); MS (EI) for C28H35N7O3S: 550 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3S)-pyrrolidin-3-yl]pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using (S)-tert-butyl 3-(2-amino-5-bromopyridine-3-sulfonamido)pyrrolidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.48 (d, 1H), 8.33 (s, 1H), 8.18 (d, 1H), 7.50 (d, 1H), 7.41 (dd, 1H), 7.05 (d, 1H), 4.70 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.90 (m, 1H), 3.20 (m, 3H), 2.80 (t, 2H), 2.49 (s, 2H), 2.11 (m, 1H), 1.92 (s, 3H), 1.88 (m, 2H), 1.68 (t, 2H), 0.91 (s, 6H); MS (EI) for C28H35N7O3S: 550 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(piperidin-3-ylmethyl)pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using tert-butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.45 (d, 1H), 8.33 (s, 1H), 8.15 (d, 1H), 7.50 (d, 1H), 7.41 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.33 (m, 2H), 3.96 (m, 2H), 2.81 (m, 5H), 2.48 (s, 2H), 1.90 (s, 3H), 1.86 (m, 2H), 1.69 (t, 2H), 0.91 (s, 6H); MS (EI) for C30H39N7O3S: 578 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(piperidin-2-ylmethyl)pyridine-3-sulfonamide. Prepared as dihydrochloride salt according to the method of example 5 by using tert-butyl 2-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. MS (EI) for C30H39N7O3S: 578 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3R)-piperidin-3-ylmethyl]pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using (R)-tert-butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.45 (d, 1H), 8.33 (s, 1H), 8.15 (d, 1H), 7.49 (d, 1H), 7.41 (dd, 1H), 7.05 (d, 1H), 4.71 (s, 2H), 4.33 (m, 2H), 3.96 (m, 2H), 2.87-2.76 (m, 6H), 2.64 (m, 1H), 2.49 (s, 2H), 1.91 (s, 3H), 1.87 (m, 2H), 1.71-1.57 (m, 3H), 1.22 (m, 1H), 0.91 (s, 6H); MS (EI) for C30H39N7O3S: 578 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3S)-piperidin-3-ylmethyl]pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using (S)-tert-butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)piperidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.45 (d, 1H), 8.33 (s, 1H), 8.15 (d, 1H), 7.49 (d, 1H), 7.41 (dd, 1H), 7.05 (d, 1H), 4.71 (s, 2H), 4.33 (m, 2H), 3.96 (m, 2H), 2.87-2.76 (m, 6H), 2.64 (m, 1H), 2.49 (s, 2H), 1.91 (s, 3H), 1.87 (m, 2H), 1.71-1.57 (m, 3H), 1.22 (m, 1H), 0.91 (s, 6H); MS (EI) for C30H39N7O3S: 578 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-{[(3S)-1-methylpiperidin-3-yl]methyl}pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using (S)-2-amino-5-bromo-N-((1-methylpiperidin-3-yl)methyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.44 (d, 1H), 8.34 (s, 1H), 8.15 (d, 1H), 7.49 (d, 1H), 7.41 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.08 (m, 1H), 2.80 (m, 4H), 2.48 (s, 5H), 2.31 (m, 1H), 2.06 (m, 1H), 1.91 (s, 3H), 1.77 (m, 3H), 1.69 (t, 2H), 1.60 (m, 1H), 1.01 (m, 1H), 0.91 (s, 6H); MS (EI) for C31H41N7O3S: 592 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N,N-dimethylpyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N,N-dimethylpyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.47 (s, 1H), 8.35 (s, 1H), 8.05 (s, 1H), 7.49 (s, 1H), 7.42 (d, 1H), 7.07 (d, 1H), 4.71 (s, 2H), 4.35 (m, 2H), 3.97 (m, 2H), 2.81 (m, 8H), 2.49 (s, 2H), 1.70 (m, 2H), 0.91 (s, 6H); MS (EI) for C26H32N6O3S: 509 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using 5-bromopyridine-3-sulfonamide in step 1. 1H NMR (400 MHz, methanol-d4): 9.00 (s, 1H), 8.96 (s, 1H), 8.46 (s, 1H), 8.34 (s, 1H), 7.69 (s, 1H), 7.58 (d, 1H), 7.13 (d, 1H), 4.77 (s, 2H), 4.38 (m, 2H), 3.98 (m, 2H), 2.79 (m, 2H), 2.48 (s, 2H), 1.98 (s, 3H), 1.68 (m, 2H), 0.89 (s, 6H); MS (EI) for C24H27N5O3S: 466 (MH+).

2-amino-N,N-dimethyl-5-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-ylboronic acid (reagent preparation 23) and 2-amino-5-bromo-N,N-dimethylpyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.47 (s, 1H), 8.04 (s, 1H), 7.52 (s, 1H), 7.41 (d, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.31 (m, 2H), 4.00 (m, 2H), 2.80 (s, 6H), 2.75 (m, 2H), 2.45 (s, 2H), 2.40 (s, 3H), 1.67 (m, 2H), 0.91 (s, 6H); MS (EI) for C27H34N6O3S: 523 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N,N-dimethylpyridine-3-sulfonamide. Prepared according to the method of example 5 by using 5-bromo-N,N-dimethylpyridine-3-sulfonamide in step 1. 1H NMR (400 MHz, methanol-d4): 9.08 (s, 1H), 8.88 (s, 1H), 8.33 (m, 2H), 7.60 (d, 1H), 7.14 (d, 1H), 4.77 (s, 2H), 4.40 (m, 2H), 3.99 (m, 2H), 2.79 (m, 8H), 2.49 (s, 2H), 1.69 (m, 2H), 0.90 (s, 6H); MS (EI) for C26H31N5O3S: 494 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(morpholin-4-ylsulfonyl)pyridin-2-amine. Prepared as acetate salt according to the method of example 5 by using 5-bromo-3-(morpholinosulfonyl)pyridin-2-amine (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.48 (d, 1H), 8.35 (s, 1H), 8.03 (d, 1H), 7.49 (d, 1H), 7.42 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.35 (m, 2H), 3.97 (m, 2H), 3.70 (m, 4H), 3.13 (m, 4H), 2.80 (t, 2H), 2.48 (s, 2H), 1.98 (s, 3H), 1.61 (t, 2H), 0.90 (s, 6H); MS (EI) for C28H34N6O4S: 551 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-amine. Prepared as diacetate salt according to the method of example 5 by using 5-bromo-3-(4-methylpiperazin-1-ylsulfonyl)pyridin-2-amine (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.58 (d, 1H), 8.34 (s, 1H), 8.04 (d, 1H), 7.49 (d, 1H), 7.41 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.35 (m, 2H), 3.96 (m, 2H), 3.22 (m, 4H), 2.80 (t, 2H), 2.55 (m, 4H), 2.49 (s, 2H), 2.31 (s, 3H), 1.97 (s, 3H), 1.69 (t, 2H), 0.90 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N,N-dimethylpyridine-3-carboxamide. Prepared as trifluoroacetate salt according to the method of example 5 by using 2-amino-5-bromo-N,N-dimethylnicotinamide (reagent preparation 33) in step 1. 1H NMR (400 MHz, methanol-d4): 8.51 (d, 1H), 8.23 (s, 2H), 7.66 (d, 1H), 7.50 (dd, 1H), 7.05 (d, 1H), 5.14 (s, 2H), 4.48 (m, 2H), 4.32 (m, 2H), 3.14 (s, 3H), 3.07 (s, 3H), 2.85 (t, 2H), 2.59 (s, 2H), 1.70 (t, 2H), 0.95 (s, 6H); MS (EI) for C27H32N6O2: 473 (MH+).

3-(azetidin-1-ylsulfonyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as acetate salt according to the method of example 5 by using 3-(azetidin-1-ylsulfonyl)-5-bromopyridin-2-amine (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.51 (d, 1H), 8.34 (s, 1H), 8.09 (d, 1H), 7.50 (d, 1H), 7.43 (dd, 1H), 7.07 (d, 1H), 4.71 (s, 2H), 4.35 (m, 2H), 3.96 (m, 2H), 3.88 (t, 4H), 2.79 (t, 2H), 2.49 (s, 2H), 2.15 (m, 2H), 1.96 (s, 3H), 1.69 (t, 2H), 0.90 (s, 6H); MS (EI) for C27H32N6O3S: 521 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-methylpyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-methylpyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.44 (d, 1H), 8.34 (s, 1H), 8.15 (d, 1H), 7.49 (d, 1H), 7.42 (dd, 1H), 7.06 (d, 1H), 4.70 (s, 2H), 4.35 (m, 2H), 3.96 (m, 2H), 2.79 (t, 2H), 2.55 (s, 3H), 2.48 (s, 2H), 1.69 (t, 2H), 0.90 (s, 6H); MS (EI) for C25H30N6O3S: 495 (MH+).

1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)azetidin-3-ol. Prepared according to the method of example 5 by using 1-(2-amino-5-bromopyridin-3-ylsulfonyl)azetidin-3-ol (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.51 (d, 1H), 8.34 (s, 1H), 8.09 (d, 1H), 7.50 (d, 1H), 7.43 (dd, 1H), 7.07 (d, 1H), 4.70 (s, 2H), 4.45 (m, 2H), 4.35 (m, 2H), 4.02 (m, 2H), 3.96 (m, 2H), 3.65 (m, 2H), 2.80 (t, 2H), 2.49 (s, 2H), 1.69 (t, 2H), 0.91 (s, 6H); MS (EI) for C27H32N6O4S: 537 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(pyrrolidin-1-ylsulfonyl)pyridin-2-amine. Prepared as acetate salt according to the method of example 5 by using 5-bromo-3-(pyrrolidin-1-ylsulfonyl)pyridin-2-amine (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.45 (d, 1H), 8.34 (s, 1H), 8.10 (d, 1H), 7.48 (d, 1H), 7.41 (dd, 1H), 7.06 (d, 1H), 4.70 (s, 2H), 4.35 (m, 2H), 3.96 (m, 2H), 3.32 (m, 4H), 2.80 (t, 2H), 2.49 (s, 2H), 1.96 (s, 3H), 1.84 (m, 4H), 1.69 (t, 2H), 0.91 (s, 6H); MS (EI) for C28H34N6O3S: 535 (MH+).

1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-ol. Prepared according to the method of example 5 by using 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ol (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.44 (d, 1H), 8.34 (s, 1H), 8.11 (d, 1H), 7.48 (d, 1H), 7.41 (dd, 1H), 7.06 (d, 1H), 4.70 (s, 2H), 4.35 (m, 2H), 3.95 (m, 2H), 3.47 (m, 3H), 2.79 (t, 2H), 2.49 (s, 2H), 2.03-1.80 (m, 4H), 1.69 (t, 2H), 0.91 (s, 6H); MS (EI) for C28H34N6O4S: 551 (MH+).

2-amino-N-cyclobutyl-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-cyclobutylpyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.42 (d, 1H), 8.34 (s, 1H), 8.15 (d, 1H), 7.48 (d, 1H), 7.41 (dd, 1H), 7.06 (d, 1H), 4.70 (s, 2H), 4.35 (m, 2H), 3.95 (m, 2H), 3.72 (m, 1H), 2.80 (t, 2H), 2.48 (s, 2H), 2.02 (m, 2H), 1.82 (m, 2H), 1.68 (t, 2H), 1.57 (m, 2H), 0.90 (s, 6H); MS (EI) for C28H34N6O3S: 535 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(methylsulfonyl)pyridin-2-amine. Prepared as acetate salt according to the method of example 5 by using 5-bromo-3-(methylsulfonyl)pyridin-2-amine (reagent preparation 34) in step 1. 1H NMR (400 MHz, methanol-d4): 8.52 (d, 1H), 8.34 (s, 1H), 8.19 (d, 1H), 7.52 (d, 1H), 7.43 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.15 (s, 3H), 2.79 (t, 2H), 2.49 (s, 2H), 1.97 (s, 3H), 1.69 (t, 2H), 0.91 (s, 6H); MS (EI) for C25H29N5O3S: 480 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromopyridine-3-sulfonamide (reagent preparation 25) in step 1. MS (EI) for C24H28N6O3S: 481 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-ethyl-N-methylpyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-ethyl-N-methylpyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.44 (d, 1H), 8.34 (s, 1H), 8.07 (d, 1H), 7.48 (d, 1H), 7.41 (dd, 1H), 7.06 (d, 1H), 4.70 (s, 2H), 4.35 (m, 2H), 3.96 (m, 2H), 3.24 (q, 2H), 2.83 (s, 3H), 2.80 (t, 2H), 2.48 (s, 2H), 1.69 (t, 2H), 1.14 (t, 3H), 0.90 (s, 6H); MS (EI) for C27H34N6O3S: 523 (MH+).

3-[(3,3-difluoroazetidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared according to the method of example 5 by using 5-bromo-3-(3,3-difluoroazetidin-1-ylsulfonyl)pyridin-2-amine (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.55 (d, 1H), 8.34 (s, 1H), 8.14 (d, 1H), 7.52 (d, 1H), 7.44 (dd, 1H), 7.07 (d, 1H), 4.70 (s, 2H), 4.32 (m, 6H), 3.96 (m, 2H), 2.79 (t, 2H), 2.49 (s, 2H), 1.69 (t, 2H), 0.90 (s, 6H); MS (EI) for C27H30F2N6O3S: 523 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxy-1-methylethyl)pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(1-hydroxypropan-2-yl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.43 (d, 1H), 8.34 (s, 1H), 8.20 (d, 1H), 7.50 (d, 1H), 7.42 (dd, 1H), 7.06 (d, 1H), 4.70 (s, 2H), 4.35 (m, 2H), 3.95 (m, 2H), 3.44 (m, 1H), 3.30 (m, 2H), 2.80 (t, 2H), 2.48 (s, 2H), 1.69 (t, 2H), 1.03 (d, 3H), 0.90 (s, 6H); MS (EI) for C27H34N6O4S: 539 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-methylpyridine-3-sulfonamide. Prepared according to the method of example 5 by using 4-chloro-6,6-dimethyl-5,6-dihydroquinazoline (reagent preparation 23) and 2-amino-5-bromo-N-methylpyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.43 (d, 1H), 8.38 (s, 1H), 8.15 (d, 1H), 7.48 (d, 1H), 7.42 (dd, 1H), 7.06 (d, 1H), 6.33 (d, 1H), 6.27 (d, 1H), 4.69 (s, 2H), 4.35 (m, 2H), 3.95 (m, 2H), 2.76 (s, 2H), 2.55 (s, 3H), 1.01 (s, 6H); MS (EI) for C25H28N6O3S: 493 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-fluoroethyl)pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(2-fluoroethyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.43 (d, 1H), 8.34 (s, 1H), 8.17 (d, 1H), 7.49 (d, 1H), 7.41 (dd, 1H), 7.05 (d, 1H), 4.70 (s, 2H), 4.40 (m, 2H), 4.34 (m, 2H), 3.95 (m, 2H), 3.20 (m, 2H), 2.79 (t, 2H), 2.48 (s, 2H), 1.69 (t, 2H), 0.90 (s, 6H); MS (EI) for C26H31FN6O3S: 527 (MH+).

3-[(3-aminopyrrolidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as dihydrochloride salt according to the method of example 5 by using tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.51 (m, 2H), 7.70 (s, 1H), 7.51 (d, 1H), 7.07 (d, 1H), 5.17 (s, 2H), 4.48 (m, 2H), 4.31 (m, 2H), 3.95 (m, 1H), 3.69 (m, 2H), 3.57 (m, 1H), 3.45 (m, 1H), 2.86 (t, 2H), 2.61 (s, 2H), 2.41 (m, 1H), 2.06 (m, 1H), 1.71 (t, 2H), 0.96 (s, 6H); MS (EI) for C28H35N7O3S: 550 (MH+).

1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)piperidin-4-ol. Prepared according to the method of example 5 by using 1-(2-amino-5-bromopyridin-3-ylsulfonyl)piperidin-4-ol (reagent preparation 25) in step 1. MS (EI) for C29H36N6O4S: 565 (MH+).

3-[(3-aminopiperidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as acetate salt according to the method of example 5 by using tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)piperidin-3-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.49 (d, 1H), 8.33 (s, 1H), 8.04 (d, 1H), 7.48 (d, 1H), 7.40 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.58 (m, 1H), 3.38 (m, 1H), 3.19 (m, 1H), 2.97 (m, 1H), 2.88 (m, 1H), 2.80 (t, 2H), 2.49 (s, 2H), 1.93 (s, 3H), 1.87 (m, 2H), 1.67 (m, 3H), 1.42 (m, 1H), 0.91 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

2-amino-N-(2-aminoethyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared as acetate salt according to the method of example 5 by using tert-butyl 2-(2-amino-5-bromopyridine-3-sulfonamido)ethylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.47 (d, 1H), 8.33 (s, 1H), 8.17 (d, 1H), 7.50 (d, 1H), 7.41 (dd, 1H), 7.06 (d, 1H), 4.72 (s, 2H), 4.34 (m, 2H), 3.96 (m, 2H), 3.08 (t, 2H), 2.97 (t, 2H), 2.78 (t, 2H), 2.48 (s, 2H), 1.92 (s, 3H), 1.68 (m, 3H), 0.91 (s, 6H); MS (EI) for C26H33N7O3S: 524 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(3-hydroxypropyl)pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(3-hydroxypropyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.43 (d, 1H), 8.34 (s, 1H), 8.16 (d, 1H), 7.49 (d, 1H), 7.42 (dd, 1H), 7.05 (d, 1H), 4.70 (s, 2H), 4.35 (m, 2H), 3.95 (m, 2H), 3.55 (t, 2H), 2.98 (t, 2H), 2.80 (t, 2H), 2.48 (s, 2H), 1.67 (m, 4H), 0.90 (s, 6H); MS (EI) for C27H34N6O4S: 539 (MH+).

2-amino-N-(3-aminopropyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Prepared as dihydrochloride salt according to the method of example 5 by using tert-butyl 3-(2-amino-5-bromopyridine-3-sulfonamido)propylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.57 (s, 1H), 8.53 (s, 1H), 8.46 (s, 1H), 7.73 (s, 1H), 7.52 (d, 1H), 7.07 (d, 1H), 5.16 (s, 2H), 4.48 (m, 2H), 4.32 (m, 2H), 3.31 (t, 2H), 3.04 (t, 2H), 2.86 (t, 2H), 2.61 (s, 2H), 1.90 (m, 2H), 1.71 (t, 2H), 0.96 (s, 6H); MS (EI) for C27H35N7O3S: 538 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(3,3,3-trifluoro-2-hydroxypropyl)pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(3,3,3-trifluoro-2-hydroxypropyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.44 (d, 1H), 8.34 (s, 1H), 8.18 (d, 1H), 7.48 (d, 1H), 7.42 (dd, 1H), 7.06 (d, 1H), 4.69 (s, 2H), 4.35 (m, 2H), 4.00 (m, 1H), 3.96 (m, 2H), 3.21 (m, 2H), 3.01 (m, 2H), 2.80 (t, 2H), 2.48 (s, 2H), 1.69 (t, 2H), 0.90 (s, 6H); MS (EI) for C27H31F3N6O4S: 593 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-ylsulfonyl)pyridin-2-amine. Prepared as dihydrochloride salt according to the method of example 5 by using tert-butyl 5-(2-amino-5-bromopyridin-3-ylsulfonyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.52 (m, 2H), 8.41 (m, 1H), 7.67 (s, 1H), 7.50 (s, 1H), 7.07 (d, 1H), 5.16 (s, 2H), 4.47 (m, 2H), 4.32 (m, 2H), 3.57 (m, 2H), 3.48 (m, 2H), 3.30 (m, 2H), 3.14 (m, 4H), 2.86 (t, 2H), 2.60 (s, 2H), 1.71 (t, 2H), 0.96 (s, 6H); MS (EI) for C30H37N7O3S: 576 (MH+).

3-[(3-amino-3-methylpyrrolidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as dihydrochloride salt according to the method of example 5 by using tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)-3-methylpyrrolidin-3-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.52 (m, 2H), 8.32 (m, 1H), 7.66 (m, 1H), 7.48 (m, 1H), 7.06 (m, 1H), 5.16 (s, 2H), 4.47 (m, 2H), 4.32 (m, 2H), 3.72-3.44 (m, 2H), 2.86 (t, 2H), 2.60 (s, 2H), 2.16 (m, 2H), 1.71 (t, 2H), 1.45 (m, 3H), 0.96 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+)

3-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-ylsulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as diacetate salt according to the method of example 5 by using (1S,4S)-tert-butyl 5-(2-amino-5-bromopyridin-3-ylsulfonyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.49 (d, 1H), 8.34 (s, 1H), 8.15 (d, 1H), 7.50 (d, 1H), 7.42 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.63 (s, 1H), 4.35 (m, 2H), 4.02 (s, 1H), 3.95 (m, 2H), 3.50-3.05 (m, 4H), 2.79 (t, 2H), 2.49 (s, 2H), 1.95 (s, 6H), 1.79-1.63 (m, 4H), 0.90 (s, 6H); MS (EI) for C29H35N7O3S: 562 (MH+).

3-[(3-amino-3-methylpyrrolidin-1-yl)sulfonyl]-5-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine. Prepared as dihydrochloride salt according to the method of example 5 by using {4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) and tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)-3-methylpyrrolidin-3-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.50 (m, 3H), 7.70 (s, 1H), 7.50 (d, 1H), 7.07 (d, 1H), 5.23 (d, 1H), 5.13 (d, 1H), 4.57 (m, 1H), 4.46 (m, 1H), 4.35 (m, 1H), 4.21 (m, 1H), 3.70 (m, 3H), 3.55 (m, 1H), 3.45 (m, 1H), 2.98 (m, 2H), 2.73 (m, 1H), 2.41 (m, 1H), 2.19 (m, 2H), 2.05 (m, 1H), 1.82 (m, 1H), 1.48 (m, 4H), 1.24 (m, 1H), 1.02 (t, 3H); MS (EI) for C29H37N7O3S: 564 (MH+).

3-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-ylsulfonyl]-5-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine. Prepared as dihydrochloride salt according to the method of example 5 by using {4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) and (1S,4S)-tert-butyl 5-(2-amino-5-bromopyridin-3-ylsulfonyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.65 (s, 1H), 8.52 (s, 2H), 7.74 (s, 1H), 7.53 (d, 1H), 7.08 (d, 1H), 5.24 (d, 1H), 5.14 (d, 1H), 4.56 (m, 2H), 4.46 (m, 1H), 4.36 (m, 1H), 4.21 (m, 1H), 3.69 (m, 3H), 3.53 (m, 1H), 3.38 (m, 1H), 2.99 (m, 2H), 2.74 (m, 1H), 2.42 (m, 1H), 2.05 (m, 3H), 1.83 (m, 1H), 1.47 (m, 2H), 1.24 (m, 1H), 1.01 (t, 3H); MS (EI) for C29H35N7O3S: 562 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(2S)-pyrrolidin-2-ylmethyl]pyridine-3-sulfonamide. Prepared as dihydrochloride salt according to the method of example 5 by using (R)-tert-butyl 2-((2-amino-5-bromopyridine-3-sulfonamido)methyl)pyrrolidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.66-8.48 (m, 3H), 7.75 (m, 1H), 7.52 (m, 1H), 7.06 (d, 1H), 5.16 (s, 2H), 4.48 (m, 2H), 4.31 (m, 2H), 3.73 (m, 1H), 2.86 (t, 2H), 2.61 (s, 2H), 2.17 (m, 1H), 2.07 (m, 2H), 1.72 (m, 3H), 0.95 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(2R)-pyrrolidin-2-ylmethyl]pyridine-3-sulfonamide. Prepared as dihydrochloride salt according to the method of example 5 by using (S)-tert-butyl 2-((2-amino-5-bromopyridine-3-sulfonamido)methyl)pyrrolidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.78 (s, 1H), 8.54 (s, 1H), 8.49 (s, 1H), 7.84 (s, 1H), 7.56 (m, 1H), 7.07 (d, 1H), 5.18 (s, 2H), 4.49 (m, 2H), 4.31 (m, 2H), 3.75 (m, 1H), 3.38 (m, 2H), 2.86 (m, 2H), 2.62 (s, 2H), 2.20 (m, 1H), 2.08 (m, 2H), 1.74 (m, 3H), 0.95 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

3-(2,6-diazaspiro[3.3]hept-2-ylsulfonyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as diacetate salt according to the method of example 5 by using tert-butyl 6-(2-amino-5-bromopyridin-3-ylsulfonyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.52 (d, 1H), 8.33 (s, 1H), 8.09 (d, 1H), 7.50 (d, 1H), 7.43 (dd, 1H), 7.06 (d, 1H), 4.71 (s, 2H), 4.34 (m, 2H), 4.06 (s, 8H), 3.96 (m, 2H), 2.80 (t, 2H), 2.49 (s, 2H), 1.93 (s, 2H), 1.93 (s, 6H), 1.69 (t, 2H), 0.92 (s, 6H); MS (EI) for C29H35N7O3S: 562 (MH+).

3-[(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-ylsulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as dihydrochloride salt according to the method of example 5 by using (1R,4R)-tert-butyl 5-(2-amino-5-bromopyridin-3-ylsulfonyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, methanol-d4): 8.53 (m, 2H), 8.29 (m, 1H), 7.64 (s, 1H), 7.48 (d, 1H), 7.05 (d, 1H), 5.15 (s, 2H), 4.47 (m, 2H), 4.31 (m, 2H), 3.57 (m, 2H), 3.50 (m, 1H), 2.85 (t, 2H), 2.61 (s, 2H), 1.95 (m, 2H), 1.71 (t, 2H), 0.90 (s, 6H); MS (EI) for MS (EI) for C29H35N7O3S: 562 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-piperidin-4-ylpyridine-3-sulfonamide. Prepared as dihydrochloride salt according to the method of example 5 by using tert-butyl 4-(2-amino-5-bromopyridine-3-sulfonamido)piperidine-1-carboxylate (reagent preparation 25) in step 1 followed by Boc deprotection. MS (EI) for C29H37N7O3S: 564 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]sulfonyl}pyridin-2-amine. Prepared as dihydrochloride salt according to the method of example 5 by using 5-bromo-3-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)pyridin-2-amine (reagent preparation 25) in step 1. 1H NMR (400 MHz, methanol-d4): 8.48 (d, 1H), 8.34 (s, 1H), 8.14 (d, 1H), 7.49 (d, 1H), 7.42 (dd, 1H), 7.06 (d, 1H), 4.70 (s, 2H), 4.51 (s, 1H), 4.34 (m, 2H), 3.95 (m, 2H), 3.69 (s, 1H), 3.53 (d, 1H), 3.28 (m, 1H), 3.00 (d, 1H), 2.92 (m, 1H), 2.79 (t, 2H), 2.50 (s, 3H), 2.48 (s, 2H), 1.96 (s, 6H), 1.95 (m, 1H), 1.68 (t, 2H), 1.58 (d, 1H), 0.91 (s, 3H), 0.90 (s, 3H); MS (EI) for MS (EI) for C30H37N7O3S: 576 (MH+).

3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Synthesized according to the method of example 5 using (R)-tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate (reagent preparation 25) and [4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1 and BOC group deprotection. 1H NMR (400 MHz, d6-DMSO): 8.54 (s, 1H), 8.48 (br s, 1H), 8.01 (d, 1H), 8.58 (d, 1H), 7.47 (dd, 1H), 7.02 (d, 1H), 6.76 (br s, 2H), 5.99 (d, 1H), 4.60 (s, 2H), 4.32 (m, 2H), 383 (m, 2H), 3.40-3.32 (m, 4H), 3.30-3.26 (m, 2H), 2.90 (m, 1H), 2.70 (s, 2H), 1.97 (s, 3H), 1.89 (s, 6H), 1.63 (m, 1H), 0.93 (s, 6H); MS (EI) for C29H35N7O3S: 562 (MH+).

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-3H-imidazo[4,5-c]pyridin-7-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 5 using 7-bromo-3-((2-methoxyethoxy)methyl)-2-methyl-3H-imidazo[4,5-c]pyridine (reagent preparation 19) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.72 (s, 1H), 8.48 (br s, 1H) 8.36 (s, 1H), 8.11 (br s, 1H), 7.62 (br m, 1H), 7.22 (br d, 1H), 4.67 (s, 2H), 4.36 (m, 2H), 3.88 (m, 2H), 2.70 (t, 2H), 2.57 (s, 3H), 2.47 (s, 2H), 1.59 (t, 2H), 0.85 (s, 6H); MS (EI) for C26H28N6O: 441 (MH+).

2-amino-N-[(3R)-1-methylpyrrolidin-3-yl]-5-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Synthesized according to the method of example 5 using (S)-2-amino-5-bromo-N-(1-methylpyrrolidin-3-yl)pyridine-3-sulfonamide (reagent preparation 25) and [4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.52 (d, 1H), 8.07 (d, 1H), 7.61 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.68 (br s, 2H), 4.57 (s, 2H), 4.25 (br t, 2H), 3.82 (br m, 2H), 3.63 (br m, 1H), 2.65 (t, 2H), 2.43 (m, 4H), 2.33 (s, 3H), 2.22 (br m, 2H), 2.13 (s, 3H), 1.84 (s, 5H), 1.57 (t, 2H), 1.45 (m, 1H), 0.83 (s, 6H); MS (EI) for C30H39N7O3S: 578 (MH+).

2-amino-N-[(3R)-1-methylpyrrolidin-3-yl]-5-[4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. Synthesized according to the method of example 5 using (S)-2-amino-5-bromo-N-(1-methylpyrrolidin-3-yl)pyridine-3-sulfonamide (reagent preparation 25) and [4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.52 (d, 1H), 8.37 (s, 1H), 8.12 (s, H), 8.06 (d, 1H), 7.56 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.69 (br s, 2H), 6.12 (s, 1H), 4.62 (s, 2H), 4.32 (br t, 2H), 3.84 (br m, 2H), 3.63 (br s, 1H), 2.68 (s, 2H), 2.44 (m, 2H), 2.26-2.16 (m, 2H), 2.14 (s, 3H), 1.88 (s, 3H), 1.86 (s, 2H), 1.48-1.42 (m, 1H), 0.91 (s, 6H); MS (EI) for C30H37N7O3S: 576 (MH+).

3-{[(3S)-3-aminopyrrolidin-1-yl]sulfonyl}-5-{4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine. Synthesized according to the method of example 5 using (S)-tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate (reagent preparation 25) and {4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) in step 1 and BOC group deprotection. 1H NMR (400 MHz, d6-DMSO): 8.80 (s, 1H), 8.65 (d, 1H), 8.41 (m, 2H), 8.22 (m, 1H), 8.04 (d, 1H), 7.78 (s, 1H), 7.53 (d, 1H), 7.35 (m, 2H), 6.98 (br m, 2H), 5.43 (S, 2H), 4.62 (s, 2H), 4.49 (s, 2H), 3.92 (s, 3H), 3.79 (m, 1H), 3.69 (m, 1H), 3.55-3.45 (m, 3H), 3.32 (m, 2H), 2.20 (m, 1H), 1.91 (M, 1H); MS (EI) for C27H29N7O4S: 548 (MH+).

N-(2-chloro-5-{4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-3-yl)methanesulfonamide. Synthesized according to the method of example 5 using N-(5-bromo-2-chloropyridin-3-yl)methanesulfonamide (reagent preparation 25) and {4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO): 8.92 (br s, 1H), 8.75 (s, 1H), 8.62 (d, 1H), 8.19 (d, 1H), 8.10 (d, 1H), 7.89 (s, 1H), 7.62 (dd, 1H), 7.33 (dd, 1H), 7.25 (d, 1H), 7.04 (d, 1H), 5.41 (s, 2H), 4.65 (s, 2H), 4.47 (s, 2H), 3.96 (s, 3H), 3.19 (s, 3H); MS (EI) for C24H22ClN5O4S: 514 (MH+).

N-[6-(4-{2-[(dimethylamino)methyl]-7-(methyloxy)quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide. Synthesized according to the method of example 5 using N-(6-bromothiazolo[5,4-b]pyridin-2-yl)acetamide (J. Heterocyclic Chemistry 2003, 40, 261) and {4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO) δ 12.60 (s, 1H), 8.86 (d, 1H), 8.45 (d, 1H), 8.23-8.07 (m, 2H), 7.70 (dd, 1H), 7.27-7.17 (m, 2H), 7.02 (d, 1H), 5.43 (s, 2H), 4.65-4.57 (m, 2H), 4.46 (s, 2H), 4.43-4.37 (m, 2H), 3.94 (s, 3H), 2.73 (s, 6H), 2.25 (s, 3H); MS (EI) for C29H29N7O3S: 556 (MH+).

(3S)-1-({2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-amine. Prepared as in example 5 using (R)-tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate (reagent preparation 25) in step 1 and BOC group deprotection. 1H NMR (400 MHz, CD3OD) δ 8.83 (d, 1H), 8.59 (d, 1H), 8.33 (s, 1H), 7.68 (d, 1H), 7.58 (dd, 1H), 7.12 (d, 1H), 4.75 (s, 2H), 4.44-4.33 (m, 2H), 4.01-3.92 (m, 2H), 3.75-3.42 (m, 4H), 3.23 (dd, 1H), 2.79 (t, 2H), 2.47 (s, 2H), 2.28-2.09 (m, 1H), 1.88-1.77 (m, 1H), 1.69 (t, 2H), 0.90 (s, 6H); MS (ES) for C28H33ClN6O3S: 569.2 (MH+).

3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as in example 5 using (R)-tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)pyrrolidin-3-ylcarbamate (reagent preparation 25) and [4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1 and BOC group deprotection. 1H NMR (400 MHz, d6-DMSO) δ 8.54 (s, 1H), 8.37 (s, 1H), 8.01 (d, 1H), 7.57 (d, 1H), 7.48 (dd, 1H), 7.02 (d, 1H), 6.76 (s, 2H), 6.13 (d, 1H), 4.62 (s, 2H), 4.33 (s, 2H), 3.84 (s, 2H), 3.44-3.20 (m, 3H), 2.89 (d, 1H), 2.69 (s, 2H), 1.88 (d, 5H), 1.53 (s, 1H), 0.92 (s, 6H); MS (ES) for C29H35N7O3S: 562.2 (MH+).

2-amino-N-(azetidin-3-ylmethyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. The diacetate salt was prepared as in example 5 using tert-butyl 3-((2-amino-5-bromopyridine-3-sulfonamido)methyl)azetidine-1-carboxylate (reagent preparation 25) in step 1 and BOC group deprotection. 1H NMR (400 MHz, d6-DMSO) δ 8.52 (d, 1H), 8.37 (s, 1H), 8.06 (d, 1H), 7.60 (d, 1H), 7.46 (dd, 1H), 7.03 (d, 1H), 6.68 (bs, 2H), 4.62 (s, 2H), 4.37-4.24 (m, 2H), 3.87-3.77 (m, 2H), 3.48 (t, 2H), 3.26-3.14 (m, 2H), 2.96 (d, 2H), 2.76-2.56 (m, 3H), 2.45 (s, 2H), 1.60 (t, 2H), 0.84 (s, 6H); MS (ES) for C28H35N7O3S: 550.2 (MH+).

2-amino-N-(2-amino-2-methylpropyl)-5-[4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide. The diacetate salt was prepared as in example 5 using 2-amino-N-(2-amino-2-methylpropyl)-5-bromopyridine-3-sulfonamide (reagent preparation 25) and [4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.05 (d, 1H), 7.55 (s, 1H), 7.45 (d, 1H), 7.02 (d, 1H), 6.73 (s, 2H), 6.12 (s, 1H), 4.62 (s, 2H), 4.38-4.26 (m, 2H), 3.88-3.79 (m, 2H), 2.69 (s, 2H), 2.60 (s, 2H), 2.50 (s, 3H), 1.02-0.83 (m, 12H); MS (ES) for C29H37N7O3S: 564.3 (MH+).

7-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 5 using 7-bromo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine in step 1. 1H NMR (400 MHZ, DMSO-d6): 8.37 (s, 1H), 7.89 (d, 1H), 7.54 (d, 1H), 7.39 (dd, 1H), 7.22 (d, 1H), 6.97 (d, 1H), 6.83 (s, 1H), 4.57 (s, 2H), 4.29 (br s, 2H), 4.14 (tr, 2H), 3.82 (br s, 2H), 3.42 (br s, 2H), 2.71 (tr, 2H), 2.45 (tr, 2H), 1.60 (tr, 2H), 0.85 (s, 6H); MS (EI) for C26H29N5O2: 444 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyrimidin-2-amine. Synthesized according to the method of example 5 using 5-bromo-2-aminopyrimidine in step 1. 1H NMR (400 MHZ, DMSO-d6): 8.54 (s, 2H), 8.37 (s, 1H), 7.59 (d, 1H), 7.44 (dd, 1H), 7.00 (d, 1H), 6.75 (s, 2H), 4.59 (s, 2H), 4.30 (br s, 2H), 3.83 (br s, 2H), 2.71 (tr, 2H), 2.45 (s, 2H), 1.60 (tr, 2H), 0.84 (s, 6H); MS (EI) for C23H26N6O: 403 (MH+).

(2E)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-iminopyrimidin-1(2H)-ol. Synthesized according to the method of example 5 using 5-bromo-2-iminopyrimidin-1(2H)-ol in step 1. 1H NMR (400 MHZ, CD3OD): 8.59 (d, 1H), 8.38 (d, 1H), 8.34 (s, 1H), 7.55 (d, 1H), 7.44 (dd, 1H), 7.08 (d, 1H), 4.72 (s, 2H), 4.35 (tr, 2H), 3.95 (tr, 2H), 2.79 (tr, 2H), 2.46 (s, 2H), 1.68 (tr, 2H), 0.90 (s, 6H); MS (EI) for C23H26N6O2: 419 (MH+).

5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(ethylsulfonyl)pyridin-2-amine. Synthesized according to the method of example 5 using 5-bromo-3-(ethylsulfonyl)pyridin-2-amine (reagent preparation 34) in step 1. 1H NMR (400 MHZ, CD3CN): 8.56 (d, 1H), 8.37 (s, 1H), 8.10 (d, 1H), 7.50 (d, 1H), 7.45 (dd, 1H), 7.06 (d, 1H), 6.13 (s, 2H), 4.64 (s, 2H), 4.34 (tr, 2H), 3.90 (tr, 2H), 3.24 (q, 2H), 2.78 (tr, 2H), 2.46 (s, 2H), 1.66 (tr, 2H), 1.23 (tr, 3H), 0.90 (s, 6H). MS (EI) for C26H31N5SO3: 494 (MH+).

3-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)propane-1,2-diol. Synthesized according to the method of example 5 using 3-(2-amino-5-bromopyridin-3-ylsulfonyl)propane-1,2-diol in step 1. 1H NMR (400 MHZ, CD3OD): 8.49 (d, 1H), 8.33 (s, 1H), 8.18 (d, 1H), 7.50 (d, 1H), 7.42 (dd, 1H), 7.04 (d, 1H), 4.69 (s, 2H), 4.34 (tr, 2H), 4.15-4.06 (m, 1H), 3.95 (tr, 2H), 3.54-3.37 (m, 4H), 2.79 (tr, 2H), 2.48 (s, 2H), 1.68 (tr, 2H), 0.90 (s, 6H). MS (EI) for C27H33N5SO5: 540 (MH+).

3-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)propan-1-ol. Synthesized according to the method of example 5 using 3-(2-amino-5-bromopyridin-3-ylsulfonyl)propan-1-ol (reagent preparation 34) in step 1. 1H NMR (400 MHZ, CD3OD): 8.52 (d, 1H), 8.34 (s, 1H), 8.14 (d, 1H), 7.50 (d, 1H), 7.42 (dd, 1H), 7.06 (d, 1H), 4.69 (d, 2H), 4.34 (tr, 2H), 3.95 (tr, 2H), 3.61 (tr, 2H), 3.37-3.33 (m, 2H), 2.80 (tr, 2H), 2.48 (s, 2H), 1.94-1.86 (m, 2H), 1.69 (tr, 2H), 0.90 (s, 6H). MS (EI) for C27H33N5SO4: 524 (MH+).

(2S)-3-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-2-methylpropan-1-ol. Synthesized according to the method of example 5 using (S)-3-(2-amino-5-bromopyridin-3-ylsulfonyl)-2-methylpropan-1-ol (reagent preparation 34) in step 1. 1H NMR (400 MHZ, CD3OD): 8.51 (d, 1H), 8.33 (s, 1H), 8.15 (d, 1H), 7.50 (d, 1H), 7.42 (dd, 1H), 7.05 (d, 1H), 4.69 (s, 2H), 4.34 (tr, 2H), 3.95 (tr, 2H), 3.52-3.37 (m, 3H), 3.06 (dd, 1H), 2.79 (tr, 2H), 2.48 (s, 2H), 2.23-2.16 (m, 1H), 1.68 (tr, 2H), 1.08 (d, 3H), 0.90 (s, 6H). MS (EI) for C28H35N5SO4: 538 (MH+).

(2R)-3-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-2-methylpropan-1-ol. Synthesized according to the method of example 5 using (R)-3-(2-amino-5-bromopyridin-3-ylsulfonyl)-2-methylpropan-1-ol (reagent preparation 34) in step 1. 1H NMR (400 MHZ, CD3OD): 8.51 (d, 1H), 8.33 (s, 1H), 8.15 (d, 1H), 7.50 (d, 1H), 7.42 (dd, 1H), 7.05 (d, 1H), 4.69 (s, 2H), 4.34 (tr, 2H), 3.95 (tr, 2H), 3.52-3.37 (m, 3H), 3.06 (dd, 1H), 2.79 (tr, 2H), 2.48 (s, 2H), 2.23-2.16 (m, 1H), 1.68 (tr, 2H), 1.08 (d, 3H), 0.90 (s, 6H). MS (EI) for C28H35N5SO4: 538 (MH+).

7-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2H-pyrido[2,3-e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxide. Synthesized according to the method of example 5 using 7-bromo-2H-pyrido-[2,3-e][1,2,4]-thiadiazin-3(4H)-one 1,1-dioxide (reagent preparation 37) in step 1. 1H NMR (400 MHZ, CD3OD): 8.66 (d, 1H), 8.39 (s, 1H), 8.24 (d, 1H), 7.61 (d, 1H), 7.50 (dd, 1H), 7.07 (d, 1H), 4.81 (s, 2H), 4.38 (tr, 2H), 4.04 (tr, 2H), 2.80 (tr, 2H), 2.51 (tr, 2H), 1.68 (tr, 2H), 0.91 (s, 6H). MS (EI) for C25H26N6SO4: 507 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonic acid. Synthesized according to the method of example 5 using 2-amino-5-bromopyridine-3-sulfonic acid (reagent preparation 38) in step 1. 1H NMR (400 MHZ, CD3OD): 8.37 (s, 1H), 8.24 (d, 1H), 8.20 (d, 1H), 7.49 (d, 1H), 7.40 (dd, 1H), 7.03 (d, 1H), 4.74 (s, 2H), 4.35 (tr, 2H), 3.99 (tr, 2H), 2.80 (tr, 2H), 2.49 (s, 2H), 1.68 (tr, 2H), 0.90 (s, 6H). MS (EI) for C24H27N5SO4: 482 (MH+).

N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-(phenylamino)pyridin-3-yl}methanesulfonamide. Synthesized according to the method of example 5 using N-(5-bromo-2-(phenylamino)pyridin-3-yl)methanesulfonamide (reagent preparation 39) in step 1. 1H NMR (400 MHZ, DMSO-d6): 9.27 (br s, 1H), 8.35 (s, 2H), 8.30 (s, 1H), 7.78 (s, 1H), 7.67 (d, 2H), 7.57 (s, 1H), 7.44 (d, 1H), 7.27 (s, 2H), 7.01 (d, 1H), 6.94 (s, 1H), 4.62 (br s, 2H), 4.30 (br s, 2H), 3.82 (br s, 2H), 3.05 (s, 3H), 2.69 (br s, 2H), 2.42 (s, 2H), 1.58 (br s, 2H), 0.83 (s, 6H). MS (EI) for C31H34N6SO3: 572 (MH+).

N-{2-(dimethylamino)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide. Synthesized according to the method of example 5 using N-(5-bromo-2-(dimethylamino)pyridin-3-yl)methanesulfonamide (reagent preparation 39) in step 1. 1H NMR (400 MHZ, DMSO-d6): 9.09 (br s, 1H), 8.36 (s, 1H), 8.35 (d, 1H), 7.71 (d, 1H), 7.56 (d, 1H), 7.44 (dd, 1H), 7.03 (d, 1H), 4.64 (s, 2H), 4.32 (br, 2H), 3.84 (br, 1H), 3.11 (s, 3H), 2.94 (s, 6H), 2.71 (tr, 2H), 2.44 (s, 2H), 1.60 (tr, 2H), 0.85 (s, 6H). MS (EI) for C27H34N6SO3: 523 (MH+).

3-[(4-aminopiperidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine. Prepared as a dihydrochloride salt according to the method of example 5 by using tert-butyl 1-(2-amino-5-bromopyridin-3-ylsulfonyl)piperidin-4-ylcarbamate (reagent preparation 25) in step 1 followed by Boc deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.72 (s, 1H), 8.66 (d, 1H), 8.39 (br s, 3H), 8.10 (d, 1H), 7.73 (s, 1H), 7.54 (d, 1H), 7.00 (d, 1H), 5.11 (s, 2H), 4.53-4.45 (m, 2H), 4.37-4.22 (m, 4H, buried), 3.78 (d, 2H), 3.14 (br s, 1H), 2.86-2.78 (m, 2H), 2.73 (t, 2H), 2.53 (s, 2H), 2.00 (d, 2H), 1.68-1.52 (m, 4H), 0.85 (s, 6H); MS (EI) for C29H37N7O3S: 564 (MH+).

2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxy-2-methylpropyl)pyridine-3-sulfonamide. Prepared according to the method of example 5 by using 2-amino-5-bromo-N-(2-hydroxy-2-methylpropyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, 1H), 8.37 (s, 1H), 8.05 (d, 1H), 7.71 (t, 1H), 7.58 (d, 1H), 7.45 (dd, 1H), 7.02 (d, 1H), 6.74 (br s, 2H), 4.62 (s, 2H), 4.31 (s, 2H), 3.83 (s, 2H), 2.71 (t, 2H), 2.64 (d, 2H), 2.44 (s, 2H), 1.59 (t, 2H), 1.04 (s, 6H), 0.84 (s, 6H); MS (EI) for C28H36N6O4S: 553 (MH+).

6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-ethyl-1H-imidazo[4,5-b]pyridin-2-amine. Prepared as in example 5 using 6-bromo-N-ethyl-3-(methoxymethyl)-3H-imidazo[4,5-b]pyridin-2-amine (reagent preparation 36) in step 1 and MOM group deprotection. 1H NMR (400 MHz, CD3OD) δ 8.53 (s, 1H), 8.29 (d, 1H), 7.99 (d, 1H), 7.72 (d, 1H), 7.53 (dd, 1H), 7.07 (d, 1H), 5.17 (s, 2H), 4.48 (m, 2H), 4.32 (m, 2H), 3.56 (q, 2H), 2.86 (t, 2H), 2.61 (s, 2H), 1.70 (t, 2H), 1.36 (t, 3H); MS (ES) for C27H31N7O: 470 (MH+).

1-{4-[7-(1,3-benzothiazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-7-(methyloxy)-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine. The trifluoroacetate salt was synthesized according to the method of example 5 using 5-bromobenzo[d]thiazole and (4-{2-[(dimethylamino)methyl]-7-methoxy-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO) δ 9.45 (s, 1H), 8.36 (d, 1H), 8.26 (d, 1H), 7.81 (m, 2H), 7.64 (dd, 1H), 7.05 (d, 1H), 4.84 (s, 2H), 4.41 (m, 2H), 4.30 (s, 2H), 3.97 (m, 2H), 3.35 (s, 3H), 3.28 (t, 1H), 3.00 (dd, 1H), 2.80 (s, 6H), 2.72 (dd, 1H), 2.62 (d, 1H), 2.44 (d, 1H), 0.85 (d, 6H). MS (ES) for C30H35N5O2S: 530 (MH+).

1-{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-7-(methyloxy)-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine. The bistrifluoroacetate salt was synthesized according to the method of example 5 using isobutyl 6-bromo-2-methyl-1H-imidazo[4,5-b]pyridine-1-carboxylate (reagent preparation 19) and (4-{2-[(dimethylamino)methyl]-7-methoxy-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (reagent preparation 23) in step 1. 1H NMR (400 MHz, d6-DMSO) δ 9.55 (s, 1H), 8.75 (d, 1H), 8.31 (s, 1H), 7.80 (d, 1H), 7.63 (dd, 1H), 7.09 (d, 1H), 4.82 (s, 2H), 4.42 (m, 2H), 4.30 (s, 2H), 3.97 (m, 2H), 3.35 (s, 3H), 3.27 (t, 1H), 3.00 (dd, 1H), 2.81 (s, 6H), 2.72 (m, 1H), 2.71 (s, 3H), 2.61 (d, 1H), 2.43 (d, 1H), 0.83 (d, 6H); MS (ES) for C30H37N7O2: 528 (MH+).

6-(4-{2-[(dimethylamino)methyl]-7-(methyloxy)quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine. The dihydrochloride salt was synthesized according to the method of example 5 using N-(6-bromothiazolo[5,4-b]pyridin-2-yl)acetamide (J. Heterocyclic Chem 2003, 40, 261) and (4-{2-[(dimethylamino)methyl]-7-methoxyquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (reagent preparation 23) in step 1 and acetyl group hydrolysis. 1H NMR (400 MHz, d6-DMSO) δ 8.48 (d, 1H), 8.16-7.96 (m, 4H), 7.94 (d, 1H), 7.60 (dd, 1H), 7.26-7.17 (m, 2H), 7.00 (d, 1H), 5.37 (s, 2H), 4.63-4.53 (m, 2H), 4.43 (s, 2H), 4.41-4.31 (m, 2H), 3.93 (s, 3H), 2.76 (s, 6H); MS (ES) for C27H27N7O2S: 514 (MH+).

Example 6 1-{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine

STEP 1: A mixture of isobutyl 6-bromo-2-methyl-1H-imidazo[4,5-b]pyridine-1-carboxylate (2.2 g, 7.1 mmol) (reagent preparation 19), (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (2.7 g, 9.2 mmol, example 1, step 2), potassium acetate (2.8 g, 28.3 mmol), and dichloro[1,1-bis(diphenylphosphino]-ferrocenepalladium (II) dichloromethane adduct (0.78 g, 1.1 mmol) in dioxane (50 ml) was stirred at 95° C. under nitrogen for 29 h. The mixture was cooled to room temperature, filtered through celite, and the filter cake was washed with ethyl acetate (100 ml). The filtrate was concentrated and purified by column chromatography on silica (0-100% ethyl acetate in hexanes) to give 1,1-dimethylethyl 7-(2-methyl-1-{[(2-methylpropyl)oxy]carbonyl}-1H-imidazo[4,5-b]pyridine-6-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)carboxylate (1.1 g, 33% yield) as a yellow solid. 1H NMR (400 MHz, CDCl3): 8.74 (d, 1H), 8.39 (s, 1H), 7.47 (d, 1H), 7.43 (s, 1H), 7.14 (d, 1H), 4.50 (s, 2H), 4.34 (d, 2H), 4.12 (m, 2H), 3.88 (m, 2H), 2.96 (s, 3H), 2.22 (m, 1H), 1.42 (s, 9H), 1.21 (d, 6H); MS (EI) for C26H32N4O5: 481 (MH+).

STEP 2: A mixture of 1,1-dimethylethyl 7-(2-methyl-1-{[(2-methylpropyl)-oxy]carbonyl}-1H-imidazo[4,5-b]pyridine-6-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)carboxylate (1.1 g, 2.3 mmol) in methanol (6 ml) and 4 N hydrochloric acid in dioxane (12 ml) was stirred at room temperature for 1 h and then concentrated. The resulting solid was triturated with ethyl acetate to afford the hydrochloride salt of 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate (0.92 g, 91% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6): 9.78 (s, 1H), 8.79 (d, 1H), 8.42 (d, 1H), 7.88 (d, 1H), 7.70 (dd, 1H), 7.24 (d, 1H), 4.42 (brs, 2H), 4.32 (d, 2H), 4.27 (brs, 2H), 3.50 (brs, 2H), 2.82 (s, 3H), 2.19 (m, 1H), 1.06 (d, 6H); MS (EI) for C21H24N4O3: 381 (MH+).

STEP 3: A solution of 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (73 mg, 0.16 mmol), 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (41 mg, 0.16 mmol, reagent preparation 17), and diisopropylethyl amine (0.13 ml, 0.8 mmol) in N-methylpyrrolidinone (1.5 mL) was stirred at 135° C. for 3 h. Purification by preparatory HPLC (0.1% aqueous ammonium acetate-acetonitrile) provided the triacetate salt of the title Compound (10 mg, 9% yield). 1H NMR (400 MHz, methanol-d4) δ 8.53 (d, 1H), 8.07 (d, 1H), 7.64 (d, 1H), 7.51 (dd, 1H), 7.08 (d, 1H), 4.79 (s, 2H), 4.38 (s, 2H), 4.01 (s, 2H), 3.84 (s, 2H), 2.81 (t, 2H), 2.64 (s, 3H), 2.55 (s, 6H), 1.92 (s, 9H), 1.68 (t, 2H), 0.91 (s, 6H); MS (EI) for C29H35N7O: 498 (MH+)

Using analogous synthetic techniques and substituting with alternative starting reagents the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-ethylethanamine. Prepared as triacetate salt according to the method of example 6 by using N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-ethylethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4) δ 8.52 (s, 1H), 8.06 (s, 1H), 7.63 (s, 1H), 7.52 (d, 1H), 7.08 (d, 1H), 4.80 (s, 2H), 4.39 (m, 2H), 4.05 (s, 2H), 4.02 (m, 2H), 3.05 (q, 4H), 2.82 (t, 2H), 2.64 (s, 3H), 2.52 (s, 2H), 1.92 (s, 9H), 1.69 (t, 2H), 1.17 (t, 6H), 0.91 (s, 6H); MS (EI) for C31H39N7O: 526 (MH+).

4-[6,6-dimethyl-2-(morpholin-4-ylmethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as acetate salt according to the method of example 6 by using 4-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)morpholine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4) δ 1H NMR (400 MHz, methanol-d4) δ 8.53 (s, 1H), 8.06 (s, 1H), 7.64 (s, 1H), 7.49 (d, 1H), 7.06 (d, 1H), 4.78 (s, 2H), 4.36 (s, 2H), 4.36 (s, 2H), 4.00 (s, 2H), 3.58 (s, 4H), 3.49 (s, 2H), 2.79 (t, 2H), 2.64 (s, 3H), 2.50 (s, 3H), 2.46 (m, 4H), 1.95 (s, 3H), 1.68 (t, 2H), 0.92 (s, 6H); MS (EI) for C31H37N7O2: 540 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-ethylpropan-2-amine. Prepared according to the method of example 6 by using N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-ethylpropan-2-amine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4) δ 1H NMR (400 MHz, methanol-d4) δ 8.52 (s, 1H), 8.06 (s, 1H), 7.63 (s, 1H), 7.51 (d, 1H), 7.08 (d, 1H), 4.79 (s, 2H), 4.37 (s, 2H), 4.01 (m, 2H), 2.81 (t, 2H), 2.64 (s, 3H), 2.51 (s, 2H), 1.68 (t, 2H), 1.07 (m, 9H), 0.91 (s, 6H); MS (EI) for C32H41N7O: 540 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-methylpropan-1-amine. Prepared according to the method of example 6 by using N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-2-methylpropan-1-amine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4) δ 1H NMR (400 MHz, methanol-d4) δ 8.53 (s, 1H), 8.06 (s, 1H), 7.63 (d, 1H), 7.51 (dd, 1H), 7.07 (d, 1H), 4.81 (s, 2H), 4.37 (s, 2H), 4.02 (m, 2H), 3.78 (s, 2H), 2.79 (t, 2H), 2.64 (s, 3H), 2.51 (s, 2H), 2.43 (s, 2H), 1.68 (m, 3H), 0.93 (s, 6H), 0.82 (d, 6H); MS (EI) for C31H39N7O: 526 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclopropanamine. Prepared according to the method of example 6 by using N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)cyclopropanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4) δ 1H NMR (400 MHz, methanol-d4) δ 8.57 (s, 1H), 8.10 (s, 1H), 7.70 (d, 1H), 7.51 (dd, 1H), 7.04 (d, 1H), 4.83 (s, 2H), 4.35 (s, 2H), 4.01 (m, 2H), 3.70 (s, 2H), 2.77 (t, 2H), 2.64 (s, 3H), 2.50 (s, 2H), 2.00 (m, 1H), 1.67 (t, 2H), 0.94 (s, 6H), 0.24 (m, 2H), 0.13 (m, 2H); MS (EI) for C30H35N7O: 510 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2,2-difluoroethanamine. Prepared according to the method of example 6 by using benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(2,2-difluoroethyl)carbamate (reagent preparation 17) in step 3 followed by Cbz deprotection. 1H NMR (400 MHz, methanol-d4) 6 1H NMR (400 MHz, methanol-d4) δ 8.53 (s, 1H), 8.06 (s, 1H), 7.64 (d, 1H), 7.50 (dd, 1H), 7.07 (d, 1H), 5.75 (m, 1H), 4.79 (s, 2H), 4.37 (s, 2H), 4.01 (m, 2H), 3.72 (s, 2H), 2.78 (m, 4H), 2.64 (s, 3H), 2.50 (s, 2H), 1.68 (t, 2H), 0.92 (s, 6H); MS (EI) for C29H33F2N7O: 534 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclobutanamine. Prepared as acetate salt according to the method of example 6 by using benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(cyclobutyl)carbamate (reagent preparation 17) in step 3 followed by Cbz deprotection. 1H NMR (400 MHz, methanol-d4) δ 1H NMR (400 MHz, methanol-d4) δ 8.54 (s, 1H), 8.07 (s, 1H), 7.65 (s, 1H), 7.52 (d, 1H), 7.08 (d, 1H), 4.82 (s, 2H), 4.38 (m, 2H), 4.03 (m, 2H), 3.82 (m, 2H), 3.51 (m, 1H), 2.80 (t, 2H), 2.64 (s, 3H), 2.51 (s, 2H), 2.07 (m, 2H), 1.92 (s, 3H), 1.83 (m, 2H), 1.68 (m, 4H), 0.92 (s, 6H); MS (EI) for C31H37N7O: 524 (MH+).

{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl acetate. Prepared according to the method of example 6 by using (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl acetate (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4) δ 1H NMR (400 MHz, methanol-d4) δ 8.53 (s, 1H), 8.07 (s, 1H), 7.61 (d, 1H), 7.50 (dd, 1H), 7.09 (d, 1H), 4.99 (s, 2H), 4.74 (s, 2H), 4.34 (m, 2H), 3.99 (m, 2H), 2.78 (t, 2H), 2.64 (s, 3H), 2.50 (s, 2H), 2.08 (s, 3H), 1.67 (t, 2H), 0.92 (s, 6H); MS (EI) for C29H32N6O3: 513 (MH+).

6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methanol. Prepared from {6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl acetate by ester saponification using standard techniques. 1H NMR (400 MHz, methanol-d4) δ 1H NMR (400 MHz, methanol-d4) δ 8.54 (s, 1H), 8.08 (s, 1H), 7.65 (d, 1H), 7.50 (dd, 1H), 7.08 (d, 1H), 4.78 (s, 2H), 4.48 (s, 2H), 4.35 (m, 2H), 4.03 (m, 2H), 2.79 (t, 2H), 2.64 (s, 3H), 2.50 (s, 2H), 1.68 (t, 2H), 0.92 (s, 6H); MS (EI) for C27H30N6O2: 471 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)alanine. Prepared as acetate salt according to the method of example 6 by using ethyl 2-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methylamino)propanoate (reagent preparation 17) in step 3 followed by saponification using standard techniques. 1H NMR (400 MHz, methanol-d4) δ 1H NMR (400 MHz, methanol-d4) δ 8.51 (s, 1H), 8.07 (d, 1H), 7.64 (s, 1H), 7.52 (dd, 1H), 7.09 (d, 1H), 4.82 (s, 2H), 4.40 (m, 2H), 4.15 (s, 2H), 4.05 (m, 2H), 3.66 (q, 1H), 2.81 (t, 2H), 2.64 (s, 3H), 2.52 (s, 2H), 1.94 (s, 3H), 1.68 (t, 2H), 1.45 (d, 3H), 0.91 (d, 6H); MS (EI) for C30H35N7O3: 542 (MH+).

4-[5-(cyclopropylmethyl)-6-methylpyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-5-(cyclopropylmethyl)-6-methylpyrimidine (reagent preparation 5) in step 3. 1H NMR (400 MHz, methanol-d4) δ 8.51 (s, 1H), 8.35 (s, 1H), 8.05 (s, 1H), 7.61 (d, 1H), 7.51 (dd, 1H), 7.09 (d, 1H), 4.69 (s, 2H), 4.41-4.33 (m, 2H), 3.95-3.86 (m, 2H), 2.70 (d, 2H), 2.63 (s, 3H), 2.48 (s, 3H), 0.96-0.81 (m, 1H), 0.46-0.31 (m, 4H); MS (EI) for C25H26N6O: 427 (MH+).

4-(5-ethyl-6-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-5-ethyl-6-methylpyrimidine in step 3. 1H NMR (400 MHz, methanol-d4) δ 8.51 (s, 1H), 8.33 (s, 1H), 8.04 (s, 1H), 7.59 (d, 1H), 7.51 (dd, 1H), 7.09 (d, 1H), 4.71 (s, 2H), 4.37 (m, 2H), 3.90 (m, 2H), 2.74 (q, 2H), 2.64 (s, 3H), 2.44 (s, 3H), 1.20 (t, 3H); MS (EI) for C23H24N6O: 401 (MH+).

4-(5-ethyl-2,6-dimethylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-5-ethyl-2,6-dimethylpyrimidine (reagent preparation 8) in step 3. 1H NMR (400 MHz, methanol-d4) δ 8.86 (d, 1H), 8.44 (d, 1H), 7.83 (d, 1H), 7.61 (dd, 1H), 7.09 (d, 1H), 5.16 (s, 2H), 4.50 (m, 2H), 4.27 (m, 2H), 2.92 (s, 3H), 2.78 (q, 2H), 2.51 (s, 3H), 2.49 (s, 3H), 1.22 (t, 3H); MS (EI) for C24H26N6O: 415 (MH+).

4-[5-(cyclopropylmethyl)-2,6-dimethylpyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-5-(cyclopropylmethyl)-2,6-dimethylpyrimidine (reagent preparation 8) in step 3. 1H NMR (400 MHz, methanol-d4) δ 8.52 (s, 1H), 8.05 (s, 1H), 7.63 (d, 1H), 7.51 (dd, 1H), 7.09 (d, 1H), 4.66 (s, 2H), 4.33 (m, 2H), 3.91 (m, 2H), 2.67 (d, 2H), 2.64 (s, 3H), 2.44 (s, 3H), 2.42 (s, 3H), 0.87 (m, 1H), 0.38 (m, 4H); MS (EI) for C26H28N6O: 441 (MH+).

7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[5-(cyclopropylmethyl)-2,6-dimethylpyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 1-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (reagent preparation 19) and 4-chloro-5-(cyclopropylmethyl)-2,6-dimethylpyrimidine (reagent preparation 8) in step 3. 1H NMR (400 MHz, methanol-d4) δ 8.71 (s, 1H), 8.25 (s, 1H), 7.78 (d, 1H), 7.58 (dd, 1H), 7.09 (d, 1H), 5.14 (s, 2H), 4.50 (m, 2H), 4.29 (m, 2H), 2.72 (d, 2H), 2.52 (s, 3H), 2.51 (s, 3H), 2.39 (m, 1H), 1.43 (m, 4H), 0.88 (m, 1H), 0.50 (m, 2H), 0.10 (m, 2H); MS (EI) for C28H30N6O: 467 (MH+).

7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 1-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (reagent preparation 19) and 4-chloro-2,6,6-trimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 8) in step 3. 1H NMR (400 MHz, methanol-d4) δ 8.50 (s, 1H), 7.98 (s, 1H), 7.61 (d, 1H), 7.49 (dd, 1H), 7.09 (d, 1H), 4.71 (s, 2H), 4.32 (m, 2H), 3.97 (m, 2H), 2.75 (t, 2H), 2.46 (s, 2H), 2.40 (s, 3H), 2.21 (m, 1H), 1.66 (t, 2H), 1.22 (m, 4H), 0.91 (s, 6H); MS (EI) for C29H32N6O: 481 (MH+).

1-cyclopropyl-N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)ethanamine. Prepared according to the method of example 6 by using N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-1-cyclopropylethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4) δ 8.52 (s, 1H), 8.05 (s, 1H), 7.63 (d, 1H), 7.50 (dd, 1H), 7.08 (d, 1H), 5.49 (s, 2H), 4.80 (s, 2H), 4.37 (m, 2H), 4.02 (m, 2H), 3.81 (m, 1H), 2.79 (m, 2H), 2.64 (s, 3H), 2.50 (s, 3H), 1.68 (m, 2H), 1.07 (d, 3H), 0.92 (s, 6H), 0.60 (m, 1H), 0.40 (m, 2H), 0.14 (m, 1H); MS (EI) for C32H39N7O: 538 (MH+).

1-{5-(cyclopropylmethyl)-4-methyl-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine. Prepared according to the method of example 6 by using 1-(4-chloro-5-(cyclopropylmethyl)-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4) δ 8.52 (s, 1H), 8.05 (s, 1H), 7.64 (d, 1H), 7.49 (dd, 1H), 7.07 (d, 1H), 4.73 (s, 2H), 4.37 (m, 2H), 3.95 (m, 2H), 3.50 (s, 2H), 2.70 (d, 2H), 2.65 (s, 3H), 2.48 (s, 3H), 2.27 (s, 6H), 0.88 (m, 1H), 0.39 (m, 2H), 0.02 (m, 2H); MS (EI) for C28H33N7O: 538 (MH+).

4-(5,6-dimethylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-5,6-dimethylpyrimidine in step 3. 1H NMR (400 MHz, methanol-d4): 8.50 (s, 1H), 8.31 (s, 1H), 8.04 (s, 1H), 7.57 (s, 1H), 7.50 (d, 1H), 7.09 (d, 1H), 4.71 (s, 2H), 4.35 (m, 2H), 3.93 (s, 2H), 2.64 (s, 3H), 2.39 (s, 3H), 2.27 (s, 3H); MS (EI) for C22H22N6O: 387 (MH+).

4-(6-ethyl-5-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-6-ethyl-5-methylpyrimidine (reagent preparation 5) in step 3. 1H NMR (400 MHz, methanol-d4): 8.72 (d, 1H), 8.51 (s, 1H), 8.26 (d, 1H), 7.74 (d, 1H), 7.57 (dd, 1H), 7.08 (d, 1H), 5.17 (s, 2H), 4.48 (m, 2H), 4.27 (m, 2H), 2.82 (q, 2H), 2.80 (s, 3H), 2.38 (s, 3H), 1.29 (t, 3H); MS (EI) for C23H24N6O: 401 (MH+).

4-(5-bromo-6-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 5-bromo-4-chloro-6-methylpyrimidine in step 3. 1H NMR (400 MHz, methanol-d4): 8.49 (br. s, 1H), 8.33 (s, 1H), 8.02 (br. s, 1H), 7.60 (d, 1H), 7.48 (dd, 1H), 7.08 (d, 1H), 5.05 (s, 2H), 4.36 (m, 2H), 4.16 (m, 2H), 2.64 (s, 3H), 2.55 (s, 3H); MS (EI) for C21H19BrN6O: 451/453 (MH+).

7-(2-ethyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as trifluoroacetate salt according to the method of example 6 by using 2-methylpropyl 2-ethyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (reagent preparation 19) and 4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin (reagent preparation 8) in step 3. 1H NMR (400 MHz, methanol-d4): 8.67 (d, 1H), 8.19 (d, 1H), 7.76 (s, 1H), 7.57 (d, 1H), 7.09 (d, 1H), 5.13 (s, 2H), 4.45 (m, 2H), 4.31 (m, 2H), 3.09 (m, 2H), 2.81 (m, 2H), 2.57 (s, 2H), 2.50 (s, 3H), 1.68 (m, 2H), 1.48 (m, 3H), 0.94 (s, 6H); MS (EI) for C28H32N6O: 469 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-methylpropan-2-amine. Prepared as acetate salt according to the method of example 6 by using N-[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl]-2-methylpropanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4): 8.52 (d, 1H), 8.06 (d, 1H), 7.63 (d, 1H), 7.52 (dd, 1H), 7.09 (d, 1H), 4.83 (s, 2H), 4.39 (m, 2H), 4.04 (m, 4H), 2.82 (m, 2H), 2.64 (s, 3H), 2.52 (s, 2H), 1.92 (s, 3H), 1.69 (m, 2H), 1.29 (s, 9H), 0.92 (s, 6H); MS (EI) for C31H39N7O: 526 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2,2,2-trifluoroethanamine. Prepared according to the method of example 6 by using N-[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl]-2,2,2-trifluoroethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4): 8.53 (s, 1H), 8.06 (s, 1H), 7.65 (d, 1H), 7.50 (dd, 1H), 7.07 (d, 1H), 4.80 (s, 2H), 4.37 (m, 2H), 4.01 (m, 2H), 3.75 (s, 2H), 3.03 (q, 2H), 2.77 (m, 2H), 2.64 (s, 3H), 2.50 (s, 2H), 1.68 (m, 2H), 0.92 (s, 6H); MS (EI) for C29H32F3N7O: 552 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclopentanamine. Prepared as acetate salt according to the method of example 6 by using phenylmethyl[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl]cyclopentylcarbamate (reagent preparation 17) in step 3 followed by Cbz deprotection. 1H NMR (400 MHz, methanol-d4): 8.53 (s, 1H), 8.07 (s, 1H), 7.65 (d, 1H), 7.51 (dd, 1H), 7.07 (d, 1H), 4.84 (s, 2H), 4.36 (m, 2H), 4.03 (m, 2H), 3.81 (s, 2H), 3.13 (m, 1H), 2.78 (m, 2H), 2.64 (s, 3H), 2.51 (s, 2H), 1.89 (s, 3H), 1.76 (m, 2H), 1.68 (m, 2H), 1.54 (m, 2H), 1.43 (m, 2H), 1.25 (m, 2H), 0.92 (s, 6H); MS (EI) for C32H39N7O: 538 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)ethanamine. Prepared as acetate salt according to the method of example 6 by using phenylmethyl[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl](2-fluoroethyl)carbamate (reagent preparation 17) in step 3 followed by Cbz deprotection. 1H NMR (400 MHz, methanol-d4): 8.52 (d, 1H), 8.06 (d, 1H), 7.63 (d, 1H), 7.52 (dd, 1H), 7.09 (d, 1H), 4.82 (s, 2H), 4.40 (m, 2H), 4.05 (s, 2H), 4.03 (m, 2H), 2.99 (q, 2H), 2.80 (m, 2H), 2.64 (s, 3H), 2.52 (s, 2H), 1.91 (s, 3H), 1.69 (m, 2H), 1.17 (t, 3H), 0.91 (s, 6H); MS (EI) for C29H35N7O: 498 (MH+).

1-{4,5-dimethyl-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine. Prepared as triacetate salt according to the method of example 6 by using 1-(4-chloro-5,6-dimethylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4): 8.51 (d, 1H), 8.05 (d, 1H), 7.62 (d, 1H), 7.49 (dd, 1H), 7.06 (d, 1H), 4.78 (s, 2H), 4.36 (m, 2H), 3.97 (m, 2H), 3.79 (s, 2H), 2.64 (s, 3H), 2.49 (s, 6H), 2.41 (s, 3H), 2.27 (s, 3H), 1.91 (s, 9H); MS (EI) for C25H29N7O: 444 (MH+).

(2R)—N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)butan-2-amine. Prepared as a trifluoroacetate salt according to the method of example 6 by using 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate and (R)-benzyl sec-butyl((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)carbamate (reagent preparation 17) in step 3 followed by Cbz deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.69 (br s, 3H), 8.24 (br s, 1H), 7.80 (s, 1H), 7.62 (d, 1H), 7.09 (d, 1H), 4.79 (s, 2H), 4.43-4.36 (m, 2H), 4.17-4.11 (m, 2H), 4.00-3.94 (m, 2H), 3.15 (br s, 1H), 2.75 (t, 2H), 2.67 (s, 2H), 2.50 (s, 2H, buried), 1.79-1.66 (m, 1H), 1.62 (t, 2H), 1.46-1.33 (m, 1H), 1.17 (d, 3H), 0.89-0.78 (m, 9H); MS (EI) for C31H39N7O: 526 (MH+).

(2S)—N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)butan-2-amine. Prepared according to the method of example 6 by using 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate and (S)-benzyl sec-butyl((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)carbamate (reagent preparation 17) in step 3 followed by Cbz deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.61-8.44 (m, 1H), 8.12-7.93 (m, 1H), 7.71 (d, 1H), 7.54 (dd, 1H), 7.03 (d, 1H), 4.67 (s, 2H), 4.35-4.27 (m, 2H), 3.92-3.84 (m, 2H), 3.56 (q, 2H), 2.69 (t, 3H), 2.54 (s, 2H), 2.45 (s, 3H), 2.42-2.30 (m, 1H), 1.59 (t, 2H), 1.27 (dd, 2H), 1.18-1.04 (m, 1H), 0.87 (s, 6H), 0.83 (d, 3H), 0.70 (t, 3H); MS (EI) for C31H39N7O: 526 (MH+).

1-{4-ethyl-5-methyl-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine. Prepared according to the method of example 6 by using 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate and 1-(4-chloro-6-ethyl-5-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (br s, 1H), 8.03 (br s, 1H), 7.70 (d, 1H), 7.52 (dd, 1H), 7.03 (d, 1H), 4.61 (s, 2H), 4.33-4.28 (m, 2H), 3.84-3.79 (m, 2H), 3.36 (s, 2H), 2.63 (q, 2H), 2.53 (d, 3H), 2.20 (s, 3H), 2.13 (s, 6H), 1.89 (s, 3H), 1.14 (t, 3H); MS (EI) for C26H31N7O: 458 (MH+).

1-{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methanamine. Prepared as an acetate salt by the method of example 6 using 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate and 2-(azidomethyl)-4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 45) in step 3 followed by reduction of the azide to the amine (LaRock, R. C. Comprehensive Organic Transformations: A Guide to Functional Group Preparations 1989, VCH Publishers, Inc., New York). 1H NMR (400 MHz, DMSO-d6) δ 8.52 (d, 1H), 8.04 (d, 1H), 7.74 (d, 1H), 7.54 (dd, 1H), 7.04 (d, 1H), 4.68 (s, 2H), 4.34-4.28 (m, 2H), 3.92-3.87 (m, 2H), 3.63-3.59 (m, 2H), 2.69 (t, 2H), 2.54 (s, 3H), 2.46 (s, 2H), 1.86 (s, 5H), 1.59 (t, 2H), 0.86 (s, 6H); MS (EI) for C27H31N7O: 470 (MH+).

1-{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}-N-methylmethanamine. Prepared by the method of example 6 using 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate and N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-methyl-2-nitrobenzenesulfonamide (reagent preparation 17) in step 3 followed by 2-nitrobenzenesulfonyl-group deprotection. 1H NMR (400 MHz, DMSO-d6) δ 8.53 (br s, 1H), 8.06 (br s, 1H), 7.75 (d, 1H), 7.53 (dd, 1H), 7.01 (d, 1H), 4.68 (s, 2H), 4.33-4.27 (m, 2H), 3.91-3.85 (m, 2H), 3.48 (s, 2H), 2.68 (t, 2H), 2.54 (s, 3H), 2.45 (s, 2H), 2.12 (s, 3H), 1.59 (t, 2H), 0.87 (s, 6H); MS (EI) for C28H33N7O: 484 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-fluoroethanamine. Prepared by the method of example 6 using 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate and benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(2-fluoroethyl)carbamate (reagent preparation 17) in step 3 followed by Cbz deprotection. 1H NMR (400 MHz, DMSO-d6) δ 12.83 (s, 0.5H), 12.55 (s, 0.5H), 8.57 (d, 0.5H), 8.49 (d, 0.5H), 8.09 (d, 0.5H), 7.97 (d, 0.5H), 7.73 (d, 1H), 7.54 (dd, 1H), 7.03 (dd, 1H), 4.68 (s, 2H), 4.45 (t, 1H), 4.38-4.25 (m, 3H), 3.93-3.82 (m, 2H), 3.66 (s, 2H), 2.85-2.65 (m, 4H), 2.57-2.52 (m, 3H), 2.46 (s, 2H), 1.59 (t, 2H), 0.86 (s, 6H); MS (EI) for C29H34FN7O: 516 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)methanesulfonamide. Prepared by the method of example 6 using 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate and N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)methanesulfonamide (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6) δ 8.52 (br s, 1H), 8.05 (br s, 1H), 7.74 (d, 1H), 7.56 (dd, 1H), 7.27 (t, 1H), 7.06 (d, 1H), 4.68 (s, 2H), 4.37-4.31 (m, 2H), 4.12 (d, 2H), 3.93-3.87 (m, 2H), 2.85 (s, 3H), 2.71 (t, 2H), 2.54 (s, 3H), 2.47 (s, 2H), 1.60 (t, 2H), 0.85 (s, 6H); MS (EI) for C28H33N7O3S: 548 (MH+).

1-{5-ethyl-4-methyl-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine. Prepared as a diacetate salt by the method of example 6 using 2-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate and 1-(4-chloro-5-ethyl-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (br s, 1H), 8.03 (br s, 1H), 7.67 (d, 1H), 7.52 (dd, 1H), 7.02 (d, 1H), 4.63 (s, 2H), 4.35-4.30 (m, 2H), 3.83-3.78 (m, 2H), 3.32 (s, 2H), 2.65-2.57 (m, 1H), 2.54 (s, 3H), 2.52-2.45 (m, 1H (buried)), 2.36 (s, 3H), 2.10 (s, 6H), 1.86 (s, 8H), 1.15 (t, 3H); MS (EI) for C28H31N7O: 458 (MH+).

1-{4-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine. Prepared as acetate according to the method of example 6 by using 2-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate (reagent preparation 19) in step 1 and 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.49 (s, 1H), 7.98 (s, 1H), 7.68 (d, 1H), 7.51 (dd, 1H), 7.01 (d, 1H), 4.63 (s, 2H), 4.30 (m, 2H), 3.85 (m, 2H), 2.68 (m, 2H), 2.44 (s, 2H), 2.14 (m, 1H), 2.10 (s, 6H), 1.88 (s, 2H), 1.59 (m, 2H), 1.10 (m, 4H), 0.85 (s, 6H). MS (EI) for C31H37N7O: 524 (MH+).

4-[6,6-dimethyl-2-({[2-(methyloxy)ethyl]oxy}methyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-6,6-dimethyl-2-({[2-(methyloxy)ethyl]oxy}methyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. MS (EI) for C30H36N6O3: 529 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-(methyloxy)ethanamine. Prepared according to the method of example 6 by using N-[(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl]-2-(methyloxy)ethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO): 9.50 (brs, 1H), 8.89 (s, 1H), 8.46 (s, 1H), 8.06 (brs, 1H), 7.69 (dd, 1H), 7.08 (d, 1H), 5.08 (brs, 1H), 4.48 (s, 2H), 4.26 (s, 2H), 4.12 (m, 2H), 3.54 (m, 1H), 3.20 (s, 3H), 3.12 (m, 2H), 2.84 (s, 3H), 2.76 (m, 2H), 2.54 (s, 2H), 2.51 (s, 3H), 1.62 (m, 2H), 0.84 (s, 6H). MS (EI) for C30H37N7O2: 527 (MH+).

4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using (7S)-4-chloro-7-ethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. 1H NMR (400 MHz, Methanol-d4): 8.49 (br, 1H), 8.32 (s, 1H), 8.04 (br, 1H), 7.57 (s, 1H), 7.46 (d, 1H), 7.08 (d, 1H), 4.74 (b, 2H), 4.42 (m, 1H), 4.27 (m, 1H), 4.08 to 3.89 (m, 2H), 2.94 to 2.80 (m, 2H), 2.65 (s, 3H), 2.60 (m, 1H), 2.29 (m, 1H), 1.97 (m, 1H), 1.72 (m, 1H), 1.40 (m, 2H), 1.11 (m, 1H), 0.97 (t, 3H); MS (EI) for C26H28N6O: 441 (MH+).

4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using (7S)-4-chloro-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 8) in step 3. 1H NMR (400 MHz, Methanol-d4): 8.39 (s, 1H), 7.95 (s, 1H), 7.52 (s, 1H), 7.31 (d, 1H), 6.98 (d, 1H), 4.75 (b, 2H), 4.43 (m, 1H), 4.12 (m, 1H), 4.00 (m, 1H), 3.88 (m, 1H), 2.82 to 2.67 (m, 2H), 2.54 (s, 3H), 2.49 (m, 1H), 2.28 (s, 3H), 2.19 (m, 1H), 1.86 (m, 1H), 1.63 (m, 1H), 1.31 (m, 2H), 1.05 (m, 1H), 0.91 (t, 3H); MS (EI) for C27H30N6O: 455 (MH+).

4-[6,6-dimethyl-2-(pyrrolidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetic acid salt according to the method of example 6 by using 4-chloro-6,6-dimethyl-2-(pyrrolidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. 1H NMR (400 MHz, Methanol-d4): 8.95 (br, 1H), 8.44 (br, 1H), 7.85 (s, 1H), 7.59 (s, 1H), 7.48 (d, 1H), 7.12 (d, 1H), 5.09 (s, 2H), 4.56 (s, 2H), 4.54 (m, 2H), 4.22 (m, 2H), 3.38 (m, 4H), 2.85 (t, 2H), 2.85 (s, 3H), 2.56 (s, 2H), 1.93 (m, 4H), 1.68 (t, 2H), 0.90 (s, 6H); MS (EI) for C31H37N7O: 524 (MH+).

1-{6,6-dimethyl-4-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylethanamine. Prepared according to the method of example 6 by using 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylethanamine (reagent preparation 46) in step 3. 1H NMR (400 MHz, Methanol-d4): 8.52 (s, 1H), 8.04 (s, 1H), 7.63 (s, 1H), 7.54 (d, 1H), 7.03 (d, 1H), 5.03 (s, 2H), 4.78 (m, 2H), 3.99 (m, 2H), 3.52 (s, 1H), 2.77 (t, 2H), 2.63 (s, 3H), 2.49 (s, 2H), 2.13 (s, 6H), 1.66 (t, 2H), 1.28 (d, 3H), 0.91 (s, 6H); MS (EI) for C30H37N7O: 512 (MH+).

4-[6,6-dimethyl-2-(1-pyrrolidin-1-ylethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-6,6-dimethyl-2-(1-pyrrolidin-1-ylethyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 46) in step 3. 1H NMR (400 MHz, Methanol-d4): 8.54 (s, 1H), 8.05 (s, 1H), 7.65 (s, 1H), 7.48 (d, 1H), 7.05 (d, 1H), 4.77 (s, 2H), 4.37 (m, 2H), 4.02 (m, 2H), 3.57 (s, 1H), 2.77 (t, 2H), 2.67 (m, 2H), 2.63 (s, 3H), 2.50 (s, 2H), 2.47 (m, 2H), 1.69 to 1.64 (m, 6H), 1.37 (d, 3H), 0.90 (s, 6H); MS (EI) for C32H39N7O: 538 (MH+).

Phenylmethyl(2S)-2-{6,6-dimethyl-4-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}pyrrolidine-1-carboxylate. Prepared according to the method of example 6 by using phenylmethyl((2S))-2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate (reagent preparation 18) in step 3. 1H NMR (400 MHz, Methanol-d4): 8.47 (s, 0.35H), 8.43 (s, 0.65H), 7.99 (s, 0.35H), 7.95 (0.65H), 7.48 (br, 1H), 7.45 to 7.38 (m, 2H), 7.32 (br, 1H), 7.08 to 7.01 (m, 3H), 6.72 (dd, 1H), 5.03 (dd, 2H), 4.77 (s, 0.35H), 4.73 (s, 0.65H), 4.69 to 4.64 (m, 3H), 4.44 to 4.21 (m, 2H), 4.01 to 3.77 (m, 2H), 3.53 to 3.58 (m, 2H), 2.78 to 1.68 (m, 2H), 2.63 (s, 3H), 2.51 (d, 2H), 2.25 (m, 1H), 1.76 (m, 1H), 1.64 (m, 2H), 0.98 to 0.83 (m, 6H); MS (EI) for C38H41N7O3: 644 (MH+).

4-{6,6-dimethyl-2-[(2S)-pyrrolidin-2-yl]-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using phenylmethyl((2S))-2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate (reagent preparation 18) in step 3 followed by Cbz group deprotection. 1H NMR (400 MHz, Methanol-d4): 8.53 (s, 1H), 8.07 (s, 1H), 7.67 (s, 1H), 7.52 (d, 1H), 7.08 (d, 1H), 4.84 (s, 2H), 4.50 (m, 1H), 4.38 (m, 2H), 4.02 (m, 2H), 3.27 to 3.10 (m, 3H), 2.82 (t, 2H), 2.66 (s, 3H), 2.51 (s, 2H), 2.33 (m, 1H), 1.99 (m, 1H), 1.81 (m, 1H), 1.68 (t, 2H), 0.90 (d, 6H); MS (EI) for C30H35N7O: 510 (MH+).

4-{6,6-dimethyl-2-[(2R)-pyrrolidin-2-yl]-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using phenylmethyl(2R)-2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylat (reagent preparation 18) in step 3 followed by Cbz group deprotection. 1H NMR (400 MHz, Methanol-d4): 8.55 (s, 1H), 8.09 (s, 1H), 7.67 (s, 1H), 7.52 (d, 1H), 7.07 (d, 1H), 4.85 (s, 2H), 4.49 (m, 1H), 4.38 (m, 2H), 4.01 (m, 2H), 3.28 to 3.10 (m, 3H), 2.79 (t, 2H), 2.63 (s, 3H), 2.52 (s, 2H), 2.32 (m, 1H), 1.99 (m, 1H), 1.79 (m, 1H), 1.67 (t, 2H), 0.91 (d, 6H); MS (EI) for C30H35N7O: 510 (MH+).

4-(6,6-dimethyl-2-pyrrolidin-2-yl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using phenylmethyl 2-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)pyrrolidine-1-carboxylate (reagent preparation 18) in step 3 followed by Cbz group deprotection. 1H NMR (400 MHz, Methanol-d4): 8.53 (s, 1H), 8.08 (s, 1H), 7.67 (s, 1H), 7.51 (d, 1H), 7.04 (d, 1H), 4.83 (s, 2H), 4.37 (m, 3H), 4.02 (m, 2H), 3.27 (m, 1H), 3.17 to 3.01 (m, 2H), 2.80 (t, 2H), 2.64 (s, 3H), 2.51 (s, 2H), 2.28 (m, 1H), 1.90 (m, 1H), 1.76 (m, 1H), 1.69 (t, 2H), 0.91 (d, 6H); MS (EI) for C30H35N7O: 510 (MH+).

4-{6,6-dimethyl-2-[(methyloxy)methyl]-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-6,6-dimethyl-2-[(methyloxy)methyl]-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. 1H NMR (400 MHz, Methanol-d4): 8.55 (br, 1H), 8.07 (br, 1H), 7.66 (s, 1H), 7.50 (d, 1H), 7.08 (d, 1H), 4.76 (s, 2H), 4.37 (s, 2H), 4.32 (m, 2H), 4.01 (m, 2H), 3.33 (s, 3H), 2.77 (t, 2H), 2.63 (s, 3H), 2.49 (s, 2H), 1.67 (t, 2H), 0.91 (s, 6H); MS (EI) for C28H32N6O2: 485 (MH+).

4-(2-ethenyl-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-[6,6-dimethyl-2-(2-pyrrolidin-1-ylethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine in step 3. 1H NMR (400 MHz, Methanol-d4): 8.51 (s, 1H), 8.07 (s, 1H), 7.63 (s, 1H), 7.49 (d, 1H), 7.06 (d, 1H), 6.59 (dd, 1H), 6.40 (d, 1H), 5.51 (d, 1H), 4.77 (2H), 4.37 (m, 2H), 4.00 (m, 2H), 2.77 (t, 2H), 2.63 (s, 3H), 2.51 (s, 2H), 1.67 (t, 2H), 0.92 (s, 6H); MS (EI) for C28H30N6O: 485 (MH+).

4-[6,6-dimethyl-2-(2-pyrrolidin-1-ylethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-6,6-dimethyl-2-(2-pyrrolidin-1-ylethyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 8) in step 3. 1H NMR (400 MHz, Methanol-44): 8.56 (s, 1H), 8.11 (s, 1H), 7.68 (s, 1H), 7.52 (d, 1H), 7.06 (d, 1H), 4.81 (2H), 4.37 (m, 2H), 4.00 (m, 2H), 3.34 (m, 2H), 2.99 (m, 6H), 2.75 (t, 2H), 2.64 (s, 3H), 2.49 (s, 2H), 1.95 (m, 4H), 1.67 (t, 2H), 0.92 (s, 6H); MS (EI) for C32H39N7O: 538 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(5-methylpyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-5-methylpyrimidine in step 3. 1H NMR (400 MHz, d6-DMSO): 8.89 (d, 1H), 8.80 (s, 1H), 8.45 (d, 1H), 8.28 (s, 1), 7.91 (d, 1H), 7.69 (dd, 1H), 7.10 (d, 1H), 5.27 (s, 2H), 4.50 (m, 2H), 4.33 (m, 2H), 2.84 (s, 3H), 2.43 (s, 3H), 1.76 (s, 3H); MS (EI) for C21H20N6O: 373 (MH+).

4-[2,6-dimethyl-5-(1-methylethyl)pyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-5-isopropyl-2,6-dimethylpyrimidine (reagent preparation 8) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.74 (s, 1H), 8.29 (s, 1H), 7.82 (s, 1H), 7.63 (dd, 1H), 7.30 (s, 1H), 7.17 (s, 1H), 7.04 (s, 1H), 5.06 (s, 2H), 4.50 (m, 2H), 4.03 (m, 2H), 3.08 (m, 1H) 2.71 (s, 3H), 2.54 (s, 3H), 2.41 (s, 3H), 1.32 (d, 6H); MS (EI) for C25H28N6O: 429 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[6-methyl-5-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-5-isopropyl-6-methylpyrimidine (reagent preparation 5) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.81 (s, 1H), 8.64 (s, 1H), 8.36 (s, 1H), 7.65 (d, 1H), 7.03 (d, 1H), 5.04 (s, 2H), 4.53 (s, 2H), 4.02 (s, 2H), 3.11 (m, 1H), 2.76 (s, 3H), 2.56 (s, 3H), 1.34 (d, 6H); MS (EI) for C24H26N6O: 415 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(7-methyl-7-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-7-methyl-7-phenyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.49 (s, 1H), 8.37 (s, 1H), 7.92 (d, 1H), 7.48 (d, 1H), 7.31 (s, 1H), 7.29 (s, 1H), 7.22 (d, 1H), 7.13 (m, 2H), 7.02 (m, 1H), 6.94-6.80 (m, 1H), 4.42-4.56 (m, 2H), 4.32 (m, 2H), 3.94 (d, 1H), 3.76 (m, 1H), 3.14 (d, 1H), 2.81 (d, 1H), 2.68 (d, 1H), 2.55 (d, 3H), 2.55 (d, 3H), 2.29 (m, 1H), 2.09 (m, 1H), 1.84 (m, 1H), 1.32 (s, 3H); MS (EI) for C31H30N6O: 503 (MH+).

N,N,2-trimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidine-5-sulfonamide. Synthesized according to the method of example 6 using 4-chloro-N,N,2-trimethylpyrimidine-5-sulfonamide in step 3. 1H NMR (400 MHz, d6-DMSO): 8.51 (s, 1H), 8.03 (s, 1H), 7.94 (s, 1H), 7.52 (dd, 1H) 7.04 (d, 1H), 6.71 (d, 1H), 5.05 (s, 2H), 4.31 (d, 2H), 4.24 (d, 2H), 2.84 (s, 6H), 2.54 (s, 3H), 2.40 (s, 3H); MS (EI) for C23H25N7O3S: 480 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[2-methyl-5-(morpholin-4-ylsulfonyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-(4-chloro-2-methylpyrimidin-5-ylsulfonyl)morpholine in step 3. 1H NMR (400 MHz, d6-DMSO): 8.58 (s, 1H), 8.50 (d, 1H), 8.03 (d, 1H), 7.81 (s, 1H), 7.53 (d, 1H), 7.03 (d, 1H), 5.04 (s, 2H), 4.29 (s, 2H), 3.61 (s, 2H), 3.12 (s, 2H), 2.42 (s, 3H); MS (EI) for C25H27N7O4S: 522 (MH+).

7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using isobutyl 6-bromo-2-cyclopropyl-1H-imidazo[4,5-b]pyridine-1-carboxylate (reagent preparation 19) in step 1 and 4-chloro-6,6-dimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.64 (s, 1H), 8.61 (s, 1H), 8.14 (m, 1H), 7.77 (d 1H), 7.59 (dd, 1H), 7.04 (d, 1H), 6.47 (d, 1H), 6.34 (d, 1H), 5.00 (s, 2H), 4.46 (m, 2H), 4.11 (s, 2H), 2.83 (s, 2H), 2.24 (m, 1H), 1.24-1.18 (m, 5H), 0.99 (s, 6H); MS (EI) for C28H28N6O: 465 (MH+).

4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-6,6-dimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.64 (s, 1H), 8.59 (s, 1H), 8.18 (s, 1H), 7.77 (d, 1H), 7.60 (dd, 1H), 7.05 (d, 1H), 6.43 (d, 1H), 6.32 (d, 1H), 4.94 (s, 2H), 4.43 (m, 2H), 4.06 (br s, 2H), 2.82 (s, 2H), 2.62 (s, 3H), 0.99 (s, 6H); MS (EI) for C26H26N6O: 439 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-6,6,8-trimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.74 (d, 1H), 8.54 (s, 1H), 8.30 (d, 1H), 7.77 (d, 1H), 7.61 (dd, 1H), 7.05 (d, 1H), 6.09 (s, 1H), 4.82 (s, 2H), 4.42 (m, 2H), 3.96 (br s, 2H), 2.73 (s, 2H), 2.69 (s, 3H), 1.96 (d, 3H), 0.92 (s, 6H); MS (EI) for C27H26N6O: 453 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6,7,8-tetramethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-6,6,7,8-tetramethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.69 (s, 1H), 8.53 (s, 1H), 8.24 (s, 1H), 7.77 (d, 1H), 7.61 (dd, 1H), 7.06 (d, 1H), 4.86 (s, 2H), 4.42 (m, 2H), 4.00 (br s, 2H), 2.71 (s, 2H), 2.66 (s, 3H), 1.97 (s, 3H), 1.87 (s, 3H), 0.88 (s, 6H); MS (EI) for C28H30N6O: 467 (MH+).

N,N-dimethyl-1-{4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-7-(methyloxy)quinazolin-2-yl}methanamine. Synthesized according to the method of example 6 using 1-(4-chloro-7-methoxyquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 20) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.59-8.50 (br d, 1H), 8.11-7.98 (br d, 1H), 7.94 (d, 1H), 7.76 (d, 1H), 7.53 (dd, 1H), 7.16 (d, 1H), 7.08 (dd, 1H), 6.99 (d, 1H), 5.06 (s, 2H), 4.46 (s, 2H), 4.21 (m, 2H), 3.89 (s, 3H), 3.45 (s, 2H), 2.52 (s, 3H), 2.13 (s, 6H), 1.91 (s, 2H); MS (EI) for C28H29N7O2: 496 (MH+).

1-{6-fluoro-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-2-yl}-N,N-dimethylmethanamine. Synthesized according to the method of example 6 using 1-(4-chloro-6-fluoroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 20) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.63-8.54 (br d, 1H), 8.15-8.03 (br d, 1H), 7.90-7.75 (m, 4H), 7.58 (dd, 1H), 7.02 (d, 1H), 5.16 (s, 1H), 4.54 (br m, 2H), 4.27 (br m, 2H), 4.00 (br s, 2H), 3.34 (s, 6H), 2.54 (s, 3H); MS (EI) for C27H26FN7O: 484 (MH+).

4-{2-[(3,3-difluoropyrrolidin-1-yl)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 2-((3,3-difluoropyrrolidin-1-yl)methyl)-4,6,6-trimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.88 (d, 1H), 8.44 (d, 1H), 7.99 (s, 1H), 7.67 (dd, 1H), 7.05 (d, 1H), 5.08 (s, 1H), 4.49 (br m, 2H), 4.15 (br m, 2H), 4.10 (br s, 2H), 3.24 (br t, 2H), 3.10 (br m, 2), 2.81 (m, 4H), 2.54 (s, 2H), 2.31-2.23 (m, 2H), 1.59 (t, 2H), 0.87 (s, 6H); MS (EI) for C31H35F2N7O: 560 (MH+).

4′-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]. The dihydrochloride salt was prepared as in example 6 using 4′-chloro-7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline] (reagent example 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.87 (d, 1H), 8.53 (s, 1H), 8.41 (d, 1H), 7.80 (d, 1H), 7.61 (dd, 1H), 7.11 (d, 1H), 5.19 (s, 2H), 4.48 (t, 2H), 4.31 (t, 2H), 2.93 (t, 2H), 2.91 (s, 3H), 2.72 (bs, 2H), 1.75 (t, 3H), 0.52-0.34 (m, 4H); MS (ES) for C26H26N6O: 439.2 (MH+).

4-(7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride was prepared as in example 6 using 4-chloro-7,7-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.85 (t, 1H), 8.54 (s, 1H), 8.41 (t, 1H), 7.82 (d, 1H), 7.66-7.55 (m, 1H), 7.12 (d, 1H), 5.25 (s, 2H), 4.54-4.46 (m, 2H), 4.45-4.37 (m, 2H), 2.91 (s, 3H), 2.88 (t, 2H), 2.60 (s, 2H), 1.60 (t, 2H), 1.10 (s, 6H); MS (ES) for C26H28N6O: 441.2 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using 4-chloro-6-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.87 (d, 1H), 8.53 (s, 1H), 8.43 (d, 1H), 7.81 (d, 1H), 7.61 (dd, 1H), 7.10 (d, 1H), 5.20 (dd, 2H), 4.70-4.47 (m, 2H), 4.42-4.10 (m, 2H), 2.91 (s, 3H), 2.94-2.86 (m, 2H), 2.71-2.58 (m, 2H), 2.02-1.91 (m, 1H), 1.74-1.48 (m, 2H), 1.08 (d, 3H) MS (ES) for C25H26N6O: 427.2 (MH+).

4-(6-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride was prepared as in example 6 using 4-chloro-6-ethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.86 (d, 1H), 8.54 (s, 1H), 8.41 (d, 1H), 7.81 (d, 1H), 7.62 (dd, 1H), 7.12 (d, 1H), 5.19 (q, 2H), 4.70-4.48 (m, 2H), 4.27 (dd, 2H), 2.91 (s, 3H), 2.97-2.76 (m, 2H), 2.72-2.53 (m, 2H), 2.01 (dd, 1H), 1.62-1.46 (m, 1H), 1.46-1.32 (m, 3H), 0.83 (t, 3H); MS (ES) for C26H28N6O: 441.2 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as in example 6 using 4-chloro-7-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.48 (d, 1H), 8.31 (s, 1H), 8.02 (d, 1H), 7.57 (d, 1H), 7.48 (dd, 1H), 7.07 (d, 1H), 4.86-4.72 (m, 2H), 4.48-4.22 (m, 2H), 4.10-3.91 (m, 2H), 2.95-2.81 (m, 2H), 2.64 (s, 3H), 2.68-2.55 (m, 1H), 2.30 (dd, 1H), 2.05-1.86 (m, 2H), 1.29-1.13 (m, 1H), 1.09 (d, 3H); MS (ES) for C25H26N6O: 427.2 (MH+).

4-(6,6-difluoro-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using 4-chloro-6,6-difluoro-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.86 (d, 1H), 8.60 (s, 1H), 8.40 (d, 1H), 7.81 (d, 1H), 7.62 (dd, 1H), 7.11 (d, 1H), 5.20 (s, 2H), 4.54 (t, 2H), 4.34 (t, 2H), 3.46 (t, 2H), 3.10 (t, 2H), 2.90 (s, 3H), 2.50-2.34 (m, 2H). MS (ES) for C24H22F2N6O: 449.3 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[(7R)-7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using (R)-4-chloro-7-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.85 (d, 1H), 8.52 (s, 1H), 8.40 (d, 1H), 7.80 (d, 1H), 7.61 (dd, 1H), 7.11 (d, 1H), 5.26 (d, 1H), 5.17 (d, 1H), 4.64-4.42 (m, 2H), 4.42-4.17 (m, 2H), 3.10-2.83 (m, 2H), 2.90 (s, 3H), 2.74 (d, 1H), 2.40 (dd, 1H), 2.14-1.87 (m, 2H), 1.35-1.21 (m, 1H), 1.12 (d, 3H); MS (ES) for C25H26N6O: 427.2 (MH+).

4-(2,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepare as in example 6 using 4-chloro-2,6-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.84 (s, 1H), 8.37 (s, 1H), 7.82 (s, 1H), 7.61 (d, 1H), 7.11 (d, 1H), 5.21 (d, 1H), 5.10 (d, 1H), 4.66-4.42 (m, 2H), 4.40-3.99 (m, 2H), 2.88 (s, 3H), 2.95-2.72 (m, 2H), 2.72-2.37 (m, 2H), 2.50 (s, 3H), 1.98-1.88 (m, 1H), 1.74-1.60 (m, 1H), 1.58-1.43 (m, 1H), 1.07 (d, 3H); MS (ES) for C26H28N6O: 441.2 (MH+).

4-(6-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using 4-chloro-6-ethyl-2-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.82 (d, 1H), 8.35 (d, 1H), 7.80 (d, 1H), 7.61 (dd, 1H), 7.12 (d, 1H), 5.19 (d, 1H), 5.11 (d, 1H), 4.68-4.46 (m, 2H), 4.44-4.01 (m, 2H), 2.87 (s, 3H), 2.96-2.71 (m, 2H), 2.69-2.42 (m, 2H), 2.51 (s, 3H), 2.01 (d, 1H), 1.59-1.30 (m, 4H), 0.82 (s, 3H); MS (ES) for C27H30N6O: 455.3 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[7-(trifluoromethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride was prepared as in example 6 using 4-chloro-7-(trifluoromethyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.86 (d, 1H), 8.57 (s, 1H), 8.42 (d, 1H), 7.82 (d, 1H), 7.61 (dd, 1H), 7.11 (d, 1H), 5.28 (d, 1H), 5.19 (d, 1H), 4.68-4.44 (m, 2H), 4.44-4.15 (m, 2H), 3.22-3.01 (m, 2H), 2.89 (s, 3H), 2.98-2.73 (m, 3H), 2.25 (d, 1H), 1.66-1.47 (m, 1H); MS (ES) for C25H23F3N6O: 481.2 (MH+).

4-[trans-6,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using trans-4-chloro-6,7-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.86 (s, 1H), 8.53 (s, 1H), 8.43 (s, 1H), 7.82 (s, 1H), 7.62 (d, 1H), 7.11 (d, 1H), 5.24 (s, 2H), 4.49 (s, 2H), 4.45-4.24 (m, 2H), 3.03-2.78 (m, 2H), 2.91 (s, 3H), 2.70-2.44 (m, 2H), 2.20-1.90 (m, 2H), 1.02 (d, 3H), 0.89 (d, 3H); MS (ES) for C26H28N6O: 441.2 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[(7S)-7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using (S)-4-chloro-7-methyl-5,6,7,8-tetrahydroquinazoline, (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.84 (s, 1H), 8.52 (d, 1H), 8.39 (s, 1H), 7.79 (s, 1H), 7.60 (d, 1H), 7.11 (d, 1H), 5.27 (d, 1H), 5.18 (d, 1H), 4.65-4.43 (m, 2H), 4.32 (dd, 2H), 3.11-2.83 (m, 2H), 2.90 (s, 3H), 2.75 (d, 1H), 2.41 (dd, 1H), 2.10-1.89 (m, 2H), 1.36-1.22 (m, 1H), 1.12 (d, 3H); MS (ES) for C25H26N6O: 427.2 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[5-(trifluoromethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using 4-chloro-5-(trifluoromethyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.86 (d, 1H), 8.51 (s, 1H), 8.40 (d, 1H), 7.81 (d, 1H), 7.60 (dd, 1H), 7.05 (d, 1H), 5.39 (d, 1H), 5.28 (d, 1H), 4.86-4.74 (m, 1H), 4.55-4.39 (m, 1H), 4.38-4.03 (m, 3H), 3.06-2.64 (m, 2H), 2.89 (s, 3H), 2.41-2.13 (m, 2H), 2.13-1.81 (m, 2H); MS (ES) for C25H23F3N6O: 481.2 (MH+).

7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[(7S)-7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using isobutyl 6-bromo-2-cyclopropyl-1H-imidazo[4,5-b]pyridine-1-carboxylate (reagent preparation 19) in step 1 and (S)-4-chloro-7-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.78 (d, 1H), 8.52 (s, 1H), 8.39 (d, 1H), 7.80 (d, 1H), 7.60 (dd, 1H), 7.11 (d, 1H), 5.25 (d, 1H), 5.17 (d, 1H), 4.64-4.43 (m, 2H), 4.42-4.18 (m, 2H), 3.15-2.85 (m, 2H), 2.74 (d, 1H), 2.54-2.33 (m, 2H), 2.10-1.90 (m, 2H), 1.61-1.40 (m, 4H), 1.37-1.20 (m, 1H), 1.12 (d, 3H); MS (ES) for C27H28N6O: 453.4 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using 4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine in step 3. 1H NMR (400 MHz, CD3OD) δ 8.84 (s, 1H), 8.47 (s, 1H), 8.40 (s, 1H), 8.04-7.77 (m, 1H), 7.65-7.23 (m, 2H), 7.20-6.97 (m, 2H), 5.43 (s, 2H), 4.66-4.37 (m, 4H), 4.00 (s, 3H), 2.91 (s, 3H); MS (ES) for C23H21N7O: 412.3 (MH+).

{4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-7-yl}methanol. Prepared as in example 6 using 4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (reagent preparation 42) in step 3. 1H NMR (400 MHz, d6-DMSO) δ 8.50 (bs, 1H), 8.35 (s, 1H), 8.04 (bs, 1H), 7.69 (d, 1H), 7.54 (dd, 1H), 7.05 (d, 1H), 4.80-4.57 (m, 3H), 4.47-4.19 (m, 2H), 3.96-3.78 (m, 2H), 2.94-2.63 (m, 3H), 2.54 (s, 3H), 2.40-2.25 (m, 2H), 1.92 (bs, 2H), 1.20-1.00 (m, 1H); MS (ES) for C25H26N6O2: 443.4 (MH+).

1-{4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-7-yl}ethanol. The dihydrochloride salt was prepared as in example 6 using 1-(4-chloro-5,6,7,8-tetrahydroquinazolin-7-yl)ethanol (reagent preparation 43) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.62 (s, 1H), 8.42 (s, 1H), 8.17 (s, 1H), 7.68 (s, 1H), 7.48 (dd, 1H), 7.00 (d, 1H), 5.15 (d, 1H), 5.06 (d, 1H), 4.57-4.32 (m, 2H), 4.30-4.05 (m, 2H), 3.67-3.53 (m, 1H), 2.99-2.42 (m, 4H), 2.70 (s, 3H), 2.18-1.62 (m, 2H), 1.38-1.03 (m, 4H); MS (ES) for C26H28N6O2: 457.4 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-{7-[(methyloxy)methyl]-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using 4-chloro-7-(methoxymethyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 44) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.74 (s, 1H), 8.53 (s, 1H), 8.31 (s, 1H), 7.77 (s, 1H), 7.58 (d, 1H), 7.10 (d, 1H), 5.24 (d, 1H), 5.16 (d, 1H), 4.64-4.41 (m, 2H), 4.41-4.17 (m, 2H), 3.46-3.33 (m, 2H), 3.35 (s, 3H), 2.82 (s, 3H), 3.09-2.49 (m, 4H), 2.29-2.11 (m, 1H), 2.07-1.96 (m, 1H), 1.42-1.28 (m, 1H); MS (ES) for C26H28N6O2: 457.4 (MH+).

4-(8,8-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using 4-chloro-8,8-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.74 (d, 1H), 8.52 (s, 1H), 8.30 (d, 1H), 7.77 (d, 1H), 7.58 (dd, 1H), 7.09 (d, 1H), 5.20 (s, 2H), 4.53-4.41 (m, 2H), 4.38-4.24 (m, 2H), 2.83 (s, 3H), 2.87-2.74 (m, 2H), 1.88-1.63 (m, 4H), 1.38 (s, 6H); MS (ES) for C26H28N6O: 441.2 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using 4-chloro-6,6,7-trimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO) δ 8.80 (s, 1H), 8.66 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.66 (d, 1H), 7.06 (d, 1H), 6.24 (s, 1H), 5.10 (s, 2H), 4.50 (bs, 2H), 4.17 (bs, 2H), 2.84 (s, 2H), 2.75 (s, 3H), 1.97 (s, 3H), 0.96 (s, 6H); MS (ES) for C27H28N6O: 453.2 (MH+).

4-[(8S)-8-ethenyl-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using (S)-4-chloro-8-vinyl-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidine (reagent preparation 3) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.75 (d, 1H), 8.47 (s, 1H), 8.29 (d, 1H), 7.73 (d, 1H), 7.58 (dd, 1H), 7.08 (d, 1H), 5.87 (ddd, 1H), 5.23-5.00 (m, 4H), 4.51 (t, 2H), 4.28-3.97 (m, 2H), 3.13-2.71 (m, 4H), 2.82 (s, 3H), 2.53-2.38 (m, 1H), 2.16-1.93 (m, 2H), 1.84-1.48 (m, 2H); MS (ES) for C27H28N6O: 453.2 (MH+).

4-[(8S)-8-ethyl-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The dihydrochloride salt was prepared as in example 6 using (S)-4-chloro-8-vinyl-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidine (reagent preparation 3) in step 3, followed by hydrogenation. 1H NMR (400 MHz, CD3OD) δ 8.77 (d, 1H), 8.47 (s, 1H), 8.32 (d, 1H), 7.74 (d, 1H), 7.59 (dd, 1H), 7.08 (d, 1H), 5.18-5.04 (m, 2H), 4.51 (t, 2H), 4.25-4.05 (m, 2H), 2.97-2.67 (m, 2H), 2.84 (s, 3H), 2.12-1.86 (m, 2H), 1.69-1.52 (m, 3H), 1.47-1.33 (m, 2H), 0.98 (t, 3H); MS (ES) for C27H30N6O: 455.2 (MH+).

1-{(7S)-7-ethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine. Prepared as in example 6 using (S)-1-(4-chloro-7-ethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine, (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO) δ 12.33 (m, 1H), 8.48 (d, 1H), 7.96 (d, 1H), 7.63 (d, 1H), 7.47 (dd, 1H), 7.01 (d, 1H), 4.71 (s, 2H), 4.34 (dd, 2H), 4.04-3.78 (m, 2H), 3.34 (s, 2H), 2.81 (dd, 2H), 2.64-2.50 (m, 4H), 2.27 (dd, 1H), 2.17 (d, 6H), 1.88 (d, 1H), 1.70 (s, 1H), 1.45-1.06 (m, 3H), 0.94 (t, 3H); MS (ES) for C29H35N7O: 498.2 (MH+).

4-(2-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The trihydrochloride salt was prepared as in example 6 using (R)-4-chloro-2-((3-fluoropyrrolidin-1-yl)methyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. 1H NMR (400 MHz, CD3OD) δ 8.94 (s, 1H), 8.52 (s, 1H), 8.00 (s, 1H), 7.69 (d, 1H), 7.13 (d, 1H), 5.40-5.21 (m, 3H), 4.77-4.64 (m, 2H), 4.64-4.55 (m, 2H), 4.42-4.27 (m, 2H), 3.63 (s, 4H), 2.90 (s, 3H), 2.94-2.81 (m, 2H), 2.61 (s, 2H), 2.23 (s, 2H), 1.72 (t, 2H), 0.93 (d, 6H); MS (ES) for C31H36FN7O: 542.4 (MH+).

4-(2-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The trihydrochloride salt was prepared as in example 6 using (S)-4-chloro-2-((3-fluoropyrrolidin-1-yl)methyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO) δ 8.95 (d, 1H), 8.53 (d, 1H), 8.17 (s, 1H), 7.71 (dd, 1H), 7.07 (d, 1H), 5.37-5.03 (m, 3H), 4.63-4.52 (m, 2H), 4.52-4.46 (m, 2H), 4.16 (bs, 2H), 3.73-3.22 (m, 4H), 2.82 (s, 3H), 2.79 (t, 2H), 2.55 (s, 2H), 2.25-2.01 (m, 2H), 1.60 (t, 2H), 0.87 (d, 6H); MS (ES) for C31H36FN7O: 542.4 (MH+).

4-(6,6-dimethyl-2-pyridin-2-yl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. The trihydrochloride salt was prepared as in example 6 using 4-chloro-6,6-dimethyl-2-(pyridin-2-yl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO) δ 8.90 (s, 1H), 8.81 (d, 1H), 8.54 (d, 1H), 8.48 (s, 1H), 8.25 (s, 1H), 8.07 (t, 1H), 7.71 (dd, 1H), 7.66 (dd, 1H), 7.01 (d, 1H), 5.31 (s, 2H), 4.59 (bs, 2H), 4.33 (bs, 2H), 2.95 (t, 2H), 2.87 (s, 3H), 2.66 (s, 2H), 1.62 (t, 2H), 0.93 (s, 6H); MS (ES) for C31H31N7O: 518.3 (MH+). 7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(5-methylpyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-5-methylpyrimidine in step 3. 1H NMR (400 MHz, d6-DMSO): 8.89 (d, 1H), 8.80 (s, 1H), 8.45 (d, 1H), 8.28 (s, 1), 7.91 (d, 1H), 7.69 (dd, 1H), 7.10 (d, 1H), 5.27 (s, 2H), 4.50 (m, 2H), 4.33 (m, 2H), 2.84 (s, 3H), 2.43 (s, 3H), 1.76 (s, 3H); MS (EI) for C21H20N6O: 373 (MH+).

4-[2,6-dimethyl-5-(1-methylethyl)pyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-5-isopropyl-2,6-dimethylpyrimidine (reagent preparation 8) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.74 (s, 1H), 8.29 (s, 1H), 7.82 (s, 1H), 7.63 (dd, 1H), 7.30 (s, 1H), 7.17 (s, 1H), 7.04 (s, 1H), 5.06 (s, 2H), 4.50 (m, 2H), 4.03 (m, 2H), 3.08 (m, 1H) 2.71 (s, 3H), 2.54 (s, 3H), 2.41 (s, 3H), 1.32 (d, 6H); MS (EI) for C25H28N6O: 429 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[6-methyl-5-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-5-isopropyl-6-methylpyrimidine (reagent preparation 5) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.81 (s, 1H), 8.64 (s, 1H), 8.36 (s, 1H), 7.65 (d, 1H), 7.03 (d, 1H), 5.04 (s, 2H), 4.53 (s, 2H), 4.02 (s, 2H), 3.11 (m, 1H), 2.76 (s, 3H), 2.56 (s, 3H), 1.34 (d, 6H); MS (EI) for C24H26N6O: 415 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(7-methyl-7-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-7-methyl-7-phenyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.49 (s, 1H), 8.37 (s, 1H), 7.92 (d, 1H), 7.48 (d, 1H), 7.31 (s, 1H), 7.29 (s, 1H), 7.22 (d, 1H), 7.13 (m, 2H), 7.02 (m, 1H), 6.94-6.80 (m, 1H), 4.42-4.56 (m, 2H), 4.32 (m, 2H), 3.94 (d, 1H), 3.76 (m, 1H), 3.14 (d, 1H), 2.81 (d, 1H), 2.68 (d, 1H), 2.55 (d, 3H), 2.55 (d, 3H), 2.29 (m, 1H), 2.09 (m, 1H), 1.84 (m, 1H), 1.32 (s, 3H); MS (EI) for C31H30N6O: 503 (MH+).

N,N,2-trimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidine-5-sulfonamide. Synthesized according to the method of example 6 using 4-chloro-N,N,2-trimethylpyrimidine-5-sulfonamide in step 3. 1H NMR (400 MHz, d6-DMSO): 8.51 (s, 1H), 8.03 (s, 1H), 7.94 (s, 1H), 7.52 (dd, 1H) 7.04 (d, 1H), 6.71 (d, 1H), 5.05 (s, 2H), 4.31 (d, 2H), 4.24 (d, 2H), 2.84 (s, 6H), 2.54 (s, 3H), 2.40 (s, 3H); MS (EI) for C23H25N7O3S: 480 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[2-methyl-5-(morpholin-4-ylsulfonyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-(4-chloro-2-methylpyrimidin-5-ylsulfonyl)morpholine in step 3. 1H NMR (400 MHz, d6-DMSO): 8.58 (s, 1H), 8.50 (d, 1H), 8.03 (d, 1H), 7.81 (s, 1H), 7.53 (d, 1H), 7.03 (d, 1H), 5.04 (s, 2H), 4.29 (s, 2H), 3.61 (s, 2H), 3.12 (s, 2H), 2.42 (s, 3H); MS (EI) for C25H27N7O4S: 522 (MH+).

7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using isobutyl 6-bromo-2-cyclopropyl-1H-imidazo[4,5-b]pyridine-1-carboxylate (reagent preparation 19) in step 1 and 4-chloro-6,6-dimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.64 (s, 1H), 8.61 (s, 1H), 8.14 (m, 1H), 7.77 (d 1H), 7.59 (dd, 1H), 7.04 (d, 1H), 6.47 (d, 1H), 6.34 (d, 1H), 5.00 (s, 2H), 4.46 (m, 2H), 4.11 (s, 2H), 2.83 (s, 2H), 2.24 (m, 1H), 1.24-1.18 (m, 5H), 0.99 (s, 6H); MS (EI) for C28H28N6O: 465 (MH+).

4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-6,6-dimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.64 (s, 1H), 8.59 (s, 1H), 8.18 (s, 1H), 7.77 (d, 1H), 7.60 (dd, 1H), 7.05 (d, 1H), 6.43 (d, 1H), 6.32 (d, 1H), 4.94 (s, 2H), 4.43 (m, 2H), 4.06 (br s, 2H), 2.82 (s, 2H), 2.62 (s, 3H), 0.99 (s, 6H); MS (EI) for C26H26N6O: 439 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-6,6,8-trimethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.74 (d, 1H), 8.54 (s, 1H), 8.30 (d, 1H), 7.77 (d, 1H), 7.61 (dd, 1H), 7.05 (d, 1H), 6.09 (s, 1H), 4.82 (s, 2H), 4.42 (m, 2H), 3.96 (br s, 2H), 2.73 (s, 2H), 2.69 (s, 3H), 1.96 (d, 3H), 0.92 (s, 6H); MS (EI) for C27H26N6O: 453 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6,7,8-tetramethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-6,6,7,8-tetramethyl-5,6-dihydroquinazoline (reagent preparation 3) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.69 (s, 1H), 8.53 (s, 1H), 8.24 (s, 1H), 7.77 (d, 1H), 7.61 (dd, 1H), 7.06 (d, 1H), 4.86 (s, 2H), 4.42 (m, 2H), 4.00 (br s, 2H), 2.71 (s, 2H), 2.66 (s, 3H), 1.97 (s, 3H), 1.87 (s, 3H), 0.88 (s, 6H); MS (EI) for C28H30N6O: 467 (MH+).

N,N-dimethyl-1-{4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-7-(methyloxy)quinazolin-2-yl}methanamine. Synthesized according to the method of example 6 using 1-(4-chloro-7-methoxyquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 20) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.59-8.50 (br d, 1H), 8.11-7.98 (br d, 1H), 7.94 (d, 1H), 7.76 (d, 1H), 7.53 (dd, 1H), 7.16 (d, 1H), 7.08 (dd, 1H), 6.99 (d, 1H), 5.06 (s, 2H), 4.46 (s, 2H), 4.21 (m, 2H), 3.89 (s, 3H), 3.45 (s, 2H), 2.52 (s, 3H), 2.13 (s, 6H), 1.91 (s, 2H); MS (EI) for C28H29N7O2: 496 (MH+).

1-{6-fluoro-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-2-yl}-N,N-dimethylmethanamine. Synthesized according to the method of example 6 using 1-(4-chloro-6-fluoroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 20) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.63-8.54 (br d, 1H), 8.15-8.03 (br d, 1H), 7.90-7.75 (m, 4H), 7.58 (dd, 1H), 7.02 (d, 1H), 5.16 (s, 1H), 4.54 (br m, 2H), 4.27 (br m, 2H), 4.00 (br s, 2H), 3.34 (s, 6H), 2.54 (s, 3H); MS (EI) for C27H26FN7O: 484 (MH+).

4-{2-[(3,3-difluoropyrrolidin-1-yl)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 2-(3,3-difluoropyrrolidin-1-yl)methyl)-4,6,6-trimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.88 (d, 1H), 8.44 (d, 1H), 7.99 (s, 1H), 7.67 (dd, 1H), 7.05 (d, 1H), 5.08 (s, 1H), 4.49 (br m, 2H), 4.15 (br m, 2H), 4.10 (br s, 2H), 3.24 (br t, 2H), 3.10 (br m, 2), 2.81 (m, 4H), 2.54 (s, 2H), 2.31-2.23 (m, 2H), 1.59 (t, 2H), 0.87 (s, 6H); MS (EI) for C31H35F2N7O: 560 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-methylethanamine. Prepared according to the method of example 6 by using N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-methylethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6): 12.70 (d, 1H), 8.53 (d, 1H), 8.02 (d, 1H), 7.71 (d, 1H), 7.55-7.50 (m, 1H), 7.03 (d, 1H), 4.64 (s, 2H), 4.31 (m, 2H), 3.86 (m, 2H), 3.44 (s, 2H), 2.68 (t, 2H), 2.54 (s, 3H), 2.45 (s, 2H), 2.38 (q, 2H), 2.13 (s, 3H), 1.59 (t, 2H), 0.91 (t, 3H), 0.85 (s, 6H); MS (EI) for C30H37N7O: 512 (MH+).

4-[6,6-dimethyl-2-(piperidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-6,6-dimethyl-2-(piperidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazoline (reagent preparation 17) in step 3. 1H NMR (400 MHz, (DMSO-d6): 12.70 (d, 1H), 8.52 (m, 1H), 8.00 (m, 1H), 7.70 (d, 1H), 7.54-7.50 (m, 1H), 7.02 (m, 1H), 4.66 (s, 2H), 4.33 (m, 2H), 3.87 (m, 2H), 2.68 (t, 2H), 2.56 (s, 2H), 2.46 (s, 2H), 2.33 (m, 4H), 1.59 (t, 2H), 1.38 (m, 4H), 1.26 (m, 2H). 0.86 (s, 6H); MS (EI) for C32H39N7O: 538 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-methylpropan-2-amine. Prepared according to the method of example 6 by using N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-methylpropan-2-amine (reagent preparation 17) in step 3. 1H NMR (400 MHz, DMSO-d6): 12.68 (d, 1H), 8.52 (m, 1H), 8.01 (m, 1H), 7.71 (d, 1H), 7.55-7.50 (m, 1H), 7.03 (m, 1H), 4.65 (s, 2H), 4.31 (m, 2H), 3.86 (m, 2H), 2.69 (t, 2H), 2.56 (s, 2H), 2.45 (s, 2H), 2.11 (m, 3H), 1.59 (t, 2H), 1.23 (m, 2H), 0.91-0.84 (m, 12H); MS (EI) for C31H39N7O: 526 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-methylcyclopropanamine. Prepared according to the method of example 6 by using N-((4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl)-N-methylcyclopropanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, Methanol-d4): 8.48 (s, 1H), 8.01 (s, 1H), 7.58 (d, 1H), 7.46-7.41 (m, 1H), 7.02 (d, 1H), 4.73 (s, 2H), 4.31 (t, 2H), 3.96 (t, 2H), 3.62 (s, 2H), 2.75 (t, 2H), 2.61 (s, 3H), 2.46 (s, 2H), 2.30 (s, 3H), 1.83-1.76 (m, 1H), 1.64 (t, 2H), 0.89 (s, 6H), 0.32-0.23 (m, 4H); MS (EI) for C31H37N7O: 524 (MH+).

N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)propan-2-amine. Prepared according to the method of example 6 by using benzyl (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl(isopropyl)carbamate (reagent preparation 17) in step 3 and Cbz group removal. 1H NMR (400 MHz, DMSO-d6): 12.7 (d, 1H), 8.60-8.46 (m, 1H), 8.11-7.94 (m, 1H), 7.72 (s, 1H), 7.54 (d, 1H), 7.03 (d, 1H), 4.68 (s, 2H), 4.32 (m, 2H), 3.89 (m, 2H), 3.65 (s, 2H), 2.69 (t, 2H), 2.53 (m, 1H), 2.46 (s, 2H), 1.59 (t, 2H), 1.23 (s, 1H), 0.92 (d, 6H), 0.86 (s, 6H); MS (EI) for C30H37N7O: 512 (MH+).

1-{5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine. Synthesized according to the method of example 6 using 1-(4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHZ, CD3OD): 8.38 (d, 1H), 7.92 (d, 1H), 7.44 (dd, 1H), 7.09 (dd, 2H), 7.03-6.95 (m, 3H), 6.92 (d, 1H), 4.60 (s, 2H), 4.28 (tr, 2H), 4.01 (s, 2H), 3.92 (tr, 2H), 3.54 (s, 2H), 2.66 (s, 3H), 2.30 (s, 6H), 2.21 (s, 3H). MS (EI) for C31H32N7OF: 538 (MH+).

N,N-dimethyl-1-{4-methyl-5-(1-methylethyl)-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}methanamine. Synthesized according to the method of example 6 using 1-(4-chloro-5-isopropyl-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHZ, CDCl3): 12.78 (br, 1H), 8.51 (s, 1H), 8.08 (br, 1H), 7.46 (d, 1H), 7.43 (s, 1H), 7.14 (d, 1H), 4.37 (s, 2H), 4.30 (tr, 2H), 3.76 (tr, 2H), 3.55 (s, 2H), 3.40 (m, 1H), 2.75 (s, 3H), 2.55 (s, 3H), 2.34 (s, 6H), 1.35 (d, 6H). MS (EI) for C28H34N7O: 472 (MH+). 7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 6 using 4-chloro-7-methoxy-2-methylquinazoline in step 3. 1H NMR (400 MHz, DMSO-d6) δ 8.53 (s, 1H), 8.06 (s, 1H), 7.90 (d, 1H), 7.74 (d, 1H), 7.56 (dd, 1H), 7.11 (d, 1H), 7.03 (m, 3H), 5.02 (s, 3H), 4.41 (t, 3H), 4.11 (d, J=36.2 Hz, 3H), 3.88 (s, 5H), 2.55 (s, 5H), 2.43 (s, 5H), 1.90 (s, 1H); MS (EI) for C26H24N6O2: 453.3 (MH+).

{4-[7-(2-amino[1,3]thiazolo[5,4-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}methanol. The dihydrochloride salt was prepared as in example 6 using (4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)methyl acetate (reagent preparation 17) in step 3 and acetate ester hydrolysis. 1H NMR (400 MHz, CD3OD) δ 8.66 (d, 1H), 8.02 (d, 1H), 7.79 (d, 1H), 7.57 (dd, 1H), 7.09 (d, 1H), 5.14 (s, 2H), 4.62 (s, 2H), 4.52-4.39 (m, 2H), 4.37-4.25 (m, 2H), 2.88 (t, 2H), 2.58 (s, 2H), 1.69 (t, 2H), 0.94 (s, 6H); MS (ES) for C26H28N6O2S: 498.2 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[6-methyl-5-(1-methylpropyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 6 by using 4-chloro-6-methylpyrimidine in step 3. 1H NMR (400 MHz, methanol-d4): 8.52 (s, 1H), 8.06 (s, 1H), 8.01 (d, 1H), 7.76 (d, 1H), 7.49 (dd, 1H), 7.10 (d, 1H), 6.74 (d, H), 4.24 (br. s, 2H), 4.19 (m, 2H), 2.64 (s, 3H), 2.42 (s, 3H); MS (EI) for C21H20N6O: 373 (MH+).

Example 7 7-(1-Methyl-1H-indazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine

STEP 1: A solution of 7-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepine hydrochloride (1.50 g, 5.67 mmol) (example 2, step 1), 4-chloroquinoline (0.973 g, 5.95 mmol), diisopropylethylamine (2.93 g, 22.7 mmol) in 1-butanol (15 mL) was stirred at 170° C. for 1 hour in a microwave synthesizer. The reaction mixture was diluted with ethyl acetate (100 mL), washed with saturated sodium bicarbonate (50 mL) and brine (50 mL), dried over sodium sulfate. Filtration and concentration afforded a crude brown oil that was purified by silica gel chromatography (9:1 dichloromethane/methanol) to provide 7-bromo-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine (1.70 g, 84.6% yield) as a yellow oil. MS (EI) for C18H15BrN2O: 356 (MH+).

STEP 2: A mixture of 7-bromo-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine (206 mg, 0.58 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-methyl-1H-indazole (158 mg (0.58 mmol) (reagent preparation 50), potassium carbonate (320 mg, 2.32 mmol), and dichloro[1,1-bis(diphenylphosphino]ferrocenepalladium (II) dichloromethane adduct (50 mg, 0.06 mmol) in dimethoxyethane (4.0 mL) and water (1.0 mL) was degassed with nitrogen, and then stirred at 100° C. for 1 h. The reaction mixture was cooled to room temperature and partitioned between water and ethyl acetate. The mixture was filtered through celite and then the layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography on silica ((2S)-100% ethyl acetate in hexanes) afforded the title Compound (23 mg, 10% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6): 8.63 d, 1H), 8.11 (s, 1H), 8.03 (m, 2H), 7.95 (d, 1H), 7.75 (m, 3H), 7.70 (m, 1H), 7.61 (dd, 1H), 7.51 (m, 1H), 7.11 (d, 1H), 7.02 (d, 1H), 4.61 (s, 2H), 4.39 (m, 2H), 4.09 (s, 3H), 3.84 (m, 2H); MS (EI) for C26H22N4O: 407 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in steps 1 or 2 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

7-(1H-indazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 7 by using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole in step 2. 1H NMR (400 MHz, methanol-d4): 8.41 (s, 1H), 8.38 (d, 1H), 8.34 (d, 1H), 8.14 (s, 1H), 7.97 (m, 1H), 7.90 (m, 2H), 7.83 (d, 1H), 7.73 (d, 1H), 7.69 (m, 1H), 7.62 (dd, 1H), 7.07 (m, 2H), 5.28 (s, 2H), 4.63 (m, 2H), 4.44 (m, 2H); MS (EI) for C25H20N4O: 393 (MH+).

7-(1H-indazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 7 by using tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate in step 2. 1H NMR (400 MHz, d6-DMSO): 13.18 (br. s, 1H), 8.56 (d, 1H), 8.33 (d, 1H), 8.12 (s, 1H), 8.03-7.92 (m, 3H), 7.87 (d, 1H), 7.79 (s, 1H), 7.72-7.62 (m, 2H), 7.50 (d, 1H), 7.02-6.96 (m, 2H), 5.31 (s, 2H), 4.63 (t, 2H), 4.42 (t, 2H); MS (EI) for C25H20N4O: 393 (MH+).

7-(1H-pyrazol-4-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 7 by using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole in step 2. 1H NMR (400 MHz, d6-DMSO): 8.57 (d, 1H), 8.31 (d, 1H), 8.08-7.92 (m, 4H), 7.83 (s, 1H), 7.68 (t, 1H), 7.47 (d, 1H), 6.94 (d, 1H), 6.89 (d, 1H), 5.20 (s, 2H), 4.56 (t, 2H), 4.38 (t, 2H); MS (EI) for C21H18N4O: 343 (MH+).

7-(2,3-dihydro-1-benzofuran-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as trifluoroacetate salt according to the method of example 7 by using 2,3-dihydro-1-benzofuran-1-ylboronic acid in step 2. 1H NMR (400 MHz, methanol-d4): 8.37 (d, 1H), 8.32 (d, 1H), 7.97 (m, 1H), 7.89 (d, 1H), 7.67 (m, 2H), 7.51 (s, 1H), 7.46 (dd, 1H), 7.37 (d, 1H), 7.05 (d, 1H), 6.98 (d, 1H), 6.80 (d, 1H), 5.22 (s, 2H), 4.59 (m, 4H), 4.41 (m, 2H), 3.26 (m, 2H); MS (EI) for C26H22N2O2: 395 (MH+).

7-(1-methyl-1H-indol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 7 by using 1-methyl-1H-indol-5-ylboronic acid in step 2. 1H NMR (400 MHz, DMSO-d6): 8.57 (d, 1H), 8.34 (d, 1H), 7.96 (m, 4H), 7.88 (s, 1H), 7.69 (m, 1H), 7.55 (m, 3H), 7.38 (m, 1H), 6.98 (m, 2H), 6.50 (m, 1H), 5.29 (s, 2H), 4.60 (m, 2H), 4.42 (m, 2H), 3.84 (s, 3H); MS (EI) for C27H23N3O: 406 (MH+).

N,N-dimethyl-3-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide. Prepared as the trifluoroacetate salt according to the method of example 7 by 3-(dimethylcarbamoyl)phenylboronic acid in step 2. 1H NMR (400 MHz, DMSO-d6): 8.56 (d, 1H), 8.34 (d, 1H), 8.01 (m, 1H), 7.98 (d, 1H), 7.94 (m, 1H), 7.80 (d, 1H), 7.76 (m, 1H), 7.68 (m, 1H), 7.62 (dd, 1H), 7.55 (m, 1H), 7.39 (d, 1H), 6.97 (m, 2H), 5.30 (s, 2H), 4.63 (m, 2H), 4.43 (m, 2H), 3.03 (s, 3H), 2.98 (s, 3H); MS (EI) for C27H25N3O2: 424 (MH+).

4-quinolin-4-yl-7-quinoxalin-6-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as the trifluoroacetate salt according to the method of example 7 by using quinoxalin-6-ylboronic acid in step 2. 1H NMR (400 MHz, d6-DMSO): 8.99 (d, 2H), 8.57 (d, 1H), 8.46 (s, 1H), 8.37-8.29 (m, 2H), 8.27-8.20 (m, 2H), 8.01-7.92 (m, 2H), 7.84 (d, 1H), 7.69 (t, 1H), 7.06 (d, 1H), 7.01 (d, 1H), 5.35 (s, 2H), 4.67 (t, 2H), 4.45 (t, 2H); MS (EI) for C26H20N4O: 405 (MH+).

N-(4-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}phenyl)acetamide. Synthesized according to the method of example 7 using 4-chloro-7-methoxy-2-methylquinazoline in step 1 and 4-acetamidophenylboronic acid in step 2. 1H NMR (400 MHz, DMSO-d6): 10.0 (s, 1H), 7.99 (s, 2H), 7.89 (d, 1H), 7.60 (s, 1H), 7.50 (dd, 1H), 7.40 (t, 1H), 7.31 (m, 1H), 7.11 (m, 2H), 7.03 (d, 1H), 4.97 (s, 2H), 4.44 (s, 2H), 4.15 (s, 2H), 3.88 (s, 3H), 2.42 (s, 3H); MS (EI) for C27H26N4O3: 455.2 (MH+).

1-methyl-3-(4-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}phenyl)urea. Prepared according to the method of example 7 by using 4-chloro-7-methoxy-2-methylquinazoline in step 1 and 1-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea in step 2. 1H NMR (400 MHz, DMSO-D6); δ 8.62 (s, 1H), 7.89 (d, 1H), 7.64-7.36 (m, 6H), 7.24-6.95 (m, 3H), 6.11-6.03 (m, 1H), 4.99 (s, 2H), 4.47-4.37 (m, 2H), 4.18-4.09 (m, 2H), 3.88 (s, 3H), 2.70-2.60 (m, 3H), 2.43 (s, 3H); MS (EI) for C27H27N5O3: 470 (MH+).

5-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridin-2-amine. Prepared according to the method of example 7 by using 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 1 and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine in step 2. 1H NMR (400 MHz, DMSO-d6): 8.22 (d, 1H), 7.68-7.63 (m, 1H), 7.55 (d, 1H), 7.39-7.32 (m, 1H), 6.96 (d, 1H), 6.50 (d, 1H), 6.02 (s, 2H), 4.58 (s, 2H), 4.26 (m, 2H), 3.85 (m, 2H), 3.39 (m, 2H), 2.69 (m, 2H), 2.44 (s, 2H), 2.17 (s, 6H), 1.59 (t, 2H), 0.85 (s, 6H); MS (EI) for C27H34N6O: 459 (MH+).

2-chloro-5-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide. Prepared according to the method of example 7 by using 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 1 and 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide in step 2. 1H NMR (400 MHz, DMSO-d6): 7.95 (s, 1H), 7.73-7.64 (m, 4H), 7.57-7.49 (m, 2H), 7.01 (d, 1H), 4.64 (s, 2H), 4.31 (m, 2H), 3.86 (m, 2H), 3.38 (m, 2H), 2.69 (t, 2H), 2.43 (s, 2H), 2.14 (s, 6H), 1.59 (t, 2H), 0.85 (s, 6H); MS (EI) for C29H34ClN5O2: 520 (MH+).

3-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide. Prepared according to the method of example 7 by using 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 1 and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide in step 2. 1H NMR (400 MHz, DMSO-d6): 8.14 (m, 1H), 8.08 (s, 1H), 7.84-7.71 (m, 3H), 7.58-7.49 (m, 2H), 7.44 (s, 1H), 7.03 (d, 1H), 4.65 (s, 2H), 4.32 (m, 2H), 3.87 (m, 2H), 2.69 (t, 2H), 2.44 (s, 2H), 2.15 (s, 6H), 1.59 (t, 2H), 0.85 (s, 6H); MS (EI) for C29H35N5O2: 486 (MH+).

1-(4-{7-[4-chloro-3-(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine. Prepared according to the method of example 7 by using 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 1 and 2-(4-chloro-3-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in step 2. 1H NMR (400 MHz, Methanol-d4): 7.60 (s, 1H), 7.49-7.43 (m, 1H), 7.39 (d, 1H), 7.23 (d, 1H), 7.17-7.12 (m, 1H), 7.02 (d, 1H), 4.75 (s, 2H), 4.34 (t, 2H), 4.00 (m, 2H), 3.95 (s, 3H), 3.55 (s, 2H), 2.79 (t, 2H), 2.49 (s, 2H), 2.31 (s, 6H), 1.67 (t, 2H), 0.90 (s, 6H); MS (EI) for C29H35ClN4O2: 507 (MH+).

Example 8 5-(4-{5-[(4-Fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine

STEP 1: (4-{[(1,1-dimethylethyl)oxycarbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (Example 1, step 2) (1.07 g, 3.64 mmol) was dissolved into 4M hydrogen chloride in dioxane and the resulting solution was allowed to stir at room temperature for 1.3 h. The heterogeneous mixture was then diluted with ethyl ether (100 mL) and the solid collected by filtration to give 2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ylboronic acid hydrochloride salt (791 mg, 95%). 1H NMR (400 MHz, D2O): 7.79 (dd, 1H), 7.74 (d, 1H), 7.21 (d, 1H), 4.47 (s, 2H), 4.36 (m, 2H), 3.69 (m, 2H).

STEP 2: A mixture of 2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ylboronic acid hydrochloride salt (1.20 g, 5.2 mmol), 4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidine (reagent preparation 5) (1.24 g, 5.2 mmol), diisopropylethylamine (0.40 mL, 2.10 mmol) 50% aqueous 1,4-dioxane (50 mL) was deoxygenated for five minutes by bubbling nitrogen gas then stirred at 95° C. for 18 hours. The reaction mixture was concentrated, diluted with water (50 mL), adjusted to pH 14, and then washed with isopropyl acetate (3×30 mL). The aqueous mixture was adjusted to pH 8 and the white solid precipitated was collected by filtration, washed with water and dried to give (4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (0.72 g, 35% yield). MS (EI) for C2H21BFN3O3: 394 (MH+).

STEP 3: A solution of N-(5-bromothiazolo[5,4-b]pyridin-2-yl)benzamide (reagent preparation 13) (0.14 g, 0.42 mmol), (4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (0.14 g, 0.35 mmol) and diisopropyethylamine (0.40 mL, 2.10 mmol) in 10% aqueous dimethylformamide (3 mL) was deoxygenated for five minutes by bubbling nitrogen gas, followed by the addition of 1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) complex with dichloromethane (20 mg, 0.021 mmol). The reaction mixture was heated to 105° C. for 4 hours. On cooling to room temperature the mixture was diluted with ethyl acetate (50 mL) then it was filtered through a pad of Celite. The organic filtrate was washed with 10% aqueous citric acid (20 mL), brine, aqueous saturated sodium bicarbonate (20 mL) and brine then dried over anhydrous sodium sulfate, filtered and concentrated. Silica gel chromatography (chloroform/methanol 95:5 to 9:1) provided N-[5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-yl]benzamide (86 mg. 41%). MS (EI) for C34H27FN6O2S: 603 (MH+).

STEP 4: A solution of N-[5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-yl]benzamide (84 mg, 0.14 mmol) in 70% aqueous sulfuric acid (2 mL) was heated to reflux for thirty minutes. On cooling to room temperature the pH of the mixture was adjusted to ˜5 by the addition of 50% aqueous sodium hydroxide. Concentration and purification by preparative reverse phase HPLC (0.1% aqueous ammonium acetate-acetonitrile) provided 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine (26 mg, 37%). 1H NMR (400 MHz, d6-DMSO): 8.44 (d, 1H), 8.36 (s, 1H), 8.08 (d, 1H), 8.01 (br s, 2H), 7.52 (dd, 1H), 7.16-7.10 (m, 4H), 7.00 (d, 1H), 6.90 (d, 1H), 4.48 (s, 2H), 4.28 (m, 2H), 3.96 (s, 2H), 3.76 (m, 2H), 2.14 (s, 3H). MS (EI) for C27H23FN6OS: 499 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 3 and conducting protecting group removal step 4 as required according to literature techniques appropriate for a given protecting group (see for example: Greene and Wuts, Protective Groups in Organic Synthetic, Wiley-Interscience) the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 8 using 6-bromo-1-trityl-1H-imidazo[4,5-b]pyridine (reagent preparation 15) in step 3. 1H NMR (400 MHz, d6-DMSO); 8.49 (m, 3H), 7.54 (d, 1H), 7.08 (m, 5H), 6.99 (m, 1H), 4.52 (s, 2H), 4.24 (br s, 2H), 3.96 (s, 2H), 3.77 (br s, 2H), 2.16 (s, 3H); MS (EI) for C27H23FN6O: 467 (MH+).

5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine. Synthesized according to the method of example 8 using N-(6-bromothiazolo[4,5-b]pyridin-2-yl)benzamide (J. of Heterocyclic Chemistry 2003, 40(2), 261-268) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.51 (s, 1H), 8.37 (d, 1H), 8.10 (d, 1H), 8.02 (br s, 2H), 7.49 (dd, 1H), 7.13-7.08 (m, 4H), 7.02 (d, 1H), 6.88 (d, 1H), 4.50 (s, 2H), 4.29 (m, 2H), 3.98 (s, 2H), 3.78 (m, 2H), 2.16 (s, 3H). MS (EI) for C27H23N6O2: 499 (MH+).

6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)quinazolin-2-amine. Synthesized according to the method of example 8 using 6-bromoquinazolin-2-amine in step 3. MS (EI) for C29H25FN6O: 493 (MH+).

6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,2,4]triazolo[1,5-c]pyridin-2-amine. Prepared according to the method of example 8 by using bis(1,1-dimethylethyl)(6-bromo[1,2,4]triazolo[1,5-a]pyridine-2-yl)imidodicarbonate (reagent preparation 14) in step 3. 1H NMR (400 MHz, DMSO-d6): 8.69 (m, 1H), 8.48 (s, 1H), 7.51 (m, 2H), 7.40 (d, 1H), 7.10 (d, 4H), 6.99 (d, 1H), 6.91 (m, 1H), 6.06 (s, 2H), 4.47 (s, 2H), 4.26 (m, 2H), 3.95 (s, 2H), 3.74 (m, 2H), 2.14 (s, 3H); MS (EI) for C27H24FN7O: 482 (MH+).

6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)imidazo[1,2-c]pyridin-2-amine. Prepared according to the method of example 8 by using N-(6-bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide (Tetrahedron Letters 2002, 43(50), 9051-9054) in step 3. 1H NMR (400 MHz, methanol-d4): 8.47 (s, 1H), 8.25 (s, 1H), 7.41 (dd, 1H), 7.32 (d, 1H), 7.24 (dd, 1H), 7.10 (m, 2H), 7.00 (m, 3H), 6.71 (m, 1H), 4.53 (s, 2H), 4.29 (m, 2H), 3.98 (s, 2H), 3.88 (m, 2H), 2.21 (s, 3H); MS (EI) for C28H25FN6O: 481 (MH+).

5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-benzothiazol-2-amine. Prepared according to the method of example 8 by using N-(5-bromobenzo[d]thiazol-2-yl)acetamide (Journal of the Indian Chemical Society (1958), 35 807-10) in step 3. 1H NMR (400 MHz, methanol-d4): 8.47 (s, 1H), 7.62 (d, 1H), 7.46 (d, 1H), 7.43 (dd, 1H), 7.08 (m, 3H), 6.99 (m, 3H), 6.81 (d, 1H), 4.53 (s, 2H), 4.29 (m, 2H), 4.00 (s, 2H), 3.89 (m, 2H), 2.22 (s, 3H); MS (EI) for C28H24FN5OS: 498 (MH+).

6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)imidazo[1,2-a]pyrimidin-2-amine. Synthesized according to the method of example 8 using N-(6-bromoimidazo[1,2-a]pyrimidin-2-yl)-2,2,2-trifluoroacetamide (Synthesis 1999, 12, 2124-2130) in step 3. 1H NMR (400 DMSO-D6): 8.91 (s, 1H), 8.61 (br, 1H), 8.46 (s, 1H), 8.33 (br, 1H), 7.44 (dd, 1H), 7.13 to 6.98 (m, 5H), 6.78 (br, 1H), 4.56 (s, 2H), 4.29 (m, 2H), 4.00 (s, 2H), 3.88 (m, 2H), 2.22 (s, 3H), MS (EI) for C27H24FN7O: 482 (MH+).

7-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,2,4]triazolo[1,5-a]pyridin-2-amine. Prepared according to the method of example 8 by using N-(7-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)acetamide (reagent preparation 16) in step 3. 1H NMR (400 MHz, methanol-d4): 8.47-8.42 (m, 2H), 7.55 (d, 1H), 7.40 (s, 1H), 7.12-6.99 (m, 6H), 6.91 (s, 1H), 4.58 (s, 2H), 4.32 (t, 2H), 4.00 (s, 2H), 3.89 (t, 2H), 2.22 (s, 3H); MS (EI) for C27H24FN7O: 482 (MH+).

6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-c]pyridin-2-amine. Prepared according to the method of example 8 by using methyl (6-bromo-1H-imidazo[4,5-c]pyridine-2-yl)carbamate (reagent preparation 45) in step 3. 1H NMR (400 MHz, methanol-d4): 8.45 (s, 1H), 8.35 (s, 1H), 7.62 (m, 1H), 7.72 (m, 1H), 7.41 (s, 1H), 7.04 (m, 4H), 6.93 (m, 2H), 4.57 (s, 2H), 4.32 (m, 2H), 3.97 (s, 2H), 3.88 (m, 2H), 2.21 (s, 3H), 1.96 (s, 3H); MS (EI) for C27H24FN7O: 482 (MH+).

2-amino-5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-methylpyridine-3-sulfonamide. Prepared according to the method of example 8 by using 2-amino-5-bromo-N-methylpyridine-3-sulfonamide (WO 2008144463) in step 3. 1H NMR (400 MHz, DMSO-d6): 8.48 (s, 1H), 8.36 (m, 1H), 7.93 (m, 1H), 7.71 (br. s, 1H), 7.41 (m, 1H), 7.09 (m, 4H), 7.00 (d, 1H), 6.92 (m, 1H), 6.70 (br. s, 1H), 4.50 (s, 2H), 4.26 (m, 2H), 3.96 (s, 2H), 3.75 (m, 2H), 2.45 (s, 3H), 2.15 (s, 3H); MS (EI) for C27H27FN6O3S: 535 (MH+).

6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine. Synthesized according to the method of example 8 using N-(6-bromothiazolo[5,4-b]pyridin-2-yl)acetamide (J. Heterocyclic Chemistry 2003, 40, 261) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.47 (s, 1H), 8.20 (d, 1H), 7.88 (s, 2H), 7.69 (d, 1H), 7.54 (dd, 1H), 7.09 (d, 4H), 6.99 (d, 1H), 6.94 (d, 1H), 4.45 (s, 2H), 4.24 (m, 2H), 3.97 (s, 2H), 3.77 (m, 2H), 2.14 (s, 3H); MS (EI) for C27H23FN6OS: 499 (MH+).

N-ethyl-6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine. Prepared as in example 8 using 6-bromo-N-ethyl-N,3-bis(methoxymethyl)-3H-imidazo[4,5-b]pyridin-2-amine (reagent preparation 36) in step 3. 1H NMR (400 MHz, d6-DMSO) δ 11.04 (s, 1H), 8.49 (s, 1H), 8.04 (s, 1H), 7.89 (s, 1H), 7.52-7.35 (m, 2H), 7.10 (d, 4H), 7.00 (d, 1H), 6.91 (d, 1H), 4.48 (s, 2H), 4.26 (t, 2H), 4.00 (s, 2H), 3.77 (t, 2H), 3.33 (q, 2H), 2.16 (s, 3H), 1.20 (q, 3H); MS (ES) for C29H28FN7O: 510.2 (MH+).

5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-indazol-3-amine. Prepared according to example 8 using tert-butyl 3-(bis(tert-butoxycarbonyl)amino)-5-bromo-1H-indazole-1-carboxylate (reagent preparation 48) in step 1 and BOC group deprotection. 1H NMR (400 MHz, d6-DMSO) δ 11.44 (s, 1H), 8.50 (s, 1H), 7.86 (s, 1H), 7.42 (dd, 1H), 7.28 (s, 2H), 7.19-7.07 (m, 4H), 7.01 (d, 1H), 6.87 (s, 1H), 5.42 (s, 2H), 4.49 (s, 2H), 4.26 (t, 2H), 4.00 (s, 2H), 3.77 (t, 2H), 2.17 (s, 3H). MS (EI) for C28H25FN6O: 481 (MH+).

Example 9 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyrazin-2-amine

STEP 1: 1,1-Dimethylethyl 7-bromo-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (5.0 g, 20.1 mmol), bis(pinacolato)diboron (5.6 g, 22.1 mmol), potassium acetate (5.9 g, 60.2 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (440 mg, 0.62 mmol) were heated in DMSO (5 mL) solution at 80 C for 1.5 h. The mixture was then cooled to room temperature and diluted with an excess of ethyl acetate and filtered through a bed of celite. The filtrate was partitioned with 1M aqueous hydrochloric acid and the organic phase washed with brine and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated and the residue purified by silica chromatography using 4:1 hexanes:ethyl acetate as eluent to give 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (7.6 g, 100%). 1H NMR (400 MHz, CDCl3): 7.77 (s, 0.4H), 7.67 (s, 1H), 7.65 (s, 0.6H), 7.04-6.98 (m, 1H), 4.54 (s, 0.7H), 4.43 (s, 1.3H), 4.09-4.01 (m, 2H), 3.79 (dd, 2H), 1.40 (br s, 9H), 1.26 (s, 12H). MS (EI) for C20H30BNO5: 376 (MH+).

STEP 2: A solution of 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (3.0 g, 8.00 mmol) in dichloromethane (90 mL) and trifluoroacetic acid (10 mL) was heated to reflux for 1 h, and then cooled to room temperature. The reaction mixture was concentrated and the residue was azeotroped with toluene (100 mL) to give 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine trifluoroacetate salt (2.9 g, quantitative yield). MS (EI) for C15H22BNO3: 276 (MH+).

STEP 3: A mixture of 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine trifluoroacetate salt (2.9 g, 8.00 mmol, 4-chloro-5-[(4-fluorophenyl)methyl]-6-methylpyrimidine (reagent preparation 5) (1.9 g, 8.00 mmol) and N,N-diisopropylethylamine (7.0 mL, 40.0 mmol) in N-methyl-2-pyrrolidone (10 mL) was reacted in a microwave apparatus (250 W) for 2 h at 150° C. After cooling to room temperature the reaction mixture was partitioned between ethyl acetate (500 mL) and brine (100 mL). The organic layer was separated, washed with brine (100 mL), dried over sodium sulfate then filtered and concentrated. Column chromatography of the residue on silica (gradient 20 to 40% ethyl acetate in hexane) gave 4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (1.6 g, 42% yield). 1H NMR (400 MHz, DMSO-D6): 8.58 (s, 1H), 7.62 (dd, 1H), 7.08 (m, 4H), 7.02 (d, 1H), 6.96 (d, 1H), 4.36 (s, 2H), 4.30 (m, 2H), 3.92 (s, 2H), 3.84 (m, 2H), 2.26 (s, 3H), 1.36 (s, 12H); MS (EI) for C27H31BFN3O3: 476 (MH+).

STEP 4: A solution of 4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (0.10 g, 0.21 mmol), 2-amino-5-bromopyrazine (40 mg, 0.21 mmol) and potassium carbonate (0.12 g, 0.84 mmol) in N,N-dimethylformamide (5 mL), and water (0.5 mL) was degassed by bubbling nitrogen gas for five minutes followed by the addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (15 mg, 0.021 mmol), then stirred at 95° C. for 16 hours. After cooling to room temperature the reaction mixture was partitioned between ethyl acetate (50 mL) and brine (30 mL). The organic layer was separated, washed with brine, dried over sodium sulfate then filtered and concentrated. Purification by preparative reverse phase HPLC (0.1% aqueous ammonium acetate-acetonitrile) provided 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyrazin-2-amine (18 mg, 20%). 1H NMR (400 MHz, d6-DMSO): 8.80 (s, 1H), 8.38 (s, 1H), 7.96 (s, 1H), 7.72 (d, 1H), 7.50 (br s, 1H), 7.25-7.14 (m, 4H), 6.93 (d, 1H), 4.90 (s, 2H), 4.32 (m, 2H), 4.00 (m, 4H), 2.22 (s, 3H). MS (EI) for C25H23FNO6: 443 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in steps 3 or 4 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridazin-3-amine. Synthesized according to the method of example 9 using 6-bromopyridazin-3-amine in step 4. 1H NMR (400 MHz, d6-DMSO): 8.46 (s, 1H), 7.74 (dd, 1H), 7.54 (d, 1H), 7.28 (d, 1H), 7.18-7.06 (m, 4H), 6.98 (d, 1H), 6.82 (d, 1H), 6.47 (s, 2H), 4.51 (s, 2H), 4.29) m, 2H), 3.95 (s, 2H), 3.75 (m, 2H), 2.16 (s, 3H). MS (EI) for C25H23FN6O: 463 (MH+).

5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyrimidin-2-amine. Synthesized according to the method of example 9 using 5-bromopyrimidin-2-amine in step 4. 1H NMR (400 MHz, DMSO-D6): 8.49 (s, 1H), 8.37 (s, 2H), 7.42 (d, 1H), 7.09 (d, 4h), 6.98 (d, 1H), 6.76-6.83 (m, 3H), 4.46 (s, 2H), 4.25-4.27 (m, 2H), 3.96 (s, 2H), 3.74-3.76 (m, 2H), 2.15 (s; 3H); MS (EI) for C25H23FN6O: 443 (MH+).

6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-methylpyridine-3-carboxamide. Synthesized according to the method of example 9 using 6-bromo-N-methylnicotinamide in step 4. 1H NMR (400 MHz, DMSO-D6): 9.05 (s, 1H), 8.65-8.72 (m, 2H), 8.47 (s, 1H), 8.23 (dd, 1h), 7.95 (dd, 1H), 7.83 (d, 1H), 7.45 (s, 1H), 7.02-7.18 (m, 5H), 4.54 (s, 2H), 4.31-4.38 (m, 2H), 3.94 (s, 2H), 3.75-3.81 (m, 2H), 2.84 (s, 3H), 2.15 (s; 3H); MS (EI) for C28H26FN5O2: 484 (MH+).

4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(1,3-thiazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 9 using 5-bromothiazole in step 4. 1H NMR (400 MHz, d6-DMSO): 9.05 (s, 1H), 8.48 (s, 1H), 8.08 (s, 1H), 7.51 (dd, 1H), 7.18-7.06 (m, 4H), 6.99 (d, 1H), 6.90 (d, 1H), 4.49 (s, 2H), 4.29 (m, 2H), 3.92 (s, 2H), 3.72 (m 2H), 2.14 (s, 3H). MS (EI) for C24H21FN4OS: 433 (MH+).

4-(7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1,3-thiazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 9 using 4-chloro-7,7-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3 and 5-bromo-2-methylthiazole in step 4. 1H NMR (400 MHz, d6-DMSO): 8.32 (s, 1H), 7.91 (s, 1H), 7.53 (d, 1H), 7.40 (dd, 1H), 7.08 (d, 1H), 4.72 (s, 2H), 4.34 (m, 2H), 3.90 (m, 2H), 2.68 (m ands, 5H), 2.46 (s, 2H), 1.46 (t, 2H), 1.00 (6H). MS (EI) for C23H26N4OS: 407 (MH+).

5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-4-methyl-1,3-thiazol-2-amine. Synthesized according to the method of example 9 using bis(1,1-dimethylethyl)(5-bromo-4-methyl-1,3-thiazol-2-yl)imidodicarbonate (reagent preparation 14) in step 4. 1H NMR (400 MHz, d6-DMSO): 8.46 (s, 1H), 7.13-7.02 (m, 5H), 6.94 (br s, 2H), 6.91 (s, 1H), 6.68 (d, 1H), 4.42 (s, 2H), 4.22 (m, 2H), 4.14 (s, 2H), 3.73 (m, 2H), 2.14 (s, 3H), 2.06 (s, 3H). MS (EI) for C25H24FN5OS: 462 (MH+).

5-[4-(7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-4-methyl-1,3-thiazol-2-amine. Synthesized according to the method of example 9 using 4-chloro-7,7-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 3 and bis(1,1-dimethylethyl)(5-bromo-4-methyl-1,3-thiazol-2-yl)imidodicarbonate (reagent preparation 14) in step 4. 1H NMR (400 MHz, d6-DMSO): 8.34 (s, 1H), 7.24 (d, 1H), 7.11 (dd, 1H), 6.96 (d, 1H), 6.92 (s, 2H), 4.68 (s, 2H), 4.30 (m, 2H), 3.89 (m, 2H), 2.62 (t, 2H), 2.44 (s, 2H), 2.12 (s, 3H), 1.42 (t, 2H), 1.00 (s, 6H). MS (EI) for C23H27N5OS: 422 (MH+).

Example 10 N,N-dimethyl-3-({4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-6-yl}oxy)propan-1-amine and 4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-6-ol

STEP 1; A solution of 7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine (example 1) (26 mg, 0.05 mmol) in trifluoroacetic acid (3.0 mL) was heated to 68° C. for 3.5 hours then concentrated and dried. This material was then carried forward into step 2 without further purification. A sample of material obtained in this manner was purified by preparative reverse phase HPLC to give 4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-6-ol. 1H NMR (400 MHz, d6-DMSO): 10.1 (s, 1H), 8.44 (s, 1H), 7.73 (d, 1H), 7.70 (d, 1H), 7.65 (d, 1H), 7.55-7.51 (m, 2H), 7.48 (d, 0.5H), 7.46 (d, 0.5H), 7.40 (dd, 1H), 7.33 (d, 1H), 7.04 (d, 1H), 5.00 (s, 2H), 4.46 (t, 2H), 4.24 (t, 2H), 2.54 (s, 3H). MS (EI) for C25H22N5O2: 424 (MH+).

STEP 2: 4-[7-(2-Methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-6-ol as obtained in step 1 without purification was taken into N,N-dimethylacetamide (5.0 mL), and then combined with 3-chloro-N,N-dimethylpropan-1-amine hydrochloride (9.61 mg, 0.06 mmol) and potassium carbonate (41 mg, 0.30 mmol) and heated to 50° C. for 18 hours. The reaction mixture was concentrated and the residue purified by preparative reverse phase HPLC to give N,N-dimethyl-3-({4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-6-yl}oxy)propan-1-amine as the trifluoroacetic acid salt (6.5 mg, 21% yield). 1H NMR (400 MHz, d6-DMSO): 8.69 (s, 1H), 7.97 (s, 2H), 8.23 (m, 3H), 7.61 (dd, 2H), 7.30 (br s, 1H), 7.07 (d, 1H), 5.30 (br s, 2H), 4.63 (br s, 2H), 4.37 (br s, 2H), 3.98 (br, s, 2H), 2.98 (br s, 2H), 2.80 (s, 2H), 2.68 (s, 3H), 2.50 (s, 6H); MS (EI) for C30H32N6O2: 509 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in steps 1 or 2 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

4-[6-(ethyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 10 using iodoethane in step 2. 1H NMR (400 MHz, d6-DMSO): 12.22 (s, 1H), 8.53 (s, 1H), 7.84 (d, 1H), 7.79 (m, 0.5H), 7.73 (d, 1H), 7.65 (m, 0.5H), 7.58 (dd, 1H), 7.54 (m, 0.5H), 7.46 (br s, 1H), 7.44 (m, 0.5H), 7.40 (dd, 1H), 7.09 (br s, 1H), 7.05 (d, 1H), 5.06 (s, 2H), 4.54 (t, 2H), 4.08 (t, 2H), 3.72 (dd, 2H), 2.50 (s, 3H), 0.78 (t, 3H). MS (EI) for C27H26N5O2: 452 (MH+).

({4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-6-yl}oxy)acetonitrile. Synthesized according to the method of example 10 using bromoacetonitrile in step 2. 1H NMR (400 MHz, d6-DMSO): 12.22 (s, 1H), 8.53 (s, 1H), 7.83 (s, 0.5H), 7.81 (s, 0.5H), 7.72 (d, 1H), 7.67 (m, 0.5H), 7.62 (d, 0.5H), 7.59 (d, 0.5H), 7.53 (d, 1H), 7.52 (d, 1H), 7.50 (m, 0.5H), 7.44 (d, 1H), 7.40 (dd, 1H), 7.04 (d, 1H), 5.22 (s, 2H), 5.10 (s, 2H), 4.50 (t, 2H), 4.18 (t, 2H), 2.50 (s, 3H). MS (EI) for C27H23N6O2: 463 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(propyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 10 using 1-bromopropane in step 2. 1H NMR (400 MHz, d6-DMSO): 8.75 (s, 1H), 7.97 (s, 2H), 7.81 (s, 2H), 7.75 (d, 1H), 7.70 (d, 1H), 7.58 (d, 1H), 7.22 (br s, 1H), 7.11 (d, 1H), 5.27 (s, 2H), 4.62 (br s, 2H) 4.32 (br s, 2H), 3.73 (br s, 2H), 1.33 (br s, 2H), 0.70 (br s, 3H); MS (EI) for C28H27N5O2: 466 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-{[2-(methyloxy)ethyl]oxy}quinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 10 using 2-(methoxy)-1-bromoethane in step 2. 1H NMR (400 MHz, d6-DMSO): 8.52 (s, 1H), 7.88 (d, 1H), 7.58 (dd, 1H), 7.43 (m, 3H), 7.40 (m, 3H), 7.06 (m, 2H), 5.07 (s, 2H), 4.57 (br s, 2H) 4.08 (br s, 2H), 3.75 (br s, 2H), 2.85 (br s, 2H), 2.79 (s, 3H), 1.82 (s, 3H); MS (EI) for C28H27N5O3: 482 (MH+).

N,N-dimethyl-2-({4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-8-(methyloxy)quinazolin-7-yl}oxy)ethanamine. Synthesized according to the method of example 10 using 7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine (example 1) in step 1 and 2-(N,N-dimethylamino)-1-chloroethane in step 2. 1H NMR (400 MHz, d6-DMSO): 8.57 (s, 1H), 7.93 (s, 1H), 7.82 (m, 3H), 7.59 (d, 1H), 7.51 (d, 1H), 7.01 (d, 1H), 7.01 (d, 1H), 5.38 (br s, 2H), 4.61 (m, 4H), 4.45 (br s, 2H), 3.95 (br s, 2H), 3.72 (t, 2H), 2.90 (s, 6H), 2.77 (s, 3H); MS (EI) for C30H32N6O3: 525 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(2-methylpropyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 10 using 7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine (example 1) in step 1 and isobutyl bromide in step 2. 1H NMR (400 MHz, d6-DMSO): 8.48 (s, 1H), 7.96 (s, 1H), 7.83 (m, 3H), 7.63 (d, 1H), 7.52 (d, 1H), 7.04 (d, 1H), 5.46 (s, 2H), 4.65 (br s, 3H) 4.53 (br s, 2H), 4.07 (d, 2H), 3.92 (s, 3H), 2.79 (s, 3H), 2.13 (m, 1H), 1.04 (d, 6H); MS (EI) for C30H31N5O3: 510 (MH+).

4-{7-[(cyclopropylmethyl)oxy]-8-(methyloxy)quinazolin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 10 using 7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine (example 1) in step 1 and cyclopropylmethyl bromide in step 2. 1H NMR (400 MHz, d6-DMSO): 8.66 (s, 1H), 8.08 (s, 1H), 7.92 (s, 1H), 7.81 (m, 3H), 7.63 (d, 1H), 7.50 (d, 1H), 7.04 (d, 1H), 5.44 (s, 2H), 4.63 (br s, 3H) 4.53 (br s, 2H), 4.17 (d, 2H), 3.92 (s, 3H), 0.83 (m, 1H), 0.61 (m, 2H), 0.41 (m, 2H); MS (EI) for C30H29N5O3: 508 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(quinolin-2-ylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 10 using 7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine (example 1) in step 1 and 2-bromomethylquinoline in step 2. 1H NMR (400 MHz, d6-DMSO): 8.64 (s, 1H), 8.47 (d, 1H), 8.03 (m, 4H), 7.83 (m, 4H), 7.73 (d, 1H), 7.63 (m, 3H), 7.02 (d, 1H), 5.64 (s, 2H), 5.43 (br s, 3H) 4.62 (br s, 2H), 4.51 (br s, 2H), 4.01 (s, 1H), 2.80 (s, 3H); MS (EI) for C36H30N6O3: 595 (MH+).

4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-8-(methyloxy)quinazolin-7-ol. Synthesized according to the method of example 10 using 7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine (example 1) in step 1. 1H NMR (400 MHz, d6-DMSO): 12.86 (br s, 1H), 10.29 (br s, 1H), 8.48 (s, 1H), 7.76-7.67 (m, 3H), 7.56 (d, 1H), 7.51 (dd, 1H), 7.46 (dd, 1H), 7.11 (d, 1H), 7.00 (d, 1H), 5.12 (s, 2H), 4.50 (m, 2H), 4.22 (m, 2H), 3.88 (s, 3H), 2.54 (s, 3H). MS (EI) for C26H23N5O3: 454 (MH+)

4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6-(methyloxy)quinazolin-7-ol. Prepared according to the method of example 10 by using 7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine (example 1) in step 1. 1H NMR (400 MHz, Methanol-D4): 8.41, (s, 1H), 7.67 (br, 2H), 7. (dd, 2H), 7.45 (dd, 1H), 7.10 (d, 2H), 7.03 (dd, 1H), 5.03 (s, 2H), 4.54 (m, 2H), 4.15 (m, 2H), 3.48 (s, 3H), 2.60 (s, 3H), MS (EI) for C26H23N5O3: 454 (MH+).

N-ethyl-6-{4-[7-(ethyloxy)-2-methylquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared according to the method of example 10 using 4-{7-[2-(ethylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-2-methylquinazolin-7-ol (example 11) and ethyl iodide in step 2. 1H NMR (400 MHz, DMSO-d6) δ 10.36 (s, 1H), 7.91-7.82 (m, 1H), 7.63 (dd, 1H), 7.52-7.36 (m, 2H), 7.26-7.13 (m, 2H), 6.99 (dd, 1H), 6.94-6.86 (m, 2H), 6.70 (q, 1H), 4.96 (s, 2H), 4.45-4.35 (m, 2H), 4.16-3.98 (m, 4H), 3.46-3.36 (m, 2H), 2.44-2.37 (m, 3H), 1.28-1.17 (m, 6H); MS (EI) for C29H30N6O2: 495 (MH+).

Example 11 N-ethyl-6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine

STEP 1: To a solution of 1,1-dimethylethyl 7-(4-amino-3-nitrophenyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (Example 26, 1.35 g, 3.1 mmol) in ethyl acetate (30 mL) was added 5% palladium on carbon (wet). The resulting suspension was subjected to an atmosphere of hydrogen (40 psi) for 15 h. The catalyst was then removed by filtration through celite. The filtrate was concentrated to provide 1,1-dimethylethyl 7-(3,4-diaminophenyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (748 mg, 210 mmol, 68% yield) as an orange viscous syrup. MS (EI) for C20H25N3O3: 356 (MH+).

STEP 2: A solution of 1,1-dimethylethyl 7-(3,4-diaminophenyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (750 mg, 2.10 mmol) in ethyl acetate (20 mL) was treated with ethyl isothiocyanate (184 uL, 2.10 mmol). The mixture was heated to 60° C. for 4.25 h. After cooling to rt, water was added and the layers were partitioned. The organic phase was washed once with saturated sodium bicarbonate, dried over magnesium sulfate, filtered, and concentrated. The residue was then dissolved in ethyl acetate (20 mL), and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (403 mg, 2.10 mmol) was added. The mixture was heated to 60° C. for 50 minutes before cooling to rt. Water was added, and the biphasic mixture was partitioned. The aqueous phase was extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (gradient: 98:2 dichloromethane:methanol to 90:10 dichloromethane:methanol) to provide 1,1-dimethylethyl 7-[2-(ethylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (337 mg, 0.83 mmol, 39% yield) as an orange film. 1H NMR (400 MHz, DMSO-d6) δ 10.83 (br s, 1H), 7.47-7.38 (m, 2H), 7.32 (s, 1H), 7.20-7.08 (m, 2H), 7.05-6.96 (m, 1H), 6.68-6.58 (m, 1H), 4.55-4.40 (m, 2H), 4.09-3.98 (m, 2H), 3.77-3.65 (m, 2H), 3.33-3.26 (m, 2H), 1.41-1.28 (m, 9H), 1.18 (t, 3H); MS (EI) for C23H28N4O3: 409 (MH+).

STEP 3: A solution of hydrogen chloride in dioxane (4 M, 2.09 mL, 8.3 mmol) was added to 1,1-dimethylethyl 7-[2-(ethylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (337 mg, 0.83 mmol) in methanol (4 mL). The mixture was heated to 60° C. and stirred for 1 h before cooling to rt. The volatile materials were removed to provide N-ethyl-5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine dihydrochloride in quantitative yield. 1H NMR (400 MHz, DMSO-d6) δ 12.85 (d, 2H), 9.48 (br s, 2H), 9.11-9.03 (m, 1H), 7.77 (d, 1H), 7.63 (dd, 1H), 7.55 (d, 1H), 7.52-7.42 (m, 2H), 7.19 (d, 1H), 4.42 (br s, 2H), 4.28-4.20 (m, 2H), 3.55-3.41 (m, 4H), 1.26 (t, 3H); MS (EI) for C18H20N4O: 309 (MH+).

STEP 4: To a mixture of N-ethyl-5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine dihydrochloride (50 mg, 0.13 mmol) and 4-chloro-7-methoxy-2-methylquinazoline (27 mg, 0.13 mmol) in NMP (1 mL) was added diisopropylethylamine (91 uL, 0.52 mmol). The mixture was heated to 90° C. and stirred for 1 h. After cooling to rt, water was added, and the resulting aqueous mixture was extracted twice with 10% methanol in ethyl acetate. The organic extracts were combined, dried over magnesium sulfate, filtered, and then concentrated. The residue was purified by reverse-phase preparative HPLC to provide N-ethyl-6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine as an acetate salt (34.2 mg, 0.063 mmol, 49% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.91 (br s, 1H), 10.83 (br s, 1H), 7.92 (d, 1H), 7.58 (d, 1H), 7.43 (dd, 1H), 7.35 (s, 1H), 7.20-7.10 (m, 3H), 7.05-6.97 (m, 2H), 6.61 (br s, 1H), 4.99 (s, 2H), 4.44-4.38 (m, 2H), 4.18-4.11 (m, 2H), 3.33-3.25 (m, 2H), 2.44 (s, 3H), 1.91 (s, 4H), 1.19 (t, 3H); MS (EI) for C28H28N6O2: 481 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 4 the following compounds of the invention were prepared. Protecting group introduction and removal steps were conducted as required according to literature techniques appropriate for a given protecting group (see for example: Greene and Wuts, Protective Groups in Organic Synthetic, Wiley-Interscience). Alternative starting materials were obtained commercially unless otherwise indicated.

N-ethyl-6-{4-[2-methyl-6,7-bis(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-6,7-dimethoxy-2-methylquinazoline in step 4. 1H NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 7.68 (s, 1H), 7.46 (d, 1H), 7.35 (br s, 1H), 7.21-7.06 (m, 3H), 7.06-6.97 (m, 2H), 6.60 (t, 1H), 4.94 (s, 2H), 4.49-4.41 (m, 2H), 4.09-3.97 (m, 2H), 3.87 (s, 3H), 3.51 (s, 3H), 3.32-3.26 (m, 2H), 2.47 (s, 3H), 1.90 (s, 3H), 1.18 (t, 3H); MS (EI) for C29H30N6O3: 511 (MH+).

N-ethyl-6-[4-(7-fluoroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-7-fluoroquinazoline in step 4. 1H NMR (400 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.52 (s, 1H), 8.15 (dd, 1H), 7.65-7.58 (m, 1H), 7.56-7.49 (m, 1H), 7.48-7.32 (m, 3H), 7.23-7.08 (m, 2H), 6.97 (d, 1H), 6.60 (t, 1H), 5.11 (s, 2H), 4.54-4.44 (m, 2H), 4.27-4.16 (m, 2H), 3.31-3.24 (m, 2H), 1.90 (s, 2H), 1.18 (t, 3H); MS (EI) for C26H23FN6O: 455 (MH+).

4-{7-[2-(ethylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-2-methylquinazolin-7-ol. Prepared as an acetate salt according to the method of example 11 by using 7-(benzyloxy)-4-chloro-2-methylquinazoline in step 4 followed by benzyl deprotection. 1H NMR (400 MHz, DMSO-d6) δ 7.87 (d, 1H), 7.57 (d, 1H), 7.43 (dd, 1H), 7.33 (s, 1H), 7.19-7.11 (m, 2H), 7.02-6.93 (m, 2H), 6.91 (d, 1H), 6.83-6.73 (m, 1H), 4.94 (s, 2H), 4.43-4.35 (m, 2H), 4.15-4.08 (m, 2H), 3.36-3.28 (m, 2H), 2.41 (s, 3H), 1.87 (s, 10H), 1.18 (t, 3H); MS (EI) for C27H26N6O2: 467 (MH+).

N-ethyl-6-[4-(2-methylquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-2-methylquinoline in step 4. 1H NMR (400 MHz, DMSO-d6) δ 10.84 (br s, 1H), 7.95 (d, 1H), 7.85 (d, 1H), 7.64 (t, 1H), 7.61-7.56 (m, 1H), 7.50 (dd, 1H), 7.43 (t, 1H), 7.38 (s, 1H), 7.17 (br s, 2H), 7.08 (d, 1H), 6.98 (s, 1H), 6.63 (t, 1H), 4.55 (s, 2H), 4.39-4.30 (m, 2H), 3.79-3.70 (m, 2H), 3.35-3.27 (m, 2H), 2.55 (s, 3H), 1.18 (t, 3H); MS (EI) for C28H27N5O: 450 (MH+).

N-ethyl-6-{4-[2-methyl-7-(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-7-methoxy-2-methylquinoline in step 4. 1H NMR (400 MHz, DMSO-d6) δ 10.81 (br s, 1H), 7.84 (d, 1H), 7.57 (br s, 1H), 7.49 (dd, 1H), 7.37 (br s, 1H), 7.26 (d, 1H), 7.17 (br s, 2H), 7.09-7.03 (m, 2H), 6.84 (s, 1H), 6.61 (t, 1H), 4.53 (s, 2H), 4.37-4.30 (m, 2H), 3.88 (s, 3H), 3.75-3.67 (m, 2H), 3.34-3.27 (m, 2H), 2.51 (s, 3H), 1.93-1.89 (m, 3H), 1.18 (t, 3H); MS (EI) for C29H29N5O2: 480 (MH+).

6-{4-[6,7-bis(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-N-ethyl-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-6,7-dimethoxyquinazoline in step 4. 1H NMR (400 MHz, DMSO-D6-d6) δ 8.48 (s, 1H), 7.68 (s, 1H), 7.46-7.41 (m, 1H), 7.36-7.32 (m, 1H), 7.20 (s, 1H), 7.17-7.13 (m, 2H), 7.07 (s, 1H), 7.01 (d, 1H), 6.60 (d, 1H), 4.99 (s, 2H), 4.53-4.48 (m, 2H), 4.07-4.02 (m, 2H), 3.90 (s, 3H), 3.53 (s, 3H), 3.33-3.28 (m, 2H), 1.92-1.89 (m, 4H), 1.18 (t, 3H); MS (EI) for C28H28N6O3: 497 (MH+).

N-ethyl-6-[4-(2-ethylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-2-ethylquinazoline in step 4. 1H NMR (400 MHz, DMSO-D6-d6) δ 8.03 (d, 1H), 7.78-7.69 (m, 2H), 7.60 (d, 1H), 7.47-7.39 (m, 2H), 7.35 (s, 1H), 7.19-7.11 (m, 2H), 6.96 (d, 1H), 6.69 (s, 1H), 5.05 (s, 2H), 4.47-4.40 (m, 2H), 4.24-4.18 (m, 2H), 3.37-3.28 (m, 2H), 2.71 (q, 2H), 1.90 (s, 4H), 1.22-1.15 (m, 6H); MS (EI) for C28H28N6O: 465 (MH+).

6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-N-ethyl-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-6,7-dimethoxyquinoline in step 4. 1H NMR (400 MHz, DMSO-d6) δ 10.79 (br s, 1H), 8.47 (d, 1H), 7.67 (br s, 1H), 7.52-7.46 (m, 1H), 7.42-7.32 (m, 1H), 7.31 (s, 1H), 7.21-7.13 (m, 2H), 7.11 (s, 1H), 7.06 (d, 1H), 6.95 (d, 1H), 6.60 (t, 1H), 4.55 (s, 2H), 4.42-4.35 (m, 2H), 3.89 (s, 3H), 3.75-3.67 (m, 2H), 3.53 (s, 3H), 3.32-3.26 (m, 2H), 1.91 (s, 3H), 1.18 (t, 3H); MS (EI) for C29H29N5O3: 496 (MH+).

N-ethyl-6-{4-[6-(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-6-methoxyquinoline in step 4. 1H NMR (400 MHz, DMSO-d6) δ 10.81 (br s, 1H), 8.53 (d, 1H), 7.86 (d, 1H), 7.67 (br s, 1H), 7.49 (d, 1H), 7.45-7.29 (m, 2H), 7.24-7.11 (m, 3H), 7.10-7.02 (m, 2H), 6.61 (t, 1H), 4.57 (s, 2H), 4.43-4.35 (m, 2H), 3.78-3.69 (m, 2H), 3.58 (s, 3H), 3.33-3.27 (m, 2H), 1.90 (s, 3H), 1.18 (t, 3H); MS (EI) for C28H27N5O2: 466 (MH+).

N-ethyl-6-{4-[2-ethyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared as its acetate salt according to the method of example 11 by using 4-chloro-2-ethyl-7-methoxyquinazoline (prepared according to the methods described by Abe et al. J. Med. Chem. 1998, 41, 4062-4079 using 2-amino-4-methoxybenzoic acid and propionyl chloride) in step 4. 1H NMR (400 MHz, DMSO-D6-d6) δ 7.93 (d, 1H), 7.58 (d, 1H), 7.44-7.38 (m, 1H), 7.34 (s, 1H), 7.19-7.10 (m, 3H), 7.04-6.99 (m, 1H), 6.94 (d, 1H), 6.64 (s, 1H), 5.02 (s, 2H), 4.43 (s, 2H), 4.17 (s, 2H), 3.88 (s, 3H), 3.33-3.28 (m, 2H), 2.68 (q, 2H), 1.89 (s, 6H), 1.21-1.16 (m, 6H); MS (EI) for C29H30N6O2.2C2H4O2: 495 (MH+).

N-ethyl-6-{4-[7-(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-7-methoxyquinoline in step 4. 1H NMR (400 MHz, DMSO-d6) δ 10.81 (br s, 1H), 8.53 (d, 1H), 7.91 (d, 1H), 7.60 (s, 1H), 7.49 (dd, 1H), 7.38 (br s, 1H), 7.31 (d, 1H), 7.24-7.09 (m, 3H), 7.05 (d, 1H), 6.88 (d, 1H), 6.67-6.57 (m, 1H), 4.60 (s, 2H), 4.39-4.30 (m, 2H), 3.82-3.74 (m, 2H), 3.33-3.27 (m, 2H), 1.90 (s, 3H), 1.18 (t, 3H); MS (EI) for C28H27N5O2: 466 (MH+).

N-ethyl-6-[4-(7-fluoro-2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-7-fluoro-2-methylquinazoline (prepared according to the methods described by Abe et al. J. Med. Chem. 1998, 41, 4062-4079 using 2-amino-4-fluorobenzoic acid and acetyl chloride) in step 4. 1H NMR (400 MHz, DMSO-d6) δ 8.13-8.06 (m, 1H), 7.61 (d, 1H), 7.45-7.41 (m, 2H), 7.37-7.30 (m, 2H), 7.19-7.12 (m, 2H), 6.98 (d, 1H), 6.68-6.62 (m, 1H), 5.05 (s, 2H), 4.43 (d, 2H), 4.20 (d, 2H), 3.35-3.28 (m, 2H), 2.46 (s, 3H), 1.89 (s, 4H), 1.18 (t, 3H); MS (EI) for C27H25FN6O: 469 (MH+).

N-ethyl-6-[4-(7-fluoro-2-methylquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 11 by using 4-chloro-7-fluoro-2-methylquinoline in step 4. 1H NMR (400 MHz, DMSO-d6) δ 10.86 (br s, 1H), 8.00 (dd, 1H), 7.64-7.53 (m, 2H), 7.49 (dd, 1H), 7.43-7.30 (m, 2H), 7.17 (br s, 2H), 7.07 (d, 1H), 6.96 (s, 1H), 6.63 (t, 1H), 4.57 (s, 2H), 4.39-4.30 (m, 2H), 3.80-3.69 (m, 2H), 3.36-3.26 (m, 2H), 2.54 (s, 3H), 1.89 (s, 3H), 1.18 (t, 3H); MS (EI) for C28H26FN5O: 468 (MH+).

N-ethyl-6-(4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine. Prepared as an acetate salt according to the method of example 11 by using tert-butyl 7-(6-amino-5-nitropyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (Example 26) in step 1 and 4-chloropyrimidine in step 4. 1H NMR (400 MHz, DMSO-D6-d6) δ 8.13-8.06 (m, 1H), 7.61 (d, 1H), 7.45-7.41 (m, 2H), 7.37-7.30 (m, 2H), 7.19-7.12 (m, 2H), 6.98 (d, 1H), 6.68-6.62 (m, 1H), 5.05 (s, 2H), 4.43 (d, 2H), 4.20 (d, 2H), 3.35-3.28 (m, 2H), 2.46 (s, 3H), 1.89 (s, 4H), 1.18 (t, 3H); MS (EI) for C21H21N7O: 388 (MH+).

N-ethyl-6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine. Prepared according to the method of example 11 by using tert-butyl 7-(6-amino-5-nitropyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (Example 26) in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 4. 1H NMR (400 MHz, DMSO-d6) δ 8.22 (s, 0.5H), 8.07 (s, 0.5H), 7.90 (d, 1H), 7.68-7.42 (m, 3H), 7.17-6.84 (m, 4H), 5.00 (s, 2H), 4.47-4.39 (m, 2H), 4.18-4.10 (m, 2H), 3.88 (s, 3H), 3.40-3.30 (m, 2H), 2.43 (s, 3H), 1.26-1.13 (m, 3H); MS (EI) for C27H27N7O2: 482 (MH+).

6-{4-[2,5-dimethyl-6-(phenylamino)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-N-ethyl-1H-benzimidazol-2-amine. Prepared as a trifluoroacetate salt according to the method of example 11 by using 6-chloro-2,5-dimethyl-N-phenylpyrimidin-4-amine (prepared according to the methods described by Chen et al. J. Med. Chem. 1996, 39, 4358-4360 using 4,6-dichloro-2,5-dimethylpyrimidine and aniline) in step 4. 1H NMR (400 MHz, DMSO-d6) δ 8.99 (t, 1H), 7.60 (d, 1H), 7.56-7.39 (m, 5H), 7.29 (s, 2H), 7.11-6.97 (m, 2H), 4.65 (s, 2H), 4.35-4.29 (m, 2H), 3.87-3.80 (m, 2H), 3.47-3.37 (m, 2H), 2.30 (s, 3H), 2.09 (s, 3H), 1.26 (t, 3H); MS (EI) for C30H31N7O: 506 (MH+).

N-ethyl-6-{4-[6-(phenylamino)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared according to the method of example 11 by using 6-chloro-N-phenylpyrimidin-4-amine (reagent preparation 49) in step 4. 1H NMR (400 MHz, DMSO-d6) δ 12.03 (br s, 1H), 9.01 (s, 1H), 8.13 (s, 1H), 7.50 (m, 6H), 7.01 (m, 6H), 6.02 (s, 1H), 4.87 (br s, 2H), 4.24 (br s, 4H), 3.48 (q, 2H), 1.23 (t, 3H); MS (EI) for C28H27N7O: 478.3 (MH+).

N-ethyl-6-[4-(6-{[4-(methyloxy)phenyl]amino}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared according to the method of example 11 by using 6-chloro-N-(4-methoxyphenyl)pyrimidin-4-amine (reagent preparation 49) in step 4. 1H NMR (400 MHz, DMSO-d6) δ 12.03 (br s, 1H), 9.23 (br s, 1H), 9.02 (t, 1H), 8.13 (s, 1H), 7.50 (m, 5H), 7.30 (d, 2H), 7.01 (d, 1H), 6.75 (br s, 2H), 6.02 (s, 1H), 4.87 (br s, 2H), 4.24 (br s, 4H), 3.77 (s, 3H), 3.48 (q, 2H), 1.23 (t, 3H); MS (EI) for C29H29N7O2: 508.2 (MH+).

N-ethyl-6-(4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine. Prepared according to the method of example 11 by using 4-chloropyrimidine in step 4. 1H NMR (400 MHz, DMSO-d6) δ 12.03 (br s, 1H), 9.23 (br s, 1H), 8.75 (s, 1H), 8.47 (d, 1H), 8.03 (br s, 1H), 7.50 (m, 5H), 7.01 (d, 1H), 5.02 (br s, 2H), 4.34 (br s, 4H), 3.48 (q, 2H), 1.23 (t, 3H); MS (EI) for C22H22N6O: 387.3 (MH+).

N-ethyl-6-[4-(6-{[3-(methyloxy)phenyl]amino}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared according to the method of example 11 by using 6-chloro-N-(3-methoxyphenyl)pyrimidin-4-amine (reagent preparation 49) in step 4. 1H NMR (400 MHz, DMSO-d6) δ 12.03 (br s, 1H), 8.20 (s, 1H), 7.60 (s, 1H), 7.40 (m, 2H), 7.15 (m, 7H), 6.70 (br s, 1H), 6.50 (m, 1H), 6.15 (s, 1H), 4.72 (br s, 2H), 4.18 (s, 4H), 3.77 (s, 3H), 3.48 (q, 2H), 1.23 (t, 3H); MS (EI) for C29H29N7O2: 508.2 (MH+).

N-ethyl-6-[4-(5-methyl-6-{[4-(methyloxy)phenyl]amino}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared according to the method of example 11 by using 6-chloro-N-(4-methoxyphenyl)-5-methylpyrimidin-4-amine (reagent preparation 49) in step 4. 1H NMR (400 MHz, DMSO-d6) δ 12.03 (br s, 1H), 8.20 (s, 1H), 8.01 (s, 1H), 7.51 (m, 5H), 7.18 (m, 2H), 7.01 (d, 1H), 6.81 (d, 2H), 6.75 (br s, 1H), 4.50 (s, 2H), 4.23 (br s, 2H), 3.78 (br s, 2H), 3.33 (q, 2H), 2.18 (s, 3H), 1.81 (s, 3H), 1.23 (t, 3H); MS (EI) for C30H31N7O2: 522.0 (MH+).

N-ethyl-6-{4-[5-methyl-6-(phenylamino)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared according to the method of example 11 by using 6-chloro-5-methyl-N-phenylpyrimidin-4-amine (reagent preparation 49) in step 4. 1H NMR (400 MHz, MeOH-d4) δ 8.01 (s, 1H), 7.51 (m, 10H), 7.02 (d, 1H), 6.75 (brs, 2H), 4.50 (brs, 4H), 4.14 (brs, 4H), 3.48 (q, 2H), 2.21 (s, 3H), 1.38 (t, 3H); MS (EI) for C29H29N7O: 492.2 (MH+).

Example 12 4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-methylbenzamide

STEP 1: A suspension of {4-[(methyloxy)carbonyl]phenyl}boronic acid (0.36 g, 2.0 mmol), 1,1-dimethylethyl 7-bromo-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.66 g, 2.0 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (70.0 mg, 0.10 mmol), and tripotassium phosphate (1.30 g, 12.0 mmol) in dioxane (20 mL) was refluxed for 3 h, and then cooled to room temperature. The reaction mixture was partitioned between ethyl acetate (50 mL) and water (80 mL), the organic layer was washed with brine (40 mL), dried over sodium sulfate then filtered and concentrated. Column chromatography on silica (ethyl acetate:hexanes 1:4) gave 1,1-dimethylethyl 7-{4-[(methyloxy)carbonyl]phenyl}-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.47 g, 60% yield). 1H NMR (400 MHZ, DMSO-D6): 8.11 (m, 2H), 7.63-7.52 (m, 2H), 7.43 (m, 2H), 7.10 (t, 1H), 4.57-4.43 (br, 2H), 4.08 (m, 2H), 3.82 (m, 2H), 1.40 (s, 9H); MS (EI) for C22H25NO5: 469 (MH+).

STEP 2: To a solution of 1,1-dimethylethyl 7-{4-[(methyloxy)carbonyl]phenyl}-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (1.90 g, 4.96 mmol) in dry methanol (10 mL) was added drop wise 4 N hydrogen chloride in dioxane (10 mL) at room temperature. The reaction mixture was warmed to 55° C. for 60 min, at which time it was cooled to room temperature. The precipitated product was isolated by filtration, washed with diethyl ether, and dried to yield methyl 4-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzoate hydrochloride (1.53 g, 97% yield) as a white solid.

STEP 3: A suspension of -(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzoate hydrochloride (1.30 g, 4.14 mmol), 4-chloro-5-[(4-fluorophenyl)methyl]-6-methylpyrimidine (reagent preparation 5) (0.98 g, 4.14 mmol), and potassium carbonate (1.71 g, 12.4 mmol) in DMF (20 mL) was heated to 130° C. for 18 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (40 mL), and then washed with water (50 mL) and brine (20 mL). The organic layer was dried over sodium sulfate then filtered and concentrated. Column chromatography on silica (gradient 10 to 20% ethyl acetate in hexane) followed by recrystallization from 1:1 ethyl acetate and ether (40 mL) provided methyl 4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzoate (1.05 g, 50% yield) as a white solid. 1H NMR (400 MHZ, DMSO-D6): 8.48 (s, 1H), 8.01 (d, 2H), 7.62 (d, 2H), 7.56 (dd, 1H), 7.11 (d, 4H), 7.02 (d, 1H), 6.91 (d, 1H), 4.52 (s, 2H), 4.32 (m, 2H), 3.95 (s, 2H), 3.90 (s, 3H), 3.76 (m, 2H), 2.13 (s, 3H); MS (EI) for C29H26FN3O3: 484 (MH+).

STEP 4: To a solution of methyl 4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzoate (1.0 g, 2.0 mmol) in 1:1 methanol and THF (10 mL) was added drop wise 2N aqueous potassium hydroxide (8 mL). The reaction mixture was stirred at room temperature for 18 h and then refluxed for 90 min. The mixture was cooled by adding ice, and the pH adjusted to 6 with 2N aqueous hydrochloric acid. The precipitate was filtered, washed with water, azeotroped with toluene (20 mL), and dried to afford 4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzoic acid (0.97 g, 100% yield).

STEP 5: To a solution of 4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzoic acid (0.50 g, 1.07 mmol) and DMF (20 μL) in chloroform (15 mL) was added drop wise oxalyl chloride (0.35 mL, 4.0 mmol). The reaction mixture was refluxed for 15 min, and then concentrated to give 4-(4-{5-[(4-fluorophenyl)-methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzoyl chloride as an oil.

STEP 6: To a solution of 4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzoyl chloride (30.0 mg, 62 μmol) in THF (5 mL) was added drop wise 40% aqueous methylamine (0.25 mL, 2.0 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 h, at which time it was concentrated. The resulting solid was dissolved in chloroform (30 mL), washed with water (20 mL), and dried over sodium sulfate then filtered. To the solution was then added drop wise 4N hydrogen chloride in dioxane (0.25 mL) and the mixture concentrated. The residue was taken up in 4:1 water and acetonitrile (2 mL) and lyophilized to give 4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-methylbenzamide hydrochloride salt (16.5 mg, 53% yield) as a white powder. 1H NMR (400 MHZ, DMSO-d6): 8.79 (s, 1H), 8.53 (dd, 1H), 7.97 (d, 2H), 7.65 (d, 2H), 7.57 (d, 1H), 7.30-7.13 (m, 5H), 6.97 (d, 1H), 4.92 (s, 1H), 4.35 (br 2H), 4.04-3.97 (m, 4H), 3.83 (d, 3H), 2.24 (s, 3H); MS (EI) for C29H27FN4O2: 483 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 6 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

N-cyclopropyl-4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide. Synthesized according to the method of example 12 using cyclopropylamine in step 6. 1H NMR (400 MHz, d6-DMSO): 8.79 (s, 1H), 8.53 (d, 1H), 7.92 (d, 2H), 7.61 (d, 2H), 7.58 (d, 1H), 7.12 (m, 5H), 7.02 (d, 1H), 4.92 (s, 2H), 4.38 (br s, 2H), 4.05 (s, 2H), 4.00 (br s, 2H), 2.88 (m, 1H), 2.25 (s, 3H), 0.73 (m, 2H), 0.61 (m, 2H); MS (EI) for C31H26FN4O2: 509 (MH+).

4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-[(3S)-pyrrolidin-3-yl]benzamide. Synthesized according to the method of example 12 using ((3S))—N1—BOC-pyrrolidin-3-ylamine in step 6. 1H NMR (400 MHz, d6-DMSO): 9.38 (br s, 1H), 9.14 (br s, 1H), 8.03 (d, 2H), 7.67 (d, 2H), 7.59 (d, 1H), 7.21 (m, 4H), 7.05 (d, 1H), 4.92 (s, 2H), 4.60 (m, 1H), 4.36 (br s, 2H), 4.08 (br s, 2H), 3.98 (br s, 2H), 3.68 (m, 3H), 3.49 (m, 3H), 3.24 (m, 1H), 2.24 (s, 3H); MS (EI) for C32H32FN5O2: 538 (MH+).

N-(2,2-difluoroethyl)-4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide. Synthesized according to the method of example 12 using 2,2-difluoroethylamine in step 6. 1H NMR (400 MHz, d6-DMSO); 8.95 (t, 1H), 8.80 (s, 1H), 7.98 (d, 2H), 7.68 (d, 2H), 7.59 (d, 1H), 7.21 (m, 4H), 7.04 (d, 1H), 6.17 (tt, 1H), 4.93 (s, 2H), 4.37 (br s, 2H), 4.08 (s, 2H), 3.99 (br s, 2H), 3.61 (br m, 2H), 2.25 (s, 3H); MS (EI) for C30H27F3N4O2: 533 (MH+).

4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide. Synthesized according to the method of example 12 using ammonia in step 6. 1H NMR (400 MHz, d6-DMSO): 8.63 (br s, 1H), 8.05 (br s, 1H), 7.96 (d, 2H), 7.59 (d, 2H), 7.55 (dd, 1H), 7.41 (br s, 1H), 7.16 (m, 4H), 7.10 (br s, 1H), 7.01 (d, 1H), 4.70 (br s, 2H), 4.32 (m, 2H), 4.00 (s, 2H), 3.86 (m, 2H), 2.20 (s, 3H). MS (EI) for C28H25FN4O2: 469 (MH+).

4-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-methylbenzamide. Prepared according to the method of example 12 by using 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 3. 1H NMR (400 MHz, methanol-d4): 7.88 (d, 2H), 7.72 (d, 2H), 7.66 (d, 1H), 7.52 (dd, 1H), 7.04 (d, 1H), 4.78 (s, 2H), 4.37 (m, 2H), 4.01 (m, 2H), 3.76 (s, 2H), 2.94 (s, 3H), 2.80 (t, 2H), 2.50 (s, 2H), 2.47 (s, 6H), 1.92 (s, 3H), 1.68 (t, 2H), 0.90 (s, 6H); MS (EI) for C30H37N5O2: 500 (MH+).

N-methyl-4-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide. Prepared according to the method of example 12 using 4-chloroquinoline in step 3 and methylamine in step 6. 1H NMR (400 MHz, DMSO-d6); δ 8.60 (d, 1H), 8.53-8.46 (m, 1H), 8.06 (d, 1H), 7.98-7.70 (m, 6H), 7.68-7.62 (m, 1H), 7.56-7.50 (m, 1H), 7.09 (d, 1H), 6.99 (d, 1H), 4.82 (s, 2H), 4.50-4.41 (m, 2H), 4.02-3.89 (m, 2H), 2.81 (d, 3H); MS (EI) for C26H23N3O2: 410 (MH+).

N-ethyl-4-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide. Prepared according to the method of example 12 using 4-chloroquinoline in step 3 and ethylamine in step 6. 1H NMR (400 MHz, DMSO-d6); δ 8.61 (d, 1H), 8.55-8.50 (m, 1H), 8.02-7.90 (m, 4H), 7.81-7.76 (m, 3H), 7.72-7.62 (m, 2H), 7.50-7.45 (m, 1H), 7.12 (d, 1H), 7.00 (d, 1H), 4.68 (s, 2H), 4.43-4.37 (m, 2H), 3.86-3.80 (m, 2H), 1.14 (t, 3H); MS (EI) for C27H25N3O2: 424 (MH+).

N-propyl-4-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide. Prepared according to the method of example 12 using 4-chloroquinoline in step 3 and propylamine in step 6. 1H NMR (400 MHz, DMSO-d6); δ 8.61 (d, 1H), 8.54-8.48 (m, 1H), 8.03 (d, 1H), 7.98-7.91 (m, 3H), 7.84-7.77 (m, 3H), 7.75-7.68 (m, 1H), 7.68-7.62 (m, 1H), 7.55-7.48 (m, 1H), 7.10 (d, 1H), 7.00 (d, 1H), 4.75 (s, 2H), 4.46-4.39 (m, 2H), 3.93-3.85 (m, 2H), 3.28-3.20 (m, 2H), 1.61-1.49 (m, 2H), 0.91 (t, 3H); MS (EI) for C28H27N3O2: 438 (MH+).

3-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}benzoic acid. Prepared according to the method of example 12 using 3-(methoxycarbonyl)phenylboronic acid in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 3 and omission of steps 5 and 6. 1H NMR (400 MHz, DMSO-d6); δ 8.21 (m, 1H), 7.96-7.86 (m, 1H), 7.78-7.72 (m, 3H), 7.64-7.50 (m, 2H), 7.15-7.00 (m, 3H), 5.03 (s, 2H), 4.49-4.42 (m, 2H), 4.20-4.12 (m, 2H), 3.88 (s, 3H), 2.42 (s, 3H); MS (EI) for C26H23N3O4: 440 (M−).

N-methyl-3-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}benzamide. Prepared according to the method of example 12 using 3-(methoxycarbonyl)phenylboronic acid in step 1,4-chloro-7-methoxy-2-methylquinazoline in step 3, and methylamine in step 6. 1H NMR (400 MHz, DMSO-d6); δ 8.61-8.52 (m, 1H), 8.12-8.09 (m, 1H), 7.89 (d, 1H), 7.84-7.73 (m, 3H), 7.61-7.51 (m, 2H), 7.12-7.09 (m, 1H), 7.08-7.00 (m, 2H), 5.03 (s, 2H), 4.51-4.41 (m, 2H), 4.22-4.12 (m, 2H), 3.88 (s, 3H), 2.85-2.79 (d, 3H), 2.42 (s, 3H); MS (EI) for C27H26N4O3: 455 (MH+).

N-ethyl-3-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}benzamide. Prepared according to the method of example 12 using 3-(methoxycarbonyl)phenylboronic acid in step 1,4-chloro-7-methoxy-2-methylquinazoline in step 3, and ethylamine in step 6. 1H NMR (400 MHz, DMSO-d6); δ 8.64-8.57 (m, 1H), 8.14-8.08 (m, 1H), 7.97-7.89 (d, 1H), 7.84-7.75 (m, 3H), 7.61-7.51 (m, 2H), 7.12 (d, 1H), 7.08-7.02 (m, 2H), 5.06 (s, 2H), 4.53-4.43 (m, 2H), 4.23-4.14 (m, 2H), 3.88 (s, 3H), 2.44 (s, 3H), 1.15 (t, 3H); MS (EI) for C28H28N4O3: 469 (MH+).

Example 13 Methyl [6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate and 6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine

STEP 1: To a slurry of 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) (3.3 g, 8.8 mmol) in methanol (25 mL) was added anhydrous hydrogen chloride (6.0 mL, 4 N in dioxane, 24 mmol). The reaction mixture was heated (60° C.) for 1.5 h and was concentrated. The resulting solid was suspended in ethyl ether (50 mL), collected by filtration and washed with ethyl ether (2×30 mL) to afford 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine hydrochloride (1.4 g, 50% yield) as a white solid. MS (EI) for C15H22BNO3: 276 (MH+).

STEP 2: To a solution of 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine hydrochloride (1.4 g, 4.5 mmol) and DIPEA (6.4 mL, 37 mmol) in NMP (24 mL) was added and 4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidine (reagent preparation 5) (1.7 g, 7.3 mmol). The resulting mixture was heated (120° C.) for 12 h and then partitioned between ethyl acetate (100 mL) and 1N aqueous hydrochloric acid (50 mL). The organic layer was washed with additional 1N aqueous hydrochloric acid (50 mL), brine (50 mL), dried over anhydrous magnesium sulfate, filtered and concentrated. Column chromatography on silica (0-30% ethyl acetate/hexanes) provided 4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (1.7 g, 47% yield) as a white foam. MS (EI) for C27H31BFN3O3: 476 (MH+).

STEP 3: To a solution of 4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (1.3 g, 2.7 mmol), potassium hydrogen carbonate (1.4 g, 14 mmol), 2-amino-5-bromo-3-nitropyridine (0.98 g, 4.5 mmol) and DIPEA (1.4 mL, 8.2 mmol) in dioxane (8 mL) and water (1 mL) was added dichloro[1,1-bis(diphenylphosphino]ferrocenepalladium (II) dichloromethane adduct (0.20 g, 0.27 mmol). The biphasic mixture was then heated (90° C.) for 2 h and the organic layer was separated and purified by column chromatography on silica (0-10% methanol/dichloromethane) to provide 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-3-nitropyridin-2-amine (0.49 g, 37% yield) as a orange-red solid. MS (EI) for C26H23FN6O3: 487 (MH+).

STEP 4: To a solution of 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-3-nitropyridin-2-amine (0.36 g, 0.75 mmol) in acetic acid (10 mL) was added tin (II) chloride (0.75 g, 3.8 mmol). The reaction mixture was heated (50° C.) for 2 h and then partitioned between ethyl acetate (10 mL) and 1 N aqueous sodium hydroxide (20 mL). The resulting mixture was filtered through Celite and the organic layer was washed with brine (10 mL), dried over anhydrous magnesium sulfate then filtered and concentrated. Column chromatography on silica (5% methanol/dichloromethane) provided 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridine-2,3-diamine (0.21 g, 60% yield) as a pale yellow solid. MS (EI) for C26H25FN6O: 457 (MH+).

STEP 5: To a solution of 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridine-2,3-diamine (0.21 g, 0.45 mmol) in acetic acid (5 mL) was added 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (0.09 g, 0.45 mmol). The reaction mixture was heated (60° C.) for 12 h and then concentrated. The resulting residue was dissolved in acetonitrile and purified by preparative reverse phase HPLC to provide methyl [6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate (0.01 g, 4% yield) as a white solid. 1H NMR (400 MHz, DMSO-D6): δ 11.97 (bs, 1H), 8.51 (d, 1H), 8.28 (s, 1H), 7.79 (s, 1h), 7.42-7.50 (m, 1H), 6.95-7.13 (m, 6H), 4.53 (s, 2H), 4.25-4.32 (m, 2H), 4.00 (s, 2H), 3.74-3.84 (m, 5H), 2.16 (s; 3H); MS (EI) for C29H26FN7O3: 540 (MH+).

STEP 6: A mixture of methyl [6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate (15 mg, 0.028 mmol) in methanol and 2 M aqueous potassium hydroxide (1:1, 2 mL) was stirred at 65° C. for 18 hours. The reaction mixture was cooled, adjusted to pH 10 with 2 N hydrochloric acid, concentrated, diluted with ethyl acetate (10 mL), washed with brine solution (5 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative reverse phase HPLC to give 6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine (8.9 mg, 67% yield). 1H NMR (400 MHz, DMSO-D6): 8.46 (1H), 8.02 (br, 1H), 7.47 (d, 1H), 7.39 (dd, 1H), 7.10 to 6.96 (m, 5H), 7.75 (br, 1H), 4.53 (s, 2H), 4.30 (m, 2H), 4.00 (s, 2H), 3.89 (m, 2H), 2.22 (s, 3H), MS (EI) for C27H24FN7O: 428 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 2 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine. Synthesized as the dihydrochloride salt according to the method of example 13 using (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (example 1, step 2) in step 1 and with 4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 2. 1H NMR (400 MHz, DMSO-D6): 8.68 (s, 1H), 8.62 (bs, 2H), 8.41 (s, 1H), 7.96 (s, 1h), 7.78 (s, 1H), 7.57 (d, 1H), 7.06 (d, 1H), 5.07 (s, 2H), 4.43-4.51 (m, 2H), 4.13-4.22 (m, 1H), 2.74-2.84 (m, 2H), 2.53 (s, 2H), 1.53-1.62 (m, 2H), 0.86 (s, 6H); MS (EI) for C25H27N7O: 442.4 (MH+).

6-[4-(6-bromoquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine. Synthesized as the dihydrochloride salt according to the method of example 13 using (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (example 1, step 2) in step 1 and 6-bromo-4-chloroquinazoline in step 2. 1H NMR (400 MHz, DMSO-D6): δ 8.69 (s, 1H), 8.47 (s, 1H), 8.36 (s, 1H), 8.15 (dd, 1h), 8.11 (s, 1H), 7.82 (s, 1H), 7.79 (d, 1H), 7.64 (d, 1H), 7.16 (s, 1H), 5.14 (s, 2H), 4.66-4.74 (m, 2H), 4.54-4.61 (m, 2H); MS (EI) for C23H18BrN

6-[4-(6-fluoroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine. Synthesized according to the method of example 13 using 4-chloro-6-fluoroquinazoline in step 2. 1H NMR (400 MHz, CDCl3): 8.68 (s, 1H), 8.39 (d, 1H), 8.10-7.84 (m, 4H), 7.79 (d, 1H), 7.59-7.54 (dd, 1H), 7.09 (d, 1H), 5.47 (s, 2H), 4.69-4.59 (m, 4H). MS (EI) for C25H22FN7O4: 428.1 (MH+).

6-[4-(6-chloroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine. Synthesized according to the method of example 13 using 4,6-dichloroquinazoline in step 2. 1H NMR (400 MHz, MeOH): 8.55 (s, 1H), 8.31 (m, 1H), 8.09 (m, 1H), 7.83-7.79 (m, 3H), 7.68 (m, 1H), 7.55-7.52 (m, 1H), 7.13-7.09 (m, 1H), 5.08 (s, 2H), 4.55-4.50 (m, 2H), 4.30-4.25 (m, 2H); MS (EI) for C23H18ClN7O: 444.1 (MH+).

6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine. Prepared by a modification of the example 13 sequence starting with step 3 using 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) and 2-amino-5-bromo-3-nitropyridine, followed by conducting steps 4 and 5, then 1. Subsequently step 2 was carried out using 4-chloro-5-(4-fluorobenzyl)-6-methylpyrimidine (reagent preparation 5) followed by step 6. 1H NMR (400 MHz, DMSO-D6): 8.46 (s, 1H), 8.02 (br, 1H), 7.47 (d, 1H), 7.39 (dd, 1H), 7.10 to 6.96 (m, 5H), 7.75 (br, 1H), 4.53 (s, 2H), 4.30 (m, 2H), 4.00 (s, 2H), 3.89 (m, 2H), 2.22 (s, 3H), MS (EI) for C27H24FN7O: 428 (MH+).

6-[4-(6-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine. Prepared by a modification of the example 13 sequence starting with step 3 using 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) and 2-amino-5-bromo-3-nitropyridine, followed by conducting steps 4 and 5, then 1. Subsequently step 2 was carried out using 4-chloro-6-ethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 8) followed by step 6. 1H NMR (400 MHz, Methanol-D4): 8.39 (s, 1H), 8.18 (s, 1H), 7.61 (s, 1H), 7.54 (br, 1H), 7.40 (d, 1H), 7.02 (d, 1H), 4.72 (dd, 2H), 4.50 (m, 1H), 4.33 (m, 1H), 4.09 (m, 1H), 3.84 (dd, 1H), 2.88 (m, 1H), 2.76 (m, 1H), 2.57 (dd, 1H), 2.41 (dd, 1H), 1.95 (m, 1H), 1.46 (m, 1H), 1.36 (m, 2H), 0.88 (t, 3H). MS (EI) for C25H27N7O: 442 (MH+).

6-[4-(7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine. Prepared by a modification of the example 13 sequence starting with step 3 using 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) and 2-amino-5-bromo-3-nitropyridine, followed by conducting steps 4 and 5, then 1. Subsequently step 2 was carried out using 4-chloro-7-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 8) followed by step 6. 1H NMR (400 MHz, DMSO-D6): 8.31 (1H), 8.13 (br, 1H), 7.64 (d, 1H), 7.49 (br, 1H), 7.41 (dd, 1H), 7.02 (d, 2H), 4.76 (dd, 2H), 4.41 (m, 1H), 4.23 (m, 1H), 4.06 to 3.91 (m, 2H), 2.88 (m, 2H0, 2.59 (dt, 1H), 2.30 (dd, 1H), 1.92 (m, 2H), 1.19 (m, 1H), 1.08 (d, 3H), MS (EI) for C24H25N7O: 428 (MH+).

6-{4-[6,7-bis(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine. Prepared by a modification of the example 13 sequence starting with step 3 using 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) and 2-amino-5-bromo-3-nitropyridine, followed by conducting steps 4 and 5, then 1. Subsequently step 2 was carried out using 4-chloro-6,7-dimethoxyquinazoline followed by step 6. 1H NMR (400 MHz, Methanol-D4): 8.46 (s, 1H), 8.19 (br, 1H), 7.69 (br, 1H), 7.64 (d, 1H), 7.50 (dd, 1H), 7.14 (s, 1H), 7.12 (s, 1H), 7.10 (d, 1H), 5.04 (s, 2H), 4.54 (m, 2H), 4.16 (m, 2H), 3.95 (s, 3H), 3.56 (s, 3H), MS (EI) for C25H23FN7O3: 470 (MH+).

6-{4-[6-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine. Prepared by a modification of the example 13 sequence starting with step 3 using 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) and 2-amino-5-bromo-3-nitropyridine, followed by conducting steps 4 and 5, then 1. Subsequently step 2 was carried out using 4-chloro-6-methoxyquinazoline followed by step 6. 1H NMR (400 MHz, Methanol-D4): 8.45 (s, 1H), 8.19 (br, 1H), 7.71 (br, 1H), 7.67 (br, 1H), 7.61 (br, 1H), 7.48 (dd, 1H), 7.42 (dd, 1H), 7.18 (d, 1H), 7.10 (d, 1H), 5.02 (s, 2H), 4.53 (m, 2H), 4.17 (m, 2H), 3.58 (s, 3H), MS (EI) for C24H21N7O2: 440 (MH+).

6-[4-(6-iodoquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine. Prepared by a modification of the example 13 sequence starting with step 3 using 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) and 2-amino-5-bromo-3-nitropyridine, followed by conducting steps 4 and 5, then 1. Subsequently step 2 was carried out using 4-chloro-6-iodoquinazoline followed by step 6. 1H NMR (400 MHz, Methanol-D4): 8.56 (s, 1H), 8.38 (br, 1H), 8.34 (br, 1H), 8.03 (dd, 1H), 7.81 (br, 1H), 7.65 (br, 1H), 7.54 (s, 1H), 7.52 (s, 1H), 7.11 (d, 1H), 5.01 (s, 2H), 4.51 (m, 2H), 4.21 (m, 2H), MS (EI) for C23H18N7O: 536 (MH+).

6-{4-[7-bromo-6-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine. Prepared by a modification of the example 13 sequence starting with step 3 using 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) and 2-amino-5-bromo-3-nitropyridine, followed by conducting steps 4 and 5, then 1. Subsequently step 2 was carried out using 7-bromo-4-chloro-6-methoxyquinazoline (reagent preparation 1) followed by step 6. 1H NMR (400 MHz, Methanol-D4): 8.48 (s, 1H), 8.19 (br, 1H), 8.00 (br, 1H), 7.67 (br, 1H), 7.66 (br, 1H), 7.58 (dd, 1H), 7.17 (s, 1H), 7.10 (d, 1H), 5.07 (s, 2H), 4.55 (m, 2H), 4.19 (m, 2H), 3.59 (s, 3H), MS (EI) for C24H20BrN7O2: 518 (MH+).

6-[4-(6-bromo-7-chloroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine. Prepared by a modification of the example 13 sequence starting with step 3 using 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) and 2-amino-5-bromo-3-nitropyridine, followed by conducting steps 4 and 5, then 1. Subsequently step 2 was carried out using 6-bromo-4,7-dichloroquinazoline (reagent preparation 1) followed by step 6. 1H NMR (400 MHz, Methanol-D4): 8.55 (s, 1H), 8.36 (s, 1H), 8.31 (br, 1H), 7.91 (br, 1H), 7.78 (br, 1H), 7.68 (br, 1H), 7.53 (dd, 1H), 7.10 (d, 1H), 5.05 (s, 2H), 4.52 (m, 2H), 4.25 (m, 2H), MS (EI) for C23H17BrClN7O: 522 (MH+).

6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine. Prepared by a modification of the example 13 sequence starting with step 3 using 1,1-dimethylethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (example 9, step 1) and 2-amino-5-bromo-3-nitropyridine, followed by conducting steps 4 and 5, then 1. Subsequently step 2 was carried out using 4-chloro-6,7-dimethoxyquinoline followed by step 6. 1H NMR (400 Methanol-D4): 8.51 (d, 1H), 8.19 (d, 1H), 7.68 (br, 1H), 7.61 (br, 1H), 7.51 (dd, 1H), 7.24 (s, 1H), 7.20 (s, 1H), 7.12 (d, 1H), 7.00 (d, 1H), 4.75 (s, 2H), 4.49 (m, 2H), 4.00 (s, 3H), 3.92 (m, 2H), 3.59 (s, 3H), MS (EI) for C26H24N6O3: 469 (MH+).

Methyl (6-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)carbamate. Prepared according to the method of example 13 by using (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (example 8, step 1) in step 1 and (7S)-4-chloro-7-ethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 2. 1H NMR (400 MHz, Methanol-d4): 8.44 (s, 1H), 8.34 (s, 1H), 7.88 (s, 1H), 7.60 (s, 1H), 7.47 (d, 1H), 7.05 (d, 1H), 4.72 (dd, 2H), 4.38 (m, 1H), 4.29 (m, 1H), 3.95 to 3.81 (m, 2H), 2.85 (m, 2H), 2.48 (m, 1H), 2.26 (m, 1H), 1.88 (m, 1H), 1.69 (m, 1H), 1.35 (m, 2H), 1.11 (m, 1H), 0.92 (t, 3H); MS (EI) for C27H29N7O2: 500 (MH+).

Methyl (6-{4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)carbamate. Prepared according to the method of example 13 by using (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (example 8, step 1) in step 1 and (7S)-4-chloro-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) in step 2. 1H NMR (400 MHz, Methanol-d4): 8.42 (s, 1H), 7.95 (s, 1H), 7.58 (s, 1H), 7.45 (d, 1H), 7.06 (d, 1H), 4.62 (br, 2H), 4.44 (m, 1H), 4.19 (m, 1H), 4.06 (m, 1H), 3.95 (m, 1H), 3.88 (s, 3H), 2.88 (m, 1H), 2.78 (m, 1H), 2.61 (m, 1H), 2.39 (s, 3H), 2.28 (m, 1H), 1.97 (m, 1H), 1.74 (m, 1H), 1.41 (m, 2H), 1.16 (m, 1H), 0.98 (t, 3H); MS (EI) for C28H31N7O3: 514 (MH+).

Methyl [6-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate. The dihydrochloride salt was prepared as in example 13 using 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 2 and omission of step 6. 1H NMR (400 MHz, CD3OD) δ 8.70-8.54 (m, 2H), 8.02 (d, 1H), 7.61 (dt, 1H), 7.10 (d, 1H), 5.18 (s, 2H), 4.57-4.50 (m, 2H), 4.47 (s, 2H), 4.27-4.15 (m, 2H), 3.93 (s, 3H), 2.93-2.81 (m, 8H), 2.57 (s, 2H), 1.71 (t, 2H), 0.92 (s, 6H); MS (ES) for C30H36N8O3: 557.2 (MH+).

Methyl [6-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate. Prepared as in example 13 using 1-(4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine (reagent preparation 17) in step 2,4-bromo-2-nitroaniline in step 3 then omission of step 6. 1H NMR (400 MHz, CD3OD) δ 7.62 (d, 1H), 7.58 (d, 1H), 7.45 (td, 2H), 7.40 (dd, 1H), 7.01 (d, 1H), 4.76 (s, 2H), 4.37-4.31 (m, 2H), 4.03-3.96 (m, 2H), 3.85 (s, 3H), 3.65 (s, 2H), 2.79 (t, 2H), 2.50 (s, 2H), 2.37 (s, 6H), 1.68 (t, 2H), 0.91 (s, 6H); MS (ES) for C31H37N7O3: 556.2 (MH+).

Example 14 6-(4-{5-[(4-Fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine

STEP 1: A mixture of methyl [6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate (example 2) (60 mg, 0.11 mmol) in methanol and 2M potassium hydroxide (1:1, 2 mL) was stirred at 65° C. for 18 hours. The reaction mixture was cooled, adjusted to pH 10 with 2M hydrochloric acid, concentrated, diluted with ethyl acetate (10 mL), washed with brine solution (5 mL), dried over sodium sulfate, filtered, concentrated. The residue was purified by preparative reverse phase HPLC to give 6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine (29 mg, 54% yield). 1H NMR (400 MHz, Methanol-d4): 8.44 (1H), 7.37 (dd, 1H), 7.31 (s, 1H), 7.29 (s, 1H), 7.14 (dd, 1H), 7.07-7.01 (m, 2H), 6.99 to 6.91 (m, 3H), 6.70 (br, 1H), 4.49 (s, 2H), 4.26 (m, 2H), 3.95 (s, 2H), 3.86 (m, 2H), 2.19 (s, 3H), MS (EI) for C28H25FN6O: 481 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared according to the method of example 14 by using methyl (6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-yl)carbamate (example 2). 1H NMR (400 MHz, Methanol-D4): 8.51 (d, 1H), 8.19 (d, 1H), 7.68 (br, 1H), 7.61 (br, 1H), 7.51 (dd, 1H), 7.24 (s, 1H), 7.20 (s, 1H), 7.12 (d, 1H), 7.00 (d, 1H), 4.75 (s, 2H), 4.49 (m, 2H), 4.00 (s, 3H), 3.92 (m, 2H), 3.59 (s, 3H), MS (EI) for C27H25N5O3: 468 (MH+).

6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared according to the method of example 14 by using methyl {6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-yl}carbamate (example 27). 1H NMR (400 MHz, d6-DMSO): 8.70 (s, 1H), 8.56 (s, 2H), 7.68 (m, 1H), 7.58 (s, 1H), 7.51-7.47 (m, 2H), 7.01 (d, 1H), 5.08 (br s, 2H), 4.47 (m, 2H), 4.19 (m, 2H), 2.79 (t, 2H), 2.54 (s, 2H), 1.73 (s, 3H), 1.58 (t, 2H), 0.84 (s, 6H); MS (EI) for C26H28N6O: 441 (MH+).

Example 15 N-(2-Fluoroethyl)-5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine

STEP 1: 2-Fluoroethylamine hydrochloride salt (282.4 mg, 2.83 mmol) was suspended in 1:1 THF:DCM (6 mL) followed by addition of DIPEA (2.5 mL, 14.35 mmol). The mixture was cooled to 0° C. followed by slow addition of thiophosgene (217 uL, 2.8 mmol) by syringe over five minutes then allowed to slowly warm to room temperature over 30 minutes. 4-Bromobenzene-1,2-diamine (530 mg, 2.8 mmol) was then added and the reaction mixture was allowed to stir at room temperature over an additional 12 h. The mixture was concentrated and the residue partitioned with ethyl acetate and 10% aqueous citric acid. The organic phase was washed twice with additional 10% aqueous citric acid then brine, dried over anhydrous sodium sulfate, filtered and concentrated. The crude mixture of thiourea thus obtained was taken into THF (15 mL) followed by addition of mercury (II) oxide (640 mg, 2.95 mmol). The mixture was brought to reflux for 6 h then stirred an additional 60 h at room temperature. The crude mixture was filtered through a bed of celite with ethyl acetate washing and the filtrate concentrated then taken back into ethyl acetate. The organic solution was washed once with 1 M aqueous hydrochloric acid and the organic phase discarded. The aqueous phase was filtered to remove trace insoluble residue and the filtrate basified to pH 9-10 by dropwise addition of 50% aqueous sodium hydroxide. The aqueous phase was then extracted once with ethyl acetate and the organic solution was washed with brine then dried over anhydrous sodium sulfate, filtered and concentrated to afford crude 5-bromo-N-(2-fluoroethyl)-1H-benzo[d]imidazol-2-amine (390 mg, 53% yield) which was carried forward without further purification. MS (EI) for C9H9BrFN3: 258, 260 (MH+).

STEP 2: 5-bromo-N-(2-fluoroethyl)-1H-benzo[d]imidazol-2-amine (390 mg, 1.51 mmol) thus obtained in step 1 was taken into THF (15 mL) followed by addition of DIPEA (600 uL, 3.4 mmol) and isobutyl chloroformate (400 uL, 3.06 mmol) and the mixture was stirred at room temperature for 1 h. The mixture was concentrated and the residue partitioned with ethyl acetate and 10% aqueous citric acid. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography to afford isobutyl 5-bromo-2-(2-fluoroethylamino)-1H-benzo[d]imidazole-1-carboxylate (290 mg, 54% yield) as a colorless crystalline solid. MS (EI) for C14H17BrFN3O2: 358, 360 (MH+).

STEP 3: Isobutyl 5-bromo-2-(2-fluoroethylamino)-1H-benzo[d]imidazole-1-carboxylate (76 mg, 0.21 mmol) and (4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (example 8 step 2) (100 mg, 0.25 mmol), and [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (8.5 mg, 0.01 mmol) were taken into dioxane (1 mL) and water (200 uL) followed by addition of DIPEA (180 uL, 1.03 mmol) and the mixture was heated to 95° C. over 12 h. On cooling to room temperature the crude mixture was diluted with ethyl acetate and dried over anhydrous sodium sulfate then filtered through a bed of silica gel. The filtrate was concentrated and the residue taken into methanol (5 mL) and basified by addition of 5 drops of 50% aqueous sodium hydroxide. The methanol solution was stirred for 0.5 h at room temperature then concentrated. The residue was partitioned with isopropyl acetate and 1M aqueous sodium hydroxide. The organic phase was washed twice with additional 1M aqueous sodium hydroxide then dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography using 20:1 ethyl acetate:ethanol then 10% methanol in dichloromethane as eluent. Fractions containing pure material were concentrated and the residue triturated with ethyl ether. The suspension collected by filtration to give N-(2-fluoroethyl)-5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine (27.4 mg, 25% yield). 1H NMR (400 MHZ, DMSO-d6): 10.84 (br s, 1H), 8.50 (s, 1H), 7.34 (d, 1H), 7.26 (br s, 1H), 7.18 (d, 1H), 7.12 (d, 4H), 6.98-6.91 (m, 3H), 6.85 (s, 1H), 4.68 (m, 1H), 4.55 (m, 1H), 4.46 (s, 2H), 4.25 (br s, 2H), 4.01 (s, 2H), 3.77 (br s, 2H), 2.16 (s, 3H). MS (EI) for C30H28F2N6O: 528 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 and conducting protecting group introduction/removal in steps 2 and 3 as required according to literature techniques appropriate for a given protecting group (see for example: Greene and Wuts, Protective Groups in Organic Synthetic, Wiley-Interscience) the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

N-Ethyl-6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine. Synthesized according to the method of example 15 using ethyl isothiocyanate in step 1. 1H NMR (400 MHz, d6-DMSO): 10.78 (s, 1H), 8.50 (s, 1H), 7.38 (br s, 1H), 7.24 (br d, 1H), 7.14 (d, 6H), 6.98 (d, 1H), 6.86 (br s, 1H), 6.60 (br s, 1H), 4.46 (s, 2H), 4.25 (m, 2H), 4.02 (s, 2H), 3.77 (m, 2H), 3.32 (dd, 2H), 2.16 (s, 3H), 1.19 (t, 3H). MS (EI) for C30H29FN6O: 509 (MH+).

6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-fluoroethyl)-1H-benzimidazol-2-amine. Synthesized according to the method of example 15 using [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 3. 1H NMR (400 MHZ, DMSO-d6): 9.41 (tr, 1H), 8.71 (s, 1H), 7.69 (s, 1H), 7.60 (s, 1H), 7.53-7.45 (m, 3H), 7.01 (d, 1H), 5.09 (s, 2H), 4.73 (tr, 1H), 4.62 (tr, 1H), 4.47 (s, 2H), 4.20 (s, 2H), 3.86 (q, 1H), 3.79 (q, 1H), 2.54 (s, 2H), 1.57 (tr, 2H), 0.86 (s, 6H); MS (EI) for C28H31FN6O: 487 (MH+).

6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-ethyl-1H-benzimidazol-2-amine. Prepared according to the method of example 15 by using ethyl isothiocyanate in step 1 and [4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) in step 3. 1H NMR (400 MHz, d6-DMSO): 8.37 (s, 1H), 7.56 (d, 1), 7.43 (dd, 1H), 7.38 (s, 1H), 7.20 (s, 2H), 7.00 (d, 1H), 4.62 (s, 2H), 4.29 (m, 2H), 3.83 (m, 2H), 3.35 (q, 2H), 2.70 (t, 2H), 2.47 (s, 2H), 1.60 (t, 2H), 1.19 (t, 3H), 0.86 (s, 6H); MS (EI) for C28H32N6O: 469 (MH+).

Example 16 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-3H-imidazo[4,5-b]pyridin-2-amine

STEP 1: To a solution of (4-{5-[(4-fluorophenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (example 8, step 2) (0.200 g, 0.509 mmol) and 2-amino-6-chloro-3-nitropyridine (0.106 g, 0.610 mmol) in dioxane (3 mL) and water (0.4 ml) was added potassium carbonate (0.211 g, 1.53 mmol). The solution was sparged with N2 (g) for five minutes before the addition of dichloro[1,1-bis(diphenylphosphino]ferrocenepalladium (II) dichloromethane adduct (0.042 g, 10 mol %). The resulting suspension was heated at 90° C. for 20 h in a sealed tube vessel. On cooling to room temperature the mixture was diluted with acetonitrile (25 mL) then filtered and concentrated to afford 6-(4-{5-[(4-fluorophenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-3-nitropyridin-2-amine (0.247 g, 100% yield) as an oil that was used without further purification. MS (EI) for C26H23FN6O3: 487 (MH+).

STEP 2: To a solution 6-(4-{5-[(4-fluorophenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-3-nitropyridin-2-amine as obtained in step 1 (0.247 g, 0.508) in ethanol (20 mL) was added 10% palladium on carbon (0.200 g) and glacial acetic acid (1 mL). The solution was sparged with N2 (g) for five minutes then hydrogenated using a Parr apparatus for 1 hour under H2 (g) at 40 psi. Filtration and concentration afforded a brown residue that was purified by silica gel chromatography (9:1 dichloromethane/methanol) to provide 6-(4-{5-[(4-fluorophenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridine-2,3-diamine (0.200 g, 86%) as a light brown oil. MS (EI) for C26H25FN6O: 457 (MH+).

STEP 3: To a solution of 6-(4-{5-[(4-fluorophenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridine-2,3-diamine (0.200 g, 0.438 mmol) in glacial acetic acid (3 mL) was added 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (0.117 g, 0.570 mmol). The reaction mixture was stirred at 80° C. for 2 h and then concentrated. Ethyl acetate (100 mL) was added to the residue, and the solution was washed with saturated sodium bicarbonate (50 mL) then dried over anhydrous sodium sulfate. Filtration and concentration afforded a brown residue that was taken up in diethyl ether (10 mL) and the resulting precipitate was collected by filtration to give methyl [5-(4-{5-[(4-fluorophenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-3H-imidazo[4,5-b]pyridine-2-yl]carbamate (0.70 g, 30% yield) as a brown solid. MS (EI) for C26H25FN6O: 457 (MH+).

STEP 4: To a solution of methyl [5-(4-{5-[(4-fluorophenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-3H-imidazo[4,5-b]pyridine-2-yl]carbamate (0.70 g, 0.129 mmol) in methanol (3 mL) was added 2 M aqueous potassium hydroxide (3 mL) and the mixture was heated at 100° C. for 1 hour. After cooling to room temperature the reaction mixture was concentrated and then diluted with water (5 mL) and the pH adjusted to 9 with 1 M hydrochloric acid. The resulting precipitate was collected by filtration, dissolved in a minimum of methanol and purified by preparative reverse phase HPLC to afford 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-3H-imidazo[4,5-b]pyridin-2-amine (0.0283 g, 46% yield. 1H NMR (400 MHz, methanol-d4): 8.45 (s, 1H), 7.75 (d, 1H), 7.51 (d, 1H), 7.17 (d, 1H), 7.11-7.06 (m, 3H), 7.01-6.96 (m, 3H), 4.55 (s, 2H), 4.30 (t, 2H), 4.00 (s, 2H), 3.89 (t, 2H), 2.22 (s, 3H); MS (EI) for C27H24FN7O: 482 (MH+)

Example 17 N,N-dimethyl-6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine

STEP 1: A solution of 4-(4-quinolin-4-yl-2,3,4,5-tetrahydrobenzoxazepin-7-yl)benzene-1,2-diamine (example 2) (50 mg, 0.13 mmol), N-(chloro(dimethylamino)methylene)-N-methylmethanaminium hexafluorophosphate (44 mg, 0.16 mmol) and N-methylmorpholine (0.20 g, 1.9 mmol) in N,N-dimethylformamide (10 mL) was heated to 140° C. for 1 hour. After cooling the reaction was diluted with ethyl acetate (80 mL), and washed twice with water (2×20 mL) and brine (20 mL). The solution was dried over anhydrous sodium sulfate, filtered and concentrated to a solid residue. The residue was then taken into N,N-dimethylformamide (3 mL), then diluted with chloroform (15 mL). The resulting solid was collected by filtration and the filter cake was precipitated once more using the same technique to give N,N-dimethyl-6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine (27 mg, 48% yield) as a gray powder. 1H NMR (400 MHz, d6-DMSO): 8.56 (d, 1H), 8.30 (d, 1H), 8.06-7.97 (m, 2H), 7.90 (br s, 1H), 7.72 (t, 1H), 7.62 (br s, 1H), 7.56 (m, 2H), 7.48 (d, 1H), 6.99 (dd, 2H), 5.28 (s, 2H), 4.61 (s, 2H), 4.38 (s, 2H), 3.28 (s, 6H); MS (EI) for C27H25N5O: 436 (MH+).

Example 18 7-(2-cyclopropyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine

STEP 1: To cyclopropanecarboxylic acid (33 mg, 0.39 mmol) in N,N-dimethylformamide (10 mL) added O-benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.15 g, 0.40 mmol) and the mixture stirred at 25° C. for 30 minutes. 4-(4-quinolin-4-yl-2,3,4,5-tetrahydrobenzoxazepin-7-yl)benzene-1,2-diamine (example 2) (100 mg, 0.26 mmol) was added followed by and N-methylmorpholine (66 uL, 0.60 mmol) and stirred 18 hours at 25° C. The reaction was diluted with ethyl acetate (80 mL), and washed with 2M aqueous sodium hydroxide (40 mL), water (40 mL) and brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (methanol/ethyl acetate, 1:8). This afforded N-(2-amino-5-(4-quinolin-4-yl-2,3,4,5-tetrahydrobenzoxazepin-7-yl)phenyl)cyclopropanecarboxamide (55 mg, 47% yield). MS (EI) for C28H26N4O2: 451 (MH+).

STEP 2: As solution of N-(2-amino-5-(4-quinolin-4-yl-2,3,4,5-tetrahydrobenzoxazepin-7-yl)phenyl)cyclopropanecarboxamide (55 mg, 0.12 mmol) in acetic acid (10 mL) was heated to 110° C. for 4 hours. The reaction mixture was then cooled and concentrated. The residue was chromatographed on silica gel using (methanol/ethyl acetate, 1:10) as eluent. Product containing fractions were concentrated and the residue purified by preparative reverse phase HPLC (0.1% trifluoroacetic acid buffered aqueous acetonitrile mobile phase) to give 7-(2-cyclopropyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine (16.6 mg, 32% yield) as the trifluoroacetic acid salt. 1H NMR (400 MHz, d6-DMSO): 8.57 (d, 1H), 8.31 (d, 1H), 7.98 (m, 3H), 7.88 (s, 1H), 7.70 (m, 3H), 7.61 (dd, 1H), 6.99 (dd, 2H), 5.30 (br s, 2H), 4.62 (br s, 2H), 4.41 (br s, 2H), 2.46 (m, 1H), 1.36 (m, 4H); MS (EI) for C28H24N4O: 433 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 1 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

7-{2-[(methyloxy)methyl]-1H-benzimidazol-6-yl}-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 18 using methoxyacetic acid in step 1. 1H NMR (400 MHz, d6-DMSO): 8.57 (d, 1H), 8.33 (d, 1H), 7.96 (m, 3H), 7.89 (s, 1H), 7.68 (m, 3H), 7.61 (d, 1H), 6.98 (dd, 2H), 5.33 (s, 2H), 4.81 (s, 2H) 4.58 (br s, 2H), 4.39 (br s, 2H), 3.47 (s, 3H); MS (EI) for C27H24N4O2: 437 (MH+).

7-(2-propyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 18 using butyric acid in step 1. 1H NMR (400 MHz, d6-DMSO): 8.62 (d, 1H), 8.03 (d, 1H), 7.94 (d, 1H), 7.68 (m, 3H), 7.58 (d, 1H), 7.50 (t, 1H), 7.42 (m, 1H), 7.11 (d 1H), 7.02 (d, 1H), 4.61 (s, 2H) 4.38 (br s, 2H), 4.82 (br s, 2H), 2.81 (t, 2H), 1.82 (q, 2H), 0.95 (t, 3H)); MS (EI) for C28H26N4O: 435 (MH+).

7-(2-cyclopentyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 18 using cyclopentanecarboxylic acid in step 1. 1H NMR (400 MHz, d6-DMSO): 8.61 (d, 1H), 8.04 (d, 1H), 7.95 (d, 1H), 7.70 (m, 2H), 7.59-7.41 (m, 4H), 7.11 (d, 1H), 7.04 (d, 1H), 4.63 (s, 2H) 4.38 (br s, 2H), 3.82 (br s, 2H), 2.11 (m, 2H), 1.90 (m, 2H), 1.79 (m, 2H), 1.67 (m, 2H); MS (EI) for C30H28N4O: 462 (MH+).

7-(2-cyclohexyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 18 using cyclohexanecarboxylic acid in step 1. 1H NMR (400 MHz, d6-DMSO): 8.62 (d, 1H), 8.03 (d, 1H), 7.95 (m, 3H), 7.68 (m, 3H), 7.63 (m, 3H), 7.42 (d, 1H), 7.10 (d, 1H), 7.03 (d, 1H), 4.63 (s, 2H), 4.39 (br s, 2H), 3.81 (br s, 2H), 2.84 (m, 1H), 2.03 (d, 2H), 1.89-1.74 (m, 8H), 1.63-1.25 (m, 2H); MS (EI) for C31H30N4O: 475 (MH+).

7-(2-azetidin-3-yl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 18 using N—BOC azetidine-3-carboxylic acid in step 1. 1H NMR (400 MHz, d6-DMSO): 8.96 (br d, 2H), 8.61 (d, 1H), 7.55 (d, 1H), 7.95 (m, 3H), 7.88 (s, 1H), 7.70 (m, 2H), 7.60 (m, 1H), 7.02 (d, 2H), 5.30 (s, 2H), 4.62 (br s, 2H), 4.22 (br s, 2H), 4.38 (br s, 5H); MS (EI) for C28H25N5O: 448 (MH+).

7-(2-piperidin-2-yl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 18 using racemic N—BOC pipecolinic acid in step 1. 1H NMR (400 MHz, d6-DMSO): 9.96 (br d, 1H), 9.37 (m, 1H), 8.58 (d, 1H), 8.35 (d, 1H), 7.98 (m, 3H), 7.90 (s, 1H), 7.77-7.58 (m, 4H), 7.00 (m, 2H), 5.30 (s, 2H), 4.62 (m, 3H) 4.42 (br s, 2H), 3.41 (d, 1H), 3.13 (m, 1H), 2.42 (m, 2H), 0.80 (m, 5H); MS (EI) for C31H33N5O: 492 (MH+).

7-[2-(1-methylethyl)-1H-benzimidazol-6-yl]-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 18 using isobutyric acid in step 1. 1H NMR (400 MHz, d6-DMSO): 8.59 (d, 1H), 8.35 (d, 1H), 7.97 (m, 3H), 7.91 (br s, 1H), 7.75 (br s, 2H), 7.68 (m, 1H), 7.61 (m, 1H), 7.00 (dd, 2H), 5.29 (s, 2H), 4.62 (br s, 3H) 4.40 (br s, 2H), 3.43 (m, 1H), 1.44 (d, 6H); MS (EI) for C29H30N4O: 451 (MH+).

4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-ethyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 18 omitting step 1 and by using 4-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]benzene-1,2-diamine and trimethyl orthopropionate in step 2. 1H NMR (400 MHz, d6-DMSO): 8.69 (s, 1H), 7.94 (s, 1H), 7.84-7.78 (m, 3H), 7.60 (m, 1H), 7.35 (s, 1H), 7.23 (s, 1H), 7.04 (d, 1H), 5.09 (s, 2H), 4.48 (m, 2H), 4.19 (m, 2H), 3.18 (dd, 2H), 2.70 (t, 2H), 2.54 (s, 2H), 1.58 (t, 2H), 1.45 (t, 3H), 0.85 (s, 6H); MS (EI) for C28H31N5O: 454 (MH+).

Example 19 7-[2-(methylthio)-1H-benzimidazol-6-yl]-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine

STEP 1: To a solution of 4-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-benzene-1,2-diamine (630 mg, 1.65 mmol, synthesized according to the method of example 2 step) in tetrahydrofuran (30 mL) was added 1,1′-thiocarbonyldiimidazole (587 mg, 3.29 mmol), and the reaction mixture was stirred at room temperature for 20 h. The mixture was concentrated and the residue crystallized from methanol to give 5-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-dihydro-2H-benzimidazole-2-thione (357 mg, 51% yield) as a brown solid. 1H NMR (400 MHz, DMSO-d6): 12.74 (s, 1H), 12.66 (s, 1H), 8.57 (d, 1H), 8.28 (d, 1H), 8.00 (d, 1H), 7.95 (m, 1H), 7.88 (d, 1H), 7.67 (m, 1H), 7.53 (dd, 1H), 7.49 (dd, 1H), 7.40 (s, 1H), 7.24 (d, 1H), 6.97 (m, 2H), 5.21 (s, 2H), 4.58 (m, 2H), 4.33 (m, 2H); MS (EI) for C25H20N4OS: 425 (MH+).

STEP 2: A suspension of 5-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-dihydro-2H-benzimidazole-2-thione (355 mg, 0.84 mmol), potassium carbonate (578 mg, 4.18 mmol), and methyl iodide (119 mg, 0.84 mmol) in dimethylformamide (5 mL) was stirred at room temperature for 1 h. Ethyl acetate (100 mL) was added, and the organic layer was washed with water (2×20 mL), 5% aqueous lithium chloride (2×20 mL), and brine (20 mL), dried over sodium sulfate, filtered and concentrated. Column chromatography on silica (dichloromethane/methanol 95:5) provided the title Compound (220 mg, 60% yield) as a brown solid. 1H NMR (400 MHz, CDCl3): 8.71 (d, 1H), 8.09 (m, 2H), 7.66 (m, 1H), 7.57-7.42 (m, 5H), 7.17 (d, 1H), 6.98 (d, 1H), 4.54 (s, 2H), 4.36 (m, 2H), 3.84 (m, 2H), 2.82 (s, 3H); MS (EI) for C26H22N4OS: 439 (MH+).

Example 20 N-ethyl-6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine

A solution of 7-[2-(methylthio)-1H-benzimidazol-6-yl]-4-quinolin-4-yl-2,3,4,5-tetra-hydro-1,4-benzoxazepine (52 mg, 0.12 mmol, prepared according to the method of example 19) and ethylamine (1.5 mL) in ethanol (3 mL) heated with microwave irradiation at 150° C. for 8 h. Purification of the crude material by preparative reverse phase HPLC (0.1% aqueous ammonium acetate-acetonitrile) provided the title Compound as acetate salt (4 mg, 7% yield) as a colorless solid. 1H NMR (400 MHz, methanol-d4): 8.55 (d, 1H), 8.15 (d, 1H), 7.95 (d, 1H), 7.73 (m, 1H), 7.60-7.50 (m, 3H), 7.42 (m, 1H), 7.33 (dd, 1H), 7.29 (d, 1H), 7.09 (m, 2H), 4.69 (s, 2H), 4.41 (m, 2H), 3.92 (m, 2H), 3.44 (q, 2H), 1.94 (s, 3H), 1.31 (t, 3H); MS (EI) for C27H25N5O: 436 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

N-(1-methylethyl)-6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine. Prepared as trifluoroacetate salt according to the method of example 20 by using isopropylamine. 1H NMR (400 MHz, methanol-d4): 8.38 (d, 1H), 8.33 (d, 1H), 7.98 (m, 1H), 7.91 (d, 1H), 7.76 (m, 1H), 7.68 (m, 1H), 7.60 (m, 2H), 7.56 (dd, 1H), 7.46 (d, 1H), 7.06 (m, 2H), 5.26 (s, 2H), 4.63 (m, 2H), 4.43 (m, 2H), 3.92 (h, 1H), 1.40 (d, 6H); MS (EI) for C28H27N5O: 450 (MH+).

Example 21 Methyl (6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)carbamate

STEP 1: A mixture of commercially available 4-chloro-6,7-dimethoxyquinoline (120 mg, 0.53 mmol), 7-bromo-2,3-dihydro-1,4-benzoxazepine hydrochloride (example 2, step 1) (200 mg, 0.53 mmol), diisopropylethylamine (0.14 g, 1.1 mmol), in NMP (2 mL) was stirred in a microwave reactor at 120° C. for 45 min. After cooling to room temperature, the reaction mixture was purified directly by silica gel flash chromatography (0-10% methanol-dichloromethane gradient) to give 4-[6,7-bis(methyloxy)quinolin-4-yl]-7-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepine (155 mg, 70% yield), MS (EI) for C20H19N2O3: 415 (MH+).

STEP 2: A mixture of commercially available 3-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (125 mg, 0.47 mmol), 4-[6,7-bis(methyloxy)quinolin-4-yl]-7-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepine (155 mg, 0.47 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (34 mg, 0.05 mmol), cesium carbonate (300 mg, 2.4 mmol) in 1,4-dioxane (20 mL) and water (2 mL) was degassed with nitrogen for 5 minutes and then stirred at 93° C. for 18 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (80 mL) then filtered through a celite bed. The filtrate was washed with brine (2×50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel flash chromatography (0 to 10% methanol-dichloromethane) to give 5-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-3-nitropyridin-2-amine (135 mg, 76% yield); MS (EI) for C25H23N5O5: 474 (MH+).

STEP 3: A mixture of 5-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-3-nitropyridin-2-amine (135 mg, 0.28 mmol), palladium (10% on charcoal, 135 mg) and methanol (15 mL) was hydrogenated in a Parr apparatus at 45 psi for 18 hours. The mixture was filtered then concentrated to give 5-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridine-2,3-diamine (115 mg, 91% yield), MS (EI) for C25H25N5O3: 444 (MH+).

STEP 4: To a solution of 5-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridine-2,3-diamine (85 mg, 0.19 mmol) in acetic acid (3 mL) was added 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (40 mg, 0.19 mmol). The reaction mixture was heated (65° C.) for 18 h and then concentrated. The resulting residue was dissolved in acetonitrile and purified by preparative reverse phase HPLC to provide methyl (6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)carbamate (55 mg, 54% yield) as a white solid. 1H NMR (400 MHz, DMSO-D6): δ 7.93 (br, 2H), 7.93 (br, 1H), 7.78 (br, 1H), 7.59 (dd, 1h), 7.31 (s, 1H), 7.14 (dd, 1H), 7.09 (s, 1H), 6.95 (d, 1H), 4.60 (s, 2H), 4.43 (m, 2H), 3.89 (s, 3H), 3.78 (s, 3H), 3.73 (m, 2H), 3.53 (s, 3H), MS (EI) for C28H26N6O5: 527 (MH+).

Example 22 4-(7-ethyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine

STEP 1: A solution of 7-(2-methyl-1H-benzimidazol-6-yl)-4-[7-(phenylmethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine (Example 1) (0.13 g, 0.26 mmol) in a mixture of 50% acetic acid in methanol (5 mL) was hydrogenated in the presence of 10% Pd/C at 30 psi using a Parr shaker apparatus. The catalyst was filtered off and the solvent was concentrated to give 7-(2-methyl-1H-benzimidazol-6-yl)-4-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (0.1 g, quantitative). MS (EI) for C24H24N6O: 413 (MH+).

STEP 2: To a solution of 7-(2-methyl-1H-benzimidazol-6-yl)-4-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (0.1 g, 0.26 mmol) and acetaldehyde (18 μL, 0.31 mmol) in a mixture of 10% aqueous tetrahydrofuran (5 mL) at 0° C. was added sodium triacetoxyborohydride (66 mg, 0.31 mmol) and the reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (25 mL), dried over sodium sulfate, filtered and the solvent was concentrated. Purification by preparative reverse phase HPLC (0.1% aqueous ammonium acetate-acetonitrile) provided 4-(7-ethyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (48 mg, 42%). 1H NMR (400 MHz, d6-DMSO): 8.44 (s, 1H), 7.94 (d, 1H), 7.83 (d, 1H), 7.76 (dd, 1H), 7.70 (d, 1H), 7.56 (dd, 1H), 7.06 (d, 1H), 4.84 (br d, 2H), 4.40 (br s, 4H), 4.18 (br s, 1H), 3.98 (br s, 1H), 3.62 (br s, 1H), 3.28 (dd, 2H), 3.18 (br s, 2H), 2.84 (br s, 1H), 1.22 (t, 3H). MS (EI) for C26H28N6O: 441 (MH+).

Example 23 6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine

To a solution of 4-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-benzene-1,2-diamine (90 mg, 0.14 mmol, synthesized according to the method of example 2) in methanol (1 mL) was added a 3M solution of cyanogen bromide in dichloromethane (0.10 mL), and the reaction mixture was stirred at room temperature for 8 d. During this time additional cyanogen bromide was added after 1 d (0.10 mL), 2 d (0.20 mL), 3 d (0.20 mL), and 4 d (0.20 mL) reaction time. Ethyl acetate (50 mL) was added, and the solution was washed with 0.5N aqueous sodium hydroxide (2×50 mL), water (50 mL), and brine (50 mL), dried over sodium sulfate, filtered and concentrated. Purification by preparative reverse phase HPLC (0.1% aqueous ammonium acetate-acetonitrile) provided the title Compound as the acetate salt (8 mg, 7% yield) as an off-white solid. 1H NMR (400 MHz, methanol-d4): 8.54 (d, 1H), 8.14 (d, 1H), 7.94 (d, 1H), 7.73 (m, 1H), 7.60-7.47 (m, 4H), 7.38 (m, 1H), 7.31 (d, 1H), 7.10 (d, 1H), 7.07 (d, 1H), 4.70 (s, 2H), 4.41 (m, 2H), 3.93 (m, 2H), 1.94 (s, 3H); MS (EI) for C25H21N5O: 408 (MH+).

Example 24 N-ethyl-6-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine

STEP 1: To a solution of 1,1-dimethylethyl 7-(4-amino-3-nitrophenyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (10 g, 26 mmol) in dioxane (50 mL) was added hydrogen chloride in dioxane (4 M, 50 mL, 200 mmol), and the mixture was stirred at rt for 16 h. The volatile materials were then removed to provide 2-nitro-4-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)aniline dihydrochloride in quantitative yield. MS (EI) for C15H15N3O3: 286 (MH+).

STEP 2: A solution of 2-nitro-4-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)aniline dihydrochloride (323 mg, 1.0 mmol), 4-chloro-2-methylquinazoline (179 mg, 1.0 mmol), and diisopropylethylamine (700 uL, 4.0 mmol) in NMP (11 mL) was heated to 90° C. and stirred for 40 min. After cooling to rt, water was added to the reaction mixture. The orange precipitate formed was collected by filtration and then dried to provide 4-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-nitroaniline (380 mg, 0.89 mmol, 89% yield) as a bright orange powder. MS (EI) for C24H21N5O3: 428 (MH+).

STEP 3: To a solution of 4-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-nitroaniline (380 mg, 0.89 mmol) in THF (12 mL) was added palladium on carbon (wet, 100 mg). The resulting suspension was subjected to an atmosphere of hydrogen at 40 psi for 5 h. The catalyst was removed by filtration through celite, and the filtrate was concentrated to provide 4-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]benzene-1,2-diamine (333 mg, 0.84 mmol, 94% yield) as a yellow-orange solid. MS (EI) for C24H23N5O: 398 (MH+).

STEP 4: To a solution of 4-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]benzene-1,2-diamine (333 mg, 0.84 mmol) in THF (5 mL) at 0° C. was added ethyl isothiocyanate (74 uL, 0.84 mmol). After stirring for 2 h at 0° C., the reaction mixture was warmed to rt for 1 h and was then heated to 45° C. for 4 h. The mixture was then cooled back to rt and allowed to stir for 3 d. Addition of water was followed by extraction into ethyl acetate. The organic phase was then dried over magnesium sulfate, filtered, and concentrated. The residue obtained was then dissolved in acetonitrile (5 mL) and ethyl acetate (2 mL). To this solution was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (161 mg, 0.84 mmol). The mixture was heated to reflux for 1.5 h and was then cooled to rt. Water and ethyl acetate were then added. The biphasic mixture was filtered to remove solid materials, and the filtrate was then partitioned. The aqueous phase was extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and then concentrated. The residue was purified by reverse-phase preparative HPLC to provide N-ethyl-6-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine as a diacetate salt (137 mg, 0.24 mmol, 29% yield). 1H NMR (400 MHz, dmso) δ 8.01 (d, 1H), 7.79-7.72 (m, 1H), 7.72-7.67 (m, 1H), 7.60 (d, 1H), 7.47-7.39 (m, 2H), 7.35 (s, 1H), 7.20-7.11 (m, 2H), 6.99 (d, 1H), 6.72 (br s, 1H), 5.02 (s, 2H), 4.47-4.38 (m, 2H), 4.22-4.13 (m, 2H), 3.37-3.27 (m, 2H), 2.48 (s, 3H), 1.89 (s, 7H), 1.18 (t, 3H); MS (EI) for C27H26N6O: 451 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in step 4 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

N-ethyl-6-[4-(7-fluoroquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared according to the method of example 24 by using 4-chloro-7-fluoroquinoline in step 2. 1H NMR (400 MHz, CD3OD): 8.50 (d, 1H), 8.09 (t, 1H), 7.56-7.44 (m, 4H), 7.38-7.26 (m, 3H), 7.06 (d, 1H), 6.97 (d, H), 4.67 (s, br, 2H), 4.36 (s, br, 2H), 3.85 (s, br, 2H), 3.46 (q, 2H), 1.37 (t, 3H); MS (EI) for C27H24FN5O: 454 (MH+).

N-ethyl-6-[4-(8-fluoroquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared according to the method of example 24 by using 4-chloro-8-fluoroquinoline in step 2. 1H NMR (400 MHz, CD3OD): 8.53 (d, 1H), 7.85 (d, 1H), 7.52-7.36 (m, 5H), 7.22 (m, 2H), 7.07-7.02 (m, 2H), 4.56 (s, 2H), 4.36-4.30 (m, 2H), 3.84-3.78 (m, 2H), 3.42 (q, 2H), 1.28 (t, 3H); MS (EI) for C27H25FN5O2: 452 (MH+).

N-ethyl-6-[4-(6-fluoroquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Prepared according to the method of example 24 by using reagent 4-chloro-6-fluoroquinoline in step 2. 1H NMR (400 MHz, CD3OD): 8.55 (d, 1H), 8.02-7.96 (dd, 1H), 7.79-7.73 (dd, 1H), 7.60-7.42 (m, 4H), 7.30-7.21 (m, 2H), 7.12-7.07 (m, 2H), 4.56 (s, 2H), 4.39-4.34 (m, 2H), 3.84-3.79 (m, 2H), 3.42 (q, 2H), 1.29 (t, 3H); MS (EI) for C27H24FN5O: 454 (MH+).

Example 25 N-ethyl-5-methyl-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-4-amine and 4-(6-chloro-5-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine

STEP 1: A solution of 1-methylpropyl 2-methyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (0.213 g, 0.512 mmol, example 6, step 2), 4,6-dichloro-5-methylpyrimidine (0.100 g, 0.613 mmol), and diisopropylethylamine (0.330 g, 2.56 mmol) in N-methylpyrrolidinone (2 mL) was stirred at room temperature for 17 h. The reaction mixture was diluted with ethyl acetate (100 mL), washed with saturated sodium bicarbonate (50 mL) and brine (25 mL), and dried over sodium sulfate. Filtration, concentration and purification by column chromatography on silica (97:3 dichloromethane/methanol) provided 4-(6-chloro-5-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (0.06 g, 31% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.50 (s, 1H), 8.22 (s, 1H), 8.04 (s, 1H), 7.60 (s, 1H), 7.50 (d, 1H), 7.08 (d, 1H), 4.81 (s, 2H), 4.39-4.32 (m, 2H), 4.03-3.97 (m, 2H), 2.64 (s, 3H), 2.37 (s, 3H); MS (EI) for C21H19ClN6O: 407 (MH+).

STEP 2: A suspension of 4-(6-chloro-5-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine (44 mg, 0.11 mmol), and ethylamine (29 mg, 0.65 mmol), in N-methylpyrrolidinone (2 mL) was stirred at 100° C. for 6 h. The reaction mixture was diluted with ethyl acetate (75 mL), washed with saturated sodium bicarbonate (75 mL) and brine (50 mL), and dried over sodium sulfate. Concentration and purification by preparatory HPLC (0.1% aqueous ammonium acetate-acetonitrile) gave N-ethyl-5-methyl-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-4-amine (13 mg, 30% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.50 (s, 1H), 8.07 (s, 1H), 8.04 (d, 1H), 7.56-7.48 (m, 2H), 7.11 (d, 1H), 4.57 (s, 2H), 4.33 (d, 2H), 3.79 (d, 2H), 3.53-3.39 (q, 2H), 2.64 (s, 3H), 2.04 (s, 3H), 1.21 (t, 3H); MS (EI) for C23H25N7O: 416 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

N,5-dimethyl-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-4-amine. Prepared as diacetate salt according to the method of example 25 by using methylamine in step 2. 1H NMR (400 MHz, methanol-d4): 8.49 (s, 1H), 8.07 (s, 1H), 8.03 (m, 1H), 7.50 (m, 2H), 7.11 (d, 1H), 4.49 (s, 2H), 4.30 (m, 2H), 3.74 (m, 2H), 2.93 (s, 3H), 2.64 (s, 3H), 2.02 (s, 3H), 1.93 (s, 6H); MS (EI) for C22H23N7O: 402 (MH+).

5-methyl-N-(1-methylethyl)-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-4-amine. Prepared according to the method of example 25 by using isopropylamine in step 2. 1H NMR (400 MHz, methanol-d4): 8.50 (s, 1H), 8.05 (s, 2H), 7.51 (m, 2H), 7.12 (d, 1H), 4.49 (s, 2H), 4.31 (m, 2H), 4.26 (m, 1H), 3.74 (m, 2H), 2.64 (s, 3H), 2.02 (s, 3H), 1.22 (d, 6H); MS (EI) for C24H27N7O: 430 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(5-methyl-6-morpholin-4-ylpyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 25 by using morpholine in step 2. 1H NMR (400 MHz, methanol-d4): 8.49 (s, 1H), 8.11 (s, 1H), 8.03 (s, 1H), 7.57 (d, 1H), 7.48 (dd, 1H), 7.09 (d, 1H), 4.71 (s, 2H), 4.35 (m, 2H), 3.92 (m, 2H), 3.75 (t, 4H), 3.33 (t, 4H), 2.64 (s, 3H), 2.19 (s, 3H); MS (EI) for C25H27N7O2: 458 (MH+).

7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[5-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared as triacetate salt according to the method of example 25 by using N-methylpiperazine in step 2. 1H NMR (400 MHz, methanol-d4): 8.50 (s, 1H), 8.10 (s, 1H), 8.04 (s, 1H), 7.56 (d, 1H), 7.49 (dd, 1H), 7.09 (d, 1H), 4.71 (s, 2H), 4.34 (m, 2H), 3.92 (m, 2H), 3.40 (m, 4H), 2.64 (s, 3H), 2.59 (m, 4H), 2.34 (s, 3H), 2.19 (s, 3H), 1.93 (s, 9H); MS (EI) for C26H30N8O: 471 (MH+).

4-(6-azetidin-1-yl-5-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Prepared according to the method of example 25 by using azetidine in step 2. 1H NMR (400 MHz, methanol-d4): 8.50 (s, 1H), 8.04 (s, 1H), 7.99 (s, 1H), 7.55 (d, 1H), 7.49 (dd, 1H), 7.09 (d, 1H), 4.62 (s, 2H), 4.32 (m, 2H), 4.18 (t, 4H), 3.84 (m, 2H), 2.63 (s, 3H), 2.33 (m, 2H), 2.07 (s, 3H); MS (EI) for C24H25N7O: 428 (MH+).

N-{6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methylpyrimidin-4-yl}-N,N′-dimethylethane-1,2-diamine. Prepared as acetate salt according to the method of example 25 by using 1-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (example 6) in step 1 and N,N′-dimethylethylenediamine in step 2. 1H NMR (400 MHz, methanol-d4): 8.44 (d, 1H), 8.06 (s, 1H), 7.96 (d, 1H), 7.55 (d, 1H), 7.46 (dd, 1H), 7.06 (d, 1H), 4.75 (s, 2H), 4.34 (m, 2H), 3.94 (m, 2H), 3.69 (t, 2H), 3.21 (t, 2H), 3.07 (s, 3H), 2.67 (s, 3H), 2.21 (m, 4H), 1.91 (s, 3H), 1.22 (m, 4H); MS (EI) for C27H32N8O: 485 (MH+).

6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methyl-N-(1-methylpiperidin-4-yl)pyrimidin-4-amine. Prepared according to the method of example 25 by using 1-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (example 6) in step 1 and 4-amino-1-methylpiperidine in step 2. 1H NMR (400 MHz, methanol-d4): 8.46 (s, 1H), 8.06 (s, 1H), 7.98 (s, 1H), 7.50 (m, 2H), 7.12 (d, 1H), 4.52 (s, 2H), 4.32 (m, 2H), 4.04 (m, 1H), 3.77 (m, 2H), 3.13 (m, 2H), 2.56 (m, 2H), 2.53 (s, 3H), 2.21 (m, 1H), 2.08 (m, 2H), 2.05 (s, 3H), 1.71 (m, 2H), 1.23 (m, 4H); MS (EI) for C29H34N8O: 511 (MH+).

6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-N,5-dimethyl-N-[(1R)-1-phenylethyl]pyrimidin-4-amine. Prepared according to the method of example 25 by using 1-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (example 6) in step 1 and (R)-(+)-N-methyl-1-phenylethylamine in step 2. 1H NMR (400 MHz, methanol-d4): 8.43 (s, 1H), 8.02 (s, 1H), 7.92 (s, 1H), 7.54 (d, 1H), 7.48 (dd, 1H), 7.17-7.08 (m, 6H), 5.28 (m, 1H), 4.72 (m, 2H), 4.36 (m, 2H), 3.94 (m, 2H), 2.63 (s, 3H), 2.25 (s, 3H), 2.19 (m, 1H), 1.59 (d, 3H), 1.21 (m, 4H); MS (EI) for C32H33N7O: 532 (MH+).

6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-N,5-dimethyl-N-[(1S)-1-phenylethyl]pyrimidin-4-amine. Prepared according to the method of example 25 by using 1-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (example 6) in step 1 and (S)-(−)-N-methyl-1-phenylethylamine in step 2. 1H NMR (400 MHz, methanol-d4): 8.43 (s, 1H), 8.02 (s, 1H), 7.92 (s, 1H), 7.54 (d, 1H), 7.48 (dd, 1H), 7.17-7.08 (m, 6H), 5.28 (m, 1H), 4.72 (m, 2H), 4.36 (m, 2H), 3.94 (m, 2H), 2.63 (s, 3H), 2.25 (s, 3H), 2.19 (m, 1H), 1.59 (d, 3H), 1.21 (m, 4H); MS (EI) for C32H33N7O: 532 (MH+).

6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methyl-N-[(1-methylpiperidin-4-yl)methyl]pyrimidin-4-amine. Prepared according to the method of example 25 by using 1-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (example 6) in step 1 and 4-aminomethyl-1-methylpiperidine in step 2. 1H NMR (400 MHz, methanol-d4): 8.44 (d, 1H), 8.03 (s, 1H), 7.97 (d, 1H), 7.48 (m, 2H), 7.10 (d, 1H), 4.50 (m, 2H), 4.31 (m, 2H), 3.75 (m, 2H), 3.35 (m, 2H), 3.24 (m, 2H), 2.62 (s, 3H), 2.58 (m, 2H), 2.21 (m, 1H), 2.04 (s, 3H), 1.88 (m, 2H), 1.41 (m, 2H), 1.22 (m, 4H); MS (EI) for C30H36N8O: 525 (MH+).

6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methyl-N-[2-(1-methylpyrrolidin-2-yl)ethyl]pyrimidin-4-amine. Prepared as acetate salt according to the method of example 25 by using 1-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (example 6) in step 1 and 2-aminoethyl-1-methylpyrrolidine in step 2. 1H NMR (400 MHz, methanol-d4): 8.44 (d, 1H), 8.07 (s, 1H), 7.97 (d, 1H), 7.48 (m, 2H), 7.10 (d, 1H), 4.52 (m, 2H), 4.31 (m, 2H), 3.76 (m, 2H), 3.52 (m, 2H), 3.46 (m, 1H), 3.08 (m, 1H), 2.91 (m, 1H), 2.74 (s, 3H), 2.31 (m, 1H), 2.19 (m, 2H), 2.04 (s, 3H), 1.98 (m, 1H), 1.92 (s, 3H), 1.75 (m, 2H), 1.22 (m, 4H); MS (EI) for C30H36N8O: 525 (MH+).

6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methyl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine. Prepared according to the method of example 25 by using 1-methylpropyl 2-cyclopropyl-6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridine-1-carboxylate hydrochloride (example 6) in step 1 and 4-aminotetrahydropyran in step 2. 1H NMR (400 MHz, methanol-d4): 8.47 (s, 1H), 8.11 (s, 1H), 7.99 (s, 1H), 7.52 (m, 2H), 7.11 (d, 1H), 4.66 (s, 2H), 4.35 (m, 2H), 4.11 (m, 1H), 3.98 (m, 2H), 3.84 (m, 2H), 3.50 (m, 2H), 2.22 (m, 1H), 2.07 (s, 3H), 1.89 (m, 2H), 1.67 (m, 2H), 1.23 (m, 4H); MS (EI) for C28H31N7O2: 498 (MH+).

N-ethyl-2,5-dimethyl-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-4-amine. Prepared according to the method of example 25 by using 4,6-dichloro-2,5-dimethylpyrimidine in step 1. 1H NMR (400 MHz, methanol-d4): 8.49 (d, 1H), 8.03 (d, 1H), 7.49 (m, 2H), 7.11 (d, 1H), 4.46 (s, 2H), 4.27 (m, 2H), 3.72 (m, 2H), 3.45 (q, 2H), 2.63 (s, 3H), 2.34 (s, 3H), 1.98 (s, 3H), 1.19 (t, 3H); MS (EI) for C24H27N7O: 430 (MH+).

4-{7-[2-(ethylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-N-methylquinazolin-2-amine. Prepared according to the method of example 25 by using N-ethyl-5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine dihydrochloride (example 11, step 3) and 2,4-dichloroquinazoline in step 1 and methylamine in step 2. 1H NMR (400 MHz, DMSO-d6) δ 7.80 (d, 1H), 7.51 (d, 2H), 7.43 (d, 1H), 7.33 (s, 1H), 7.15 (t, 2H), 7.06-6.96 (m, 2H), 6.74-6.61 (m, 2H), 4.94 (s, 2H), 4.43 (s, 2H), 4.07 (s, 2H), 3.31 (q, 2H), 2.77 (s, 3H), 1.87 (s, 6H), 1.18 (t, 3H); MS (EI) for C27H27N7O: 466.

N-ethyl-4-{7-[2-(ethylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}quinazolin-2-amine. Prepared according to the method of example 25 by using N-ethyl-5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine dihydrochloride (example 11, step 3) and 2,4-dichloroquinazoline in step 1 and ethylamine in step 2. 1H NMR (400 MHz, DMSO-d6) δ 7.80 (d, 1H), 7.57-7.48 (m, 2H), 7.43 (s, 1H), 7.36-7.28 (m, 2H), 7.19-7.11 (m, 2H), 7.07-6.95 (m, 2H), 6.72-6.58 (m, 1H), 4.95 (s, 2H), 4.43 (s, 2H), 4.11 (s, 2H), 3.32-3.25 (m, 4H), 1.91 (d, 4H), 1.18 (t, 6H); MS (EI) for C28H29N7O: 480 (MH+).

N-ethyl-6-{4-[6-(ethylamino)-5-methylpyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Prepared as an acetate salt according to the method of example 25 by using N-ethyl-5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine dihydrochloride (example 11, step 3) in step 1 and ethylamine in step 2. 1H NMR (400 MHz, DMSO-d6) δ 8.01 (s, 1H), 7.45 (br s, 1H), 7.38 (d, 1H), 7.30 (br s, 1H), 7.16-7.04 (m, 2H), 6.98 (d, 1H), 6.60 (t, 1H), 6.42 (t, 1H), 4.40 (s, 2H), 4.24-4.18 (m, 2H), 3.68-3.61 (m, 2H), 3.30-3.25 (m, 4H), 1.96 (s, 3H), 1.89-1.86 (m, 3H), 1.16 (t, 3H), 1.08 (t, 3H); MS (EI) for C25H29N7O: 444 (MH+).

Example 26 6-[4-(6-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine

STEP 1: A suspension of 5-bromo-3-nitropyridin-2-amine (4.84 g, 22.2 mmol), (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (6.51 g, 22.2 mmol) (example 1, step 2), dichloro[1,1-bis(diphenyl)phosphino]ferrocenepalladium (II) dichloromethane adduct (1.60 g, 10 mol %) in dioxane (75 mL) and water (15 mL) was degassed with nitrogen, and then cesium carbonate (14.46 g, 44.4 mmol) was added. The reaction mixture was stirred at 90° C. overnight. The mixture was cooled to room temperature, water (150 ml) was added and stirred for 30 min to give a precipitate. The product 1,1-dimethylethyl-7-(6-amino-5-nitropyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (8.1 g, 94% yield) was collected by filtration, dried under vacuum. MS (EI) for C19H22N4O5: 387.1 (MH+).

STEP 2: A suspension of 1,1-dimethylethyl-7-(6-amino-5-nitropyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (6.12 g, 15.84 mmol), palladium on carbon (0.6 g) in acetic acid (100 mL) was degassed with nitrogen for 10 minutes. The reaction mixture was hydrogenated (45 psi) on a parr shaker for 60 minutes. Upon completion of hydrogenation, the reaction mixture was filtered through a pad of celite. The filtrate was concentrated and the residue was diluted with ethyl acetate (200 ml), washed with water, saturated sodium bicarbonate solution and brine then dried over sodium sulfate and filtered. Evaporation of ethyl acetate afforded 1,1-dimethylethyl-7-(5,6-diaminopyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (5.6 g, 99% yield). 1H NMR (400 MHz, CD3OD): 7.56-7.27 (m, 4H), 7.08-7.02 (m, 1H), 4.51 (s, 2H), 4.07-4.03 (m, 2H), 3.86-3.74 (m, 2H), 1.3 (s, 9H).

STEP 3: A solution of 1,1-dimethylethyl-7-(5,6-diaminopyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (5.64 g, 15.84 mmol) and 1,3-bis(benzyloxycarbonyl)-2-methyl-2-thiopseudourea (11.8 g, 32.92 mmol) in acetic acid (30 mL) was heated to 86° C. for 3 hours. After cooling to room temperature, ethyl acetate (100 mL) was added and the precipitate was collected by filtration, washed several times with ethyl acetate, and dried to give 1,1-dimethylethyl-7-[2-({[(phenylmethyl)oxy]carbonyl}amino)-1H-imidazo[4,5-b]pyridine-6-yl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (4.50 g, 55% yield). 1HNMR (400 MHz, DMSO-d6): 11.9 (s, br, 2H), 8.42 (s, 1H), 7.90 (s, 1H), 7.52-7.36 (m, 7H), 5.28 (s, 2H), 4.60-4.34 (m, 2H), 4.18-4.02 (m, 2H), 3.79-3.67 (m, 2H), 1.38 (s, 9H).

STEP 4: To the solution of 1,1-dimethylethyl-7-[2-({[(phenylmethyl)oxy]carbonyl}amino)-1H-imidazo[4,5-b]pyridine-6-yl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (4.5 g, 8.73 mmol) in methanol (20 ml) was added 4 N HCl in dioxane at room temperature. Then the reaction mixture was heated to 55° C. for 3 hours. After cooling to room temperature, the precipitate collected by filtration, washed with a minimum of methanol and dried to give phenylmethyl[6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate hydrochloride (3.0 g, 76% yield). 1HNMR (400 MHz, CD3OD): 8.59 (m, 1H), 8.51 (s, 1H), 7.85 (m, 1H), 7.79-7.75 (m, 1H), 5.37 (s, 2H), 4.53 (s, 2H), 4.37-4.32 (m, 2H), 3.67-3.64 (m, 2H).

STEP 5: Diisopropylethylamine (0.23 g, 1.76 mmol) was added to a solution of phenylmethyl[6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate hydrochloride (0.2 g, 0.44 mmol) and 4-chloro-6-methylquinazoline (0.08 g, 0.44 mmol), in NMP (5 ml) at room temperature. The reaction mixture was heated to 90° C. for 30 minutes, and then cooled to room temperature. Water was added and the resulting suspension was stirred overnight. The precipitate was collected by filtration and dried under vacuum to give phenylmethyl{6-[4-(6-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3H-imidazo[4,5-b]pyridin-2-yl}carbamate (0.215 g, 87% yield). MS (EI) for C32H27N7O3: 558.1 (MH+).

STEP 6: Phenylmethyl{6-[4-(6-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3H-imidazo[4,5-b]pyridin-2-yl}carbamate (0.1 g, 0.18 mmol) in acetic acid (8 ml) was placed under nitrogen. Palladium on carbon (0.25 g, 10 W %) was added and the reaction mixture saturated with hydrogen then stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of celite then concentrated. The residue was taken into a minimum of methanol and purified by preparative reverse phase HPLC to give 6-[4-(6-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3H-imidazo[4,5-b]pyridin-2-amine (0.0033 g). 1H NMR (400 MHz, d6-DMSO); δ 8.52 (s, 1H), 8.32-8.12 (s, 1H), 7.84-7.47 (m, 6H), 7.07-7.00 (d, 1H), 6.80-6.50 (s, 1H), 5.04 (s, 2H), 4.56-4.44 (m, 2H), 4.20-4.09 (m, 2H), 2.83 (s, 3H); MS (EI) for C24H21N7O: 424.1 (MH+).

Using analogous synthetic techniques and substituting with alternative starting reagents in steps 1, 3 or 5 the following compounds of the invention were prepared. Alternative starting materials were obtained commercially unless otherwise indicated.

6-[7-(1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-2,5-dimethyl-N-phenylpyrimidin-4-amine. Synthesized according to the method of example 26 using 4-bromo-2-nitroaniline in step 1, triethyl orthoformate in refluxing ethanol step 3, and 6-chloro-2,5-dimethyl-N-phenylpyrimidin-4-amine (Prepared according to the general method in Journal of Medicinal Chemistry (1996), 39(22), 4358-4360) in step 5. 1H NMR (400 MHz, dmso-d6) δ 12.03 (brs, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 7.80 (brs, 1H), 7.60 (m, 6H), 7.21 (t, 2H), 7.18 (d, 1H), 6.92 (t, 1H), 4.60 (s, 2H), 4.23 (brs, 2H), 3.78 (brs, 2H), 2.23 (s, 3H), 2.18 (s, 3H); MS (EI) for C28H26N6O: 463.2 (MH+).

6-[7-(1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-2,5-dimethyl-N-phenylpyrimidin-4-amine. Synthesized according to the method of example 26 using triethyl orthoformate in refluxing ethanol step 3 and 6-chloro-2,5-dimethyl-N-phenylpyrimidin-4-amine (Prepared according to the general method in Journal of Medicinal Chemistry (1996), 39(22), 4358-4360) in step 5. 1H NMR (400 MHz, MeOH-d4): δ 8.61 (s, 1H), 8.41 (s, 1H), 8.21 (s, 1H), 7.60 (m, 4H), 7.21 (t, 2H), 7.18 (d, 1H), 6.92 (t, 1H), 4.60 (s, 2H), 4.23 (brs, 2H), 3.78 (brs, 2H), 2.23 (s, 3H), 2.18 (s, 3H); MS (EI) for C27H25N7O: 464.2 (MH+).

7-(1H-benzimidazol-6-yl)-4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 26 by using 4-bromo-2-nitroaniline in step 1, triethylorthoformate in refluxing ethanol step 3, and using 4-chloropyrimidine in step 5. 1H NMR (400 MHz, DMSO-d6) δ 8.49 (s, 1H), 8.25 (s, 1H), 8.17 (d, 1H), 7.93-7.86 (m, 2H), 7.71 (s, 1H), 7.55-7.43 (m, 2H), 7.04 (d, 2H), 4.87 (s, 2H), 4.16 (s, 4H); MS (EI) for C20H17N5O: 344 (MH+).

7-(1H-imidazo[4,5-b]pyridin-6-yl)-4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 26 using triethylorthoformate in refluxing ethanol in step 3 and 4-chloropyrimidine in step 5. 1H NMR (400 MHz, DMSO-d6): δ 8.65 (d, 1H), 8.51-8.46 (m, 2H), 8.23 (d, 1H), 8.17 (d, 1H), 7.96 (s, 1H), 7.59-7.55 (m, 1H), 7.07 (d, 2H), 4.88 (s, 2H), 4.18 (s, 4H), 1.85 (s, 8H); MS (EI) for C19H16N6O: 343 (MH+).

6-(4-pyrido[3,2-d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine. Synthesized according to the method of example 26 using 4-chloropyrido[3,2-d]pyrimidine in step 5. 1H NMR (400 MHz, MeOH-d4): δ 9.01 (d, 1H), 8.75 (br, 2H), 8.43 (s, 1H), 8.01 (s, 1H), 7.75 (m, 2H), 7.52 (brs, 1H), 7.01 (brs, 1H), 5.70 (s, 2H), 4.71 (s, 4H); MS (EI) for C22H18N8O: 410.9 (MH+).

6-{4-[5-Methyl-6-(phenylamino)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridine-2-amine. Synthesized according to the method of example 26 using 6-chloro-5-methyl-N-phenylpyrimidin-4-amine (reagent preparation 49) in step 5. 1H NMR (400 MHz, dmso-d6) δ 12.03 (brs, 1H), 8.25 (s, 1H), 8.18 (s, 1H), 7.60 (m, 5H), 7.42 (d, 1H), 7.21 (t, 2H), 7.05 (d, 1H), 6.89 (t, 1H), 6.60 (br, 2H), 4.58 (s, 2H), 4.32 (s, 2H), 3.78 (s, 2H), 2.15 (s, 3H); MS (EI) for C26H24N8O: 464.2 (MH+).

7-(1H-benzimidazol-6-yl)-4-(2-phenylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 26 using 4-bromo-2-nitroaniline in step 1, triethylorthoformate in refluxing ethanol in step 3 and 4-chloro-2-phenylquinazoline in step 5. 1H NMR (400 MHz, DMSO-d6): 12.60-12.46 (m, 1H), 8.55-8.22 (m, 3H), 8.21-7.72 (m, 6H), 7.70-7.22 (m, 7H), 5.24 (s, br, 2H), 4.53 (s, br, 2H), 4.38 (s, br, 2H); MS (EI) for C30H23N5O: 470.2 (MH+).

6-[4-(2-phenylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine. Synthesized according to the method of example 26 using 4-bromo-2-nitroaniline in step 1, and 4-chloro-2-phenylquinazoline in step 5. 1H NMR (400 MHz, DMSO-d6): 8.36 (m, 2H), 8.25 (s, 1H), 8.21-8.11 (m, 2H), 7.92-7.73 (m, 3H), 7.65 (d, 1H), 7.612-7.36 (m, 4H), 7.30 (t, 2H), 6.91 (d, 2H), 6.70 (s, br, 2H), 5.22 (s, 2H), 4.52 (m, 2H), 4.37 (m, 2H); MS (EI) for C30H24N6O: 486.1 (MH+).

4-(7-fluoroquinolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 26 using 4-bromo-2-nitroaniline in step 1, triethylorthoacetate in refluxing ethanol in step 3 and 4-chloro-7-fluoroquinoline in step 5. 1H NMR (400 MHz, CD3OD): 8.52 (d, 1H), 8.19-8.11 (m, 1H), 7.69 (s, 1H), 7.65-7.44 (m, 5H), 7.38-7.29 (m, 1H), 7.14-6.98 (m, 2H), 4.67 (s, 2H), 4.39 (m, 2H), 3.89 (m, 2H), 2.59 (s, 3H); MS (EI) for C26H21FN4O 425.0 (MH+).

4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinoline-7-carbonitrile. Synthesized according to the method of example 26 using 4-bromo-2-nitroaniline in step 1, triethylorthoacetate in refluxing ethanol in step 3 and 4-chloro-7-cyanoquinoline in step 5. 1H NMR (400 MHz, CD3OD): 8.64 (d, 1H), 8.22 (d, 1H), 8.07 (d, 1H), 7.82 (t, 1H), 7.71-7.34 (m, 6H), 7.09 (d, 1H), 4.85-4.52 (dd, 2H), 4.48-4.38 (m, 1H), 4.24-3.66 (m, 3H), 2.57 (s, 3H); MS (EI) for C27H21N5O: 432.0 (MH+).

7-(2-methyl-1H-benzimidazol-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 26 using 4-bromo-2-nitroaniline in step 1, triethylorthoacetate in refluxing ethanol in step 3 and 4-chloro-7-methoxy-2-methylquinazoline in step 5. 1H NMR (400 MHz, CD3OD): 8.20 (d, 2H), 7.92 (s, 1H), 7.87-7.78 (m, 3H), 7.58 (d, 1H), 7.26 (dd, 1H), 7.11-7.02 (m, 2H), 5.44 (s, 2H), 4.65-4.54 (m, 4H), 3.99 (s, 3H), 2.88 (s, 3H), 2.58 (s, 3H); MS (EI) for C30H24N6O: 486.1 (MH+).

7-(1H-benzimidazol-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 26 using 4-bromo-2-nitroaniline in step 1, triethylorthoformate in refluxing ethanol in step 3 and 4-chloro-7-methoxy-2-methylquinazoline in step 5. 1H NMR (400 MHz, DMSO); δ 8.25 (s, 1H), 8.00-7.42 (m, 6H), 7.17-6.98 (m, 3H), 5.02 (s, 2H), 4.50-4.38 (m, 2H), 4.21-4.10 (m, 2H), 3.88 (s, 3H), 2.44 (s, 2H); MS (EI) for C26H23N5O2: 438.2 (MH+).

6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine. Synthesized according to the method of example 26 using 4-chloro-7-methoxy-2-methylquinazoline in step 5. 1H NMR (400 MHz, DMSO); δ 8.15 (s, 1H), 7.90 (d, 1H), 7.71-7.42 (m, 3H), 7.17-6.95 (m, 3H), 6.70 (s, 2H), 5.00 (s, 2H), 4.48-4.38 (m, 2H), 4.20-4.09 (m, 2H), 3.87 (s, 3H), 2.44 (s, 3H); MS (EI) for C25H23N7O2: 454.2 (MH+).

6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine. Synthesized according to the method of example 26 using 4-bromo-2-nitroaniline in step 1 and 4-chloro-7-methoxy-2-methylquinazoline in step 5. 1H NMR (400 MHz, DMSO); δ 7.92 (d, 1H), 7.61-7.57 (m, 1H), 7.46-7.40 (m, 1H), 7.33 (s, 1H), 7.18-7.09 (m, 3H), 7.06-6.96 (m, 2H), 6.23 (s, 2H), 4.99 (s, 2H), 4.45-4.32 (m, 2H), 4.18-4.10 (m, 2H), 3.88 (s, 3H), 2.44 (s, 3H); MS (EI) for C26H24N6O2: 453.0 (MH+).

7-(1H-imidazo[4,5-b]pyridin-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine. Synthesized according to the method of example 26 using triethylorthoformate in refluxing ethanol in step 3 and 4-chloro-7-methoxy-2-methylquinazoline in step 5. 1H NMR (400 MHz, DMSO); δ 8.68-8.64 (m, 1H), 8.48 (s, 1H), 8.21 (s, 1H), 7.93-7.87 (d, 1H), 7.80-7.75 (m, 1H), 7.62-7.56 (m, 1H), 7.11 (d, 1H), 7.08-7.00 (m, 2H), 5.03 (s, 2H), 4.50-4.25 (m, 2H), 4.20-4.12 (m, 2H), 3.88 (s, 2H), 2.43 (s, 3H); MS (EI) for C25H22N6O2: 438.9 (MH+).

Example 27 methyl {6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}carbamate

STEP 1: A mixture of 1,1-dimethylethyl 7-(6-amino-5-nitropyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (3.5 g, 9.1 mmol, example 26, step 1) in methanol (75 mL) and 4N hydrogen chloride in dioxane (11 mL) was stirred at 50° C. for 1.5 h and then concentrated. The resulting residue was triturated with a 10% methanol in diethyl ether solution (50 mL) to provide 3-nitro-5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridin-2-amine dihydrochloride (3.1 g, 95%) as a red solid. 1H NMR (400 MHz, d6-DMSO) δ 9.76 (bs, 2H), 8.80 (d, 1H), 8.60 (s, 1H), 7.90 (s, 1H), 7.73 (dd, 1H), 7.16 (d, 1H), 4.39 (bs, 2H), 4.25 (bs, 2H), 3.48 (bs, 2H); MS (EI) for C14H14N4O3: 287 (MH+).

STEP 2: A solution of 3-nitro-5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridin-2-amine dihydrochloride (540 mg, 1.50 mmol), 4-chloro-6,6-dimethyl-5,6,7,8-tetrahydroquinazoline (270 mg, 1.37 mmol, reagent preparation 3), and diisopropylethylamine (970 mg, 7.49 mmol) in N-methylpyrrolidinone (3 mL) was stirred at 120° C. for 18 h. After cooling to room temperature ethyl acetate (100 mL) was added, the formed precipitate was filtered off, the organic filtrate was washed with saturated sodium bicarbonate (50 mL), water (2×50 mL), and brine (50 mL), dried over sodium sulfate, filtered and concentrated to afford crude 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-nitropyridine-2-amine (0.5 g) as a brown solid which was used in the next step without further purification. MS (EI) for C24H26N6O3: 447 (MH+).

STEP 3: A mixture of 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-nitropyridine-2-amine (0.5 g, 1.37 mmol) and palladium on carbon (0.5 g, 50% water) in methanol (50 mL) was hydrogenated in a Parr apparatus at 40 psi for 90 min. The mixture was filtered through celite and concentrated. Column chromatography of the residue on silica (dichloromethane/methanol 9:1) provided 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine (174 mg, 30% yield over 2 steps) as a brown solid. MS (EI) for C24H28N6O: 417 (MH+).

STEP 4: A mixture of 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine (174 mg, 0.42 mmol) and 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (86 mg, 0.42 mmol) in acetic acid (5 mL) was stirred at 80° C. for 10 h. After cooling to room temperature the mixture was concentrated, methanol (10 mL) was added, the precipitate was filtered off, and lyophilized from a mixture of acetonitrile (2 mL), water (6 mL), and 1N hydrochloric acid (0.25 mL) to give the hydrochloride salt of the title Compound (107 mg, 48% yield) as a yellow solid. 1H NMR (400 MHz, methanol-d4): 8.53 (m, 2H), 8.35 (s, 1H), 7.78 (s, 1H), 7.58 (d, 1H), 7.10 (d, 1H), 5.18 (s, 2H), 4.49 (m, 2H), 4.34 (m, 2H), 3.93 (s, 3H), 2.86 (m, 2H), 2.61 (s, 2H), 1.71 (m, 2H), 0.95 (s, 6H); MS (EI) for C27H29N7O3: 500 (MH+).

Methyl {6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-yl}carbamate. Prepared according to the method of example 27 by 4-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-nitroaniline in step 3. 1H NMR (400 MHz, d6-DMSO): 8.71 (s, 1H), 7.61 (s, 1H), 7.58-7.44 (m, 3H), 6.99 (d, 1H), 5.10 (s, 2H), 4.43 (m, 2H), 4.18 (m, 2H), 3.81 (s, 3H), 2.78 (t, 2H), 2.56 (s, 2H), 1.57 (t, 2H), 0.86 (s, 6H); MS (EI) for C28H30N6O3: 499 (MH+).

Example 28 ethyl {6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}carbamate

STEP 1: A solution of 5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine (188 mg, 0.45 mmol, example 27, step 3) and ethyl isothiocyanatoformate (59 mg, 0.45 mmol) in dioxane (2 mL) was stirred at room temperature for 30 h. After 24 h and 48 h reaction time, additional ethyl isothiocyanatoformate (50 mg, 0.38 mmol) was added each time. The mixture was concentrated and the residue purified directly by column chromatography on silica (ethyl acetate) to give crude ethyl [1-({3-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2-yl}amino)ethenyl]carbamate (82 mg) which was used in the next step without further purification. MS (EI) for C28H33N7O3S: 548 (MH+).

STEP 2: A mixture of ethyl [1-({3-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2-yl}amino)ethenyl]carbamate (82 mg, 0.15 mmol) and mercury(II) oxide (33 mg, 0.15 mmol) in tetrahydrofuran (8 mL) was stirred at 70° C. for 24 h. On cooling to room temperature, the mixture filtered then concentrated and the residue purified by preparative reverse phase HPLC to afford the title Compound (6 mg, 3% yield over 2 steps) as a colorless solid. 1H NMR (400 MHz, methanol-d4): 8.51 (s, 1H), 8.49 (d, 1H), 8.22 (d, 1H), 7.72 (d, 1H), 7.66 (dd, 1H), 7.09 (d, 1H), 5.17 (s, 2H), 4.48 (m, 2H), 4.36 (q, 2H), 4.33 (m, 2H), 2.85 (m, 2H), 2.60 (s, 2H), 1.69 (m, 2H), 1.38 (t, 3H), 0.95 (s, 6H); MS (EI) for C28H31N7O3: 514 (MH+).

Example 29 methyl {6-[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}carbamate

STEP 1: To a solution of 3-nitro-5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridin-2-amine dihydrochloride (1.0 g, 2.8 mmol) in acetic acid (20 mL) and ethanol (20 mL) was added Pd/C (10% wt/wt, 0.5 g) and the reaction mixture was stirred under H2 (45 PSI) for 1 hour. The resulting pale yellow solution was filtered through Celite and the filtrate was concentrated to give 5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridine-2,3-diamine dihydrochloride (0.92 g, 100%) as a yellow powder. MS (EI) for C14H16N4O: 257.3 (MH+).

STEP 2: To a slurry of 5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridine-2,3-diamine dihydrochloride (0.92 g, 2.8 mmol) and 4-chloro-6,6-dimethyl-5,6-dihydroquinazoline (0.55 g, 2.8 mmol) in NMP was added diisopropylethylamine (2.4 mL, 14 mmol) and the reaction mixture was heated (90° C.) for 12 hours. The resulting dark red solution was loaded directly on to a column of dry silica and elution with MeOH (w/8% NH4OH v/v) in CH2Cl2 (0-5%) provided 5-[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine (0.86, 74% yield) as a brown solid. MS (EI) for C24H26N6O: 415.1 (MH+).

Step 3: To a solution of 5-[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2,3-diamine (0.24 g, 0.58 mmol) in acetic acid (3 mL) was added 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (0.19 g, 0.93 mmol). The reaction mixture was heated (60° C.) for 12 h and then concentrated. Purification by preparative reverse phase HPLC followed by the formation of the dihydrochloride salt provided methyl {6-[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}carbamate dihydrochloride (0.12 g, 38% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.57-8.44 (m, 2H), 8.25 (bs, 1H), 7.73 (bs, 1H), 7.56 (dd, 1H), 7.09 (d, 1H), 6.59 (d, 1H), 6.35 (d, 1H), 5.15 (s, 2H), 4.53-4.42 (m, 2H), 4.33-4.21 (m, 2H), 3.91 (s, 3H), 2.92 (s, 2H), 1.09 (s, 6H); MS (ES) for C27H27N7O3: 498.6 (MH+).

Example 30 6-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine

STEP 1: A mixture of 2-amino-5-bromo-3-nitropyridine (0.70 g, 3.2 mmol), (4-{[(1,1-dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)boronic acid (example 1, step 2) (1.0 g, 3.1 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.15 mg, 0.2 mmol), diisopropylethylamine (1.8 g, 14 mmol) in 50% aqueous 1,4-dioxane (40 mL) was degassed with nitrogen for 5 minutes and then stirred at 90° C. for one hour. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (80 mL) then filtered over celite. The filtrate was washed twice with brine (50 mL), filtered and the filtrate dried over sodium sulfate, filtered again and concentrated. The residue was purified by silica gel chromatography (25% to 95% ethyl acetate in hexanes gradient) to give 1,1-dimethylethyl 7-(6-amino-5-nitropyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.58 g, 48% yield); MS (EI) for C19H22N4O5: 389 (MH+).

STEP 2: A mixture of 1,1-dimethylethyl 7-(6-amino-5-nitropyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.58 g, 1.5 mmol), palladium (10% on charcoal, 0.50 g) and methanol (30 mL) was hydrogenated in a Parr apparatus at 45 psi for 18 hours. The mixture was filtered then concentrated and dried to give 1,1-dimethylethyl 7-(5,6-diaminopyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.51 g, 96% yield), MS (EI) for C19H24N4O3: 357 (MH+).

STEP 3: To a solution of 1,1-dimethylethyl 7-(5,6-diaminopyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.51 g, 1.4 mmol) in acetic acid (5 mL) was added 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (0.3 g, 1.4 mmol). The reaction mixture was heated 65° C. for 18 h and then concentrated. The resulting residue was suspended in water and basified with portion wise addition of solid sodium bicarbonate. After complete neutralization of the aqueous mixture the insoluble solid was collected by filtration and washed with water then 50% ethyl acetate in hexanes and the filter cake dried to give 1,1-dimethylethyl 7-(2-{[(methyloxy)carbonyl]amino}-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.52 g, 83% yield), MS (EI) for C22H25N5O5: 440 (MH+).

STEP 4: To a mixture of 1,1-dimethylethyl 7-(2-{[(methyloxy)carbonyl]amino}-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.52 g, 1.2 mmol) was taken into acetonitrile (5 mL) followed by addition of 4M hydrogen chloride in 1,4-dioxane (5 mL) and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated to give a white solid. It was washed with ether then dried to give methyl [6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate hydrochloride salt (0.40 g, 100% yield), MS (EI) for C17H17N5O3: 340 (MH+).

STEP 5: A mixture of methyl [6-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate hydrochloride (84 mg, 0.23 mmol, (7S)-4-chloro-7-ethyl-5,6,7,8-tetrahydroquinazoline (reagent preparation 3) (35 mg, 0.18 mmol) and N,N-diisopropylethylamine (0.15 mL, 0.90 mmol) in N-methyl-2-pyrrolidone (2.0 mL) was reacted in a microwave apparatus (250 W) for 5 min. at 110° C. After cooling to room temperature the reaction mixture was diluted with methanol (2 mL) and purified by preparative reverse phase HPLC (0.1% aqueous ammonium acetate-acetonitrile) to give 6-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine. 1H NMR (400 MHz, Methanol-d4): 8.33 (s, 1H), 8.13 (brs, 1H), 7.63 (s, 1H), 7.50 (brs, 1H), 7.31 (d, 1H), 7.04 (d, 1H), 4.75 (b, 2H), 4.44 (m, 1H), 4.24 (m, 1H), 3.99 to 3.86 (m, 2H), 2.94 to 2.86 (m, 2H), 2.60 (m, 1H), 2.28 (m, 1H), 1.97 (m, 1H), 1.75 (m, 1H), 1.36 (m, 2H), 1.14 (m, 1H), 0.97 (t, 3H); MS (EI) for C25H27N7O: 442 (MH+).

The following compounds were prepared using the procedures described herein.

Compound Name NMR MS 1-(6,6-dimethyl-4-{7-[4- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for (methyloxy)-3-{[2- 7.61 (d, 1H), 7.44 (dd, 1H), C32H42N4O4: (methyloxy)ethyl]oxy}phenyl]- 7.20-7.14 (m, 2H), 7.02 (d, 1H), 547 (MH+) 2,3-dihydro-1,4-benzoxazepin- 6.97 (d, 1H), 4.60 (s, 2H), 4(5H)-yl}-5,6,7,8- 4.31-4.24 (m, 2H), 4.18-4.13 (m, 2H), tetrahydroquinazolin-2-yl)-N,N- 3.87-3.82 (m, 2H), 3.79 (s, 3H), dimethylmethanamine 3.70-3.66 (m, 2H), 3.33 (s, 3H), 2.69 (t, 2H), 2.45 (s, 2H), 2.14 (s, 6H), 1.59 (t, 2H), 0.86 (s, 6H) 1-{4-[7-{3- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(difluoromethyl)oxy]-4- 7.66 (d, 1H), 7.54 (dd, 1H), C30H36F2N4O3: (methyloxy)phenyl}-2,3- 7.51-7.44 (m, 2H), 7.24 (d, 1H), 7.13 (t, 539 (MH+) dihydro-1,4-benzoxazepin- 3H), 7.00 (d, 1H), 4.74 (br s, 2H), 4(5H)-yl]-6,6-dimethyl-5,6,7,8- 4.41-4.32 (m, 2H), 4.31-4.18 (m, tetrahydroquinazolin-2-yl}- 2H), 3.97-3.89 (m, 2H), 3.87 (s, N,N-dimethylmethanamine. 3H), 2.84-2.69 (m, 8H), 2.48 (s, 2H), 1.62 (t, 2H), 0.85 (s, 6H) 1-[5-(4-{2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(dimethylamino)methyl]-6,6- 7.84-7.78 (m, 2H), 7.62 (d, 1H), C31H38N4O3: dimethyl-5,6,7,8- 7.44 (dd, 1H), 7.26 (d, 1H), 515 (MH+) tetrahydroquinazolin-4-yl}- 6.99 (d, 1H), 4.62 (s, 2H), 2,3,4,5-tetrahydro-1,4- 4.33-4.25 (m, 2H), 3.93 (s, 3H), benzoxazepin-7-yl)-2- 3.88-3.82 (m, 2H), 3.39 (br s, 2H), 2.69 (t, (methyloxy)phenyl]ethanone. 2H), 2.57 (s, 3H), 2.44 (s, 2H), 2.15 (s, 6H), 1.59 (t, 2H), 0.86 (s, 6H) 1-(6,6-dimethyl-4-{7-[4- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for (methyloxy)-3- 8.00 (d, 1H), 7.96 (dd, 1H), C30H38N4O4S: (methylsulfonyl)phenyl]-2,3- 7.63 (d, 1H), 7.45 (dd, 1H), 7.40 (d, 551 (MH+) dihydro-1,4-benzoxazepin- 1H), 7.01 (d, 1H), 4.66 (s, 2H), 4(5H)-yl}-5,6,7,8- 4.34-4.28 (m, 2H), 4.00 (s, 3H), tetrahydroquinazolin-2-yl)-N,N- 3.90-3.83 (m, 2H), 3.41 (br s, 2H), dimethylmethanamine. 3.28 (s, 3H), 2.68 (t, 2H), 2.43 (s, 2H), 2.16 (br s, 7H), 1.59 (t, 2H), 0.85 (s, 6H) N-[5-(4-{2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(dimethylamino)methyl]-6- 9.03 (s, 1H), 7.51 (d, 1H), C28H37N5O4S: methyl-5-(1- 7.49-7.39 (m, 3H), 7.17 (d, 1H), 540 (MH+) methylethyl)pyrimidin-4-yl}- 7.02 (d, 1H), 4.45 (s, 2H), 2,3,4,5-tetrahydro-1,4- 4.33-4.26 (m, 2H), 3.87 (s, 3H), benzoxazepin-7-yl)-2- 3.74-3.66 (m, 2H), 3.32 (s, 2H), (methyloxy)phenyl]methanesulfonamide. 3.30-3.21 (m, 1H), 2.98 (s, 3H), 2.48 (s, 3H), 2.30 (br s, 6H), 1.32 (d, 6H) N′-{5-[(4-fluorophenyl)methyl]- 1H NMR (400 MHz, CD3OD) δ MS (EI) for 4-methyl-6-[7-(2-methyl-1H- 7.58-7.47 (m, 2H), 7.42 (dd, 1H), C33H36FN7O: benzimidazol-5-yl)-2,3-dihydro- 7.25 (dd, 1H), 7.15-7.08 (m, 2H), 566 (MH+) 1,4-benzoxazepin-4(5H)- 7.01-6.92 (m, 3H), 6.86 (s, 1H), yl]pyrimidin-2-yl}-N,N- 4.49 (s, 2H), 4.28-4.22 (m, 2H), dimethylethane-1,2-diamine 3.90 (s, 2H), 3.84-3.78 (m, 2H), 3.45 (t, 2H), 2.63-2.53 (m, 5H), 2.34 (s, 6H), 2.06 (s, 3H) 2-fluoro-N-({4-methyl-6-[7-(2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for methyl-1H-benzimidazol-5-yl)- 7.63 (s, 1H), 7.55 (s, 1H), 7.50 (d, C28H33FN6O: 2,3-dihydro-1,4-benzoxazepin- 2H), 7.37 (d, 1H), 7.02 (d, 1H), 489 (MH+) 4(5H)-yl]-5-(1- 4.45 (dd, 3H), 4.36-4.22 (m, methylethyl)pyrimidin-2- 3H), 3.71 (s, 2H), 3.63 (s, 2H), yl}methyl)ethanamine 3.40-3.21 (m, 1H), 2.76 (t, 1H), 2.69 (t, 1H), 2.47 (s, 3H), 1.87 (s, 3H), 1.33 (d, 6H) 6-{4-[2-{[(2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for fluoroethyl)amino]methyl}-6- 8.37 (d, 1H), 7.88 (s, 2H), 7.81 (d, C26H30FN7O: methyl-5-(1- 1H), 7.63 (s, 1H), 7.57 (d, 1H), 508 (MH+) methylethyl)pyrimidin-4-yl]- 7.04 (d, 1H), 4.51 (s, 2H), 4.43 (t, 2,3,4,5-tetrahydro-1,4- 1H), 4.31 (s, 3H), 3.71 (s, 2H), benzoxazepin-7- 3.61 (s, 2H), 3.24 (s, 1H), 2.74 (t, yl}[1,3]thiazolo[5,4-b]pyridin- 1H), 2.67 (s, 1H), 2.46 (s, 3H), 2-amine. 1.31 (d, 6H) N,N-dimethyl-1-{4-methyl-6- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [7-(2-methyl-1H-benzimidazol- 7.61 (d, 2H), 7.46 (dd, 2H), C28H34N6O: 6-yl)-2,3-dihydro-1,4- 7.37 (d, 1H), 6.99 (d, 1H), 4.61 (s, 2H), 471 (MH+) benzoxazepin-4(5H)-yl]-5- 4.32 (s, 2H), 3.78 (s, 2H), 3.34 (br propylpyrimidin-2- s, 2H), 2.50 (m, 5H), 2.35 (s, 3H), yl}methanamine 2.12 (s, 6H), 1.45 (d, 2H), 0.75 (t, 3H) N,N-dimethyl-1-{4-methyl-6- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [7-(2-methyl-1H-benzimidazol- 7.61 (d, 1H), 7.55-7.41 (m, 3H), C28H32N6O: 6-yl)-2,3-dihydro-1,4- 7.35 (dt, 1H), 6.97 (dd, 1H), 469 (MH+) benzoxazepin-4(5H)-yl]-5-prop- 6.23-6.01 (m, 1H), 5.25 (t, 1H), 2-en-1-ylpyrimidin-2- 4.93 (t, 1H), 4.61 (s, 2H), 4.27 (d, 2H), yl}methanamine 3.82 (s, 2H), 3.37 (s, 2H), 3.32 (s, 2H), 2.50 (m, 3H), 2.27 (s, 3H), 2.15 (s, 6H) 6-(4-{2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(dimethylamino)methyl]-6- 8.38 (d, 1H), 7.88 (s, 2H), 7.82 (d, C26H31N7OS: methyl-5-propylpyrimidin-4- 1H), 7.70 (s, 1H), 7.53 (d, 1H), 490 (MH+) yl}-2,3,4,5-tetrahydro-1,4- 7.01 (d, 1H), 4.63 (s, 2H), 4.34 (s, benzoxazepin-7- 2H), 3.78 (s, 2H), 3.33 (d, 2H), yl)[1,3]thiazolo[5,4-b]pyridin- 2.51 (m, 2H), 2.34 (s, 3H), 2.11 (s, 2-amine 6H), 1.46 (s, 2H), 0.75 (t, 3H) 6-(4-{2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(dimethylamino)methyl]-6- 8.36 (d, 1H), 7.88 (s, 2H), 7.80 (d, C26H29N7OS: methyl-5-prop-2-en-1- 1H), 7.60 (d, 1H), 7.53 (dd, 1H), 488 (MH+) ylpyrimidin-4-yl}-2,3,4,5- 7.02 (d, 1H), 6.10 (dd, 1H), tetrahydro-1,4-benzoxazepin-7- 5.23 (d, 1H), 4.94 (d, 1H), 4.63 (s, 2H), yl)[1,3]thiazolo[5,4-b]pyridin- 4.28 (s, 2H), 3.83 (s, 2H), 3.34 (s, 2-amine 2H), 3.30 (s, 2H), 2.26 (s, 3H), 2.13 (s, 6H) N,N-dimethyl-1-{4-methyl-6- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [7-(2-methyl-1H-benzimidazol- 7.73-7.42 (m, 4H), C31H32N6O: 5-yl)-2,3-dihydro-1,4- 7.41-7.27 (m, 5H), 7.23 (d, 1H), 6.92 (dd, 505.0 (MH+) benzoxazepin-4(5H)-yl]-5- 1H), 4.51 (d, 2H), 4.07-3.91 (m, phenylpyrimidin-2- 2H), 3.53 (d, 2H), 3.38 (d2H), yl}methanamine 2.49 (s, 3H), 2.16 (d, 6H), 2.02 (d, 3H) 6-(4-{2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(dimethylamino)methyl]-6- 8.34 (d, 1H), 7.89 (s, 2H), 7.78 (d, C29H29N7OS: methyl-5-phenylpyrimidin-4- 1H), 7.52-7.39 (m, 3H), 7.32 (t, 523.9 (MH+) yl}-2,3,4,5-tetrahydro-1,4- 4H), 6.95 (d, 1H), 4.57 (s, 2H), benzoxazepin-7- 4.04 (s, 2H), 3.48 (s, 2H), 3.36 (d, yl)[1,3]thiazolo[5,4-b]pyridin- 2H), 2.15 (s, 6H), 2.01 (s, 3H) 2-amine N,N-dimethyl-1-{4-methyl-6- 1H NMR (400 MHz, DMSO-d6) MS (EI) for [7-(2-methyl-1H-benzimidazol- δ12.22 (s, 1H), 7.67 (s, 1H), C29H36N6O: 5-yl)-2,3-dihydro-1,4- 7.59 (d, 1H), 7.56-7.39 (m, 2H), 485.0 (MH+) benzoxazepin-4(5H)-yl]-5-(2- 7.34 (d, 1H), 6.96 (d, 1H), 4.56 (s, 2H), methylpropyl)pyrimidin-2- 4.29 (s, 2H), 3.73 (s, 2H), 2.60 (t, yl}methanamine 2H), 2.32 (s, 3H), 2.10 (s, 6H), 1.88 (s, 2H, OAc), 1.76-1.53 (m, 1H), 0.52 (d 6H) 6-(4-{5-(cyclopropylmethyl)-2- 1H NMR (400 MHz, DMSO-d6) MS (EI) for [(dimethylamino)methyl]-6- δ 8.42 (d, 1H), 7.93 (s, 2H), C27H31N7OS: methylpyrimidin-4-yl}-2,3,4,5- 7.87 (d, 1H), 7.76 (d, 1H), 7.58 (dd, 502.0 (MH+) tetrahydro-1,4-benzoxazepin-7- 1H), 7.07 (d, 1H), 4.70 (d, 2H), yl)[1,3]thiazolo[5,4-b]pyridin- 4.37 (s, 2H), 3.85 (s, 2H), 2-amine 3.50-3.42 (m, 2H), 2.74-2.58 (m, 2H), 2.42 (d, 3H), 2.28-2.03 (m, 6H), 0.90 (s, 1H), 0.48-0.31 (m, 2H), 0.14-−0.28 (m, 2H) 6-(4-{2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(dimethylamino)methyl]-6- 8.37 (d, 1H), 7.88 (s, 2H), 7.81 (d, C27H33N7OS: methyl-5-(2- 1H), 7.72 (s, 1H), 7.53 (d, 1H), 504.0 (MH+) methylpropyl)pyrimidin-4-yl}- 7.01 (d, 1H), 4.61 (s, 2H), 4.33 (s, 2,3,4,5-tetrahydro-1,4- 2H), 3.76 (s, 2H), 3.37 (s, 2H), benzoxazepin-7- 2.59 (d, 2H), 2.35 (s, 3H), 2.14 (s, yl)[1,3]thiazolo[5,4-b]pyridin- 6H), 1.79-1.53 (m, 1H), 0.55 (d, 2-amine 6H) 7-(2-methyl-1H-benzimidazol- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for 5-yl)-4-[6-methyl-5-(1- 7.60 (s, 1H), 7.52-7.43 (m, 3H), C30H36N6O: methylethyl)-2-(pyrrolidin-1- 7.33 (dt, 1H), 6.99 (t, 1H), 4.40 (s, 497.2 (MH+) ylmethyl)pyrimidin-4-yl]- 2H), 4.27 (d, 2H), 3.65 (br s, 2H), 2,3,4,5-tetrahydro-1,4- 3.47 (s, 2H), 3.28 (dt, 1H), 2.47 (s, benzoxazepine 3H), 2.44 (s, 3H), 2.41 (m, 4H), 1.85 (s, 6H, OAc), 1.64-1.49 (m, 4H), 1.30 (d, 6H) 1-{6,6-dimethyl-4-[7-(2- 1H NMR (400 MHz, dmso) δ MS (ES) for methyl-1H-benzimidazol-5-yl)- 8.60 (s, 2H), 8.02-7.89 (m, 2H), C29H34N6O: 2,3-dihydro-1,4-benzoxazepin- 7.85 (d, 1H), 7.82 (d, 1H), 7.59 (d, 1H), 483 (MH+) 4(5H)-yl]-5,6,7,8- 7.05 (d, 1H), 5.02 (s, 2H), tetrahydroquinazolin-2- 4.53-4.29 (m, 3H), 4.24-3.99 (m, 2H), yl}ethanamine 2.83 (s, 3H), 2.79 (t, 2H), 2.52 (s, 2H), 1.60 (t, 2H), 1.44 (d, 3H), 0.86 (s, 6H) 6-[4-(2,6,6-trimethyl-5,6,7,8- 1H NMR (400 MHz, dmso) δ MS (ES) for tetrahydroquinazolin-4-yl)- 8.38 (d, 1H), 7.89 (s, 2H), 7.83 (d, 1H), C26H28N6OS: 2,3,4,5-tetrahydro-1,4- 7.73 (d, 1H), 7.56 (dd, 1H), 473 (MH+) benzoxazepin-7- 7.05 (d, 1H), 4.59 (s, 2H), 4.29 (m, yl][1,3]thiazolo[5,4-b]pyridin- 2H), 3.84 (m, 2H), 2.66 (t, 2H), 2-amine 2.42 (s, 2H), 2.34 (s, 3H), 1.58 (t, 2H), 0.84 (s, 6H) 4-[2-(fluoromethyl)-6,6- 1H NMR (400 MHz, dmso) δ MS (ES) for dimethyl-5,6,7,8- 7.69 (s, 1H), 7.67 (d, 1H), 7.54 (d, 1H), C28H30FN5O: tetrahydroquinazolin-4-yl]-7-(2- 7.50 (dd, 1H), 7.44 (dd, 1H), 472 (MH+) methyl-1H-benzimidazol-5-yl)- 7.03 (d, 1H), 5.23 (d, 2H), 4.66 (s, 2H), 2,3,4,5-tetrahydro-1,4- 4.30 (m, 2H), 3.89 (s, 1H), 2.73 (t, benzoxazepine 2H), 2.54 (s, 3H), 1.91 (s, 2H), 1.61 (t, 2H), 0.86 (s, 6H) 6-{4-[2-methyl-7- 1H NMR (400 MHz, dmso) δ MS (EI) (methyloxy)quinazolin-4-yl]- 8.45 (d, 1H), 8.25-8.1 (br, 3H), Calculated for 2,3,4,5-tetrahydro-1,4- 7.89 (d, 2H), 7.59 (s, 1H), C25H22N6O2S: benzoxazepin-7- 7.34-7.19 (m, 2H), 7.01 (d, 1H), 470.6 Found: yl}[1,3]thiazolo[5,4-b]pyridin- 4.72-4.32 (m, 6H), 3.95 (s, 3H), 2.56 (s, 3H) 471.2 (MH+) 2-amine. Prepared as a dihydrochloride salt. 6-(4-{5-chloro-2- 1H NMR (400 MHz, methanol- MS (EI) for [(dimethylamino)methyl]-6- d4): 8.34 (d, 1H), 7.81 (d, 1H), C23H24ClN7OS: methylpyrimidin-4-yl}-2,3,4,5- 7.65 (d, 1H), 7.48 (dd, 1H), 482 (MH+) tetrahydro-1,4-benzoxazepin-7- 7.06 (d, 1H), 5.07 (s, 2H), 4.36 (m, yl)[1,3]thiazolo[5,4-b]pyridin- 2H), 4.23 (m, 2H), 3.76 (s, 2H), 2-amine. Prepared as an acetate 2.50 (s, 3H), 2.47 (s, 6H), 1.94 (s, salt. 3H) 6-(4-{5-bromo-2- 1H NMR (400 MHz, methanol- MS (EI) for [(dimethylamino)methyl]-6- d4): 8.35 (d, 1H), 7.81 (d, 1H), C23H24BrN7OS: methylpyrimidin-4-yl}-2,3,4,5- 7.65 (d, 1H), 7.48 (dd, 1H), 526 (MH+) tetrahydro-1,4-benzoxazepin-7- 7.05 (d, 1H), 5.06 (s, 2H), 4.38 (m, yl)[1,3]thiazolo[5,4-b]pyridin- 2H), 4.19 (m, 2H), 3.78 (s, 2H), 2-amine. Prepared as a 2.56 (s, 3H), 2.48 (s, 6H), 1.94 (s, diacetate salt. 3H) 1-{5-chloro-4-methyl-6-[7-(2- 1H NMR (400 MHz, methanol- MS (EI) for methyl-1H-benzimidazol-5-yl)- d4): 7.63 (s, 1H), 7.61 (d, 1H), C25H27ClN6O: 2,3-dihydro-1,4-benzoxazepin- 7.52 (d, 1H), 7.43 (m, 2H), 463 (MH+) 4(5H)-yl]pyrimidin-2-yl}-N,N- 7.02 (d, 1H), 5.08 (s, 2H), 4.34 (m, dimethylmethanamine. 2H), 4.23 (m, 2H), 3.84 (s, 2H), Prepared as a diacetate salt. 2.58 (s, 3H), 2.52 (s, 6H), 2.50 (s, 3H), 1.94 (s, 6H) 1-{5-bromo-4-methyl-6-[7-(2- 1H NMR (400 MHz, methanol- MS (EI) for methyl-1H-benzimidazol-5-yl)- d4): 7.64 (d, 1H), 7.61 (d, 1H), C25H27BrN6O: 2,3-dihydro-1,4-benzoxazepin- 7.52 (d, 1H), 7.43 (m, 2H), 507 (MH+) 4(5H)-yl]pyrimidin-2-yl}-N,N- 7.00 (d, 1H), 5.06 (s, 2H), 4.36 (m, dimethylmethanamine. 2H), 4.19 (m, 2H), 3.79 (s, 2H), Prepared as a diacetate salt. 2.58 (s, 3H), 2.56 (s, 3H), 2.47 (s, 6H), 1.93 (s, 6H) 4-[7-(1H-benzimidazol-5-yl)- 1H NMR (400 MHz, DMSO) δ MS (EI) for 2,3-dihydro-1,4-benzoxazepin- 8.22 (s, 1H), 7.81 (s, 2H), 7.62 (s, C21H20N6O: 4(5H)-yl]-6-methylpyrimidin-2- 1H), 7.45 (dd, 2H), 7.00 (d, 1H), 373.2 (MH+) amine 6.09 (s, 1H), 5.94 (s, 2H), 4.73 (s, 2H), 4.03 (dd, 4H), 2.03 (d, 3H) 5-(4-fluorobenzyl)-4-[7-(3H- 1H NMR (400 MHz, DMSO) δ MS (EI) for imidazo[4,5-b]pyridin-6-yl)- 8.47 (dd, 2H), 8.12-7.95 (d, 1H), C27H24FN7O: 2,3-dihydro-1,4-benzoxazepin- 7.53 (s, 1H), 7.12 (t, 2H), 7.05 (t, 482.2 (MH+) 4(5H)-yl]-6-methylpyrimidin-2- 3H), 6.88 (d, 1H), 6.13 (s, 2H), amine 4.34 (s, 2H), 4.22 (s, 2H), 3.83 (s, 2H), 3.65 (s, 2H), 1.97 (s, 3H) 5-(4-fluorobenzyl)-4-methyl-6- 1H NMR (400 MHz, DMSO) δ MS (EI) for [7-(2-methyl-3H-imidazo[4,5- 8.29 (s, 1H), 7.94 (s, 1H), 7.50 (d, C28H26FN7O: b]pyridin-6-yl)-2,3-dihydro-1,4- 1H), 7.11 (t, 2H), 7.05 (t, 3H), 496.2 (MH+) benzoxazepin-4(5H)- 6.86 (s, 1H), 6.12 (s, 2H), 4.33 (s, yl]pyrimidin-2-amine 2H), 4.22 (s, 2H), 3.83 (s, 2H), 3.65 (s, 2H), 2.54 (s, 3H), 1.89 (s, 3H) 1-{4-[7-(3H-imidazo[4,5- 1H NMR (400 MHz, DMSO) δ MS (EI) for b]pyridin-6-yl)-2,3-dihydro-1,4- 8.62 (t, 1H), 8.45 (d, 1H), 8.17 (d, C27H27N7O2: benzoxazepin-4(5H)-yl]-7- 1H), 7.90 (t, 1H), 7.74 (t, 1H), 482.3 (MH+) methoxyquinazolin-2-yl}-N,N- 7.52 (dt, 1H), 7.12 (t, 1H), dimethylmethanamine 7.05 (dd, 1H), 6.98 (d, 1H), 5.04 (s, 2H), 4.44 (d, 2H), 4.18 (s, 2H), 3.86 (s, 3H), 3.41 (s, 2H), 2.08 (d, 6H) 6-{4-[2-amino-5-(4- 1H NMR (400 MHz, DMSO) δ MS (EI) for fluorobenzyl)-6- 8.13 (d, 1H), 7.82 (s, 2H), 7.62 (d, C27H24FN7OS: methylpyrimidin-4-yl]-2,3,4,5- 1H), 7.44 (dt, 1H), 7.09-6.92 (m, 514.2 (MH+) tetrahydro-1,4-benzoxazepin-7- 5H), 6.83 (d, 1H), 6.05 (s, 2H), yl}[1,3]thiazolo[5,4-b]pyridin- 4.27 (s, 2H), 4.14 (s, 2H), 3.72 (d, 2-amine 2H), 3.55 (d, 2H), 1.91 (d, 3H) 4-[7-(1H-benzimidazol-5-yl)- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for 2,3-dihydro-1,4-benzoxazepin- 8.24 (d, 1H), 7.92-7.50 (m, 1H), C28H25FN6O: 4(5H)-yl]-5-[(4- 7.47 (d, 1H), 7.20 (d, 1H), 481.0 (MH+) fluorophenyl)methyl]-6- 7.12 (dq, 5H), 7.02 (d, 1H), 6.75 (d, methylpyrimidin-2-amine 1H), 6.11 (d, 2H), 4.31 (s, 2H), 4.20 (d, 2H), 3.82 (d, 2H), 3.65 (s, 2H), 1.98 (s, 3H) 1-{4-[7-(1H-benzimidazol-5- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for yl)-2,3-dihydro-1,4- 8.25 (s, 1H), 7.95 (d, 1H), 7.81 (s, C28H28N6O2: benzoxazepin-4(5H)-yl]-7- 1H), 7.74-7.62 (m, 2H), 7.49 (d, 481.3 (MH+) (methyloxy)quinazolin-2-yl}- 2H), 7.16 (s, 1H), 7.10-7.03 (m, N,N-dimethylmethanamine 1H), 6.98 (d, 1H), 5.05 (s, 2H), 4.45 (s, 2H), 4.20 (s, 2H), 3.87 (d, 3H), 3.47 (s, 2H), 2.13 (d, 6H) N,N-dimethyl-1-{4-[7-(2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for methyl-1H-benzimidazol-5-yl)- 7.97-7.91 (m, 1H), 7.67 (d, 2H), C29H30N6O2: 2,3-dihydro-1,4-benzoxazepin- 7.52 (d, 1H), 7.47 (dd, 1H), 495.2 (MH+) 4(5H)-yl]-7- 7.40 (dd, 1H), 7.16 (d, 1H), 7.06 (dd, (methyloxy)quinazolin-2- 1H), 6.96 (dd, 1H), 5.04 (s, 2H), yl}methanamine 4.45 (s, 2H), 4.19 (s, 2H), 3.90 (d, 3H), 3.44 (s, 2H), 2.58 (s, 3H), 2.24 (m, 6H) 5-[(4-fluorophenyl)methyl]-4- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for methyl-6-[7-(2-methyl-1H- 7.62 (s, 1H), 7.48 (m, 3H), C29H27FN6O: benzimidazol-5-yl)-2,3-dihydro- 7.26-7.06 (m, 6H), 7.00 (d, 1H), 495.3 (MH+) 1,4-benzoxazepin-4(5H)- 6.84 (s, 1H), 6.45 (s, 2H), 4.40 (s, 2H), yl]pyrimidin-2-amine 4.22 (s, 2H), 3.85 (s, 2H), 3.71 (s, 2H), 2.52 (s, 3H), 2.01 (s, 3H) 6-(4-{2- 1H NMR (400 MHz, d6-DMSO): MS (EI) for [(dimethylamino)methyl]-6- 8.38 (d, 1H), 7.88 (brs, 2H), C26H31N7OS: methyl-5-(1- 7.81 (d, 1H), 7.61 (d, 1H), 7.54 (dd, 490 (MH+) methylethyl)pyrimidin-4-yl}- 1H), 7.03 (d, 1H), 4.46 (s, 2H), 2,3,4,5-tetrahydro-1,4- 4.30 (brt, 2H), 3.68 (brt, 2H), benzoxazepin-7- 3.35 (s, 2H), 3.25 (m, 1H), 2.47 (s, yl)[1,3]thiazolo[5,4-b]pyridin- 3H), 2.10 (s, 6H), 1.30 (d, 6H) 2-amine N-ethyl-N-({4-methyl-6-[7-(2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for methyl-1H-benzimidazol-5-yl)- 7.62 (s, 1H), 7.55 (br s, 1H), C30H38N6O: 2,3-dihydro-1,4-benzoxazepin- 7.47 (m, 3H), 7.35 (d, 1H), 6.99 (d, 499.3 (MH+) 4(5H)-yl]-5-(1- 1H), 4.43 (s, 2H), 4.27 (br t, 2H), methylethyl)pyrimidin-2- 3.68 (br s, 2H), 3.59 (s, 2H), yl}methyl)ethanamine 2.47 (s, 3H), 1.91 (s, 3H), 1.32 (d, 6H), 0.89 (t, 6H) {4-methyl-6-[7-(2-methyl-1H- 1H NMR (400 MHz, DMSO-d6 MS (EI) for benzimidazol-5-yl)-2,3-dihydro- plus D2O) δ 7.70 (s, 1H), 7.56 (m, C28H31N5O3: 1,4-benzoxazepin-4(5H)-yl]-5- 3H), 7.38 (m, 1H), 7.06 (d, 1H), 486.3 (MH+) (1-methylethyl)pyrimidin-2- 4.96 (s, 2H), 4.43 (s, 2H), 4.30 (br yl}methyl acetate s, 2H), 3.68 (br s, 2H), 3.31-3.20 (m, 1H), 2.46 (s, 3H), 2.08 (s, 3H), 1.32 (d, 6H) {4-methyl-6-[7-(2-methyl-1H- 1H NMR (400 MHz, DMSO-d6 MS (EI) for benzimidazol-5-yl)-2,3-dihydro- plus D2O) δ 7.59 (m, 1H), C26H29N5O2: 1,4-benzoxazepin-4(5H)-yl]-5- 7.54-7.45 (m, 3H), 7.36 (d, 1H), 444.3 (MH+) (1-methylethyl)pyrimidin-2- 7.01 (d, 1H), 4.80 (br t, 0.2H), 4.43 (s, yl}methanol 2H), 4.32 (s, 2H), 4.26 (br s, 2H), 3.66 (br s, 2H), 3.25 (m, 1H), 2.47 (s, 3H), 2.45 (s, 3H), 1.87 (s, 1H- OAc peak), 1.29 (d, 6H) 6-(4-{2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(dimethylamino)methyl]-5- 8.37 (d, 1H), 7.87 (s, 2H), 7.81 (d, C25H29N7OS: ethyl-6-methylpyrimidin-4-yl}- 1H), 7.68 (d, 1H), 7.53 (dd, 1H), 476.2 (MH+) 2,3,4,5-tetrahydro-1,4- 7.01 (d, 1H), 4.63 (s, 2H), 4.33 (br benzoxazepin-7- t, 2H), 3.81 (br t, 2H), 2.62 (q, yl)[1,3]thiazolo[5,4-b]pyridin- 2H), 2.35 (s, 3H), 2.10 (s, 6H), 2-amine 1.88 (s, 2H-OAc peak), 1.13 (t, 3H) N,N-dimethyl-1-{4-methyl-6- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [7-(2-methyl-1H-benzimidazol- 12.25 (s, 1H), 7.67 (m, 2H), C28H34N6O2: 6-yl)-2,3-dihydro-1,4- 7.47 (dd, 2H), 7.39 (br d, 1H), 7.01 (d, 487.3 (MH+) benzoxazepin-4(5H)-yl]-5-[2- 1H), 4.60 (s, 2H), 4.29 (br t, 2H), (methyloxy)ethyl]pyrimidin-2- 3.79 (br t, 2H), 3.53 (t, 2H), yl}methanamine 3.18 (s, 3H), 3.17 (s, 1H), 2.92 (t, 2H), 2.39 (s, 3H), 2.13 (s, 6H) 6-(4-{2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(dimethylamino)methyl]-6- 8.36 (d, 1H), 7.89 (br s, 2H), C26H31N7O2S: methyl-5-[2- 7.82 (d, 1H), 7.68 (d, 1H), 7.52 (dd, 506.3 (MH+) (methyloxy)ethyl]pyrimidin-4- 1H), 7.00 (d, 1H), 4.59 (s, 2H), yl}-2,3,4,5-tetrahydro-1,4- 4.29 (br t, 2H), 3.78 (br t, 2H), benzoxazepin-7- 3.49 (t, 2H), 3.18 (s, 3H), 2.85 (t, yl)[1,3]thiazolo[5,4-b]pyridin- 2H), 2.35 (s, 3H), 2.09 (s, 6H), 2-amine 1.87 (s, 2H-OAc peak) 6-(4-{2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for [(dimethylamino)methyl]-5,6- 8.37 (d, 1H), 7.87 (s, 2H), 7.82 (d, C24H27N7OS: dimethylpyrimidin-4-yl}- 1H), 7.70 (d, 1H), 7.52 (dd, 1H), 462.2 (MH+) 2,3,4,5-tetrahydro-1,4- 7.02 (d, 1H), 4.63 (s, 2H), 4.30 (br benzoxazepin-7- t, 2H), 3.82 (br t, 2H), 3.33 (s, yl)[1,3]thiazolo[5,4-b]pyridin- 2H), 2.30 (s, 3H), 2.16 (s, 3H), 2-amine 2.10 (s, 6H), 1.90 (s, 3H-OAc peak) 1-{4,5-dimethyl-6-[7-(2- 1H NMR (400 MHz, DMSO-d6) δ MS (EI) for methyl-1H-benzimidazol-6-yl)- 7.61 (m, 2H), 7.53-7.43 (m, 2H), C26H30N6O: 2,3-dihydro-1,4-benzoxazepin- 7.36 (d, 1H), 7.00 (d, 1H), 4.61 (s, 443.3 (MH+) 4(5H)-yl]pyrimidin-2-yl}-N,N- 2H), 4.29 (br t, 2H), 3.82 (br t, dimethylmethanamine 2H), 3.39 (s, 2H), 2.31 (s, 3H), 2.17 (s, 3H), 2.16 (s, 6H), 1.91 (s, 3H-OAc Peak) {4-[7-(2- 1H NMR (400 MHz, d6-DMSO) δ MS (ES) for amino[1,3]thiazolo[5,4- 8.39 (d, 1H), 7.88 (d, 1H), 7.85 (s, C27H27N7OS: b]pyridin-6-yl)-2,3-dihydro-1,4- 2H), 7.75 (s, 1H), 7.56 (d, 1H), 498.2 (MH+) benzoxazepin-4(5H)-yl]-6,6- 7.05 (d, 1H), 4.70 (s, 2H), dimethyl-5,6,7,8- 4.34 (m, 2H), 4.06 (s, 2H), 3.91 (m, tetrahydroquinazolin-2- 2H), 2.70 (t, 2H), 2.46 (s, 2H), yl}acetonitrile 1.59 (t, 2H), 0.85 (s, 6H)

Biological Examples

Compounds of the Invention have activity for PI3K-alpha, mTOR, or for both. Compounds of this invention have been tested using the assays described in Biological Examples 1 and 3 and have been determined to be inhibitors of PI3K-alpha, mTOR, or for both.

Suitable in vitro assays for measuring PI3K, mTORc1, and mTORc2 activity and the inhibition thereof by compounds are known in the art. Biological Examples, Example 1, 2, and 3 describe in vitro assay for measuring PI3K and mTOR activity. Cell-based assays for measurement of in vitro efficacy in treatment of cancer are known in the art. Biological Examples, Example 5 and 6 describe assays to measure in vitro cell activity. Suitable in vivo models for cancer are known to those of ordinary skill in the art. Biological Examples 7, 8, 9, 10, 11, 12, and 13 describe in vivo models for prostate adenocarcinoma, glioblastoma, lung carcinoma, and melanoma. Following the examples disclosed herein, as well as that disclosed in the art, a person of ordinary skill in the art can determine the PI3K-inhibitory and/or mTOR-inhibitory activity of a Compound of this invention.

Thus, compounds of Formula I are useful for treating diseases, particularly cancer in which activity against PI3K-alpha, mTOR, or both contributes to the pathology and/or symptomatology of the disease. For example, cancer in which activity against PI3K-alpha, mTOR, or both contributes to its pathology and/or symptomatology include breast cancer, mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK-transformed anaplastic large cell lymphoma, diffuse large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervical cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, colon cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreatic cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangioma, glioblastoma, or head and neck cancer.

Biological Example 1 mTOR/GbL/Raptor (mTORC1) ELISA Assay

The measurement of mTORC1 enzyme activity was performed in an ELISA assay format following the phosphorylation of 4E-BP1 protein. All experiments were performed in the 384-well format. Generally, 0.5 μL DMSO containing varying concentrations of the test Compound was mixed with 15 μL enzyme solution. Kinase reactions were initiated with the addition of 15 μL of substrates-containing solution. The assay conditions were as follows; 0.2 nM mTORC1, 10 μM ATP and 50 nM NHis-tagged 4E-BP1 in 20 mM Hepes, pH 7.2, 1 mM DTT, 50 mM NaCl, 10 mM MnCl2, 0.02 mg/mL BSA, 0.01% CHAPS, 50 mM β-glycerophosphate. Following an incubation of 120 minutes at ambient temperature, 20 μL of the reaction volume was transferred to a Ni-Chelate-coated 384-well plate. The binding step of the 4E-BP1 protein proceeded for 60 minutes, followed by washing 4 times each with 50 μL of Tris-buffered saline solution (TBS). Anti-phospho-4E-BP1 rabbit-IgG (20 μL, 1:5000) in 5% BSA-TBST (0.2% Tween-20 in TBS) was added and further incubated for 60 minutes. Incubation with a secondary HRP-tagged anti-IgG was similarly performed after washing off the primary antibody (4 washes of 50 μL). Following the final wash step with TBST, 20 μL of SuperSignal ELISA Femto (Pierce Biotechnology) was added and the luminescence measured using an EnVision plate reader.

As numbered in Table 1, Compounds 12, 13, 55, 65, 66, 70, 72-74, 78-80, 83, 89, 93, 94, 97, 102, 103, 124, 131, 142, 147, 148, 153, 170, 171, 174-178, 181, 183, 189, 192, 193, 213, 215, 217-221, 224-225, 229, 234, 236, 238, 248, 250, 252, 254, 255, 264-265, 290, 304, 308, 310-313, 321, 325, 339, 347-348, 352-354, 369, 371, 373, 375, 387, 397, 399, 401-402, 405-406, 409, 436, 439-440, 443, 447-450, 452, 474, 478-479, 483-484, 486, 488-491, 495, 500-502, 506-508, 514, 520, 537, 544-545, 548, 550, 552-555, 558, 564, 582-584, 586, 589, 590, 592-593, 596-601, 605, 607, 651, 660, 668-669, 676, 680, 684, 687, 689-690, and 692 have an IC50 in this assay of less than or equal to 10 nM. As numbered in Table 1, Compounds 9, 11, 15, 16, 17, 21, 30, 37, 38, 68, 81, 82, 84, 86, 90-91, 95, 101, 113, 140-141, 143-146, 156, 158, 179-180, 182, 185-187, 194, 216, 226, 251, 256, 289, 291, 299-301, 305, 314-316, 318, -320, 322, 334, 351, 358, 360, 363-368, 370, 372, 376, 380, 382, 388-391, 396, 403, 407, 408, 411, 412, 414, 415, 418, 425, 426, 430-432, 434, 435, 437, 441, 442, 444-446, 451, 460, 462, 464, 465, 473, 482, 485, 487, 487, 492-494, 497, 503, 505, 510, 512, 517, 519, 526, 530, 540, 547, 556, 559, 566, 575-578, 585, 587-588, 591, 594-595, 602, 604, 606, 608, 614, 617, 619, 623, 626, 628, 636, 642, 665, 670, 674, 679, 682-683, and 686 have an IC50 in this assay of greater than 10 nM but less than or equal to 50 nM. As numbered in Table 1, Compounds 1, 3, 8, 14, 19, 20, 22, 24-26, 28, 29, 32, 34-36, 39, 40, 43, 49, 58-61, 63, 64, 69, 76, 85, 98, 99, 105, 123, 149-151, 154, 159, 172, 188, 207, 208, 227, 228, 230, 233, 235, 239, 243, 244-246, 249, 253, 259, 260, 263, 268, 272, 275, 278, 281, 282, 283, 285, 287, 292, 295, 297, 298, 309, 317, 331-332, 336, 340, 346, 350, 355, 356, 362, 374, 377-379, 383-385, 392-395, 398, 400, 410, 413, 416-417, 422-424, 427, 438, 453, 455, 457-459, 461, 463, 466, 468, 469-472, 481, 498-499, 509, 511, 513, 515-516, 518, 523, 536, 538-539, 542, 546, 560, 565, 567-571, 580, 603, 612, 616-617, 620, 625, 627, 633, 641, 650, 654, 657, 662-663, 667, 675, 681, and 685 have an IC50 in this assay of greater than 50 nM but less than or equal to 250 nM. As numbered in Table 1, Compounds 4, 5, 10, 18, 23, 27, 31, 33, 41, 42, 45, 46, 50, 51, 53-54, 56, 62, 67, 75, 87, 92, 96, 100, 108-109, 112, 114, 126-127, 129, 130, 152, 155, 157, 160, 162, 164, 166, 168-169, 173, 184, 190-191, 199, 202, 210, 212, 214, 222, 237, 241, 247, 257, 258, 261, 266-267, 269-271, 273, 276, 279, 280, 284, 302-303, 306-307, 323-324, 326-327, 330, 337, 341-342, 344-345, 349, 357, 359, 381, 386, 419-421, 429, 454, 476-477, 480, 496, 504, 521-522, 525, 527, 529, 531-532, 535, 551, 557, 561-563, 573, 579, 610-611, 613, 618, 621-622, 624, 629, 632, 634-635, 637, 639-640, 643, 647-649, 652-653, 655-656, 659, 661, 664, 671, 673, 678, and 688 have an IC50 in this assay of greater than 250 nM but less than or equal to 1000 nM. As numbered in Table 1, Compounds 6, 7, 44, 48, 52, 71, 77, 88, 106, 111, 116, 133, 135-137, 161, 195, 197, 200-201, 203, 205-206, 211, 231, 277, 335, 343, 524, 534, 543, 574, 581, and 691 have an IC50 in this assay of greater than 1000 nM but less than 2000 nM. As numbered in Table 1, Compounds 2, 47, 57, 104, 107, 110, 115, 117-122, 128, 132, 134, 138, 163, 165, 167, 196, 198, 204, 209, 223, 232, 240, 242, 262, 274, 286, 288, 293-294, 296, 328-329, 333, 338, 361, 428, 433, 456, 475, 533, 541, 572, 609, 630, 631, 638, 644-646, 658, 666, 672, and 677 have an IC50 in this assay of greater than or equal to 2,000 nM or are not active under the conditions the assay was run.

Biological Example 2 Immune-Complex mTORC2 Kinase (mTORC2 IP-Kinase) Assay

HeLa (ATCC) cells are grown in suspension culture and lysed in ice-cold lysis buffer containing 40 mM HEPES pH 7.5, 120 mM NaCl, 1 mM EDTA, 10 mM sodium pyrophosphate, 10 mM β-glycerophosphate, 10 mM NaF, 10 mM NaN3, one tablet of protease inhibitors (Complete-Mini, EDTA-free, Roche), 0.3% cholamidopropyldimethylammoniopropanesulfonate (CHAPS), 1 mM AEBSF, 0.5 mM benzamidine HCl, 20 μg/mL heparin, and 1.5 mM Na3VO4. The mTORC2 complex is immunoprecipitated with anti-RICTOR antibody for 2 h. The immune complexes are immobilized on Protein A sepharose (GE Healthcare, 17-5280-01), washed sequentially 3 times with wash buffer (40 mM HEPES pH 7.5, 120 mM NaCl, 10 mM β-glycerophosphate, 0.3% CHAPS, 1 mM AEBSF, 20 μg/mL heparin, 1.5 mM Na3VO4, and Complete-Mini, EDTA-free) and resuspended in kinase buffer (40 mM HEPES, pH 7.5, 120 mM NaCl, 0.3% CHAPS, 20 μg/mL heparin, 4 mM MgCl2, 4 mM MnCl2, 10% Glycerol, and 10 mM DTT). The immune complexes (equivalent to 1×107 cells) are pre-incubated at 37° C. with a test Compound or 0.6% DMSO for 5 min, and then subjected to a kinase reaction for 8 min in a final volume of 33 μL (including 5 μL bed volume) containing kinase buffer, 50 μM ATP, and 0.75 μg full length dephosphorylated AKT1. Kinase reactions are terminated by addition of 11 μL 4×SDS sample buffer containing 20% β-mercaptoethanol and resolved in a 10% Tris Glycine gels. The gels are transferred onto PVDF membrane at 50 V for 20 h at 4° C. The membranes are blocked in 5% non-fat milk in TBST for 1 h and incubated overnight at 4° C. with 1/1000 dilution of rabbit anti-pAKT (S473) (Cell Signaling Technology, 4060) in 3% BSA/TBST. The membranes are washed 3 times in TBST and incubated for 1 h with a 1/10000 dilution of secondary goat anti-rabbit HRP antibody (Cell Signaling Technology, 2125) in 5% non-fat milk/TBST. The signal is detected using Amersham ECL-plus. The scanned data are analyzed using ImageQuant software. IC50 for the test Compound is determined relative to DMSO treated sample using XLfit4 software.

Biological Example 3 PI3K Biochemical Assays

PI3Kα activity is measured as the percent of ATP consumed following the kinase reaction using luciferase-luciferin-coupled chemiluminescence. Reactions were conducted in 384-well white, medium binding microtiter plates (Greiner). Kinase reactions were initiated by combining test compounds, ATP, substrate (PIP2), and kinase in a 20 μL volume in a buffer solution. The standard PI3Kalpha assay buffer is composed 50 mM Tris, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 1 mM DTT and 0.03% CHAPS. The standard assay concentrations for enzyme, ATP, and substrate are 1.5 nM, 1 μM, and 10 μM, respectively. The reaction mixture was incubated at ambient temperature for approximately 2 h. Following the kinase reaction, a 10 μL aliquot of luciferase-luciferin mix (Promega Kinase-Glo) was added and the chemiluminescence signal measured using a Victor2 plate reader (Perkin Elmer). Total ATP consumption was limited to 40-60% and IC50 values of control compounds correlate well with literature references. Substituting PI3Kα with PI3Kβ, PI3Kγ, or PI3Kδ, the inhibitory activity of the compounds for the other isoforms of I3K were measured.

As numbered in Table 1, Compounds 9, 94, 103, 113, 119, 124, 131, 175-183, 185-188, 192, 208, 217-218, 237, 241, 246-247, 250, 256, 264, 268, 279-282, 285, 289-292, 295, 301, 303, 308, 310, 315, 319, 321-322, 325, 332, 334, 339, 346-348, 350-355, 364, 366, 368, 370-371, 375, 397, 399, 412, 414, 441, 454, 462, 487-488, 499-501, 506, 526, 527, 537, 539-540, 542, 565, 568, 577-580, 582-583, 586, 589, 596, 600-601, 605-608, 613-616, 623, 628, 641-643, 651, 654, 657-664, 670, 671, 674, 680, and 689-692 have an IC50 for PI3Kα in this assay of less than or equal to 10 nM. As numbered in Table 1, Compounds 1, 3, 4, 13-15, 18, 19, 21, 26, 30, 37-39, 55, 63, 65, 68, 70, 72-74, 79-81, 83, 89-91, 93, 97-98, 101-102, 108-109, 111-112, 123, 125-126, 142, 145-147, 157, 160, 164, 168, 170-171, 184, 189, 190-191, 193, 194, 199, 207, 210, 213, 215, 220-221, 224, 227-228, 234-235, 238, 248, 251, 255, 258-261, 263, 265, 271, 278, 283, 287, 293, 299-300, 302, 304-305, 309, 311-314, 316, 318, 320, 323, 331, 333, 335, 340-341, 343, 344-345, 349, 356, 359-360, 369, 372-373, 377-378, 380-381, 387-388, 390-392, 396, 401-402, 405, 407-409, 413, 415-416, 424, 426-427, 430-432, 434, 436-437, 439-440, 442-443, 445-446, 447, 449-452, 459-461, 463-464, 474, 478-479, 482-483, 489-492, 495, 497-498, 502, 505, 507-508, 510, 512, 519-520, 525, 530-531, 545, 546-548, 550, 552-556, 558, 560, 564, 567, 575, 584-585, 587-588, 590, 592-595, 597-598, 599, 602-603, 610, 612, 617-619, 633, 636-637, 639-640, 649, 652-653, 656, 667-669, 672-673, 675-676, 678-679, 682-685, and 687 have an IC50 for PI3Kα in this assay of greater than 10 nM but less than or equal to 50 nM. As numbered in Table 1, Compounds 5, 8, 11, 12, 16, 17, 20, 22, 23, 25, 27, 29, 36, 40, 42, 43, 46, 48, 51, 56-58, 62, 64, 66, 69, 76-78, 82, 84, 86, 92, 95, 99-100, 105, 120-122, 132, 140-141, 144, 148, 153, 156, 158-159, 166, 174, 197, 214, 216, 219, 225-226, 229-230, 233, 236, 239, 242, 245, 249, 252, 254, 257, 267, 269, 270, 272-273, 275, 286, 297-298, 317, 327, 330, 342, 358, 361-363, 365, 367, 374, 376, 382-386, 389, 393-395, 398, 400, 403, 406, 410-411, 417-423, 425, 429, 435, 438, 444, 448, 453, 455, 458, 465-466, 468-470, 473, 480-481, 485-486, 493-494, 496, 503, 509, 511, 513-518, 521-522, 529, 532, 534, 538, 544, 551, 559, 563, 566, 570-571, 576, 591, 604, 620, 625, 626-627, 632, 634, 648, 665-666, 677, 681, and 686 have an IC50 for PI3Kα in this assay of greater than 50 nM but less than or equal to 250 nM. As numbered in Table 1, Compounds 2, 10, 24, 28, 31-33, 44, 45, 47, 49, 50, 54, 59-61, 96, 107, 110, 116-117, 129, 137-138, 143, 149-152, 154-155, 161, 162-163, 165, 167, 169, 172, 195-196, 209, 211, 222, 240, 243-244, 253, 266, 274, 276-277, 284, 296, 306-307, 324, 336-338, 357, 379, 428, 456-457, 471-472, 476-477, 504, 523-524, 533, 536, 541, 543, 569, 573-574, 609, 621, 624, 635, 650, and 655 have an IC50 for PI3Kα in this assay of greater than 250 nM but less than or equal to 1000 nM. As numbered in Table 1, Compounds 41, 67, 71, 75, 85, 106, 115, 118, 130, 139, 204-205, 232, 288, 294, 326, 328-329, 433, 535, 561-562, 572, 611, 622, 645, 646, and 688 have an IC50 for PI3Kα in this assay of greater than 1000 nM but less than 2000 nM. As numbered in Table 1, Compounds 6, 7, 52-53, 87-88, 104, 127-128, 133-135, 173, 198, 200-203, 206, 212, 223, 231, 262, 475, 557, 581, 629-631, 638, 644, and 647 have an IC50 for PI3Kα in this assay of greater than or equal to 2,000 nM or are not active under the conditions the assay was run.

Biological Example 5 pS6 (S240/244) ELISA Assay

MCF-7 cells (ATCC) cells were seeded at 24000 cells per well in 96-well plates (Corning, 3904) in DMEM (Cellgro) containing 10% FBS (Cellgro), 1% NEAA (Cellgro) and 1% penicillin-streptomycin (Cellgro). Cells were incubated at 37° C., 5% CO2 for 48 h, and the growth medium was replaced with serum-free DMEM or in medium containing 0.4% BSA. Serial dilutions of the test Compound in 0.3% DMSO (vehicle) were added to the cells and incubated for 3 h. To fix the cells, medium was removed and 100 μL/well of 4% formaldehyde (Sigma Aldrich, F8775) in TBS (20 mM Tris, 500 mM NaCl) was added to each well at RT for 30 min. Cells were washed 4 times with 200 μL TBS containing 0.1% Triton X-100 (Sigma, catalog #T9284). Plates were blocked with 100 μL Odyssey blocking buffer (Li-Cor Biosciences, 927-40000) for 1 h at RT. Anti-pS6 (S240/244) antibody (Cell Signaling Technology, 2215) and anti-total-S6 antibody (R&D systems, MAB5436) were diluted 1:400 in Odyssey blocking buffer, and 50 μL of the antibody solution containing both antibodies was added to one plate to detect pS6 and total S6. After incubation overnight at 4° C., plates were washed 4 times with 200 μL TBS containing 0.1% Tween20 (Bio-Rad, catalog #170-6351) (TBST). Goat anti-rabbit and Goat anti-mouse secondary antibody (Li-Cor Biosciences, catalog #926-32221 and 926-32210) conjugated to IRDye were diluted 1:400 in Odyssey blocking buffer containing 0.1% Tween20. 50 μL of antibody solution containing both antibodies was added to each well and incubated for 1 h at RT. Plates were washed 3 times with 200 μL TBST and 2 times with 200 μL TBS. Fluorescence was read on an Odyssey plate reader. IC50 values were determined based on the ratio of pS6 to total S6 signal for Compound treated wells, normalized to the DMSO-treated control wells.

In one embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 1.5 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 1.0 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 0.5 μM or less. In one embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 0.3 μM or less. In one embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 0.1 μM or less. In one embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of 0.03 μM or less.

In one embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 1.7 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 0.55 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 0.55 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 0.3 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 0.1 μM or less. In another embodiment, the Compound of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 0.05 μM or less.

Biological Example 6 pAKT (T308) ELISA Assay

MCF-7 cells (ATCC) cells were seeded at 24000 cells per well in 96-well plates (Corning, 3904) in DMEM (Cellgro) containing 10% FBS (Cellgro), 1% NEAA (Cellgro) and 1% penicillin-streptomycin (Cellgro). Cells were incubated at 37° C., 5% CO2 for 48 h, and the growth medium was replaced with serum-free DMEM or in medium containing 0.4% BSA. Serial dilutions of the test Compound in 0.3% DMSO (vehicle) were added to the cells and incubated for 3 h. At the end of the incubation period, cells were stimulated for 10 minutes by the addition of L-IGF (Sigma, I-1271) at a final concentration of 100 ng/ml. Afterwards, media was discarded from cell plates and 110 W/well of cold lysis buffer (see table below) were added. Cell plates were incubated on ice and then put on shaker in 4° C. cold room for 1 h. Two capture plates (Thermo Scientific, Reacti-bind plate, 15042) were prepared for each cell plate by pre-coating with capture Akt antibody from the two sandwich ELISA antibody pairs used (Cell Signaling Technology 7142 and 7144). The Akt capture antibodies were diluted 1:100 in PBS and 100 μl of diluted capture antibody was added per well. Capture plates were incubated at 4 C overnight. Prior to use, capture plates were washed 3 times in TBS containing 0.1% Tween20 (Bio-Rad, 170-6351) (TBST) and blocked in blocking buffer (Thermo Scientific, Starting Block T20, 37543) for 1-2 h at room temperature. After 1 h of cell lysis, 85 μl of cell lysate/well was transferred to the capture plate for detection of pAkt(T308). 15 μl of cell lysate was transferred from same well to the second capture plate for detection of total Akt1. After incubation overnight at 4° C., plates were washed 3 times with 200 μL TBST. Primary antibodies, diluted 1:100 in blocking buffer, were added to the corresponding capture plates for pAkt(T308) (Cell Signaling Technology, 7144) and total Akt1 (Cell Signaling Technology, 7142) detection and incubated at room temperature for 1 h. Plates were washed 3 times with 200 μL of TBST. Goat anti-mouse secondary antibody (Cell Signaling Technology, 7076) conjugated to HRP was diluted 1:1000 in blocking buffer and 100 μl were added to each well and incubated for 30 minutes at room temperature. Plates were then washed 3 times with 200 μL of TBST. 100 μL of SuperSignal ELISA Femto stable peroxidase solution (Thermo Scientific, 37075) was added to each well. After 1 minute incubation, chemiluminescence was read on a Wallac Victor2 1420 multilabel counter. IC50 values were determined based on the ratio of pAkt(T308) to total Akt1 signal for Compound treated wells, normalized to the DMSO-treated control wells.

Stock Final /10 mL Water 6 mL Complete Protease 1 mini-tablet Inhibitors (Roche 1 836 170) 5x RIPA  5x 1x 2 mL NaF 200 mM 1 mM 50 μL B-glycerophosphate 100 mM 20 mM  1.8 mL Phosphatase Inhibitor I 100x 1x 100 μL (Sigma P2850) Na orthovanadate 200 mM 1 mM 50 μL EDTA, pH 8 500 mM 1 mM 20 μL

In one embodiment, the Compounds of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 2.0 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 1.0 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 0.3 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in PC-3 cells had an inhibitory activity of about 0.2 μM or less.

In one embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of about 3.0 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of about 3.0 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of about 1.5 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of about 0.75 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of about 0.5 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of about 0.25 μM or less. In another embodiment, the Compounds of the Invention tested in this assay in MCF-7 cells had an inhibitory activity of about 0.1 μM or less.

Biological Example 7-13 Pharmacodynamic Xenograft Tumor Models

Female and male athymic nude mice (NCr) 5-8 weeks of age and weighing approximately 20-25 g are used in the following models. Prior to initiation of a study, the animals are allowed to acclimate for a minimum of 48 h. During these studies, animals are provided food and water ad libitum and housed in a room conditioned at 70-75° F. and 60% relative humidity. A 12 h light and 12 h dark cycle is maintained with automatic timers. All animals are examined daily for compound-induced or tumor-related deaths.

MCF-7 Breast Adenocarcinoma Model

MCF7 human mammary adenocarcinoma cells are cultured in vitro in DMEM (Cellgro) supplemented with 10% Fetal Bovine Serum (Cellgro), Penicillin-Streptomycin and non-essential amino acids at 37° C. in a humidified 5% CO2 atmosphere. On day 0, cells are harvested by trypsinization, and 5×106 cells in 100 μL of a solution made of 50% cold Hanks balanced salt solution with 50% growth factor reduced matrigel (Becton Dickinson) implanted subcutaneously into the hindflank of female nude mice. A transponder is implanted into each mouse for identification and data tracking, and animals are monitored daily for clinical symptoms and survival.

Tumors are established in female athymic nude mice and staged when the average tumor weight reached 100-200 mg. A Compound of the Invention is orally administered as a solution/fine suspension in water (with 1:1 molar ratio of 1 NHCL) once-daily (qd) or twice-daily (bid) at 10, 25, 50 and 100 mg/kg for 14 days. During the dosing period of 14-19 days, tumor weights are determined twice-weekly and body weights are recorded daily.

Colo-205 Colon Model

Colo-205 human colorectal carcinoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37° C. in a humidified, 5% CO2 atmosphere. On day 0, cells are harvested by trypsinization, and 3×106 cells (passage 10-15, >95% viability) in 0.1 mL ice-cold Hank's balanced salt solution are implanted intradermally in the hind-flank of 5-8 week old female athymic nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival.

Tumors are established in female athymic nude mice and staged when the average tumor weight reached 100-200 mg. A Compound of the Invention is orally administered as a solution/fine suspension in water (with 1:1 molar ratio of 1 NHCL) once-daily (qd) or twice-daily (bid) at 10, 25, 50 and 100 mg/kg for 14 days. During the dosing period of 14 days, tumor weights are determined twice-weekly and body weights are recorded daily.

PC-3 Prostate Adenocarcinoma Model

PC-3 human prostate adenocarcinoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 20% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37° C. in a humidified 5% CO2 atmosphere. On day 0, cells are harvested by trypsinization and 3×106 cells (passage 10-14, >95% viability) in 0.1 mL of ice-cold Hank's balanced salt solution are implanted subcutaneously into the hindflank of 5-8 week old male nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival.

Tumors are established in male athymic nude mice and staged when the average tumor weight reached 100-200 mg. A Compound of the Invention is orally administered as a solution/fine suspension in water (with 1:1 molar ratio of 1 N HCl) once-daily (qd) or twice-daily (bid) at 10, 25, 50, or 100-mg/kg for 19 days. During the dosing period of 14-19 days, tumor weights are determined twice-weekly and body weights are recorded daily.

U-87 MG Human Glioblastoma Model

U-87 MG human glioblastoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37° C. in a humidified 5% CO2 atmosphere. On day 0, cells are harvested by trypsinization and 2×106 cells (passage 5, 96% viability) in 0.1 mL of ice-cold Hank's balanced salt solution are implanted intradermally into the hindflank of 5-8 week old female nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. Body weights are recorded daily.

A549 Human Lung Carcinoma Model

A549 human lung carcinoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37° C. in a humidified 5% CO2 atmosphere. On day 0, cells are harvested by trypsinization and 10×106 cells (passage 12, 99% viability) in 0.1 mL of ice-cold Hank's balanced salt solution are implanted intradermally into the hindflank of 5-8 week old female nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. Body weights are recorded daily.

A2058 Human Melanoma Model

A2058 human melanoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37° C. in a humidified, 5% CO2 atmosphere. On day 0, cells are harvested by trypsinization and 3×106 cells (passage 3, 95% viability) in 0.1 mL ice-cold Hank's balanced salt solution are implanted intradermally in the hind-flank of 5-8 week old female athymic nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. Body weights are recorded daily.

WM-266-4 Human Melanoma Model

WM-266-4 human melanoma cells are cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37° C. in a humidified, 5% CO2 atmosphere. On day 0, cells are harvested by trypsinization and 3×106 cells (passage 5, 99% viability) in 0.1 mL ice-cold Hank's balanced salt solution are implanted intradermally in the hind-flank of 5-8 week old female athymic nude mice. A transponder is implanted in each mouse for identification, and animals are monitored daily for clinical symptoms and survival. Body weights are recorded daily.

Tumor weight (TW) in the above models is determined by measuring perpendicular diameters with a caliper, using the following formula:
tumor weight (mg)=[tumor volume=length (mm)×width2 (mm2)]/2
These data were recorded and plotted on a tumor weight vs. days post-implantation line graph and presented graphically as an indication of tumor growth rates. Percent inhibition of tumor growth (TGI) is determined with the following formula:

[ 1 - ( ( X f - X 0 ) ( Y f - X 0 ) ) ] * 100

where X0=average TW of all tumors on group day

Xf=TW of treated group on Day f

Yf=TW of vehicle control group on Day f

If tumors regress below their starting sizes, then the percent tumor regression is determined with the following formula:

( X 0 - X f X 0 ) * 100
Tumor size is calculated individually for each tumor to obtain a mean±SEM value for each experimental group. Statistical significance is determined using the 2-tailed Student's t-test (significance defined as P<0.05).

The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. The invention has been described with reference to various specific embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled. All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

Claims

1. The compound according to formula I(a)

or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof, where
R1 is phenyl optionally substituted with one, two, or three R6 groups; or
R1 is heteroaryl optionally substituted with one, two, or three R7;
R2 is heteroaryl substituted with R3, R3a, R3b, R3c, and R3d;
R3, R3a, R3b, R3c, and R3d are independently hydrogen; cyano; alkyl; alkenyl; halo; haloalkyl; hydroxyalkyl; alkoxyalkyl; cyanoalkyl; —SR12; —S(O)2R20; alkoxycarbonyl; halocarbonyl; —NR11R11a; —OR11a; phenyl optionally substituted with one or two groups which are independently alkyl or halo; phenylalkyl optionally substituted with one or two R19; cycloalkylalkyl; heterocycloalkyl optionally substituted with one or two groups which are independently alkyl or alkoxycarbonyl; heterocycloalkylalkyl optionally substituted with one or two groups which are independently alkyl or alkoxycarbonyl; heteroaryl; heteroarylalkyl; or alkyl substituted with one or two R16; or
two of R3, R3a, R3b, R3c, and R3d, when attached to the same carbon, form a cycloalkyl or a heterocycoalkyl; and the other of R3, R3a, R3b, R3c, and R3d are hydrogen;
each R6, when R6 is present, is independently nitro; cyano; halo; alkyl; haloalkyl; —OR8a; —NR8R8a; —C(O)NR8R8a; —S(O)2R8; —NR8C(O)R9; —NR8S(O)2R8a; —NHC(O)NHR9; carboxy, —C(O)OR9; or heteroaryl optionally substituted with 1, 2, or 3 R14;
each R7, when R7 is present, is independently oxo; nitro; cyano; alkyl; alkenyl; halo; haloalkyl; hydroxyalkyl; alkoxyalkyl; —OR8a; —SR13; —S(O)R13; —S(O)2R13a; —NR8R8a; —C(O)NR8R8a; —NR8C(O)OR9; —NR8C(O)R9; —NR8S(O)2R8a; —NR8C(O)NR8aR9; —C(O)OR9; halocarbonyl; —S(O)2NR8R9; alkylsulfonylalkyl; alkyl substituted with one or two —NR8R8a; alkyl substituted with one or two —NR8C(O)R8a; alkyl substituted with one or two —NR8C(O)OR9; alkyl substituted with one or two —S(O)2R13a; cycloalkyl; cycloalkylalkyl; heterocycloalkyl optionally substituted with one or two groups which are independently alkyl or amino; phenyl; phenylalkyl; heterocycloalkylalkyl; heteroaryl; or heteroarylalkyl;
R8, R11, R15, R17, and R18 are independently hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, or haloalkyl;
R8a; R11a; and R15a are independently hydrogen; alkyl; alkenyl; alkynyl; haloalkyl; hydroxyalkyl; cyanoalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; alkoxyalkyl; carboxyalkyl; cycloalkyl; cycloalkylalkyl; heterocycloalkyl optionally substituted with one or two groups which are independently alkyl or alkoxycarbonyl; heterocycloalkylalkyl optionally substituted with one or two groups which are independently alkyl or alkoxycarbonyl; phenyl optionally substituted with one or two groups which are independently halo, alkyl, or alkoxy; phenylalkyl; heteroaryl; or heteroarylalkyl;
R9 is hydrogen; alkyl; alkenyl; alkynyl; hydroxyalkyl; alkoxyalkyl; aminoalkyl; alkylaminoalkyl; dialkylaminoalkyl; haloalkyl; hydroxyalkyl substituted with one, two, or three groups which are independently halo, amino, alkylamino, or dialkylamino; alkyl substituted with one or two aminocarbonyl; phenyl; phenylalkyl; cycloalkyl; cycloalkylalkyl optionally substituted with one or two groups which are independently amino or alkyl; heterocycloalkyl optionally substituted with one or two groups which are independently alkyl or alkoxycarbonyl; or heterocycloalkylalkyl optionally substituted with one or two groups which are independently alkyl or alkoxycarbonyl;
R12 is alkyl or phenylalkyl;
R13 is alkyl, hydroxyalkyl, or haloalkyl; and
R13a is hydroxy, alkyl, haloalkyl, hydroxyalkyl, or heterocycloalkyl optionally substituted with one or two groups which are independently halo, amino, alkylamino, dialkylamino, hydroxy, alkyl, or hydroxyalkyl;
each R14, when R14 is present, is independently amino, alkylamino, dialkylamino, acylamino, halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, or phenyl;
each R16 is independenity —NR11R11a, —NR15S(O)R15a, —OC(O)R17, or —OR18;
each R19 is independently halo, alkyl, haloalkyl, amino, alkylamino, dialkylamino, or alkoxy; and
R20 is amino, alkylamino, dialkylamino, or heterocycloalkyl.

2. The compound of claim 1 where R1 is phenyl optionally substituted with one, two, or three R6 groups; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 where R1 is phenyl substituted with one or two R6 groups independently nitro, halo, alkoxy, —OR8a, —S(O)2R8; —NR8R8a, —NR8S(O)2R8a, —NR8C(O)R9, —C(O)NR8R8a, —NHC(O)NHR9, carboxy, alkoxycarbonyl, or heteroaryl optionally substituted with one or two R14; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

4. The compound of claim 3 where R1 is phenyl substituted with one R6 where R6 is —S(O)2R8, —C(O)NR8R8a or heteroaryl optionally substituted with one or two R14; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 where R1 is heteroaryl optionally substituted with one, two, or three R7; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

6. The compound of claim 5 where R1 is a 9-membered heteroaryl optionally substituted with one, two, or three R7; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

7. The compound of claim 6 where R1 is a 9-membered heteroaryl and the 9-membered heteroaryl is benzimidazolyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, 1H-imidazo[4,5-c]pyridinyl, 3H-imidazo[4,5-c]pyridinyl, thiazolo[4,5-b]pyridinyl, thiazolo[4,5-c]pyridinyl, thiazolo[5,4-c]pyridinyl, or thiazolo[5,4-b]pyridinyl where R1 is optionally substituted with one, two, or three R7; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

8. The compound of claim 5 where R1 is a 5-membered heteroaryl that is thiazolyl or pyrazolyl and where the 5-membered heteroaryl is optionally substituted with one, two, or three R7; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

9. The compound of claim 5 where R1 is a 6-membered heteroaryl that is pyrimidinyl, pyridinyl, pyrazinyl, or pyridazinyl and where the 6-membered heteroaryl is optionally substituted with one, two, or three R7; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

10. The compound of claim 9 where R1 is pyridinyl optionally substituted with one, two, or three R7; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

11. The compound of claim 5 where R1 is optionally substituted with one or two R7 where each R7, when R7 is present, is independently halo, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, —NR8R8a, or —NR8C(O)OR9; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

12. The compound of claim 5 where R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; where R3c and R3d are hydrogen; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

13. The compound of claim 5 where R2 is quinolin-4-yl substituted with R3, R3a, R3b, R3c and R3d; where R3c and R3d are hydrogen; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

14. The compound of claim 5 where R2 is isoquinolin-4-yl substituted with R3, R3a, R3b, R3c and R3d; where R3c and R3d are hydrogen; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

15. The compound of claim 5 where R2 is according to formula (a)

or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

16. The compound of claim 15 where R3 is hydrogen, halo, alkyl, cycloalkylalkyl, or phenylalkyl optionally substituted with one or two R19; R3a is hydrogen, alkyl, halo, optionally substituted heterocycloalkyl, or —NR11R11a; and R3b is hydrogen, alkyl, hydroxyalkyl, or alkyl substituted with one or two R16; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

17. The compound according to claim 5 where R2 is according to formula (g)

or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

18. The compound according to claim 5 where R2 is according to formula (d)

where m is 1; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

19. The compound of claim 18 where R3 and R3a together with the carbon to which they are attached form an optionally substituted cycloalkyl; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

20. The compound of claim 18 where R3 and R3a are halo or R3 and R3a are alkyl; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

21. The compound according to claim 17 where R3b is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, optionally substituted heteorcycloalkyl, optionally substituted heteorcycloalkylalkyl, or alkyl substituted with one R16; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

22. The compound according to claim 5 where R2 is according to formula (e)

where R3, R3a, R3b, R3c, and R3d are positioned on any substitutable carbon on the ring of formula (e); or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

23. A compound selected from:

7-(2-methyl-1H-benzimidazol-6-yl)-4-quinazolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(7-iodoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
ethyl 4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazoline-2-carboxylate
N,N-diethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-2-amine
4-(2,6-diphenylpyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6,7-bis(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-bromoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-chloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(8-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-iodoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-fluoroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(7-fluoroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[8-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(7-chloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(8-chloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(7-bromoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,7-difluoroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-bromo-7-chloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(8-bromoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(7-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(8-fluoroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[8-(trifluoromethyl)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(8-bromo-6-methylquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[7-bromo-8-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[7-bromo-6-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,8-dichloroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[2-chloro-6-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[7,8-bis(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(7-chloro-6-iodoquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[7-(trifluoromethyl)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6-iodo-7-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6-chloro-7-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(phenylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[7-(methylsulfonyl)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[5-methyl-6-(phenylmethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6-chloro-7,8-bis(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6-bromo-7-(methyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(5-methylpyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-thieno[2,3-d]pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(5-methylthieno[2,3-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(5,6-dimethylpyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(methylsulfonyl)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile
7-(2-methyl-1H-benzimidazol-6-yl)-4-[1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7(2-methyl-1H-benzimidazol-6-yl)-4-{2-[(phenylmethyl)thio]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[2-(ethylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-5-(phenylmethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4(6-ethyl-5-methylpyrimidin-4-yl)-7(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6,7,8-tris(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(5,6-diethylpyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[7-(phenylmethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[5-ethyl-6-(1-methylethyl)pyrimidin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[5-methyl-6-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7(2-methyl-1H-benzimidazol-6-yl)-4-[7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4(5-ethyl-6-methylpyrimidin-4-yl)-7(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-5-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-5-(2-methylpropyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[5-(cyclopropylmethyl)-6-methylpyrimidin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6-ethyl-5-(phenylmethyl)pyrimidin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{5-[(3-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{5-[(3-chlorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-methyl-5-(1-phenylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
5-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl)-N-phenylpyrimidin-4-amine
7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-methyl-5-[(4-methylphenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{5-[(4-chlorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-5-{[3-(methyloxy)phenyl]methyl}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-methyl-5-[(3-methylphenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{5-[(3-chloro-5-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-5-{[2-(methyloxy)phenyl]methyl}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(2-methylpyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-{6-methyl-5-[(2-methylphenyl)methyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(4-methylphenyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{5-[(3,4-difluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-5-{[4-(trifluoromethyl)phenyl]methyl}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{5-[(3,5-difluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-methyl-5-{[3-(trifluoromethyl)phenyl]methyl}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
2-chloro-N,N-dimethyl-5-({4-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-5-yl}methyl)aniline
4-{5-[ 1-(3-fluorophenyl)ethyl]-6-methylpyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-amine
4-{5-[(4-fluorophenyl)methyl]-2,6-dimethylpyrimidin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[2-(trifluoromethyl)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[2-phenylquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[2-methyl-3-(phenylmethyl)pyridin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{3-[(4-fluorophenyl)methyl]-2-methylpyridin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{3-[(3-fluorophenyl)methyl]-2-methylpyridin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-pyridin-2-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-isoquinolin-1-yl-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-pyrimidin-2-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine methyl [6-(4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate
methyl {6-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-yl}carbamate
methyl [6-[4-quinazolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate
methyl {6-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-yl}carbamate
methyl (6-{4-[6,7-bis(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-yl)carbamate
methyl (6-{4-[6-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-yl)carbamate
methyl [6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate
methyl [6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate
methyl [1-methyl-5-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate
1-methyl-5-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine
methyl [1-methyl-6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate
2-(methyloxy)ethyl [6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate
methyl (6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-yl)carbamate
4-piperidin-1-yl-N-[6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]butanamide
methyl [6-(4-isoquinolin-1-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate
methyl {6-[4-(3-methylpyridin-2-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-yl}carbamate
7-(1H-benzimidazol-6-yl)-4-quinazolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-amine
4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1-ethyl-1H-benzimidazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1,3-benzothiazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1,3-benzothiazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1-methyl-1H-benzimidazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-[4-(1H-imidazol-2-yl)phenyl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-quinolin-4-yl-7-quinoxalin-6-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1-methyl-1H-indol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
N,N-dimethyl-3-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide
7-(2,3-dihydro-1-benzofuran-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1H-indazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1H-pyrazol-4-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1H-indazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1-methyl-1H-indazol-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benioiazepin-7-yl)[1,2,4]triazolo[1,5-a]pyridin-2-amine
4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
6-(4-{5-[(4-fluorophenypmethyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)quinazolin-2-amine
6-(4-{5-[(4-fluorophenypmethyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ypimidazo[1,2-a]pyrimidin-2-amine
6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)imidazo[ 1,2-a]pyridin-2-amine
7-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[ 1,2,4]triazolo [ 1,5-a]pyridin-2-amine
5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine
5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-benzothiazol-2-amine
6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridazin-3-amine
4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-7-(1,3-thiazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyrazin-2-amine
4-(7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1,3-thiazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyrimidin-2-amine
5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-4-methyl-1,3-thiazol-2-amine
6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-methylpyridine-3-carboxamide
5-[4-(7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-4-methyl-1,3-thiazol-2-amine
4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6-(methyloxy)quinazolin-7-ol
4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-6-ol
4-[6-(ethyloxy)quinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
({4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-6-yl}oxy)acetonitrile
N,N-dimethyl-3-({4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-6-yl}oxy)propan-1-amine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[6-(propyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-(6-{[2-(methyloxy)ethyl]oxy}quinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-8-(methyloxy)quinazolin-7-ol
N,N-dimethyl-2-({4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-8-(methyloxy)quinazolin-7-yl}oxy)ethanamine
7-(2-methyl-1H-benzimidazol-6-yl)-4-{ 8-(methyloxy)-7-[(2-methylpropyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-{8-(methyloxy)-7-[(quinolin-2-ylmethyl)oxy]quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{7-[(cyclopropylmethyl)oxy]-8-(methyloxy)quinazolin-4-yl}-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(5-methylppimidin-4-yl)-3,4,5-tetrahydro-1,4-benzoxazepine
4-(4-{5-[(4-fluorophenypmethyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide
4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-methylbenzamide
N-cyclopropyl-4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide
4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-[(3S)-pyrrolidin-3-yl]benzamide
N-(2,2-difluoroethyl)-4-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide
methyl [6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate
6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine
6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
6-[4-(6-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
6-[4-(7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
6-{4-[6,7-bis(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine
6-[4-(6-bromoquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
6-{4-[6-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine
6-[4-[6-iodbquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
6-{4-[7-bromo-6-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine
6-[4-(6-bromo-7-chloroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
6-[4-(6-chloroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
6-[4-(6-fluoroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine
6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine
6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine
6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
N-ethyl-6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine
N-(2-fluoroethyl)-5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine
5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-3H-imidazo[4,5-b]pyridin-2-amine
N,N-dimethyl-6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine
7-{2-[(methyloxy)methyl]-1H-benzimidazol-6-yl}-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-propyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-cyclopentyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-cyclopropyl-1H-b enzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-cyclohexyl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-azetidin-3-yl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-piperidin-2-yl-1H-benzimidazol-6-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-[2-(1-methyl ethyl)-1H-benzimidazol-6-yl]-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-quinolin-4-yl-7-(3-thienyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-quinolin-3-yl-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1-benzothien-2-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-[2-(methylthio)-1H-benzimidazol-6-yl]-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
N-ethyl-6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine
N-(1-methylethyl)-6-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine
methyl (6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)carbamate
4-(7-ethyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
{5-[4-(4-pyrido[3,2-d]pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)phenyl]-1H-imidazol-2-yl}methanol
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-[4-(1H-imidazol-2-yl)phenyl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2,4-dimethyl-1H-benzimidazol-6-yl)-4-pyrido[3,2-d]pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-fluoroethyl)-1H-benzimidazol-2-amine
6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-c]pyridin-2-amine
6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
6-[4-(6-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
7-(1H-benzimidazol-6-yl)-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-ethyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1-ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-cyclopropyl-3H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-propyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
5-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridin-2-amine
6-(4-pyrido[3,2-d]pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine
N-ethyl-6-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
7-[2-(difluoromethyl)-3H-imidazo[4,5-b]pyridin-6-yl]-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
N-ethyl-6-(4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine
(2E)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-iminopyrimidin-1(2H)-ol
7-(1H-benzimidazol-6-yl)-4-(2-phenylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
6-[4-(2-phenylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
methyl {6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-yl}carbamate
6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
N-ethyl-6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-[2-(fluoromethyl)-3H-imidazo[4,5-b]pyridin-6-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
N-methyl-4-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide
7-[4-(1H-benzimidazol-2-yl)phenyl]-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(7-fluoroquinolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-ylJquinoline-7-carbonitrile
N-ethyl-4-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide
N-propyl-4-(4-quinolin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide
4-(6-ethyl-5-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
N-ethyl-6-[4-(2-methylquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
N-ethyl-6-{4-[2-methyl-7-(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl][1,3]thiazolo[5,4-b]pyridin-2-amine
5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-indazol-3-amine
N-ethyl-6-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine
7-[4-(1H-imidazol-2-yl)phenyl]-4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
1-{6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3H-imidazo[4,5-b]pyridin-2-yl}ethanol
4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-N-phenylpyrimidin-2-amine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-ethyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-ethyl-1H-benzimidazol-2-amine
7-[4-(1H-imidazol-2-yl)phenyl]-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(5,6-dimethylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-benzimidazol-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
6-{4-[6,7-bis(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-N-ethyl-1H-benzimidazol-2-amine
N-ethyl-6-[4-(2-ethylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
6-{4-[6,7-bis(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-N-ethyl-1H-benzimidazol-2-amine
4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyridin-2-amine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-[1H-pyrazolo[3,4-b]pyridin-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-ethyl-1H-imidazo[4,5-b]pyridin-2-amine
7-[2-(difluoromethyl)-1H-benzimidazol-5-yl]-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
5-[4-(2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-7-(1H-pyrrolo[2,3-b]pyridin-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
N-ethyl-6-[4-(7-fluoroquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
4-{7-[2-(ethylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-N-methylquinazolin-2-amine
N-ethyl-4-{7-[2-(ethylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}quinazolin-2-amine
N-ethyl-6-{4-[2-methyl-6,7-bis(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
4-[6,7-bis(methyloxy)quinolin-4-yl]-7-[4-(1H-imidazol-2-yl)phenyl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine
7-(1H-indazol-5-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
N-ethyl-6-{4-[6-(phenylamino)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
N-ethyl-6-[4-(6-{[4-(methyloxy)phenyl]amino}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
N-ethyl-6-(4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine
N-ethyl-6-{4-[6-(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
N-ethyl-6-{4-[2-ethyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
7-(1H-benzimidazol-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
N-ethyl-6-[4-(7-fluoroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
N-ethyl-6-[4-(8-fluoroquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
N-ethyl-6-[4-(6-fluoroquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
N-ethyl-6-[4-(6-{[3-(methyloxy)phenyl]amino}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
4-{7-[2-(ethylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-2-methylquinazolin-7-ol
5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyrimidin-2-amine
N-ethyl-6-{4-[5-methyl-6-(phenylamino)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
N-ethyl-6-{4-[7-(ethyloxy)-2-methylquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin,7-yl}-1H-benzimidazol-2-amine
6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine
N-ethyl-6-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-amine
N-ethyl-6-{4-[7-(methyloxy)quinolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1,3-thiazol-2-amine
N-(5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1,3-thiazol-2-yl)acetamide
7-(1,3-benzothiazol-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
N-ethyl-6-[4-(7-fluoro-2-methylquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1,3-dihydro-2H-benzimidazol-2-one
(1R)-1-(6-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)ethanamine
(1S)-1-(6-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)ethanamine
(2R)-3-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-2-methylpropan-1-ol
(2R)—N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)butan-2-amine
(2S)-3-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-2-methylpropan-1-ol
(2S)-3-[(2-amino-5-{4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-3-yl)sulfinyl]-2-methylpropan-1-ol
(2S)-3-[(2-amino-5-{4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-3-yl)sulfonyl]-2-methylpropan-1-ol
(2S)—N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)butan-2-amine
(3R)-1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-ol
(3S)-1-({2-[(3S)-3-aminopyrrolidin-1-yl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-amine
(3S)-1-({2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-amine
{4-[7-(2-amino[1,3]thiazolo[5,4-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}methanol
{4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-7-yl}methanol
{5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}methanol
{5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}methyl acetate
{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methanol
{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl acetate
1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-3-(hydroxymethyl)azetidin-3-ol
1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)azetidin-3-ol
1-({2-amino-5-[4-(6;6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)piperidin-3-ol
1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)piperidin-4-ol
1-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)pyrrolidin-3-ol
1-(4-{7-[2-(difluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine
1-(4-{7-[2-(difluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-{4-(7-[2-(fluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5-[(4-fluorophenypmethyl]-6-methylpyrimidin-2-yl)-N,N-dimethylmethanamine
1-(4-{7-[2-(fluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-(4-{7-[3,4-bis(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-(4-{7-[3-chloro-4-(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-(4-{7-[4-(1H-imidazol-2-yl)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-(4-{7-[4-chloro-3-(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-(6,6-dimethyl-4-{7-[3-(methyloxy)-4-{[2-(methyloxy)ethyl]oxy}phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-(6,6-dimethyl-4-{7-[3-(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-(6,6-dimethyl-4-{7-[4-(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-(6,6-dimethyl-4-{7-[6-(methyloxy)pyridin-3-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-[4-{7-[2-(difluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6-methyl-5-(1-methylethyl)pyrimidin-2-yl]-N,N-dimethylmethanamine
1-[4-{7-[2-(fluoromethyl)-1H-benzimidazol-5-yl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-6-methyl-5-(1-methylethyl)pyrimidin-2-yl]-N,N-dimethylmethanamine
1-[4-{7-[3,4-bis(methyloxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-7-(methyloxy)quinazolin-2-yl]-N,N-dimethylmethanamine
1-{(7S)-7-ethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl}-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-{4,5-dimethyl-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
1-{4-[7-(1,3-benzothiazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(4-fluorophenyl)methyl]-6-methylpyrimidin-2-yl}-N,N-dimethylmethanamine
1-{4-[7-(1,3-benzothiazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine
1-{4-(7-(1,3-benzothiazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-7-(methyloxy)-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine
1-{4-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine
1-{4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-7-yl}ethanol
1-{4-[7-(4-fluoro-2-methyl-1H-benzimidazol-5-yl}-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-{4-[7-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine
1-{4-ethyl-5-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
1-{4-ethyl-5-methyl-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
1-{5-(cyclopropylmethyl)-4-methyl-6-[7(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
1-[5-(cyclopropylmethyl)-4-methyl-6-[7(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl]-N,N-dimethylmethanamine
1-[5-(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl)-N,N-dimethylmethanamine
1-{5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
1-{5-ethyl-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
1-{5-ethyl-4-methyl-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
1-{6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine
1-{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methanamine
1-{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine
1-{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}-N-methylmethanamine
1-{6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-7-(methyloxy)-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine
1-{6,6-dimethyl-4-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylethanamine
1-{6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}-N,N-dimethylmethanamine
1-{6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}-N-methylmethanamine
1-{6-fluoro-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]quinazolin-2-yl}-N,N-dimethylmethanamine
1-cyclopropyl-N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)ethanamine
1-methyl-3-(4-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}phenyl)urea
2-{6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}propan-2-ol
2-amino-5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-methylpyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(1-methylethyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2,2,2-trifluoroethyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-fluoroethyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxy-1,1-dimethylethyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxy-1-methylethyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxy-2-methylpropyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxyethyl)-N-methylpyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxyethyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxypropyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(3,3,3-trifluoro-2-hydroxypropyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(3-hydroxy-2,2-dimethylpropyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(3-hydroxypropyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(piperidin-2-ylmethyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(piperidin-3-ylmethyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(piperidin-4-ylmethyl)pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N,N-dimethylpyridine-3-carboxamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N,N-dimethylpyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(1-methylpiperidin-4-yl)methyl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(2R)-pyrrolidin-2-ylmethyl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(2S)-pyrrolidin-2-ylmethyl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3R)-1-methylpyrrolidin-3-yl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3R)-piperidin-3-ylmethyl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3R)-pyrrolidin-3-yl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3R)-pyrrolidin-3-ylmethyl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3S)-piperidin-3-ylmethyl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(33)-pyrrolidin-3-yl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[(3S)-pyrrolidin-3-ylmethyl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-[2-(methyloxy)ethyl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-{[(3,5)-1-methylpiperidin-3-yl]methyl}pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-{[(3S)-1-methylpyrrolidin-3-yl]methyl}pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-ethyl-N-methylpyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-ethylpyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-methylpyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-piperidin-4-ylpyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonic acid
2-amino-5-[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-methylpyridine-3-sulfonamide
2-amino-N-(2,3-dihydroxypropyl-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(2-amino-1,1-dimethylethyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(2-amino-2-methylpropyl)-5-[4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(2-amino-2-methylpropyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(2-amino-2-methylpropyl)-5-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridine-3-sulfonamide
2-amino-N-(2-aminobutyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(2-aminoethyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(2-aminopropyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(3-amino-2,2-dimethylpropyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(3-amino-2-hydroxypropyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(3-amino-3-methylbutyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(3-aminopropyl)-5-[4-(6,6=dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(azetidin-3-ylmethyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-(trans-4-aminocyclohexyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N,N-dimethyl-5-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-[(1-aminocyclopropyl)methyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-[(1-methylpiperidin-4-yl)methyl]-5-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-[(1-methylpiperidin-4-ypmethyl]-5-[4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-[(3R)-1-methylpyrrolidin-3-yl]-5-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-[(3R)-1-methylpyrrolidin-3-yl]-5-[4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-[2-(dimethylamino)ethyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-{[(3S)-1-methylpyrrolidin-3-yl]methyl}-5-[4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-8-azabicyclo[3.2.1]oct-3-yl-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-azetidin-3-yl-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-amino-N-cyclobutyl-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
2-chloro-5-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide
2-chloro-N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}-6-methylbenzenesulfonamide
3-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)propan-1-ol
3-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)propane-1,2-diol
3-(2,6-diazaspiro [3.3]hept-2-ylsulfonyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide
3-(azetidin-1-ylsulfonyl)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-[(1R,4R)-2,5-diazabicyclo [2.2.1]hept-2-ylsulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-ylsulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-[(1S,4S)-2,5-diazabicyclo [2.2.1]hept-2-ylsulfonyl]-5-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine
3-[(3,3-difluoroazetidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-[(3-amino-3-methylazetidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-[(3-amino-3-methylpyrrolidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-[(3-amino-3-methylpyrrolidin-1-yl)sulfonyl]-5-{4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine
3-[(3-amino-3-methylpyrrolidin-1-yl)sulfonyl]-5-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine
3-[(3-aminoazetidin-1-ypsulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-[(3-aminopiperidin-1-yl)sulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-[(3-aminopyrrolidin-1-ypsulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-[(4-aminopiperidin-1-ypsulfonyl]-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-5-{4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine
3-{[(3S)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-{[(3S)-3-aminopyrrolidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-ol
3-{[(3S)-3-aminopyrrolidin-1-yl]sulfonyl}-5-{4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-2-amine
3-{[3-(dimethylamino)azetidin-1-yl]sulfonyl}-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-2-amine
3-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}benzoic acid
3-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-2-carboxamide
4-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfinyl)-2-methylbutan-2-ol
4-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-2-methylbutan-2-ol
4-(2,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(2-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(2-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(2-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(2-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(2-ethenyl-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-N-methylbenzamide
4-(5-bromo-6-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(5-ethyl-2,6-dimethylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(5-ethyl-6-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-difluoro-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-2-pyridin-2-yl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-2-pyridin-2-yl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-2-pyrrolidin-2-yl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-3H-imidazo[4,5-c]pyridin-7-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-[5-(methyloxy)pyridin-3-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-pyrido[2,3-b]pyrazin-7-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-7-[4-(1H-imidazol-2-yl)phenyl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-azetidin-1-yl-5-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-chloro-5-methylpyrimidin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(6-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-(8,8-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[(6S,7S)-6,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[(7S)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[(8S)-8-ethenyl-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[(8S)-8-ethyl-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[2,6-dimethyl-5-(1-methylethyl)pyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[5-(cyclopropylmethyl)-2,6-dimethylpyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[5-(cyclopropylmethyl)-6-methylpyrimidin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6,6-dimethyl-2-({[2-(methyloxy)ethyl]oxy}methyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6,6-dimethyl-2-({[2-(methyloxy)ethyl]oxy}methyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6,6-dimethyl-2-(1-pyrrolidin-1-ylethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6,6-dimethyl-2-(2-pyrrolidin-1-ylethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6,6-dimethyl-2-(morpholin-4-ylmethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahy dro-1,4-benzoxazepine
4-[6,6-dimethyl-2-(piperidin-1-ylmethyl)=5,6,7;8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6,6-dimethyl-2-(pyrrolidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[6,6-dimethyl-2-(pyrrolidin-1-ylmethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4′-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-7′,8′-dihydro-5′H-spiro[cyclopropane-1,6′-quinazoline]
4-{2-[(3,3-difluoropyrrolidin-1-yl)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}aniline
4-{6,6-dimethyl-2-[(2R)-pyrrolidin-2-yl]-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-1H-benzimidazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{6,6-dimethyl-2-[(2R)-pyrrolidin-2-yl]-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{6,6-dimethyl-2-[(25)-pyrrolidin-2-yl]-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-{6,6-dimethyl-2-[(methyloxy)methyl]-5,6,7,8-tetrahydroquinazolin-4-yl}-7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
5-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(ethylsulfonyl)pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(hexahydropyrrolo [3,4-c]pyrrol-2(1H)-ylsulfonyl)pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(methylsulfonyl)pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(morpholin-4-ylsulfonyl)pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(piperazin-1-ylsulfonyl)pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-(pyrrolidin-1-ylsulfonyl)pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-[(methylsulfonyl)methyl]pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-{[(1S,4S)-5-methyl-2,5-diazabicyclo [2.2.1]hept-2-yl]sulfonyl}pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-3-{[3-(methylamino)azetidin-1-yl]sulfonyl}pyridin-2-amine
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N-(2-hydroxyethyl)-2-(methylamino)pyridine-3-sulfonamide
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N,N-dimethylpyridine-3-sulfonamide
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridine-3-sulfonamide
5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyrimidin-2-amine
5-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1,3-dihydro-2H-indol-2-one
5-methyl-N-(1-methylethyl)-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-4-amine
6-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
6-(4-{2-[(dimethylamino)methyl]-7-(methyloxy)quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
6-[7-(1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-2,5-dimethyl-N-phenylpyrimidin-4-amine
6-[7-(1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-2,5-dimethyl-N-phenylpyrimidin-4-amine
6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methyl-N-(1-methylpiperidin-4-yl)pyrimidin-4-amine
6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methyl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine
6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methyl-N4(1-methylpiperidin-4-yl)methyl]pyrimidin-4-amine
6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methyl-N-[2-(1-methylpyrrolidin-2-yl)ethyl]pyrimidin-4-amine
6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-N,5-dimethyl-N-[(1R)-1-phenylethyl]pyrimidin-4-amine
6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-N,5-dimethyl-N-[(1 S′)-1-phenylethyl]pyrimidin-4-amine
6-{4-[(73)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine
6-{4-[2,5-dimethyl-6-(phenylamino)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-N-ethyl-1H-benzimidazol-2-amine
6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
6-{4-[5-methyl-6-(phenylamino)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine
7-(1H-benzimidazol-6-yl)-4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine 7-(1H-imidazo[4,5-b]pyridin-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(1H-imidazo[4,5-b]pyridin-6-yl)-4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[(7S)-7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[5-(cyclopropylmethyl)-2,6-dimethylpyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-ethyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(5-methyl-6-morpholin-4-ylpyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6,7,8-tetramethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6,7-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6,6,8-trimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(6-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-(7=methyl-7-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[(7R)-7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[(73)-7-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[2-methyl-5-(morpholin-4-ylsulfonyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[5-(trifluoromethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[5-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[6-methyl-5-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-[7-(trifluoromethyl)-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4-{7-[(methyloxy)methyl]-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-[4-(1H-imidazol-4-yl)phenyl]-4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2H-pyrido[2,3-e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxide
7-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)=2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
7-{6-chloro-5-[(difluoromethyl)oxy]pyridin-3-yl}-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
7-{6-chloro-5-[(methylsulfonyl)methyl]pyridin-3-yl}-4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
8-({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine
ethyl {6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}carbamate
methyl (6-{4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)carbamate
methyl (6-{4-[(73)-7-ethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)carbamate
methyl [6-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-yl]carbamate
methyl [6-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-yl]carbamate
methyl {2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}carbamate
methyl {6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}carbamate
methyl {6-[4-(6,6-dimethyl-5,6-dihydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}carbamate
N-({5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}methyl)cyclopropanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-(methyloxy)ethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-fluoroethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclobutanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclopropanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)ethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-(methyloxy)ethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2,2,2-trifluoroethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2,2-difluoroethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-fluoroethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-methylpropan-1-amine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-2-methylpropan-2-amine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)alanine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclobutanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclopentanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)cyclopropanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)ethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)methanesulfonamide
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-ethylethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-ethylpropan-2-amine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-methylcyclopropanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-methylethanamine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)-N-methylpropan-2-amine
N-({6,6-dimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}methyl)propan-2-amine
N-(2-chloro-5-{4-[7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}pyridin-3-yl)methanesulfonamide
N-(4-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}phenyl)acetamide
N,5-dimethyl-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-4-amine
N,N,2-trimethyl-4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidine-5-sulfonamide
N,N-dimethyl-1-{4-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(1-methylethyl)pyrimidin-2-yl}methanamine
N,N-dimethyl-1-{4-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-7-(methyloxy)quinazolin-2-yl}methanamine
N,N-dimethyl-1-{4-methyl-5-(methylethyl)-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}methanamine
N,N-dimethyl-1-{4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(1-methylethyl)pyrimidin-2-yl}methanamine
N-[2-chloro-5-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)pyridin-3-yl]methanesulfonamide
N-[6-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide
N-[6-(4-{2-[(dimethylamino)methyl]-7-(methyloxy)quinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide
N-{2-(dimethylamino)-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide
N-{2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide
N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]phenyl}methanesulfonamide
N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}acetamide
N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide
N-{2-chloro-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}-N-methylmethanesulfonamide
N-{2-cyano-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide
N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-(ethyloxy)pyridin-3-yl}methanesulfonamide
N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-(methylamino)pyridin-3-yl}methanesulfonamide
N-{5-[4-(6,6-dimethyl-5,6;7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-(methyloxy)pyridin-3-yl}methanesulfonamide
N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-(phenylamino)pyridin-3-yl}methanesulfonamide
N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-[(phenylmethyl)amino]pyridin-3-yl}methanesulfonamide
N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-[(phenylmethyl)oxy]pyridin-3-yl}methanesulfonamide
N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-fluoropyridin-3-yl}methanesulfonamide
N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-2-methylppidin-3-yl}methanesulfonamide
N-{5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}methanesulfonamide
N-{6-[7-(2-cyclopropyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-methylpyrimidin-4-yl}-N,N′-dimethyl ethane-1,2-diamine
N˜2˜({2-amino-5-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]pyridin-3-yl}sulfonyl)glycinamide
N-ethyl-2,5-dimethyl-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-4-amine
N-ethyl-3-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}benzamide
N-ethyl-5-methyl-6-[7-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-4-amine
N-ethyl-6-[4-(5-methyl-6-{[4-(methyloxy)phenyl]amino}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
N-ethyl-6-[4-(7-fluoro-2-methylquinolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-benzimidazol-2-amine
N-ethyl-6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-amine
N-ethyl-6-{4-[6-(ethylamino)-5-methylpyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-benzimidazol-2-amine
N-methyl-3-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}benzamide
phenylmethyl (2S)-2-{6,6-dimethyl-4-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}pyrrolidine-1-carboxylate
phenylmethyl [(1S)-1-(6-{4-[(7S)-7-ethyl-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}-1H-imidazo[4,5-b]pyridin-2-yl)ethyl]carbamate
phenylmethyl [(1S)-1-{6-[4-(6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-1H-imidazo[4,5-b]pyridin-2-yl}ethyl]carbamate
1-(6,6-dimethyl-4-{7-[4-(methyloxy)-3-{[2-(methyloxy)ethyl]oxy}phenyl]-2,3-dihydro-1,4-benzoxazepin-4(511)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
1-{4-[7-{3-[(difluoromethyl)oxy]-4-(methyloxy)phenyl}-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}-N,N-dimethylmethanamine
1-[5-(4-{2-[(dimethylamino)methyl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-2-(methyloxy)phenyl]ethanone
4-[7-(1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-2-amine
1-(6,6-dimethyl-4-{7-[4-(methyloxy)-3-(methylsulfonyl)phenyl]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)-N,N-dimethylmethanamine
N,N-dimethyl-1-{4-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(511)-yl]-5-propylpyrimidin-2-yl}methanamine
N,N-dimethyl-1-{4-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(511)-yl]-5-prop-2=en-1-ylpyrimidin-2-yl}methanamine
N,N-dimethyl-1-{4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(2-methylpropyl)pyrimidin-2-yl}methanamine
N-[5-(4-{2-[(dimethylamino)methyl]-6-methyl-5-(1-methylethyl)pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-2-(methyloxy)phenyl]methanesulfonamide
6-(4-{2-[(dimethylamino)methyl]-6-methyl-5-propylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
1-{4-[7-(1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(511)-yl]-7-(methyloxy)quinazolin-2-yl}-N,N-dimethylmethanamine
N,N-dimethyl-1-{4-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-7-(methyloxy)quinazolin-2-yl}methanamine
5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-amine
6-{4-[2-methyl-7-(methyloxy)quinazolin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}[1,3]thiazolo[5,4-b]pyridin-2-amine
6-(4-{2-[(dimethylamino)methyl]-5-ethyl-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
6-(4-{5-(cyclopropylmethyl)-2-[(dimethylamino)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
N,N-dimethyl-1-{4-methyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-[2-(methyloxy)ethyl]pyrimidin-2-yl}methanamine
6-(4-{2-[(dimethylamino)methyl]-6-methyl-5-(2-methylpropyl)pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
1-{5-bromo-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
6-(4-{2-[(dimethylamino)methyl]-6-methyl-5-[2-(methyloxy)ethyl]pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
1-{6,6-dimethyl-4-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5,6,7,8-tetrahydroquinazolin-2-yl}ethanamine
6-[4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl][1,3]thiazolo[5,4-b]pyridin-2-amine
6-(4-{2-[(dimethylamino)methyl]-6-methyl-5-prop-2-en-1-ylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
6-(4-{2-[(dimethylamino)methyl]-5,6-dimethylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
1-{4,5-dimethyl-6-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
6-(4-{5-bromo-2-[(dimethylamino)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
6-(4-{2-[(dimethylamino)methyl]-6-methyl-5-(1-methylethyl)pyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
7-(2-methyl-1H-benzimidazol-5-yl)-4-[6-methyl-5-(1-methylethyl)-2-(pyrrolidin-1-ylmethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine
4-[2-(fluoromethyl)-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl]-7-(2-methyl-1H-benzimidazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine
1-{5-chloro-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylmethanamine
6-(4-{5-chloro-2-[(dimethylamino)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
2-fluoro-N-({4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(1-methylethyl)pyrimidin-2-yl}methyl)ethanamine
6-{4-[2-{[(2-fluoroethyl)amino]methyl}-6-methyl-5-(1-methylethyl)pyrimidin-4-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl}[1,3]thiazolo[5,4-b]pyridin-2-amine
N,N-dimethyl-1-{4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-phenylpyrimidin-2-yl}methanamine
6-(4-{2-[(dimethylamino)methyl]-6-methyl-5-phenylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
N′-{5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-yl}-N,N-dimethylethane-1,2-diamine
{4-[7-(2-amino[1,3]thiazolo[5,4-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,6-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl}acetonitrile
N-ethyl-N-({4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(1-methylethyl)pyrimidin-2-yl}methyl)ethanamine
{4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(1-methylethyl)pyrimidin-2-yl}methyl acetate
{4-methyl-6-[7-(2-methyl-1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-5-(1-methylethyl)pyrimidin-2-yl}methanol
4-[7-(1H-benzimidazol-5-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6-methylpyrimidin-2-amine
5-[(4-fluorophenyl)methyl]-4-[7-(3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6-methylpyrimidin-2-amine
5-[(4-fluorophenyl)methyl]-4-methyl-6-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]pyrimidin-2-amine
1-{4-[7-(3H-imidazo[4,5-b]pyridin-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-7-(methyloxy)quinazolin-2-yl}-N,N-dimethylmethanamine; and
6-(4-{2-amino-5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine
or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition which comprises a compound, optionally as pharmaceutically acceptable salt thereof, of claim 1 and a pharmaceutically acceptable carrier, excipient, or diluent.

25. A method of making a compound of formula Ia, according to claim 1 which method comprises where R1 is as defined in claim 1; with an intermediate of formula R2X where X is halo, and R2 is as defined in claim 1 to yield a compound of formula Ia; and optionally separating individual isomers; and optionally modifying any of the R1 and R2 groups; and optionally forming a pharmaceutically acceptable salt thereof; or where R is halo or —B(OR′)2 (where both R′ are hydrogen or the two R′ together form a boronic ester), and R2 is as defined in claim 1; with an intermediate of formula R1Y where Y is halo when R is —B(OR′)2 and Y is —B(OR′)2 when R is halo, and R2 is as defined in claim 1 to yield a compound of the invention of formula Ia; and optionally separating individual isomers; and optionally modifying any of the R1 and R2 groups; and optionally forming a pharmaceutically acceptable salt thereof.

(a) reacting the following, or a salt thereof:
(b) reacting the following intermediate, or a salt thereof:

26. The compound of claim 2 where R2 is quinazolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; where R3c and R3d are hydrogen; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

27. The compound of claim 2 where R2 is quinolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; where R3c and R3d are hydrogen; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

28. The compound of claim 2 where R2 is isoquinolin-4-yl substituted with R3, R3a, R3b, R3c, and R3d; where R3c and R3d are hydrogen; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

29. The compound of claim 2 where R2 is according to formula (a) or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

30. The compound according to claim 2 where R2 is according to formula (g) or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

31. The compound according to claim 2 where R2 is according to formula (d) where m is 1; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

32. The compound according to claim 2 where R2 is according to formula (e) where R3, R3a, R3b, R3c, R3d are positioned on any substitutable carbon on the ring of formula (e); or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

33. The compound according to claim 18 where R3b is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, optionally substituted heteorcycloalkyl, optionally substituted heteorcycloalkylalkyl, or alkyl substituted with one R16; or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

34. A method of treating cancer, where the cancer is mammary adenocarcinoma, colorectal carcinoma, prostate adenocarcinoma, glioblastoma, lung carcinoma, or melanoma, the method comprising administering to a patient a therapeutically effective amount of a compound of claim 1, optionally as a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, excipient, or diluent.

Referenced Cited
U.S. Patent Documents
5221681 June 22, 1993 Kabbe et al.
20040044048 March 4, 2004 Sikorski et al.
20060148800 July 6, 2006 Stadtmueller et al.
20080221093 September 11, 2008 Gege et al.
20120258953 October 11, 2012 Aay et al.
Foreign Patent Documents
101497612 August 2009 CN
0496238 July 1992 EP
0540334 January 1996 EP
2123644 November 2009 EP
97/24122 July 1997 WO
97/24124 July 1997 WO
00/46215 August 2000 WO
01/16263 March 2001 WO
01/16274 March 2001 WO
01/16275 March 2001 WO
01/16276 March 2001 WO
02/096873 December 2002 WO
03/059898 July 2003 WO
03/075858 September 2003 WO
2004/078733 September 2004 WO
2006/125119 November 2006 WO
2008/108445 September 2008 WO
2008/109599 September 2008 WO
2008/144483 November 2008 WO
2009/026444 February 2009 WO
2009/042092 April 2009 WO
2009/076631 June 2009 WO
Other references
  • International Search Report for PCT/US2010/035565, mailed Aug. 27, 2010.
  • U.S. Appl. No. 13/322,160, filed Nov. 23, 2011 Gembeh, Shirley V., Pending.
  • U.S. Appl. No. 13/989,330, filed May 23, 2011, To Be Determined, Pending.
  • U.S. Appl. No. 13/988,903, filed May 23, 2011, To Be Determined, Pending.
  • U.S. Appl. No. 13/988,948, filed May 23, 2011, To Be Determined, Pending.
  • U.S. Appl. No. 13/989,156, filed May 23, 2011, To Be Determined, Pending.
  • U.S. Appl. No. 13/989,366, filed May 23, 2011, To Be Determined, Pending.
  • U.S. Appl. No. 13/885,307, filed May 14, 2013, To Be Determined, Pending.
  • U.S. Appl. No. 13/885,323, filed May 14, 2013, To Be Determined, Pending.
Patent History
Patent number: 8648066
Type: Grant
Filed: May 20, 2010
Date of Patent: Feb 11, 2014
Patent Publication Number: 20100298290
Assignee: Exelixis, Inc. (South San Francisco, CA)
Inventors: Neel Kumar Anand (Burlingame, CA), Charles M. Blazey (San Francisco, CA), Owen Joseph Bowles (Pacifica, CA), Chris Allen Buhr (Redwood City, CA), Joerg Bussenius (Foster City, CA), Jeffry Kimo Curtis (San Anselmo, CA), Steven Charles DeFina (Burlingame, CA), Larisa Dubenko (San Francisco, CA), Jason R. Harris (San Bruno, CA), Eileen E. Jackson-Ugueto (Palo Alto, CA), Anagha Joshi (Fremont, CA), Angie Inyoung Kim (San Mateo, CA), Amy Lew Tsuhako (Milpitas, CA), Sunghoon Ma (Foster City, CA), Jean-Claire Limun Manalo (Daly City, CA), Stephanie Ng (Palo Alto, CA), Csaba J. Peto (Alameda, CA), Kenneth D. Rice (San Rafael, CA), Tsze H. Tsang (El Cerrito, CA), Cristiana A. Zaharia (Redwood City, CA)
Primary Examiner: Brenda Coleman
Application Number: 12/784,254
Classifications
Current U.S. Class: Polycyclo Ring System Which Contains The Seven-membered Hetero Ring As One Of The Cyclos (514/211.09); Bicyclo Ring System Which Contains The Hetero Ring As One Of The Cyclos (540/552)
International Classification: A61P 35/00 (20060101); A61K 31/553 (20060101); C07D 267/14 (20060101);